Clustering O 0 4.669383088184986e-06
of O 0 4.260393779986771e-07
missense O 0 1.113314283429645e-05
mutations O 0 2.88141876580994e-07
in O 0 3.801584380624945e-09
the O 0 3.015734932887426e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.2195059753139503e-06
in O 0 7.024560044754935e-09
a O 0 1.9618108026975278e-08
sporadic B-Disease 0 6.087518613639986e-06
T I-Disease 0 0.025413652881979942
- I-Disease 0 0.0014479360543191433
cell I-Disease 0 0.00040122048812918365
leukaemia I-Disease 1 0.6045480370521545
. O 0 1.4419173339774716e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9941222071647644
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 7.547829028453634e-10
is O 0 7.271767216154856e-11
a O 0 1.8001607149376042e-10
recessive B-Disease 0 8.11167979009042e-07
multi I-Disease 1 0.9976050853729248
- I-Disease 1 0.997194766998291
system I-Disease 0 0.0005796518526040018
disorder I-Disease 1 0.9999959468841553
caused O 0 4.2762934526763274e-08
by O 0 7.381872890732666e-11
mutations O 0 1.639738123060397e-09
in O 0 4.2393196592049875e-11
the O 0 2.42145248297021e-10
ATM O 0 3.1429101454705233e-07
gene O 0 2.5081785537395263e-09
at O 0 2.031484136466588e-08
11q22 O 0 1.5983538332875469e-06
- O 0 4.409177165598521e-07
q23 O 0 4.3740819819504395e-06
( O 0 7.3019341684243955e-09
ref O 0 1.3715221029997338e-06
. O 0 2.213806027384635e-09
3 O 0 2.6606253200611718e-08
) O 0 2.4759942984786676e-09
. O 0 4.0704787096501605e-08

The O 0 1.1662233134757116e-07
risk O 0 1.412576580150926e-06
of O 0 1.2007883924525231e-05
cancer B-Disease 1 0.9999985694885254
, O 0 1.6034386263186207e-08
especially O 0 1.8792244205201314e-08
lymphoid B-Disease 1 0.9563756585121155
neoplasias I-Disease 1 0.9983488321304321
, O 0 3.6147523863050424e-10
is O 0 2.4057164246804597e-11
substantially O 0 3.5359568051340773e-10
elevated O 0 4.2857816850983e-08
in O 0 2.6278417220026995e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 5.2289190755061554e-09
and O 0 5.514980833121186e-11
has O 0 5.542398137658999e-11
long O 0 1.141590086350952e-10
been O 0 7.335904800287452e-11
associated O 0 9.959657543134881e-10
with O 0 7.933279033700558e-10
chromosomal O 1 1.0
instability O 1 1.0
. O 0 5.2119692554697394e-05

By O 0 5.4227498935688345e-08
analysing O 0 1.301384941143624e-06
tumour B-Disease 1 1.0
DNA O 0 5.09893595790345e-07
from O 0 1.1384145182091743e-08
patients O 0 3.1952751555763825e-10
with O 0 6.890945453141839e-11
sporadic B-Disease 0 5.344989517652721e-07
T I-Disease 0 2.1463238226715475e-05
- I-Disease 0 3.075589347645291e-06
cell I-Disease 0 1.672174448685837e-06
prolymphocytic I-Disease 0 7.014903530944139e-05
leukaemia I-Disease 1 0.8687940835952759
( O 0 1.5779326290044082e-08
T B-Disease 0 1.1010754406015621e-06
- I-Disease 0 5.778550189461384e-07
PLL I-Disease 0 1.642885763430968e-06
) O 0 1.7381955597084442e-10
, O 0 3.792932634638646e-11
a O 0 3.1332936245576093e-10
rare O 0 3.151479743834784e-09
clonal B-Disease 0 2.687402002266026e-06
malignancy I-Disease 0 0.00010779906733660027
with O 0 8.318537525475733e-11
similarities O 0 9.010044932367123e-10
to O 0 8.058072542560524e-10
a O 0 1.0523252491623225e-08
mature B-Disease 0 3.3559769008206786e-07
T I-Disease 0 3.216697905372712e-06
- I-Disease 0 1.2305296195336268e-06
cell I-Disease 0 1.1123315744043794e-06
leukaemia I-Disease 0 0.00010514644236536697
seen O 0 4.722457092043442e-09
in O 0 8.438941767607844e-10
A B-Disease 1 1.0
- I-Disease 1 0.9999960660934448
T I-Disease 1 1.0
, O 0 1.0108841541622837e-09
we O 0 8.424849706756277e-11
demonstrate O 0 4.727111757585334e-11
a O 0 5.512267378660063e-11
high O 0 3.9747641289444857e-10
frequency O 0 4.687977561701473e-09
of O 0 7.423462289324334e-09
ATM O 0 3.09236093016807e-05
mutations O 0 6.562039516211371e-07
in O 0 9.9767014205554e-08
T B-Disease 0 0.00015923344471957535
- I-Disease 0 4.4016043830197304e-05
PLL I-Disease 0 0.00012399589468259364
. O 0 6.949055659788428e-07

In O 0 3.628080236239839e-08
marked O 0 1.6001665770204454e-08
contrast O 0 1.4454584196244014e-09
to O 0 5.629745558621835e-10
the O 0 1.158498075248815e-09
ATM O 0 3.65923301615112e-06
mutation O 0 2.134808241294195e-08
pattern O 0 3.6807463743571134e-08
in O 0 5.091178145733011e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 1.1854328629823385e-09
the O 0 3.3361247098184776e-10
most O 0 1.3303251729379628e-11
frequent O 0 3.713502769175925e-11
nucleotide O 0 6.339721525527864e-10
changes O 0 4.206473364076757e-11
in O 0 6.829264931340617e-11
this O 0 7.058885143074178e-10
leukaemia B-Disease 0 2.22859325731406e-05
were O 0 8.537335105529564e-08
missense O 0 1.785347740224097e-05
mutations O 0 8.528514626959804e-06
. O 0 9.124851771957765e-07

These O 0 8.875980839206932e-09
clustered O 0 1.281209733861033e-07
in O 0 4.1428718788871777e-10
the O 0 7.794763723367737e-10
region O 0 1.2818912153989004e-08
corresponding O 0 1.4629329747606334e-08
to O 0 2.209701310817991e-09
the O 0 2.6753559367875823e-09
kinase O 0 1.1027184143586055e-07
domain O 0 4.0054690231272616e-08
, O 0 5.4731063431345817e-11
which O 0 1.3621924768725258e-11
is O 0 2.9480962809858013e-11
highly O 0 1.208250444140191e-10
conserved O 0 1.8296892889679839e-09
in O 0 1.9199306033890196e-10
ATM O 0 5.966656317468733e-06
- O 0 1.2608280997028487e-07
related O 0 4.121916141741622e-09
proteins O 0 4.5205030690942394e-11
in O 0 3.967687636774464e-11
mouse O 0 1.0294269880972706e-09
, O 0 2.1052676268951132e-10
yeast O 0 3.305257578745113e-08
and O 0 7.66169439003761e-09
Drosophila O 0 2.479569332081155e-07
. O 0 3.0110673066019444e-08

The O 0 8.838596272653376e-07
resulting O 0 5.875536430721695e-07
amino O 0 3.5741427950597426e-07
- O 0 8.47870467168832e-08
acid O 0 7.646583810583252e-09
substitutions O 0 5.038145012292716e-09
are O 0 1.4772878753621654e-10
predicted O 0 6.893426984788675e-08
to O 0 2.92220159181511e-09
interfere O 0 2.4900426609519855e-08
with O 0 9.911598208844907e-10
ATP O 0 9.188622061628848e-05
binding O 0 2.1378382086822967e-07
or O 0 2.0385172661008255e-08
substrate O 0 9.247533512279915e-07
recognition O 0 8.861842815122145e-08
. O 0 1.1427702872879308e-07

Two O 0 5.589478035972206e-08
of O 0 9.77868467089138e-07
seventeen O 0 1.6554267858737148e-06
mutated O 0 6.329185566755768e-07
T B-Disease 0 3.2046157230070094e-06
- I-Disease 0 5.791283683720394e-07
PLL I-Disease 0 1.1657200502668275e-06
samples O 0 8.08260847140474e-10
had O 0 1.6027827676179385e-10
a O 0 1.1796311150114036e-10
previously O 0 2.7033475458182465e-09
reported O 0 1.4106882773035068e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999959468841553
T I-Disease 1 1.0
allele O 0 1.668909862928558e-05
. O 0 4.5401850456983084e-07

In O 0 5.06359967289427e-08
contrast O 0 3.363935618949654e-08
, O 0 5.153402593549572e-09
no O 0 5.828520333039933e-09
mutations O 0 1.8149840741443768e-08
were O 0 1.9022818875669145e-09
detected O 0 5.043971462725949e-09
in O 0 1.0276863388058999e-10
the O 0 6.454805578925971e-10
p53 O 0 6.763910764817638e-09
gene O 0 9.59132551159314e-10
, O 0 3.975876919359855e-11
suggesting O 0 3.54280216274816e-10
that O 0 3.355471803190291e-11
this O 0 2.103891727500695e-09
tumour B-Disease 1 1.0
suppressor O 0 0.0006224078824743629
is O 0 8.274739782265783e-10
not O 0 1.275779759613016e-10
frequently O 0 1.604694571666343e-10
altered O 0 1.3553130839838445e-09
in O 0 3.808491577661499e-10
this O 0 6.04580874252747e-09
leukaemia B-Disease 0 0.00022195474593900144
. O 0 6.037577691131446e-07

Occasional O 0 2.8194147034810157e-06
missense O 0 1.076878106687218e-05
mutations O 0 2.649287864642247e-07
in O 0 3.0656084337721268e-09
ATM O 0 9.370058251079172e-05
were O 0 6.293676690916072e-09
also O 0 1.1128165056106809e-10
found O 0 6.207641345401527e-11
in O 0 7.057643358621135e-11
tumour B-Disease 1 0.9999995231628418
DNA O 0 3.747934229636485e-08
from O 0 2.1285455620301263e-09
patients O 0 3.6177092571643144e-11
with O 0 9.27587173737976e-12
B B-Disease 0 8.845915431265894e-07
- I-Disease 0 1.0689238649774779e-07
cell I-Disease 0 8.59235285588511e-07
non I-Disease 0 7.17728107701987e-05
- I-Disease 0 0.0002634715929161757
Hodgkins I-Disease 1 0.9999969005584717
lymphomas I-Disease 0 1.964231614692835e-06
( O 0 4.091217919999224e-10
B B-Disease 0 1.1482083550617972e-07
- I-Disease 0 1.4693143590704949e-08
NHL I-Disease 0 1.979110386685079e-08
) O 0 3.0899029862530014e-11
and O 0 3.457063454948006e-11
a O 0 2.3966415518827944e-09
B B-Disease 0 2.237423359474633e-06
- I-Disease 0 5.161836043043877e-07
NHL I-Disease 0 2.3247509943757905e-06
cell O 0 1.8458005115462583e-06
line O 0 3.2165139600692783e-06
. O 0 6.656254640802217e-07

The O 0 3.291266637006629e-08
evidence O 0 7.40561478806967e-09
of O 0 5.557509563658414e-09
a O 0 4.1124040284223895e-10
significant O 0 1.583726927378848e-09
proportion O 0 1.7037974586742166e-08
of O 0 4.650078366807975e-08
loss O 0 1.041153367964398e-07
- O 0 1.5331764302572992e-07
of O 0 1.1985031278527458e-07
- O 0 8.346072277731764e-09
function O 0 2.472831106548057e-10
mutations O 0 5.1563864289505545e-11
and O 0 1.937309904512241e-12
a O 0 3.33368020688507e-11
complete O 0 1.3785348418338117e-09
absence O 0 2.1152315454742165e-08
of O 0 1.0522891003006407e-08
the O 0 4.946900666880083e-10
normal O 0 4.4290560108350974e-10
copy O 0 4.97536400967391e-10
of O 0 3.803267034641067e-09
ATM O 0 2.66525307779375e-06
in O 0 2.481884697758119e-10
the O 0 3.120554370461548e-10
majority O 0 2.6225827065573526e-10
of O 0 2.179131719515226e-08
mutated O 0 1.3757245369561133e-06
tumours B-Disease 1 0.9999982118606567
establishes O 0 8.306277976544152e-08
somatic O 0 5.296424774314801e-07
inactivation O 0 1.3345506886253133e-06
of O 0 7.864703555071628e-09
this O 0 9.83594247716546e-11
gene O 0 1.4120085656266212e-10
in O 0 1.9018446539842415e-11
the O 0 2.5782129209339644e-10
pathogenesis O 0 4.0836954440237605e-07
of O 0 4.0530986211706477e-07
sporadic B-Disease 0 0.001706874929368496
T I-Disease 1 0.9996824264526367
- I-Disease 0 0.0264060627669096
PLL I-Disease 0 3.882770033669658e-05
and O 0 3.9309602795079e-10
suggests O 0 3.364522549453852e-10
that O 0 1.5376422357604724e-11
ATM O 0 3.3106400110227696e-07
acts O 0 7.2534755979347665e-09
as O 0 2.1914516867838074e-09
a O 0 8.06172337775024e-08
tumour B-Disease 1 1.0
suppressor O 0 0.0035251814406365156
. O 0 2.0201375718897907e-06

As O 0 1.0855308651969153e-08
constitutional O 0 6.493758775150127e-08
DNA O 0 3.014124416722552e-08
was O 0 2.0341817119629013e-09
not O 0 1.2820066189189738e-11
available O 0 2.3249235869826634e-11
, O 0 2.4708214640956072e-11
a O 0 1.4388732427761397e-09
putative O 0 3.3064920899050776e-06
hereditary O 1 0.9999998807907104
predisposition O 1 1.0
to O 0 0.0003463032771833241
T B-Disease 1 0.9956232905387878
- I-Disease 0 6.427877087844536e-05
PLL I-Disease 0 6.928000402695034e-06
will O 0 5.195532892798838e-10
require O 0 2.4387877828324633e-10
further O 0 2.1989001730560176e-09
investigation O 0 2.24257448167009e-08
. O 0 6.020745235701952e-09
. O 0 2.3929292325419738e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 1.3233949403002043e-06
kinase O 0 2.9349843089221395e-07
is O 0 1.6413143066884572e-10
involved O 0 8.472161167061287e-11
in O 0 8.996847537801056e-12
the O 0 2.5210633927685855e-11
modulation O 0 2.7527990997811003e-09
of O 0 5.522396318013989e-09
the O 0 4.151670118801576e-09
Ca2 O 0 6.105118188770575e-08
+ O 0 2.048511760222027e-07
homeostasis O 0 2.1562787821949314e-07
in O 0 4.226132332973975e-09
skeletal O 0 1.533952854515519e-06
muscle O 0 6.76823560752382e-07
cells O 0 6.50188951567543e-07
. O 0 4.4413400246412493e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0003578364267013967
DM B-Disease 1 1.0
) O 0 1.2854609821033591e-08
, O 0 3.0417790508607823e-10
the O 0 2.582923319671693e-10
most O 0 8.162716336190812e-11
prevalent O 0 9.224755785908201e-07
muscular B-Disease 1 0.9999314546585083
disorder I-Disease 1 0.9999450445175171
in O 0 1.952220385348369e-09
adults O 0 1.8116420585911897e-09
, O 0 2.0994522093031875e-11
is O 0 3.8989391576427224e-11
caused O 0 8.230163772715571e-10
by O 0 4.4270206944752033e-10
( O 0 4.878240478234375e-09
CTG O 0 1.0943412007691222e-06
) O 0 2.222388939543407e-10
n O 0 5.803250768821044e-09
- O 0 4.443773349294133e-09
repeat O 0 2.8259705686650705e-09
expansion O 0 2.8976254728974027e-09
in O 0 9.141878920537749e-11
a O 0 3.178910745749164e-10
gene O 0 1.4062971620543152e-10
encoding O 0 5.255091362066366e-10
a O 0 1.2123924086893112e-09
protein O 0 1.25690062802164e-08
kinase O 0 1.432909471077437e-07
( O 0 8.03044386543661e-09
DM B-Disease 1 0.9999978542327881
protein O 0 2.4175555779493152e-08
kinase O 0 2.1804872574193723e-08
; O 0 2.7123533974382497e-10
DMPK O 0 8.353611519851256e-06
) O 0 4.91162249760535e-11
and O 0 1.2257937720416834e-11
involves O 0 1.1495083357404567e-10
changes O 0 2.8260502271670873e-10
in O 0 7.452285455400443e-10
cytoarchitecture O 0 2.3343352495430736e-06
and O 0 2.7766621002456304e-08
ion O 0 4.467353210202418e-05
homeostasis O 0 2.519046756788157e-05
. O 0 1.144470957115118e-06

To O 0 1.0169146946736873e-07
obtain O 0 2.161230128194802e-07
clues O 0 1.297546532441629e-07
to O 0 1.0372436243244465e-09
the O 0 1.0772921443802375e-09
normal O 0 5.8212763498488584e-09
biological O 0 9.936930389642384e-09
role O 0 1.6150062398523346e-09
of O 0 1.7426089016225887e-08
DMPK O 0 0.42547285556793213
in O 0 5.157729354721141e-09
cellular O 0 2.1212919421031984e-08
ion O 0 1.7035234805007349e-06
homeostasis O 0 5.072919293525047e-07
, O 0 4.007787990367717e-10
we O 0 2.6830557220414164e-10
have O 0 2.2275865180221288e-11
compared O 0 5.211461817644647e-10
the O 0 4.830886801698853e-10
resting O 0 1.2345051203510593e-08
[ O 0 1.6837090610621885e-09
Ca2 O 0 2.3002777460590096e-09
+ O 0 6.1375731164048375e-09
] O 0 5.93029669815337e-09
i O 0 1.3384735542132375e-09
, O 0 2.582877661749805e-11
the O 0 3.736465650772125e-11
amplitude O 0 1.9046344501560952e-09
and O 0 2.7123624526947943e-11
shape O 0 3.81531339854746e-09
of O 0 8.57180815216907e-09
depolarization O 0 9.323070315758741e-08
- O 0 7.93479983940415e-08
induced O 0 1.565407217185566e-07
Ca2 O 0 7.883070196612607e-09
+ O 0 8.883737301346173e-09
transients O 0 1.1113201026091701e-08
, O 0 2.0322406951711613e-11
and O 0 1.1507757420592402e-11
the O 0 4.556791402543503e-11
content O 0 3.8449124439843274e-10
of O 0 2.0397101785363247e-09
ATP O 0 9.863832701739739e-07
- O 0 4.468866521278869e-08
driven O 0 1.4511718049448064e-08
ion O 0 1.0731955057963205e-07
pumps O 0 4.075518145185697e-09
in O 0 2.755613515148525e-10
cultured O 0 3.507259194179824e-08
skeletal O 0 3.1963146795987996e-08
muscle O 0 3.0375193471599005e-09
cells O 0 1.361404211586148e-09
of O 0 5.529616320387731e-09
wild O 0 1.4460981301311904e-09
- O 0 8.094163672645038e-10
type O 0 2.068234250529599e-09
and O 0 8.292578290713948e-10
DMPK O 0 5.678929665009491e-05
[ O 0 6.71765349125053e-07
- O 0 1.0530989129620139e-05
/ O 0 0.00014208188804332167
- O 0 7.618663221364841e-05
] O 0 5.706100637326017e-06
knockout O 0 0.0004164931015111506
mice O 0 6.498702873614093e-07
. O 0 8.698216902303102e-08

In O 0 3.284221747890115e-07
vitro O 0 2.0449722342164023e-06
- O 0 1.0646849659678992e-06
differentiated O 0 5.690888542631001e-07
DMPK O 0 0.001046710298396647
[ O 0 2.447113274683943e-06
- O 0 2.165584737667814e-05
/ O 0 8.363763481611386e-05
- O 0 1.7531341654830612e-05
] O 0 5.333517947292421e-07
myotubes O 0 1.4437337085837498e-06
exhibit O 0 1.3700341972011643e-09
a O 0 1.1813159339624235e-09
higher O 0 1.813274685957822e-08
resting O 0 1.2457456932679634e-07
[ O 0 1.3505836449212438e-08
Ca2 O 0 1.4086879218666581e-08
+ O 0 2.8571029986323992e-08
] O 0 2.603298199232995e-08
i O 0 6.8992642709986285e-09
than O 0 7.51305573309935e-10
do O 0 7.155674386361e-10
wild O 0 1.0310894360543443e-09
- O 0 1.0290501784027128e-09
type O 0 4.158517530328254e-09
myotubes O 0 1.5005025488790125e-06
because O 0 3.6241065703990216e-10
of O 0 1.0327900756834651e-09
an O 0 1.705892198333725e-11
altered O 0 1.7528846429915035e-10
open O 0 5.4847193453611e-10
probability O 0 4.925023500135239e-09
of O 0 3.776117640796883e-09
voltage O 0 4.029010597150773e-06
- O 0 1.9545171880963608e-07
dependent O 0 1.3687211364299401e-08
l O 0 4.019079236083911e-10
- O 0 6.302658950296802e-10
type O 0 7.217879627319235e-10
Ca2 O 0 9.909576492717065e-10
+ O 0 1.8271678614567577e-09
and O 0 4.954823218383808e-10
Na O 0 7.988862193997193e-08
+ O 0 1.2826029127666061e-08
channels O 0 3.659082281615156e-08
. O 0 4.006172105164296e-08

The O 0 2.196157538492116e-06
mutant O 0 7.159337201301241e-06
myotubes O 0 2.2380880182026885e-05
exhibit O 0 9.899303599070208e-09
smaller O 0 4.569608247351198e-09
and O 0 1.4600637365802527e-09
slower O 0 7.93917536157096e-08
Ca2 O 0 2.3628460965596787e-08
+ O 0 4.403132525254705e-09
responses O 0 1.4199867670594557e-10
upon O 0 2.1190818544347678e-10
triggering O 0 1.6473620245704979e-09
by O 0 1.7708495780865974e-10
acetylcholine O 0 9.176639537145093e-08
or O 0 1.301055352342928e-08
high O 0 9.23421197285279e-08
external O 0 5.825316975460737e-07
K O 0 3.4137681268475717e-06
+ O 0 4.399982458380691e-07
. O 0 9.047767690617547e-08

In O 0 1.912483860166958e-08
addition O 0 4.2462513505370225e-09
, O 0 1.653150394353986e-09
we O 0 1.1970385793702576e-09
observed O 0 2.037420010481128e-09
that O 0 1.7954792166929856e-11
these O 0 4.7148025067444976e-11
Ca2 O 0 2.4131882270239657e-08
+ O 0 7.470195129144486e-08
transients O 0 9.198105743735141e-08
partially O 0 3.159713601874614e-09
result O 0 3.4347907851284276e-10
from O 0 2.8282015618330547e-10
an O 0 2.7993163342898697e-11
influx O 0 9.644851584056369e-11
of O 0 3.2685790185560393e-10
extracellular O 0 2.1972776931278304e-09
Ca2 O 0 1.4171924744843523e-09
+ O 0 8.187747702059767e-10
through O 0 4.820032914465422e-11
the O 0 2.3266726045800823e-10
l O 0 8.991675737313187e-10
- O 0 1.7425316745089958e-09
type O 0 4.531548469799418e-09
Ca2 O 0 1.0002781714035791e-08
+ O 0 2.246830277385925e-08
channel O 0 1.0823143981042449e-07
. O 0 4.400019903982866e-08

Neither O 0 4.031483626931731e-07
the O 0 3.4207099375294092e-09
content O 0 2.637839946473264e-09
nor O 0 7.44554062848124e-09
the O 0 8.7817925153999e-10
activity O 0 2.7239679400992145e-09
of O 0 3.142741888950695e-08
Na O 0 5.231879640632542e-07
+ O 0 1.0001870265341495e-07
/ O 0 3.009259330610803e-07
K O 0 2.1781747250315675e-07
+ O 0 2.4506807250190832e-08
ATPase O 0 3.558056249630681e-08
and O 0 1.7583370315321645e-09
sarcoplasmic O 0 2.7952930281571753e-07
reticulum O 0 1.570474807977007e-07
Ca2 O 0 5.2534637973167264e-08
+ O 0 2.5874475895193427e-08
- O 0 1.4782421509096366e-08
ATPase O 0 1.8211844476923034e-08
are O 0 2.0657562466164237e-11
affected O 0 2.6641314154751683e-10
by O 0 1.0945659933980778e-09
DMPK O 1 0.6412912011146545
absence O 0 2.1402654965640977e-05
. O 0 1.3696909491045517e-06

In O 0 6.550860121024016e-08
conclusion O 0 3.4358041034465714e-07
, O 0 3.494163847150844e-09
our O 0 5.892949461738795e-10
data O 0 2.575897828371865e-10
suggest O 0 2.973681023643593e-10
that O 0 3.738104964456923e-11
DMPK O 0 0.03781616687774658
is O 0 4.2226652730015246e-10
involved O 0 1.6625062437825022e-10
in O 0 4.627968494541612e-11
modulating O 0 2.542545285422193e-09
the O 0 2.4031493461862397e-10
initial O 0 6.543910413547849e-10
events O 0 1.186364201322121e-10
of O 0 2.1854533738263626e-09
excitation O 0 4.200220701022772e-06
- O 0 9.749337550601922e-06
contraction O 0 3.891323103744071e-07
coupling O 0 1.6459180685046704e-08
in O 0 1.2993731646204765e-09
skeletal O 0 7.275440339071793e-08
muscle O 0 2.0778831100187745e-08
. O 0 1.5944905840115098e-08
. O 0 8.19620851189029e-08

Constitutional O 0 0.00013258930994197726
RB1 O 0 0.0021766379941254854
- O 0 9.195909115078393e-06
gene O 0 1.418577788570019e-08
mutations O 0 1.0115828175116803e-08
in O 0 2.9583271943245393e-10
patients O 0 3.243637580752079e-10
with O 0 1.200692184566421e-10
isolated O 0 1.6609252497801208e-06
unilateral B-Disease 0 0.49713796377182007
retinoblastoma I-Disease 1 0.9999997615814209
. O 0 8.324330701725557e-05

In O 0 9.726797856046687e-08
most O 0 2.75348166489664e-09
patients O 0 8.667950246454836e-10
with O 0 1.0778999914862197e-10
isolated O 0 4.379251947739249e-07
unilateral B-Disease 0 0.00061326491413638
retinoblastoma I-Disease 1 0.9999985694885254
, O 0 7.34647329636573e-08
tumor B-Disease 0 0.0016760341823101044
development O 0 1.1788248599486906e-08
is O 0 2.1884265233307332e-10
initiated O 0 1.3022909417514938e-09
by O 0 6.632318999555409e-11
somatic O 0 5.9266138663360834e-08
inactivation O 0 4.6746487214477384e-07
of O 0 5.287569937451053e-09
both O 0 1.887700551428395e-10
alleles O 0 1.719945852407534e-09
of O 0 1.2482615829867427e-08
the O 0 2.1805870886737466e-08
RB1 O 0 1.9762603187700734e-05
gene O 0 2.150949001133995e-07
. O 0 8.993090006015336e-08

However O 0 1.3092608242004644e-07
, O 0 1.2236388569064616e-09
some O 0 9.422076313603256e-11
of O 0 4.552331400731191e-09
these O 0 2.0549739687680812e-10
patients O 0 7.866079454466046e-10
can O 0 1.4975675144413003e-09
transmit O 0 3.6327614338915737e-07
retinoblastoma B-Disease 0 0.0002805828698910773
predisposition O 0 0.002574002370238304
to O 0 2.954569993107725e-07
their O 0 4.7740819297814596e-08
offspring O 0 2.99887119581399e-07
. O 0 1.2312369790379307e-07

To O 0 3.5713330071018845e-09
determine O 0 1.75535130875204e-09
the O 0 1.250455017309804e-10
frequency O 0 9.923993182781032e-09
and O 0 4.4730899539935365e-11
nature O 0 7.631310583455786e-10
of O 0 4.898492278471167e-09
constitutional O 0 1.707739556877641e-06
RB1 O 0 3.487171125016175e-05
- O 0 9.759448715840335e-08
gene O 0 6.314619382941089e-10
mutations O 0 9.959105762291642e-10
in O 0 4.212905024836289e-11
patients O 0 4.5775595119978973e-11
with O 0 2.447029037733195e-11
isolated O 0 5.199682391321403e-07
unilateral B-Disease 0 0.039571765810251236
retinoblastoma I-Disease 1 0.999974250793457
, O 0 1.778304437038969e-08
we O 0 2.726650238926709e-09
analyzed O 0 2.371423279967644e-09
DNA O 0 7.277880076372867e-09
from O 0 5.102724909278322e-10
peripheral O 0 2.2659392584500893e-07
blood O 0 1.559546092266828e-08
and O 0 1.8868662188253893e-09
from O 0 1.1396620180903483e-07
tumor B-Disease 0 7.437138992827386e-05
tissue O 0 7.970163096615579e-06
. O 0 8.08901461368805e-07

The O 0 2.128644283061476e-08
analysis O 0 1.0639054970340567e-08
of O 0 1.0020121408160776e-06
tumors B-Disease 1 1.0
from O 0 2.988684286719945e-07
54 O 0 9.173646731142071e-08
( O 0 3.1478497586334697e-10
71 O 0 2.6377758644002824e-08
% O 0 2.8036470922643275e-09
) O 0 6.348564035585369e-11
of O 0 1.6958533466393533e-09
76 O 0 6.329759116852074e-08
informative O 0 1.0537109851327386e-08
patients O 0 6.425079912553144e-10
showed O 0 5.758086785156991e-10
loss O 0 6.517009154549669e-09
of O 0 6.764958015992306e-08
constitutional O 0 0.00020640375441871583
heterozygosity O 1 0.9999921321868896
( O 0 1.5816649465705268e-06
LOH O 1 0.9999988079071045
) O 0 3.818050320347766e-09
at O 0 4.986275214946545e-08
intragenic O 0 2.5265198928536847e-06
loci O 0 1.3880795677323476e-06
. O 0 2.692979705898324e-07

Three O 0 3.345788357478341e-08
of O 0 4.301037961340626e-07
13 O 0 3.7052524248792906e-07
uninformative O 0 0.00012698248610831797
patients O 0 2.2162279122994732e-08
had O 0 6.292599152857292e-08
constitutional O 0 6.022934030625038e-06
deletions O 0 3.4932825656142086e-05
. O 0 1.8078067114402074e-06

For O 0 1.953559234380009e-07
39 O 0 4.884602731181076e-07
randomly O 0 2.1623304036211266e-08
selected O 0 6.561501209034759e-08
tumors B-Disease 1 1.0
, O 0 2.5680765247670934e-07
SSCP O 1 0.9999979734420776
, O 0 5.95849712681229e-07
hetero O 0 3.175816345901694e-06
- O 0 6.15363475731101e-08
duplex O 0 4.893246696724418e-08
analysis O 0 1.1259345678027444e-09
, O 0 1.3572189205834917e-10
sequencing O 0 2.8029305543242344e-09
, O 0 2.5919891233350256e-10
and O 0 1.4820687732619575e-10
Southern O 0 8.38340596942544e-09
blot O 0 1.0295988062125616e-07
analysis O 0 1.0431620012241183e-09
were O 0 1.3527633180299148e-10
used O 0 9.513269338956576e-11
to O 0 5.280108572591757e-10
identify O 0 1.2975461594066928e-08
mutations O 0 2.646520158577914e-07
. O 0 1.941172058650409e-07

Mutations O 0 2.037784497588291e-06
were O 0 2.693379741458557e-08
detected O 0 3.240091928091715e-08
in O 0 5.554433579746387e-10
21 O 0 7.147643810156978e-09
( O 0 3.2649652426108844e-10
91 O 0 1.4779827139932422e-08
% O 0 1.9012953433872326e-09
) O 0 2.051015052240146e-10
of O 0 3.5154229749423394e-08
23 O 0 1.3924541235610377e-05
tumors B-Disease 1 1.0
with O 0 4.474475645110942e-06
LOH O 1 1.0
. O 0 3.1086019589565694e-05

In O 0 1.0973995046015261e-07
6 O 0 2.1201640265644528e-07
( O 0 1.6404950731185863e-09
38 O 0 3.464626630034218e-08
% O 0 2.1010206907590145e-09
) O 0 7.9013517950699e-11
of O 0 1.0861936239336956e-08
16 O 0 2.8174688395665726e-06
tumors B-Disease 1 1.0
without O 0 3.432608718867414e-05
LOH O 1 1.0
, O 0 1.575609975823511e-09
one O 0 8.47426226413539e-11
mutation O 0 2.294501255661885e-10
was O 0 5.526145097078938e-10
detected O 0 5.53967427485702e-10
, O 0 1.4274074977560502e-11
and O 0 3.1275242812212056e-11
in O 0 1.903101148892361e-10
9 O 0 1.685705264264925e-08
( O 0 3.781420732096308e-10
56 O 0 9.637837194986787e-09
% O 0 5.882886955355104e-10
) O 0 2.9895801112456155e-11
of O 0 3.391915193162731e-09
the O 0 1.8027125747721584e-07
tumors B-Disease 1 1.0
without O 0 0.0003066424687858671
LOH O 1 1.0
, O 0 5.757606391654235e-09
both O 0 8.555208763638689e-10
mutations O 0 6.652825401687323e-09
were O 0 3.2638587388333917e-09
found O 0 6.5026810602830665e-09
. O 0 2.4725176572815144e-08

Thus O 0 2.325601826669299e-07
, O 0 1.0123910598736074e-09
a O 0 5.408829495401335e-10
total O 0 6.019754694719381e-10
of O 0 2.074611149538441e-09
45 O 0 5.815417036814097e-09
mutations O 0 9.123906075103605e-10
were O 0 2.423393152817255e-10
identified O 0 2.6265287722537778e-09
in O 0 2.454665137818779e-09
tumors B-Disease 1 1.0
of O 0 6.175869930302724e-05
36 O 0 1.0082551852974575e-05
patients O 0 3.563856409982691e-08
. O 0 2.7392491119826445e-07

Thirty O 0 3.0468509066849947e-06
- O 0 2.6911209261015756e-07
nine O 0 5.285592852288801e-09
of O 0 2.919855912608682e-09
the O 0 9.579771420575867e-10
mutations O 0 6.087348403127635e-09
- O 0 2.6694292998286073e-08
including O 0 8.224890768460114e-10
34 O 0 2.1747347034306586e-08
small O 0 7.056220052703566e-10
mutations O 0 2.49731506585249e-08
, O 0 1.873289967591063e-09
2 O 0 9.423904856475929e-08
large O 0 3.4548917060561735e-09
structural O 0 4.582056192248274e-07
alterations O 0 7.395680086119683e-07
, O 0 2.8501456750262832e-09
and O 0 1.2723515574464273e-09
hypermethylation O 0 0.0422847643494606
in O 0 5.9062450930014165e-08
3 O 0 7.769819785607979e-05
tumors O 1 1.0
- O 0 3.928701062250184e-07
were O 0 3.864073505610577e-09
not O 0 5.063884311873323e-10
detected O 0 2.2973662971992326e-09
in O 0 4.089093993964177e-11
the O 0 2.0229523611803302e-10
corresponding O 0 9.445423110321371e-09
peripheral O 0 1.5165024933594395e-06
blood O 0 2.8478439162427094e-07
DNA O 0 2.350983550059027e-06
. O 0 1.7781528072191577e-07

In O 0 7.52203845877375e-08
6 O 0 1.8795833511831006e-07
( O 0 9.094717201563185e-10
17 O 0 4.104992346043446e-09
% O 0 7.288392112059228e-10
) O 0 2.0678259451956116e-11
of O 0 9.09228914380833e-10
the O 0 1.5715970747010033e-09
36 O 0 2.897289697045835e-08
patients O 0 3.6684494331140627e-10
, O 0 5.134843591991789e-11
a O 0 4.692555233276607e-10
mutation O 0 2.3316417241403542e-08
was O 0 2.6781805217979127e-08
detected O 0 4.188416280470619e-09
in O 0 6.489515869123608e-11
constitutional O 0 2.1299763730553423e-08
DNA O 0 7.359417963925807e-08
, O 0 1.0280372386706205e-10
and O 0 2.7816565023597306e-11
1 O 0 1.6353288501136376e-08
of O 0 3.0906704973077126e-10
these O 0 4.998786974630409e-12
mutations O 0 2.9058372374990427e-10
is O 0 1.1399054443417267e-11
known O 0 3.092290659645336e-11
to O 0 3.521363409197953e-11
be O 0 1.7971417409778923e-10
associated O 0 1.955462680669484e-09
with O 0 1.0893502766506913e-10
reduced O 0 2.311783617869878e-07
expressivity O 0 5.8750607422553e-05
. O 0 7.726399076091184e-07

The O 0 2.6165247746234854e-08
presence O 0 1.010656669464538e-09
of O 0 1.787703429734222e-09
a O 0 1.8612723862165836e-10
constitutional O 0 2.206863669584891e-08
mutation O 0 5.949058135001906e-09
was O 0 5.582355133704198e-10
not O 0 3.5408394966074397e-12
associated O 0 1.2635810800465386e-11
with O 0 3.8236175835780484e-13
an O 0 1.2490932767283969e-11
early O 0 5.00197083752596e-09
age O 0 3.689813965479516e-08
at O 0 2.966783441138432e-08
treatment O 0 6.369737803879616e-08
. O 0 1.2843733543377311e-07

In O 0 1.9750798685436166e-07
1 O 0 9.286169188271742e-06
patient O 0 3.94293465433293e-07
, O 0 1.561349627365871e-08
somatic O 0 0.00041447055991739035
mosaicism O 1 0.9951533079147339
was O 0 8.969330167474254e-08
demonstrated O 0 4.769089012590655e-10
by O 0 3.128592176993017e-11
molecular O 0 1.2499359325346404e-09
analysis O 0 4.0820805069508026e-11
of O 0 1.6219696419295104e-10
DNA O 0 8.60855331463739e-10
and O 0 2.633418483277694e-11
RNA O 0 2.0786124821370322e-08
from O 0 3.012295302085022e-09
peripheral O 0 1.3681622021977091e-06
blood O 0 5.373349267756566e-07
. O 0 2.2996830750798836e-07

In O 0 5.455427753986442e-07
2 O 0 4.827538759855088e-06
patients O 0 3.743410026402216e-09
without O 0 2.0220201069065524e-09
a O 0 8.09521782940692e-09
detectable O 0 7.158722837630194e-06
mutation O 0 7.683458846940994e-08
in O 0 3.676589033219102e-10
peripheral O 0 9.858322300715372e-07
blood O 0 1.0071129707966975e-07
, O 0 1.7135115548683189e-09
mosaicism O 0 0.00019492220599204302
was O 0 2.4189624525661202e-08
suggested O 0 1.907353830432612e-09
because O 0 1.0655981652618607e-10
1 O 0 1.4129449610322808e-08
of O 0 7.457346962169709e-10
the O 0 4.138638876050038e-10
patients O 0 3.2928457183167836e-10
showed O 0 6.506228888980559e-09
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 4.1263152894543964e-08
the O 0 1.8813187452337843e-08
other O 0 1.8401634382936294e-10
later O 0 3.2463010057881547e-09
developed O 0 1.584401587706452e-08
bilateral B-Disease 0 1.5727300706203096e-05
retinoblastoma I-Disease 0 0.0011333476286381483
. O 0 2.4331693566637114e-06

In O 0 2.2383909836776184e-08
conclusion O 0 9.812870160885723e-08
, O 0 1.4928193126095834e-09
our O 0 3.4005742666209926e-10
results O 0 1.6632228927448978e-10
emphasize O 0 8.811876228698168e-10
that O 0 1.660135223735537e-11
the O 0 1.8718139538353995e-10
manifestation O 0 2.2106465991100777e-08
and O 0 1.443892644337197e-10
transmissibility O 0 3.579436906875344e-07
of O 0 3.844196072577688e-09
retinoblastoma B-Disease 0 2.946092365618824e-07
depend O 0 2.1650201631473465e-09
on O 0 3.4422362737984713e-09
the O 0 2.92878443719502e-10
nature O 0 3.854796204461053e-10
of O 0 5.331071140091126e-10
the O 0 4.707667589087805e-11
first O 0 7.197749340992488e-11
mutation O 0 1.9606005707828444e-10
, O 0 2.266764033420632e-12
its O 0 2.689190450183565e-12
time O 0 1.0305875597360625e-10
in O 0 2.4015903848928488e-11
development O 0 7.2050604371654e-10
, O 0 5.273423711593672e-11
and O 0 1.602222521324137e-11
the O 0 6.223455778497922e-11
number O 0 1.9400951331571825e-11
and O 0 4.61964060755049e-12
types O 0 7.274610774876678e-11
of O 0 1.456697984458799e-09
cells O 0 6.620947123892051e-10
that O 0 1.9741494897140832e-11
are O 0 3.619987296032967e-11
affected O 0 7.124460466023663e-10
. O 0 2.815721211746336e-09
. O 0 4.8635829585919055e-08

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9990639090538025
the I-Disease 0 8.632684512122069e-06
fifth I-Disease 0 5.477082822835655e-07
component I-Disease 0 4.385675467233341e-08
of I-Disease 0 1.2422715300886011e-08
complement I-Disease 0 1.540846894521053e-09
in O 0 3.4784704006085576e-09
man O 0 3.894218991717935e-07
. O 0 9.634752728970852e-08

I O 1 0.663662850856781
. O 0 2.1328551156329922e-05

Clinical O 0 7.91307320469059e-06
, O 0 2.0458324812011597e-08
immunochemical O 0 0.0003271928580943495
, O 0 9.076110529804282e-09
and O 0 3.63274565984284e-09
family O 0 6.180899347896229e-09
studies O 0 2.4102028817196697e-08
. O 0 1.0412666284764782e-07

The O 0 5.5847468871661476e-08
first O 0 4.4249888198066856e-09
recognized O 0 2.6102726646826113e-09
human O 0 3.2995617349484974e-09
kindred O 0 1.709641423985886e-07
with O 0 1.1107240682761699e-09
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999998807907104
the I-Disease 0 3.408216798561625e-05
fifth I-Disease 0 1.7676529751042835e-07
component I-Disease 0 1.7823623466028948e-08
of I-Disease 0 1.5493911931230286e-08
complement I-Disease 0 5.0875477164424865e-09
( O 0 7.575509108903589e-09
C5 O 0 0.04229363054037094
) O 0 7.551644864989271e-10
is O 0 8.466640721849217e-10
described O 0 2.2328602966581457e-08
. O 0 7.054934769712418e-08

The O 0 1.6140884895321506e-07
proband O 0 1.475267799833091e-05
, O 0 9.430350944583665e-10
a O 0 8.946768881301637e-10
20 O 0 3.2273228534052123e-09
- O 0 2.7178286288176423e-09
year O 0 9.791286670335353e-10
- O 0 3.013227711790023e-08
old O 0 1.5814880072184678e-08
black O 0 6.954883891019392e-10
female O 0 4.986743309953745e-11
with O 0 9.742046058747178e-11
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.3901291489601135
age O 0 0.0001084686882677488
11 O 0 1.1979255809535516e-08
, O 0 6.079591691188213e-11
lacked O 0 2.4265764952957625e-09
serum O 0 9.33343979880874e-09
hemolytic O 0 5.910882237003534e-07
complement O 0 1.2755322353896759e-09
activity O 0 7.719767936009703e-09
, O 0 1.7329089552209354e-10
even O 0 1.0896749058630917e-09
during O 0 3.333049392040266e-08
remission O 0 1.0872278153328807e-06
. O 0 1.5859440338772401e-07

C5 O 0 0.007931455038487911
was O 0 3.7793950014020083e-06
undetectable O 0 1.1296261845927802e-06
in O 0 1.8521223443812573e-09
her O 0 9.955189450572277e-11
serum O 0 1.1792448129099853e-09
by O 0 1.815529254711734e-10
both O 0 7.624898046287854e-09
immunodiffusion O 0 9.84686630545184e-05
and O 0 3.339107763622451e-07
hemolytic O 1 0.9993122816085815
assays O 0 0.00016667184536345303
. O 0 6.029359155945713e-06

Other O 0 4.418300836306344e-09
complement O 0 6.599777946370011e-10
components O 0 2.2248074493802505e-09
were O 0 4.3347253564363086e-10
normal O 0 8.390695915849733e-10
during O 0 1.2061648346772813e-09
remission O 0 2.8330635615247957e-08
of O 0 1.4788230195961205e-08
lupus O 0 1.4550071227859007e-06
, O 0 8.608767587681143e-10
but O 0 1.4494561106914716e-09
C1 O 0 1.2939597127115121e-06
, O 0 9.15605813389675e-09
C4 O 0 2.054580363619607e-05
, O 0 7.99294408437845e-09
C2 O 0 1.3372861076277331e-06
, O 0 6.9543837355467986e-09
and O 0 2.9708038695730465e-08
C3 O 0 0.0011322072241455317
levels O 0 2.0611093987099594e-06
fell O 0 0.00017878215294331312
during O 0 9.415187491867982e-07
exacerbations O 0 0.0002967352047562599
. O 0 7.928807121970749e-07

A O 0 1.4383040252141654e-06
younger O 0 4.023386424023556e-08
half O 0 3.661525838083435e-08
- O 0 1.4876303566779825e-07
sister O 0 3.436793249989023e-08
, O 0 5.496448296504752e-10
who O 0 2.11074890898999e-09
had O 0 7.992699835313033e-09
no O 0 8.83662298889476e-09
underlying O 1 0.8469239473342896
disease O 0 0.00036559035652317107
, O 0 3.6243694157001016e-10
was O 0 4.207739578987457e-08
also O 0 1.4662500380513421e-10
found O 0 2.0552873292167817e-10
to O 0 2.2823507528357823e-09
lack O 0 4.2044345605063427e-07
immunochemically O 0 0.003537942888215184
detectable O 1 0.9771293997764587
C5 O 1 0.9993354678153992
. O 0 2.5087549602176296e-06

By O 0 2.2457084014604334e-07
hemolytic O 1 0.8726977109909058
assay O 0 2.0908630176563747e-05
, O 0 2.8102340010605076e-08
she O 0 3.246088398078939e-10
exhibited O 0 1.86054116557699e-10
1 O 0 2.070844473678335e-08
- O 0 4.747980675290364e-09
2 O 0 1.1164466684476793e-08
% O 0 4.066323111562298e-10
of O 0 3.2768815438899423e-10
the O 0 3.6110103796005433e-10
normal O 0 7.512486632776927e-09
serum O 0 1.9676193119266827e-08
C5 O 0 2.1388916593423346e-06
level O 0 2.309097091313106e-08
and O 0 1.0222145352400958e-10
normal O 0 2.165309043178354e-09
concentrations O 0 2.506337359875488e-09
of O 0 3.081335187005152e-10
other O 0 2.3158816878088295e-11
complement O 0 4.411216669719664e-10
components O 0 3.353800437366772e-08
. O 0 5.0563421893912164e-08

C5 O 0 0.002149405423551798
levels O 0 1.0039541820106024e-07
of O 0 1.2230025880910489e-08
other O 0 5.216063692081718e-11
family O 0 5.7551192977900456e-11
members O 0 4.153533419981592e-12
were O 0 2.252559597182291e-11
either O 0 3.0653615756826014e-10
normal O 0 2.704533708097756e-09
or O 0 2.506450880179756e-10
approximately O 0 5.450503381965177e-10
half O 0 4.934576747217534e-09
- O 0 8.051363131755807e-09
normal O 0 1.4243956014681203e-09
, O 0 2.5974467368627963e-11
consistent O 0 1.9014430308050834e-10
with O 0 1.1942734128023158e-11
autosomal O 0 1.3787044395030534e-07
codominant O 0 5.0777284741343465e-06
inheritance O 0 5.553559390136797e-07
of O 0 3.786339064504318e-08
the O 0 3.888523281148082e-09
gene O 0 3.19435216056263e-08
determining O 0 9.169164513878059e-06
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.0492393812455703e-05

Normal O 0 0.00017309165559709072
hemolytic O 1 0.8858253359794617
titers O 0 3.8635382225038484e-05
were O 0 1.7955573028416438e-08
restored O 0 2.0365742869898895e-08
to O 0 3.2354339207785188e-09
both O 0 4.267646236399969e-09
homozygous O 0 2.2499837086797925e-06
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 1.3719406979362248e-06
C5D B-Disease 1 1.0
) O 0 1.1710552527688378e-08
sera O 0 4.64442315717406e-08
by O 0 2.390621901826595e-11
addition O 0 1.8420175107447534e-10
of O 0 1.274052152666627e-08
highly O 0 1.8876807672540963e-08
purified O 0 3.8409444869103027e-07
human O 0 3.0333816880556697e-07
C5 O 0 0.0012460829457268119
. O 0 1.407749891768617e-06

In O 0 3.844461815560862e-08
specific O 0 6.683403341867233e-08
C5 O 0 0.0005704119685105979
titrations O 0 1.0143930921913125e-05
, O 0 1.1216133577462983e-09
however O 0 5.038257588907413e-10
, O 0 2.4921198785166077e-11
it O 0 1.484390735329022e-11
was O 0 1.79857961857266e-09
noted O 0 7.121237627361054e-11
that O 0 3.1877295941784567e-12
when O 0 1.0467825391213825e-11
limited O 0 1.2420705089444262e-11
amounts O 0 5.339252928671101e-10
of O 0 1.1108602038234494e-08
C5 O 0 1.147371222032234e-05
were O 0 1.8435649673520516e-09
assayed O 0 1.90041156145071e-08
in O 0 2.7106091676776245e-11
the O 0 2.4088295594304476e-11
presence O 0 1.98031938070109e-11
of O 0 4.3305603547594274e-10
low O 0 9.841338410865319e-09
dilutions O 0 3.2548931017117866e-07
of O 0 2.4904510453893636e-08
either O 0 4.4794745690523996e-07
C5D B-Disease 1 1.0
serum O 0 1.224779907715856e-06
, O 0 9.002349421471934e-10
curving O 0 3.102941903421197e-08
rather O 0 1.905658270073829e-10
than O 0 5.890204296532531e-11
linear O 0 8.089938496880222e-09
dose O 0 5.546932513311731e-08
- O 0 1.1303002978024779e-09
response O 0 3.110106616688313e-11
plots O 0 6.868549617955466e-10
were O 0 7.843004024010725e-11
consistently O 0 3.004203552592344e-10
obtained O 0 3.0834457209749644e-10
, O 0 8.428224784751137e-11
suggesting O 0 1.2583776243246803e-09
some O 0 3.5253977515026236e-10
inhibitory O 0 2.926750255483057e-07
effect O 0 7.6145818184159e-07
. O 0 3.055115200822911e-07

Further O 0 5.453441431768624e-08
studies O 0 4.997631641856515e-09
suggested O 0 2.9962734515720513e-09
that O 0 1.1032511709752058e-10
low O 0 4.7793662361073075e-08
dilutions O 0 4.268896191206295e-06
of O 0 3.7974086808389984e-06
C5D B-Disease 1 1.0
serum O 0 7.93682914945748e-08
contain O 0 2.2299638524625465e-10
a O 0 7.535698454130824e-11
factor O 0 5.726652485549266e-10
( O 0 1.246889050343647e-11
or O 0 1.6566534255524346e-10
factors O 0 4.0761150010837355e-10
) O 0 2.1914661058053397e-11
interfering O 0 1.8842984950140362e-09
at O 0 2.1223673929426923e-09
some O 0 1.9327895187104538e-11
step O 0 4.631257599641003e-09
in O 0 1.1138209105032715e-10
the O 0 5.854656759396448e-10
hemolytic O 0 1.944122914210311e-06
assay O 0 1.2797931958630215e-07
of O 0 5.03594321799028e-07
C5 O 0 0.3476211130619049
, O 0 2.502533735793122e-10
rather O 0 1.2729675646916405e-10
than O 0 7.728746809210207e-11
a O 0 9.403624545711864e-10
true O 0 1.2732650489510888e-08
C5 O 0 5.038454219175037e-06
inhibitor O 0 1.1736495508785083e-07
or O 0 3.07571887958602e-08
inactivator O 0 8.981269274954684e-06
. O 0 2.408643240414676e-07

Of O 0 1.5292583839254803e-06
clinical O 0 1.981038167286897e-06
interest O 0 2.7971536198379e-08
are O 0 2.4568563850024816e-10
( O 0 2.1748444711811032e-10
a O 0 7.470872254167205e-10
) O 0 2.6625554191972434e-11
the O 0 4.286805285746986e-11
documentation O 0 2.453485636877417e-09
of O 0 1.2533097226707923e-08
membranous O 1 0.9105058908462524
glomerulonephritis B-Disease 1 1.0
, O 0 1.6484258935633989e-07
vasculitis B-Disease 1 1.0
, O 0 2.506357965614825e-08
and O 0 1.285696953345905e-07
arthritis B-Disease 1 1.0
in O 0 1.6766147581392943e-08
an O 0 3.0988339672077814e-10
individual O 0 1.292947277020673e-10
lacking O 0 1.4978232343310083e-07
C5 O 1 0.6082849502563477
( O 0 1.0435221575733067e-09
and O 0 8.317966454507442e-11
its O 0 5.1764398323328464e-11
biologic O 0 7.644804789208592e-09
functions O 0 4.184467702894601e-11
) O 0 7.554229811135293e-12
, O 0 1.1607441570415933e-11
and O 0 2.4109714225062362e-11
( O 0 1.402057497879028e-10
b O 0 4.4287120637420685e-09
) O 0 1.1788140776014533e-11
a O 0 8.578390775504374e-11
remarkable O 0 2.908926155509306e-10
propensity O 0 9.244821086440425e-08
to O 0 3.864146780330202e-09
bacterial B-Disease 1 1.0
infections I-Disease 1 0.6239438652992249
in O 0 1.493966339527475e-10
the O 0 2.762675921363922e-10
proband O 0 1.2845792696225544e-07
, O 0 2.955043501562393e-11
even O 0 3.9027933662616476e-11
during O 0 1.826090390011359e-10
periods O 0 9.332634665071282e-10
of O 0 6.522576923018164e-10
low O 0 9.544721457643845e-09
- O 0 1.5947909659530524e-09
dose O 0 3.953286142888146e-09
or O 0 5.184752072118215e-10
alternate O 0 2.5602493458620756e-09
- O 0 2.440614288445886e-08
day O 0 9.764883124319113e-09
corticosteroid O 0 2.2843653368909145e-06
therapy O 0 3.045893492981122e-07
. O 0 6.060820112452348e-08

Other O 0 1.0383605975050614e-08
observations O 0 1.665046411858384e-08
indicate O 0 2.3311423902327988e-09
that O 0 6.03366037688069e-11
the O 0 4.092312710923807e-09
C5D B-Disease 1 1.0
state O 0 3.833827477706109e-09
is O 0 2.7248447942440635e-10
compatible O 0 3.1699334268608936e-09
with O 0 1.7757259204720377e-11
normal O 0 3.0820774821194163e-09
coagulation O 0 6.314456868494744e-08
function O 0 1.1573541014442412e-09
and O 0 1.9430354894489632e-11
the O 0 8.048667288207412e-11
capacity O 0 1.8717960514891274e-10
to O 0 6.050350775943514e-10
mount O 0 5.28119244336267e-07
a O 0 1.4568327344477439e-07
neutrophilic O 0 0.0012802095152437687
leukocytosis O 0 8.180169243132696e-05
during O 0 8.125864496832946e-07
pyogenic B-Disease 0 9.886053157970309e-05
infection I-Disease 0 1.5045045529404888e-06
. O 0 5.6693192362899936e-08
. O 0 2.0422230306849087e-07

Susceptibility O 0 0.0006324960850179195
to O 0 1.1632807400019374e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 1.4437267054745462e-05
twins O 0 9.940421819010226e-08
: O 0 3.6815200193940356e-11
the O 0 5.704519148719278e-11
role O 0 1.0546872403205398e-10
of O 0 3.898837086513396e-10
genes O 0 3.0337313217110307e-10
, O 0 3.266933668033545e-10
HLA O 0 3.969900262745796e-06
, O 0 3.4679556448757864e-10
and O 0 4.25604412823688e-10
the O 0 1.828113482815752e-08
environment O 0 3.7928049323454616e-07
. O 0 3.147778500078857e-07

OBJECTIVE O 0 2.7098876671516337e-05
To O 0 3.3139799793246993e-09
determine O 0 2.2189929893556837e-09
the O 0 2.568435741867603e-10
relative O 0 1.104730529277731e-08
effects O 0 3.5966891687166935e-08
of O 0 1.6324616325391617e-08
genetic O 0 2.075435290294081e-08
and O 0 3.081022242890086e-11
environmental O 0 3.0358282554487914e-09
factors O 0 2.563942391731189e-10
in O 0 1.4270808493255238e-11
susceptibility O 0 2.4915390639534962e-08
to O 0 1.231751411978621e-07
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 1.3102418961352669e-05
AS B-Disease 1 1.0
) O 0 2.150579447857126e-08
. O 0 4.081222471086221e-08

METHODS O 0 4.8231304390355945e-06
Twins O 0 6.831867693790628e-08
with O 0 6.208493441572926e-11
AS B-Disease 1 0.999541163444519
were O 0 2.1895536772564839e-10
identified O 0 6.283043529897725e-11
from O 0 2.588707199990825e-11
the O 0 3.766173484187618e-11
Royal O 0 1.4927060476566112e-08
National O 0 3.5282945987091807e-07
Hospital O 0 3.8535072235390544e-05
for O 0 1.1411214728695995e-07
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 0.9999995231628418
database O 0 8.125639396894258e-06
. O 0 1.956224878085777e-06

Clinical O 0 1.029128998197848e-05
and O 0 8.124917627583272e-09
radiographic O 0 4.7085904952837154e-07
examinations O 0 1.2518448784248903e-06
were O 0 2.5148176874267847e-09
performed O 0 1.9407178641905887e-10
to O 0 4.2999565713630616e-11
establish O 0 2.8178110955678903e-09
diagnoses O 0 3.352129851919017e-06
, O 0 3.7577536637911635e-09
and O 0 1.0762802205022126e-08
disease O 0 0.00015109336527530104
severity O 0 0.06390590220689774
was O 0 8.578354737664995e-08
assessed O 0 1.8773398835492117e-08
using O 0 9.041407206256125e-11
a O 0 2.0122313537651593e-10
combination O 0 1.873097010829383e-09
of O 0 1.5727582791669192e-08
validated O 0 1.3971848034088907e-07
scoring O 0 6.765823457044462e-08
systems O 0 1.280907099499018e-06
. O 0 4.139859584029182e-07

HLA O 0 0.0001536000199848786
typing O 0 2.791499298382405e-07
for O 0 3.674377424545128e-08
HLA O 0 1.3218310414231382e-05
- O 0 6.96982908721111e-07
B27 O 0 2.6084730961883906e-06
, O 0 2.5098487732577723e-09
HLA O 0 2.9540601076405437e-07
- O 0 3.377062895992822e-08
B60 O 0 3.873735749948537e-07
, O 0 3.1280270040845437e-10
and O 0 1.9084271940528197e-09
HLA O 0 1.0758721145975869e-05
- O 0 9.721323976918939e-07
DR1 O 0 0.0026094994973391294
was O 0 2.284756206449856e-08
performed O 0 4.111413640095485e-11
by O 0 7.516745906266387e-12
polymerase O 0 6.134694530146589e-09
chain O 0 7.700499682350426e-10
reaction O 0 6.807806401942784e-11
with O 0 6.392266056753915e-12
sequence O 0 1.7187971879106811e-10
- O 0 1.856174380865383e-10
specific O 0 4.347209051069889e-11
primers O 0 4.52230120018271e-09
, O 0 1.112860983920605e-10
and O 0 2.933206455502102e-10
zygosity O 0 1.7802816500989138e-06
was O 0 9.607575179870764e-08
assessed O 0 1.647611895805312e-07
using O 0 1.8590744943480786e-08
microsatellite O 0 1.5382600395241752e-05
markers O 0 2.7213216071686475e-06
. O 0 4.3305155372763693e-07

Genetic O 0 7.744835784251336e-06
and O 0 3.0588449551061103e-09
environmental O 0 1.3281544752885566e-08
variance O 0 1.0763253399659334e-08
components O 0 1.690105499996264e-09
were O 0 1.1343146560927053e-10
assessed O 0 4.141033294047247e-09
with O 0 7.1916248997605514e-12
the O 0 4.952678822611745e-10
program O 0 3.7070646552450626e-10
Mx O 0 3.012566907045766e-08
, O 0 8.504925930186147e-12
using O 0 7.188593904167151e-12
data O 0 1.6760431584272872e-11
from O 0 1.4812371815220438e-11
this O 0 5.864261767157819e-12
and O 0 5.3133517551040566e-12
previous O 0 8.02051550174987e-11
studies O 0 5.856083673538848e-11
of O 0 3.907368595346128e-10
twins O 0 2.1875594669040765e-09
with O 0 2.8872521040668175e-10
AS B-Disease 1 0.999998927116394
. O 0 1.0523914397708722e-06

RESULTS O 0 2.2385290776583133e-06
Six O 0 8.931670691936233e-08
of O 0 1.887960365820618e-07
8 O 0 8.891706784197595e-07
monozygotic O 0 6.029623818903929e-06
( O 0 1.1468994642882535e-07
MZ O 0 0.00012274841719772667
) O 0 1.9360235636867174e-09
twin O 0 1.3462704728794961e-08
pairs O 0 3.3687092004797137e-10
were O 0 1.5930641250605504e-09
disease O 0 6.24672651383662e-08
concordant O 0 1.932698523887666e-06
, O 0 3.982877083696934e-10
compared O 0 7.634222143337865e-10
with O 0 1.4710451606836372e-11
4 O 0 1.765994284141925e-08
of O 0 8.799485584631839e-09
15 O 0 1.477915034797661e-08
B27 O 0 6.239069989533164e-07
- O 0 3.2365093716180127e-08
positive O 0 3.864661368702116e-10
dizygotic O 0 1.2840500573929603e-07
( O 0 3.2346316736209246e-09
DZ O 0 4.915744284517132e-06
) O 0 2.1272539285632774e-10
twin O 0 1.7359963466745398e-09
pairs O 0 1.138927407245971e-11
( O 0 3.93523442998589e-11
27 O 0 2.646058705479959e-09
% O 0 9.469571793374598e-10
) O 0 1.0966211445861962e-11
and O 0 4.752868237867247e-11
4 O 0 1.982019171009597e-08
of O 0 3.2384111392502746e-08
32 O 0 2.1743412048635946e-07
DZ O 0 2.029962524829898e-05
twin O 0 1.4704694351053149e-08
pairs O 0 1.9949730756252393e-10
overall O 0 1.338067767697737e-09
( O 0 3.3576311175842477e-10
12 O 0 4.562989097678383e-09
. O 0 2.781880559243888e-10
5 O 0 2.56715519952877e-08
% O 0 1.338596788968971e-08
) O 0 3.640291845741217e-09
. O 0 7.738848495364437e-08

Nonsignificant O 0 0.0018360305111855268
increases O 0 1.2908594726468436e-07
in O 0 4.657734198332264e-10
similarity O 0 5.074945463867664e-10
with O 0 6.915893639020121e-12
regard O 0 2.5249591306675256e-09
to O 0 7.495249976230411e-10
age O 0 7.931244283554406e-08
at O 0 3.165222395296041e-08
disease O 0 6.521550233173912e-08
onset O 0 2.005837086471729e-05
and O 0 2.5575683237910596e-10
all O 0 1.9880370960567717e-10
of O 0 6.714397926543825e-09
the O 0 4.600259284615049e-09
disease O 0 5.3841421987499416e-08
severity O 0 1.6852078488227562e-07
scores O 0 1.136010618907335e-09
assessed O 0 1.9542182982945633e-08
were O 0 4.1142400597493634e-10
noted O 0 8.058333444971311e-10
in O 0 1.348459344185926e-09
disease O 0 4.6348301907528366e-07
- O 0 1.307914544668165e-06
concordant O 0 0.00018408760661259294
MZ O 0 0.0008641750318929553
twins O 0 8.189254430135406e-08
compared O 0 8.418417074551598e-09
with O 0 1.4318318752870596e-09
concordant O 0 0.00041013749432750046
DZ O 1 0.9988238215446472
twins O 0 5.766192771261558e-06
. O 0 6.097670279814338e-07

HLA O 0 0.0020231918897479773
- O 0 1.409022297593765e-05
B27 O 0 1.6898709873203188e-05
and O 0 1.7341497127176808e-09
B60 O 0 1.0174303497478832e-06
were O 0 2.830748968563057e-10
associated O 0 2.7496385723857486e-10
with O 0 4.84740329473321e-12
the O 0 1.471144761566734e-09
disease O 0 3.8236930066659625e-08
in O 0 3.191072406316664e-10
probands O 0 9.235466677637305e-06
, O 0 1.7213626357648337e-10
and O 0 4.036585649069835e-11
the O 0 2.525540609976673e-10
rate O 0 7.237928034697916e-09
of O 0 2.1707355912781168e-08
disease O 0 1.5947377107750071e-07
concordance O 0 3.072974763540515e-08
was O 0 6.012126796406392e-09
significantly O 0 6.791727735766528e-10
increased O 0 1.1452021553282066e-09
among O 0 8.937575679546228e-10
DZ O 0 1.1036058822355699e-05
twin O 0 8.288897568320408e-09
pairs O 0 2.267119651733207e-11
in O 0 4.612984473573167e-12
which O 0 4.074999452458039e-12
the O 0 1.1173253294805008e-10
co O 0 8.93505325283428e-10
- O 0 3.6239078404776137e-09
twin O 0 1.7418803066604482e-09
was O 0 2.021117717632137e-09
positive O 0 3.00098904060242e-11
for O 0 4.8348661879638044e-11
both O 0 1.3372182250392939e-09
B27 O 0 2.896547084674239e-05
and O 0 1.8609871688113344e-07
DR1 O 1 0.9994353652000427
. O 0 3.1069803299033083e-06

Additive O 0 4.403178081702208e-06
genetic O 0 2.405074042144406e-07
effects O 0 7.189964890130796e-08
were O 0 5.496878507926795e-10
estimated O 0 3.56823320890598e-10
to O 0 3.578093030198737e-11
contribute O 0 3.552749205937289e-10
97 O 0 1.1346231509890004e-08
% O 0 9.645849674555507e-10
of O 0 8.494883685372656e-10
the O 0 1.2387075809527914e-09
population O 0 6.069930669205803e-10
variance O 0 2.0891579310955422e-07
. O 0 2.4696456080164353e-07

CONCLUSION O 0 7.90956401033327e-05
Susceptibility O 0 0.00048240734031423926
to O 0 4.7683663240150054e-08
AS B-Disease 1 1.0
is O 0 1.3008164545524892e-09
largely O 0 7.803465096323237e-10
genetically O 0 1.280013595117424e-10
determined O 0 9.878438067545403e-10
, O 0 3.539281367981317e-11
and O 0 3.303500528684111e-11
the O 0 6.195330914948727e-10
environmental O 0 2.3899689338691132e-08
trigger O 0 3.786129454397269e-08
for O 0 4.835901679101084e-10
the O 0 1.0960206076049417e-08
disease O 0 4.130835975502123e-07
is O 0 1.3010322819084763e-09
probably O 0 1.2670201954279037e-07
ubiquitous O 0 3.001051140927302e-07
. O 0 2.518561643682915e-07

HLA O 0 0.003958636429160833
- O 0 8.54116296977736e-06
B27 O 0 1.808113552215218e-06
accounts O 0 1.7682304231936286e-10
for O 0 1.2955485642618392e-11
a O 0 8.365284853706356e-11
minority O 0 1.8039794658086805e-10
of O 0 9.051746574506581e-10
the O 0 5.45507916616117e-10
overall O 0 7.2075376778002465e-09
genetic O 0 1.2616423816780298e-07
susceptibility O 0 3.700111165017006e-06
to O 0 1.8111771282747213e-07
AS B-Disease 1 1.0
. O 0 2.9493858164642006e-06

Cell O 0 1.6047708413680084e-05
cycle O 0 1.607089075150725e-06
- O 0 2.0207492923418613e-07
dependent O 0 8.79643522466722e-08
colocalization O 0 3.2129944429470925e-06
of O 0 3.7042772760287335e-07
BARD1 O 1 0.7029431462287903
and O 0 3.5805083342665966e-08
BRCA1 O 0 8.363477377315576e-08
proteins O 0 2.7299168481320635e-10
in O 0 1.0471464667594077e-10
discrete O 0 3.821819305471763e-08
nuclear O 0 2.840276010829257e-06
domains O 0 4.912374606647063e-06
. O 0 3.565577344488702e-07

Germ O 0 7.968380668899044e-05
- O 0 8.306664653900953e-07
line O 0 7.914213995263708e-08
mutations O 0 4.764346250851759e-09
of O 0 4.35051461522562e-09
the O 0 9.338172457518112e-10
BRCA1 O 0 1.2333048360346766e-08
gene O 0 8.00447319537767e-10
predispose O 0 6.809582231426248e-08
women O 0 1.695279160107699e-11
to O 0 1.0681051876293424e-10
early O 0 4.5162263972997607e-07
- O 0 1.85338722076267e-05
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 3.958781036317305e-08
compromising O 0 1.8117540889761585e-07
the O 0 1.4800469738673883e-09
genes O 0 1.2424699047386412e-09
presumptive O 0 4.907088424488393e-08
function O 0 2.1253965254430796e-10
as O 0 3.5024406985773027e-11
a O 0 8.144804830578778e-10
tumor B-Disease 0 1.5551341903119464e-06
suppressor O 0 1.9130231521558017e-05
. O 0 4.0497641862202727e-07

Although O 0 1.0399804040162053e-07
the O 0 1.3782095464875965e-08
biochemical O 0 2.003183112719853e-07
properties O 0 2.770568414689478e-07
of O 0 3.049244412522967e-07
BRCA1 O 0 7.683017884119181e-07
polypeptides O 0 4.588962987384093e-09
are O 0 1.0392229611577708e-11
not O 0 3.5965740802224033e-11
understood O 0 1.9008239426909768e-09
, O 0 3.255437239224612e-11
their O 0 4.827234098558897e-12
expression O 0 2.5563393069027995e-10
pattern O 0 4.861576918813171e-09
and O 0 1.3173247215281236e-10
subcellular O 0 4.057696969539393e-07
localization O 0 1.6249525458533753e-07
suggest O 0 1.727448295518741e-09
a O 0 6.055314583086613e-10
role O 0 1.4958604355186367e-09
in O 0 6.170412514272527e-10
cell O 0 1.349417715346135e-07
- O 0 1.1706805480571347e-07
cycle O 0 3.9908053395265597e-07
regulation O 0 6.508838055196975e-07
. O 0 1.6822178849906777e-07

When O 0 6.727988761667802e-07
resting O 0 2.7886096631846158e-06
cells O 0 5.392495339151537e-09
are O 0 1.3070083904054286e-10
induced O 0 7.86272664754506e-08
to O 0 8.91299367644649e-10
proliferate O 0 7.764453080483236e-09
, O 0 4.6507631079606426e-11
the O 0 1.7183775236073728e-10
steady O 0 2.6290700727571448e-09
- O 0 3.052269270664709e-10
state O 0 7.994063050409395e-11
levels O 0 3.363964384828222e-10
of O 0 3.57743279444378e-10
BRCA1 O 0 1.8675960777869705e-09
increase O 0 1.9440707377249566e-10
in O 0 2.1897959834316083e-10
late O 0 2.7544609793039854e-07
G1 O 0 1.23512506888801e-07
and O 0 2.94854626825547e-11
reach O 0 8.459924982773259e-10
a O 0 1.588984777090019e-10
maximum O 0 1.494782964073238e-08
during O 0 2.0530718458644515e-08
S O 0 2.0002576093247626e-06
phase O 0 3.046182655452867e-06
. O 0 2.497110926924506e-07

Moreover O 0 2.5149640805466333e-06
, O 0 2.0465504846356453e-08
in O 0 6.780962014119041e-09
S O 0 3.9428732634405605e-06
phase O 0 3.428207946853945e-06
cells O 0 1.6785152823217686e-08
, O 0 1.1326980464687608e-09
BRCA1 O 0 4.0493308262057326e-08
polypeptides O 0 9.269606415784892e-09
are O 0 1.795212867250484e-10
hyperphosphorylated O 0 3.6041339512848936e-07
and O 0 2.447390956561435e-09
accumulate O 0 2.276721566829565e-08
into O 0 5.298574023981928e-09
discrete O 0 1.2030653806505143e-07
subnuclear O 0 6.367542937368853e-06
foci O 0 1.8645628188096453e-06
termed O 0 7.39531344606803e-07
" O 0 2.8609267133106187e-07
BRCA1 O 0 9.92077730188612e-07
nuclear O 0 1.8532688045524992e-05
dots O 0 7.997893590072636e-06
. O 0 9.661598596721888e-07

" O 0 3.4944485378218815e-05
BRCA1 O 0 5.59315703867469e-05
associates O 0 3.3698104289214825e-06
in O 0 3.334142917310601e-08
vivo O 0 6.614502581214765e-07
with O 0 2.3148273575746003e-10
a O 0 2.6385610141232974e-08
structurally O 0 1.9815483938145917e-06
related O 0 1.7966847565276112e-07
protein O 0 1.2286300261621363e-06
termed O 0 9.146108823188115e-06
BARD1 O 1 0.9984737038612366
. O 0 2.096411662932951e-06

Here O 0 1.7746053515566018e-07
we O 0 2.16854956214263e-09
show O 0 1.5792465946073975e-10
that O 0 1.0678112907780424e-11
the O 0 1.5136047970543132e-10
steady O 0 4.413272414183211e-09
- O 0 1.0911350711850787e-09
state O 0 2.0547544221649616e-10
levels O 0 1.275962890900928e-09
of O 0 5.7541371667468866e-09
BARD1 O 0 0.0611308254301548
, O 0 1.595404641729914e-10
unlike O 0 1.1181013059857747e-10
those O 0 3.631175915508322e-11
of O 0 2.77116352087603e-09
BRCA1 O 0 7.180426564445952e-08
, O 0 2.035710072734176e-10
remain O 0 7.1309047555701e-10
relatively O 0 2.346214056370144e-10
constant O 0 4.318799984304178e-09
during O 0 1.02276160873771e-08
cell O 0 3.23104217159198e-07
cycle O 0 4.5089879563420254e-07
progression O 0 1.1686119023579522e-06
. O 0 1.0140404782532642e-07

However O 0 4.7180481033137767e-07
, O 0 2.521634634433667e-08
immunostaining O 0 9.174858860205859e-05
revealed O 0 3.941783859318093e-07
that O 0 4.874836534440874e-09
BARD1 O 0 0.16717760264873505
resides O 0 7.252953082570457e-08
within O 0 3.083983912688382e-08
BRCA1 O 0 3.1238630526786437e-07
nuclear O 0 3.074533651670208e-06
dots O 0 6.841086275244379e-08
during O 0 1.4666263759011144e-08
S O 0 9.344754658968668e-08
phase O 0 3.2607491817771006e-08
of O 0 1.2359817613827317e-09
the O 0 2.954064493021491e-10
cell O 0 2.6010733567005673e-09
cycle O 0 1.1259603249769157e-09
, O 0 1.0728598565101777e-11
but O 0 1.45645197291433e-11
not O 0 1.0684556017714897e-10
during O 0 9.381218468718089e-09
the O 0 1.284605577467346e-08
G1 O 0 1.690993485681247e-06
phase O 0 1.7687975741864648e-06
. O 0 1.309627890577758e-07

Nevertheless O 0 1.4648263459093869e-05
, O 0 5.971410388383447e-08
BARD1 O 0 0.00040716922376304865
polypeptides O 0 5.147540349526025e-08
are O 0 6.502202942737512e-11
found O 0 2.850447308744286e-11
exclusively O 0 5.6187790531403436e-11
in O 0 1.7099804211495595e-11
the O 0 1.939182286969654e-10
nuclear O 0 4.332812153506893e-08
fractions O 0 2.34776074137244e-08
of O 0 5.3219708640028784e-09
both O 0 7.806055801751199e-10
G1 O 0 2.2657900444755796e-07
- O 0 2.2452537606909573e-08
and O 0 1.4600552988852655e-09
S O 0 6.299816277532955e-07
- O 0 7.508936050726334e-08
phase O 0 6.291710974437592e-07
cells O 0 3.5939461184852917e-08
. O 0 2.0705048342506416e-08

Therefore O 0 6.274597694755357e-07
, O 0 1.0082120027732344e-08
progression O 0 1.3924918107477424e-07
to O 0 3.3020171041897584e-09
S O 0 8.321896984853083e-07
phase O 0 5.004483227821765e-07
is O 0 3.2433777885643167e-10
accompanied O 0 2.0727589089553078e-10
by O 0 4.182225399329553e-11
the O 0 7.108958977042334e-10
aggregation O 0 1.1664653243315115e-08
of O 0 9.582791449247452e-09
nuclear O 0 4.250550318829482e-06
BARD1 O 0 0.0003444720059633255
polypeptides O 0 1.403308971248407e-07
into O 0 8.602358292364443e-08
BRCA1 O 0 5.830112854710023e-07
nuclear O 0 6.259109341044677e-06
dots O 0 3.0514308946294477e-06
. O 0 3.366914427260781e-07

This O 0 4.5136516746424604e-08
cell O 0 3.3097370533141657e-07
cycle O 0 2.2258682008668984e-07
- O 0 3.746683674421547e-08
dependent O 0 2.2200694616003602e-08
colocalization O 0 9.585954785507056e-07
of O 0 9.499139252966415e-08
BARD1 O 1 0.9882140159606934
and O 0 3.0250195681702507e-09
BRCA1 O 0 2.352440375830156e-08
indicates O 0 3.1478616935309844e-10
a O 0 5.3458123344674036e-11
role O 0 1.84800688640685e-10
for O 0 1.5222470506337515e-10
BARD1 O 0 0.0006450932123698294
in O 0 1.46039589310476e-08
BRCA1 O 0 1.228995643032249e-06
- O 0 1.9285337202745723e-06
mediated O 0 0.0004931676667183638
tumor B-Disease 1 0.999909520149231
suppression O 0 0.0009037903510034084
. O 0 1.1617181598921889e-06

Ethnic O 0 1.7171659010273288e-06
differences O 0 4.0278595747622603e-07
in O 0 1.0744424905340111e-08
the O 0 2.9562938763660895e-08
HFE O 0 2.7587735530687496e-05
codon O 0 2.658931407495402e-06
282 O 0 1.061714101524558e-06
( O 0 1.3611470706109685e-07
Cys O 0 0.0004513878666330129
/ O 0 5.968444384052418e-05
Tyr O 0 3.816791650024243e-05
) O 0 3.023094308218788e-08
polymorphism O 0 2.399361164862057e-06
. O 0 3.2881550282581884e-07

Recent O 0 3.0102349057870015e-08
studies O 0 2.8888347269884207e-09
have O 0 4.2117559440058017e-11
shown O 0 1.5955263499289885e-10
that O 0 1.2165765284066765e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9579336643218994
HH B-Disease 1 1.0
) O 0 1.6591048535019581e-09
is O 0 1.4911252788074592e-10
likely O 0 2.309596819349835e-10
to O 0 3.881369184388639e-11
be O 0 1.0343113865385334e-10
caused O 0 7.437829241396798e-10
by O 0 5.3233664004670445e-11
homozygosity O 0 1.4514159829559503e-07
for O 0 1.4248731361465872e-10
a O 0 1.4945655824050164e-09
Cys282Tyr O 0 1.0112183872479363e-06
mutation O 0 8.961033692855835e-09
in O 0 7.246047095677e-10
the O 0 6.3249414594679365e-09
HFE O 0 5.4139381973072886e-05
gene O 0 9.234070574848374e-08
located O 0 1.7675890262580651e-07
4 O 0 1.1553506737982389e-06
. O 0 2.0094073249765643e-07

5 O 0 2.068113099085167e-05
Mb O 0 0.00011678406735882163
telomeric O 0 2.9489579901564866e-05
to O 0 1.3989849776407937e-06
HLA O 0 0.0003899867879226804
- O 0 5.336648882803274e-06
A O 0 4.9847290028992575e-06
. O 0 5.69607948364137e-07

Population O 0 1.186216103121751e-08
studies O 0 9.188278471405908e-10
of O 0 6.103202943030794e-10
this O 0 2.6076276554709565e-11
polymorphism O 0 4.828935917799981e-09
are O 0 4.458284002389901e-12
facilitated O 0 1.6748233355734499e-10
by O 0 1.4224719492583748e-11
the O 0 9.421034091738889e-11
fact O 0 5.4539529142916265e-11
that O 0 1.6650186437927594e-11
the O 0 5.798246882626756e-10
Cys282Tyr O 0 1.0194116839556955e-06
mutation O 0 2.4337994730672108e-08
creates O 0 6.5135421500883695e-09
a O 0 1.59433550805943e-08
Rsal O 0 1.6596346540609375e-05
restriction O 0 4.869087320003018e-07
site O 0 1.935646594120044e-07
. O 0 1.1325791859917445e-07

We O 0 1.5265263186847733e-07
have O 0 7.191275352980142e-10
studied O 0 2.5716639484585357e-08
the O 0 2.750563110609505e-09
codon O 0 9.151120394790269e-08
282 O 0 1.235465418858439e-07
( O 0 4.364546413171411e-08
Cys O 0 0.00041410033009015024
/ O 0 2.504153235349804e-05
Tyr O 0 5.024739948567003e-06
) O 0 2.206263644000117e-10
polymorphism O 0 2.4893147543281202e-09
in O 0 1.3365791980135544e-11
different O 0 5.973517253760052e-12
ethnic O 0 8.014586772020493e-10
groups O 0 4.924006757889288e-10
. O 0 9.331838413118021e-09

In O 0 1.8112698896288748e-08
agreement O 0 5.2560494623321574e-08
with O 0 6.771381233505736e-10
previous O 0 1.720228759438669e-08
observations O 0 1.06113517972517e-08
the O 0 1.9865749045777648e-09
Tyr O 0 3.2108087566484755e-07
allele O 0 1.2320493958384304e-08
appeared O 0 1.9036165699315433e-10
to O 0 1.5062171995761098e-11
be O 0 7.715667688090733e-11
rare O 0 4.212111492929438e-10
or O 0 1.825190310000835e-08
absent O 0 3.134238681923307e-07
in O 0 6.098199167858809e-10
Asiatic O 0 1.4023184391476207e-08
( O 0 1.7568609067541985e-10
Indian O 0 8.867379608368253e-10
, O 0 1.498409729627781e-10
Chinese O 0 2.749843130978036e-10
) O 0 6.489939141651746e-10
populations O 0 4.2027243907227785e-09
. O 0 2.379185204404166e-08

The O 0 1.3599493797755713e-07
highest O 0 1.6992481732813758e-07
allele O 0 1.2133924975898935e-08
frequency O 0 3.248842261882601e-08
( O 0 3.729802855456654e-10
7 O 0 5.0927515538035095e-09
. O 0 6.422602033540059e-11
5 O 0 1.869756127703681e-09
% O 0 1.1132373911593163e-09
) O 0 7.131934626203318e-11
was O 0 1.0569094932577627e-08
found O 0 8.582355381925311e-10
in O 0 3.5339224879749054e-09
Swedes O 0 3.26727263200155e-06
. O 0 7.22157608379348e-07

Saamis O 0 0.0003478347207419574
( O 0 6.220783177468547e-08
2 O 0 8.166916245500033e-07
% O 0 3.636268885998106e-08
) O 0 1.3933533493659667e-10
and O 0 2.308486873880966e-10
Mordvinians O 0 7.365104011114454e-07
( O 0 6.1344335167135e-10
1 O 0 1.98353191649403e-08
. O 0 7.07629857488179e-11
8 O 0 2.69653943618664e-09
% O 0 6.470385893742048e-10
) O 0 2.1569680069832842e-11
had O 0 2.577947300075323e-10
significantly O 0 3.0247640503411333e-10
lower O 0 1.2541508942476298e-09
frequencies O 0 7.568274007496711e-09
of O 0 9.950377410916644e-09
the O 0 2.490745565353336e-08
Tyr O 0 9.681201845523901e-06
allele O 0 2.486247240085504e-06
. O 0 1.7305234223385924e-07

Comparisons O 0 4.698256077517726e-07
with O 0 9.601429651340254e-10
allele O 0 2.5772274980795373e-08
frequencies O 0 8.498939330081612e-09
based O 0 4.697829902866602e-10
on O 0 5.736165764602674e-09
prevalence O 0 2.9671285872723274e-08
estimates O 0 1.5212725523738868e-09
of O 0 4.36025295869058e-08
HH B-Disease 1 0.9997827410697937
showed O 0 2.6722718260430156e-08
some O 0 2.3532817361449077e-10
disagreements O 0 5.329693664180013e-08
with O 0 4.973900111227003e-11
the O 0 2.0812773726675005e-09
RFLP O 0 1.998654965973401e-07
data O 0 1.0570723185665543e-09
, O 0 1.6699046312407262e-10
particularly O 0 2.0988819571243766e-09
in O 0 8.649193361520702e-09
Finns O 0 1.3568057966040215e-06
. O 0 1.550661608007431e-07

The O 0 6.273531880651717e-07
newly O 0 2.9052230843262805e-07
described O 0 2.3434127172095032e-07
HFE O 0 0.0003869932552333921
marker O 0 6.614168341911864e-07
provides O 0 1.5512170714604423e-10
a O 0 1.033286026186353e-10
new O 0 1.558699176673617e-11
approach O 0 3.7863787105685276e-10
to O 0 3.470050982667949e-11
the O 0 5.7510808615379716e-11
screening O 0 6.483727998940481e-10
of O 0 4.946865139743295e-09
HH B-Disease 0 0.02467595599591732
as O 0 1.2804513005448825e-09
well O 0 9.270464257360445e-11
as O 0 2.6310287282171885e-11
studies O 0 8.08075412139786e-11
of O 0 2.0765975050629493e-10
the O 0 1.8061761808407795e-10
relationship O 0 6.726315060490151e-10
between O 0 1.0992488697070257e-08
the O 0 2.546934396718825e-08
HFE O 0 8.617312414571643e-05
Tyr O 0 3.962853043049108e-06
allele O 0 6.056567514178823e-08
and O 0 1.8914560195870678e-10
different O 0 8.9348828336e-10
disorders O 0 0.00027076504193246365
including O 0 4.424079520504165e-07
cancer B-Disease 1 0.9999995231628418

Autosomal B-Disease 1 0.9999992847442627
dominant I-Disease 1 0.9999998807907104
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999974966049194
associated O 0 7.644005961537914e-08
with O 0 1.8218773711886627e-10
a O 0 5.109193956798208e-09
missense O 0 4.3193131205043755e-07
mutation O 0 1.8270922552687807e-08
encoding O 0 4.293882227557333e-08
Gly23 O 0 3.617162292357534e-05
- O 0 6.859175300633069e-06
- O 0 2.759645894911955e-06
> O 0 5.094035259389784e-06
Val O 0 4.737055974146642e-07
in O 0 1.3619295025080191e-08
neurophysin O 0 5.04765375808347e-05
II O 1 0.999922513961792
. O 0 7.016399194981204e-06

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 1.518557724011771e-07
ADNDI B-Disease 1 0.9999998807907104
) O 0 1.9925013028387895e-10
is O 0 1.1042343428524504e-10
an O 0 8.120947248002608e-10
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 8.086762136372272e-06
by O 0 6.436097876871827e-09
progressive O 1 0.9999876022338867
degeneration O 1 1.0
of O 0 0.012082870118319988
the O 0 1.2633978485609987e-07
magnocellular O 0 1.6040925174820586e-06
neurons O 0 1.4129718728383978e-08
of O 0 9.629975750158337e-08
the O 0 1.3098097717545443e-08
hypothalamus O 0 3.596161377572571e-07
leading O 0 1.7593977830188123e-08
to O 0 6.837766464151684e-10
decreased O 0 6.55983489750156e-09
ability O 0 5.914453649058515e-11
to O 0 1.3734242909624328e-10
produce O 0 8.088268388384279e-10
the O 0 5.81063863691611e-09
hormone O 0 5.6928510794307385e-09
arginine O 0 3.490008992912408e-08
vasopressin O 0 4.113734917154943e-07
( O 0 5.646376521895036e-08
AVP O 0 1.7664377082837746e-05
) O 0 1.6365456545486268e-08
. O 0 7.985617855865712e-08

Affected O 0 1.8172639215663366e-07
individuals O 0 9.916419907440854e-10
are O 0 8.923365518720416e-11
not O 0 9.336070805332497e-10
symptomatic O 0 1.6171914012375055e-06
at O 0 1.938031175541255e-07
birth O 0 3.575928886334623e-08
, O 0 1.1565304269822718e-10
but O 0 1.1359991419768178e-10
usually O 0 1.703042706857616e-09
develop O 0 3.28007445205003e-07
diabetes B-Disease 1 1.0
insipidus I-Disease 1 0.9998838901519775
at O 0 7.675118467886932e-06
1 O 0 2.938553734566085e-05
- O 0 4.755660029331921e-06
6 O 0 2.3812929157429608e-06
yr O 0 1.793282717699185e-05
of O 0 1.1481251505074397e-07
age O 0 3.443394405167055e-07
. O 0 7.451809125313957e-08

The O 0 2.498167894771086e-08
genetic O 0 1.5783840012772998e-08
locus O 0 6.047125111763307e-08
of O 0 1.988395581520308e-08
the O 0 1.8042840110865654e-08
disease O 0 5.388788395066513e-06
is O 0 2.540519128402252e-09
the O 0 5.152609361402938e-08
AVP O 0 0.00020485643472056836
- O 0 1.300202711718157e-06
neurophysin O 0 0.00390984769910574
II O 1 1.0
( O 0 5.553602022700943e-08
NPII O 1 0.5332151055335999
) O 0 5.201213904015844e-10
gene O 0 5.628478239039225e-10
, O 0 3.206078805217949e-11
and O 0 4.430034117319792e-11
mutations O 0 2.413587329996858e-09
that O 0 1.0229127267447069e-10
cause O 0 9.485520990892837e-07
ADNDI B-Disease 1 0.9999985694885254
have O 0 7.287530578992119e-10
been O 0 2.0963519808958608e-10
found O 0 7.492212579507385e-12
in O 0 1.8130773575195103e-12
both O 0 1.9511790187026756e-12
the O 0 2.293463162439391e-11
signal O 0 2.1427211116531453e-09
peptide O 0 4.51874848650391e-09
of O 0 1.9235246284665664e-08
the O 0 2.2660248788497483e-08
prepro O 0 0.0002463502751197666
- O 0 0.00037512462586164474
AVP O 0 0.00012475706171244383
- O 0 1.4549237903338508e-06
NPII O 0 3.87251639040187e-05
precursor O 0 7.53030704458979e-08
and O 0 5.21887255633402e-10
within O 0 2.1136910888230886e-08
NPII O 0 0.002284217393025756
itself O 0 1.7373693594890938e-07
. O 0 2.481646390606329e-07

An O 0 2.6468072178431612e-08
affected O 0 8.906340553949121e-08
girl O 0 7.102202204123387e-08
who O 0 3.59368229618795e-10
presented O 0 1.3602309278937241e-09
at O 0 3.847218099650718e-09
9 O 0 2.6582802625796376e-09
months O 0 2.149310035504115e-10
of O 0 8.170430998433176e-10
age O 0 7.421848025046529e-09
and O 0 4.053265362236047e-11
her O 0 6.133280949088826e-12
similarly O 0 2.3771810908623792e-11
affected O 0 1.9190958544523795e-10
younger O 0 8.590363420601932e-10
brother O 0 5.684431592101191e-09
and O 0 2.282558586585992e-10
father O 0 7.964971793228415e-09
were O 0 4.710022927234547e-10
all O 0 3.522996130933542e-11
found O 0 1.476582918435998e-11
to O 0 1.522051755464826e-11
have O 0 6.752840040619157e-12
a O 0 6.917837136466432e-11
novel O 0 6.692632559257561e-10
missense O 0 5.155568416626011e-08
mutation O 0 1.0920516935186697e-08
( O 0 8.978651155899797e-10
G1758 O 0 2.289842313984991e-06
- O 0 7.741962235741084e-07
- O 0 1.7733985941958963e-06
> O 0 1.6143653738254216e-06
T O 0 9.452816129851271e-08
) O 0 8.239520177255599e-11
encoding O 0 4.560289645905158e-10
the O 0 4.976749568008643e-10
amino O 0 7.814725533350497e-10
acid O 0 1.8066446949571713e-10
substitution O 0 2.4889588168264254e-09
Gly23 O 0 2.894362751248991e-06
- O 0 1.4908131333868369e-06
- O 0 1.938332161444123e-06
> O 0 5.347551450540777e-06
Val O 0 1.3371890190683189e-06
within O 0 2.8522526918095537e-07
NPII O 0 0.0022063259966671467
. O 0 1.108757146539574e-06

The O 0 6.095751814427786e-07
mutation O 0 3.0083239721534483e-07
was O 0 4.9323212181207055e-08
confirmed O 0 1.8538117707578294e-09
by O 0 2.434656087846321e-10
restriction O 0 4.393210417674709e-08
endonuclease O 0 1.610559479559015e-06
analysis O 0 1.388574588645497e-07
. O 0 1.235379443187412e-07

A O 0 0.00039122378802858293
T1 O 0 0.018193542957305908
- O 0 7.047953204164514e-06
weighted O 0 1.0577588938076588e-07
magnetic O 0 1.1054308401980961e-07
resonance O 0 2.2050542725082778e-08
imaging O 0 1.3940383780663979e-07
of O 0 7.865622109193282e-08
the O 0 1.496073025464284e-07
fathers O 0 3.4275935831828974e-06
pituitary O 0 5.539423364098184e-05
gland O 0 3.903539891325636e-06
demonstrates O 0 9.653511767737655e-09
an O 0 3.1693589974679526e-09
attenuated O 0 9.58820351115719e-07
posterior O 0 0.004052751697599888
pituitary O 1 0.9938831329345703
bright O 0 3.4924632927868515e-05
spot O 0 6.964493513805792e-05
. O 0 8.715369403944351e-07

This O 0 2.523722919534066e-08
mutation O 0 3.8960985193625675e-07
may O 0 7.021291104081229e-09
be O 0 4.660000163525524e-10
valuable O 0 2.5265378678085426e-10
for O 0 1.8913324031921697e-11
developing O 0 9.17842954417658e-11
models O 0 1.0349685691801724e-10
of O 0 7.166933269076026e-09
dominantly B-Disease 1 0.561668872833252
inherited I-Disease 1 0.9999983310699463
neurodegeneration I-Disease 1 1.0
, O 0 3.08271830284923e-09
as O 0 6.488327236597868e-11
the O 0 4.121149255187362e-11
early O 0 3.6375694123513824e-10
age O 0 6.788127282497669e-10
of O 0 1.092051116202697e-09
onset O 0 0.09753040224313736
of O 0 1.997790832319879e-06
symptoms O 0 6.70857707518735e-06
suggests O 0 2.1502049030175385e-09
that O 0 1.2104780719446318e-11
this O 0 4.3239221231283764e-11
mutation O 0 3.799482062305515e-09
may O 0 5.339934605608221e-10
be O 0 4.1011088969256093e-10
particularly O 0 1.575396590958178e-09
deleterious O 0 7.484384809686162e-07
to O 0 1.1036101810191212e-08
the O 0 4.305904965917762e-08
magnocellular O 0 1.2741106729663443e-05
neuron O 0 4.041494776174659e-06
. O 0 5.744643871707922e-08
. O 0 2.3273501881249103e-07

Frequent O 0 6.529871257043851e-07
inactivation O 0 0.000201807648409158
of O 0 8.074950164882466e-05
PTEN O 1 1.0
/ O 1 0.9998794794082642
MMAC1 O 1 0.9999998807907104
in O 0 8.336671157849196e-07
primary O 1 0.9999983310699463
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0004433876893017441

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 1.790538226487115e-05
the O 0 2.387381137225475e-08
most O 0 9.253980914891713e-11
common O 0 3.5177689650112143e-09
male B-Disease 0 3.3070406413315823e-09
cancer I-Disease 0 8.481822355577151e-09
in O 0 2.4696342193486487e-11
the O 0 2.055820652602236e-10
Western O 0 1.9100159676099793e-08
world O 0 4.0821374058808146e-10
, O 0 6.380279984896653e-12
yet O 0 1.729655481341741e-11
many O 0 9.821347294464156e-13
of O 0 9.410886653293815e-11
the O 0 5.973269795456204e-11
major O 0 8.53590975680163e-10
genetic O 0 6.862945212127158e-10
events O 0 8.949455759799108e-12
involved O 0 2.4212480978502704e-11
in O 0 1.45809475604608e-11
the O 0 1.72066680348415e-10
progression O 0 3.07561336398976e-08
of O 0 5.985292816923504e-10
this O 0 1.831235024729594e-10
often O 0 5.565964134035539e-09
fatal O 0 0.0002052114432444796
cancer B-Disease 0 0.03565792739391327
remain O 0 9.533935241279323e-08
to O 0 6.528592333410188e-09
be O 0 4.697395894481815e-08
elucidated O 0 7.912379260233138e-06
. O 0 3.3429503787374415e-07

Numerous O 0 3.4260600045854517e-07
cytogenetic O 0 0.00011708278907462955
and O 0 2.9357337893998192e-08
allelotype O 0 0.0001723479072097689
studies O 0 1.3958445066464265e-08
have O 0 1.2593039111497006e-10
reported O 0 7.603211948925548e-10
frequent O 0 1.4494947464527286e-09
loss O 0 3.333176579189967e-08
of O 0 1.0273276984662516e-06
heterozygosity O 1 0.7823541760444641
on O 0 6.2074645938992035e-06
chromosomal O 0 0.029625609517097473
arm O 0 3.779787220992148e-05
10q O 0 0.0006148761603981256
in O 0 5.303784078591889e-08
sporadic B-Disease 1 0.9994701743125916
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.004586501512676477

Deletion O 0 1.3140310329617932e-05
mapping O 0 4.5920040747660096e-07
studies O 0 1.342600963738505e-08
have O 0 3.582957264214315e-10
unambiguously O 0 1.4520828095498928e-08
identified O 0 7.111209954224762e-10
a O 0 3.2301664121270335e-10
region O 0 6.775572813921826e-08
of O 0 2.3700864915099373e-07
chromosome O 0 0.0001390506513416767
10q23 O 0 6.340710115182446e-06
to O 0 2.875995830375899e-10
be O 0 1.7122660234125675e-10
the O 0 2.8340010893579404e-10
minimal O 0 8.247834415442412e-08
area O 0 2.07148914910249e-07
of O 0 3.5201674108975567e-07
loss O 0 4.931605872116052e-06
. O 0 1.7783812609195593e-06

A O 0 2.2192791675479384e-06
new O 0 1.9799559325406335e-08
tumor B-Disease 0 3.0705427889188286e-06
suppressor O 0 2.7485671125759836e-06
gene O 0 2.8209852231952937e-08
, O 0 2.395718290415516e-09
PTEN O 0 0.011292289942502975
/ O 0 0.00013830617535859346
MMAC1 O 1 0.9999996423721313
, O 0 5.287246640506282e-09
was O 0 1.1932033316952584e-07
isolated O 0 1.9511196214239135e-08
recently O 0 5.332189689788436e-10
at O 0 2.92281338021283e-10
this O 0 8.046836634523213e-12
region O 0 2.2388080278545885e-09
of O 0 7.26489846059053e-09
chromosome O 0 8.837956556817517e-06
10q23 O 0 9.365858204546385e-06
and O 0 2.1439464092942728e-10
found O 0 2.31485264984288e-11
to O 0 1.112489093901825e-11
be O 0 1.3838391370313285e-11
inactivated O 0 1.35356087449523e-10
by O 0 4.5377950529112976e-12
mutation O 0 1.1082502693327e-09
in O 0 7.617059205600185e-10
three O 0 1.3169749024655175e-07
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9183494448661804
lines O 0 4.9583818508835975e-06
. O 0 7.531857590947766e-07

We O 0 2.953940338557004e-06
screened O 0 1.1292360795778222e-05
80 O 0 2.140926881111227e-05
prostate B-Disease 1 1.0
tumors I-Disease 1 1.0
by O 0 2.6071180769804414e-09
microsatellite O 0 2.6014004106400535e-07
analysis O 0 2.0278982937327328e-09
and O 0 2.0338354611570963e-10
found O 0 5.990432594416006e-10
chromosome O 0 6.08144432590052e-07
10q23 O 0 1.1648043027889798e-06
to O 0 1.7014973874296402e-09
be O 0 3.2084315204627956e-09
deleted O 0 1.5516476992161188e-08
in O 0 5.993015528282797e-10
23 O 0 1.5121059959710692e-08
cases O 0 1.4259613489997491e-09
. O 0 5.1174087190020145e-08

We O 0 1.1057744586651097e-07
then O 0 4.201073711129766e-09
proceeded O 0 1.4627871136596582e-09
with O 0 6.921076667505688e-13
sequence O 0 2.05219972959636e-11
analysis O 0 2.734887490085658e-11
of O 0 2.869891269074998e-10
the O 0 7.327769502296633e-10
entire O 0 3.2785669645818416e-07
PTEN O 0 0.05372541397809982
/ O 0 1.8576425645733252e-05
MMAC1 O 0 0.0001874548033811152
coding O 0 3.9124293493841833e-07
region O 0 6.04696381856229e-08
and O 0 2.409331623098865e-10
tested O 0 2.5661636704477075e-10
for O 0 1.0070136391426843e-10
homozygous O 0 1.1708670699661639e-09
deletion O 0 9.157314906360625e-09
with O 0 1.1010139848444123e-11
new O 0 4.855829072170081e-10
intragenic O 0 1.3636234143632464e-05
markers O 0 9.958488078609662e-08
in O 0 2.6041896417083876e-10
these O 0 1.469387805874689e-11
23 O 0 1.4708669837659727e-09
cases O 0 6.805131458342828e-11
with O 0 1.1394930138353132e-10
10q23 O 0 0.0005095439264550805
loss O 0 2.932465577032417e-06
of O 0 3.297408693470061e-05
heterozygosity O 1 0.9985993504524231
. O 0 3.922833457181696e-06

The O 0 1.3969472689723261e-08
identification O 0 5.701522809431481e-09
of O 0 2.979054158913641e-08
the O 0 1.0071990352855664e-08
second O 0 6.428800247704203e-08
mutational O 0 2.7890296223631594e-06
event O 0 1.874291477577117e-08
in O 0 5.066628228078685e-10
10 O 0 2.6600048830260903e-09
( O 0 6.067546465260421e-10
43 O 0 1.2980318331301532e-07
% O 0 6.881314362772173e-08
) O 0 2.735715831647667e-08
tumors B-Disease 1 1.0
establishes O 0 3.210244130968931e-06
PTEN O 1 0.9999539852142334
/ O 0 0.00548664340749383
MMAC1 O 1 0.9031707048416138
as O 0 1.3342907889679623e-09
a O 0 2.906768714616703e-10
main O 0 2.427854361997106e-09
inactivation O 0 2.124892084509611e-08
target O 0 5.0344182156436545e-09
of O 0 2.0690716695526135e-08
10q O 0 0.00020472209143918008
loss O 0 1.362781404168345e-06
in O 0 1.9861049338487646e-07
sporadic B-Disease 1 0.9999994039535522
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.561326366252615e-06
. O 0 9.158836178357888e-07

Risk O 0 9.363876597490162e-05
reversals O 0 4.336435722507304e-06
in O 0 1.433788532345659e-09
predictive O 0 2.1728565613443607e-08
testing O 0 1.7088941817178238e-08
for O 0 4.588142843431342e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.0827539881574921e-05

The O 0 8.639848658731353e-08
first O 0 9.039272663713405e-10
predictive O 0 8.214672497786069e-09
testing O 0 1.1988444015287314e-08
for O 0 8.381987015582126e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 4.719002077990808e-08
HD B-Disease 0 4.900818021269515e-05
) O 0 3.0070354539724065e-10
was O 0 1.9879622392693364e-09
based O 0 1.4434822781517198e-10
on O 0 6.799076301966522e-10
analysis O 0 2.4376622942412496e-10
of O 0 2.017978228963102e-09
linked O 0 1.7172260058373467e-08
polymorphic O 0 2.6972816868919836e-08
DNA O 0 2.1541387340562324e-08
markers O 0 1.3067947834954907e-09
to O 0 3.84722878554733e-11
estimate O 0 8.706956267090504e-10
the O 0 1.229925605805704e-10
likelihood O 0 4.73810146672804e-09
of O 0 1.8622614561536466e-08
inheriting O 0 2.707926967104868e-07
the O 0 9.437122194810854e-09
mutation O 0 5.045090389899087e-08
for O 0 1.503392432766759e-08
HD B-Disease 0 0.00020998716354370117
. O 0 9.109966185860685e-07

Limits O 0 3.498537353152642e-07
to O 0 2.4482873506315173e-09
accuracy O 0 1.568055729705975e-08
included O 0 7.381580902077189e-10
recombination O 0 3.2831140028832806e-09
between O 0 3.713407581429351e-09
the O 0 1.938787574928824e-09
DNA O 0 1.1888571904705714e-08
markers O 0 2.438268031923485e-09
and O 0 3.67381125521149e-11
the O 0 2.9661578748729767e-10
mutation O 0 4.9982897820655126e-09
, O 0 1.0120488475040545e-10
pedigree O 0 3.121281899609585e-09
structure O 0 4.048031687631237e-09
, O 0 1.9160747988244964e-10
and O 0 3.808344264943919e-11
whether O 0 2.2239664276835214e-10
DNA O 0 1.3455792036154435e-09
samples O 0 2.2318095288520468e-11
were O 0 4.3722031203841105e-12
available O 0 1.0892333042467062e-11
from O 0 4.0364184217267507e-10
family O 0 6.987966871818685e-10
members O 0 6.953040920798514e-10
. O 0 2.3472322752127184e-08

With O 0 1.3003251808640925e-09
direct O 0 1.3851669145026335e-08
tests O 0 4.904865957833238e-10
for O 0 1.2952748595917996e-10
the O 0 1.0617298151771593e-09
HD B-Disease 0 8.023854206840042e-06
mutation O 0 4.437990241967782e-08
, O 0 1.8668117052200728e-10
we O 0 1.4706474926740043e-10
have O 0 8.944472766614364e-12
assessed O 0 4.199471437260627e-09
the O 0 8.970293258192541e-11
accuracy O 0 2.663121945190028e-09
of O 0 8.694642228412874e-10
results O 0 1.0806667366525247e-10
obtained O 0 2.782586383531793e-10
by O 0 2.9007633101096886e-11
linkage O 0 8.0331394869404e-09
approaches O 0 2.9605922158282283e-09
when O 0 1.4397996683790382e-11
requested O 0 1.342062017073431e-10
to O 0 4.586351090574148e-11
do O 0 3.9503501164661614e-11
so O 0 4.2357775273393905e-12
by O 0 1.0425503342570419e-11
the O 0 1.396996407443396e-10
test O 0 1.9387200178577757e-10
individuals O 0 3.576266227600655e-10
. O 0 5.5547147326251434e-08

For O 0 1.3634213757995894e-08
six O 0 3.791820468723728e-10
such O 0 1.7988933259660556e-11
individuals O 0 8.79056966107683e-11
, O 0 9.438803905137405e-11
there O 0 1.4697557060294741e-10
was O 0 6.6908105722518485e-09
significant O 0 1.0643129710885546e-09
disparity O 0 5.081343701363039e-08
between O 0 1.316012632202046e-08
the O 0 2.597505144308343e-08
tests O 0 1.536899851828366e-08
. O 0 4.007807774542016e-08

Three O 0 1.0510979109312757e-07
went O 0 8.592191136358451e-08
from O 0 1.4318836116800071e-09
a O 0 1.6592062168641064e-09
decreased O 0 5.2741757627927655e-08
risk O 0 2.024497458563701e-09
to O 0 1.869925395081573e-11
an O 0 5.85451652435065e-12
increased O 0 2.2338975114166715e-10
risk O 0 8.493284298083381e-09
, O 0 5.254387550057693e-11
while O 0 4.293883651418362e-11
in O 0 1.7887658368409554e-11
another O 0 1.4736462050635168e-10
three O 0 2.2574886404669314e-11
the O 0 1.912660724245896e-10
risk O 0 4.2295673630121655e-09
was O 0 7.355306053113964e-08
decreased O 0 3.184285048973834e-07
. O 0 9.635248687800413e-08

Knowledge O 0 7.306506404347601e-07
of O 0 2.3126523274186184e-07
the O 0 6.771785354686699e-09
potential O 0 1.2564811413540156e-08
reasons O 0 1.2436910390434264e-09
for O 0 1.0767406063982854e-11
these O 0 2.976321879927246e-12
changes O 0 2.5116084559351215e-11
in O 0 1.2374783489588204e-11
results O 0 7.724768047445707e-11
and O 0 2.302364895956366e-11
impact O 0 6.798613227942951e-09
of O 0 8.904293968825527e-10
these O 0 8.740558624098504e-12
risk O 0 1.4171627205072923e-09
reversals O 0 1.290049223001688e-08
on O 0 2.1162152030740344e-09
both O 0 4.5759881994733576e-11
patients O 0 2.2611084879442522e-11
and O 0 1.4620967631051585e-11
the O 0 2.2887010342476088e-10
counseling O 0 3.4739336407518806e-10
team O 0 2.231493418866637e-12
can O 0 5.220779104170292e-12
assist O 0 1.027574692002986e-10
in O 0 2.0649803048056192e-11
the O 0 4.967604799732683e-11
development O 0 7.921088784890173e-11
of O 0 7.65918786727049e-11
strategies O 0 4.4775117641338014e-11
for O 0 9.400710244966692e-12
the O 0 7.549307706744557e-11
prevention O 0 1.6913953571062734e-09
and O 0 1.3346585121809529e-11
, O 0 8.618929354942129e-12
where O 0 1.6834922345054792e-11
necessary O 0 4.843009326904735e-10
, O 0 8.273062790387087e-11
management O 0 5.832699323526924e-10
of O 0 1.9070627299555554e-09
a O 0 2.9271551849063826e-09
risk O 0 3.685207161652215e-08
reversal O 0 2.9158226055869818e-08
in O 0 1.264454513316693e-10
any O 0 5.027679383928785e-10
predictive O 0 3.670928894194958e-09
testing O 0 8.203614454416197e-10
program O 0 3.645820867426153e-10
. O 0 3.978351814648562e-10
. O 0 1.6625364196443115e-08

A O 0 9.117136414715787e-07
novel O 0 6.233420180024041e-08
common O 0 1.9882854473962652e-08
missense O 0 2.2593499124923255e-06
mutation O 0 3.9288136122195283e-07
G301C O 0 2.284387164763757e-06
in O 0 8.628346370720408e-10
the O 0 3.90422671969759e-09
N O 0 1.1270394679741003e-06
- O 0 4.289653929845372e-07
acetylgalactosamine O 0 8.470106877211947e-06
- O 0 1.9398298718442675e-06
6 O 0 1.5823741250642342e-06
- O 0 3.596720432597067e-07
sulfate O 0 4.285691659333679e-07
sulfatase O 0 2.375192025283468e-06
gene O 0 1.5318486035198475e-08
in O 0 1.4683785742874989e-08
mucopolysaccharidosis B-Disease 0 0.0010198646923527122
IVA I-Disease 1 0.9999997615814209
. O 0 3.120548353763297e-05

Mucopolysaccharidosis B-Disease 1 0.9999897480010986
IVA I-Disease 1 1.0
( O 0 0.0013049651170149446
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 1.5778724105075526e-08
is O 0 3.711793095106941e-09
an O 0 5.827564653060335e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 8.300833542307373e-06
by O 0 1.3567174050876929e-09
a O 0 9.485234642170326e-08
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999996423721313
in O 0 7.293290860133084e-09
N O 0 5.034391961089568e-07
- O 0 6.256360762790791e-08
acetylgalactosamine O 0 1.2577851293826825e-06
- O 0 2.309877373818381e-07
6 O 0 2.2646558761607594e-07
- O 0 5.818571224835978e-08
sulfate O 0 1.7228893511855858e-07
sulfatase O 0 4.460650870896643e-06
( O 0 1.7908851290826533e-08
GALNS O 0 0.0002478242968209088
) O 0 2.894147144161252e-08
. O 0 1.6885120146525878e-07

In O 0 3.7799676277927574e-08
previous O 0 9.158712899193233e-09
studies O 0 3.970311190926168e-09
, O 0 1.3556097910871756e-10
we O 0 2.0487903040766753e-10
have O 0 1.3827336844962623e-11
found O 0 1.3236736359778511e-11
two O 0 2.0202357581960984e-12
common O 0 1.1954706669037307e-10
mutations O 0 2.7912046007827485e-09
in O 0 6.611394209876664e-10
Caucasians O 0 5.059757413050647e-08
and O 0 5.002712688551014e-10
Japanese O 0 5.059178320721003e-08
, O 0 2.304959556553854e-09
respectively O 0 1.8922703759471915e-07
. O 0 1.6079138731583953e-07

To O 0 9.595579086862926e-08
characterize O 0 9.279619916924275e-07
the O 0 2.5675271686509404e-08
mutational O 0 3.3915823678398738e-06
spectrum O 0 5.942040957052086e-07
in O 0 6.657286527600448e-11
various O 0 1.4689421554137105e-11
ethnic O 0 7.018310932416227e-11
groups O 0 4.489832550885753e-12
, O 0 6.02806693450475e-12
mutations O 0 1.145717132278179e-10
in O 0 2.4325333414232375e-11
the O 0 3.7114794571024845e-10
GALNS O 0 3.736373400897719e-05
gene O 0 1.4586970520369391e-09
in O 0 9.053283678284174e-10
Colombian O 0 6.706894964736421e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 8.361053005501162e-08
were O 0 4.460425362395881e-09
investigated O 0 1.206050939117631e-07
, O 0 6.127487961471445e-10
and O 0 4.3463821430833605e-10
genetic O 0 2.916423369470067e-08
backgrounds O 0 3.2501545899066286e-09
were O 0 4.832342859195649e-10
extensively O 0 1.338957972274457e-10
analyzed O 0 1.3136113030665086e-10
to O 0 2.5435858280742352e-11
identify O 0 3.1996724714211666e-10
racial O 0 2.841661350672098e-09
origin O 0 2.712575997154687e-10
, O 0 2.2082032383186068e-11
based O 0 1.0259843669091495e-10
on O 0 2.699163781372249e-09
mitochondrial O 0 7.965244464003263e-09
DNA O 0 3.850638918834193e-09
( O 0 2.6408691899959535e-10
mtDNA O 0 6.0589688821721666e-09
) O 0 6.529522478260219e-10
lineages O 0 1.951461925386866e-08
. O 0 2.429495360445344e-08

Three O 0 5.095921906672629e-08
novel O 0 5.304947592321696e-08
missense O 0 1.2120057363063097e-05
mutations O 0 1.1513316167111043e-06
never O 0 3.55555940245722e-08
identified O 0 4.597794589500381e-09
previously O 0 3.909813861557865e-10
in O 0 5.5998179183947006e-12
other O 0 2.656309850898597e-12
populations O 0 1.488873781207989e-11
and O 0 5.26337220335682e-12
found O 0 7.192643702857993e-11
in O 0 4.816843798827186e-11
16 O 0 8.153882569139626e-10
out O 0 7.034232224478743e-11
of O 0 1.966608875747511e-09
19 O 0 1.7249041306399704e-08
Colombian O 0 2.3148709260567557e-06
MPS B-Disease 1 0.9997329115867615
IVA I-Disease 1 1.0
unrelated O 0 1.282437125382785e-07
alleles O 0 3.906640344553125e-09
account O 0 3.3506514229841855e-10
for O 0 2.286367983828086e-09
84 O 0 6.136499450803967e-07
. O 0 1.6067704677880101e-07

2 O 0 1.1379974012015737e-06
% O 0 2.5156058569564266e-08
of O 0 8.751481317403886e-09
the O 0 2.0933326183580903e-09
alleles O 0 3.219889244121532e-09
in O 0 3.7087480309061505e-10
this O 0 9.682236123964572e-10
study O 0 1.5326669711157592e-08
. O 0 4.393411501268929e-08

The O 0 9.339690905108e-07
G301C O 0 7.30736501282081e-05
and O 0 2.9373971699442336e-08
S162F O 0 9.715589840197936e-06
mutations O 0 2.1507638336970558e-08
account O 0 2.9289535241616704e-09
for O 0 7.487309439113687e-09
68 O 0 2.1003800156904617e-06
. O 0 3.079805424022197e-07

4 O 0 9.741678695718292e-06
% O 0 5.125291977492452e-07
and O 0 2.7928781065611474e-08
10 O 0 3.4402697224322765e-07
. O 0 5.851798050571233e-07

5 O 0 1.0624919468682492e-06
% O 0 4.827547783747832e-08
of O 0 2.0565639857750284e-08
mutations O 0 4.074385984154105e-08
, O 0 8.793139549823081e-10
respectively O 0 7.3977934889057906e-09
, O 0 1.130051885400718e-10
whereas O 0 1.2663061710327383e-09
the O 0 1.4766802225452125e-09
remaining O 0 4.349156057514847e-08
F69V O 0 6.361633131746203e-05
is O 0 2.3354670974917724e-10
limited O 0 3.7988986956172255e-11
to O 0 1.1473179351018103e-10
a O 0 2.0380381826612393e-09
single O 0 9.406643464160425e-09
allele O 0 3.1918554554977163e-07
. O 0 5.838181138528853e-08

The O 0 9.503452957915215e-08
skewed O 0 3.180455223628087e-07
prevalence O 0 2.067896787139034e-07
of O 0 1.3924355890537754e-08
G301C O 0 5.332680302672088e-06
in O 0 6.012984554715217e-10
only O 0 7.831258419521703e-10
Colombian O 0 1.8529790679622238e-07
patients O 0 4.511873652468523e-10
and O 0 8.387875810589307e-11
haplotype O 0 1.202402977185102e-08
analysis O 0 2.2631892193647474e-10
by O 0 2.458594092202837e-11
restriction O 0 2.4475823590108803e-09
fragment O 0 2.0435042102917578e-08
length O 0 5.406872727320433e-09
polymorphisms O 0 9.00781582657828e-09
in O 0 1.1484739548262013e-10
the O 0 8.055368039272537e-10
GALNS O 0 0.0004312502278480679
gene O 0 3.2746587663723403e-09
suggest O 0 9.128083844345269e-10
that O 0 8.155619929395286e-11
G301C O 0 2.312932423365055e-07
originated O 0 5.857292428856908e-10
from O 0 2.1751681011927815e-10
a O 0 2.9658073219529513e-10
common O 0 3.417781613279658e-09
ancestor O 0 4.896990617453412e-07
. O 0 1.6651932810418657e-07

Investigation O 0 1.0684279914130457e-06
of O 0 2.7967863047706487e-07
the O 0 1.2454126618877126e-08
genetic O 0 9.116726928937169e-09
background O 0 9.332451478272219e-11
by O 0 1.6670428926168768e-11
means O 0 5.668040259365625e-09
of O 0 1.3099297646590458e-08
mtDNA O 0 1.0490186497236209e-08
lineages O 0 5.084925813747532e-10
indicate O 0 5.971401845217272e-11
that O 0 6.731390618519573e-12
all O 0 8.486329000634285e-11
our O 0 1.1445988601366253e-10
patients O 0 1.556556966653133e-11
are O 0 5.751067157222511e-12
probably O 0 4.464919989288774e-09
of O 0 2.7610351338580585e-08
native O 0 2.323911907353704e-08
American O 0 1.300906973256133e-07
descent O 0 6.358540849760175e-05

Low O 0 2.2444289697887143e-06
frequency O 0 3.7702656641158683e-07
of O 0 3.186958679179952e-07
BRCA1 O 0 5.6877261158660986e-06
germline O 0 9.19610192795517e-06
mutations O 0 1.403407434708015e-08
in O 0 2.9442431825899007e-10
45 O 0 9.410270962462164e-08
German O 1 0.9999996423721313
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.923686563211959e-06
. O 0 1.5322393664973788e-06

In O 0 1.2351269340626914e-08
this O 0 2.850464864145863e-10
study O 0 2.6883112402842357e-10
we O 0 5.669007624442557e-11
investigated O 0 2.4909629914304787e-09
45 O 0 9.935398992411137e-08
German O 1 0.9999994039535522
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0219972423897161e-08
for O 0 4.832695132961362e-09
germline O 0 1.042069698087289e-06
mutations O 0 8.255290673275795e-09
in O 0 6.448357403598948e-10
the O 0 3.939338633074385e-09
BRCA1 O 0 2.9968813919367676e-07
gene O 0 8.230500725403544e-08
. O 0 6.650569872590495e-08

We O 0 1.8081759378674178e-07
identified O 0 1.5567852784670322e-08
four O 0 1.3187030356576201e-09
germline O 0 2.536057536417502e-06
mutations O 0 3.1862832372553385e-08
in O 0 9.27267929107245e-10
three O 0 2.452751113324325e-09
breast B-Disease 1 0.9977619647979736
cancer I-Disease 1 0.9776831269264221
families O 0 1.7523505979610832e-09
and O 0 7.89855292282482e-10
in O 0 1.3060428294409121e-08
one O 0 0.004839090630412102
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.3621746575154248e-06
. O 0 6.214384562497344e-10
among O 0 1.466338855893312e-11
these O 0 3.0566007624271974e-12
were O 0 6.319520601261175e-11
one O 0 5.540199202180851e-11
frameshift O 0 4.264376940454895e-08
mutation O 0 7.60840990210454e-09
, O 0 2.173206614664025e-10
one O 0 4.125004782196129e-10
nonsense O 0 1.5677214548759366e-07
mutation O 0 5.5226731632274095e-08
, O 0 1.2394349435673746e-10
one O 0 6.926788309602472e-11
novel O 0 4.880741921731158e-10
splice O 0 2.2127432330876218e-08
site O 0 8.790490002574813e-10
mutation O 0 1.20256293811849e-09
, O 0 1.1633268653943318e-10
and O 0 5.437606476199619e-10
one O 0 1.386530890101767e-08
missense O 0 4.4253250962356105e-05
mutation O 0 6.052053868188523e-05
. O 0 3.88947091778391e-06

The O 0 3.6298317240834876e-07
missense O 0 7.831018592696637e-06
mutation O 0 7.522998544118309e-07
was O 0 1.614160822782651e-07
also O 0 4.3662071180783357e-10
found O 0 7.035632076934917e-10
in O 0 1.5057246560701287e-09
2 O 0 1.3963071978650987e-06
. O 0 2.2760664819543308e-07

8 O 0 1.183183485409245e-06
% O 0 6.451586642697293e-08
of O 0 7.765341258902936e-09
the O 0 1.0568282915457416e-09
general O 0 1.3648290497769722e-08
population O 0 1.0134705574760261e-10
, O 0 1.4805367001824443e-11
suggesting O 0 1.8592073713907808e-10
that O 0 4.086986825357908e-12
it O 0 1.2441997952750139e-11
is O 0 1.0925756133151054e-10
not O 0 1.968488927417411e-09
disease O 0 2.0214682194819034e-07
associated O 0 3.0554184604625334e-07
. O 0 4.06591681212376e-07

The O 0 4.89234146527906e-08
average O 0 1.1660626242360195e-08
age O 0 4.717957935440609e-08
of O 0 7.137238355880982e-08
disease O 0 0.00014177874254528433
onset O 1 0.9538512825965881
in O 0 1.9096251246963902e-09
those O 0 4.2984005244051104e-10
families O 0 2.006777105600932e-10
harbouring O 0 5.3285958756532636e-08
causative O 0 1.2845737806799207e-08
mutations O 0 1.6027721372324777e-08
was O 0 3.344091226153978e-08
between O 0 3.404465331868778e-08
32 O 0 3.373027368525072e-07
. O 0 9.111949594853286e-08

3 O 0 2.723681609495543e-05
and O 0 3.6133846492703015e-07
37 O 0 6.4260389081027824e-06
. O 0 6.792736826355394e-07

4 O 0 3.0834248718747403e-06
years O 0 1.4813100968069648e-08
, O 0 2.230636092503957e-10
whereas O 0 2.062529924629075e-09
the O 0 1.4191346986436315e-09
family O 0 7.397902845873716e-10
harbouring O 0 4.1709114384502755e-08
the O 0 8.786668059812541e-10
missense O 0 1.6010831416224391e-07
mutation O 0 1.1571207103600045e-08
had O 0 5.440220496311099e-10
an O 0 1.535602547897419e-11
average O 0 1.1924758402948044e-10
age O 0 1.6598867835782016e-09
of O 0 9.532241662668639e-09
onset O 0 0.0001838059542933479
of O 0 8.70684834808344e-06
51 O 0 1.7136751921498217e-05
. O 0 6.259929818952514e-07

2 O 0 0.0001257332623936236
years O 0 2.989835365951876e-06
. O 0 2.057103301922325e-06

These O 0 5.598907559800637e-09
findings O 0 2.4556112698803645e-09
show O 0 7.927074274771684e-11
that O 0 1.7614130640164483e-11
BRCA1 O 0 1.0693275953599368e-07
is O 0 4.073682502436782e-10
implicated O 0 2.9744324336888894e-08
in O 0 6.930383350534086e-11
a O 0 1.3060265369180257e-10
small O 0 8.493324099578814e-11
fraction O 0 2.7319510209622422e-08
of O 0 0.008738430216908455
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.079889315278251e-09
suggesting O 0 9.236387210620478e-10
the O 0 2.2173587965745867e-10
involvement O 0 1.7290766596289586e-09
of O 0 9.049019311646589e-10
another O 0 4.3014269923702386e-10
susceptibility O 0 7.755160424949281e-08
gene O 0 1.3482774896544925e-08
( O 0 1.1561147594818522e-08
s O 0 2.7589617275225464e-06
) O 0 2.8168031462882936e-07

Paternal O 0 0.00019074423471465707
transmission O 0 0.011931616812944412
of O 1 0.9999986886978149
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9793796539306641

We O 0 3.531633865350159e-07
report O 0 2.019418410270646e-09
a O 0 6.14892470274242e-10
rare O 0 1.1058430837707078e-09
case O 0 1.6403520319840936e-08
of O 0 4.522514984728332e-07
paternally O 1 0.9999997615814209
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0007634195499122143
DM B-Disease 1 1.0
) O 0 1.3621483674342016e-07
. O 0 1.1745230210635782e-07

The O 0 1.7216081005244632e-07
proband O 0 5.2645995310740545e-05
is O 0 2.58846277745306e-09
a O 0 2.868962400981445e-09
23 O 0 1.4614687238179158e-08
year O 0 2.057685133394216e-09
old O 0 2.453101330956997e-07
, O 0 3.647396695782845e-08
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 5.413626695371931e-06
who O 0 5.210672497923952e-07
suffers O 1 0.9999986886978149
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 0.10979568958282471

He O 0 9.946509749170218e-08
presented O 0 5.996211172032417e-08
with O 0 1.3270250676100659e-08
respiratory O 1 0.7790008187294006
and O 0 2.9808819590471103e-07
feeding O 0 6.472564564319327e-07
difficulties O 0 1.503509224676236e-06
at O 0 4.457342583918944e-06
birth O 0 1.1122870091639925e-06
. O 0 2.6203713332506595e-07

His O 0 6.640582796535455e-06
two O 0 4.668812607633299e-07
sibs O 1 0.9999740123748779
suffer O 0 0.00010842710616998374
from O 0 5.661274826707086e-06
childhood O 1 0.9959499835968018
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 3.505329368636012e-05

Their O 0 1.105615865526488e-08
late O 0 1.3260757896205178e-06
father O 0 7.872330343161593e-08
had O 0 2.1407766670478168e-09
the O 0 1.088108492197648e-10
adult O 0 6.861593238038921e-11
type O 0 9.233956932419574e-10
of O 0 6.503080385300564e-08
DM B-Disease 1 1.0
, O 0 8.889161406955282e-09
with O 0 5.350364595813062e-10
onset O 0 0.0017699971795082092
around O 0 2.2574058178292944e-08
30 O 0 4.677368892203049e-08
years O 0 2.0596690575303e-08
. O 0 2.1816811468511332e-08

Only O 0 2.4221572303417815e-08
six O 0 7.561935522204521e-10
other O 0 7.442220451014947e-12
cases O 0 1.804047536357878e-11
of O 0 1.5951316933993098e-09
paternal O 0 5.42852831131313e-07
transmission O 0 0.0005602214368991554
of O 1 0.9999996423721313
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 1.5885703987805755e-06
been O 0 2.2242739206035367e-08
reported O 0 4.974531453427744e-09
recently O 0 1.9482115476421313e-08
. O 0 2.775851726255496e-08

We O 0 3.5301987111324706e-08
review O 0 3.776823298551335e-09
the O 0 6.628035897904283e-10
sex O 0 2.0616479357027373e-10
related O 0 2.7383650902379486e-10
effects O 0 9.205508355591974e-09
on O 0 3.7673142827543415e-08
transmission O 0 1.219297814714082e-06
of O 0 0.00025389459915459156
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.047709234058856964

Decreased O 0 2.6395987333671656e-06
fertility O 0 1.0005152262237971e-07
of O 0 3.570229667460012e-09
males O 0 6.232959287588713e-11
with O 0 2.2089224980398336e-12
adult O 0 4.244712581424892e-09
onset O 0 0.0006189091945998371
DM B-Disease 1 1.0
and O 0 1.567439689154071e-08
contraction O 0 2.8448201305764087e-07
of O 0 8.087408964740916e-09
the O 0 4.744583614879616e-10
repeat O 0 6.993327583693087e-10
upon O 0 1.718121894755953e-10
male O 0 2.8501536200598032e-11
transmission O 0 2.5839273429251186e-11
contribute O 0 5.770394578830107e-12
to O 0 3.776834053836886e-11
the O 0 2.0122696564595088e-10
almost O 0 1.313141040348853e-09
absent O 0 4.5771622048107474e-09
occurrence O 0 1.5938970143736242e-09
of O 0 1.9598576095347653e-09
paternal O 0 9.214330987106223e-08
transmission O 0 2.9074703888909426e-06
of O 0 0.0003354019427206367
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0002558600390329957

Also O 0 1.703219076887308e-08
the O 0 5.3654920506573944e-09
fathers O 0 3.1967594793513854e-08
of O 0 1.9728501499116646e-08
the O 0 1.0231771874202877e-08
reported O 0 1.6456614559956506e-07
congenitally O 0 0.0022995304316282272
affected O 0 8.804862261513335e-08
children O 0 1.4138904491645121e-09
showed O 0 6.291945298109169e-10
, O 0 1.5622268756398938e-10
on O 0 9.907841658218786e-09
average O 0 2.8085229697438763e-09
, O 0 1.2224142809103e-09
shorter O 0 4.567815778955264e-07
CTG O 0 1.6437821614090353e-05
repeat O 0 5.668497138344719e-08
lengths O 0 5.437092909232888e-07
and O 0 9.463591715830333e-11
hence O 0 1.9051940025605063e-09
less O 0 3.1983498072207794e-09
severe O 0 1.700351958788815e-06
clinical O 0 4.81562949516956e-07
symptoms O 0 9.829689062712532e-09
than O 0 6.816069236803557e-11
the O 0 5.093992450078133e-10
mothers O 0 5.194777247252702e-11
of O 0 5.375702105681057e-10
children O 0 6.878906888552194e-10
with O 0 1.0273327077925387e-08
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.003156705992296338

We O 0 4.028162337021968e-08
conclude O 0 6.205021918503917e-08
that O 0 1.5711677792129564e-10
paternal O 0 1.2191532050565002e-07
transmission O 0 4.641630312107736e-06
of O 1 0.9884280562400818
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 7.108257705112919e-06
rare O 0 1.7321728496000333e-09
and O 0 3.62031203626767e-11
preferentially O 0 2.582834779385479e-10
occurs O 0 3.873750972771539e-11
with O 0 2.833074269972813e-12
onset O 0 1.8924918094853638e-06
of O 0 2.4860100893420167e-06
DM B-Disease 1 1.0
past O 0 3.3950794886550284e-07
30 O 0 7.475194685468978e-09
years O 0 2.6626631455251015e-10
in O 0 1.3463789111378688e-11
the O 0 1.372570668234374e-10
father O 0 5.147636095159669e-09
. O 0 2.1776349612423473e-09
. O 0 4.5649237279121735e-08

The O 0 7.519455493820715e-07
RB1 O 0 1.3830432180839125e-05
gene O 0 5.9137832408850954e-09
mutation O 0 3.996690978169681e-09
in O 0 4.241335893606646e-10
a O 0 1.0446817633180672e-08
child O 0 3.524141334310116e-07
with O 0 4.9370271426596446e-08
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.00036424820427782834

The O 0 1.0775145256047836e-06
RB1 O 0 2.8097489121137187e-05
gene O 0 1.3183515612524843e-08
mutation O 0 1.315716424699076e-08
was O 0 5.849636330879093e-09
investigated O 0 9.1435268245732e-09
in O 0 2.0265594757873373e-10
a O 0 7.414801661553838e-09
child O 0 1.413312133990985e-07
with O 0 9.822247903912285e-09
ectopic B-Disease 1 0.9999998807907104
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 0 2.0657396817114204e-05
using O 0 1.6270893521408425e-09
DNA O 0 4.543587284189243e-09
obtained O 0 2.1901552793579526e-10
from O 0 2.2033409818877914e-10
both O 0 8.695566489080875e-11
the O 0 1.3299585877035724e-09
pineal B-Disease 0 1.6401165339630097e-05
and I-Disease 0 1.9769371917277567e-08
retinal I-Disease 1 0.9978786706924438
tumours I-Disease 1 1.0
of O 0 0.23641234636306763
the O 0 4.824979441764299e-06
patient O 0 2.8261392799322493e-06
. O 0 5.450248181659845e-07

A O 0 3.0942653665988473e-06
nonsense O 0 8.162935955624562e-06
mutation O 0 1.5448460999323288e-07
in O 0 5.597199592699553e-09
exon O 0 1.9858568123254372e-07
17 O 0 1.732457910463836e-08
( O 0 5.803380553892623e-10
codon O 0 2.7154310799915038e-08
556 O 0 9.675114931440021e-09
) O 0 1.4090116573495237e-10
of O 0 3.857585806343877e-09
the O 0 9.196242878317662e-09
RB1 O 0 7.338591785810422e-06
gene O 0 6.719419687328809e-09
was O 0 6.964857579561112e-09
found O 0 5.679267472968874e-11
to O 0 3.477345841829127e-11
be O 0 1.280853617613431e-10
present O 0 1.0922052151585149e-09
homozygously O 0 3.3791297937568743e-06
in O 0 1.1531938737263658e-09
both O 0 5.974617467430221e-10
the O 0 4.6197885517074155e-09
retinal B-Disease 0 5.659083399223164e-06
and I-Disease 0 1.0537436168078784e-07
the I-Disease 0 1.6766920225563808e-06
pineal I-Disease 1 0.9999973773956299
tumours I-Disease 1 1.0
. O 0 2.0596709873643704e-05

The O 0 2.956090838779346e-08
same O 0 3.415305371845534e-09
mutation O 0 2.267598908645141e-08
was O 0 1.0121772753279856e-08
present O 0 9.95872606601722e-10
heterozygously O 0 8.362167704945023e-07
in O 0 2.064016457747897e-10
the O 0 2.766055440250881e-10
DNA O 0 1.0925302884601251e-09
from O 0 4.588346022571521e-11
the O 0 3.0194364369906523e-11
constitutional O 0 1.909057134596992e-09
cells O 0 1.8549922708999134e-10
of O 0 3.1995442406618224e-10
the O 0 2.9468161244494695e-10
patient O 0 1.7481643910244316e-09
, O 0 7.656413003598317e-11
proving O 0 5.771151556643872e-09
it O 0 2.3809110932804245e-11
to O 0 1.3495625450499205e-10
be O 0 7.515606470498426e-10
of O 0 2.815051303173277e-08
germline O 0 1.7457450667279772e-05
origin O 0 5.120484729559394e-07
. O 0 3.0864211453263124e-07

The O 0 2.4908120010991297e-08
initial O 0 8.590695266263992e-09
mutation O 0 1.316803555084789e-08
was O 0 7.800969648030787e-09
shown O 0 1.2100907775813852e-10
to O 0 1.865434057224391e-10
have O 0 7.170534999101363e-11
occurred O 0 1.4426882799511986e-08
in O 0 1.6668688651577668e-10
the O 0 1.520535697352443e-09
paternally O 0 1.4104224987931957e-07
derived O 0 9.86174839567866e-08
RB1 O 0 2.3694728952250443e-05
allele O 0 2.252540753033827e-06
. O 0 2.4233870021816983e-07

The O 0 3.0153088914630644e-08
mutation O 0 3.768708367601903e-08
is O 0 1.444228625580024e-10
in O 0 2.0958394741921182e-11
an O 0 1.4650305274477304e-11
area O 0 3.383560320813217e-09
of O 0 3.105551149573671e-09
the O 0 5.907061506604805e-10
gene O 0 2.664868326007763e-10
that O 0 1.5373374448457433e-11
encodes O 0 9.086250501999515e-11
the O 0 4.9545274133366846e-11
protein O 0 2.1783316817014509e-10
- O 0 4.742946035918294e-10
binding O 0 1.7789355766240078e-08
region O 0 6.128989866738266e-07
known O 0 4.200546754873358e-08
as O 0 7.443761718128883e-10
the O 0 1.1439010849656484e-09
pocket O 0 3.122226917184889e-05
region O 0 6.731917210345273e-07
and O 0 1.2643633917619468e-09
has O 0 6.077600089859914e-10
been O 0 4.518117546759015e-10
detected O 0 1.7496387672011338e-09
in O 0 1.0728783313151968e-11
other O 0 2.4036558333995206e-12
cases O 0 6.560603449390356e-11
of O 0 9.594185002015365e-09
retinoblastoma B-Disease 0 1.2393458746373653e-05
. O 0 9.780656284874567e-08
. O 0 5.229659905126027e-07

Low O 0 3.9761976040608715e-06
levels O 0 1.8360282183493837e-08
of O 0 1.9092839309564624e-08
beta O 0 1.5185996744548902e-06
hexosaminidase O 0 7.994705811142921e-06
A O 0 5.193298946437608e-08
in O 0 2.153865280574152e-10
healthy O 0 3.097355358305798e-11
individuals O 0 2.6549168679473878e-12
with O 0 1.3370075879759469e-11
apparent O 0 0.005156669300049543
deficiency O 1 0.9992502331733704
of O 0 0.00019916925521101803
this O 0 1.9945420604017272e-07
enzyme O 0 1.333859813712479e-06
. O 0 1.6216164056004345e-07

Appreciable O 0 5.753910954808816e-05
beta O 0 1.3079696145723574e-05
hexosaminidase O 0 6.37306657154113e-05
A O 0 6.0678348745568655e-06
( O 0 3.795471315015675e-08
hex O 0 2.0918143945891643e-06
A O 0 1.7662628692960425e-07
) O 0 3.983036678256724e-10
activity O 0 2.1980113285025027e-09
has O 0 1.838903751494314e-10
been O 0 7.627236064955412e-10
detected O 0 1.2007758343202113e-08
in O 0 1.2269646409990287e-09
cultured O 0 3.7187751900091826e-07
skin O 0 1.5646013480363763e-06
fibroblasts O 0 1.2749742381856777e-06
and O 0 9.138823031662469e-08
melanoma B-Disease 1 0.9999997615814209
tissue O 0 7.472712604794651e-05
from O 0 1.7200918023263512e-07
healthy O 0 5.704141603501967e-10
individuals O 0 2.985636737840025e-11
previously O 0 8.635573367499205e-10
reported O 0 1.4272014126071042e-10
as O 0 1.1961297230467238e-10
having O 0 5.419820148233612e-09
deficiency B-Disease 0 2.234557314295671e-06
of I-Disease 0 8.322936650984047e-07
hex I-Disease 0 7.93862000136869e-07
A I-Disease 0 4.353237326171211e-09
activity O 0 2.9754737562726064e-10
indistinguishable O 0 6.134620589293149e-10
from O 0 1.6175819364527833e-11
that O 0 1.17623966122693e-12
of O 0 8.862201250625645e-11
patients O 0 9.942285189579181e-11
with O 0 1.3490646821878727e-08
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 6.271989150263835e-07
TSD B-Disease 0 0.07268232107162476
) O 0 5.210006648326271e-08
. O 0 1.790270971468999e-07

Identification O 0 4.95571669034689e-07
and O 0 3.9315565913966566e-08
quantitation O 0 0.0009971196996048093
of O 0 9.466695337323472e-05
hex O 0 0.00012787434388883412
A O 0 1.8967272126246826e-06
, O 0 2.1813013617588695e-09
amounting O 0 4.73125894018267e-08
to O 0 1.6788611389984e-08
3 O 0 1.089351258087845e-06
. O 0 1.5900361916010297e-07

5 O 0 8.871057616488542e-06
% O 0 2.654408945090836e-06
- O 0 4.335037829150679e-06
6 O 0 7.419525445584441e-06
. O 0 3.9615085256627935e-07

9 O 0 1.6053090803325176e-06
% O 0 4.314224710810777e-08
of O 0 1.4277581783517235e-08
total O 0 3.1490883234397415e-09
beta O 0 9.952051271966411e-08
hexosaminidase O 0 2.355348129867707e-07
activity O 0 1.8798040901657487e-09
, O 0 3.759491676302851e-11
has O 0 1.976983333984439e-11
been O 0 3.5875986209576993e-11
obtained O 0 1.6341829278676556e-10
by O 0 4.1519851445848133e-10
cellulose O 0 3.809709312463383e-07
acetate O 0 3.860657216137042e-08
gel O 0 5.999082475227624e-08
electrophoresis O 0 3.323983577274703e-08
, O 0 1.3822684108433236e-09
DEAE O 0 1.4437693607760593e-05
- O 0 5.328484462552296e-07
cellulose O 0 1.3540704912884394e-06
ion O 0 1.4200905980032985e-06
- O 0 5.226807786584686e-08
exchange O 0 1.049803266539584e-08
chromatography O 0 9.865699013289486e-08
, O 0 1.8906913534788572e-10
radial O 0 2.2457248505247662e-08
immunodiffusion O 0 3.9124145700952795e-07
, O 0 1.1406744437891803e-09
and O 0 3.051444208423959e-09
radioimmunoassay O 0 2.0585421225405298e-05
. O 0 4.5685908389714314e-07

Previous O 0 1.77808283297054e-06
family O 0 3.0391016370145962e-09
studies O 0 5.448091422444179e-10
suggested O 0 4.5876133447642076e-10
that O 0 7.087560573160179e-12
these O 0 1.6142585315334634e-12
individuals O 0 1.3225606373956644e-11
may O 0 8.857930500205669e-10
be O 0 5.15160136771442e-10
compound O 0 7.561304471437325e-09
heterozygotes O 0 4.863042413205676e-09
for O 0 3.033481105196856e-11
the O 0 1.628491924643427e-10
common O 0 1.5968850686221003e-09
mutant O 0 2.5224862199024756e-08
TSD B-Disease 0 1.4921757838237681e-06
gene O 0 7.850731176262116e-10
and O 0 3.439502502255998e-11
a O 0 6.174603606190487e-10
rare O 0 2.6836814992492464e-09
( O 0 8.70715943790401e-09
allelic O 0 9.901363000608399e-07
) O 0 1.3668114640097428e-08
mutant O 0 2.2925291887077037e-07
gene O 0 9.411527912561723e-08
. O 0 8.140278140444934e-08

Thus O 0 5.820424462399387e-07
, O 0 4.606502290727121e-09
the O 0 2.5413624538117574e-09
postulated O 0 3.8305333305288514e-07
rate O 0 3.407394899568317e-08
mutant O 0 9.402911338440845e-09
gene O 0 3.7105593597708264e-10
appears O 0 6.88080634136945e-11
to O 0 4.3950871587983276e-12
code O 0 8.677105908794225e-12
for O 0 1.164545109649806e-11
the O 0 4.195896408099031e-11
expression O 0 3.0346686274995704e-10
of O 0 1.4168194395480782e-09
low O 0 8.333665313386973e-09
amounts O 0 4.803160535971074e-09
of O 0 4.663223407419537e-08
hex O 0 1.1639220247161575e-05
A O 0 3.6237415770301595e-06
. O 0 5.118414492244483e-07

Heterozygotes O 0 3.925196870113723e-05
for O 0 3.3870744431396815e-08
the O 0 1.4039831519596646e-08
rare O 0 3.7087357629417284e-09
mutant O 0 5.792858459585659e-08
may O 0 1.4688092964121324e-09
be O 0 3.46816048102383e-10
indistinguishable O 0 5.002352310157221e-09
from O 0 5.15358644648245e-10
heterozygotes O 0 4.893318639176414e-09
for O 0 3.023149230951816e-10
the O 0 5.650424128589293e-09
common O 0 2.56093528605561e-07
TSD B-Disease 0 0.000867747759912163
mutant O 0 6.828995083196787e-06
. O 0 3.979604912274226e-07

However O 0 2.2927412146600545e-07
, O 0 2.7854500928015113e-09
direct O 0 1.3046088653823062e-08
visualization O 0 3.3778690067265416e-07
and O 0 6.296509980074916e-09
quantitation O 0 0.0052893334068357944
of O 0 1.2925591363455169e-05
hex O 0 1.0731617294368334e-05
A O 0 2.3780918567695153e-08
by O 0 1.8504467055868723e-11
the O 0 3.384215130353141e-11
methods O 0 1.6674857328258241e-10
described O 0 1.64284280623761e-10
may O 0 8.883457858210875e-11
prevent O 0 3.039743456945132e-10
false O 0 1.7714247846356557e-09
- O 0 2.533431597839808e-08
positive O 0 3.338581633371973e-10
prenatal O 0 6.096879445749437e-08
diagnosis O 0 8.079317836973132e-08
of O 0 1.3270229715089954e-07
TSD B-Disease 0 0.041034236550331116
in O 0 1.9839063725157757e-08
fetuses O 0 2.5612177267930747e-08
having O 0 2.7816685066461844e-10
the O 0 4.2745357253792804e-10
incomplete O 0 3.8277210734349865e-08
hex B-Disease 0 1.1979141163465101e-05
A I-Disease 0 4.311692919145571e-06
deficiency I-Disease 0 0.00022527389228343964
of O 0 1.2565642748540995e-07
the O 0 1.0118736959441321e-09
type O 0 1.2799172388611169e-08
described O 0 2.474200622160083e-09
in O 0 1.5072898484902453e-10
the O 0 1.3459310332919472e-09
four O 0 1.6719163831169226e-09
healthy O 0 5.530913949058913e-09
individuals O 0 4.0357448938266316e-08

The O 0 1.1277596740910667e-06
tumor B-Disease 0 3.6830744647886604e-05
suppressor O 0 1.4357851796376053e-05
gene O 0 2.8334778789940174e-07
Smad4 O 0 6.2492661527358e-05
/ O 0 4.379800884635188e-06
Dpc4 O 0 7.270637524925405e-06
is O 0 3.1210067863440827e-10
required O 0 2.268132903715525e-10
for O 0 3.113170554680522e-10
gastrulation O 0 1.7792994810861273e-07
and O 0 1.7554273312736512e-10
later O 0 1.3068395254833831e-09
for O 0 1.166319540946148e-10
anterior O 0 3.1075796869117767e-07
development O 0 2.115126562785008e-08
of O 0 4.191127445096754e-08
the O 0 1.2807475080478525e-08
mouse O 0 7.832699822074574e-08
embryo O 0 1.1144976497234893e-06
. O 0 2.2368335805822426e-07

Mutations O 0 1.7722219354254776e-06
in O 0 1.6342685427161996e-08
the O 0 1.1605715144469286e-07
SMAD4 O 1 0.9999996423721313
/ O 1 0.9993088245391846
DPC4 O 1 0.9999634027481079
tumor B-Disease 0 0.00024261696671601385
suppressor O 0 4.58628073829459e-06
gene O 0 7.079572927892741e-09
, O 0 1.1255947562904822e-10
a O 0 5.239099154508153e-10
key O 0 4.783670704000542e-08
signal O 0 1.768105022392774e-07
transducer O 0 9.23647235140379e-07
in O 0 2.8018991571343577e-09
most O 0 1.844064345668528e-09
TGFbeta O 0 0.00042883752030320466
- O 0 9.727889391797362e-07
related O 0 3.7275874831266265e-08
pathways O 0 4.24676116494993e-09
, O 0 2.1725217111412398e-11
are O 0 1.970593610164939e-12
involved O 0 3.563857889354871e-11
in O 0 6.014185677249984e-11
50 O 0 2.2141901645511552e-09
% O 0 2.1860007137775028e-08
of O 0 9.796840458875522e-07
pancreatic B-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.00016436041914857924

Homozygous O 0 4.1260020225308836e-05
Smad4 O 0 0.0018865157617256045
mutant O 0 1.9682234778883867e-05
mice O 0 5.642984319820243e-07
die O 0 7.820099199307151e-07
before O 0 6.233491234297617e-08
day O 0 1.3878477034268144e-07
7 O 0 9.198699331136595e-07
. O 0 1.9703689702055271e-07

5 O 0 1.68372589541832e-05
of O 0 6.53196002531331e-06
embryogenesis O 0 9.189928096020594e-05
. O 0 4.2583160393405706e-06

Mutant O 0 1.586919893270533e-06
embryos O 0 4.045470802793716e-08
have O 0 6.154189657880949e-11
reduced O 0 8.376336846360743e-10
size O 0 8.753847646758572e-10
, O 0 1.8689313985298384e-10
fail O 0 1.4825706884380452e-08
to O 0 3.1903197861282706e-09
gastrulate O 0 9.119109563471284e-06
or O 0 3.573683793334226e-09
express O 0 1.0852715393028234e-09
a O 0 1.3048145897087693e-09
mesodermal O 0 2.632564530813397e-07
marker O 0 1.6410412229106441e-07
, O 0 5.031592920090588e-10
and O 0 6.838758448424187e-10
show O 0 9.596399230815678e-09
abnormal O 0 1.9366694914424443e-07
visceral O 0 1.0656342055881396e-05
endoderm O 0 0.0007415482541546226
development O 0 8.630906449980102e-06
. O 0 1.087161535906489e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 0.016615983098745346
the O 0 1.6431113181170076e-05
Smad4 O 1 0.9999949932098389
- O 0 0.0019885869696736336
deficient O 0 8.03038346930407e-07
embryos O 0 4.69216354659352e-09
results O 0 4.2206685368917363e-10
from O 0 2.7903832022779795e-10
reduced O 0 5.609254394300933e-09
cell O 0 7.18940107446997e-09
proliferation O 0 8.83419559727372e-09
rather O 0 1.1201056748788574e-10
than O 0 1.8085616337870647e-10
increased O 0 4.58032367589567e-09
apoptosis O 0 7.958488481563109e-07
. O 0 1.3434905099529715e-07

Aggregation O 0 5.122983566252515e-06
of O 0 1.307499246649968e-06
mutant O 0 1.6768982504800078e-06
Smad4 O 0 0.00014471536269411445
ES O 0 3.502355684759095e-05
cells O 0 3.6401253122875232e-09
with O 0 4.501453723659843e-11
wild O 0 3.406938509087354e-09
- O 0 8.20756174135795e-09
type O 0 5.766841582044435e-08
tetraploid O 0 1.0107448360940907e-05
morulae O 0 4.923898814013228e-05
rescues O 0 1.248018520527694e-06
the O 0 1.1514696041103889e-07
gastrulation B-Disease 0 4.682566213887185e-05
defect I-Disease 0 4.952077870257199e-05
. O 0 9.47042622101435e-07

These O 0 8.503317161512314e-09
results O 0 9.000327594321789e-09
indicate O 0 6.688093190376776e-09
that O 0 1.231042767724233e-10
Smad4 O 0 7.080249702084984e-07
is O 0 4.805996572931903e-11
initially O 0 5.915920531229801e-11
required O 0 8.568362165617405e-12
for O 0 1.1968868604550487e-11
the O 0 8.860680938971299e-11
differentiation O 0 5.31097876788067e-09
of O 0 2.21661999866285e-09
the O 0 6.222877768635726e-10
visceral O 0 1.0697110752744265e-07
endoderm O 0 7.257200422827736e-07
and O 0 1.645897584889866e-10
that O 0 2.926884429266252e-11
the O 0 5.390415336314902e-10
gastrulation B-Disease 0 5.558926545745635e-07
defect I-Disease 0 1.0417373630389193e-07
in O 0 3.1575370096348365e-10
the O 0 1.0621045154479702e-09
epiblast O 0 5.824366553497384e-07
is O 0 4.835384870283121e-10
secondary O 0 1.1473278327400749e-08
and O 0 5.169584760267298e-10
non O 0 8.694216830917867e-07
- O 0 2.535941575843026e-06
cell O 0 6.207014394021826e-06
autonomous O 0 4.43103954239632e-06
. O 0 7.787613753862388e-07

Rescued O 0 1.9112907466478646e-05
embryos O 0 4.799966859536653e-07
show O 0 2.4778808338510316e-08
severe O 0 6.298798325587995e-06
anterior O 0 0.015989769250154495
truncations O 0 0.10662684589624405
, O 0 1.7481385228279578e-08
indicating O 0 5.1685152158142955e-08
a O 0 1.1648416675669182e-09
second O 0 3.731797093564637e-09
important O 0 3.6035657791089193e-10
role O 0 5.669854030720956e-10
for O 0 3.9278422181432404e-10
Smad4 O 0 1.9025579604203813e-05
in O 0 9.803025946553134e-09
anterior O 0 5.267412052489817e-05
patterning O 0 0.0004427380918059498
during O 0 1.9835259081446566e-05
embryogenesis O 0 1.5949301086948253e-05
. O 0 4.210557733586029e-07

Prevalence O 0 2.9017284759902395e-05
of O 0 6.95960750363156e-07
p16 O 0 6.632102213188773e-06
and O 0 1.175602122316377e-07
CDK4 O 1 0.999996542930603
germline O 1 0.6449836492538452
mutations O 0 1.3395950873018592e-06
in O 0 8.359774206212478e-09
48 O 0 3.301066954009002e-06
melanoma B-Disease 1 0.9999731779098511
- O 0 7.472755441995105e-06
prone O 0 1.6810914530651644e-05
families O 0 1.854048581328982e-09
in O 0 3.792582248252074e-09
France O 0 4.434631364347297e-07
. O 0 7.39360643819964e-07

The O 0 1.7736083464114927e-06
French O 0 0.00011819342034868896
Familial B-Disease 1 0.9999949932098389
Melanoma I-Disease 1 1.0
Study O 0 2.6126358534384053e-06
Group O 0 2.084208858832426e-07
. O 0 1.862887160086757e-07

Germline O 0 0.004748466424643993
mutations O 0 2.7632852379610995e-06
in O 0 9.977515702530582e-09
the O 0 1.6482932352346324e-08
p16 O 0 4.1223356106456777e-07
and O 0 8.002950302454792e-09
CDK4 O 1 0.7826718688011169
genes O 0 1.829271489839357e-08
have O 0 1.7974742527737675e-10
been O 0 4.254339658338324e-10
reported O 0 1.1485528500498887e-10
in O 0 7.490926282049948e-12
a O 0 1.0382091020222362e-10
subset O 0 4.116426310929455e-08
of O 0 6.832766530351364e-08
melanoma B-Disease 1 0.6279482245445251
pedigrees O 0 7.217321496000295e-08
, O 0 3.325375530494057e-10
but O 0 7.722336659021778e-11
their O 0 2.5588114960228836e-11
prevalence O 0 3.745167287405593e-09
is O 0 1.922751541316714e-11
not O 0 1.191652748699923e-10
well O 0 1.0155996044147741e-09
known O 0 8.5339003419449e-08
. O 0 3.953005887069594e-07

We O 0 2.4110264007504156e-07
searched O 0 6.093751636626621e-08
for O 0 1.0577680953360868e-09
such O 0 2.140343902112818e-09
germline O 0 0.00014674957492388785
mutations O 0 2.0912409581796965e-07
in O 0 2.4800308473515997e-09
48 O 0 1.66408682389374e-07
French O 0 1.4850696970825084e-05
melanoma B-Disease 1 1.0
- O 0 2.1636069504893385e-05
prone O 0 1.3599977819467313e-06
families O 0 4.158814959076551e-11
selected O 0 1.4310712337373133e-11
according O 0 6.9075487517389345e-12
to O 0 1.8882180541357485e-11
two O 0 2.0667877131952395e-12
major O 0 2.1979977560260267e-10
criteria O 0 1.2772485291634439e-09
families O 0 5.134615389118524e-12
with O 0 1.93444088872341e-12
at O 0 1.3349754635072486e-09
least O 0 1.287255718684932e-10
three O 0 1.8113639060901576e-11
affected O 0 8.383685412560737e-11
members O 0 1.8397342677056727e-11
( O 0 8.517105770655675e-11
n O 0 5.072741782186085e-09
= O 0 2.5142232740194004e-09
20 O 0 4.0164355175065225e-10
) O 0 3.5429877347920025e-12
or O 0 2.229971242384554e-11
families O 0 2.1026290517728308e-12
with O 0 6.480665071424696e-13
two O 0 7.083154809212067e-12
affected O 0 8.782374133486925e-11
members O 0 9.33495641897153e-12
, O 0 1.461915484501919e-11
one O 0 2.4613294041797573e-11
of O 0 1.5980816669980413e-10
them O 0 1.7566548259420611e-12
affected O 0 9.455556997106651e-12
before O 0 5.115722429005487e-11
the O 0 1.0424315577406418e-10
age O 0 1.207582922546635e-09
of O 0 9.117279153869617e-10
50 O 0 1.282184025619415e-09
( O 0 2.2693359691405846e-10
n O 0 8.555081976169276e-09
= O 0 5.306725725517936e-09
28 O 0 1.6758594512111813e-09
) O 0 1.7178392389127772e-11
, O 0 1.6357318277648858e-11
and O 0 1.1899215120181328e-11
one O 0 4.629522112886697e-11
additional O 0 2.8237226445959607e-10
minor O 0 1.2170261243227287e-07
criterion O 0 0.00011977775284321979
. O 0 8.981225505522161e-07

Sixteen O 0 2.1509051748580532e-06
different O 0 1.0595677224500832e-08
p16 O 0 2.170298557757633e-06
germline O 0 1.374826933897566e-05
mutations O 0 9.076563856069697e-08
were O 0 8.167954090865237e-10
found O 0 6.894087384301528e-11
in O 0 2.7603462918190935e-11
21 O 0 4.484659310577399e-10
families O 0 1.562804399779516e-11
, O 0 4.980032358714581e-11
while O 0 2.7906812971600914e-10
one O 0 8.332484702222587e-10
germline O 0 1.1519972531459644e-06
mutation O 0 6.380852113352375e-08
, O 0 2.4724928771036048e-09
Arg24His O 0 2.0173607481410727e-05
, O 0 2.119430630997954e-09
was O 0 3.682986715602965e-08
detected O 0 7.777347654780442e-09
in O 0 4.974414768987856e-10
the O 0 2.2147403910821595e-08
CDK4 O 0 0.006238302681595087
gene O 0 1.527424842606706e-06
. O 0 6.371287213369214e-07

The O 0 9.733683015156203e-08
frequency O 0 3.145446783037187e-07
of O 0 5.697307869922952e-08
p16 O 0 1.6998932039768988e-07
gene O 0 1.8885009112068474e-09
mutation O 0 2.081841143919405e-09
in O 0 3.832741415910057e-11
our O 0 2.452070317626731e-11
sample O 0 3.686656882551098e-11
( O 0 2.5114936172410118e-11
44 O 0 1.0353856660927363e-09
% O 0 4.3632017443506754e-10
) O 0 6.930035972158022e-12
is O 0 1.53357118670705e-11
among O 0 6.4469488775253936e-12
the O 0 3.581657193052479e-11
highest O 0 8.874271095749009e-09
rates O 0 4.499653150080718e-10
yet O 0 2.914163077516463e-10
reported O 0 5.710422690263783e-10
and O 0 6.126876783696389e-11
the O 0 7.291075521109747e-10
CDK4 O 0 1.4271763575379737e-05
mutation O 0 6.51958309560996e-09
is O 0 9.219099789126162e-11
the O 0 1.9480313195874288e-10
second O 0 4.004878650931687e-09
mutation O 0 6.40389297146271e-09
detected O 0 7.0888424019699414e-09
in O 0 1.2113471337116266e-10
this O 0 4.569274403287693e-10
gene O 0 1.4607413945100234e-08
worldwide O 0 1.9720413746426857e-08
. O 0 1.585304403306509e-07

In O 0 2.7813742420335075e-08
summary O 0 3.371001469076873e-07
, O 0 1.4991508034967183e-09
our O 0 2.41967973435564e-10
results O 0 3.3903416185587787e-10
show O 0 7.186774092504677e-11
frequent O 0 7.789616868203453e-11
involvement O 0 5.580601758481407e-09
of O 0 8.160592201988948e-09
the O 0 3.96595156715307e-09
p16 O 0 5.629697596987171e-08
gene O 0 1.499127932902411e-09
in O 0 6.569522703614439e-10
familial B-Disease 0 0.009953612461686134
melanoma I-Disease 1 0.9999980926513672
and O 0 1.9326733546876085e-09
confirm O 0 2.6299777911020783e-09
the O 0 6.018308074118295e-10
role O 0 3.8095523957615285e-10
of O 0 1.7248604766706421e-09
the O 0 1.0368995662091152e-09
CDK4 O 0 0.00013974557805340737
gene O 0 2.049096003986506e-09
as O 0 2.1849980158528126e-10
a O 0 1.158392670674857e-08
melanoma B-Disease 0 0.07629405707120895
- O 0 1.1164976058353204e-05
predisposing O 0 6.031729299138533e-06
gene O 0 6.620194881179486e-08
. O 0 1.862893661552789e-08
. O 0 1.2351179634606524e-07

Progression O 0 0.0009166525560431182
of O 0 5.769576091552153e-05
somatic O 0 0.019447671249508858
CTG O 0 0.0017052654875442386
repeat O 0 5.048362936577178e-07
length O 0 3.2056924226253614e-08
heterogeneity O 0 2.875154905268573e-07
in O 0 1.9884238700029755e-10
the O 0 2.381911889948185e-10
blood O 0 1.6691921178590974e-09
cells O 0 1.2249449454770911e-08
of O 0 1.2087677987437928e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.00011081428965553641
. O 0 4.411601821630029e-06

The O 0 2.3363293522038475e-08
genetic O 0 1.6523065582418894e-08
basis O 0 3.6009723203278554e-08
of O 0 2.68855046670069e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.5338047180412104e-06
DM B-Disease 1 1.0
) O 0 1.830920692835747e-10
is O 0 1.4163695390145836e-11
the O 0 2.0357633981338275e-11
expansion O 0 1.0183462961776968e-09
of O 0 6.60977095279236e-09
an O 0 4.102268746919435e-09
unstable O 0 3.097132866969332e-05
CTG O 0 6.235194450709969e-05
repeat O 0 7.619798481073303e-08
in O 0 5.350976883811143e-10
the O 0 1.344460764940436e-09
34 O 0 1.5349430171340828e-08
UTR O 0 8.800462637736928e-06
of O 0 5.7021132704448974e-08
the O 0 1.1055003312776535e-07
DM B-Disease 1 0.9999997615814209
protein O 0 1.8855043038001895e-07
kinase O 0 1.5086079940829222e-07
gene O 0 6.0913092347902875e-09
on O 0 3.967814876659759e-08
chromosome O 0 4.580374934448628e-06
19 O 0 9.03174679933727e-07
. O 0 1.6032345229177736e-07

One O 0 6.831932353179582e-08
of O 0 5.2688470475459326e-08
the O 0 3.6451415219573846e-09
principal O 0 1.806412264215851e-08
features O 0 5.845203487897521e-11
of O 0 1.3138481413932368e-08
the O 0 5.1986607019216535e-08
DM B-Disease 1 1.0
mutation O 0 6.447508553719672e-07
is O 0 2.169301266397028e-10
an O 0 4.486401875003487e-11
extraordinarily O 0 1.1625317597463436e-08
high O 0 6.128486518264253e-08
level O 0 1.3821684206050122e-06
of O 0 1.753292849571153e-06
somatic O 1 0.992771327495575
mosaicism O 1 0.9999791383743286
, O 0 2.41278175217019e-09
due O 0 1.0379487491718464e-08
to O 0 8.6225672435436e-11
an O 0 1.3447311840442122e-11
extremely O 0 5.5590407277428255e-11
high O 0 4.914755269425086e-10
degree O 0 3.3441931890365595e-08
of O 0 3.281619243011846e-08
somatic O 0 1.1397198250051588e-05
instability O 0 1.5713333141320618e-06
both O 0 3.2304436903274336e-10
within O 0 1.6413840286944037e-09
and O 0 6.577957623044028e-11
between O 0 1.5852500423463312e-09
different O 0 1.1064128502269455e-09
tissues O 0 4.018846055942049e-08
. O 0 2.4038762092004617e-08

This O 0 7.163300352885926e-08
instability O 0 4.4977074139751494e-05
appears O 0 5.291070692692301e-09
to O 0 8.428385767089708e-11
be O 0 5.819450130117865e-11
biased O 0 9.16346110102495e-10
towards O 0 3.845572749128223e-10
further O 0 2.3402014701079388e-11
expansion O 0 4.128845876305576e-10
and O 0 2.3453758032920824e-11
continuous O 0 2.89755908156053e-09
throughout O 0 9.543619367002876e-11
the O 0 8.778472393444758e-11
life O 0 7.171465504773877e-11
of O 0 8.458711509007344e-11
an O 0 8.781247430589278e-12
individual O 0 4.6340604964445475e-12
, O 0 7.864391429746043e-12
features O 0 1.6579571916752744e-12
that O 0 2.7239222162578347e-12
could O 0 4.958801078092101e-11
be O 0 3.434795503576282e-11
associated O 0 9.908852210971375e-11
with O 0 1.7601796756250288e-12
the O 0 3.4516425828634567e-10
progressive O 0 5.701970735572104e-07
nature O 0 2.921088615437384e-08
of O 0 3.043843150862813e-07
the O 0 3.3133247256955656e-07
disease O 0 3.4044613130390644e-05
. O 0 5.689477688974875e-07

Although O 0 1.5903751204859873e-08
increasing O 0 4.420576349417615e-09
measured O 0 6.939543606421239e-09
allele O 0 1.0654935600484805e-08
size O 0 1.1619480932978377e-09
between O 0 3.6704739247994667e-09
patients O 0 5.288101068146034e-10
clearly O 0 2.942300569852563e-10
correlates O 0 5.006692838094295e-10
with O 0 1.7753177671431947e-13
an O 0 7.858764095210191e-13
increased O 0 2.9438486370825245e-11
severity O 0 1.481033820027733e-07
of O 0 2.6650237572312108e-08
symptoms O 0 5.543799197482713e-09
and O 0 1.4371601998741657e-11
an O 0 2.3642791283778886e-12
earlier O 0 1.1234713159780085e-10
age O 0 4.923959573410741e-10
of O 0 5.876069075760881e-10
onset O 0 6.556359721798799e-07
, O 0 1.4183971705494791e-11
this O 0 7.699463462629286e-12
correlation O 0 4.911269169127763e-10
is O 0 1.2233505874981176e-11
not O 0 1.2222031546549328e-11
precise O 0 1.0630286650936682e-09
and O 0 3.502654416509543e-11
measured O 0 1.8132253476466076e-09
allele O 0 2.480447180985834e-09
length O 0 4.5906681234164637e-10
cannot O 0 1.7776415062176198e-10
be O 0 1.1559653408099724e-11
used O 0 5.0037764730281875e-12
as O 0 2.7189288147322355e-12
an O 0 1.3987040692331476e-12
accurate O 0 8.466333745182908e-10
predictor O 0 6.849076044090907e-07
of O 0 1.0660790472627468e-08
age O 0 2.0588548466093926e-07
of O 0 3.6804661363021296e-07
onset O 1 0.9199286699295044
. O 0 9.926152415573597e-07

In O 0 5.0190198663813135e-09
order O 0 1.4007298654306055e-09
to O 0 3.7483738335453154e-10
further O 0 7.556572034772557e-10
characterize O 0 4.992137192516566e-08
the O 0 5.864450258741272e-09
dynamics O 0 2.501298581591982e-07
of O 0 4.104508661839645e-06
DM B-Disease 1 1.0
CTG O 0 0.001157052000053227
repeat O 0 4.4336758264762466e-07
somatic O 0 3.858136551571079e-06
instability O 0 3.8905318433535285e-06
, O 0 3.877382581674027e-10
we O 0 1.68734748395849e-10
have O 0 9.582448549927403e-12
studied O 0 3.4652511415877996e-10
repeat O 0 9.050965532608757e-11
length O 0 5.2977400244458295e-11
changes O 0 1.0057098383253749e-11
over O 0 7.166187782070566e-11
time O 0 2.7396190871442627e-10
in O 0 2.584909508662747e-10
111 O 0 3.1719480375613784e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 9.891583552246175e-09
with O 0 2.8147463526639882e-11
varying O 0 3.5797009800830892e-09
clinical O 0 1.936697202609139e-07
severity O 0 0.00011613310198299587
and O 0 1.0716507681252097e-08
CTG O 0 4.293744950700784e-06
repeat O 0 1.9901778003372783e-09
size O 0 1.6862278240381556e-10
over O 0 1.1244961212186766e-10
time O 0 1.848253772251951e-10
intervals O 0 1.5423730070907027e-09
of O 0 1.4514229818018975e-09
1 O 0 8.372032311854127e-08
- O 0 1.0279563866788521e-07
7 O 0 1.4342876397677173e-07
years O 0 3.899078748759166e-08
. O 0 6.196506063815832e-08

We O 0 1.186285487619898e-07
have O 0 3.873516507546526e-10
found O 0 6.232246663184782e-11
a O 0 3.947999913100908e-11
direct O 0 1.8300312376595684e-09
progression O 0 1.3565906442636333e-07
of O 0 4.120807695073836e-09
the O 0 1.0111406156809721e-09
size O 0 2.6137552122662555e-09
heterogeneity O 0 1.2429995877027977e-07
over O 0 3.0549967000581546e-09
time O 0 2.6009046028008243e-09
related O 0 1.5019614441058593e-09
to O 0 5.383612999843024e-10
initial O 0 1.0084273860400117e-08
CTG O 0 1.6893607153178891e-06
repeat O 0 2.4264192877154755e-09
size O 0 2.7986449269157276e-10
and O 0 2.95485164114595e-11
the O 0 1.6600504304520314e-10
time O 0 5.69437996755795e-10
interval O 0 5.639743339003189e-09
and O 0 4.8596064672334904e-11
always O 0 3.724286434803048e-10
biased O 0 5.842366146424638e-09
towards O 0 3.79612075107616e-09
further O 0 4.774297845955289e-09
expansion O 0 2.5423389615752967e-07
. O 0 2.3323829623222991e-07

Attempts O 0 3.0988672961029806e-07
to O 0 4.042815415772338e-09
mathematically O 0 8.298898990233283e-08
model O 0 4.274056664144155e-09
the O 0 1.7181424061263328e-09
dynamics O 0 8.508513360538927e-08
have O 0 1.51530052394655e-10
proved O 0 8.43736902567116e-09
only O 0 7.25536367096602e-11
partially O 0 2.358863993023874e-09
successful O 0 1.5885968929207905e-10
suggesting O 0 1.5837019196052182e-10
that O 0 2.3659258146374595e-12
individual O 0 8.605798907691808e-13
specific O 0 7.974692434187247e-11
genetic O 0 2.247396047039274e-08
and O 0 1.3705647727846326e-09
/ O 0 2.4525086701032706e-05
or O 0 2.6974975142479707e-08
environmental O 0 1.6204722896873136e-07
factors O 0 2.4103210538584108e-09
also O 0 1.631855414685468e-11
play O 0 1.161329366006214e-10
a O 0 2.528529052803208e-10
role O 0 1.6363265187280263e-09
in O 0 1.5078743809127104e-09
somatic O 0 5.678236902895151e-06
mosaicism O 0 0.00127965968567878
. O 0 1.0741744205233772e-07
. O 0 2.643540994995419e-07

Aspartylglucosaminuria B-Disease 1 0.9999998807907104
among O 0 5.652679533341143e-07
Palestinian O 0 3.407651456655003e-05
Arabs O 0 7.40780342312064e-06
. O 0 7.738832437098608e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9998008608818054
AGU B-Disease 1 1.0
) O 0 2.1313255160748668e-08
is O 0 2.407867460973989e-09
a O 0 3.2196989518951113e-09
rare O 0 7.327371776000291e-08
disorder B-Disease 1 0.9999970197677612
of I-Disease 0 0.002440331969410181
glycoprotein I-Disease 0 0.0007921374635770917
metabolism I-Disease 0 1.597682603460271e-05
caused O 0 1.4744181875414597e-08
by O 0 1.5466851410739224e-10
the O 0 2.1789738013922033e-08
deficiency B-Disease 0 2.1505324184545316e-05
of I-Disease 0 5.404696821642574e-06
the I-Disease 0 3.4222196632072155e-07
lysosomal I-Disease 0 5.9309182688593864e-05
enzyme I-Disease 0 3.41730498121251e-07
aspartylglucosaminidase I-Disease 0 1.0144452971871942e-05
( O 0 1.2969349150182552e-08
AGA O 0 3.437788473092951e-05
) O 0 1.1456397608355928e-08
. O 0 6.45817337385779e-08

AGU B-Disease 1 1.0
is O 0 7.656495881747105e-07
inherited O 0 3.0972772947279736e-05
as O 0 8.956214436750543e-09
an O 0 3.7010756681610246e-09
autosomal O 0 0.014311620965600014
recessive O 1 0.9936360120773315
trait O 0 7.825523425708525e-06
and O 0 8.94825324948556e-10
occurs O 0 3.927857483709829e-10
with O 0 1.948092511958044e-12
a O 0 7.406398411236026e-11
high O 0 1.8643644406068915e-09
frequency O 0 2.0326934802028518e-08
in O 0 2.345645622181536e-10
Finland O 0 6.690236808992722e-09
because O 0 2.377255059471395e-10
of O 0 5.853185935933425e-09
a O 0 6.6313901037062806e-09
founder O 0 4.015390686618048e-07
effect O 0 6.309364266599005e-07
. O 0 2.3087541478616913e-07

While O 0 2.6811662223735766e-07
very O 0 9.065072248404249e-09
few O 0 4.32187352572555e-09
patients O 0 1.2090302092815364e-09
with O 0 2.198694781796462e-09
AGU B-Disease 1 1.0
have O 0 8.871783307995429e-09
been O 0 1.210220701430842e-09
reported O 0 3.0911123660715134e-10
from O 0 2.840261914549558e-10
non O 0 1.004484406763595e-08
- O 0 3.348097799005245e-09
Finnish O 0 3.5266385367549447e-08
origin O 0 1.4497021361137286e-09
, O 0 3.126565673028381e-10
we O 0 2.641550533866166e-09
diagnosed O 0 0.01186065748333931
the O 0 2.736858917273821e-08
disorder O 1 0.7682185173034668
in O 0 2.4498383321969186e-09
8 O 0 4.690054566935942e-08
patients O 0 3.7892591842059176e-11
originating O 0 1.9463226863525307e-10
from O 0 3.3393904308454125e-10
3 O 0 2.486178374283554e-09
unrelated O 0 3.4994374065178135e-10
families O 0 2.191381407931625e-12
, O 0 1.6024142733203628e-12
all O 0 2.3914598600016657e-12
Palestinian O 0 1.24414656355043e-09
Arabs O 0 7.401402823958847e-10
from O 0 9.757239460839173e-11
the O 0 1.3166137624587293e-10
region O 0 5.255796242664701e-09
of O 0 2.7116527689940995e-08
Jerusalem O 0 2.0707453586510383e-05
. O 0 4.129882711367827e-07

The O 0 1.6000331015675329e-07
clinical O 0 2.8958481834706618e-06
diagnosis O 1 0.9999216794967651
of O 1 0.9999939203262329
AGU B-Disease 1 1.0
is O 0 1.5755392723804107e-07
often O 0 7.570594706685085e-10
difficult O 0 3.0918632099030674e-09
, O 0 1.8086364003688793e-11
in O 0 5.763838625133522e-12
particular O 0 1.1745079908642708e-10
early O 0 1.3867206272166754e-09
in O 0 1.1651716050331551e-11
the O 0 2.369856220985067e-11
course O 0 1.4997055819421234e-09
of O 0 1.1872611782592912e-09
the O 0 1.866086396518085e-09
disease O 0 6.46950368832222e-08
, O 0 2.6351872073338e-11
and O 0 1.1327185717169286e-11
most O 0 1.1430863200434516e-11
of O 0 1.1200484983930892e-09
the O 0 4.692107813397683e-10
patients O 0 1.4462683828320166e-10
are O 0 3.0347484941684044e-11
diagnosed O 0 1.611057456329945e-07
after O 0 1.4011413140835316e-09
the O 0 6.044929001802757e-10
age O 0 8.600828493854351e-09
of O 0 7.513230926292636e-09
5 O 0 3.108510071569981e-08
years O 0 1.926653148132118e-08
. O 0 6.894597248674472e-08

However O 0 7.067419005579723e-07
, O 0 1.0051628862584039e-08
since O 0 9.135421308315017e-09
these O 0 1.553775580420691e-10
patients O 0 2.8322233447397593e-10
excrete O 0 2.0438930548039025e-09
early O 0 6.854062872818645e-10
large O 0 9.085297791866509e-11
amounts O 0 1.2186753828302699e-09
of O 0 2.088499861940818e-08
aspartylglucosamine O 0 4.864130460191518e-06
in O 0 2.9254696443103967e-09
urine O 0 1.5721995927364674e-09
, O 0 1.8927000591806298e-11
biochemical O 0 6.054182710713008e-10
screening O 0 8.767616632709974e-10
is O 0 1.0161534114150328e-10
easy O 0 1.0294545216282813e-09
by O 0 1.0165337460676938e-09
urine O 0 1.3855579794608275e-08
chromatography O 0 7.360399649769533e-07
. O 0 2.7479112318928856e-08
. O 0 1.6736248653614894e-07

Detection O 0 2.0162017335678684e-06
of O 0 1.1384898357391648e-07
heterozygous O 0 3.653229496691779e-09
carriers O 0 4.3133149829621686e-10
of O 0 3.091782119213349e-08
the O 0 6.07692754783784e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 2.502995357644977e-06
ATM O 1 0.8097218871116638
) O 0 3.4619760391763066e-09
gene O 0 6.078829106748174e-10
by O 0 4.093372030222753e-10
G2 O 0 2.460803898429731e-06
phase O 0 5.010040695196949e-06
chromosomal O 0 0.00016896500892471522
radiosensitivity O 0 6.790338375139982e-05
of O 0 5.206269179325318e-06
peripheral O 0 0.11693323403596878
blood O 0 2.6075327696162276e-05
lymphocytes O 0 4.988938144379063e-06
. O 0 1.0581780998109025e-06

In O 0 2.7323134418111295e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.8523310422897339
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.6194186253956104e-09
patients O 0 3.5350464222538847e-10
, O 0 3.452516397772776e-11
mutations O 0 2.689773126451911e-10
in O 0 3.878201579321505e-11
a O 0 9.089475005996661e-11
single O 0 2.464586312811434e-10
gene O 0 8.06420277776887e-11
, O 0 2.1208033593178577e-11
ATM O 0 1.8841718656403827e-06
, O 0 9.19014933598028e-11
result O 0 5.211730491616606e-10
in O 0 4.476471970882301e-10
an O 0 3.41127055492052e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 2.7051003144151764e-06
embraces O 0 3.395263448169317e-08
a O 0 1.9964653541482136e-10
variety O 0 5.4203010135811525e-11
of O 0 4.834038724865763e-10
clinical O 0 1.8042763949566165e-09
features O 0 4.7904385319652576e-11
and O 0 4.812766157824555e-11
manifests O 0 9.96672633313267e-10
extreme O 0 2.962712812859536e-07
radiosensitivity O 0 5.410870016930858e-06
and O 0 6.156094523035449e-10
a O 0 2.551036493159131e-09
strong O 0 3.8044136729809e-09
pre O 0 1.1104598343081307e-05
- O 0 2.2852893835079158e-06
disposition O 0 1.4144397027848754e-05
to O 0 6.039346089892206e-07
malignancy B-Disease 0 0.26965469121932983
. O 0 9.296645089307276e-07

Heterozygotes O 0 1.1440955631769612e-06
for O 0 3.5248681751198774e-09
the O 0 2.549256361561447e-09
ATM O 0 1.5834300938877277e-05
gene O 0 1.7218430015120134e-09
have O 0 3.099612927437434e-11
no O 0 5.4854804726334194e-11
clinical O 0 3.5389527419660283e-10
expression O 0 1.5425671850977096e-09
of O 0 9.190466130348796e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 6.130807528315074e-10
may O 0 1.5111479845231202e-09
be O 0 1.4596739372763068e-09
cancer B-Disease 0 8.808204654542351e-08
prone O 0 2.139682653279351e-09
with O 0 1.7237988380464087e-12
a O 0 6.044605926902591e-10
moderate O 0 3.022529995178047e-07
increase O 0 4.388727603554798e-09
in O 0 2.509906060765843e-09
in O 0 6.203717539676745e-09
vitro O 0 1.7172461639347603e-06
radiosensitivity O 0 2.583020796009805e-05
. O 0 6.08665516210749e-07

We O 0 1.7973292187889456e-07
performed O 0 1.0954980922406321e-08
a O 0 1.0301955732927581e-08
blind O 0 3.1176725201476074e-07
chromosomal O 0 1.5674299902457278e-06
analysis O 0 7.478303309937928e-09
on O 0 4.149218213456152e-08
G2 O 0 6.089824751143169e-07
- O 0 1.8404179513709096e-08
phase O 0 1.8398920076379e-07
lymphocytes O 0 8.909458171224571e-10
from O 0 2.293066292402557e-10
7 O 0 3.871723830428664e-09
unrelated O 0 1.868651722247705e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 6.600057833594519e-09
, O 0 2.3600690846059535e-10
13 O 0 1.1271851230176821e-09
obligate O 0 2.148082778319349e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
heterozygotes O 0 2.163562413670661e-07
( O 0 7.896049092348534e-11
parents O 0 2.114857247659252e-11
of O 0 9.827147429142258e-11
the O 0 5.757819915297446e-11
patients O 0 2.569139866126502e-11
) O 0 1.660173214179661e-11
, O 0 7.680898278517034e-11
and O 0 3.1707358960630927e-10
14 O 0 7.536080204317841e-09
normal O 0 4.062727931852805e-09
controls O 0 4.033342104747817e-09
following O 0 8.634568615661919e-10
X O 0 6.248275781217671e-07
- O 0 2.4626668704286203e-08
irradiation O 0 1.6682317749427966e-08
with O 0 1.8127403744738757e-10
1 O 0 3.185074888278905e-07
Gy O 0 4.943717613059562e-07
in O 0 3.1842858211339475e-11
order O 0 3.995421701818991e-11
to O 0 5.497190549985653e-11
evaluate O 0 2.696697587456498e-10
this O 0 3.0261015915300504e-11
cytogenetic O 0 3.426464445510646e-08
method O 0 2.390911690852704e-09
as O 0 2.1700202398888813e-11
a O 0 3.8977494842828975e-11
tool O 0 8.665834716481413e-10
for O 0 4.002820644388727e-11
detection O 0 2.8570159571472686e-08
of O 0 1.058895406913507e-07
ATM O 0 0.0017650098307058215
carriers O 0 2.591567636045511e-07
. O 0 6.102272323005309e-07

Both O 0 3.708571966853924e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 0.0001259029086213559
and O 0 4.316321078334795e-09
heterozygotes O 0 6.264169627456795e-08
showed O 0 1.5731468905322288e-10
significantly O 0 6.41995692718389e-11
increased O 0 5.94621574201426e-11
levels O 0 4.1727854505069217e-10
of O 0 4.471217618373657e-09
radiation O 1 0.9983128309249878
- O 0 0.0003122691123280674
induced O 0 0.010727254673838615
chromatid O 0 0.00023719703312963247
damage O 0 1.8603590490329225e-07
relative O 0 1.0792959415084624e-08
to O 0 7.314138184000285e-11
that O 0 2.7156237328296307e-11
of O 0 1.3584626756824036e-09
normal O 0 1.8828407277737824e-08
controls O 0 1.7847513333890674e-07
. O 0 8.264574091754184e-08

These O 0 6.06100281075328e-09
results O 0 8.071443069468387e-09
show O 0 1.3982259794431684e-09
that O 0 1.5929478569542965e-10
the O 0 4.788890173301752e-09
G2 O 0 4.831642399949487e-06
- O 0 9.151955282504787e-07
phase O 0 8.842525858199224e-06
chromosomal O 0 6.827869128755992e-06
radiosensitivity O 0 7.696224884057301e-07
assay O 0 9.066144279756827e-09
can O 0 2.360077064333943e-11
be O 0 7.471519930524195e-12
used O 0 4.806929160272588e-12
for O 0 3.173709559045612e-12
the O 0 1.4131125956884372e-11
detection O 0 3.913374513331291e-09
of O 0 2.525604259062675e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 3.765364090213552e-05
. O 0 7.667266004318662e-07

In O 0 5.7891909932550334e-08
combination O 0 4.202085435167646e-08
with O 0 1.9670516326897314e-09
molecular O 0 1.0430868542243843e-06
genetic O 0 7.91207028782992e-08
analyses O 0 3.893087630046921e-09
, O 0 2.010116552375596e-11
this O 0 6.310616092186638e-12
test O 0 5.012528933590055e-11
may O 0 2.8108943991855817e-11
be O 0 2.656696217184784e-11
of O 0 1.2605486099381835e-10
value O 0 1.2180008390760833e-10
in O 0 1.1435246846658309e-11
studies O 0 6.50459686113436e-11
of O 0 5.06021557988845e-10
familial B-Disease 0 2.4474070414726157e-07
and I-Disease 0 4.613765369754219e-09
sporadic I-Disease 0 7.878967380747781e-07
cancers I-Disease 0 8.564995368942618e-05
aimed O 0 7.326460327305995e-09
at O 0 2.723895331513404e-09
determination O 0 1.012497308217064e-09
of O 0 8.918673577440472e-10
the O 0 8.357454311935797e-11
potential O 0 2.2482640749110772e-10
involvement O 0 1.3952475841350065e-09
of O 0 3.220214761512352e-09
ATM O 0 1.6256270100711845e-05
mutations O 0 2.9645999433114412e-08
in O 0 6.625444637364808e-10
tumor B-Disease 0 8.846221317071468e-05
risk O 0 1.1077968764539037e-07
or O 0 6.810943364854438e-09
development O 0 3.020126371211518e-08
. O 0 4.687700005945317e-09
. O 0 3.550761107362632e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 2.7221723541970277e-08
identification O 0 8.730507872201088e-09
and O 0 1.2164964868777162e-10
detection O 0 7.756965914040848e-08
of O 0 3.7847476619390363e-07
founder O 0 2.8381423362588976e-06
- O 0 6.688350850936331e-08
effect O 0 6.978356736908609e-08
mutations O 0 6.4962093482279215e-09
in O 0 9.486361002286614e-11
the O 0 4.25044638374672e-10
ATM O 0 3.5827572446578415e-06
gene O 0 2.161550050061578e-09
in O 0 3.940696935433863e-10
ethnic O 0 1.1508652697500565e-08
populations O 0 3.932401959616527e-09
. O 0 1.3593448144888498e-08

To O 0 1.6091464161149815e-08
facilitate O 0 5.414695358751942e-09
the O 0 1.349691913787865e-09
evaluation O 0 1.0591071131216268e-08
of O 0 6.595669077569255e-08
ATM O 1 0.5497732162475586
heterozygotes O 0 9.176847015623935e-07
for O 0 1.708671648614768e-09
susceptibility O 0 1.1614210961852223e-06
to O 0 1.8435508675196388e-09
other O 0 5.801333302635214e-10
diseases O 0 5.898644985791179e-07
, O 0 4.368370595808635e-11
such O 0 6.81619968800895e-11
as O 0 2.5378371404372047e-08
breast B-Disease 1 0.9999719858169556
cancer I-Disease 1 0.9866660237312317
, O 0 3.4396832049310433e-09
we O 0 1.8220520647815874e-09
have O 0 6.090361548416467e-11
attempted O 0 3.77846598453857e-09
to O 0 8.015744318301543e-11
define O 0 3.909308876615114e-09
the O 0 2.1209986544867832e-10
most O 0 1.783553513212688e-11
common O 0 1.4509239643079042e-10
mutations O 0 1.1576278824421138e-09
and O 0 2.1478091874471694e-11
their O 0 9.146687747485505e-12
frequencies O 0 1.9141406681910667e-08
in O 0 9.747130214066146e-09
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 2.3853341190260835e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.4794160058405623e-09
homozygotes O 0 8.50460324386404e-08
from O 0 1.9625470137896173e-09
10 O 0 2.1345301082220658e-09
ethnic O 0 3.1032361125227226e-09
populations O 0 6.599378377103449e-09
. O 0 2.7145404146722285e-08

Both O 0 5.241502876174309e-08
genomic O 0 4.3467017007969844e-07
mutations O 0 1.916680503200041e-07
and O 0 1.0064783451113613e-09
their O 0 1.597743465309165e-10
effects O 0 3.357051525654242e-08
on O 0 2.620850203527425e-08
cDNA O 0 1.0148569629109261e-07
were O 0 2.0278905221715604e-09
characterized O 0 3.049229135854148e-08
. O 0 9.75559686366978e-08

Protein O 0 6.054061714166892e-07
- O 0 7.570775295562271e-08
truncation O 0 2.2792900722379272e-07
testing O 0 3.569201600939209e-09
of O 0 4.8018229392710055e-09
the O 0 2.046682157086366e-09
entire O 0 3.5224303474024055e-08
ATM O 0 9.740329005580861e-07
cDNA O 0 8.592797229312055e-08
detected O 0 1.3842847756961874e-08
92 O 0 1.3122428477174708e-08
( O 0 4.243010665039293e-10
66 O 0 3.3985156022708907e-08
% O 0 3.3335312288329533e-09
) O 0 9.825591729129002e-11
truncating O 0 4.347953463934573e-08
mutations O 0 9.497107100742141e-09
in O 0 6.755668247038216e-10
140 O 0 8.372284199253954e-09
mutant O 0 2.6385006179907577e-08
alleles O 0 5.4220773648694376e-08
screened O 0 4.1738644540600944e-07
. O 0 1.0184695753423512e-07

The O 0 1.6486035292473389e-06
haplotyping O 1 0.7512747049331665
of O 0 1.167359368992038e-05
patients O 0 1.3227645645486064e-08
with O 0 6.656804274474126e-11
identical O 0 1.0971814567994898e-08
mutations O 0 2.9145280677767005e-07
indicates O 0 1.2590696485403896e-08
that O 0 1.9975002554795118e-11
almost O 0 2.746462501868052e-10
all O 0 1.0167810170214064e-11
of O 0 2.4512987126246166e-11
these O 0 2.0569590681359523e-13
represent O 0 6.318540742705769e-12
common O 0 1.3912661300796714e-10
ancestry O 0 1.0987912801851962e-09
and O 0 4.8644938771547075e-11
that O 0 4.1320741966943686e-11
very O 0 6.834976473690801e-10
few O 0 3.1916465026426977e-09
spontaneously O 0 1.36354159963048e-07
recurring O 0 1.4164047001941071e-07
ATM O 0 7.978097710292786e-05
mutations O 0 7.72827092987427e-07
exist O 0 4.230412855577015e-07
. O 0 3.035917188753956e-07

Assays O 0 1.8240440340377972e-06
requiring O 0 6.024722409847527e-08
minimal O 0 3.9262366158254736e-07
amounts O 0 5.816784920398277e-08
of O 0 5.711757466997369e-08
genomic O 0 3.875959464494372e-08
DNA O 0 9.258440236692422e-09
were O 0 4.878552423148719e-11
designed O 0 4.344191673055775e-11
to O 0 4.907661430020305e-11
allow O 0 4.22134271982344e-11
rapid O 0 1.2209275812580245e-09
screening O 0 3.364272194161799e-10
for O 0 6.829863757884524e-11
common O 0 5.768026500874157e-09
ethnic O 0 1.237463038705755e-07
mutations O 0 4.1124872041109484e-07
. O 0 1.20762777555683e-07

These O 0 2.624066652856527e-08
rapid O 0 1.4143341786621022e-07
assays O 0 1.8660877287857147e-07
detected O 0 7.366046617107713e-08
mutations O 0 3.675132420610794e-09
in O 0 4.6287276095346996e-11
76 O 0 4.118450469547952e-09
% O 0 9.359052421942238e-10
of O 0 3.4965370598882828e-09
Costa O 0 2.6198763407592196e-06
Rican O 0 5.88744433116517e-06
patients O 0 1.3851662039598978e-09
( O 0 5.956023174658043e-11
3 O 0 2.017774392015781e-09
) O 0 8.877609584956314e-12
, O 0 5.929269662058312e-12
50 O 0 6.536247931787642e-11
% O 0 1.0856663484881679e-10
of O 0 3.8092615173290767e-10
Norwegian O 0 3.185527361893037e-07
patients O 0 7.69098784658695e-10
( O 0 1.360419693563486e-10
1 O 0 3.181170171728809e-08
) O 0 3.4914952873332794e-11
, O 0 1.851894332327575e-11
25 O 0 2.433759860309692e-10
% O 0 2.1778830128216242e-10
of O 0 2.9252228417320225e-10
Polish O 0 7.866894407015934e-07
patients O 0 2.276603128237298e-09
( O 0 1.711123326364472e-10
4 O 0 1.026576601503848e-08
) O 0 6.273966762782024e-11
, O 0 1.7438829894023122e-11
and O 0 8.304931395364257e-12
14 O 0 3.5819461285946375e-10
% O 0 1.5794182628425801e-10
of O 0 2.725874248543647e-10
Italian O 0 3.2310481401509605e-07
patients O 0 1.205159971817693e-09
( O 0 2.5876570330929383e-10
1 O 0 2.237025711337992e-07
) O 0 2.2832465085276255e-10
, O 0 4.880655948835688e-11
as O 0 2.6123670934796728e-11
well O 0 1.91589834275252e-11
as O 0 3.27097272878607e-11
in O 0 3.362820785723919e-11
patients O 0 4.628339031476081e-11
of O 0 3.626984934612665e-09
Amish O 0 3.990930679265148e-07
/ O 0 3.4885065360867884e-06
Mennonite O 0 1.5072243968461407e-06
and O 0 3.796686076640299e-09
Irish O 0 7.471392393654241e-08
English O 0 1.1015412582082718e-07
backgrounds O 0 1.64099901667214e-07
. O 0 8.734409817634514e-08

Additional O 0 5.844386663511614e-08
mutations O 0 1.1641942165852015e-07
were O 0 2.266715481979986e-09
observed O 0 3.6815099857534506e-09
in O 0 1.4067103037973538e-10
Japanese O 0 3.087072375507205e-09
, O 0 1.6098816724152698e-10
Utah O 0 1.7972087817952342e-08
Mormon O 0 6.3365694913386506e-09
, O 0 7.84049145052812e-11
and O 0 1.1972162150541976e-10
African O 0 4.647575213567734e-09
American O 0 1.0662214222634248e-08
patients O 0 5.478919540280458e-09
. O 0 5.8682122272557535e-08

These O 0 1.0121593563283682e-09
assays O 0 5.696848770497809e-09
should O 0 1.4751058707851428e-10
facilitate O 0 6.718670064742582e-11
screening O 0 4.39132952223531e-10
for O 0 1.1304771563303007e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 2.2872596616707597e-07
in O 0 2.524693232253128e-10
the O 0 2.1329825405924652e-10
populations O 0 7.235188143051019e-11
studied O 0 2.206525628878353e-09
. O 0 8.663553763277321e-10
. O 0 1.5244802753500153e-08

The O 0 4.455098405742319e-06
von B-Disease 1 0.9999996423721313
Hippel I-Disease 1 0.9999998807907104
- I-Disease 1 0.9999910593032837
Lindau I-Disease 1 0.9999434947967529
tumor I-Disease 0 0.00010057866893475875
suppressor O 0 5.066469270786911e-07
gene O 0 4.4377318486610307e-10
is O 0 1.1449782094663519e-11
required O 0 4.163116379407583e-11
for O 0 1.4653163404876324e-10
cell O 0 4.0608707507772124e-08
cycle O 0 3.744304777342222e-08
exit O 0 3.3304058177918705e-08
upon O 0 5.809962733138718e-09
serum O 0 6.793987950004521e-08
withdrawal O 0 2.002250312216347e-06
. O 0 5.750090963374532e-07

The O 0 2.0123950150718883e-07
inactivation O 0 1.7234069673577324e-05
of O 0 3.24027780607139e-07
the O 0 1.34659075001764e-07
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 1.0
( I-Disease 0 3.763317727134563e-05
VHL I-Disease 1 0.9999611377716064
) I-Disease 0 3.821272542836596e-08
tumor I-Disease 0 0.0014104658039286733
suppressor O 0 7.341673335758969e-05
gene O 0 5.389886226225826e-08
predisposes O 0 4.0561917558079585e-07
affected O 0 7.27551685564265e-10
individuals O 0 4.083388835396384e-11
to O 0 9.705052317343643e-10
the O 0 4.893918870152447e-08
human O 0 0.00017406286497134715
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 2.3973456553250116e-09
is O 0 5.509705469641801e-10
associated O 0 2.3839945573200794e-09
with O 0 3.8958933301636023e-10
sporadic B-Disease 0 0.0051885852590203285
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 5.2688486903207377e-05
RCC B-Disease 1 0.9999991655349731
) O 0 4.447150203645833e-08
and O 0 6.09009163099472e-08
brain B-Disease 0 0.13417358696460724
hemangioblastomas I-Disease 0 0.004903464578092098
. O 0 2.8213244149810635e-06

VHL O 1 0.5610333681106567
- O 0 0.00017233377730008215
negative O 0 3.676614596770378e-06
786 O 0 2.1957930584903806e-05
- O 0 1.2115849131077994e-05
0 O 0 1.412012238688476e-06
RCC B-Disease 0 5.73072065890301e-05
cells O 0 4.7679485248863784e-08
are O 0 8.570626430781658e-10
tumorigenic O 0 3.165676389471628e-05
in O 0 2.3367169532662047e-08
nude O 0 8.17728320612332e-08
mice O 0 3.9382400118803673e-10
which O 0 8.297632546339084e-12
is O 0 5.088998319968674e-11
suppressed O 0 1.0338266909215577e-09
by O 0 1.4414820725949795e-10
the O 0 6.574815802906642e-09
reintroduction O 0 6.464002240136324e-07
of O 0 2.2463079574208678e-07
VHL B-Disease 0 0.0011021180544048548
. O 0 2.407980218777084e-06

Remarkably O 0 4.747982984554255e-06
, O 0 1.5200137815085668e-09
this O 0 7.561729714611332e-11
occurs O 0 6.888268289095834e-10
without O 0 4.6108952767021094e-10
affecting O 0 5.247489665016758e-10
the O 0 1.3403787801902212e-10
growth O 0 1.9638342341199433e-10
rate O 0 2.0809272360811093e-10
and O 0 5.5111529922990954e-11
cell O 0 1.5736855374370862e-08
cycle O 0 3.711651430648999e-09
profile O 0 9.319022636899987e-11
of O 0 2.005464683207947e-10
these O 0 2.1969067190430458e-11
cells O 0 5.432692629092628e-10
in O 0 2.263206427821629e-10
culture O 0 2.5381956092473956e-08
. O 0 3.1431735436626695e-08

The O 0 2.124865204677917e-06
786 O 0 1.2872436855104752e-05
- O 0 2.102576672768919e-06
0 O 0 1.5462124736131955e-07
cell O 0 6.838111943352487e-08
line O 0 2.2379255781856955e-08
, O 0 3.7776573535985847e-10
like O 0 1.7403153917960879e-10
many O 0 1.2969410267960058e-10
cancer B-Disease 0 4.7955648341257984e-08
cells O 0 1.3698486789337494e-09
, O 0 1.8333250195734507e-10
fails O 0 1.0737069899846574e-08
to O 0 1.2846221864037943e-09
exit O 0 6.528233598146471e-08
the O 0 3.6404028680436795e-09
cell O 0 1.5840329936622766e-08
cycle O 0 2.677453814214914e-09
upon O 0 1.6357522003573877e-09
serum O 0 1.4970057193863795e-08
withdrawal O 0 3.8137227420520503e-07
. O 0 1.9134988349378546e-07

Here O 0 1.1053484882950215e-07
, O 0 2.715687397181199e-10
it O 0 1.5135320080572612e-11
is O 0 1.1582295886269911e-11
shown O 0 1.0842917709530386e-11
that O 0 1.0531710052663623e-11
reintroduction O 0 2.1031626218359634e-08
of O 0 5.568915995013413e-09
the O 0 4.013305687777802e-09
wild O 0 1.0050746901413277e-08
- O 0 6.994507373292436e-08
type O 0 6.06320213591971e-07
VHL B-Disease 0 0.00016585855337325484
gene O 0 2.481498917461522e-08
restores O 0 1.2091738277320019e-08
the O 0 4.329528124902282e-10
ability O 0 3.055216635239333e-10
of O 0 6.172253819158868e-08
VHL O 1 0.5076238512992859
- O 0 5.107721153763123e-05
negative O 0 2.1997923340677517e-06
RCC B-Disease 1 0.5519580245018005
cancer I-Disease 0 2.4552130071242573e-06
cells O 0 1.0412755102606752e-09
to O 0 2.2545722233591192e-10
exit O 0 5.648549183945306e-09
the O 0 7.986615258026575e-10
cell O 0 6.978141176006147e-09
cycle O 0 3.521729796673867e-09
and O 0 3.733091058499838e-10
enter O 0 7.888774433695289e-08
G0 O 0 0.0004081824445165694
/ O 0 2.2180725864018314e-05
quiescence O 0 2.3275233616004698e-05
in O 0 3.366207579347247e-08
low O 0 7.873311460571131e-07
serum O 0 5.217992224970658e-07
. O 0 1.1928165122299106e-07

Both O 0 1.4516086821458885e-06
VHL O 0 0.16350683569908142
- O 0 7.881848432589322e-05
positive O 0 1.5820702969904232e-08
and O 0 8.78221495526077e-09
VHL O 0 0.0001932529849000275
- O 0 2.4130283691192744e-06
negative O 0 1.063116883415205e-07
RCC B-Disease 0 4.914075361739378e-06
cells O 0 7.267157098311827e-09
exit O 0 1.9835166398252113e-08
the O 0 1.1239562613951648e-09
cell O 0 6.411543740370007e-09
cycle O 0 8.695554276627604e-10
by O 0 5.883838555265086e-11
contact O 0 2.9114824329212752e-08
inhibition O 0 2.5546810320520308e-06
. O 0 1.009031620924361e-06

The O 0 1.3773154705631896e-06
cyclin O 0 7.70337828726042e-06
- O 0 5.379173444453045e-07
dependent O 0 9.967666159127475e-08
kinase O 0 1.65203147162174e-07
inhibitor O 0 1.7896375936743425e-07
, O 0 2.539985999305827e-09
p27 O 0 7.528877290496894e-07
, O 0 3.2608701849845545e-10
accumulates O 0 1.5695330590759227e-09
upon O 0 1.0563139252184328e-10
serum O 0 5.640923839145273e-10
withdrawal O 0 1.529308768510873e-08
, O 0 7.016678210680638e-11
only O 0 5.190775587138319e-11
in O 0 2.93617734292706e-11
the O 0 6.004546165838676e-11
presence O 0 1.428808321657371e-10
of O 0 8.039025445327752e-09
VHL B-Disease 0 8.210224041249603e-05
, O 0 1.5417016274721362e-10
as O 0 1.7664328333388823e-11
a O 0 4.4823905004376385e-11
result O 0 2.4762861206006903e-10
of O 0 1.1406416922099538e-09
the O 0 2.393387987797979e-10
stabilization O 0 9.310488735536637e-08
of O 0 1.9620956948074308e-07
the O 0 6.280847486550556e-08
protein O 0 6.263261980166135e-07
. O 0 6.756885539971336e-08

We O 0 2.7112909251059136e-08
propose O 0 3.864952446974712e-08
that O 0 6.26547869142513e-10
the O 0 5.790811830053144e-09
loss O 0 8.395699069296825e-08
of O 0 5.077420723864634e-07
wild O 0 3.9837090071159764e-08
- O 0 7.554532999165531e-08
type O 0 4.493645633374399e-07
VHL B-Disease 0 3.695553823490627e-05
gene O 0 2.871853199692964e-09
results O 0 2.979289870363999e-10
in O 0 2.174295986312469e-11
a O 0 1.4960649385997726e-10
specific O 0 1.6906922528647783e-09
cellular O 0 2.0085546736936521e-07
defect O 0 3.9558042885801115e-07
in O 0 9.380909382628033e-10
serum O 0 4.692559940622232e-08
- O 0 8.239139503984916e-08
dependent O 0 3.217932231791565e-08
growth O 0 5.436942562830893e-10
control O 0 2.156604228531478e-09
, O 0 2.1857638962674564e-11
which O 0 1.1990528361871533e-11
may O 0 5.711370265615301e-10
initiate O 0 2.925370523598758e-08
tumor B-Disease 0 4.614784756995505e-06
formation O 0 5.234819582256023e-07
. O 0 5.19321474712342e-07

This O 0 2.0262019617689475e-08
is O 0 2.9865512285454088e-09
corrected O 0 1.56334323264673e-08
by O 0 1.5939387310037745e-10
the O 0 1.8211000485379714e-09
reintroduction O 0 2.1058043842003826e-07
of O 0 3.6902150668538525e-08
wild O 0 2.8373031923933922e-08
- O 0 2.562376550940826e-07
type O 0 1.0037623724201694e-05
VHL B-Disease 1 0.9999712705612183
, O 0 9.860111305215469e-08
implicating O 0 0.0003651201550383121
VHL B-Disease 0 0.04162129387259483
as O 0 4.948582432717785e-09
the O 0 1.0001194317155182e-09
first O 0 6.566716614919699e-10
tumor B-Disease 0 4.250710006203917e-08
suppressor O 0 8.324803246750889e-08
involved O 0 5.528716928715482e-10
in O 0 6.100744215364884e-11
the O 0 1.863943999147466e-10
regulation O 0 3.683300997536776e-09
of O 0 1.843073604845813e-08
cell O 0 5.0746994162409464e-08
cycle O 0 2.2572939073484122e-08
exit O 0 2.5941778503124624e-08
, O 0 3.065886086672798e-11
which O 0 1.023634389057948e-11
is O 0 2.046008848455294e-11
consistent O 0 1.4063991637947026e-10
with O 0 1.6539712308083487e-12
its O 0 3.227565784080788e-11
gatekeeper O 0 1.9814898166714556e-08
function O 0 9.499240283261656e-10
in O 0 1.0176157833052812e-10
the O 0 2.2529098586687724e-09
kidney O 0 7.954566171974875e-06
. O 0 3.20898401184877e-08
. O 0 1.795573183471788e-07

Piebaldism B-Disease 1 1.0
with O 1 0.936123788356781
deafness B-Disease 1 1.0
: O 0 1.7741010083227593e-07
molecular O 0 2.609756961646781e-07
evidence O 0 1.2806685711908017e-09
for O 0 1.1850569137106248e-10
an O 0 3.928876390890679e-10
expanded O 0 2.6696437771533965e-07
syndrome O 1 0.99998939037323
. O 0 2.4731907615205273e-06

In O 0 2.043512026261851e-08
a O 0 1.1673845001780592e-08
South O 0 7.194272200194973e-08
African O 0 1.6594317031604078e-08
girl O 0 1.271668015334626e-08
of O 0 1.5896199911935582e-08
Xhosa O 0 1.4209197161108023e-06
stock O 0 3.0198312739315725e-09
with O 0 3.6200840936029266e-11
severe O 0 6.81773144606268e-06
piebaldism B-Disease 1 0.9983938336372375
and O 0 1.1428252264522598e-06
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 2.9473552785930224e-05
identified O 0 1.017599338126729e-08
a O 0 1.7530249474262405e-10
novel O 0 3.168178774881625e-10
missense O 0 1.1936012178637156e-08
substitution O 0 7.50326378806676e-09
at O 0 4.430384947795574e-09
a O 0 3.8819630843178743e-10
highly O 0 9.977320081233643e-10
conserved O 0 1.7653004391604554e-08
residue O 0 1.9139842777349259e-07
in O 0 1.7894288828479432e-10
the O 0 5.012722459341035e-10
intracellular O 0 3.0631537306646806e-09
kinase O 0 3.550314531253207e-08
domain O 0 2.223289996550193e-08
of O 0 2.883496286187892e-08
the O 0 2.7366136023943e-08
KIT O 0 3.8528419281647075e-06
proto O 0 7.530419679824263e-05
- O 0 7.70046972320415e-06
oncogene O 0 1.4723163076268975e-05
, O 0 3.973767448428589e-08
R796G O 0 2.903239510487765e-05
. O 0 4.6109263962534897e-07

Though O 0 7.490354505534924e-07
auditory B-Disease 0 0.37609219551086426
anomalies I-Disease 0 0.11386499553918839
have O 0 2.282193989344705e-09
been O 0 1.4171817053210134e-09
observed O 0 2.8021609477235643e-09
in O 0 1.1042702169339336e-10
mice O 0 2.0881871232170113e-10
with O 0 1.1925299289727853e-11
dominant O 0 7.09140010712872e-07
white O 0 1.4057623509700079e-08
spotting O 0 2.256185098303831e-06
( O 0 1.1008942379930886e-07
W O 0 0.04460475593805313
) O 0 2.6020805510285072e-09
due O 0 5.548096737584274e-08
to O 0 4.8298387511636065e-09
KIT O 0 7.583038495795336e-06
mutations O 0 5.194950972509105e-06
, O 0 1.6138942555699032e-06
deafness B-Disease 1 1.0
is O 0 2.7559000415067203e-08
not O 0 8.118996031036829e-10
typical O 0 9.358432251360682e-09
in O 0 9.581379023515524e-10
human O 0 1.3247667851601364e-08
piebaldism B-Disease 0 6.2056178649072535e-06
. O 0 1.8055067130262614e-07

Thus O 0 1.4236498202535586e-07
, O 0 6.599135682350266e-10
the O 0 5.410377701409175e-10
occurrence O 0 1.571232814967516e-07
of O 0 0.02674918621778488
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 0.00022596269263885915
this O 0 9.161546188352077e-08
patient O 0 1.1872305805127326e-07
extends O 0 9.738786665991483e-09
considerably O 0 2.9079454400005034e-09
the O 0 1.5976397982342405e-10
phenotypic O 0 8.699937659173429e-09
range O 0 2.3529519665999032e-08
of O 0 2.59903654153959e-08
piebaldism B-Disease 0 1.1837064448627643e-05
due O 0 1.575715202761785e-07
to O 0 4.851017365581356e-09
KIT O 0 3.641030161816161e-07
gene O 0 2.267195320371229e-09
mutation O 0 6.9149677095481366e-09
in O 0 9.879940615631355e-11
humans O 0 8.451442323753611e-10
and O 0 3.19864107423129e-10
tightens O 0 6.744728331398164e-09
the O 0 1.621196371592859e-10
clinical O 0 1.213320111048688e-09
similarity O 0 8.531710893322497e-10
between O 0 3.768562795158914e-09
piebaldism B-Disease 0 2.982141040774877e-06
and O 0 7.789498213117696e-11
the O 0 2.3002405535876846e-11
various O 0 7.689733398652532e-12
forms O 0 9.981641069245484e-10
of O 0 3.9657308548157744e-07
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999994039535522
. O 0 1.3091820960653422e-07
. O 0 3.19312817964601e-07

Cycloheximide O 0 9.304063860327005e-05
facilitates O 0 6.256122020431576e-08
the O 0 3.4698164341762094e-09
identification O 0 5.925977486498368e-09
of O 0 9.500426045860877e-08
aberrant O 0 6.098717335589754e-07
transcripts O 0 2.0041595405473345e-07
resulting O 0 2.5357373090173496e-08
from O 0 3.253683766857307e-09
a O 0 9.83620962458076e-10
novel O 0 3.6012179904787445e-09
splice O 0 1.1663077970069935e-07
- O 0 3.67076080642903e-09
site O 0 6.057336299214455e-10
mutation O 0 7.603240814724188e-10
in O 0 1.6671740377116606e-10
COL17A1 O 0 0.04563669487833977
in O 0 1.6193244523066141e-09
a O 0 8.486012781361296e-09
patient O 0 8.92487577175416e-08
with O 0 1.246619873995769e-08
generalized O 1 0.9997995495796204
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9996151924133301
. O 0 2.0992363715777174e-05

Patients O 0 4.766375695908209e-06
with O 0 6.033841515318272e-08
generalized O 1 0.9999986886978149
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999856948852539
often O 0 2.2633468432786685e-08
show O 0 1.069940802622682e-09
decreased O 0 4.6081192195401854e-09
expression O 0 1.365528801144933e-09
of O 0 4.256963670457026e-09
type O 0 4.0402935042038735e-07
XVII O 0 0.002094161231070757
collagen O 0 3.2788871067168657e-06
, O 0 7.898918852333736e-09
a O 0 4.1081591461988864e-08
transmembrane O 0 3.3810283639468253e-06
hemidesmosomal O 0 2.024141167566995e-06
protein O 0 6.686294629076883e-09
encoded O 0 1.0649607862234234e-09
by O 0 2.933157494666716e-09
COL17A1 O 0 0.0026446341071277857
. O 0 2.139432126568863e-06

This O 0 2.140683896811879e-08
report O 0 1.5294917554697918e-09
documents O 0 2.5943844850218056e-09
a O 0 1.7678604136150966e-09
novel O 0 7.84064901893089e-09
splice O 0 2.2542354827237432e-07
- O 0 7.999562789962056e-09
site O 0 8.748773927536035e-10
mutation O 0 8.257113326415322e-10
in O 0 2.8341523572450456e-10
COL17A1 O 1 0.9958311915397644
in O 0 3.0313498378120585e-09
a O 0 1.3590077507785736e-08
patient O 0 1.629883286113909e-07
with O 0 5.629747779067884e-09
generalized O 1 0.9999982118606567
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9981258511543274
, O 0 2.6841933120635986e-09
and O 0 1.3011755561898042e-10
applies O 0 9.639081754997392e-10
a O 0 1.2552223149775443e-10
new O 0 3.627901798419764e-11
methodology O 0 8.762300329756556e-10
to O 0 1.5612766635086928e-10
define O 0 1.2104544921953675e-08
and O 0 7.790021960829563e-10
characterize O 0 1.8563980574981542e-07
the O 0 1.4127886416304136e-08
resulting O 0 4.55886777217529e-08
mRNA O 0 9.194717449645395e-07
splice O 0 1.202499106511823e-06
variants O 0 1.0262949956540979e-07
. O 0 9.088829244774388e-08

Mutational O 0 2.351733564864844e-05
analysis O 0 3.8159122084380215e-08
of O 0 6.819602731411578e-07
COL17A1 O 1 0.999925971031189
identified O 0 1.9704290821209725e-07
a O 0 1.110760639022601e-08
maternally O 0 2.9775270604659454e-07
inherited O 0 2.5790377549128607e-06
G O 0 2.460935320414137e-06
- O 0 2.619356678223994e-07
to O 0 4.7261540458976015e-08
- O 0 3.439427473495016e-06
T O 0 3.3691051726236765e-07
transversion O 0 6.473848088717205e-07
at O 0 8.030749398812986e-09
the O 0 6.585957890159477e-10
- O 0 3.2338052236013937e-09
1 O 0 3.0290394192888925e-08
position O 0 2.0172249648453544e-08
of O 0 4.552437715688029e-08
exon O 0 1.1523466127982829e-06
32 O 0 6.931383609298791e-07
. O 0 1.6633870814075635e-07

This O 0 4.820086374479615e-08
acceptor O 0 4.470878778306542e-08
splice O 0 3.4850441466005577e-07
- O 0 2.3438142093823444e-08
site O 0 3.053161945487659e-09
mutation O 0 1.3253044217620413e-09
led O 0 2.944776644753233e-10
to O 0 2.1824406171155886e-10
the O 0 1.1338220362588913e-09
formation O 0 3.307515328287991e-08
of O 0 5.232843136582233e-07
aberrant O 0 4.296823021832097e-07
transcripts O 0 1.5592611646297883e-07
present O 0 5.837587746526651e-09
at O 0 3.840724005499396e-08
extremely O 0 1.3155382561080842e-08
low O 0 6.421729494832107e-07
levels O 0 1.6481807563195616e-07
. O 0 2.3974754981281876e-07

Based O 0 1.9413941743096075e-07
on O 0 1.4890186150751106e-07
our O 0 1.0574695563647651e-09
recent O 0 1.619413214637433e-10
finding O 0 6.18386730710796e-10
that O 0 1.0653827126061444e-10
cycloheximide O 0 4.408018412505044e-06
stabilized O 0 3.8115806546556996e-06
mutant O 0 4.137696407724434e-07
COL17A1 O 0 3.338319584145211e-05
transcripts O 0 8.88218352201875e-08
in O 0 1.0193899058208444e-09
keratinocytes O 0 7.09855996205988e-08
homozygous O 0 3.52914009127403e-09
for O 0 1.1912459907392758e-10
a O 0 1.6015582193773525e-09
frameshift O 0 3.193833435943816e-06
mutation O 0 1.7871050772555463e-07
, O 0 3.9631364856518303e-10
the O 0 8.057626788016137e-10
effects O 0 1.0776157921554841e-07
of O 0 7.761524045690749e-08
the O 0 1.2112905345418312e-08
splice O 0 3.217211883566051e-07
- O 0 1.5196320646282402e-08
site O 0 2.4563373557384693e-09
mutation O 0 8.569760456822451e-10
on O 0 1.7238277472131358e-09
splicing O 0 8.572985876753592e-09
of O 0 1.6325861551536036e-08
COL17A1 O 0 5.519628757610917e-05
transcripts O 0 8.345438828882834e-08
were O 0 6.322742329700759e-10
determined O 0 1.0551505225109281e-09
using O 0 3.60906887708623e-10
reverse O 0 6.117587769693955e-09
transcriptase O 0 2.3451860453604922e-09
polymerase O 0 9.369005127268792e-09
chain O 0 7.425186021592367e-10
reaction O 0 1.804227323098928e-10
of O 0 2.545952115795558e-09
total O 0 1.1357527140987145e-09
RNA O 0 1.1181749748345737e-08
from O 0 1.4565924022491572e-09
keratinocytes O 0 2.112256147768221e-08
incubated O 0 7.90249110593777e-09
for O 0 8.873538570597361e-10
2 O 0 2.3445929286936007e-07
. O 0 1.2223570422520424e-07

5 O 0 1.5760427913846797e-06
h O 0 7.571208016088349e-08
in O 0 2.2291474222058127e-10
the O 0 2.9948665769552463e-10
presence O 0 2.571234614112683e-10
or O 0 6.887667325372604e-09
absence O 0 1.4246630541947525e-07
of O 0 1.437268508652778e-07
10 O 0 5.67112472538156e-08
microg O 0 4.1176895138050895e-06
cycloheximide O 0 4.195417204755358e-06
per O 0 4.7380498813254235e-07
ml O 0 4.7598659875802696e-06
. O 0 9.309370341270551e-08

Using O 0 3.1768878638871456e-09
this O 0 1.2649079006443742e-10
approach O 0 1.0334566091785291e-08
, O 0 3.660998171284291e-10
an O 0 2.4574373092001167e-10
abnormally O 0 1.0204272982150542e-08
spliced O 0 3.642995949348915e-08
transcript O 0 7.907770793735835e-08
was O 0 1.163214857768935e-08
identified O 0 4.337363523898574e-10
that O 0 9.420723749709037e-12
contains O 0 2.4217378102875387e-11
an O 0 3.524682976041582e-11
extra O 0 4.6413364818143066e-10
264 O 0 1.8507875232387505e-09
bases O 0 8.41573144505503e-10
upstream O 0 7.482041652906446e-09
from O 0 7.13727299483935e-10
exon O 0 2.734948978400098e-08
32 O 0 4.270845899156939e-09
, O 0 4.1589735128022554e-11
resulting O 0 5.43899647542645e-10
in O 0 6.969810839585477e-10
a O 0 3.3885349637330364e-08
premature O 0 1.697367451924947e-06
termination O 0 4.919679213344352e-06
codon O 0 4.3208392526139505e-06
27 O 0 7.635626388946548e-07
bp O 0 5.453752578432614e-07
downstream O 0 2.058079360267584e-07
from O 0 1.8325192030488324e-08
the O 0 4.0333283379823115e-08
cryptic O 0 5.327681265043793e-07
splice O 0 6.494777608168079e-06
site O 0 5.159247393748956e-07
. O 0 2.1810576811276405e-07

Three O 0 1.9998363853801493e-08
other O 0 1.7340828772915984e-10
splice O 0 2.5377309142982085e-08
variants O 0 9.296746150688762e-10
, O 0 2.0725048413550162e-11
including O 0 3.548357354471454e-12
one O 0 6.88384852592927e-12
derived O 0 6.53759477109439e-11
from O 0 2.735973947398662e-10
the O 0 4.981032253326134e-10
skipping O 0 4.9409902835861885e-09
of O 0 3.5724434521711146e-09
exon O 0 4.3147675654608975e-08
32 O 0 1.549905626063719e-08
, O 0 3.54489770870714e-10
were O 0 1.4089612809797813e-09
also O 0 1.3470790038994096e-09
identified O 0 5.196152841335788e-08
. O 0 1.8838255755326827e-07

These O 0 1.1095176333242307e-08
results O 0 9.608542406169818e-09
indicate O 0 6.259736284874862e-09
the O 0 3.012387228551461e-09
usefulness O 0 6.67148185584665e-08
of O 0 2.420517830614699e-08
cycloheximide O 0 1.9345967302797362e-05
treatment O 0 3.8905060506522204e-08
in O 0 1.875705979426101e-10
evaluating O 0 1.948961436681884e-09
the O 0 7.437857552083926e-10
abnormal O 0 1.0702535746531794e-08
processing O 0 1.2814756367163227e-08
of O 0 4.4861092618475595e-08
mRNA O 0 2.14034741929936e-07
due O 0 1.9449331034593342e-08
to O 0 3.971998008278632e-10
splice O 0 5.453898666019086e-08
- O 0 4.073637871471192e-09
site O 0 2.783727692801108e-10
mutations O 0 1.5418956389456895e-10
, O 0 3.2626852608519386e-11
because O 0 2.322938924548268e-10
( O 0 1.460216947357651e-09
i O 0 9.630416286654508e-08
) O 0 7.675922120142786e-10
aberrant O 0 4.381860652102887e-09
splicing O 0 3.611618337728828e-09
often O 0 2.863394417407239e-11
generates O 0 1.4046029617187372e-10
a O 0 3.533583703418941e-10
premature O 0 1.9090435898760916e-08
termination O 0 4.6676813525436955e-08
codon O 0 1.0312713527582673e-07
, O 0 6.811939901041342e-10
( O 0 6.867200696980547e-10
ii O 0 4.1595853872422595e-06
) O 0 1.1173898473160193e-09
transcripts O 0 5.909543521198657e-09
with O 0 1.348723632776938e-10
premature O 0 8.510071580758449e-08
termination O 0 1.6137452973907784e-07
codons O 0 6.783603367921387e-08
can O 0 5.197574592941123e-10
occur O 0 8.976185350562105e-10
at O 0 3.113183932867969e-09
low O 0 1.863945797708766e-08
or O 0 1.0131966377002755e-09
undetectable O 0 4.964846311850124e-08
levels O 0 1.3665110154548188e-09
due O 0 2.3730790665865698e-09
to O 0 6.714112599226496e-10
nonsense O 0 2.8352852510238336e-08
- O 0 6.89084744820434e-09
mediated O 0 1.8175995819547097e-08
mRNA O 0 1.9448998855864374e-08
decay O 0 8.227691239426349e-08
, O 0 2.1791119256264757e-11
and O 0 1.476889964491246e-11
( O 0 9.224094404958194e-11
iii O 0 3.235547012536699e-07
) O 0 2.1233220737215674e-10
the O 0 3.578354001998463e-10
levels O 0 1.081166267624667e-09
of O 0 5.801653601977819e-10
these O 0 2.7131385679779463e-11
transcripts O 0 3.0449676113875057e-09
can O 0 1.0418273188594895e-10
be O 0 2.416073174860145e-10
increased O 0 9.11194120156722e-10
by O 0 4.99074470639016e-09
cycloheximide O 0 5.6863646022975445e-05
. O 0 1.2453411954993499e-06

A O 0 2.2940937469684286e-06
deletion O 0 5.098496785649331e-06
mutation O 0 1.2830585660594807e-07
in O 0 9.644819387588655e-10
COL17A1 O 0 0.10494127124547958
in O 0 9.25695187170561e-10
five O 0 3.4904584778061576e-10
Austrian O 0 4.330028104959638e-07
families O 0 4.2900627494901755e-10
with O 0 4.865405855980498e-10
generalized O 1 0.9658884406089783
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.999993085861206
bullosa I-Disease 0 0.0007602659170515835
represents O 0 2.8890180914231678e-08
propagation O 0 3.358704816491809e-07
of O 0 6.311590539098688e-08
an O 0 3.6362390876121253e-09
ancestral O 0 3.6783430346076784e-07
allele O 0 1.1589714858928346e-06
. O 0 1.9009161178473732e-07

Patients O 0 2.3014345060801134e-06
with O 0 2.689970735048064e-08
generalized O 1 0.9998906850814819
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9998953342437744
, O 0 1.8785899058570976e-08
a O 0 2.9655939925987695e-09
usually O 0 8.27382440338198e-10
nonlethal O 0 2.348780157035435e-07
form O 0 3.5006223697564565e-08
of O 0 4.205868663120782e-06
junctional B-Disease 1 0.9999945163726807
epidermolysis I-Disease 1 0.9999828338623047
bullosa I-Disease 1 0.9932019114494324
, O 0 1.1510430830696805e-08
have O 0 4.657494390158945e-10
generalized O 0 1.8678842650388106e-07
blistering B-Disease 0 6.539800779137295e-06
, O 0 4.4859469028324384e-08
nail B-Disease 1 0.9988287091255188
dystrophy I-Disease 1 0.9999974966049194
, O 0 4.391193670016946e-06
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 1.699136737443041e-05
and O 0 0.0007869055843912065
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 1 0.9835003614425659

Skin B-Disease 1 1.0
fragility I-Disease 1 0.8958105444908142
in O 0 6.849883771309351e-09
most O 0 9.21755241578559e-11
cases O 0 1.0170840558654248e-10
is O 0 5.997529556323045e-11
due O 0 3.2508986613777324e-09
to O 0 3.607293075358342e-10
mutations O 0 2.2694064405470726e-09
in O 0 1.4404238912746337e-10
the O 0 2.814286026442403e-10
gene O 0 1.0483895696022927e-10
encoding O 0 1.8280708058426853e-09
type O 0 2.1879574774175126e-07
XVII O 0 0.0035390006378293037
collagen O 0 1.8934608306153677e-05
( O 0 1.1728742066452469e-07
COL17A1 O 0 0.002885111141949892
) O 0 4.6767357986254865e-08
. O 0 1.4904705381013628e-07

Recently O 0 6.70577378514281e-07
, O 0 2.483211636317151e-09
we O 0 5.167898886604405e-10
reported O 0 3.2419922302295845e-10
five O 0 1.2194234511042623e-10
Austrian O 0 1.81202196358754e-07
families O 0 5.547339809730545e-10
with O 0 7.280930303110722e-10
generalized O 1 0.9983910918235779
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999957084655762
who O 0 6.454860823623676e-08
share O 0 3.213821209158141e-09
the O 0 6.2094476227514406e-09
same O 0 2.101362461814915e-08
COL17A1 O 0 0.004077156074345112
mutation O 0 5.434539616544498e-06
. O 0 3.890610571488651e-07

Affected O 0 9.041659865260954e-08
individuals O 0 5.841806482997924e-10
in O 0 1.8778034682753741e-10
three O 0 2.867783441273808e-11
families O 0 1.0204529929391803e-11
are O 0 4.130488052284109e-12
homozygous O 0 1.643626346137239e-10
for O 0 5.0475085916490414e-11
4003delTC O 0 4.697888300597697e-08
, O 0 1.2276124561338975e-10
whereas O 0 8.905143289439366e-10
those O 0 3.250305927182673e-11
in O 0 7.054466732991926e-11
two O 0 3.474037724160439e-11
others O 0 2.8150484721045643e-10
are O 0 7.15504253068211e-11
compound O 0 4.9768971166486153e-08
heterozygotes O 0 1.918055403393737e-07
. O 0 1.526491359982174e-07

To O 0 1.6601756414047486e-08
determine O 0 2.0763696539916054e-08
if O 0 7.941878821249304e-10
the O 0 4.412967213873742e-10
occurrence O 0 1.2369187452065944e-08
of O 0 1.5744301862241628e-08
4003delTC O 0 3.221528572794341e-07
in O 0 1.518303538450283e-10
these O 0 1.633471483075688e-11
unrelated O 0 2.1476882494653182e-09
families O 0 2.6809875500188873e-11
signifies O 0 1.101918445378658e-09
propagation O 0 3.657274660895382e-08
of O 0 5.412743586674651e-09
an O 0 2.414810851281146e-10
ancestral O 0 9.027234071368184e-09
allele O 0 1.8181891547897067e-08
or O 0 1.3635872431194684e-09
a O 0 1.5362727978640578e-08
mutational O 0 2.6122517738258466e-05
hot O 0 4.8315732783521526e-06
spot O 0 1.7132616392245836e-07
, O 0 1.3390193120965677e-10
haplotypes O 0 1.907146440771612e-09
were O 0 6.922615258808662e-11
determined O 0 5.565854999112219e-10
for O 0 1.5779820505823494e-10
polymorphisms O 0 3.384013780305395e-08
both O 0 6.488602433130097e-10
within O 0 3.277709836879694e-08
and O 0 1.97167278059851e-08
flanking O 0 3.6872635973850265e-05
COL17A1 O 1 0.9999983310699463
. O 0 7.2413936322845984e-06

Five O 0 1.522485945315566e-06
intragenic O 0 4.602637636708096e-05
polymorphisms O 0 1.7739600934874034e-06
were O 0 5.835595118242054e-09
chosen O 0 4.128029029715208e-09
based O 0 2.0560726454732503e-09
on O 0 4.504483541722948e-08
their O 0 2.323307990437229e-09
informativeness O 0 4.112433816771954e-05
. O 0 6.615663323827903e-07

One O 0 2.802413590075048e-08
of O 0 1.2817860550740079e-08
these O 0 3.755943819849783e-11
, O 0 9.265956751880466e-11
not O 0 1.5643081274774318e-10
previously O 0 1.5870017522345847e-09
reported O 0 3.785649294041349e-10
, O 0 4.083155341616518e-11
was O 0 6.650998418678e-09
2988 O 0 1.711484856059542e-07
A O 0 7.84660656449887e-08
or O 0 8.437626597412873e-09
C O 0 2.1372950413933722e-06
that O 0 8.390676348168924e-11
introduces O 0 2.220202771630042e-10
a O 0 2.997608064547741e-11
new O 0 7.603871525485584e-12
restriction O 0 3.410876581178002e-10
site O 0 7.988519845625319e-10
for O 0 1.0996530352969103e-09
Eco0109 O 0 3.147632742184214e-05
I O 0 0.00013280491111800075
. O 0 1.4000702321936842e-06

All O 0 4.446369672450601e-08
the O 0 1.1686387857423597e-08
4003delTC O 0 1.7112171235567075e-07
alleles O 0 5.7164957212307854e-09
showed O 0 3.1684868617709583e-10
the O 0 6.654594930655122e-11
same O 0 1.2303807972458003e-10
haplotype O 0 1.166266656582593e-07
for O 0 7.414967528873717e-10
these O 0 3.429835027102257e-10
five O 0 3.930257896911371e-09
polymorphic O 0 5.166470486983599e-07
markers O 0 2.5784768240555422e-06
. O 0 7.042511356303294e-07

Fourteen O 0 5.50311187907937e-06
microsatellite O 0 2.2739563064533286e-05
polymorphisms O 0 5.964807883174217e-07
were O 0 3.2089699786297388e-09
selected O 0 8.503632520362459e-11
based O 0 1.7905896210201888e-10
on O 0 3.121710667741695e-09
their O 0 5.984491374677603e-11
high O 0 1.9453672450708837e-08
heterozygosity O 0 2.1239575289655477e-06
and O 0 4.4754219774567616e-10
their O 0 1.348355871400031e-10
location O 0 6.925104489852174e-09
within O 0 2.215695360519021e-08
10q23 O 0 2.2985146642895415e-05
- O 0 2.453988827255671e-06
q25 O 0 3.336893496452831e-05
near O 0 3.5079328881693073e-06
COL17A1 O 0 0.0023038291838020086
. O 0 7.579732255180716e-07

Three O 0 4.2874741978948805e-08
families O 0 2.454655811945372e-09
shared O 0 6.5146230632251445e-09
microsatellite O 0 1.602923293830827e-05
polymorphisms O 0 6.425162155210273e-06
covering O 0 1.6883652733667986e-06
at O 0 1.1644350905726242e-07
most O 0 1.8832627124432122e-10
19 O 0 1.745139255326933e-09
cM O 0 7.131550461281222e-08
, O 0 3.0172950943319066e-11
whereas O 0 6.123620499565163e-10
the O 0 6.679064523673617e-10
others O 0 3.2949501460599606e-10
shared O 0 1.4839866835369975e-10
smaller O 0 1.9799993589142417e-10
regions O 0 9.579149695682077e-10
consistent O 0 6.880967462485899e-10
with O 0 8.18753658621274e-12
cross O 0 1.9169430487409045e-08
- O 0 1.856756881579713e-08
over O 0 6.094501570075295e-10
events O 0 2.107850179122739e-11
during O 0 2.966462145370663e-11
passage O 0 9.583512455835219e-11
of O 0 6.702849386641674e-11
this O 0 1.4421908979544984e-11
mutation O 0 2.8959773468173466e-10
through O 0 1.5095599770198476e-10
several O 0 4.3755779555176844e-10
generations O 0 1.1578404013334875e-08
. O 0 4.813232834521841e-08

These O 0 1.0322982468835562e-08
results O 0 1.2604584931352747e-08
indicate O 0 8.45570280461061e-09
that O 0 2.22259669002689e-10
4003delTC O 0 6.733676372050468e-08
occurs O 0 2.1185049270400214e-09
on O 0 1.8214056929366507e-09
a O 0 7.44285355569474e-10
single O 0 2.913730812181825e-09
ancestral O 0 3.127719949702623e-08
allele O 0 7.996256101705512e-08
. O 0 4.042013834748559e-09
. O 0 4.654852148178179e-08

The O 0 4.6168051426320744e-07
haptoglobin O 0 1.4748147805221379e-05
- O 0 4.848217827202461e-07
gene O 0 3.6552507687304114e-09
deletion O 0 3.538065129760071e-08
responsible O 0 4.910821971293444e-09
for O 0 3.680344473622199e-09
anhaptoglobinemia B-Disease 0 0.00936735700815916
. O 0 2.1293483314366313e-06

We O 0 1.0148840345891585e-07
have O 0 3.2917907288876336e-10
found O 0 1.4959337935049888e-10
an O 0 2.6615602083390755e-11
allelic O 0 1.683093309168271e-08
deletion O 0 2.198855781898601e-07
of O 0 2.7991558226858615e-07
the O 0 4.333125858124731e-08
haptoglobin O 0 1.4636338164564222e-05
( O 0 4.132598263595355e-09
Hp O 0 2.080070782284338e-09
) O 0 2.7130971080868704e-11
gene O 0 2.0920131946211562e-11
from O 0 4.2846799025442195e-11
an O 0 1.1178448791615558e-11
individual O 0 1.2469557504612983e-11
with O 0 3.3642530428146245e-10
anhaptoglobinemia B-Disease 0 0.48360157012939453
. O 0 3.4095517094101524e-06

The O 0 6.177377827043529e-07
Hp O 0 1.1416700829158799e-07
gene O 0 3.1685005730253124e-09
cluster O 0 2.2638261043539387e-08
consists O 0 3.7607628122771075e-10
of O 0 1.948117667183169e-09
coding O 0 6.159611842804225e-08
regions O 0 1.532535947035285e-07
of O 0 1.3924827726441436e-06
the O 0 8.705934106956192e-08
alpha O 0 3.1532857747151866e-07
chain O 0 1.535445770528554e-09
and O 0 5.112074652480203e-11
beta O 0 9.213905194371819e-09
chain O 0 6.617487668947319e-10
of O 0 3.5211908389065627e-10
the O 0 2.8163910092970923e-10
haptoglobin O 0 8.312998289738971e-08
gene O 0 9.91190129973063e-10
( O 0 7.765155185524009e-11
Hp O 0 3.2692523688204744e-10
) O 0 1.4257477143342356e-11
and O 0 2.2046302283751373e-11
of O 0 1.6386970669302059e-09
the O 0 2.263212062203479e-09
alpha O 0 5.19070439963798e-08
chain O 0 1.2606117261171335e-09
and O 0 5.4030321883224985e-11
beta O 0 3.119343361390747e-08
chain O 0 1.2102921997936278e-09
of O 0 7.406006363730455e-10
the O 0 5.793858171010413e-10
haptoglobin O 0 3.5887612170881766e-07
- O 0 1.8397019019289473e-08
related O 0 4.689739263596948e-09
gene O 0 1.1317435877344906e-09
( O 0 2.3892418599125165e-10
Hpr O 0 6.177354094916154e-08
) O 0 1.4603221409892342e-10
, O 0 7.060699941385806e-11
in O 0 1.4518458657519773e-10
tandem O 0 8.080670355070652e-09
from O 0 8.797219841483184e-09
the O 0 1.1082782691573811e-08
5 O 0 1.436686005718002e-07
side O 0 4.245310094574961e-07
. O 0 3.601344076287205e-07

Southern O 0 1.7525740076962393e-06
blot O 0 8.508814971719403e-06
and O 0 1.6261244573101408e-09
PCR O 0 7.852981376288426e-09
analyses O 0 1.335775379196491e-09
have O 0 1.0838450796579746e-11
indicated O 0 1.7016164866046068e-10
that O 0 2.763062998886734e-12
the O 0 1.7117557371548742e-11
individual O 0 1.216831648463701e-12
with O 0 1.928833395087315e-12
anhaptoglobinemia B-Disease 0 4.077748769759637e-07
was O 0 1.9495757896947907e-08
homozygous O 0 1.3467957304946765e-10
for O 0 1.507085081731141e-11
the O 0 4.137436920848003e-11
gene O 0 1.3059119063907332e-10
deletion O 0 5.919448042845943e-09
and O 0 2.7105833202978324e-11
that O 0 1.478956193623482e-11
the O 0 1.7936453711175915e-10
gene O 0 2.0698118219364403e-10
deletion O 0 1.2267148186140275e-08
was O 0 1.6078326448010216e-09
included O 0 4.705225445378325e-11
at O 0 2.929275988439173e-10
least O 0 2.7202115560065465e-11
from O 0 2.5250976309898476e-10
the O 0 2.1925627979868523e-10
promoter O 0 7.973956144269323e-07
region O 0 1.137171423692962e-07
of O 0 1.239904747762921e-07
Hp O 0 7.896297837817201e-09
to O 0 3.1360096741650523e-09
Hpr O 0 2.075131106948902e-07
alpha O 0 5.043858664066647e-08
but O 0 1.3527376441224703e-10
not O 0 1.5343208648044282e-10
to O 0 9.50790446374583e-10
Hpr O 0 2.3761111833664472e-07
beta O 0 1.0774139127534e-06
( O 0 1.215778588914418e-08
Hpdel O 0 6.0195870901225135e-06
) O 0 1.2014264250126416e-08
. O 0 7.31088505290245e-08

In O 0 9.576011983369881e-09
addition O 0 6.912972971839793e-10
, O 0 3.8467609653203283e-10
we O 0 2.9387392519453215e-10
found O 0 6.690817344612299e-11
seven O 0 1.871331041514157e-11
individuals O 0 2.377116515780986e-12
with O 0 6.079054360591529e-12
hypohaptoglobinemia B-Disease 0 3.2582115636614617e-06
in O 0 7.614386898779912e-10
three O 0 4.7608802317133936e-11
families O 0 2.982967345355192e-11
, O 0 2.1002092426281038e-11
and O 0 2.0092540478633403e-11
the O 0 2.4351437533098874e-10
genotypes O 0 1.8893954845111693e-08
of O 0 4.325460878362719e-09
six O 0 3.308426588244373e-10
of O 0 1.1998868565399334e-09
the O 0 1.9715166998945932e-10
seven O 0 3.219941327459175e-11
individuals O 0 4.346161885243616e-12
were O 0 6.483750342178851e-11
found O 0 4.848200660378943e-11
to O 0 2.928359776888101e-10
be O 0 1.4711708296033521e-08
Hp2 O 0 0.00041590610635466874
/ O 0 0.000779905472882092
Hpdel O 0 0.0020321442279964685
. O 0 2.86292106466135e-06

The O 0 1.537447360533406e-07
phenotypes O 0 1.7259118578749622e-07
and O 0 5.335892838687073e-10
genotypes O 0 3.9629437509347554e-08
in O 0 9.816113200056265e-11
one O 0 2.3999279993858202e-11
of O 0 8.52720047350708e-11
these O 0 9.68713607593652e-13
three O 0 3.6368371422040857e-12
families O 0 5.857587852264867e-12
showed O 0 5.411159020862755e-11
the O 0 2.655501929460513e-10
father O 0 1.1184558834642644e-09
to O 0 2.9850802385489317e-10
be O 0 1.281203698688671e-09
hypohaptoglobinemic B-Disease 0 2.6731468096841127e-06
( O 0 4.2247543241558105e-09
Hp2 O 0 3.8375537769752555e-06
) O 0 4.803341058234878e-10
and O 0 7.098255316861923e-10
Hp2 O 0 6.542284154420486e-06
/ O 0 1.4478314369625878e-06
Hpdel O 0 3.02090138575295e-05
, O 0 9.295096914385681e-10
the O 0 1.45117107219761e-09
mother O 0 2.5291993499543253e-10
to O 0 8.768214626586612e-11
be O 0 5.607411757146963e-10
Hp2 O 0 4.1531146166562394e-07
- O 0 2.995435366415222e-08
1 O 0 1.1492272022906036e-07
and O 0 6.142477082526909e-10
Hp1 O 0 2.1297178136592265e-06
/ O 0 1.9294098763111833e-07
Hp2 O 0 9.971295185096096e-07
, O 0 9.634665981694823e-11
one O 0 5.846798045716639e-11
of O 0 6.866388013726521e-10
the O 0 3.010983962159486e-10
two O 0 2.9300568915591185e-11
children O 0 1.89254480142953e-11
to O 0 6.108673289428879e-11
be O 0 1.929763460140066e-09
hypohaptoglobinemic B-Disease 0 1.0209839274466503e-05
( O 0 9.489483865365855e-09
Hp2 O 0 1.002388853521552e-05
) O 0 5.059221375169898e-10
and O 0 4.039606982253474e-10
Hp2 O 0 6.461595603468595e-06
/ O 0 1.3319998970473534e-06
Hpdel O 0 2.9613973310915753e-05
, O 0 6.506622463042788e-10
and O 0 7.600395313112074e-11
the O 0 3.9691502862204686e-10
other O 0 4.514815604705902e-11
child O 0 2.2445535707849018e-10
to O 0 7.173490274015037e-11
be O 0 1.6796258828222221e-09
Hp1 O 0 4.519105914368993e-06
and O 0 1.0525741167555225e-08
Hp1 O 0 0.0010461524361744523
/ O 0 0.00020220191800035536
Hpdel O 0 0.00020069009042344987
, O 0 1.1798567678411587e-09
showing O 0 4.973447209621895e-10
an O 0 8.481457897113742e-11
anomalous O 0 6.314203915280814e-07
inheritance O 0 2.564876376709435e-05
of O 0 5.30043962498894e-06
Hp O 0 1.5690466170781292e-07
phenotypes O 0 3.3346648109500165e-08
in O 0 3.8580327821335914e-10
the O 0 2.031010470915362e-09
child O 0 2.3518289538060344e-09
with O 0 3.072549714655537e-10
Hp1 O 0 0.000170309140230529
. O 0 1.4629574707214488e-06

The O 0 8.536958375771064e-07
Hp2 O 0 0.0008688497473485768
/ O 0 4.767946302308701e-05
Hpdel O 0 4.889348929282278e-05
individuals O 0 1.4620339383597525e-09
had O 0 3.332933484756495e-09
an O 0 6.009931441397498e-11
extremely O 0 8.009298779754204e-10
low O 0 4.6447684809436396e-08
level O 0 2.465597788159357e-07
of O 0 1.890059166953506e-07
Hp O 0 2.0281932577859152e-08
( O 0 2.047267688709553e-09
mean O 0 7.259582446295099e-08
+ O 0 3.0996410771422234e-08
/ O 0 1.060508409977956e-07
- O 0 1.5232484429361648e-07
SD O 0 3.5954112718172837e-06
= O 0 2.925024666922127e-08
0 O 0 5.517911016994503e-09
. O 0 1.972468299804575e-10
049 O 0 4.825090016424838e-08
+ O 0 1.234020174933903e-08
/ O 0 5.5775505103383693e-08
- O 0 6.113251060924085e-08
0 O 0 8.917078631043296e-09
. O 0 3.153378391740347e-10
043 O 0 3.4806621584948516e-08
mg O 0 3.473943621656872e-08
/ O 0 1.6156633364516892e-08
ml O 0 6.651873718510615e-09
; O 0 8.697324804796125e-11
n O 0 1.14802778394818e-09
= O 0 9.71840719010686e-10
6 O 0 7.62092500217193e-10
) O 0 5.3115580510298965e-12
, O 0 3.411862372487695e-12
compared O 0 1.936701146676434e-11
with O 0 1.8341031818303044e-12
the O 0 3.2205449418398757e-10
level O 0 4.3878177535816576e-08
( O 0 4.348753857019716e-10
1 O 0 3.8264801105469815e-08
. O 0 3.911902468622941e-10
64 O 0 6.388886752972667e-09
+ O 0 3.646671409285318e-09
/ O 0 1.6002427827288557e-08
- O 0 1.216527767411435e-08
1 O 0 1.9933928285809088e-08
. O 0 2.7830748816626283e-10
07 O 0 4.480343651636076e-09
mg O 0 1.7873428959092053e-08
/ O 0 9.43201072800548e-09
ml O 0 3.713605867261549e-09
) O 0 6.72333282797366e-12
obtained O 0 1.444763059188503e-10
from O 0 2.3269222104715936e-09
52 O 0 3.591287622839445e-08
healthy O 0 3.163203310396767e-10
volunteers O 0 8.17583639678432e-11
having O 0 4.457761382248293e-10
phenotype O 0 5.2173056985793664e-08
Hp2 O 0 2.0108748230995843e-06
, O 0 2.152300559998821e-10
whereas O 0 5.503592581668215e-10
the O 0 2.0839695247243384e-10
serum O 0 1.4314713858709638e-09
Hp O 0 2.5394714109339134e-10
level O 0 1.8019857828122099e-09
of O 0 3.170796403217935e-10
an O 0 1.7728629328472856e-11
individual O 0 1.0662279219253445e-11
with O 0 1.1517732600996311e-10
Hp1 O 0 9.839919221121818e-05
/ O 0 8.37227125884965e-05
Hpdel O 0 0.0001389577373629436
was O 0 1.7538848169351695e-06
0 O 0 6.476701059909828e-07
. O 0 7.116630484915731e-08

50 O 0 1.1434334510340705e-06
mg O 0 3.5340769954927964e-06
/ O 0 9.495205972598342e-07
ml O 0 3.115514459750557e-07
, O 0 8.134864309949918e-11
which O 0 1.5203081848991218e-11
was O 0 5.623498888773781e-10
approximately O 0 5.3940636679516984e-11
half O 0 1.0351759033300212e-10
the O 0 5.503526800954006e-11
level O 0 3.2500304669724756e-09
of O 0 1.9916130966635137e-09
Hp O 0 1.3336673987396352e-09
in O 0 1.3192306969056489e-10
control O 0 1.1593431992196201e-08
sera O 0 1.1094884655449277e-07
from O 0 4.1343545253980096e-10
the O 0 8.613645352539834e-10
Hp1 O 0 2.9535954126913566e-07
phenotype O 0 7.300430482359843e-09
( O 0 2.445047497801056e-10
1 O 0 2.2160081769584394e-08
. O 0 3.032684103843053e-10
26 O 0 4.881330895045721e-09
+ O 0 3.4497951162393292e-09
/ O 0 2.415476885175849e-08
- O 0 2.5997751507134126e-08
0 O 0 5.734087871189786e-09
. O 0 2.681832811379792e-10
33 O 0 4.235913397820923e-09
mg O 0 2.7361647170209835e-08
/ O 0 1.526394655115837e-08
ml O 0 1.517636327719174e-08
; O 0 1.4040030249518054e-10
n O 0 3.6137961512139327e-09
= O 0 2.1420509810354815e-09
9 O 0 1.6130913271794611e-09
) O 0 1.756893588944486e-11
, O 0 2.3143405594727717e-11
showing O 0 6.37159977556756e-11
a O 0 1.0155221108476553e-09
gene O 0 4.292585842335939e-09
- O 0 4.0726142458424874e-08
dosage O 0 3.8962360804362106e-07
effect O 0 4.6514441010003793e-07
. O 0 2.459696020196134e-07

The O 0 8.724102684709578e-08
other O 0 1.151422401868274e-09
allele O 0 7.763596698850961e-08
( O 0 2.034395318872839e-09
Hp2 O 0 4.4020193854521494e-06
) O 0 2.781816998975728e-10
of O 0 1.5332656255750976e-09
individuals O 0 1.0995455934637022e-10
with O 0 3.3597899462556313e-10
Hp2 O 1 0.9965925812721252
/ O 0 0.0549468956887722
Hpdel O 0 0.00407890509814024
was O 0 5.7995247715325604e-08
found O 0 4.9022817055766055e-11
to O 0 2.07140624097768e-11
have O 0 1.519148695727779e-11
, O 0 1.700522188341491e-11
in O 0 2.0325352512173822e-11
all O 0 6.771790767023944e-11
exons O 0 1.4636698075776167e-08
, O 0 1.1622556389534466e-10
no O 0 4.789883489841884e-10
mutation O 0 2.451362002275914e-09
, O 0 1.4217999000365467e-10
by O 0 6.926118567562867e-10
DNA O 0 1.7281386988088343e-07
sequencing O 0 4.169687315425108e-07
. O 0 1.1393077414822983e-07

On O 0 1.5653743901111739e-07
the O 0 9.033033765426524e-10
basis O 0 3.821912120116622e-09
of O 0 1.9147896601623415e-09
the O 0 1.6591515661357192e-10
present O 0 1.0608972728087807e-10
study O 0 8.350506397469815e-11
, O 0 7.220295108328889e-12
the O 0 2.128023798841916e-11
mechanism O 0 1.0907229563983378e-09
of O 0 6.453110490411973e-09
anhaptoglobinemia B-Disease 0 3.906772235495737e-06
and O 0 3.0291866237597276e-10
the O 0 2.9574470650217677e-10
mechanism O 0 2.806236798491568e-09
of O 0 5.05344699419652e-09
anomalous O 0 1.1069008678532555e-06
inheritance O 0 5.120912192069227e-06
of O 0 9.345839089291985e-07
Hp O 0 8.031273779351977e-08
phenotypes O 0 2.370072316182359e-08
were O 0 1.888025513707703e-09
well O 0 1.4116835478361622e-09
explained O 0 5.786828793929999e-08
. O 0 4.629696803704064e-08

However O 0 1.1962957557898335e-07
, O 0 3.338863407975623e-09
the O 0 2.2494017759555618e-09
mechanism O 0 8.111820903877742e-08
of O 0 1.1497910463731387e-06
hypohaptoglobinemia B-Disease 1 0.9991607666015625
remains O 0 5.719795444747433e-05
unknown O 0 5.821410377393477e-05

ATM O 0 0.0032296450808644295
mutations O 0 2.9635880309797358e-06
and O 0 1.3389082731407598e-08
phenotypes O 0 1.3961647482574335e-06
in O 0 2.081874725945454e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 8.536765250255485e-08
in O 0 1.2345893196652469e-09
the O 0 9.453546834237159e-10
British O 0 9.513383414372356e-10
Isles O 0 1.9047082133738513e-08
: O 0 2.0708532111335387e-11
expression O 0 1.2689772843632596e-10
of O 0 6.479945469095583e-10
mutant O 0 1.8175744243009717e-09
ATM O 0 1.7268173735374148e-07
and O 0 4.601422021188739e-11
the O 0 1.0427934904466696e-10
risk O 0 3.7204970215753974e-09
of O 0 4.5643314905419174e-08
leukemia B-Disease 1 1.0
, O 0 1.350363982055569e-05
lymphoma B-Disease 1 1.0
, O 0 3.1686362490290776e-05
and O 0 2.1111234673298895e-05
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.0003691813035402447

We O 0 1.0859496057946671e-07
report O 0 1.3141031596219932e-09
the O 0 9.029932912518746e-10
spectrum O 0 3.7348968362493906e-07
of O 0 4.139345222142765e-08
59 O 0 2.7695514859260584e-07
ATM O 0 3.112701961072162e-05
mutations O 0 1.4767152833883301e-07
observed O 0 5.744073661162474e-08
in O 0 1.717307895887643e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.050667114555835724
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.244340517407409e-09
patients O 0 4.0436926029840947e-10
in O 0 2.0303278502886712e-10
the O 0 2.5387654201125542e-09
British O 0 3.4293282880071274e-08
Isles O 0 6.0090851548011415e-06
. O 0 6.169818789203418e-07

Of O 0 6.97026871421258e-06
51 O 0 3.96772747990326e-06
ATM O 0 0.006081809289753437
mutations O 0 1.2742340231852722e-06
identified O 0 3.936576575824802e-08
in O 0 8.743001878031009e-10
families O 0 4.974434197890787e-10
native O 0 2.9038926818714117e-10
to O 0 2.1715616804751647e-10
the O 0 7.014286929063474e-10
British O 0 2.125048803591767e-09
Isles O 0 1.3548775257277157e-07
, O 0 2.9678218216311336e-10
11 O 0 1.4827142846840502e-09
were O 0 4.313594759164374e-10
founder O 0 1.673451954786742e-08
mutations O 0 5.945734127266178e-09
, O 0 1.7881902902860958e-10
and O 0 2.048997499448646e-10
2 O 0 1.0918438420048915e-07
of O 0 1.5263015740174524e-08
these O 0 1.0914424919405974e-10
11 O 0 3.179300378519656e-09
conferred O 0 3.195010123135944e-08
a O 0 2.065486670588257e-09
milder O 0 1.7981281530410342e-07
clinical O 0 1.593414467038201e-08
phenotype O 0 1.7103279903452062e-09
with O 0 8.027368700314064e-12
respect O 0 1.025476259464142e-09
to O 0 3.014628768838179e-09
both O 0 2.8793580852948253e-08
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 6.286256393650547e-06
cellular O 0 2.6354912279202836e-06
features O 0 1.9559559305548646e-08
. O 0 1.3667234100012138e-07

We O 0 4.308533974040074e-08
report O 0 8.191324285533597e-10
, O 0 3.197541537103277e-11
in O 0 3.2316066489457285e-11
two O 0 1.3433577861210466e-10
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 6.183654699398744e-10
, O 0 4.240184939274805e-11
an O 0 5.838907135569116e-11
ATM O 0 2.6816878744284622e-06
mutation O 0 6.80628389204685e-08
( O 0 2.179928904055828e-09
7271T O 0 1.4595085531254881e-06
- O 0 2.0687251378603833e-07
- O 0 1.7135884888830333e-07
> O 0 2.8616688041438465e-07
G O 0 5.9303452815129276e-08
) O 0 5.08948135372056e-12
that O 0 1.0343813479363195e-12
may O 0 3.188321134883765e-11
be O 0 1.5344109663417704e-11
associated O 0 3.0081010599092295e-11
with O 0 1.6403416439828705e-13
an O 0 1.4502059492507713e-12
increased O 0 7.949422370367998e-11
risk O 0 1.0362099622795995e-08
of O 0 1.851955744314182e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.999932050704956
in O 0 1.2592425768787052e-08
both O 0 6.343401359742984e-09
homozygotes O 0 6.310928597486054e-07
and O 0 4.0911868337545343e-10
heterozygotes O 0 2.1770629743400605e-08
( O 0 2.2300575275302492e-10
relative O 0 2.796374687363823e-08
risk O 0 5.045068363074279e-09
12 O 0 4.756498528379893e-10
. O 0 2.1015715209737884e-11
7 O 0 1.7053440881653614e-09
; O 0 1.9656141991841736e-10
P O 0 2.552197202021489e-06
= O 0 7.635201804134795e-09
. O 0 2.2540735944431844e-10
0025 O 0 5.984396977964934e-08
) O 0 8.04843344748285e-12
, O 0 2.228566940362664e-12
although O 0 2.5394397955985637e-12
there O 0 4.088850352051976e-12
is O 0 1.1845141187349917e-11
a O 0 8.387331801307241e-11
less O 0 9.13150177694888e-09
severe O 1 0.9998874664306641
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 1.4696955652482302e-08
in O 0 6.055204514882062e-12
terms O 0 6.255278933720021e-11
of O 0 9.117256255519735e-11
the O 0 9.015267005141325e-11
degree O 0 8.200289869364497e-08
of O 0 3.740564693544002e-07
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 6.878524436615407e-05

This O 0 2.720838487846322e-08
mutation O 0 3.731229725190133e-08
( O 0 1.2757001011109992e-09
7271T O 0 1.0624758033372927e-06
- O 0 1.7709535882204364e-07
- O 0 1.5223001526010194e-07
> O 0 4.1009883489095955e-07
G O 0 1.0656545867959721e-07
) O 0 8.430616448007466e-12
also O 0 1.4250998384840452e-12
allows O 0 1.48837029940313e-12
expression O 0 1.0958522284054695e-10
of O 0 4.035694833870451e-10
full O 0 1.064796251171174e-09
- O 0 4.435440903449717e-09
length O 0 2.2289359247196217e-09
ATM O 0 2.650230328526959e-07
protein O 0 1.608366329008959e-09
at O 0 4.666012021203869e-10
a O 0 6.311930839109081e-11
level O 0 1.4889632860004554e-09
comparable O 0 1.2335370502825072e-09
with O 0 5.876836343954306e-12
that O 0 5.7156283178594336e-11
in O 0 5.052981921771504e-10
unaffected O 0 2.746082650162407e-08
individuals O 0 2.795941478339614e-09
. O 0 1.2095409829271375e-07

In O 0 5.884753129237197e-09
addition O 0 5.24393750644947e-10
, O 0 3.787187508041967e-10
we O 0 1.9196193246084903e-10
have O 0 1.3887732110140494e-11
studied O 0 2.8811584229515574e-09
18 O 0 2.03155003930533e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.5840532219257852e-09
, O 0 1.912721890595659e-11
in O 0 1.313472854785891e-11
15 O 0 1.296085461177654e-10
families O 0 9.458786184857182e-12
, O 0 3.540382223499172e-11
who O 0 3.222486444354189e-10
developed O 0 6.596096113753447e-08
leukemia B-Disease 1 1.0
, O 0 0.002854787977412343
lymphoma B-Disease 1 1.0
, O 0 0.0005036980146542192
preleukemic O 1 0.9999939203262329
T O 0 9.294947813032195e-05
- O 0 1.8927878500107909e-06
cell O 0 2.6114898332707526e-07
proliferation O 0 2.275422730235732e-06
, O 0 1.1990861636945738e-09
or O 0 1.7517083961138269e-06
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 4.524840164776833e-07
mostly O 0 6.269618157972445e-09
in O 0 5.236304279065962e-09
childhood O 0 8.559082971260068e-07
. O 0 1.6178564976598864e-07

A O 0 4.21827689933707e-06
wide O 0 2.847713460596424e-07
variety O 0 5.831945149026296e-09
of O 0 4.522044605437259e-08
ATM O 0 9.628733823774382e-05
mutation O 0 9.160532954410883e-08
types O 0 4.786004481616146e-09
, O 0 1.8463652828870636e-10
including O 0 2.0169267644920552e-10
missense O 0 3.14310091198422e-06
mutations O 0 3.869674003453838e-07
and O 0 7.553574987717582e-10
in O 0 9.690365176950877e-10
- O 0 1.9018402852566396e-08
frame O 0 2.2431263957400915e-08
deletions O 0 2.613078642355049e-08
, O 0 3.5460673286635824e-10
were O 0 6.435676991323191e-10
seen O 0 7.44668715579877e-10
in O 0 6.819125819568228e-11
these O 0 1.1901263308189414e-10
patients O 0 2.1297599239744613e-09
. O 0 1.0271782713289213e-07

We O 0 6.383213246863306e-08
also O 0 3.5137301401810817e-10
show O 0 5.6644248319637214e-11
that O 0 2.6610157220080533e-12
25 O 0 2.751537886425126e-10
% O 0 3.36059735595029e-10
of O 0 1.428991591723161e-09
all O 0 9.81148140510868e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 4.319286261988964e-09
carried O 0 1.8241236299232355e-10
in O 0 6.397635893273801e-11
- O 0 1.7201950974765623e-09
frame O 0 6.084457826460721e-09
deletions O 0 1.2137490124075612e-08
or O 0 6.341876801485569e-09
missense O 0 2.4342650704056723e-06
mutations O 0 2.474877476288384e-07
, O 0 9.526087557665264e-11
many O 0 1.6562567289879482e-12
of O 0 8.194540185302301e-11
which O 0 4.042215780847291e-12
were O 0 2.674322568951837e-11
also O 0 8.566924947217558e-12
associated O 0 6.677812469657596e-11
with O 0 1.1207867967044649e-11
expression O 0 1.4400326264762953e-08
of O 0 2.9899729270255193e-07
mutant O 0 8.502314017277968e-07
ATM O 0 9.515641431789845e-05
protein O 0 3.0201781555661e-06
. O 0 1.6269697766801983e-07

The O 0 9.513896657153964e-07
DMPK O 1 0.9991165995597839
gene O 0 3.566216832950886e-07
of O 0 2.016547796301893e-06
severely O 1 0.9999825954437256
affected O 1 0.9991887211799622
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0004084301181137562
is O 0 1.0915502457464754e-07
hypermethylated O 0 2.649852649483364e-05
proximal O 0 2.2808977519162e-05
to O 0 9.257344224522512e-09
the O 0 1.0011066642334754e-08
largely O 0 1.0368841785179939e-08
expanded O 0 1.3601849424560442e-08
CTG O 0 1.1699071365001146e-05
repeat O 0 4.542515341654507e-07
. O 0 2.0334617545358924e-07

Using O 0 1.4157375005652284e-07
methylation O 0 2.188799726354773e-06
- O 0 8.860073990035744e-07
sensitive O 0 1.892468901587563e-07
restriction O 0 1.084607781365321e-08
enzymes O 0 1.5744233694547916e-09
, O 0 8.367167375622486e-11
we O 0 9.563846936622156e-11
characterized O 0 6.498052651515707e-10
the O 0 6.206696823163327e-10
methylation O 0 2.9140434065766385e-08
pattern O 0 2.1861257692989966e-08
on O 0 8.358370884309352e-09
the O 0 4.2203140981911247e-10
5 O 0 2.1194224153475716e-09
side O 0 3.5279015264677582e-09
of O 0 1.7264973450892285e-08
the O 0 1.2705746676999752e-08
CTG O 0 1.139061259891605e-05
repeat O 0 6.854065759398509e-09
in O 0 1.0942356742926762e-10
the O 0 2.397582132829257e-10
DMPK O 0 3.0832454740448156e-06
gene O 0 2.1436355468473778e-10
of O 0 2.0199025785316849e-10
normal O 0 4.728168967460533e-10
individuals O 0 1.601972027254206e-11
and O 0 9.973776665672673e-11
of O 0 1.6530787405599767e-08
patients O 0 5.909889799760037e-10
affected O 0 1.6071152186825088e-09
with O 0 1.3214985550291658e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.7551178288499614e-08
showing O 0 2.4962802935846184e-09
expansions O 0 1.9539946549684828e-08
of O 0 1.695595486239654e-08
the O 0 8.259968709012355e-09
repetitive O 0 1.1699260937803047e-07
sequence O 0 7.753046560310395e-08
. O 0 4.713478674034377e-08

The O 0 5.090559511700121e-07
gene O 0 2.2353020767695853e-08
segment O 0 3.2299972474447713e-08
analyzed O 0 4.440147360895708e-09
corresponds O 0 2.402968668491212e-08
to O 0 2.3908066637545744e-09
the O 0 1.0748934187176928e-08
genomic O 0 3.7720889167758287e-07
SacI O 0 7.455244031007169e-06
- O 0 1.6274385927772528e-07
HindIII O 0 6.826577987339988e-07
fragment O 0 1.1141517575197213e-07
carrying O 0 2.5596242902992117e-09
exons O 0 1.274155891906048e-07
11 O 0 2.5072470322129448e-08
- O 0 1.0500799874080258e-07
15 O 0 1.2421736528267502e-07
. O 0 1.0986582310579251e-07

There O 0 6.065133817401147e-08
is O 0 5.749617226769033e-09
constitutive O 0 2.64939899352612e-07
methylation O 0 3.663628831418464e-07
in O 0 2.21765290575604e-08
intron O 0 5.646834779327037e-06
12 O 0 3.1313970083601816e-08
at O 0 2.2138397781645835e-09
restriction O 0 9.605349848840206e-10
sites O 0 2.993701397890902e-10
of O 0 1.707401109385387e-09
SacII O 0 2.108425860569696e-06
and O 0 2.549781497052095e-09
HhaI O 0 1.2844048796978313e-05
, O 0 1.4057642827580707e-09
localized O 0 2.2735281390851014e-07
1 O 0 2.4685246557965e-07
, O 0 4.205865933304409e-10
159 O 0 3.5384413177297347e-09
- O 0 2.33629791068779e-08
1 O 0 1.989780855637946e-07
, O 0 8.400785067586014e-10
232 O 0 4.3232177837637664e-09
bp O 0 2.8946438135335484e-08
upstream O 0 1.600313126459696e-08
of O 0 8.68225047412352e-09
the O 0 7.065327878308381e-09
CTG O 0 9.967292498913594e-06
repeat O 0 3.604422005309971e-08
, O 0 1.365788454554817e-10
whereas O 0 5.517340473382149e-10
most O 0 1.8388011599479448e-11
, O 0 1.2351297068446954e-11
if O 0 3.1539302419725246e-11
not O 0 5.5717579855452115e-11
all O 0 3.381595697904416e-11
, O 0 3.023678182834111e-11
of O 0 2.8587027189885816e-10
the O 0 4.4545461069800396e-11
other O 0 4.1772882895807495e-12
sites O 0 1.580385683430663e-10
of O 0 1.5400800634779443e-09
SacII O 0 3.0706833058502525e-06
, O 0 1.5163825750619253e-09
HhaI O 0 2.667570333869662e-05
, O 0 1.6347480036316142e-09
and O 0 9.290028746278267e-10
HpaII O 0 1.2294328371353913e-05
in O 0 3.5647501617219746e-10
this O 0 2.2300490620796865e-10
region O 0 3.3708527524822784e-08
are O 0 2.6562008148545146e-10
unmethylated O 0 3.636838243892271e-07
, O 0 4.936680578215835e-11
in O 0 1.572906041524824e-11
normal O 0 2.410292243570922e-10
individuals O 0 1.4830069464122353e-11
and O 0 4.041847412317168e-11
most O 0 1.3809578480739049e-10
of O 0 9.928196043063053e-09
the O 0 1.1600310934056779e-08
patients O 0 4.971913103446468e-09
. O 0 5.3564349400403444e-08

In O 0 1.1527721888171527e-08
a O 0 3.63689123261679e-09
number O 0 9.244565668531379e-10
of O 0 5.1212655449717204e-08
young O 0 4.429371092129486e-09
and O 0 2.6025570587506763e-09
severely O 0 9.653298911871389e-05
affected O 0 7.726842454758298e-08
patients O 0 4.527393127062851e-09
, O 0 2.529088605207619e-10
however O 0 6.590745726953173e-10
, O 0 9.601350964283384e-11
complete O 0 4.4653519770676553e-10
methylation O 0 1.0015650531158826e-08
of O 0 3.501983369957884e-09
these O 0 1.746316286022065e-11
restriction O 0 8.490785297077252e-10
sites O 0 1.9784365812292037e-10
was O 0 7.998033346723332e-10
found O 0 4.3117502623868376e-11
in O 0 3.130114223370839e-11
the O 0 5.473756448104439e-10
mutated O 0 1.8720765382340687e-08
allele O 0 7.315668426599586e-07
. O 0 1.624850227699426e-07

In O 0 2.6435932554136343e-08
most O 0 5.412967851725625e-10
of O 0 2.85912959974155e-09
these O 0 2.2749338871030922e-11
patients O 0 1.3507137075485787e-10
, O 0 2.780319724449143e-11
the O 0 3.00115654550126e-10
onset O 0 2.8300823032623157e-05
of O 0 3.8190000850590877e-07
the O 0 1.8784275823691132e-07
disease O 1 0.9874011874198914
was O 1 0.9958714842796326
congenital O 1 1.0
. O 0 0.00043582264333963394

Preliminary O 0 2.9720209568040445e-05
in O 0 2.017725137193338e-06
vivo O 0 8.88398353708908e-05
footprinting O 0 7.494049350498244e-05
data O 0 6.946429653709174e-09
gave O 0 1.5561668620378555e-09
evidence O 0 1.2715606345636843e-09
for O 0 2.9276450708159985e-10
protein O 0 2.4323689729044418e-09
- O 0 4.326417890609946e-09
DNA O 0 4.421655930286761e-09
contact O 0 9.687224356014212e-10
in O 0 1.7474466318390114e-10
normal O 0 4.0979051263434485e-09
genes O 0 6.767701399290615e-10
at O 0 8.96626106694498e-10
an O 0 4.5741906790075504e-11
Sp1 O 0 1.1997616233827557e-08
consensus O 0 7.845345706414264e-09
binding O 0 3.454418973092288e-08
site O 0 1.2467173959862521e-08
upstream O 0 2.968504198008759e-08
of O 0 6.016038778255961e-09
the O 0 6.941847097152731e-09
CTG O 0 8.263568815891631e-06
repeat O 0 7.224494336099951e-09
and O 0 2.3131401308273958e-11
for O 0 8.073602550395798e-12
a O 0 3.246768132125766e-11
significant O 0 1.2153669737280381e-10
reduction O 0 5.500405020342214e-09
of O 0 2.1519199755459795e-09
this O 0 6.659103130024491e-11
interaction O 0 8.264266493362982e-10
in O 0 5.481464240841838e-11
cells O 0 9.663928685066381e-11
with O 0 6.251768200349339e-12
a O 0 5.449279694147435e-09
hypermethylated O 0 1.5164378964982461e-05
DMPK O 0 0.0003846441104542464
gene O 0 5.7427815391974946e-08
. O 0 1.1888752204924913e-08
. O 0 5.086977594714881e-08

The O 0 1.680464811215643e-05
hemochromatosis B-Disease 1 1.0
gene O 0 2.1092412794132542e-07
product O 0 1.9154921204744824e-08
complexes O 0 2.591634462589809e-09
with O 0 1.730909686414872e-11
the O 0 9.77712133476416e-10
transferrin O 0 4.3312175534993003e-07
receptor O 0 2.584602327715402e-07
and O 0 5.867523134028829e-10
lowers O 0 4.3025942808583295e-09
its O 0 5.295103244762345e-11
affinity O 0 2.219365580202748e-09
for O 0 4.923011442947711e-10
ligand O 0 1.1161318980157375e-07
binding O 0 1.3102392131258966e-06
. O 0 3.643997104063601e-07

We O 0 5.724440939047781e-07
recently O 0 1.905820212755316e-08
reported O 0 1.112691716542713e-09
the O 0 1.8320035766183906e-10
positional O 0 1.5809028752755694e-08
cloning O 0 2.0834538538849756e-09
of O 0 4.3095324531172707e-10
a O 0 2.4585578017877197e-10
candidate O 0 1.3815705024455838e-08
gene O 0 1.1091854545952629e-08
for O 0 7.394509538016791e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 1.0
HFE O 1 1.0
. O 0 2.312348260602448e-05

The O 0 3.034202933349661e-08
gene O 0 8.012278618352298e-10
product O 0 1.1362706331397021e-09
, O 0 4.017904758901736e-11
a O 0 4.6115899987597686e-10
member O 0 4.079811599666527e-09
of O 0 6.11626020941003e-08
the O 0 1.714542285924381e-08
major O 0 1.5160023281168833e-07
histocompatibility O 0 0.0005246559157967567
complex O 0 4.482286186657802e-08
class O 0 1.060003862463077e-09
I O 0 1.834989120652608e-07
- O 0 4.46765469064303e-09
like O 0 5.361373844881001e-11
family O 0 2.3787957714738184e-11
, O 0 5.628354553255388e-12
was O 0 4.568612155253504e-10
found O 0 1.3860290519474017e-11
to O 0 1.9129845277299218e-11
have O 0 2.7755299794596233e-11
a O 0 9.493770214419328e-10
mutation O 0 1.7311764466398927e-08
, O 0 2.315844183087279e-09
Cys O 0 1.947351620401605e-06
- O 0 6.919224802004464e-07
282 O 0 9.776403686601043e-08
- O 0 6.609042202398996e-07
- O 0 4.847274226449372e-07
> O 0 1.0461801593919517e-06
Tyr O 0 3.1321549158747075e-06
( O 0 1.2356587975048683e-09
C282Y O 0 3.7435054878187657e-07
) O 0 5.700582020318201e-11
, O 0 2.0605695968956006e-11
in O 0 3.557155264788392e-11
85 O 0 4.05507138978578e-09
% O 0 5.483247189630447e-09
of O 0 2.9590074390739574e-08
patient O 0 9.481822189627565e-07
chromosomes O 0 6.927736194484169e-06
. O 0 1.116926796385087e-06

This O 0 7.62677476728868e-09
mutation O 0 4.3232855517771895e-08
eliminates O 0 6.140772512708281e-08
the O 0 1.0641484360363052e-09
ability O 0 2.196513942953615e-10
of O 0 2.248879660271541e-08
HFE O 0 0.00011427788558648899
to O 0 7.335072993441827e-09
associate O 0 2.1780930836712287e-08
with O 0 8.928438544053563e-11
beta2 O 0 2.6098836315213703e-05
- O 0 3.095345618930878e-06
microglobulin O 0 5.330576823325828e-05
( O 0 4.19439594168125e-09
beta2m O 0 5.689956196874846e-06
) O 0 3.223740718816259e-10
and O 0 2.0511206622053635e-10
prevents O 0 6.262649954180688e-09
cell O 0 7.299709068320226e-07
- O 0 2.176803945985739e-07
surface O 0 3.208107955288142e-06
expression O 0 1.9326726032886654e-06
. O 0 3.902085268236988e-07

A O 0 8.202634376175411e-07
second O 0 8.656013505969895e-08
mutation O 0 1.4523957148071531e-08
that O 0 4.3492823925683766e-11
has O 0 2.3970140108908744e-11
no O 0 3.9793439376989426e-11
effect O 0 2.028401224762888e-09
on O 0 7.868633744578801e-09
beta2m O 0 2.1926584850007202e-06
association O 0 1.1722077752907012e-09
, O 0 6.613096736884927e-10
H63D O 1 0.6369735598564148
, O 0 9.097198550023222e-10
was O 0 9.473225759393245e-09
found O 0 3.97785658579064e-11
in O 0 1.4012975675659067e-11
eight O 0 3.743927737276387e-11
out O 0 1.2002587292114786e-11
of O 0 3.1299249303451404e-10
nine O 0 7.985655470221786e-10
patients O 0 3.965107756020991e-11
heterozygous O 0 2.4740626214381223e-10
for O 0 2.735316417812328e-10
the O 0 2.352301287089631e-08
C282Y O 0 7.457719766534865e-05
mutant O 0 1.584875121807272e-06
. O 0 1.593530640775498e-07

In O 0 2.0121412092066748e-08
this O 0 1.2993632836355573e-09
report O 0 5.299005678693902e-10
, O 0 2.0114945820104424e-10
we O 0 6.123959117587674e-10
demonstrate O 0 2.394640041814e-09
in O 0 4.808449194371178e-09
cultured O 0 2.6226661020700703e-07
293 O 0 1.3455779424020875e-07
cells O 0 4.222291138944456e-08
overexpressing O 0 6.747806082785246e-07
wild O 0 6.1333138567931655e-09
- O 0 7.60482610218105e-09
type O 0 2.185291947398582e-08
or O 0 1.9359173819566422e-08
mutant O 0 2.4451619395904345e-08
HFE O 0 3.935503514185257e-07
proteins O 0 9.954177239424045e-12
that O 0 3.5669705036878163e-12
both O 0 1.484031127152452e-11
the O 0 2.6203927916412795e-10
wild O 0 6.341668301601544e-10
- O 0 2.996822123790821e-09
type O 0 3.29455787095867e-08
and O 0 1.0059952870733468e-08
H63D O 1 0.9971876740455627
HFE O 0 6.067430877010338e-05
proteins O 0 9.314833349094442e-10
form O 0 8.977863452663826e-10
stable O 0 4.999223701673827e-09
complexes O 0 4.803295539090868e-10
with O 0 2.5479510862291832e-11
the O 0 1.8239574295364491e-09
transferrin O 0 7.429838433381519e-07
receptor O 0 1.961588168342132e-06
( O 0 1.6236798572322186e-08
TfR O 0 8.656787144900591e-07
) O 0 4.135263687032875e-09
. O 0 3.373760293357009e-08

The O 0 1.5666707895434229e-06
C282Y O 0 0.00013558799400925636
mutation O 0 4.240110627051763e-07
nearly O 0 6.0789941969119354e-09
completely O 0 2.5636699430009458e-09
prevents O 0 4.465028624611733e-10
the O 0 1.4931972325271659e-10
association O 0 4.222488192429097e-10
of O 0 5.714860140670908e-09
the O 0 4.852136914479388e-09
mutant O 0 4.281141130491051e-08
HFE O 0 3.7489680835278705e-06
protein O 0 7.917185129713289e-09
with O 0 7.922297540208234e-11
the O 0 1.7401809770944965e-08
TfR O 0 7.990407539182343e-06
. O 0 1.3521925268378254e-07

Studies O 0 2.1193352495174622e-07
on O 0 1.0333959465924636e-07
cell O 0 2.782043679872004e-07
- O 0 4.8556856313553e-08
associated O 0 1.026443463558735e-08
transferrin O 0 6.648641033280001e-07
at O 0 8.165734044496276e-08
37 O 0 1.050348075182228e-08
degrees O 0 3.264607926212193e-07
C O 0 6.606974807255028e-07
suggest O 0 2.5330579855875612e-09
that O 0 2.771912699373047e-10
the O 0 7.345825725479926e-09
overexpressed O 0 5.009739652450662e-06
wild O 0 3.9511849792006615e-08
- O 0 7.006203617265783e-08
type O 0 1.66468211659776e-07
HFE O 0 2.1207646568655036e-05
protein O 0 1.0481466361511593e-08
decreases O 0 1.1236647168288982e-09
the O 0 6.801213064955292e-11
affinity O 0 3.128088010839747e-09
of O 0 1.9396392048065536e-08
the O 0 1.7382371098051408e-08
TfR O 0 4.95237202358112e-07
for O 0 4.9664352630429676e-09
transferrin O 0 7.69961752666859e-06
. O 0 5.117526029607689e-07

The O 0 4.802008788828971e-06
overexpressed O 0 0.0009839897975325584
H63D O 1 0.9787105321884155
protein O 0 7.966007586901469e-08
does O 0 1.3741238702458247e-10
not O 0 4.0505758469588926e-11
have O 0 1.125383315182804e-12
this O 0 2.002488886515552e-12
effect O 0 4.831328670462653e-10
, O 0 6.333297167954166e-12
providing O 0 9.919966757754306e-12
the O 0 2.9255781824888416e-11
first O 0 2.7156133244887748e-11
direct O 0 2.1073727485276805e-10
evidence O 0 1.6538372060725948e-10
for O 0 1.461909759914448e-11
a O 0 2.9636076925854127e-10
functional O 0 1.5359914229406968e-08
consequence O 0 5.892427523690458e-08
of O 0 2.505679042030806e-08
the O 0 2.637720619702577e-08
H63D O 0 0.0027404972352087498
mutation O 0 2.547994881751947e-06
. O 0 1.3204962101553974e-07

Addition O 0 1.4461491559814021e-07
of O 0 2.2128333512227982e-06
soluble O 0 3.2267944334307685e-05
wild O 0 2.313576601409295e-07
- O 0 2.5018448468472343e-07
type O 0 3.2073737656901358e-06
HFE O 1 0.9999291896820068
/ O 0 0.02451164461672306
beta2m O 0 0.0001809457753552124
heterodimers O 0 3.566295163182076e-06
to O 0 6.471871039082089e-09
cultured O 0 7.615915897929426e-09
cells O 0 4.3590511755731143e-10
also O 0 9.707967069116918e-12
decreased O 0 1.9029922082580697e-10
the O 0 1.6987878118102095e-11
apparent O 0 5.462867380678915e-10
affinity O 0 3.483210830879102e-09
of O 0 8.362867731648294e-09
the O 0 8.70048144641089e-10
TfR O 0 5.055288632149768e-09
for O 0 5.6969047534938255e-12
its O 0 2.930519325469727e-12
ligand O 0 5.360211718929975e-10
under O 0 1.507100888531454e-09
steady O 0 6.890834125528045e-09
- O 0 1.0798884009233234e-09
state O 0 2.352491812462887e-10
conditions O 0 1.1144998701695386e-08
, O 0 7.983671362898903e-11
both O 0 5.2657645605025394e-11
in O 0 2.5642457601726676e-10
293 O 0 1.9260273376175974e-09
cells O 0 9.60443391484489e-10
and O 0 4.661635522040797e-10
in O 0 6.298131793869288e-09
HeLa O 0 5.303174930304522e-06
cells O 0 9.627973440728965e-08
. O 0 7.244491939673026e-08

Furthermore O 0 8.462392315777834e-07
, O 0 3.579619045623872e-09
at O 0 1.1319535531129077e-08
4 O 0 8.361304537629621e-09
degrees O 0 5.364470894164697e-07
C O 0 1.7643700402913964e-06
, O 0 5.702629479742427e-10
the O 0 1.7848961197941549e-09
added O 0 1.9222337499513742e-08
soluble O 0 7.563789949927013e-08
complex O 0 1.7342367542028114e-08
of O 0 4.1659028227059025e-08
HFE O 0 0.000337040051817894
/ O 0 8.082220119831618e-06
beta2m O 0 2.230116479040589e-06
inhibited O 0 9.547416190969216e-09
binding O 0 1.1020535595207548e-08
of O 0 1.881508993051284e-08
transferrin O 0 4.575558421038295e-07
to O 0 3.7622228887812525e-08
HeLa O 0 1.0429324902361259e-05
cell O 0 3.635798009327118e-07
TfR O 0 1.2346245625849406e-07
in O 0 6.286136194910696e-11
a O 0 1.1547698353098212e-09
concentration O 0 6.504420184683113e-07
- O 0 4.523821672819395e-08
dependent O 0 1.8676113100468683e-08
manner O 0 6.674205366152819e-08
. O 0 1.306935502043416e-07

Scatchard O 0 3.818721233983524e-05
plots O 0 3.7119013995834393e-07
of O 0 9.836743686264526e-08
these O 0 1.106952515761428e-10
data O 0 7.665242329757405e-10
indicate O 0 1.3534970921824652e-09
that O 0 8.047976868263973e-11
the O 0 1.252448811328577e-09
added O 0 1.6846084527344374e-09
heterodimer O 0 5.9165614629819174e-08
substantially O 0 2.7052249329528877e-09
reduced O 0 4.346433879476308e-09
the O 0 4.589784108333106e-10
affinity O 0 6.545461950224762e-09
of O 0 2.9574048099334505e-08
TfR O 0 3.2082192547022714e-07
for O 0 1.2319735231969275e-09
transferrin O 0 2.7728890472644707e-06
. O 0 2.684604964997561e-07

These O 0 3.645475477043192e-09
results O 0 2.311528302101351e-09
establish O 0 4.31135971368235e-09
a O 0 3.8789900180802306e-09
molecular O 0 5.038829797854305e-08
link O 0 1.2615745781374699e-08
between O 0 2.642811836039982e-08
HFE O 0 0.04325997084379196
and O 0 1.4410979076728836e-09
a O 0 1.8926404887764647e-09
key O 0 9.818126756044876e-09
protein O 0 8.373621795954023e-10
involved O 0 1.3532587550546538e-10
in O 0 8.270979734437134e-11
iron O 0 2.7608402675127763e-08
transport O 0 2.32403030153705e-09
, O 0 1.1160899981987882e-10
the O 0 2.798986598051556e-10
TfR O 0 4.73308219284263e-08
, O 0 2.816250010972965e-11
and O 0 8.938759454846235e-12
raise O 0 1.592701803776464e-10
the O 0 2.1267997085683277e-10
possibility O 0 8.552472507972197e-09
that O 0 3.718208727021555e-11
alterations O 0 2.7324082996216248e-09
in O 0 1.9592612254815123e-11
this O 0 3.027519858075922e-12
regulatory O 0 4.2997128080202174e-10
mechanism O 0 2.095202011886954e-09
may O 0 3.589722408214868e-10
play O 0 2.7905855404242175e-10
a O 0 2.1689786078304962e-10
role O 0 3.235839651782868e-10
in O 0 3.673012241578455e-11
the O 0 3.6474487319360094e-10
pathogenesis O 0 1.6439906858067843e-06
of O 0 5.203459750191541e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.000785161042585969
. O 0 3.3953656384255737e-06

Genomic O 0 2.080895228573354e-06
organization O 0 9.778715792663206e-08
of O 0 3.5125552244608116e-07
the O 0 4.048953314850223e-07
UBE3A O 1 0.9991949200630188
/ O 0 0.001431361073628068
E6 O 0 0.006516572553664446
- O 0 3.23925050906837e-05
AP O 0 3.6537792311719386e-06
gene O 0 2.3402664250937733e-09
and O 0 2.083842542965897e-10
related O 0 2.118073716417257e-08
pseudogenes O 0 2.2405235995393014e-06
. O 0 4.133354423174751e-07

The O 0 2.897052354455809e-06
UBE3A O 0 0.0003982016642112285
gene O 0 4.4676394139742115e-08
encodes O 0 6.9076255826416855e-09
the O 0 5.738266750654475e-09
E6 O 0 3.5867760743713006e-05
- O 0 4.5595043047796935e-06
AP O 0 2.51647566074098e-06
ubiquitin O 0 8.524236960738563e-08
- O 0 1.1826376322687793e-08
protein O 0 2.2247978459510875e-10
ligase O 0 1.9983778520860085e-10
and O 0 9.230394920622942e-11
has O 0 4.383210461256226e-11
recently O 0 1.3801573772731501e-10
been O 0 1.9512506194141466e-11
shown O 0 2.749546684083226e-12
to O 0 7.132855937841409e-12
be O 0 1.1134448918426187e-10
mutated O 0 4.4915800856415444e-08
in O 0 2.516542565444979e-07
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 3.6449669096327852e-06
who O 0 4.68806895526086e-08
lack O 0 1.9604254930527532e-07
15q11 O 0 5.0868915423052385e-05
- O 0 1.227606389875291e-06
q13 O 0 3.4986248920176877e-06
deletions O 0 6.494737903040004e-08
or O 0 1.5983363965688113e-08
chromosome O 0 9.720705747895408e-06
15 O 0 2.385774848789879e-07
paternal O 0 7.1094382292358205e-06
uniparental B-Disease 0 0.06337971985340118
disomy I-Disease 0 0.011394040659070015
. O 0 1.0460900739417411e-05

Previous O 0 5.56041277377517e-06
UBE3A O 0 9.402091382071376e-05
cDNA O 0 1.9833433384519594e-07
analysis O 0 2.150041034099104e-09
has O 0 6.656347001365859e-11
shown O 0 2.6990272863902653e-11
a O 0 1.6710292871646715e-10
coding O 0 6.195489987703695e-08
region O 0 2.4154013544830377e-07
of O 0 1.3600090653653751e-07
approximately O 0 9.00414320881282e-08
2 O 0 1.479262436987483e-06
. O 0 1.489755732109188e-07

6 O 0 4.3599116906989366e-05
kb O 0 5.367687117541209e-05
and O 0 1.2908959234891881e-08
a O 0 9.735001782473773e-08
3 O 0 4.649661605071742e-06
- O 0 3.3685632843116764e-06
untranslated O 0 0.0015245504910126328
region O 0 1.089440729629132e-06
( O 0 7.896193032763676e-09
UTR O 0 2.071199742204044e-05
) O 0 7.248976974238985e-10
of O 0 1.3761134454171042e-08
< O 0 5.460333341034129e-06
50 O 0 2.778860697105756e-08
bp O 0 2.7347926589982308e-08
, O 0 9.506050113738951e-11
whereas O 0 3.978639917523452e-10
Northern O 0 1.8898629328134575e-09
analysis O 0 3.14500536724438e-10
has O 0 3.8265033502904444e-11
indicated O 0 2.145983807322338e-10
mRNA O 0 8.670430484691849e-10
sizes O 0 3.3121835829597046e-10
of O 0 2.6741417968878523e-09
5 O 0 9.483714791258535e-08
- O 0 5.53661038793507e-07
8 O 0 1.1558984169823816e-06
kb O 0 8.520922165189404e-06
. O 0 3.870655689297564e-07

We O 0 6.491777639894281e-07
have O 0 1.490506162937777e-09
analyzed O 0 1.3975647306097017e-09
additional O 0 2.1024545993064692e-10
cDNA O 0 5.7701203814986e-08
clones O 0 1.1979643943504925e-08
and O 0 1.9013585844662728e-11
provide O 0 6.515085346214811e-12
evidence O 0 1.1185109088929224e-10
for O 0 5.517863249648869e-11
an O 0 2.976960900014092e-10
additional O 0 7.441409266562005e-09
0 O 0 8.42866143102583e-07
. O 0 2.3023909534458653e-07

5 O 0 1.1867219654959626e-05
kb O 0 5.5138778407126665e-05
of O 0 2.879470685002161e-06
5 O 0 3.0161427275743335e-06
- O 0 3.111789965259959e-06
UTR O 0 0.00043857053969986737
and O 0 2.3994878972644074e-08
> O 0 1.4227393876353744e-06
2 O 0 7.058352480271424e-07
kb O 0 2.3948848593136063e-06
of O 0 3.7877373415540205e-07
3 O 0 3.843395461444743e-06
- O 0 7.0486253207491245e-06
UTR O 0 0.0009365281439386308
. O 0 7.763247253933514e-07

We O 0 5.8606062225408095e-08
have O 0 2.6204927117134957e-10
established O 0 5.224818910853912e-10
the O 0 1.0106233905293749e-10
genomic O 0 2.0632580088886243e-09
organization O 0 7.5502620822121e-10
of O 0 1.2069894417265914e-08
UBE3A O 0 3.282919351477176e-05
and O 0 1.0573827369242395e-09
the O 0 1.918526004729415e-09
sequence O 0 3.822786975860026e-09
of O 0 3.929899605736864e-08
intron O 0 7.7316844908637e-06
- O 0 3.982243015343556e-06
exon O 0 1.8519380091674975e-06
borders O 0 8.176610322152555e-07
. O 0 4.6145157739374554e-07

We O 0 9.420531341675087e-07
have O 0 4.712092049885541e-09
also O 0 8.080435209834036e-10
mapped O 0 1.872126453861256e-08
two O 0 4.732715885857885e-10
highly O 0 2.3156763173659556e-09
homologous O 0 8.567117681934633e-09
processed O 0 2.435211143847482e-08
pseudogenes O 0 1.1299371038830941e-07
, O 0 1.2189635967274626e-09
UBE3AP1 O 0 0.00023860311193857342
and O 0 8.52794102002008e-09
UBE3AP2 O 1 0.6080644726753235
, O 0 1.3559259270934376e-09
to O 0 1.157702822496276e-09
chromosomes O 0 4.7598862629172345e-09
2 O 0 7.975978100205339e-09
and O 0 6.986950601417519e-11
21 O 0 1.2394851811592389e-09
, O 0 4.149584148516183e-11
respectively O 0 1.0190263077802797e-09
, O 0 3.316265664854434e-11
and O 0 3.0885179830297815e-11
determined O 0 3.4453893071884067e-09
their O 0 1.3016346334104867e-10
genomic O 0 3.046177710075426e-08
organization O 0 2.6953530962714467e-08
. O 0 1.223931747063034e-07

These O 0 3.0902183034697828e-09
results O 0 9.740807049851696e-10
will O 0 4.651028867597162e-11
form O 0 4.359564445555186e-11
the O 0 6.747771091886179e-11
basis O 0 2.0447771253984115e-10
for O 0 5.443183664216589e-12
studies O 0 3.705465448367029e-11
of O 0 1.3022953548880167e-10
mutation O 0 6.566879262592806e-10
and O 0 2.467079041057474e-10
imprinting O 0 1.0002115686802426e-06
of O 0 3.2966904655040707e-06
UBE3A O 1 0.9132156372070312
. O 0 1.0897628044403973e-06

Mutation O 0 7.1579311224923e-06
spectrum O 0 2.5294893930549733e-05
and O 0 6.891454518154205e-08
genotype O 0 2.0533581846393645e-05
- O 0 1.920430804602802e-06
phenotype O 0 5.2211081680297866e-08
analyses O 0 3.951017291115022e-09
in O 0 6.869715907242835e-10
Cowden B-Disease 0 0.00018461742729414254
disease I-Disease 0 1.3708893220609752e-06
and O 0 4.858798519080665e-08
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 8.269288542805953e-08
two O 0 6.462239809934545e-08
hamartoma B-Disease 1 0.9999967813491821
syndromes I-Disease 1 0.9846317768096924
with O 0 1.6704595964256441e-06
germline O 1 1.0
PTEN O 1 0.9999996423721313
mutation O 0 0.0009227241389453411
. O 0 2.0850507098657545e-06

The O 0 1.2724326552415732e-05
tumour B-Disease 1 1.0
suppressor O 0 0.3467563986778259
gene O 0 7.497239039366832e-06
PTEN O 0 0.01327546127140522
, O 0 3.0786286853157208e-09
which O 0 4.3262340931882193e-10
maps O 0 2.8652999972678117e-08
to O 0 1.1633440522018645e-07
10q23 O 0 0.0007566281710751355
. O 0 2.807373448376893e-06

3 O 0 3.640964450823958e-06
and O 0 1.2754551192983854e-08
encodes O 0 7.939459756300948e-09
a O 0 8.438269638588736e-09
403 O 0 1.5376212303408465e-08
amino O 0 1.9071219270472284e-08
acid O 0 4.3420427253693106e-09
dual O 0 1.5846222112259056e-08
specificity O 0 2.727960861648171e-07
phosphatase O 0 9.443560702493414e-05
( O 0 1.8388670142144292e-08
protein O 0 1.819274864089948e-08
tyrosine O 0 3.5502058182146357e-08
phosphatase O 0 1.9278739671335643e-07
; O 0 3.3166783208748996e-10
PTPase O 0 1.0036782214228879e-06
) O 0 1.1461411680846467e-10
, O 0 6.320918788382812e-11
was O 0 1.6881918085687175e-09
shown O 0 5.771344166460857e-11
recently O 0 2.0332499572894847e-10
to O 0 4.9812865637877124e-11
play O 0 1.8545888436083402e-10
a O 0 3.1848401693679307e-10
broad O 0 1.677420868873014e-08
role O 0 6.948576380949589e-09
in O 0 2.887826422437456e-09
human O 0 1.0348575329999221e-07
malignancy B-Disease 0 0.00031753783696331084
. O 0 3.6704832950817945e-07

Somatic O 0 0.004389516077935696
PTEN O 0 0.0021057401318103075
deletions O 0 1.1308109151286772e-06
and O 0 7.704381133066818e-09
mutations O 0 1.8714409577569313e-08
were O 0 8.748606838970829e-10
observed O 0 1.1302464519857836e-09
in O 0 7.533298290729462e-11
sporadic B-Disease 0 5.789621582152904e-07
breast I-Disease 1 0.9999973773956299
, I-Disease 0 2.4901385131670395e-07
brain I-Disease 1 1.0
, I-Disease 0 0.0002473554923199117
prostate I-Disease 1 1.0
and I-Disease 1 0.9999910593032837
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9995386600494385
lines O 0 1.5821703414076183e-07
and O 0 5.473317910009712e-10
in O 0 7.990313272143723e-11
several O 0 1.4829057426446468e-10
primary O 0 2.754103718416445e-07
tumours B-Disease 1 1.0
such O 0 2.6344559866942063e-09
as O 0 1.715494704512821e-06
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 1.0
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.6345691680908203

In O 0 2.1463216981487676e-08
addition O 0 4.182620472192866e-09
, O 0 1.019032680460441e-08
PTEN O 0 0.41368502378463745
was O 0 3.2651246328896377e-07
identified O 0 8.592563993659041e-09
as O 0 1.0771807057441407e-10
the O 0 2.443630020554366e-10
susceptibility O 0 2.3697062090377585e-08
gene O 0 1.7658654538621477e-09
for O 0 1.7794438145202207e-09
two O 0 4.8792482942872084e-08
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 3.661155290046736e-08
CD B-Disease 0 1.3458488865580875e-05
; O 0 3.1922812837592573e-08
MIM O 0 3.64260449714493e-05
158350 O 0 1.5222173033180297e-06
) O 0 5.869303376648816e-10
and O 0 1.987897846333908e-09
Bannayan B-Disease 0 0.02247137762606144
- I-Disease 0 0.14133593440055847
Zonana I-Disease 1 0.7128381133079529
( I-Disease 0 5.794051816110368e-08
BZS I-Disease 0 8.685555803822353e-05
) I-Disease 0 5.069237807298066e-10
or I-Disease 0 2.203842219827834e-09
Ruvalcaba I-Disease 0 1.3357552006709739e-06
- I-Disease 0 2.5845085360742814e-07
Riley I-Disease 0 2.9922435373919143e-07
- I-Disease 0 0.00013366068014875054
Smith I-Disease 0 0.00020605493045877665
syndrome I-Disease 1 1.0
( O 0 9.97630877463962e-07
MIM O 0 0.1390180140733719
153480 O 0 0.00011374984023859724
) O 0 4.470247816357187e-08
. O 0 2.741614366641443e-07

Constitutive O 0 2.055883442153572e-06
DNA O 0 3.134827579742705e-07
from O 0 1.6040841543940587e-08
37 O 0 3.476469245811131e-08
CD B-Disease 0 1.2597139686931769e-07
families O 0 7.951321268073741e-10
and O 0 9.202747452974336e-10
seven O 0 9.725235727842119e-09
BZS B-Disease 0 5.039803727413528e-05
families O 0 4.734584946319842e-10
was O 0 2.214833472180544e-08
screened O 0 3.8916493139140584e-08
for O 0 1.3969126300139578e-08
germline O 0 0.0009677343186922371
PTEN O 1 0.8664748072624207
mutations O 0 9.326156578026712e-05
. O 0 3.104898041783599e-06

PTEN O 0 0.00552054587751627
mutations O 0 8.053821716202947e-07
were O 0 7.040709792960342e-09
identified O 0 1.6973806804543301e-09
in O 0 1.3837105072855849e-10
30 O 0 1.8719970018565846e-09
of O 0 5.15026776781724e-09
37 O 0 1.7494993898026223e-08
( O 0 6.623751547252255e-10
81 O 0 5.652992740579066e-08
% O 0 3.670201031980014e-09
) O 0 6.505204708240342e-11
CD B-Disease 0 2.713360203188131e-08
families O 0 1.9217807900595574e-10
, O 0 9.988816024320002e-11
including O 0 1.7637370730572144e-10
missense O 0 3.2909409242165566e-07
and O 0 7.47646389243073e-09
nonsense O 0 5.0796948016795795e-06
point O 0 2.6735904157249024e-06
mutations O 0 1.3464451775746511e-08
, O 0 2.13430509377055e-10
deletions O 0 2.8041513999710332e-08
, O 0 1.827941575882619e-09
insertions O 0 8.330236056508511e-08
, O 0 2.182907854475502e-09
a O 0 2.636216756002341e-08
deletion O 0 4.714139777206583e-06
/ O 0 7.604039637953974e-06
insertion O 0 1.9443527889961842e-06
and O 0 6.182788325759248e-08
splice O 0 1.9745177269214764e-05
site O 0 6.60239606986579e-07
mutations O 0 1.2329694527579704e-06
. O 0 1.9295221420634334e-07

These O 0 7.111240929447149e-09
mutations O 0 4.670932085559798e-08
were O 0 2.862032388861735e-09
scattered O 0 2.5196431607810155e-09
over O 0 4.2356523843878335e-10
the O 0 2.137576643468364e-10
entire O 0 1.1530860710706747e-09
length O 0 9.637685094432413e-10
of O 0 3.951725613404733e-09
PTEN O 0 1.1463835107861087e-05
, O 0 4.9720220995919107e-11
with O 0 1.6667907288756e-12
the O 0 5.935903851783664e-11
exception O 0 2.2170119906572694e-10
of O 0 6.864921964222503e-10
the O 0 1.8392651290888296e-10
first O 0 4.907785844388002e-10
, O 0 3.339581666761404e-10
fourth O 0 2.5885434240535687e-08
and O 0 1.642292191128547e-09
last O 0 1.9446406440692954e-07
exons O 0 1.5191722013696562e-05
. O 0 3.88397467077084e-07

A O 0 3.64945808541961e-05
hot O 0 2.1960484446026385e-05
spot O 0 6.459596306740423e-07
for O 0 3.83293530248352e-09
PTEN O 0 4.788866499438882e-05
mutation O 0 2.350592431810128e-08
in O 0 5.942261682712058e-10
CD B-Disease 0 4.435291316440271e-07
was O 0 8.611846880057783e-08
identified O 0 3.272311310809073e-09
in O 0 1.9716256405288846e-10
exon O 0 9.18961440277144e-09
5 O 0 8.544478458105687e-10
that O 0 6.096588078124965e-12
contains O 0 5.467826885707794e-11
the O 0 6.039765909626738e-10
PTPase O 0 2.882369471990387e-06
core O 0 7.019312420197821e-08
motif O 0 1.4895057409702872e-09
, O 0 9.40601936616492e-12
with O 0 1.059406035119892e-12
13 O 0 5.291774241023006e-10
of O 0 9.898297737009898e-10
30 O 0 3.5804996745270046e-09
( O 0 3.9568073817441984e-10
43 O 0 1.0025818397707553e-08
% O 0 8.434339893170772e-10
) O 0 7.585623101880046e-11
CD B-Disease 0 3.943174320397702e-08
mutations O 0 4.636277584069148e-09
identified O 0 1.350603628935687e-09
in O 0 2.4063051551337367e-10
this O 0 2.1206840727927556e-09
exon O 0 2.952428076241631e-06
. O 0 2.415159485735785e-07

Seven O 0 1.1734682203723423e-07
of O 0 1.147566877079953e-07
30 O 0 5.219147070079089e-08
( O 0 9.941720779949037e-10
23 O 0 6.2224296826229875e-09
% O 0 9.104367260093227e-10
) O 0 8.113136031051571e-12
were O 0 3.646806814860959e-11
within O 0 2.9544702795369915e-10
the O 0 1.710542540944715e-10
core O 0 2.796789466685823e-09
motif O 0 1.9638791981524406e-10
, O 0 2.3986318573726573e-12
the O 0 5.122544749491809e-12
majority O 0 6.403077287137071e-12
( O 0 7.315505146099355e-11
five O 0 1.7096095372703957e-10
of O 0 1.4122517599801654e-09
seven O 0 1.628442103385197e-10
) O 0 1.6994586293783698e-11
of O 0 1.6058335217117303e-10
which O 0 3.897957651100015e-11
were O 0 9.178364179796006e-10
missense O 0 5.442067845251586e-07
mutations O 0 4.600823189093717e-08
, O 0 3.2907923608327394e-10
possibly O 0 1.938370708387538e-08
pointing O 0 1.8226090858775024e-08
to O 0 4.212497017874739e-10
the O 0 5.395589530721168e-10
functional O 0 1.104351277092519e-08
significance O 0 3.998452235975947e-09
of O 0 2.8338729141097474e-09
this O 0 6.316691614216552e-10
region O 0 4.947575575897645e-07
. O 0 2.1074679068533442e-07

Germline O 1 0.7799893021583557
PTEN O 0 0.005316626746207476
mutations O 0 4.924115160065412e-07
were O 0 3.3334293103592927e-09
identified O 0 9.304001458154687e-10
in O 0 5.3796894022850594e-11
four O 0 5.569675623484649e-11
of O 0 2.7027287075043205e-09
seven O 0 1.468607568888558e-09
( O 0 2.1559503071699737e-09
57 O 0 5.217027023718401e-07
% O 0 9.675229506456162e-08
) O 0 1.523811654635665e-08
BZS B-Disease 0 0.00024201073392760009
families O 0 1.1906021057939142e-08
studied O 0 1.0675317980712862e-06
. O 0 3.4895438716375793e-07

Interestingly O 0 3.49269089383597e-06
, O 0 7.356551812165435e-09
none O 0 3.973311013538705e-09
of O 0 4.7227270982830305e-09
these O 0 7.637335208698914e-11
mutations O 0 5.637570854588603e-09
was O 0 2.5859179686449352e-08
observed O 0 3.685634020200723e-09
in O 0 2.4677190846311703e-10
the O 0 6.144647901606959e-09
PTPase O 0 2.608841168694198e-05
core O 0 2.339108277737978e-06
motif O 0 3.9589593825439806e-07
. O 0 6.826461884656965e-08

It O 0 3.133910908559301e-09
is O 0 2.329545722989934e-10
also O 0 1.4889447313981563e-11
worthy O 0 2.7481301678733416e-09
of O 0 2.2845327851683805e-09
note O 0 3.847957230629362e-10
that O 0 1.3096279269375621e-11
a O 0 2.247372288266547e-10
single O 0 8.826612218904017e-10
nonsense O 0 6.796956597554527e-08
point O 0 1.1310820724474979e-07
mutation O 0 6.899632865042804e-09
, O 0 2.0726008409521768e-10
R233X O 0 1.1623652653725003e-06
, O 0 2.8757543568680433e-10
was O 0 1.1037953662196287e-08
observed O 0 1.6201772146118287e-09
in O 0 8.857570926723568e-11
the O 0 7.469191376507922e-10
germline O 0 1.7914868521984317e-07
DNA O 0 1.3689090749835486e-08
from O 0 5.909315259344794e-10
two O 0 1.8037377147450684e-11
unrelated O 0 7.921999167770366e-10
CD B-Disease 0 6.078544600995883e-08
families O 0 2.9542165935758646e-10
and O 0 1.088044654373732e-09
one O 0 3.1351618190456065e-08
BZS B-Disease 0 0.03146563097834587
family O 0 1.246729794956991e-07
. O 0 2.164932908499395e-07

Genotype O 0 7.915985042927787e-05
- O 0 3.0243083983805263e-06
phenotype O 0 9.74198570702356e-08
studies O 0 1.6506015443340516e-09
were O 0 1.1949713440984056e-10
not O 0 3.2666702676209525e-11
performed O 0 1.1384024278804361e-10
on O 0 2.38691427734139e-10
this O 0 1.4480010940287613e-11
small O 0 1.8521710554164628e-10
group O 0 1.6519527967773229e-09
of O 0 8.738675205677282e-08
BZS B-Disease 1 0.9392402172088623
families O 0 8.876086354803192e-08
. O 0 2.6020978793894756e-07

However O 0 6.869806838949444e-07
, O 0 2.2120005382930685e-08
genotype O 0 1.060502768268634e-06
- O 0 1.1509711583812532e-07
phenotype O 0 1.2669301163725777e-08
analysis O 0 1.03918829097438e-09
inthe O 0 4.6572327505600697e-07
group O 0 2.426723544335374e-10
of O 0 3.0508391368755383e-09
CD B-Disease 0 1.6990939002425876e-06
families O 0 7.937426271809045e-10
revealed O 0 2.346206118275518e-09
two O 0 4.972721453361251e-12
possible O 0 1.7239090710496896e-10
associations O 0 1.0466951610998976e-10
worthy O 0 8.687253583161691e-09
of O 0 1.1149506207175364e-08
follow O 0 2.3797965820193667e-09
- O 0 1.4422562699678565e-08
up O 0 7.268442514529738e-10
in O 0 7.625515496822999e-11
independent O 0 1.295581864013684e-09
analyses O 0 2.084202144203573e-08
. O 0 4.849503199011451e-08

The O 0 3.567773987356304e-08
first O 0 3.6940233094640007e-09
was O 0 1.473271193930259e-08
an O 0 8.42141148482689e-11
association O 0 2.916331343083556e-10
noted O 0 2.551988897980806e-10
in O 0 4.4192906278883726e-11
the O 0 1.9962292929776027e-10
group O 0 2.9347663188517004e-11
of O 0 9.45186928724695e-10
CD B-Disease 0 5.767891479990794e-07
families O 0 1.0638401271023668e-09
with O 0 6.6429732825668e-09
breast B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999903440475464
. O 0 2.6510988391237333e-05

A O 0 1.0225782034467557e-06
correlation O 0 2.0280953094697907e-07
was O 0 1.723309139833873e-08
observed O 0 9.4165475417185e-10
between O 0 2.905704288291844e-10
the O 0 4.1246742132905467e-10
presence O 0 1.9140082851976103e-09
/ O 0 2.038334514509188e-06
absence O 0 5.7343310544411e-08
of O 0 2.6222803484188262e-08
a O 0 1.1639783359385092e-08
PTEN O 0 2.5198492949130014e-05
mutation O 0 7.470149832045081e-09
and O 0 1.940865003435821e-11
the O 0 1.3241154700471824e-11
type O 0 2.403581778054331e-09
of O 0 4.7410960490879006e-08
breast O 0 0.00027320804656483233
involvement O 0 1.466486992285354e-05
( O 0 1.2620853340195026e-07
unaffected O 0 1.1474960047053173e-05
versus O 0 0.000593445380218327
benign O 1 0.9895781874656677
versus O 1 0.9955682158470154
malignant O 1 0.9999982118606567
) O 0 1.6957287130026089e-07
. O 0 3.613587864492729e-07

Specifically O 0 3.096869605201391e-08
and O 0 1.7755100167882176e-10
more O 0 4.363139190222132e-12
directly O 0 3.7144964881719034e-10
, O 0 5.161788357854746e-11
an O 0 5.024781285500879e-11
association O 0 1.1543448419359947e-09
was O 0 4.753056970230318e-08
also O 0 1.391430581865194e-10
observed O 0 4.2088593721345546e-10
between O 0 2.6642787975816873e-10
the O 0 2.3652063640966503e-10
presence O 0 2.1327181687347263e-10
of O 0 3.6729319585759868e-09
a O 0 2.037491064754704e-08
PTEN O 1 0.9146779775619507
mutation O 0 4.5338034396991134e-05
and O 0 2.442077857267577e-06
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 3.908098005922511e-05

Secondly O 0 4.842874841415323e-05
, O 0 2.4238579143798233e-08
there O 0 1.6911503308847387e-09
appeared O 0 1.4027992101262043e-09
to O 0 1.253600140360689e-10
be O 0 2.6687954624016186e-10
an O 0 4.711352419306536e-10
interdependent O 0 4.3918785763708e-07
association O 0 3.706932538705132e-09
between O 0 1.3313075442056288e-07
mutations O 0 6.661360316684295e-07
upstream O 0 9.653074073412427e-08
and O 0 1.3476540716705898e-10
within O 0 2.726223913285253e-09
the O 0 2.8247204575393425e-09
PTPase O 0 5.4172674026631285e-06
core O 0 9.559300195860487e-08
motif O 0 3.4743989907326522e-09
, O 0 3.7970730726311075e-11
the O 0 8.881560070728156e-11
core O 0 1.2241127000933716e-09
motif O 0 1.161641755009768e-10
containing O 0 2.4118348377483168e-12
the O 0 8.810523491331601e-12
majority O 0 7.883524562324329e-12
of O 0 8.004534257644025e-10
missense O 0 2.865218675651704e-07
mutations O 0 4.826065946872404e-08
, O 0 6.715671768686704e-11
and O 0 1.156814487951463e-11
the O 0 6.679366781892071e-11
involvement O 0 5.758507004571811e-09
of O 0 1.1235217201033265e-08
all O 0 1.235059693405205e-10
major O 0 4.127186592484122e-09
organ O 0 1.8833526382877608e-06
systems O 0 2.7862170099979267e-06
( O 0 3.781943647140906e-08
central O 0 1.830106157285627e-05
nervous O 0 3.15584287591264e-07
system O 0 4.050710344927211e-07
, O 0 1.1961154200434976e-07
thyroid O 1 1.0
, O 0 5.291184379530023e-07
breast O 1 0.9999990463256836
, O 0 1.802889528335072e-06
skin O 1 0.999997615814209
and O 0 0.00020269780361559242
gastrointestinal O 1 1.0
tract O 1 0.999998927116394
) O 0 3.059155233131605e-06
. O 0 2.4988978566398146e-06

However O 0 2.581294040737703e-07
, O 0 1.9578287879795653e-09
these O 0 4.29572662163924e-11
observations O 0 4.740452030915776e-09
would O 0 6.304366473308676e-10
need O 0 4.6466158698521554e-10
to O 0 3.809915716246337e-10
be O 0 4.677159215482618e-10
confirmed O 0 4.237696860087681e-10
by O 0 2.2193462345665438e-11
studying O 0 2.5616742060918796e-10
a O 0 2.4724054401015216e-11
larger O 0 9.607873524553057e-11
number O 0 8.00691180025126e-11
of O 0 2.2908204222460427e-09
CD B-Disease 0 1.6213887192861876e-06
families O 0 1.8998679962578535e-08
. O 0 2.7237183530814946e-07

Molecular O 0 0.4693109393119812
defects O 1 0.9999442100524902
leading O 0 4.4431826040636224e-07
to O 0 2.8750428704427122e-09
human O 0 8.878041635185241e-10
complement B-Disease 0 5.072800401961786e-09
component I-Disease 1 0.5054421424865723
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.3872443194173911e-09
an O 0 9.879714407690088e-11
African O 0 9.65420632326186e-10
- O 0 2.529166875930855e-09
American O 0 1.929704396275156e-09
family O 0 2.606506566138478e-09
. O 0 1.7829641763000836e-08

Complement B-Disease 0 1.7114845149990288e-06
component I-Disease 1 0.9986891150474548
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.2473738486562524e-08
C6D B-Disease 0 0.006748405750840902
) O 0 5.235462618990994e-10
was O 0 6.013597442233731e-08
diagnosed O 0 1.322015918958641e-07
in O 0 3.301434126079528e-11
a O 0 1.2335577004307652e-10
16 O 0 8.522245131814543e-10
- O 0 4.187790947351999e-10
year O 0 2.4046856172965647e-10
- O 0 2.669906518093512e-09
old O 0 4.233393191555024e-09
African O 0 2.6696811428195133e-10
- O 0 4.461129798905006e-10
American O 0 9.408535062149781e-11
male O 0 7.906447024863539e-11
with O 0 6.279976538792198e-11
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.1828397873614449e-05

The O 0 1.6835340943543997e-07
patients O 0 3.611606658182609e-08
father O 0 2.3106832003350064e-08
and O 0 3.8973055338509255e-10
two O 0 1.4070430931489852e-10
brothers O 0 3.4530224013451516e-08
also O 0 1.7926263251588637e-10
had O 0 3.1195086513946535e-09
C6D B-Disease 1 0.904385507106781
, O 0 9.653391280783907e-11
but O 0 1.776227255556595e-11
gave O 0 3.7312240103171135e-11
no O 0 5.549474421662204e-11
history O 0 1.1942951072541064e-09
of O 0 1.580456654437512e-08
meningitis B-Disease 1 0.9999992847442627
or O 0 8.464161993515518e-08
other O 0 7.332652707248144e-09
neisserial B-Disease 0 0.002940952545031905
infection I-Disease 0 3.054537228308618e-05
. O 0 7.873529170865368e-07

By O 0 8.99306851209758e-09
using O 0 8.222039937777481e-09
exon O 0 1.2524380110789934e-07
- O 0 5.920193668629281e-09
specific O 0 1.7172700761403092e-10
polymerase O 0 1.2621594436268424e-08
chain O 0 2.3480997146663185e-09
reaction O 0 2.124512926693356e-10
( O 0 8.175009974520364e-11
PCR O 0 1.987928044400178e-09
) O 0 1.4233139666863792e-10
/ O 0 4.8215458292588664e-09
single O 0 6.448849232398857e-10
- O 0 2.5280961768459065e-09
strand O 0 2.352766648172633e-09
conformation O 0 2.483257766083824e-10
polymorphism O 0 1.9839119236308989e-10
as O 0 1.1523219878295521e-11
a O 0 4.800499581181228e-11
screening O 0 3.254321256918047e-10
step O 0 1.8681947100418483e-09
and O 0 5.034566513684169e-11
nucleotide O 0 7.533575430151984e-10
sequencing O 0 4.157484634337294e-10
of O 0 7.777076760362434e-10
target O 0 8.401782380929035e-09
exons O 0 3.263150460952602e-08
, O 0 6.129050739156483e-11
we O 0 3.132610837397465e-11
determined O 0 2.6617288928498795e-10
that O 0 1.2339807127503821e-11
the O 0 2.270418297811716e-10
proband O 0 2.598437447431934e-07
was O 0 4.886119064906325e-09
a O 0 6.569096377972983e-10
compound O 0 4.26142321430234e-09
heterozygote O 0 1.9597800715587255e-08
for O 0 3.0958918761925247e-10
two O 0 2.0996906435755136e-09
C6 O 0 0.0003222720988560468
gene O 0 9.052028531186807e-07
mutations O 0 2.7180949473404326e-06
. O 0 5.493120625033043e-07

The O 0 3.894868996212608e-07
first O 0 3.186331909432738e-08
, O 0 1.4788110735963755e-09
1195delC O 0 1.6968546390216943e-07
located O 0 2.6851264323113355e-08
in O 0 1.9870296519286512e-09
exon O 0 1.226326844516734e-07
7 O 0 3.6949831638821706e-08
, O 0 5.979220590868195e-11
is O 0 2.183014012613338e-11
a O 0 3.334214501715671e-11
novel O 0 1.214095074475452e-10
mutation O 0 5.032725347575706e-10
, O 0 1.877358511703786e-11
while O 0 2.36311300388925e-11
the O 0 1.2998979670442168e-10
second O 0 3.2727545118405033e-09
, O 0 8.840406184873473e-11
1936delG O 0 1.0100326797157777e-08
in O 0 3.705226958583552e-10
exon O 0 1.6232279520522752e-08
12 O 0 3.0753302127095594e-09
, O 0 3.5176580398532664e-11
has O 0 1.5153113139265706e-11
been O 0 3.65434765781103e-11
described O 0 1.5138329478858736e-10
before O 0 1.6322110329980433e-10
to O 0 1.3660855779917824e-10
cause O 0 1.0254517235352978e-07
C6D B-Disease 1 0.8648969531059265
in O 0 5.714715367588497e-10
an O 0 9.908814047054904e-11
unrelated O 0 4.5782102553459936e-09
African O 0 2.9912259336128955e-09
- O 0 8.009227059346813e-09
American O 0 2.8662279216717934e-09
individual O 0 7.026498827222838e-10
. O 0 4.1329077049567786e-08

Both O 0 9.036798331862883e-08
mutations O 0 3.124935687992547e-07
result O 0 1.0612246370556022e-07
in O 0 1.7517699291147437e-08
premature O 0 1.6426743059128057e-06
termination O 0 5.8291179811931215e-06
codons O 0 4.774164153786842e-06
and O 0 2.2128978116597864e-07
C6 O 0 0.0003008973435498774
null O 0 5.34044775122311e-05
alleles O 0 1.071356336979079e-06
. O 0 2.043988160949084e-07

Allele O 0 4.1088182456405775e-07
- O 0 7.119926870302606e-09
specific O 0 1.2897378998122377e-10
PCR O 0 3.042691654187024e-09
indicated O 0 6.443660605093271e-10
that O 0 1.352365355117291e-11
the O 0 3.5554814648008914e-10
probands O 0 1.0464794968356728e-06
two O 0 3.6562947114404665e-10
brothers O 0 4.059802094502629e-08
also O 0 2.740658811006824e-10
inherited O 0 4.464436642592773e-08
the O 0 2.9893723052509813e-09
1195delC O 0 2.7234500876716083e-08
mutation O 0 2.0909383113831836e-09
from O 0 6.113292649878588e-10
their O 0 1.931632111207282e-11
heterozygous O 0 4.758984872843541e-10
mother O 0 7.061804613295308e-11
and O 0 6.6793506489637444e-12
the O 0 1.0167466174548778e-10
1936delG O 0 3.3047262704144487e-09
mutation O 0 1.749385081240007e-09
from O 0 1.4661781788660733e-09
their O 0 3.077411936391883e-10
homozygous O 0 8.90361917527116e-09
father O 0 3.210293897382144e-08
. O 0 7.989254591223016e-09
. O 0 7.792273493123503e-08

PAX6 O 0 0.022982656955718994
mutations O 0 2.771304025372956e-05
reviewed O 0 1.0969618415401783e-05
. O 0 2.2560086563316872e-06

Mutations O 0 4.716037892649183e-06
in O 0 1.8570579740639914e-08
PAX6 O 0 0.00023376378521788865
are O 0 4.968175870700975e-10
responsible O 0 1.1194724258700717e-08
for O 0 2.3520712044700076e-09
human O 0 4.0596282246951887e-07
aniridia B-Disease 1 1.0
and O 0 2.0310658044309093e-08
have O 0 3.51937784470735e-10
also O 0 4.990882360167426e-11
been O 0 5.174741538049865e-11
found O 0 7.336461299578545e-12
in O 0 4.1605265239941236e-12
patients O 0 4.123175759151998e-12
with O 0 1.0626992341666863e-11
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 1.409692572451604e-06
with O 0 0.09283320605754852
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.0033221659250557423
with O 0 7.978643878914227e-08
autosomal B-Disease 1 0.9999991655349731
dominant I-Disease 1 0.9999992847442627
keratitis I-Disease 1 0.9999997615814209
, O 0 1.2848114572250324e-08
and O 0 2.534092269357302e-09
with O 0 3.971712292383245e-09
isolated B-Disease 1 0.9987987279891968
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.4644429087638855

No O 0 1.3810468146857602e-07
locus O 0 1.5795382068972685e-07
other O 0 4.7741654379818144e-11
than O 0 1.6719922668606557e-10
chromosome O 0 9.415098247700371e-07
11p13 O 0 5.470481482916512e-06
has O 0 2.813255739475551e-10
been O 0 3.930143155361776e-10
implicated O 0 1.9894121905394968e-08
in O 0 1.961910855996507e-09
aniridia B-Disease 1 1.0
, O 0 2.980463520430021e-08
and O 0 6.187787615630214e-09
PAX6 O 1 0.9940423369407654
is O 0 3.361233735788005e-09
clearly O 0 2.114536545860801e-09
the O 0 3.1880917350513016e-10
major O 0 7.169476567980837e-09
, O 0 6.29793370232612e-11
if O 0 4.865375463625199e-11
not O 0 5.7736669611951896e-11
only O 0 8.806461115895559e-11
, O 0 1.4492396172016697e-10
gene O 0 4.005910270166169e-09
responsible O 0 6.204832914136205e-08
. O 0 2.312932423365055e-07

Twenty O 0 2.8179526907479158e-06
- O 0 2.49280901698512e-07
eight O 0 3.868438902543403e-09
percent O 0 9.107150589215962e-09
of O 0 4.522490826275316e-09
identified O 0 2.2119541753795602e-08
PAX6 O 0 2.076008968288079e-05
mutations O 0 7.309407124012068e-08
are O 0 1.6572135885795092e-09
C O 0 7.295792602235451e-05
- O 0 2.773741289274767e-05
T O 0 1.0330140867154114e-06
changes O 0 5.216645782013529e-09
at O 0 3.6950186910189586e-08
CpG O 0 2.53583010589864e-07
dinucleotides O 0 1.013106498248817e-06
, O 0 5.539864122994231e-10
20 O 0 1.0885531365190104e-09
% O 0 2.3790786007893416e-10
are O 0 2.588794846894449e-12
splicing O 0 3.1773967901216338e-09
errors O 0 3.3836005997045504e-08
, O 0 1.1500698310351609e-10
and O 0 1.461976720240621e-11
more O 0 3.4510796997899718e-12
than O 0 6.002805197358185e-11
30 O 0 1.6743960662424229e-09
% O 0 8.149093622122905e-10
are O 0 1.5064182540269755e-11
deletion O 0 5.7636713179931576e-09
or O 0 3.0867954858848634e-09
insertion O 0 1.4895326216901594e-07
events O 0 1.5703903954999987e-08
. O 0 1.0922041582261954e-07

There O 0 5.947551784402094e-08
is O 0 3.5856186908489462e-09
a O 0 4.769310280039463e-09
noticeably O 0 2.3166677465269458e-07
elevated O 0 2.028669712217379e-07
level O 0 2.7225047105616795e-08
of O 0 8.9066416464334e-09
mutation O 0 1.3005689858403002e-08
in O 0 1.78835751762918e-10
the O 0 2.5707883044567836e-10
paired O 0 1.2352953382421816e-10
domain O 0 1.0017306983911567e-09
compared O 0 1.1253628584562136e-10
with O 0 1.0163170218596695e-12
the O 0 1.920824471701721e-10
rest O 0 1.4982504126237473e-09
of O 0 2.156201217573539e-09
the O 0 6.532353769017618e-09
gene O 0 4.799811037514701e-08
. O 0 4.356811444949926e-08

Increased O 0 1.4353111055243062e-07
mutation O 0 4.312003198947423e-08
in O 0 6.17982276462925e-10
the O 0 9.416906143755455e-10
homeodomain O 0 2.5497590172562923e-07
is O 0 4.4326647907766414e-10
accounted O 0 1.3098641060693694e-09
for O 0 7.662138978847821e-11
by O 0 3.4747021926406774e-10
the O 0 1.89663840188814e-08
hypermutable O 0 1.1610807632678188e-05
CpG O 0 5.3673807087761816e-06
dinucleotide O 0 3.932321305910591e-06
in O 0 5.654556289869106e-08
codon O 0 2.6956772671837825e-06
240 O 0 3.766485008327436e-07
. O 0 2.991125143125828e-07

Very O 0 6.222218473794783e-08
nearly O 0 1.932313153929499e-08
all O 0 3.9192063483461936e-10
mutations O 0 4.708947454190593e-09
appear O 0 8.033043674693374e-10
to O 0 4.1687522878142147e-10
cause O 0 2.9502197662623075e-07
loss O 0 7.81570221874972e-08
of O 0 3.138823601034346e-08
function O 0 1.8026664605486076e-09
of O 0 6.949977815473574e-10
the O 0 6.740464436605365e-11
mutant O 0 2.2715357372860012e-10
allele O 0 7.112702093969858e-10
, O 0 4.500764778231359e-12
and O 0 1.146087565129239e-12
more O 0 3.803266566699409e-13
than O 0 1.6482466433376253e-11
80 O 0 7.844863092465459e-10
% O 0 7.468222151807424e-10
of O 0 2.363890416745562e-09
exonic O 0 9.918582009049715e-07
substitutions O 0 3.137710535838778e-08
result O 0 7.649340716398001e-09
in O 0 5.58642732073622e-09
nonsense O 0 1.6336630324076395e-06
codons O 0 2.846507413778454e-06
. O 0 1.3176985191876156e-07

In O 0 3.303341600258136e-08
a O 0 8.506106929928592e-09
gene O 0 1.3838749035599562e-09
with O 0 2.7807227007126123e-11
such O 0 1.2007110861134151e-09
extraordinarily O 0 6.492359716503415e-07
high O 0 1.4595612185530626e-07
sequence O 0 2.9349485064500414e-09
conservation O 0 4.659244656757267e-10
throughout O 0 2.968069540143503e-11
evolution O 0 7.371169785663767e-10
, O 0 2.2755327136469994e-11
there O 0 8.889152608437811e-11
are O 0 3.9138503549196457e-10
presumed O 0 5.379366484703496e-06
undiscovered O 0 7.140034722397104e-05
missense O 0 5.7695588111528195e-06
mutations O 0 3.665732890567597e-07
, O 0 1.7202173019370548e-10
these O 0 1.190425449187904e-11
are O 0 1.7227446899581444e-11
hypothesized O 0 6.928011497819853e-09
to O 0 1.9856458144396072e-10
exist O 0 2.012543243168352e-09
in O 0 2.723078429411885e-10
as O 0 8.598330936138154e-10
- O 0 1.4554683680501057e-08
yet O 0 4.241410778149657e-09
unidentified O 0 1.1076337180782048e-08
phenotypes O 0 1.7473817948143733e-08
. O 0 2.8825655196129674e-09
. O 0 5.929813440275211e-08

Genetic O 0 2.5174951588269323e-05
heterogeneity O 0 9.632392902858555e-06
and O 0 4.953002008534213e-09
penetrance O 0 2.3423848460879526e-07
analysis O 0 1.3113888863713896e-09
of O 0 3.349887833792309e-08
the O 0 1.5721585810979377e-08
BRCA1 O 0 4.651471101624338e-07
and O 0 4.153808852436214e-09
BRCA2 O 0 6.943120069990982e-07
genes O 0 1.161250828829452e-08
in O 0 6.6277481280963e-09
breast B-Disease 1 0.9967331886291504
cancer I-Disease 1 0.9995194673538208
families O 0 3.6067467590328306e-07
. O 0 2.4601397399237612e-06

The O 0 0.0005842694081366062
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.001598119386471808
Consortium O 0 2.245872929051984e-05
. O 0 1.424710831088305e-06

The O 0 2.5582005847013534e-08
contribution O 0 4.487829485810835e-08
of O 0 1.962110758313429e-07
BRCA1 O 0 1.4421787000173936e-06
and O 0 9.710055870471024e-09
BRCA2 O 0 9.16652334126411e-06
to O 0 9.25114989058784e-07
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.00022414735576603562
assessed O 0 1.9756863878228614e-07
by O 0 3.1458510796333883e-10
linkage O 0 2.7369946309363513e-08
and O 0 7.830941450848172e-11
mutation O 0 2.506847507355303e-10
analysis O 0 7.526276130098708e-11
in O 0 2.0967630409707283e-11
237 O 0 1.2662042248035021e-10
families O 0 5.976184391104367e-12
, O 0 3.4017513198675298e-12
each O 0 3.2198659970922305e-12
with O 0 3.504062708395428e-12
at O 0 1.310786257313623e-09
least O 0 5.81358121365394e-11
four O 0 9.339818848874692e-12
cases O 0 3.6661881863686574e-11
of O 0 1.0625590185497913e-08
breast B-Disease 0 0.003546410705894232
cancer I-Disease 0 3.580779321055161e-06
, O 0 3.354065636340664e-10
collected O 0 4.739816872323388e-10
by O 0 5.193848129358969e-10
the O 0 5.758223551310948e-07
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.00011538546823430806
Consortium O 0 4.857362000620924e-06
. O 0 6.022975753694482e-07

Families O 0 2.7121080492520377e-08
were O 0 1.5244037143702371e-09
included O 0 2.132616444550095e-10
without O 0 7.081473740733202e-10
regard O 0 5.074658471215798e-09
to O 0 2.508172280979437e-10
the O 0 4.0707698323316777e-10
occurrence O 0 3.605700626962971e-08
of O 0 4.017910214315634e-06
ovarian B-Disease 1 1.0
or I-Disease 0 0.0001806537329684943
other I-Disease 0 1.5696019772803993e-06
cancers I-Disease 1 0.9999998807907104
. O 0 9.396312634635251e-06

Overall O 0 3.413613376324065e-05
, O 0 1.8940541224310437e-07
disease O 0 6.300655513769016e-05
was O 0 2.884156913296465e-07
linked O 0 4.834929256958276e-08
to O 0 2.0403212452890784e-09
BRCA1 O 0 4.593922398044015e-08
in O 0 7.650544087134392e-11
an O 0 6.729875771244176e-12
estimated O 0 1.4895561173400296e-10
52 O 0 5.782387346719986e-10
% O 0 1.7564689980265058e-10
of O 0 4.3394238202765223e-10
families O 0 3.218154562278919e-11
, O 0 5.659413909731015e-11
to O 0 1.007703920308245e-09
BRCA2 O 0 4.0635747211581474e-08
in O 0 1.6502796351680615e-10
32 O 0 1.1930089138800781e-09
% O 0 3.817640648051679e-10
of O 0 1.6954902759547252e-10
families O 0 2.397773125883962e-11
, O 0 1.5573856440576073e-11
and O 0 9.261287049755484e-12
to O 0 5.103111683224526e-11
neither O 0 1.4196489539486379e-09
gene O 0 2.9718494332087175e-10
in O 0 7.552620334694282e-11
16 O 0 9.85728276781117e-10
% O 0 5.21586718260636e-10
( O 0 6.194654511570974e-11
95 O 0 1.2663479154184643e-08
% O 0 1.0898377311718832e-08
confidence O 0 2.7741263508573866e-08
interval O 0 5.643468625748937e-07
[ O 0 5.782293897027557e-07
CI O 0 2.4008462787605822e-05
] O 0 2.5116408508552013e-08
6 O 0 9.981360626909463e-09
% O 0 1.8292043435508276e-09
- O 0 2.2524673237711568e-09
28 O 0 3.1936073785487906e-09
% O 0 5.526714086379059e-10
) O 0 1.48342831074455e-11
, O 0 3.549970387095591e-11
suggesting O 0 1.2480467770359382e-09
other O 0 6.981625833013538e-10
predisposition O 0 2.0076511646038853e-05
genes O 0 4.165371194631007e-07
. O 0 2.9083750519021123e-07

The O 0 6.03547576361052e-08
majority O 0 3.5018363764294236e-09
( O 0 1.2642138447205298e-09
81 O 0 8.234992066036284e-08
% O 0 3.186731545312682e-09
) O 0 5.3484230932987487e-11
of O 0 6.683374742522119e-09
the O 0 8.633866741547536e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.2636986568281827e-08
were O 0 4.772474082592737e-10
due O 0 1.6190527807324884e-09
to O 0 1.4775668188971025e-10
BRCA1 O 0 3.931172276594452e-09
, O 0 4.838360181252943e-12
with O 0 1.0966624743730113e-12
most O 0 2.374353491596537e-11
others O 0 9.667542461011536e-11
( O 0 2.6513419237872426e-10
14 O 0 9.30968635515228e-09
% O 0 2.7545008496332457e-09
) O 0 2.2011358014051297e-10
due O 0 5.421663828997225e-08
to O 0 7.746866970137489e-08
BRCA2 O 0 2.8792461307602935e-05
. O 0 1.552487674416625e-06

Conversely O 0 1.1730446658475557e-06
, O 0 8.454376643207695e-10
the O 0 2.522295983187206e-10
majority O 0 3.1409749801092346e-11
of O 0 1.4626448940902037e-09
families O 0 3.4082670713475594e-11
with O 0 1.4773885240182416e-11
male B-Disease 0 2.2339070593346833e-09
and I-Disease 0 2.007830013361911e-10
female I-Disease 0 2.4132833509327156e-09
breast I-Disease 0 7.815842764102854e-06
cancer I-Disease 0 6.882285106257768e-06
were O 0 1.8109485466766273e-08
due O 0 4.737055974146642e-07
to O 0 3.47046658077943e-08
BRCA2 O 0 6.771160769858398e-07
( O 0 5.536909153391889e-09
76 O 0 7.814477953616006e-07
% O 0 4.995394675688658e-08
) O 0 5.2101025715955984e-09
. O 0 9.108613596708892e-08

The O 0 2.303594612840243e-07
largest O 0 7.965977744106567e-08
proportion O 0 1.1346966921621515e-08
( O 0 6.392101292718166e-10
67 O 0 3.1344566053803646e-08
% O 0 2.060693615746345e-09
) O 0 2.803494762726455e-11
of O 0 8.406603191346562e-10
families O 0 1.5396298125303076e-10
due O 0 1.8133645696138956e-08
to O 0 5.818398540746728e-10
other O 0 5.028827354536247e-11
genes O 0 8.540791684996663e-11
was O 0 2.7395563595433714e-10
found O 0 3.733813605522052e-12
in O 0 1.7697807195432569e-12
families O 0 9.46908784021927e-13
with O 0 4.047498284882184e-13
four O 0 1.7444653360731976e-11
or O 0 1.7139324681725299e-10
five O 0 3.9780387317556176e-11
cases O 0 2.1913826656061453e-11
of O 0 6.405860286662346e-09
female O 0 9.737412653976207e-09
breast B-Disease 0 2.2744703528587706e-05
cancer I-Disease 0 8.819671347737312e-05
only O 0 3.0158270192259806e-07
. O 0 1.5064800891195773e-06

These O 0 7.09536207565975e-09
estimates O 0 2.07713810596033e-08
were O 0 8.50152892528655e-10
not O 0 1.2053409659262826e-10
substantially O 0 1.546349603920305e-09
affected O 0 1.6391495105683163e-10
either O 0 2.1160445617951495e-10
by O 0 6.91353710391418e-11
changing O 0 1.4687615568220735e-09
the O 0 1.7067718072194538e-10
assumed O 0 1.0345250212040469e-09
penetrance O 0 2.4242725604750603e-09
model O 0 3.375898519064613e-11
for O 0 3.117958669029974e-11
BRCA1 O 0 3.3095075568922994e-09
or O 0 1.2290674034076687e-10
by O 0 2.9078428900874975e-11
including O 0 7.890975373125997e-11
or O 0 7.97363597371259e-09
excluding O 0 1.0800624039575268e-07
BRCA1 O 0 9.614262808099738e-07
mutation O 0 2.0342842788068083e-07
data O 0 4.4825256395597535e-08
. O 0 6.370150629209093e-08

Among O 0 1.9606773093983065e-08
those O 0 7.092111342643648e-10
families O 0 3.2045155418103377e-10
with O 0 1.3958324773799546e-10
disease O 0 1.399541474711441e-06
due O 0 3.1435695291293086e-07
to O 0 4.4430445989007694e-09
BRCA1 O 0 2.7748988884468417e-08
that O 0 4.165435704694964e-11
were O 0 3.5340536053141136e-11
tested O 0 6.562953305810915e-12
by O 0 1.1052257199717364e-12
one O 0 1.801736711215529e-11
of O 0 5.307864217596325e-11
the O 0 1.3769620860193399e-11
standard O 0 9.464042743934087e-11
screening O 0 2.8029439880228324e-11
methods O 0 1.6784369727407267e-10
, O 0 2.588811109927036e-11
mutations O 0 1.274360172942579e-09
were O 0 6.988259970697186e-10
detected O 0 4.466103931122234e-09
in O 0 5.176084214020271e-11
the O 0 1.0542307304906018e-10
coding O 0 9.220721408631505e-10
sequence O 0 1.628342738424493e-10
or O 0 4.729077546228311e-11
splice O 0 3.217887956097343e-09
sites O 0 5.0822668989924935e-11
in O 0 5.269479297353996e-12
an O 0 6.372301991630636e-12
estimated O 0 4.3205197752804736e-10
63 O 0 5.8876272746033465e-09
% O 0 1.5373153861020228e-09
( O 0 2.914163077516463e-10
95 O 0 5.405266989555457e-08
% O 0 4.7300044769826854e-08
CI O 0 4.593449830281315e-06
51 O 0 8.778551574550875e-08
% O 0 1.1158101109742802e-08
- O 0 3.167595963304848e-08
77 O 0 4.962082300608017e-08
% O 0 1.8470080576094006e-08
) O 0 3.101348511336255e-09
. O 0 5.4713510166948254e-08

The O 0 1.178505044663325e-07
estimated O 0 3.288455374672594e-08
sensitivity O 0 4.091284111495952e-08
was O 0 8.624253311495522e-09
identical O 0 1.2001197258193486e-10
for O 0 1.6829367760484715e-11
direct O 0 3.4377597990520314e-10
sequencing O 0 2.251633990368873e-09
and O 0 1.1134916599875311e-10
other O 0 1.2105710878174136e-10
techniques O 0 2.812593358214599e-08
. O 0 6.218125747636805e-08

The O 0 3.0992160304776917e-07
penetrance O 0 1.2764238817908335e-05
of O 0 3.6870778785669245e-06
BRCA2 O 0 1.01090863608988e-05
was O 0 1.2651484837533644e-07
estimated O 0 1.9117243343913515e-09
by O 0 8.67545479898979e-11
maximizing O 0 3.967322825815245e-08
the O 0 4.714698853547361e-09
LOD O 0 0.0005524161970242858
score O 0 4.813533127645542e-09
in O 0 1.7689018305677706e-10
BRCA2 O 0 1.7738532420707998e-08
- O 0 1.0603076638915354e-08
mutation O 0 1.964955531619239e-09
families O 0 1.9988951466265448e-11
, O 0 2.2670204255503812e-11
over O 0 3.0466507094928374e-10
all O 0 1.7318946277100622e-10
possible O 0 8.150077057678118e-09
penetrance O 0 1.5351733964052983e-06
functions O 0 4.523027996583551e-08
. O 0 8.534860285180912e-08

The O 0 3.575130946842364e-08
estimated O 0 1.176670583191708e-08
cumulative O 0 3.540738546803368e-08
risk O 0 4.7871207442540253e-08
of O 0 5.497544179888791e-07
breast B-Disease 1 0.9991760849952698
cancer I-Disease 0 0.0009509396622888744
reached O 0 6.149191904114559e-06
28 O 0 1.3479514393566205e-07
% O 0 1.944320260349741e-09
( O 0 3.3132309396055604e-11
95 O 0 3.761468025942349e-09
% O 0 3.1663982547058822e-09
CI O 0 2.1103276992562314e-07
9 O 0 2.7876503327917135e-09
% O 0 4.584149448927377e-10
- O 0 4.285041488305552e-10
44 O 0 2.794058040489489e-10
% O 0 2.8969814394597115e-11
) O 0 2.600973906738413e-13
by O 0 1.6446092534691537e-12
age O 0 8.959148978249232e-10
50 O 0 6.107627736895438e-10
years O 0 2.088282741175007e-10
and O 0 5.466388106056819e-11
84 O 0 6.590208379009255e-09
% O 0 1.155089246474006e-09
( O 0 1.8305086613157329e-10
95 O 0 2.399021070687013e-08
% O 0 1.634424506846699e-08
CI O 0 1.2277727137188776e-06
43 O 0 9.689833824211291e-09
% O 0 9.393693600756592e-10
- O 0 5.403612002297109e-10
95 O 0 1.1036895841698424e-09
% O 0 1.7977143385028427e-10
) O 0 4.198255458554012e-12
by O 0 2.0378610257609786e-11
age O 0 1.444858188648368e-08
70 O 0 1.402494920199615e-08
years O 0 2.7583716644130618e-08
. O 0 8.849546162537081e-08

The O 0 3.671540753202862e-06
corresponding O 1 0.999972939491272
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 1 0.9122086763381958
were O 0 5.016199793317355e-07
0 O 0 6.293577143878792e-07
. O 0 4.957569643693205e-08

4 O 0 3.0978883387433598e-06
% O 0 1.0230293412405445e-07
( O 0 1.7081991376954875e-09
95 O 0 1.0308524878155367e-07
% O 0 3.357884281740553e-08
CI O 0 1.305566797782376e-06
0 O 0 8.453025834853634e-09
% O 0 6.919476658318047e-10
- O 0 7.875822771730157e-10
1 O 0 4.8273243180574354e-09
% O 0 8.347241647888026e-11
) O 0 2.047353578988817e-13
by O 0 9.1130054891142e-13
age O 0 2.49925191653233e-10
50 O 0 2.361627005065259e-10
years O 0 7.476156499430786e-11
and O 0 2.5700807801398717e-11
27 O 0 1.9978756427008193e-09
% O 0 4.880136850182737e-10
( O 0 7.005045155050738e-11
95 O 0 8.688065378237297e-09
% O 0 6.820992659584135e-09
CI O 0 3.559998447144608e-07
0 O 0 4.224343097547489e-09
% O 0 1.0389781257558184e-09
- O 0 1.2256593517889769e-09
47 O 0 1.5038532641398206e-09
% O 0 1.31358882105026e-10
) O 0 2.680751020472938e-12
by O 0 1.9006407558919136e-11
age O 0 1.83594419667088e-08
70 O 0 1.4302439232949382e-08
years O 0 1.496891499641606e-08
. O 0 6.076748348959882e-08

The O 0 8.068599299804191e-08
lifetime O 0 5.989507485537615e-07
risk O 0 3.460965899648727e-06
of O 0 0.0019208494341000915
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
appears O 0 2.258680709132932e-08
similar O 0 5.730102156653594e-11
to O 0 3.0382132920614424e-10
the O 0 7.026673132237704e-10
risk O 0 3.6120733071243194e-09
in O 0 7.89975446169322e-11
BRCA1 O 0 4.377341156214243e-09
carriers O 0 7.923415396016154e-11
, O 0 2.1051421023043915e-11
but O 0 1.196097214328784e-11
there O 0 1.393379248787463e-11
was O 0 2.2205415284304308e-10
some O 0 1.4192028628678965e-12
suggestion O 0 5.251694634722526e-10
of O 0 8.653050498352854e-10
a O 0 8.454344446739981e-10
lower O 0 8.15416996147178e-08
risk O 0 3.2336217259398836e-08
in O 0 2.032746637681271e-09
BRCA2 O 0 6.468800251013818e-08
carriers O 0 1.8323610406767443e-09
< O 0 9.207994366988714e-07
50 O 0 3.855982200207109e-09
years O 0 8.091740055782282e-10
of O 0 4.862040547948254e-09
age O 0 1.369471078760398e-07
. O 0 7.065114715487653e-08

Eye B-Disease 1 0.9998854398727417
movement I-Disease 0 4.9628659326117486e-05
abnormalities I-Disease 0 7.601565448567271e-05
correlate O 0 3.6688657445438366e-08
with O 0 1.8237755750050155e-10
genotype O 0 1.5683899619034491e-06
in O 0 1.5889257909407206e-08
autosomal O 1 0.9086487293243408
dominant O 1 0.9999926090240479
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 4.978206561645493e-06

We O 0 4.704174330072419e-07
compared O 0 3.177877943016938e-07
horizontal O 0 1.88403319043573e-05
eye O 0 5.193012111703865e-05
movements O 0 1.7428257592655427e-07
( O 0 6.590032519682154e-09
visually O 0 3.9888239378171875e-09
guided O 0 1.4755152655254733e-08
saccades O 0 1.6982127135634073e-06
, O 0 1.6824442949925356e-09
antisaccades O 0 1.0521043805056252e-06
, O 0 3.7096678506820524e-10
and O 0 7.557202086339032e-11
smooth O 0 3.1083009499610625e-09
pursuit O 0 1.7235031180007354e-08
) O 0 4.499136133095938e-11
in O 0 5.2605846762032726e-11
control O 0 1.6348913334240933e-09
subjects O 0 3.618865651588976e-09
( O 0 1.3740217297275592e-10
n O 0 8.574391863191977e-09
= O 0 5.032334993160248e-09
14 O 0 8.155780495400222e-10
) O 0 1.3284514113753865e-11
and O 0 1.2790757168701372e-11
patients O 0 7.754939052029286e-12
with O 0 4.1067073786732466e-13
three O 0 9.841529501064539e-12
forms O 0 9.843078574434116e-10
of O 0 1.5513377604747802e-07
autosomal O 0 0.1629432588815689
dominant O 1 0.9636552929878235
cerebellar B-Disease 1 1.0
ataxias I-Disease 1 0.9998644590377808
type I-Disease 1 0.8516609072685242
I I-Disease 0 0.26560676097869873
spinocerebellar B-Disease 0 0.0007401062757708132
ataxias I-Disease 0 1.1307459317322355e-05
1 I-Disease 0 3.2872333122213604e-07
and I-Disease 0 4.673511577735212e-10
2 I-Disease 0 2.4199776404998374e-08
( O 0 1.1103068464635157e-09
SCA1 B-Disease 0 1.9618781152530573e-05
, O 0 7.368793908391069e-10
n O 0 1.2655656078663924e-08
= O 0 4.427833655284985e-09
11 O 0 6.079396985825269e-10
; O 0 1.3738356285930564e-10
SCA2 B-Disease 0 3.055440629395889e-06
, O 0 4.0225536790394756e-10
n O 0 5.456996632347e-09
= O 0 1.926122816797715e-09
10 O 0 2.583963043534254e-10
) O 0 4.9666763757283405e-11
and O 0 1.0497267499687268e-09
SCA3 B-Disease 1 1.0
/ O 0 0.0002632953110150993
Machado B-Disease 0 2.0271006633265642e-06
- I-Disease 0 8.777879543231393e-07
Joseph I-Disease 0 1.2626317584363278e-05
disease I-Disease 0 1.9092640286544338e-06
( O 0 2.0810640322110885e-08
MJD B-Disease 1 1.0
) O 0 1.7904616456121403e-08
( O 0 6.9830812243765195e-09
n O 0 2.3752637900997797e-07
= O 0 1.3091334949422162e-07
16 O 0 3.6094579769496704e-08
) O 0 3.942977055970687e-09
. O 0 3.8094256638032675e-08

In O 0 1.1659446954581654e-06
SCA1 B-Disease 0 0.34910351037979126
, O 0 2.5196106534508544e-08
saccade O 0 1.6478992392876535e-06
amplitude O 0 5.667712912327261e-07
was O 0 9.689538060797531e-09
significantly O 0 1.1616577699768982e-09
increased O 0 1.145234906907433e-09
, O 0 1.5920427476334709e-10
resulting O 0 5.925276713725225e-09
in O 0 1.208957023379753e-08
hypermetria B-Disease 0 4.199656177661382e-05
. O 0 4.5979240326232684e-07

The O 0 4.431477407251805e-07
smooth O 0 3.471241996066965e-07
pursuit O 0 1.2768956594300107e-06
gain O 0 2.5615267986722756e-06
was O 0 8.03800685389433e-06
decreased O 0 4.324590918258764e-06
. O 0 2.6951764198202e-07

In O 0 2.014942765526939e-06
SCA2 B-Disease 0 0.0037667197175323963
, O 0 4.534862441119003e-08
saccade O 0 2.056558059848612e-06
velocity O 0 4.004180937045021e-06
was O 0 4.502714148202358e-07
markedly O 0 4.6479144089062174e-07
decreased O 0 9.414478086000599e-07
. O 0 2.0415413359842205e-07

The O 0 2.6981777523360506e-07
percentage O 0 5.793145305688086e-07
of O 0 9.213785290285159e-08
errors O 0 8.113745934679173e-06
in O 0 2.1969519536924054e-08
antisaccades O 0 0.39702436327934265
was O 0 1.0846041220702318e-07
greatly O 0 9.82147585482096e-10
increased O 0 1.36718103505018e-09
and O 0 5.172906200612282e-11
was O 0 7.073387431333344e-10
significantly O 0 8.317126154455678e-11
correlated O 0 1.4213308308086425e-10
with O 0 5.289518389267611e-12
age O 0 4.9823587033870353e-08
at O 0 2.17364885202187e-07
disease O 0 1.1903192671525176e-06
onset O 0 9.608206892153248e-05
. O 0 1.1242236723774113e-06

In O 0 1.1612818262562996e-08
addition O 0 5.431926020094124e-10
, O 0 3.574895379720999e-10
a O 0 5.122305357652124e-10
correlation O 0 5.2429403041287514e-09
between O 0 4.977322110022442e-09
smooth O 0 6.053841872244448e-08
pursuit O 0 9.011599644281887e-08
gain O 0 2.734818593808086e-08
and O 0 7.228456722074839e-11
the O 0 3.959388927832208e-10
number O 0 3.5644442952786903e-10
of O 0 2.3099163470874373e-08
trinucleotide O 0 1.09500306280097e-05
repeats O 0 1.0423237029044685e-07
was O 0 7.661901690880768e-08
found O 0 7.795406986588205e-09
. O 0 2.400943621694296e-08

In O 0 9.095485438592732e-06
SCA3 B-Disease 1 1.0
, O 0 6.28406269242987e-06
gaze B-Disease 0 0.006992869544774294
- I-Disease 0 1.090839123207843e-05
evoked I-Disease 0 1.4260076568461955e-06
nystagmus I-Disease 0 7.635853762621991e-06
was O 0 2.583581348858388e-08
often O 0 4.449637880377111e-11
present O 0 7.519990880000549e-11
as O 0 8.82733053320095e-11
was O 0 5.218278253948938e-09
saccade O 0 1.739425243840742e-07
hypometria O 0 7.761618689983152e-07
and O 0 1.6890741028063871e-09
smooth O 0 9.409535550730652e-08
pursuit O 0 5.976184525025019e-07
gain O 0 7.273136475305364e-07
was O 0 1.7488973753643222e-06
markedly O 0 7.445230494340649e-07
decreased O 0 4.1611230017224443e-07
. O 0 7.833252624322995e-08

Three O 0 7.158233472637221e-08
major O 0 1.3099851514652983e-07
criteria O 0 1.6723468831969512e-07
, O 0 1.2186568421057586e-09
saccade O 0 5.52731989955646e-07
amplitude O 0 9.370652520601652e-08
, O 0 3.019340055754327e-10
saccade O 0 7.850513839002815e-08
velocity O 0 3.188922619301593e-07
, O 0 2.946147492632889e-10
and O 0 1.8882551078291954e-10
presence O 0 2.042267910340456e-09
of O 0 2.92730845785627e-07
gaze B-Disease 0 3.708517397171818e-05
- I-Disease 0 5.980585910947411e-07
evoked I-Disease 0 1.1907548014278291e-07
nystagmus I-Disease 0 1.2347386757483036e-07
, O 0 4.984251900097547e-11
permitted O 0 1.274930855332812e-10
the O 0 3.5626210315164997e-11
correct O 0 3.657878167029338e-10
assignment O 0 3.172453688637944e-10
of O 0 2.515516961398845e-10
90 O 0 2.0470414252571345e-09
% O 0 5.568202010586276e-10
of O 0 4.696817934579656e-10
the O 0 8.821023911309567e-10
SCA1 B-Disease 0 4.503622039919719e-05
, O 0 2.6568292010864525e-10
90 O 0 3.3597657989048457e-09
% O 0 3.7782196815605573e-10
of O 0 2.95832136565366e-10
the O 0 5.786999213164279e-10
SCA2 B-Disease 0 1.9363333194633015e-05
, O 0 2.0088107566262892e-10
and O 0 3.4131721754482314e-11
93 O 0 8.47478365262333e-10
% O 0 2.450977476531335e-10
of O 0 1.5677731335372869e-10
the O 0 3.699739681284342e-10
patients O 0 1.9649094851192928e-10
with O 0 3.487969080229192e-10
SCA3 B-Disease 1 1.0
to O 0 1.7468117619046097e-08
their O 0 5.4586571374137804e-11
genetically O 0 1.52364731942356e-10
confirmed O 0 2.018581690688137e-10
patient O 0 5.22826781867991e-10
group O 0 2.236599447313914e-11
and O 0 1.9274696422266757e-11
, O 0 3.3164932605744823e-11
therefore O 0 3.8718641626189765e-09
, O 0 2.433546419933208e-10
may O 0 3.947763005385241e-09
help O 0 7.083999498114224e-10
orient O 0 3.0934304504626198e-06
diagnoses O 0 1.4212920973477594e-07
of O 0 9.710004178486997e-08
SCA1 B-Disease 0 0.36793825030326843
, O 0 3.773453549626993e-09
SCA2 B-Disease 0 0.0019511017017066479
, O 0 2.099274309941279e-09
and O 0 6.35771879586855e-09
SCA3 B-Disease 1 1.0
at O 0 4.161464062235609e-07
early O 0 1.0067573441574496e-08
clinical O 0 6.613630088025957e-09
stages O 0 1.5542454434580577e-08
of O 0 1.435327057208724e-08
the O 0 5.458415230918945e-08
diseases O 0 7.307960459002061e-06
. O 0 2.9499235054686324e-08
. O 0 1.9781485605108173e-07

Genetic O 0 4.0453946326124424e-07
basis O 0 2.2987263648133194e-08
and O 0 4.39501657290009e-10
molecular O 0 2.2750935357862545e-08
mechanism O 0 4.741865211599361e-08
for O 0 1.6369740762911533e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9998503923416138

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 1.0
causes O 0 0.02225624956190586
more O 0 1.7800750873320226e-09
than O 0 7.608927377056318e-10
300 O 0 6.792608697736569e-10
, O 0 4.24768865914249e-11
000 O 0 1.124423665288532e-09
sudden O 0 1.4171519513439534e-09
deaths O 0 2.4190152658754016e-10
each O 0 2.8120417452925928e-11
year O 0 3.962267458579305e-10
in O 0 3.2749070122406465e-10
the O 0 4.740596803998187e-09
USA O 0 3.6786096302421356e-07
alone O 0 9.587091653884272e-08
. O 0 1.410024452752623e-07

In O 0 2.96527300491789e-08
approximately O 0 6.2046643378721456e-09
5 O 0 2.0004430112408045e-08
- O 0 1.57160684466362e-08
12 O 0 3.22057713830759e-09
% O 0 6.427114951357282e-10
of O 0 8.706121240598108e-11
these O 0 1.7797397670188397e-12
cases O 0 4.605320291783954e-11
, O 0 3.042897878113848e-11
there O 0 3.830753769751283e-11
are O 0 1.191147701307127e-11
no O 0 1.2268897009448665e-09
demonstrable O 0 0.00012216177128721029
cardiac O 1 0.9930140376091003
or O 0 1.0850960734387627e-06
non O 1 0.9999690055847168
- O 1 0.9995511174201965
cardiac O 1 0.9999957084655762
causes O 0 6.74642919307189e-08
to O 0 4.0693259872881526e-10
account O 0 6.308861766335383e-11
for O 0 3.52879982179477e-11
the O 0 2.383138686390396e-10
episode O 0 7.331712459368589e-10
, O 0 1.179229457137776e-12
which O 0 3.6208259697814715e-13
is O 0 2.066259706737239e-12
therefore O 0 7.792604062029085e-11
classified O 0 1.6753417542147986e-09
as O 0 1.4467885556257443e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.006484268233180046
IVF B-Disease 1 1.0
) O 0 1.3863568426586426e-07
. O 0 2.067805979777404e-07

A O 0 2.433331189877208e-07
distinct O 0 1.1967082436115106e-08
group O 0 3.494536882087118e-09
of O 0 1.4058259694138542e-06
IVF B-Disease 1 1.0
patients O 0 1.6912291300741344e-07
has O 0 1.3681454580360963e-10
been O 0 6.895863047251538e-11
found O 0 7.1123423990571144e-12
to O 0 6.120753209826191e-12
present O 0 2.8490775710876548e-11
with O 0 1.2680524165420426e-11
a O 0 2.4405200083066347e-09
characteristic O 0 2.260256479758027e-07
electrocardiographic O 0 7.023398211458698e-05
pattern O 0 8.904401511244942e-06
. O 0 6.31029706710251e-07

Because O 0 7.98671422330699e-08
of O 0 7.949039115828782e-08
the O 0 1.4807669534988577e-09
small O 0 1.0223354107719018e-10
size O 0 4.3572723207319086e-10
of O 0 1.2321967890471797e-09
most O 0 3.928949526832426e-11
pedigrees O 0 9.84582082530494e-10
and O 0 1.6420776197123566e-11
the O 0 7.840431776040546e-11
high O 0 3.889584210270414e-09
incidence O 0 2.9619897645716264e-07
of O 0 2.750365268866517e-08
sudden B-Disease 0 2.964275722661114e-07
death I-Disease 0 3.2349424827771145e-07
, O 0 2.21519441678808e-10
however O 0 3.485495503330327e-10
, O 0 1.2146092465137315e-10
molecular O 0 3.0455309385502005e-09
genetic O 0 1.1113576725563235e-09
studies O 0 3.2561839335976117e-10
of O 0 1.2610019695102892e-08
IVF B-Disease 1 1.0
have O 0 2.1774096414794997e-10
not O 0 1.5264454977792496e-10
yet O 0 5.135610270379232e-10
been O 0 4.636673822666637e-10
done O 0 3.732544495704815e-09
. O 0 2.8994181278108044e-08

Because O 0 1.615647488506511e-05
IVF B-Disease 1 1.0
causes O 1 0.9999899864196777
cardiac O 1 1.0
rhythm O 1 0.9999996423721313
disturbance O 1 0.9999374151229858
, O 0 4.405560360964955e-09
we O 0 1.2670793303470873e-09
investigated O 0 2.6503485628381895e-08
whether O 0 5.593186358510138e-09
malfunction O 0 1.148813225881895e-05
of O 0 1.035536278948257e-08
ion O 0 3.7462481827787997e-07
channels O 0 2.3420804851070898e-08
could O 0 1.67253844107762e-09
cause O 0 2.302658153041648e-08
the O 0 1.7712153965732114e-09
disorder O 0 2.5925702473728052e-08
by O 0 2.4496581846333854e-11
studying O 0 3.6187328134040797e-10
mutations O 0 2.886007821611969e-10
in O 0 4.9359651782543423e-11
the O 0 1.0628928848177566e-09
cardiac O 0 1.4811412540893798e-07
sodium O 0 1.274815843999022e-07
channel O 0 6.635548288613791e-07
gene O 0 1.916238119292757e-07
SCN5A O 0 0.00023959639656823128
. O 0 4.2438651348675194e-07

We O 0 1.3669333043253573e-07
have O 0 3.4787209224340643e-10
now O 0 2.119348724294312e-10
identified O 0 3.2282818085427323e-10
a O 0 2.948097876931399e-10
missense O 0 2.3069186738666758e-07
mutation O 0 3.668509052090485e-08
, O 0 1.52741236325582e-10
a O 0 3.2692276663581765e-10
splice O 0 4.5666830317259155e-08
- O 0 8.498711956406169e-09
donor O 0 3.2934752702828973e-09
mutation O 0 1.1291697354920416e-08
, O 0 7.668484597322944e-11
and O 0 4.7021931487423174e-11
a O 0 9.516903931583442e-10
frameshift O 0 1.0349123158448492e-06
mutation O 0 1.0730763833066703e-08
in O 0 1.2707526697575133e-10
the O 0 1.725998233226278e-10
coding O 0 1.1593696669365272e-08
region O 0 4.921757934539528e-08
of O 0 1.369460704836456e-07
SCN5A O 0 0.3515719473361969
in O 0 1.103892266485218e-08
three O 0 1.6540534275577556e-08
IVF B-Disease 1 1.0
families O 0 1.4505989298640998e-08
. O 0 1.0263968874824059e-07

We O 0 1.674956706665398e-07
show O 0 1.7100898475064241e-09
that O 0 8.05242955648211e-11
sodium O 0 3.287161876031064e-09
channels O 0 9.362498554210674e-10
with O 0 1.3040644085415831e-11
the O 0 1.7783918782043884e-09
missense O 0 2.5772328626771923e-06
mutation O 0 7.320986128434015e-07
recover O 0 1.759371883736094e-07
from O 0 6.219333048562703e-09
inactivation O 0 5.653304810948612e-07
more O 0 3.419158836268088e-12
rapidly O 0 6.394536983256316e-11
than O 0 8.65938223904017e-12
normal O 0 1.9604697032438168e-10
and O 0 4.691172363763263e-12
that O 0 2.3315926012817956e-12
the O 0 1.0027834812520453e-10
frameshift O 0 8.559346298397941e-08
mutation O 0 7.250446465434379e-09
causes O 0 8.260689354777639e-10
the O 0 2.2663944332368402e-10
sodium O 0 5.574779526895668e-10
channel O 0 1.6421793924692452e-09
to O 0 1.819890627086096e-10
be O 0 2.1914392522859316e-09
non O 0 2.710009141537739e-07
- O 0 3.425275849622267e-07
functional O 0 3.868611315738235e-07
. O 0 5.8335171360113236e-08

Our O 0 2.1923125359535334e-07
results O 0 7.913848243390476e-09
indicate O 0 6.740034308450049e-09
that O 0 2.5856788932188124e-10
mutations O 0 1.1267171196038817e-08
in O 0 7.77390263273503e-10
cardiac O 0 6.582817491107562e-07
ion O 0 5.632743523165118e-06
- O 0 6.857546850369545e-07
channel O 0 3.7000752683979954e-08
genes O 0 7.007718016982523e-11
contribute O 0 1.1490517738688144e-11
to O 0 1.3752612763873184e-11
the O 0 7.127094053815952e-11
risk O 0 9.070152962031841e-10
of O 0 6.381579709113794e-09
developing O 0 2.3433187834598357e-07
IVF B-Disease 1 1.0
. O 0 8.217543978616959e-08
. O 0 1.428810350034837e-07

Molecular O 0 1.3423903510556556e-05
heterogeneity O 0 2.4469394702464342e-05
in O 0 4.030867728488374e-08
mucopolysaccharidosis B-Disease 1 0.9998179078102112
IVA I-Disease 1 1.0
in O 0 6.953457898362103e-08
Australia O 0 3.443751395160177e-10
and O 0 8.30572763343973e-11
Northern O 0 1.6495228294388653e-08
Ireland O 0 1.8494546338843065e-08
: O 0 2.3197688214793288e-10
nine O 0 2.431454204643302e-10
novel O 0 1.0696422914069359e-10
mutations O 0 7.485321251721189e-10
including O 0 4.4845200469767477e-11
T312S O 0 2.9422192255879054e-06
, O 0 4.9370382781965816e-11
a O 0 5.4264970988926464e-11
common O 0 3.229205236543464e-10
allele O 0 6.734444557565666e-09
that O 0 4.147344620508697e-11
confers O 0 1.48022829549177e-08
a O 0 1.7034562205253678e-08
mild O 0 4.874641672358848e-05
phenotype O 0 0.00013771503290627152
. O 0 1.4065045661482145e-06

Mucopolysaccharidosis B-Disease 1 0.9999974966049194
IVA I-Disease 1 1.0
( O 0 0.0010763140162453055
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 3.432089457078291e-08
is O 0 6.7178818063950985e-09
an O 0 1.2065981103148715e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 2.946920176327694e-06
by O 0 7.85927045665602e-10
a O 0 5.375451195277492e-08
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999996423721313
in O 0 3.400342452053451e-09
N O 0 3.789684797084192e-07
- O 0 6.572236088686623e-08
acetylgalactosamine O 0 1.071769247573684e-06
- O 0 2.435216401863727e-07
6 O 0 2.4353929006792896e-07
- O 0 9.739422068832937e-08
sulfate O 0 1.7018365383592027e-07
sulfatase O 0 5.500047791429097e-06
( O 0 1.822132844608859e-08
GALNS O 0 0.0002726012608036399
) O 0 3.280912252989765e-08
. O 0 1.3666726772498805e-07

Previous O 0 8.240130000558565e-08
studies O 0 4.198021930079676e-09
of O 0 1.0596445498833873e-08
patients O 0 2.881200833471098e-10
from O 0 1.4342253773502733e-10
a O 0 2.181183844651713e-10
British O 0 9.531690992048425e-10
- O 0 5.732502028621411e-09
Irish O 0 1.1035864444508547e-09
population O 0 9.647165011283931e-12
showed O 0 3.1993212332853682e-12
that O 0 7.369724405389966e-13
the O 0 7.36293109815378e-11
I113F O 0 3.491001905331359e-07
mutation O 0 5.790358859059097e-09
is O 0 2.780118323053582e-11
the O 0 1.956471616659794e-11
most O 0 6.872011640290943e-13
common O 0 1.190579839577266e-11
single O 0 7.874271373831121e-11
mutation O 0 9.919337351504964e-09
among O 0 8.854877719954857e-09
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.0301527453293602e-07
and O 0 6.180730927063394e-10
produces O 0 1.4018309846264287e-09
a O 0 8.231109127621039e-09
severe O 0 1.5643026927136816e-05
clinical O 0 4.097753844689578e-06
phenotype O 0 1.0228892278973944e-05
. O 0 4.3414735273472616e-07

We O 0 8.821840680184323e-08
studied O 0 7.957746817055522e-08
mutations O 0 6.8307306477777274e-09
in O 0 1.487063666649746e-10
the O 0 4.923771390608067e-10
GALNS O 0 3.1573970773024485e-05
gene O 0 4.740666748048739e-10
from O 0 2.5782720403100257e-10
23 O 0 4.1980274811947993e-10
additional O 0 7.780786015487706e-10
MPS B-Disease 1 0.9999996423721313
IVA I-Disease 1 1.0
patients O 0 4.655482399584798e-08
( O 0 9.61191126691574e-10
15 O 0 4.056943669894508e-09
from O 0 5.436756600474268e-10
Australia O 0 1.8864470749391238e-11
, O 0 6.0290327418e-12
8 O 0 3.834542405822816e-10
from O 0 1.7725527989842504e-10
Northern O 0 5.090750931913135e-09
Ireland O 0 1.8639021437394376e-09
) O 0 5.031321886894702e-11
, O 0 1.5977120668142497e-11
with O 0 1.8095501225917632e-12
various O 0 1.194483678634839e-10
clinical O 0 1.5884447179814742e-07
phenotypes O 0 1.2852964346166118e-06
( O 0 2.924121034197924e-08
severe O 1 0.9298778176307678
, O 0 4.8922177420251955e-09
16 O 0 3.8292524706662334e-09
cases O 0 4.783243592876296e-11
; O 0 4.3153536299911366e-11
intermediate O 0 4.411263176962166e-08
, O 0 1.1483249767740844e-10
4 O 0 5.039605621703913e-09
cases O 0 1.6761686483235394e-10
; O 0 7.88184850719631e-10
mild O 0 8.147234211719478e-07
, O 0 3.826813976814947e-09
3 O 0 7.579414784686378e-08
cases O 0 1.6145319525762147e-09
) O 0 5.599612329376669e-09
. O 0 7.22645410178302e-08

We O 0 1.46572375570031e-07
found O 0 1.068513277857619e-09
two O 0 1.97520038519583e-11
common O 0 1.3444857727140658e-10
mutations O 0 4.4306866509025156e-10
that O 0 1.3203149511198387e-11
together O 0 1.9013441862614222e-11
accounted O 0 4.81158446419272e-10
for O 0 3.935609824146091e-11
32 O 0 3.0214331037115016e-09
% O 0 9.646070608937407e-10
of O 0 8.245530369599408e-10
the O 0 9.095306729989261e-10
44 O 0 8.662566663986127e-09
unrelated O 0 2.134758148031324e-09
alleles O 0 1.302996710528248e-09
in O 0 9.44200967412101e-11
these O 0 1.0371323938551669e-10
patients O 0 2.289269884769851e-09
. O 0 5.5636533602410054e-08

One O 0 5.2745782852525736e-08
is O 0 2.0848969217723834e-09
the O 0 2.532951848266407e-09
T312S O 0 7.653168722754344e-06
mutation O 0 3.8982683747690317e-08
, O 0 9.410850571045515e-11
a O 0 1.954201384046783e-10
novel O 0 8.170353837932964e-10
mutation O 0 1.83910464635062e-09
found O 0 1.222353052110492e-10
exclusively O 0 3.317570662630942e-10
in O 0 1.652163128529338e-10
milder O 0 3.6913879739586264e-06
patients O 0 1.3491667516518646e-07
. O 0 8.25797030756803e-07

The O 0 1.566394445262631e-07
other O 0 5.576863970624402e-10
is O 0 2.811989530115966e-10
the O 0 4.4380621400108566e-10
previously O 0 2.4884554417070603e-09
described O 0 3.6365581657094026e-09
I113F O 0 1.0549347280175425e-06
that O 0 8.407560758705301e-11
produces O 0 1.252393855288858e-09
a O 0 1.5157240795815596e-08
severe O 0 0.00022884114878252149
phenotype O 0 0.0001257478870684281
. O 0 1.4165278798827785e-06

The O 0 1.2050224995618919e-06
I113F O 0 0.00013985007535666227
and O 0 3.3753369876876604e-08
T312S O 0 1.201906616188353e-05
mutations O 0 1.6984987638579696e-08
accounted O 0 6.8965539945509136e-09
for O 0 1.3271983512197494e-10
8 O 0 4.965260647082914e-09
( O 0 1.274556293839879e-10
18 O 0 4.245555018655978e-09
% O 0 6.962715404235098e-10
) O 0 8.343831701951299e-12
and O 0 3.708533827251337e-11
6 O 0 4.689390209478006e-09
( O 0 1.7614644465258067e-10
14 O 0 2.452680947229169e-09
% O 0 6.015898335043346e-10
) O 0 2.9601994466776915e-11
of O 0 1.0107241710244352e-09
44 O 0 4.715724699622115e-09
unrelated O 0 5.408812064899848e-09
alleles O 0 4.7227270982830305e-09
, O 0 1.588446152389622e-09
respectively O 0 2.8845423116763413e-07
. O 0 1.8601213014335372e-07

The O 0 4.845933858632634e-07
relatively O 0 1.0154339946666369e-07
high O 0 6.345315455291711e-07
residual O 0 0.001079169800505042
GALNS O 1 0.9992426633834839
activity O 0 2.0309248327521345e-07
seen O 0 1.1005915290240864e-08
when O 0 5.338193775905609e-10
the O 0 9.590356286892643e-10
T312S O 0 2.5217843813152285e-07
mutant O 0 6.36376018547935e-09
cDNA O 0 2.0587107130154436e-08
is O 0 3.721126740074965e-10
overexpressed O 0 6.562815713095915e-08
in O 0 1.0190685795219423e-10
mutant O 0 1.065871169103616e-09
cells O 0 2.4150584310156376e-11
provides O 0 9.423755178983306e-13
an O 0 1.6683493779187653e-12
explanation O 0 1.5128429065036642e-10
for O 0 6.991656559263149e-11
the O 0 1.8698200765498996e-09
mild O 0 1.0367516551923472e-06
phenotype O 0 5.468898507388076e-07
in O 0 8.709713505972161e-10
patients O 0 7.294410214742086e-11
with O 0 1.0028938617068217e-11
this O 0 1.3245967656061453e-09
mutation O 0 2.476690781350044e-07
. O 0 7.589295591969858e-08

The O 0 3.1576185222093045e-08
distribution O 0 6.1388849559307346e-09
and O 0 4.822727286968309e-11
relative O 0 4.835553291115957e-09
frequencies O 0 6.856811562983012e-09
of O 0 5.186901130826982e-09
the O 0 3.120472547024633e-09
I113F O 0 2.4941127776401117e-06
and O 0 1.4215348898005686e-09
T312S O 0 3.38575546265929e-06
mutations O 0 8.644740923102745e-09
in O 0 1.1159111829028845e-10
Australia O 0 9.997273842099474e-12
corresponded O 0 7.167663684803927e-11
to O 0 4.714478460399185e-11
those O 0 3.3644698138601825e-11
observed O 0 1.4891279320750073e-09
in O 0 3.1636724490136103e-11
Northern O 0 3.908175560951577e-09
Ireland O 0 1.6869236008076882e-09
and O 0 2.6381842890832452e-11
are O 0 5.102914618637655e-12
unique O 0 5.978897498620794e-12
to O 0 4.2150994500333994e-11
these O 0 6.4242894858013155e-12
two O 0 1.707418928464932e-11
populations O 0 5.721256454704893e-11
, O 0 1.2221472098228325e-11
suggesting O 0 1.8745757723870327e-10
that O 0 1.9331765355179442e-11
both O 0 1.4922263424921312e-10
mutations O 0 2.718175906579745e-09
were O 0 2.1362152324844175e-10
probably O 0 5.166992389504799e-10
introduced O 0 8.937570822320495e-11
to O 0 5.867464847320036e-11
Australia O 0 3.832505927198193e-12
by O 0 7.088520308923263e-12
Irish O 0 2.2713766423265724e-09
migrants O 0 6.771949667694344e-10
during O 0 3.9782530047993703e-10
the O 0 3.4025010586802296e-10
19th O 0 5.981316064662678e-08
century O 0 6.91590628321137e-07
. O 0 3.397495618173707e-07

Haplotype O 0 3.611116699175909e-05
analysis O 0 1.4413933513424126e-07
using O 0 8.434508913524041e-08
6 O 0 2.135913518941379e-06
RFLPs O 0 1.1848155736515764e-05
provides O 0 2.232887902353653e-10
additional O 0 1.9352029700936413e-10
data O 0 2.1540953742960056e-10
that O 0 1.9740743761875734e-11
the O 0 9.149558888310594e-10
I113F O 0 3.698092996273772e-07
mutation O 0 2.7016566761517424e-09
originated O 0 2.506259644263764e-10
from O 0 9.976250381349416e-11
a O 0 2.7432164872998044e-10
common O 0 4.505082529249194e-09
ancestor O 0 8.896745384845417e-07
. O 0 2.5881516307890706e-07

The O 0 4.3703485630430805e-07
other O 0 1.0920718773732574e-09
9 O 0 1.632748158897357e-08
novel O 0 9.81297376689838e-10
mutations O 0 3.787269164945428e-09
identified O 0 9.92982029934808e-10
in O 0 2.629754400351736e-11
these O 0 1.2376719440987394e-11
23 O 0 2.8247797434488575e-09
patients O 0 3.753251182070372e-11
were O 0 2.0008709966656824e-11
each O 0 5.717991618386931e-12
limited O 0 1.5864946509291933e-11
to O 0 9.523072608264016e-11
a O 0 2.4862543135384385e-09
single O 0 2.57118308866211e-08
family O 0 1.4634352396569739e-08
. O 0 1.4634639455834986e-07

These O 0 2.0721996563111134e-08
data O 0 6.879842473495046e-09
provide O 0 1.7210376179743747e-10
further O 0 5.773020950172736e-10
evidence O 0 1.1863557913827094e-09
for O 0 1.0238536407580767e-10
extensive O 0 1.1224100759932298e-08
allelic O 0 1.252886363545258e-06
heterogeneity O 0 8.548758160031866e-06
in O 0 7.086979536552462e-08
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 1.0
in O 0 3.950806348740343e-09
British O 0 1.213216549444951e-08
- O 0 4.7160597205220256e-08
Irish O 0 1.0641774572661689e-08
patients O 0 4.527112365537711e-11
and O 0 4.2356322442482774e-12
provide O 0 7.116684411917484e-12
evidence O 0 1.1467184146685128e-10
for O 0 5.8154113469210955e-11
their O 0 2.4325843422934312e-11
transmission O 0 6.858744683313489e-10
to O 0 5.569547947836817e-11
Australia O 0 4.686968695100102e-12
by O 0 2.1012217573529446e-12
British O 0 1.5736426606238751e-09
- O 0 2.1341934441920785e-08
Irish O 0 2.1231256752685113e-08
migrants O 0 4.6070645076667915e-09
. O 0 3.2541289107790305e-10
. O 0 7.580467809020774e-09

Identification O 0 1.624343610728829e-07
of O 0 1.714494004545486e-07
constitutional O 0 1.1177397936990019e-05
WT1 O 1 0.9304636716842651
mutations O 0 2.986626441270346e-06
, O 0 1.4269462278448941e-09
in O 0 4.1925382610052964e-10
patients O 0 5.253949497685539e-10
with O 0 3.0974631193281255e-10
isolated O 0 0.0030184986535459757
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 1.4371240197874613e-08
and O 0 2.0287795055029534e-10
analysis O 0 7.088054587711667e-10
of O 0 2.0564739244832708e-08
genotype O 0 2.6701632123149466e-06
/ O 0 3.692711743497057e-06
phenotype O 0 2.5148143123487898e-08
correlations O 0 3.861597708265663e-09
by O 0 2.3303043522604483e-11
use O 0 2.2836298130268773e-10
of O 0 5.196109764682433e-09
a O 0 4.153048127619741e-09
computerized O 0 1.7634638993513363e-07
mutation O 0 2.0852070292676217e-07
database O 0 7.98342441044042e-08
. O 0 1.5285715448953852e-07

Constitutional O 0 1.0719557394622825e-05
mutations O 0 1.139128926297417e-06
of O 0 7.298066293515149e-07
the O 0 7.267354362738843e-08
WT1 O 0 3.2287181966239586e-05
gene O 0 1.0622671631210778e-08
, O 0 2.758474282327228e-10
encoding O 0 6.246557049394141e-09
a O 0 3.254064040447702e-08
zinc O 0 1.0122653293365147e-06
- O 0 1.434823957424669e-07
finger O 0 5.5382848529461626e-08
transcription O 0 5.355781240723445e-08
factor O 0 4.40767822240673e-09
involved O 0 4.3375206204565586e-10
in O 0 6.785861872415921e-10
renal O 1 1.0
and O 0 1.4960986050027714e-07
gonadal O 1 1.0
development O 0 9.349707852379652e-07
, O 0 2.5215599053218796e-10
are O 0 1.2623621765961435e-11
found O 0 6.337808056144922e-11
in O 0 2.3871408322273524e-11
most O 0 1.4207689712220084e-11
patients O 0 2.013236105602445e-11
with O 0 5.081917872629127e-11
Denys B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.308274113398511e-05
DDS B-Disease 1 1.0
) O 0 1.2511791602776157e-08
, O 0 1.9259025485496295e-09
or O 0 5.345310682969284e-07
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 2.876868620660389e-06
DMS B-Disease 0 0.0010344362817704678
) O 0 1.0218129814498766e-10
associated O 0 4.955759136393567e-10
with O 0 1.0375835607367989e-10
pseudohermaphroditism B-Disease 1 1.0
and O 0 6.473014764196705e-07
/ O 0 0.03794113174080849
or O 0 3.429908474572585e-06
Wilms B-Disease 1 0.9999979734420776
tumor I-Disease 1 0.9975380897521973
( O 0 5.90816000567429e-07
WT B-Disease 1 0.9999995231628418
) O 0 2.4265222720032398e-08
. O 0 9.65469411084996e-08

Most O 0 9.026565805925202e-08
mutations O 0 6.800450478294806e-07
in O 0 8.875933588115004e-08
DDS B-Disease 1 1.0
patients O 0 1.0523379387450404e-05
lie O 0 6.068640868761577e-05
in O 0 1.1511945174902394e-08
exon O 0 2.0868162664555712e-07
8 O 0 5.2445631837372275e-08
or O 0 6.807345798165443e-09
exon O 0 1.2221262579714676e-07
9 O 0 6.733817770054884e-08
, O 0 4.801151698430317e-10
encoding O 0 3.944137105804657e-08
zinc O 0 1.9345241071277997e-06
finger O 0 2.06849927053554e-05
2 O 0 3.749933739527478e-06
or O 0 1.0104185577120006e-07
zinc O 0 8.107348890007415e-07
finger O 0 4.32879801337549e-07
3 O 0 4.1831491159882717e-08
, O 0 8.74966973873903e-11
respectively O 0 3.876872434194212e-10
, O 0 1.75862345519473e-11
with O 0 3.661692910689185e-12
a O 0 4.096560868305232e-09
hot O 0 1.009043103294971e-06
spot O 0 3.929675358449458e-07
( O 0 5.585489404325017e-09
R394W O 0 2.774259428406367e-06
) O 0 1.29683774829914e-09
in O 0 3.230229861372891e-09
exon O 0 4.856009923059901e-07
9 O 0 9.176619641948491e-07
. O 0 2.0664812439008529e-07

We O 0 8.652332184055922e-08
analyzed O 0 8.56117132741474e-09
a O 0 4.810786213838014e-10
series O 0 1.1951992173742099e-10
of O 0 1.0315930332183143e-09
24 O 0 8.560518516276261e-09
patients O 0 1.8328773221387706e-10
, O 0 1.5302817346629638e-10
10 O 0 2.74093769903061e-09
with O 0 5.394344415599051e-10
isolated B-Disease 0 0.00017253599071409553
DMS I-Disease 1 0.9999557733535767
( O 0 1.7010090402891365e-07
IDMS B-Disease 0 0.21750620007514954
) O 0 1.092511525691009e-09
, O 0 1.3126896791781917e-10
10 O 0 2.3284663086542423e-10
with O 0 4.9867811269255213e-11
DDS B-Disease 1 1.0
, O 0 6.78730227576807e-09
and O 0 5.72620451055883e-10
4 O 0 2.9717334371071047e-08
with O 0 3.334082732120436e-10
urogenital B-Disease 0 0.1220821887254715
abnormalities I-Disease 1 0.9989010095596313
and O 0 7.491740348086751e-07
/ O 1 0.8508407473564148
or O 0 0.0016616310458630323
WT B-Disease 1 1.0
. O 0 7.942966817608976e-07

We O 0 1.1313167078697006e-06
report O 0 4.017558552504852e-08
WT1 O 0 4.6506760554620996e-05
heterozygous O 0 6.412500397345866e-08
mutations O 0 2.6197856328735725e-08
in O 0 1.0706022735007537e-09
16 O 0 2.2800067611683517e-08
patients O 0 6.838575816736636e-10
, O 0 2.2703663948853148e-10
4 O 0 5.1084757757280386e-08
of O 0 5.998887786518026e-08
whom O 0 4.5957538219454364e-08
presented O 0 9.210008045101858e-08
with O 0 2.6725265556137856e-08
IDMS B-Disease 1 0.9989126920700073
. O 0 6.620941803703317e-06

One O 0 1.6691268456270336e-07
male O 0 1.0646972192773774e-08
and O 0 3.384165447872789e-10
two O 0 8.53449366733372e-10
female O 0 9.591678562514971e-09
IDMS B-Disease 0 0.005846417509019375
patients O 0 9.806616851903982e-09
with O 0 5.572231120964943e-09
WT1 O 1 0.9999293088912964
mutations O 0 0.2127573937177658
underwent O 1 0.7691433429718018
normal O 0 0.0002529831253923476
puberty O 0 0.0002034180361079052
. O 0 1.8311430949324858e-07

Two O 0 9.210183549157591e-08
mutations O 0 4.7408161663042847e-07
associated O 0 2.982226376957442e-08
with O 0 9.336782458291282e-10
IDMS B-Disease 1 0.9999526739120483
are O 0 8.831322478863868e-11
different O 0 1.5033814471099305e-11
from O 0 1.313967129545901e-10
those O 0 1.953894858408578e-11
described O 0 8.759893921350681e-10
in O 0 5.4375886016089225e-09
DDS B-Disease 1 1.0
patients O 0 8.199474450520938e-07
. O 0 5.138662686476891e-07

No O 0 2.7699290967575507e-06
WT1 O 0 0.0001654399820836261
mutations O 0 2.744656626418873e-07
were O 0 2.629155115840831e-09
detected O 0 7.089599129983526e-09
in O 0 1.885937100931656e-10
the O 0 1.4800215497601243e-09
six O 0 4.3493528778526525e-09
other O 0 1.502511559614561e-09
IDMS B-Disease 1 1.0
patients O 0 3.6335787712005185e-08
, O 0 9.069737738620631e-10
suggesting O 0 2.044720659455379e-08
genetic O 0 1.3917616570324753e-07
heterogeneity O 0 1.9394803985051112e-06
of O 0 1.9594629918628925e-07
this O 0 3.532994341526319e-08
disease O 0 0.0003254203184042126
. O 0 3.464065798652882e-07

We O 0 1.34098570470087e-06
analyzed O 0 7.33574722744379e-07
genotype O 0 1.3153900908946525e-05
/ O 0 1.8250415450893342e-05
phenotype O 0 2.5496132138869143e-07
correlations O 0 8.727598554969518e-08
, O 0 1.6128075264187913e-10
on O 0 3.8049047246246914e-10
the O 0 1.7268865157293867e-11
basis O 0 2.8168209431633784e-10
of O 0 2.435004142764541e-10
the O 0 1.0944611189556142e-10
constitution O 0 3.535309545110721e-10
of O 0 4.469631775805283e-09
a O 0 6.541892361155988e-09
WT1 O 0 1.0368146831751801e-05
mutation O 0 3.1467603633927865e-08
database O 0 3.143255433712966e-09
of O 0 3.243907187311379e-08
84 O 0 2.896428838994325e-07
germ O 0 0.0002714974107220769
- O 0 1.0160468264075462e-05
line O 0 1.8692918501983513e-06
mutations O 0 6.639897520699378e-08
, O 0 1.758366230397712e-10
to O 0 2.822295730453561e-10
compare O 0 9.229889630368859e-10
the O 0 2.59824078918669e-10
distribution O 0 6.823227538532706e-10
and O 0 6.699803906107249e-12
type O 0 1.8767161158450563e-09
of O 0 9.69700764130721e-09
mutations O 0 9.604017137121446e-09
, O 0 3.572916615346422e-11
according O 0 3.4011692767732526e-11
to O 0 1.6056619922544257e-10
the O 0 7.718027328351695e-10
different O 0 1.5430026145679676e-09
symptoms O 0 5.228123995948408e-07
. O 0 2.691813847377489e-07

This O 0 1.9360170355753326e-08
demonstrated O 0 2.367835882921554e-08
( O 0 1.4647134616296853e-09
1 O 0 1.7561499987550633e-07
) O 0 9.874175782575989e-11
the O 0 1.8126712630905928e-10
association O 0 2.2775921426632095e-10
between O 0 3.3462463910893803e-09
mutations O 0 1.0586021836900272e-08
in O 0 7.153408976279252e-10
exons O 0 4.0041097548737525e-08
8 O 0 9.014862634160181e-09
and O 0 1.3821885302967019e-10
9 O 0 1.616369083023983e-08
and O 0 6.887782011411048e-10
DMS B-Disease 0 3.147606321363128e-06
; O 0 5.942341618769831e-10
( O 0 1.0537185568537666e-09
2 O 0 6.766003934899345e-08
) O 0 1.3136362830845627e-10
among O 0 4.336393744086564e-11
patients O 0 4.98067871668173e-11
with O 0 4.410095205686915e-11
DMS B-Disease 0 7.906057726358995e-05
, O 0 3.725067754256628e-10
a O 0 2.4823723632216854e-10
higher O 0 9.932661360068096e-10
frequency O 0 7.173073246491413e-09
of O 0 3.0163656017379026e-09
exon O 0 1.5983241397066195e-08
8 O 0 5.4549156303096424e-09
mutations O 0 1.2148785311083543e-09
among O 0 7.378058580753688e-11
46 O 0 8.282449392993385e-09
, O 0 1.401686544610925e-09
XY O 0 0.0001897114416351542
patients O 0 3.6587083362960016e-10
with O 0 1.8144276012210803e-11
female O 0 2.0388808696925054e-10
phenotype O 0 1.1462423232799779e-09
than O 0 7.372825266971361e-11
among O 0 5.683612608331501e-11
46 O 0 2.018183309360211e-08
, O 0 4.497681782567042e-09
XY O 0 0.4960240125656128
patients O 0 6.946651587291797e-10
with O 0 2.5156597291409177e-11
sexual O 0 6.224602167037574e-09
ambiguity O 0 4.825849373446545e-07
or O 0 2.1452740028848893e-08
male O 0 1.1055942827908893e-09
phenotype O 0 1.3483024696725465e-09
; O 0 5.6653109287152503e-11
and O 0 2.970738377516824e-10
( O 0 1.7327214107965005e-09
3 O 0 4.5949388294275195e-08
) O 0 1.1488639900525399e-10
statistically O 0 2.2222872153587758e-10
significant O 0 1.0503349578971921e-10
evidence O 0 3.0366256731362284e-10
that O 0 3.626995231931218e-11
mutations O 0 2.7381734657438983e-09
in O 0 9.85044157353343e-10
exons O 0 1.9874558176979917e-07
8 O 0 2.8074587987703126e-08
and O 0 1.013962247498057e-09
9 O 0 3.610573173773446e-08
preferentially O 0 1.4547634208383897e-08
affect O 0 1.3552853062037684e-08
amino O 0 4.3641112945635996e-09
acids O 0 1.331823817896094e-10
with O 0 8.484830676599997e-13
different O 0 9.133578442177548e-12
functions O 0 2.814071198287138e-10
. O 0 5.896558796791851e-10
. O 0 1.78004881945526e-08

The O 0 1.0047796195067349e-06
185delAG O 0 9.119300557358656e-06
BRCA1 O 0 1.327663881056651e-06
mutation O 0 1.095356072511322e-08
originated O 0 5.434008798488321e-10
before O 0 1.7874843272203123e-10
the O 0 2.738530929802252e-11
dispersion O 0 1.4067386366889423e-08
of O 0 1.6072010389223124e-09
Jews O 0 5.276185710556547e-09
in O 0 2.5015206919776212e-11
the O 0 4.847941839636327e-11
diaspora O 0 5.208629638708828e-10
and O 0 2.0257621968777784e-11
is O 0 3.807327716986997e-11
not O 0 1.0677934925151789e-10
limited O 0 4.587473456663105e-10
to O 0 2.2356983819804555e-08
Ashkenazim O 0 0.0002078989491565153
. O 0 1.3751605365541764e-06

The O 0 1.8813372548720508e-07
185delAG O 0 1.2081729892088333e-06
mutation O 0 3.1013325241247e-08
in O 0 1.810719685302331e-09
BRCA1 O 0 1.7166209431707102e-07
is O 0 3.283363025907704e-10
detected O 0 1.967028984140029e-09
in O 0 5.8780390277402e-11
Ashkenazi O 0 1.54639238303389e-07
Jews O 0 1.5154755672597275e-08
both O 0 1.1645145958638636e-10
in O 0 7.002777802078697e-10
familial B-Disease 1 0.8410919904708862
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 9.104721954145134e-08
in O 0 1.1668898070027467e-09
the O 0 1.236903801604683e-09
general O 0 7.097054055549279e-09
population O 0 8.147975072425595e-10
. O 0 1.238181468465882e-08

All O 0 2.0568039360568946e-07
tested O 0 6.88575241269973e-08
Ashkenazi O 0 7.131386610126356e-07
mutation O 0 2.1826842555583426e-08
carriers O 0 2.1595172872146406e-10
share O 0 2.5890886656831924e-10
the O 0 1.701743052029414e-10
same O 0 3.716835172973276e-10
allelic O 0 3.5915682872200705e-08
pattern O 0 2.5322576036046485e-08
at O 0 2.1259420890373804e-08
the O 0 4.58467663833062e-09
BRCA1 O 0 2.8795673756576434e-07
locus O 0 2.2267545318754856e-06
. O 0 1.0672269468159357e-07

Our O 0 2.640227876327117e-07
previous O 0 2.2435711954926774e-08
study O 0 1.3282449584650635e-09
showed O 0 7.6748350730238e-11
that O 0 2.762841821643547e-12
this O 0 4.698947481118765e-11
Ashkenazi O 0 2.6047618462143873e-07
mutation O 0 8.841579024476687e-09
also O 0 1.5446442735989052e-11
occurs O 0 4.3233451541002665e-11
in O 0 1.650366822369964e-11
Iraqi O 0 1.3906512608130583e-09
Jews O 0 2.019506784023406e-09
with O 0 3.0992090404441397e-12
a O 0 3.729390407603006e-10
similar O 0 9.91086213097958e-10
allelic O 0 2.3969917037902633e-06
pattern O 0 3.166365559081896e-06
. O 0 4.162511970662308e-07

We O 0 1.6636124655633466e-07
extended O 0 3.194266895434339e-08
our O 0 7.793588552296171e-10
analysis O 0 1.547838940352264e-10
to O 0 1.4088234745468498e-10
other O 0 7.984524152959693e-11
non O 0 1.2655758041546505e-07
- O 0 1.1958245238474774e-07
Ashkenazi O 0 2.0033033365507436e-07
subsets O 0 1.5387653817811042e-08
354 O 0 1.3625940376016388e-09
of O 0 8.150353170144342e-10
Moroccan O 0 2.436916872738948e-07
origin O 0 1.3090505568413846e-08
, O 0 1.1775814767744919e-09
200 O 0 1.5151915278011074e-09
Yemenites O 0 1.300646346180656e-07
and O 0 4.407625653346514e-10
150 O 0 3.927724812058386e-09
Iranian O 0 3.9995416045712773e-07
Jews O 0 1.3872947874915553e-06
. O 0 4.133925699534302e-07

Heteroduplex O 0 7.700850983383134e-05
analysis O 0 4.496586214486342e-08
complemented O 0 1.2404104410279615e-08
by O 0 1.2298904950025502e-10
direct O 0 5.688271187409555e-09
DNA O 0 3.8946641467418885e-08
sequencing O 0 1.94006464226959e-08
of O 0 2.6022956234328376e-08
abnormally O 0 3.023878747399067e-08
migrating O 0 7.09032610402005e-10
bands O 0 4.904419093065826e-09
were O 0 1.5191384816759523e-09
employed O 0 1.244220726448475e-08
. O 0 4.229150363244116e-08

Four O 0 1.9811043472373058e-08
of O 0 4.25432773454304e-08
Moroccan O 0 2.934986468972056e-06
origin O 0 1.0683446127757179e-08
( O 0 1.7585440048595302e-10
1 O 0 7.065906970638025e-09
. O 0 1.9884227944744204e-11
1 O 0 3.8744794039757835e-09
% O 0 2.6149604703817886e-10
) O 0 4.64758570170587e-12
and O 0 9.409966729434505e-12
none O 0 2.686804390084063e-10
of O 0 1.205914146318321e-09
the O 0 1.8368049303774114e-09
Yemenites O 0 5.826834126310132e-08
or O 0 1.1096927821085956e-09
Iranians O 0 5.076245646051802e-09
was O 0 1.1444859504550209e-09
a O 0 9.091451202980494e-11
carrier O 0 6.187702017435015e-10
of O 0 1.5942679398861515e-09
the O 0 5.1007131851577014e-09
185delAG O 0 8.729543878871482e-07
mutation O 0 9.207801667798776e-07
. O 0 1.9213013047192362e-07

BRCA1 O 0 2.615168341435492e-05
allelic O 0 1.141878556154552e-06
patterns O 0 1.7074269775818607e-09
were O 0 1.053396536665474e-10
determined O 0 4.4787182296168737e-10
for O 0 1.4825035296595068e-11
four O 0 6.448203516279394e-12
of O 0 7.457087725093459e-11
these O 0 1.1483019396463234e-12
individuals O 0 1.005341556531425e-11
and O 0 4.068198555806646e-11
for O 0 1.8439227922328882e-10
12 O 0 1.1212711870101089e-09
additional O 0 3.2864330701265487e-10
non O 0 8.965498921043036e-08
- O 0 6.925557016757011e-08
Ashkenazi O 0 2.6885087933692375e-08
185delAG O 0 1.1009982925358486e-09
mutation O 0 8.387652378205601e-11
carriers O 0 4.313642151809738e-11
who O 0 1.7887540337824248e-09
had O 0 1.809859440982109e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.6322831511497498

Six O 0 6.969191304051492e-07
non O 0 4.2531937651801854e-06
- O 0 7.199804485935601e-07
Ashkenazi O 0 8.484663567287498e-07
individuals O 0 1.0663585292558508e-10
shared O 0 1.7090945325648477e-10
the O 0 2.2117115083819527e-10
common O 0 1.1321840132083594e-09
Ashkenazi O 0 3.454557884197129e-07
haplotype O 0 2.331287305423757e-06
, O 0 1.0155027929670268e-09
four O 0 1.6484896780966096e-10
had O 0 3.7328204416375854e-10
a O 0 6.696434379227512e-11
closely O 0 5.7308671697064995e-11
related O 0 3.442799101360805e-10
pattern O 0 1.4165878248206809e-08
, O 0 1.499464580279053e-10
and O 0 9.497966996230289e-11
the O 0 2.7524524881528123e-09
rest O 0 1.4711146079093851e-08
( O 0 1.4369204714981265e-09
n O 0 1.2788768799509853e-07
= O 0 5.8544724623743605e-08
6 O 0 1.7770771520986273e-08
) O 0 4.750104476425321e-11
displayed O 0 1.6966482385694093e-10
a O 0 7.6049816444268e-10
distinct O 0 1.2486403022649029e-08
BRCA1 O 0 1.8180072629547794e-06
allelic O 0 4.223147243465064e-06
pattern O 0 4.440557859197725e-06
. O 0 5.783793426417105e-07

We O 0 2.622406043428782e-07
conclude O 0 3.198477145360812e-07
that O 0 4.0744829732375365e-10
the O 0 3.295511197265455e-09
185delAG O 0 5.491407932822767e-07
BRCA1 O 0 5.907010631744924e-07
mutation O 0 1.925264392355075e-08
occurs O 0 6.858757450878272e-10
in O 0 1.1273688579893637e-11
some O 0 4.2657453958039326e-11
non O 0 2.1248277448648878e-07
- O 0 2.289153826495749e-07
Ashkenazi O 0 6.484760888270102e-07
populations O 0 8.067433526770529e-11
at O 0 7.93067278515025e-11
rates O 0 9.71515402847789e-12
comparable O 0 7.773350019224523e-11
with O 0 7.589121171769353e-12
that O 0 5.166479466467422e-10
of O 0 1.751062654875568e-07
Ashkenazim O 0 0.00011467107833595946
. O 0 6.97446409958502e-07

The O 0 5.021665216986548e-08
majority O 0 3.355283162420619e-09
of O 0 3.134145387662102e-08
Jewish O 0 2.1670729211109574e-07
185delAG O 0 5.660976967192255e-07
mutation O 0 4.484638083113168e-08
carriers O 0 2.3992474673661945e-10
have O 0 1.2578124305995253e-11
a O 0 8.312986410352607e-11
common O 0 4.5635087375650585e-10
allelic O 0 6.737928970323992e-08
pattern O 0 2.1970190999809347e-08
, O 0 5.894407878459518e-11
supporting O 0 2.524972175788065e-10
the O 0 5.684059889432547e-10
founder O 0 8.837734988276225e-09
effect O 0 3.629697875595639e-09
notion O 0 1.1482889306080324e-08
, O 0 2.752182162724104e-11
but O 0 8.852247060375795e-12
dating O 0 5.822936577359883e-11
the O 0 1.2187253810302945e-11
mutations O 0 4.116938387421776e-11
origin O 0 4.0330915690445224e-11
to O 0 9.138004589126503e-12
an O 0 7.217513912916029e-12
earlier O 0 3.6271910475171865e-10
date O 0 6.0492690856506215e-09
than O 0 2.604417792539948e-10
currently O 0 8.944022189538714e-10
estimated O 0 2.5889681509738693e-08
. O 0 8.394065531547312e-08

However O 0 8.939339579683292e-08
, O 0 1.6587442530635599e-09
the O 0 2.0594627392345188e-10
different O 0 2.4580828691944667e-11
allelic O 0 7.785217093214669e-08
pattern O 0 3.852631991208e-08
at O 0 2.204120619353489e-08
the O 0 8.285321317913485e-10
BRCA1 O 0 3.778943735710527e-08
locus O 0 2.6086665272373466e-08
even O 0 4.3974289487547225e-11
in O 0 2.348364992049712e-12
some O 0 1.1992032800806074e-12
Jewish O 0 6.020753895441544e-10
mutation O 0 4.993294111521607e-10
carriers O 0 4.847294787779788e-11
, O 0 2.514973646006169e-11
might O 0 2.550042677018638e-10
suggest O 0 4.691034227732871e-10
that O 0 2.5382352469849323e-11
the O 0 3.674485993254706e-10
mutation O 0 1.4540136872298604e-09
arose O 0 3.5771139383911077e-09
independently O 0 1.993007758827048e-09
. O 0 3.2179123810038845e-09
. O 0 7.695177117739149e-08

Crystal O 0 3.9496564568253234e-05
structure O 0 1.175232682726346e-06
of O 0 1.351152423012536e-05
the O 0 8.964334483607672e-06
hemochromatosis B-Disease 1 1.0
protein O 0 0.000212787083000876
HFE O 0 0.002019404899328947
and O 0 3.0164464259740953e-09
characterization O 0 1.1857188297881294e-07
of O 0 2.3224538736599243e-08
its O 0 3.042011365028685e-10
interaction O 0 2.8332349799597978e-09
with O 0 4.3701567364884397e-10
transferrin O 0 5.447969215310877e-06
receptor O 0 8.922915185394231e-06
. O 0 6.026895107424934e-07

HFE O 1 0.9998142123222351
is O 0 3.9558946696161e-07
an O 0 2.8573591492886408e-08
MHC O 0 0.1363123506307602
- O 0 3.076744178542867e-05
related O 0 9.770326414582087e-08
protein O 0 4.5001100623665025e-09
that O 0 9.865398428732242e-12
is O 0 2.011439799443071e-11
mutated O 0 2.5853827412269936e-10
in O 0 1.4022019656501072e-10
the O 0 1.2669301163725777e-08
iron B-Disease 1 0.9999954700469971
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9995549321174622

HFE O 0 0.0005364885437302291
binds O 0 2.964547149986174e-07
to O 0 1.8141498969725944e-08
transferrin O 0 1.6751976090745302e-06
receptor O 0 1.078149807653972e-06
( O 0 4.926902885671325e-09
TfR O 0 1.1448778280964689e-07
) O 0 4.825754726378584e-11
and O 0 1.7624986539677145e-11
reduces O 0 5.645660050568324e-10
its O 0 4.5382302082952464e-11
affinity O 0 4.5161985262609505e-09
for O 0 5.352204457409471e-09
iron O 0 1.8942125734611182e-06
- O 0 2.7430996851762757e-07
loaded O 0 7.851063799080293e-09
transferrin O 0 2.0155006552613486e-07
, O 0 2.7630620014207352e-09
implicating O 0 6.574429107786273e-07
HFE O 0 0.00020350146223790944
in O 0 2.318833765002637e-07
iron O 0 0.0003857938863802701
metabolism O 0 8.463789708912373e-05
. O 0 6.588463747903006e-07

The O 0 1.7383919839630835e-05
2 O 0 7.026157982181758e-05
. O 0 2.8747103897330817e-06

6 O 0 9.526354551780969e-05
A O 0 1.0775233022286557e-05
crystal O 0 3.7421355955302715e-05
structure O 0 2.687263531697681e-06
of O 0 2.591273732832633e-05
HFE O 1 0.9999696016311646
reveals O 0 7.900489151779766e-08
the O 0 8.694642228412874e-10
locations O 0 1.5248923235233747e-09
of O 0 7.955606662335413e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 0.0001268505584448576
and O 0 1.3442384094730642e-08
a O 0 8.895983683032682e-08
patch O 1 0.537869930267334
of O 0 1.064596108335536e-05
histidines O 0 0.0001853441062849015
that O 0 2.4687030197867443e-10
could O 0 5.252887014250973e-10
be O 0 1.5342857540012744e-10
involved O 0 3.464629971805522e-10
in O 0 3.944464199712172e-10
pH O 0 8.752820576773956e-06
- O 0 1.2808081919502001e-06
dependent O 0 4.0038580095824727e-07
interactions O 0 2.594747741113679e-07
. O 0 3.1563124025524303e-07

We O 0 9.058833825292822e-07
also O 0 8.052867705998779e-09
demonstrate O 0 2.2343513705891382e-08
that O 0 5.2765778413288444e-09
soluble O 0 3.864086920657428e-06
TfR O 0 2.6867512588069076e-06
and O 0 2.605517135378932e-09
HFE O 0 1.0562973329797387e-05
bind O 0 3.968072093130104e-08
tightly O 0 3.537613224580127e-08
at O 0 3.810251669733589e-09
the O 0 2.0834410585646168e-10
basic O 0 1.1814826894607222e-09
pH O 0 8.576751042710384e-08
of O 0 6.035231869816471e-09
the O 0 2.7674185165693643e-09
cell O 0 4.534404141054438e-08
surface O 0 5.746133879824811e-08
, O 0 1.9650932270298682e-10
but O 0 1.7483167691345614e-10
not O 0 1.0749359180550755e-09
at O 0 2.8874314494942155e-08
the O 0 8.584553512491766e-09
acidic O 0 1.2440674481695169e-06
pH O 0 3.871744411299005e-06
of O 0 3.686880916120572e-07
intracellular O 0 1.2090559948774171e-06
vesicles O 0 6.870357083244016e-06
. O 0 4.117259209124313e-07

TfR O 0 0.001195714809000492
HFE O 0 0.0017079560784623027
stoichiometry O 0 3.554523573257029e-05
( O 0 1.1863115645383004e-07
2 O 0 1.12847953914752e-06
1 O 0 3.6351841004034213e-07
) O 0 3.3089000983643757e-10
differs O 0 1.5644521234037256e-09
from O 0 2.1157469110022475e-09
TfR O 0 9.58778585413711e-08
transferrin O 0 3.9036031296291185e-08
stoichiometry O 0 4.032405342968559e-08
( O 0 8.95506557796466e-10
2 O 0 2.5308622753072996e-08
2 O 0 1.315044073635363e-08
) O 0 7.976121846331452e-11
, O 0 2.988428601802262e-11
implying O 0 4.899965988514055e-10
a O 0 5.260062871381699e-11
different O 0 6.711468186759717e-12
mode O 0 7.551615999190631e-10
of O 0 1.7185151912624264e-10
binding O 0 5.79064574068866e-09
for O 0 1.4165600914495258e-09
HFE O 0 3.861434379359707e-05
and O 0 2.9729334549699615e-09
transferrin O 0 2.8997646950301714e-07
to O 0 7.03719216232912e-09
TfR O 0 3.502446759284794e-07
, O 0 1.4915092771961014e-10
consistent O 0 4.4430931156469455e-10
with O 0 1.2617868555553358e-11
our O 0 3.946135085364233e-10
demonstration O 0 1.2681503624989432e-09
that O 0 1.0439497183378776e-10
HFE O 0 3.5612310966826044e-06
, O 0 7.827644643576548e-10
transferrin O 0 1.0752690826620892e-07
, O 0 1.3683157940036494e-09
and O 0 9.258647182264212e-10
TfR O 0 1.6067289720922417e-07
form O 0 1.512159952810066e-09
a O 0 1.6793000767734156e-08
ternary O 0 1.4697229744342621e-06
complex O 0 2.2074711978348205e-06
. O 0 3.3202329063897196e-07

Identification O 0 1.1871977534383404e-07
of O 0 4.159058875075061e-08
three O 0 3.3254898834655933e-10
novel O 0 1.479465550069392e-09
mutations O 0 9.106190801411174e-10
and O 0 1.531407986532507e-11
a O 0 1.196170801298635e-10
high O 0 8.771464110601812e-10
frequency O 0 4.146107013269784e-09
of O 0 2.067130022709307e-09
the O 0 9.59654133936283e-10
Arg778Leu O 0 1.8544759541327949e-06
mutation O 0 1.742957955741531e-08
in O 0 4.67123062453112e-10
Korean O 0 4.351338489527734e-08
patients O 0 2.2768885388213533e-10
with O 0 1.819727563079354e-10
Wilson B-Disease 0 2.975325969600817e-06
disease I-Disease 0 1.2422888175933622e-05
. O 0 4.562669460028701e-07

Four O 0 2.951758304448049e-08
mutations O 0 3.090655908977169e-08
- O 0 1.9250886396093847e-07
- O 0 4.047555535180436e-07
R778L O 0 6.775974270567531e-06
, O 0 6.705179744770362e-10
A874V O 0 5.267174287837406e-07
, O 0 5.462992280769186e-10
L1083F O 0 3.8315494066409883e-07
, O 0 1.1295993307403052e-10
and O 0 6.101361083032941e-11
2304delC O 0 2.9493607556219104e-08
- O 0 9.575633441727405e-08
- O 0 1.0412030349016277e-07
in O 0 3.727912645246079e-09
the O 0 5.516869627797405e-09
copper O 0 1.1851852121935735e-07
- O 0 3.5220004690472706e-08
transporting O 0 4.392630259530961e-09
enzyme O 0 1.9553394459137508e-09
, O 0 4.389939523008479e-10
P O 0 1.2743835213768762e-06
- O 0 2.9269445533941507e-08
type O 0 2.0290444879833558e-08
ATPase O 0 1.007599053082231e-07
( O 0 6.024923338010524e-10
ATP7B O 0 4.424646249390207e-06
) O 0 3.216160324170936e-11
, O 0 8.546262655895198e-12
were O 0 2.7436755992149564e-11
identified O 0 2.2659060738838832e-10
in O 0 6.144969949550827e-11
Korean O 0 1.6671629410325295e-08
Patients O 0 4.688064381141999e-10
with O 0 2.8563157394856376e-10
Wilson B-Disease 0 1.008191793516744e-05
disease I-Disease 0 0.0014467340661212802
. O 0 2.637047373355017e-06

Arg778Leu O 1 0.9950363039970398
, O 0 1.472465527285749e-07
the O 0 1.9413715079963367e-08
most O 0 1.9204579593257165e-10
frequently O 0 2.158463130452759e-10
reported O 0 2.0420176660707057e-10
mutation O 0 2.6458757407255007e-10
of O 0 1.7357902615255938e-10
this O 0 1.2777686894671625e-11
enzyme O 0 3.616028310116093e-10
, O 0 1.8290698816647577e-11
was O 0 1.4680138216149885e-09
found O 0 2.036004177752293e-11
in O 0 5.774633809324525e-12
six O 0 2.6610474240795767e-11
of O 0 5.967647487281624e-10
eight O 0 8.356613179216765e-10
unrelated O 0 8.182802879730389e-09
patients O 0 7.46337713852796e-11
studied O 0 2.3666786308496057e-09
, O 0 2.4262130499108636e-11
an O 0 2.130387533050282e-11
allele O 0 1.947504602028971e-09
frequency O 0 7.442306326765902e-08
of O 0 8.963225184288603e-08
37 O 0 1.1564541182451649e-06
. O 0 1.7201246294007433e-07

5 O 0 3.121163899777457e-06
% O 0 2.0517650511919783e-07
, O 0 1.8939431967179843e-10
which O 0 2.434181155253068e-11
is O 0 2.9389789213407624e-11
considerably O 0 3.60111995778567e-10
higher O 0 3.2271119110305335e-10
than O 0 4.421145047284192e-11
those O 0 5.0794660144681814e-11
in O 0 1.0488414997622542e-10
other O 0 1.4335307940704922e-10
Asian O 0 4.901202554918882e-09
populations O 0 2.905932827701463e-09
. O 0 1.4696254879709159e-08

The O 0 6.189135604017793e-08
novel O 0 1.1865759041995716e-08
single O 0 2.5969291161942465e-09
nucleotide O 0 1.7544250496825953e-08
deletion O 0 2.7419217119017958e-08
, O 0 1.4591666763763556e-10
2304delC O 0 4.441589140924407e-08
, O 0 3.666253134415598e-10
was O 0 2.1373057990103916e-08
found O 0 3.3995561921074113e-10
in O 0 2.4940899345793355e-10
one O 0 2.564638279523024e-09
patient O 0 8.774651405474287e-08
. O 0 4.037624421471264e-07

Since O 0 1.2367539170554664e-07
a O 0 2.2963861923130935e-08
mutation O 0 4.116473562021383e-08
at O 0 4.2535731381576625e-08
cDNA O 0 2.3316466979395045e-07
nucleotide O 0 2.985812557199097e-07
2302 O 0 1.0718105841078795e-05
( O 0 4.862854563469909e-10
2302insC O 0 5.300456962231692e-08
) O 0 1.4399403891474094e-10
had O 0 5.068851449685496e-10
been O 0 1.6053804119398052e-10
previously O 0 2.0387563859358693e-10
described O 0 2.002628340935786e-10
, O 0 9.53153615063096e-12
this O 0 1.779903481546885e-11
region O 0 2.4407260212910842e-08
of O 0 1.1190715554221242e-07
the O 0 6.995468027071183e-08
ATP7B O 1 0.999993085861206
gene O 0 1.1373557384786182e-07
may O 0 9.345249907255493e-09
be O 0 3.274846172018897e-09
susceptible O 0 1.5115068663362763e-07
to O 0 8.256928474281722e-09
gene O 0 2.530633480546385e-07
rearrangements O 0 0.04385160282254219
causing O 0 0.4047139883041382
Wilson B-Disease 0 0.0004295505932532251
disease I-Disease 0 0.017961017787456512
. O 0 2.5894082682498265e-06

Disruption O 0 0.00012142510968260467
of O 0 1.0031461670223507e-06
splicing O 0 2.6779053996506264e-07
regulated O 0 6.104370342541188e-09
by O 0 1.0195158606229882e-10
a O 0 2.7649860179224106e-09
CUG O 0 4.776642890647054e-05
- O 0 5.3459530136024114e-08
binding O 0 6.339534053267926e-08
protein O 0 1.392768211871953e-07
in O 0 3.7452402068538504e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 6.123424100223929e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0005793413147330284
DM B-Disease 1 1.0
) O 0 1.0240479575429617e-08
is O 0 9.951168777888597e-10
caused O 0 4.059923508492602e-09
by O 0 3.1196140115596904e-10
a O 0 1.3296523881933808e-08
CTG O 0 9.23393508855952e-06
expansion O 0 6.371936933646793e-08
in O 0 1.2684115979766375e-09
the O 0 2.3402038085151844e-09
3 O 0 2.780674002167416e-08
untranslated O 0 6.252201728784712e-06
region O 0 1.113170426947363e-07
of O 0 2.151182911802607e-07
the O 0 4.0464399830852926e-07
DM B-Disease 1 1.0
gene O 0 1.955159859790001e-06
. O 0 2.555270270931942e-07

One O 0 2.9811289437020605e-08
model O 0 2.4217229110945482e-08
of O 0 1.8322504047318944e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9923627376556396
suggests O 0 2.1328789401309223e-08
that O 0 5.180884540822994e-11
RNAs O 0 4.740849490758592e-09
from O 0 3.496921918699769e-10
the O 0 4.997140895524055e-11
expanded O 0 3.389240971207741e-11
allele O 0 3.7540978659045265e-10
create O 0 2.557269847269783e-11
a O 0 3.648687185719979e-10
gain O 0 2.1924728699218576e-08
- O 0 3.078583077353869e-08
of O 0 8.273260299063168e-09
- O 0 4.806422815306632e-09
function O 0 1.5892757943003488e-10
mutation O 0 4.18812449998196e-11
by O 0 2.636402381128722e-12
the O 0 3.7327616692062193e-11
inappropriate O 0 6.018583409428402e-10
binding O 0 7.836880477896102e-09
of O 0 1.466755161771971e-08
proteins O 0 1.3719503311193648e-10
to O 0 7.813951152790821e-10
the O 0 2.5261213565386242e-08
CUG O 0 0.0398205928504467
repeats O 0 7.198285857157316e-06
. O 0 5.038599510953645e-07

Data O 0 2.0557411062327446e-07
presented O 0 6.62419950003823e-08
here O 0 7.680568181456238e-09
indicate O 0 4.601321101915801e-09
that O 0 1.9351734104056106e-10
the O 0 1.7188832579506652e-09
conserved O 0 5.06669159960893e-08
heterogeneous O 0 2.191283954289247e-07
nuclear O 0 9.016841431730427e-06
ribonucleoprotein O 0 8.948037248046603e-06
, O 0 1.621537570883902e-09
CUG O 0 1.9387885004107375e-06
- O 0 4.480454673938539e-09
binding O 0 6.148587416987539e-09
protein O 0 1.4843383189244719e-09
( O 0 6.264495866492581e-11
CUG O 0 3.6177057154418435e-06
- O 0 8.491328173931834e-08
BP O 0 8.492411325278226e-07
) O 0 2.0352675100809847e-10
, O 0 6.48216688658998e-11
may O 0 8.938513818002036e-10
mediate O 0 1.535590712364865e-07
the O 0 2.124956743898565e-08
trans O 0 5.017089392822527e-07
- O 0 1.463960757064342e-07
dominant O 0 4.265150010951402e-08
effect O 0 1.874513166910674e-08
of O 0 2.0178829274186683e-08
the O 0 1.6125969892755165e-08
RNA O 0 1.4271994359660312e-06
. O 0 7.840562687988495e-08

CUG O 1 0.9384918212890625
- O 0 0.00015814686776138842
BP O 0 0.00019171496387571096
was O 0 1.4482967003459635e-07
found O 0 1.4511786217141776e-10
to O 0 2.2536080640511713e-11
bind O 0 8.57042631308147e-11
to O 0 2.8508620464329226e-10
the O 0 2.6375128747702092e-09
human O 0 3.9268950757787024e-08
cardiac O 0 0.00048812039312906563
troponin O 0 0.00168532133102417
T O 0 3.8307793147396296e-05
( O 0 1.4142283788487475e-08
cTNT O 0 9.35702246351866e-07
) O 0 4.469083991764933e-10
pre O 0 1.1681289180387466e-07
- O 0 1.2804739490945849e-08
messenger O 0 1.5000317654667583e-09
RNA O 0 4.647726203899083e-09
and O 0 8.56467397003513e-11
regulate O 0 1.7601077539897148e-10
its O 0 6.696587728782788e-11
alternative O 0 1.7027254273216386e-08
splicing O 0 3.4844325114136154e-07
. O 0 6.943068342479819e-08

Splicing O 0 7.136611657188041e-07
of O 0 3.7353387938310334e-07
cTNT O 0 0.0004152950132265687
was O 0 5.9239400798105635e-06
disrupted O 0 3.1784584280103445e-06
in O 0 6.471046276601555e-08
DM B-Disease 1 1.0
striated O 0 5.704718660126673e-06
muscle O 0 1.5610972070589924e-07
and O 0 1.6249431800119396e-09
in O 0 1.4069713172304432e-09
normal O 0 2.535718124363484e-08
cells O 0 4.364119732258587e-09
expressing O 0 9.9632291306051e-10
transcripts O 0 2.511727181797596e-08
that O 0 9.35578614580379e-10
contain O 0 4.9138598967601865e-08
CUG O 0 0.00034563257941044867
repeats O 0 3.591812856029719e-06
. O 0 2.696700960314047e-07

Altered O 0 4.674252238601184e-07
expression O 0 9.31309926954782e-08
of O 0 7.583203398553451e-08
genes O 0 4.527116903574324e-09
regulated O 0 1.1332518923268253e-08
posttranscriptionally O 0 1.2968343980901409e-06
by O 0 6.290844289935649e-09
CUG O 1 0.9999368190765381
- O 0 2.5064900910365395e-05
BP O 0 8.769514352024999e-06
therefore O 0 1.0765203839468995e-08
may O 0 1.5481644854986598e-09
contribute O 0 5.937189850868663e-09
to O 0 1.0622696322570846e-07
DM B-Disease 1 1.0
pathogenesis O 0 0.0002518327964935452
. O 0 6.527038465264923e-08
. O 0 1.387126502550018e-07

Identification O 0 1.322207481280202e-07
of O 0 5.330954877535987e-08
a O 0 2.926105802103507e-09
novel O 0 5.636818123377907e-09
nonsense O 0 1.3234425466635003e-07
mutation O 0 3.6824370219790126e-09
and O 0 5.421138538075354e-11
a O 0 2.3276047755871332e-10
missense O 0 5.6540923054626546e-08
substitution O 0 1.1022659229809051e-08
in O 0 3.01005359526485e-10
the O 0 1.064708876619136e-09
vasopressin O 0 6.120554729704963e-08
- O 0 8.314759014638184e-08
neurophysin O 0 2.713940375542734e-06
II O 1 0.9418643116950989
gene O 0 1.9840606935161986e-09
in O 0 9.389461430586721e-11
two O 0 4.298349523534917e-11
Spanish O 0 2.2545831868114874e-08
kindreds O 0 6.622303772019222e-07
with O 0 1.78431069919327e-09
familial B-Disease 1 0.9751188158988953
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999997615814209
. O 0 1.4120893865765538e-05

Familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 3.834989001916256e-06
FNDI B-Disease 1 1.0
) O 0 1.5715100332158727e-09
is O 0 2.4973648149462235e-10
an O 0 3.5227759598299713e-10
autosomal B-Disease 1 0.999854326248169
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.012267876416444778
by O 0 8.54680095585536e-08
deficiency O 1 0.9997350573539734
in O 0 8.513756455386101e-08
the O 0 1.8646041155534476e-07
antidiuretic O 0 1.0635707212713896e-06
hormone O 0 3.6710705586529e-08
arginine O 0 1.5041243273117288e-07
vasopressin O 0 5.113281531521352e-07
( O 0 1.9498843428777946e-08
AVP O 0 1.2343672324277577e-06
) O 0 1.697987757343089e-11
encoded O 0 1.4515185060848257e-11
by O 0 5.38114657000488e-11
the O 0 7.214496999807807e-09
AVP O 0 4.908632490696618e-06
- O 0 6.150760327727767e-07
neurophysin O 0 2.054697870335076e-05
II O 1 0.999992847442627
( O 0 4.654754661714833e-07
AVP O 0 4.633778007701039e-05
- O 0 8.316073376590793e-07
NPII O 0 2.7569270969252102e-05
) O 0 1.0934099181625356e-09
gene O 0 2.2961397228016267e-09
on O 0 3.2654792647690556e-08
chromosome O 0 1.300613621424418e-05
20p13 O 0 0.00013754863175563514
. O 0 9.617473324396997e-07

In O 0 2.0894402652515964e-08
this O 0 9.569124381769711e-10
study O 0 1.6111295630949485e-09
, O 0 2.371078333673893e-10
we O 0 3.179747576353975e-10
analyzed O 0 7.396576684470801e-10
two O 0 2.3736020093867438e-11
families O 0 1.7716154931957107e-11
with O 0 6.796116447382872e-11
FNDI B-Disease 1 0.9999998807907104
using O 0 6.382663286785828e-09
direct O 0 1.9546581242479988e-08
automated O 0 5.1969454517575286e-08
fluorescent O 0 1.1689798462555245e-08
, O 0 4.0444561588692807e-10
solid O 0 4.005177078880706e-09
phase O 0 1.1273968425484782e-07
, O 0 5.754277054847989e-10
single O 0 2.0193067218343685e-09
- O 0 1.078740297089098e-08
stranded O 0 2.0381585308371086e-09
DNA O 0 5.427038263228212e-10
sequencing O 0 4.2326239735324123e-10
of O 0 2.9046196559079362e-09
PCR O 0 1.4382926849521027e-07
- O 0 3.1909260087559232e-06
amplified O 0 4.17342107539298e-06
AVP O 0 4.441440978553146e-05
- O 0 2.3643528948014136e-06
NPII O 0 0.00010069757263408974
DNA O 0 2.759872131719021e-06
. O 0 2.0937534372933442e-07

In O 0 1.3770480755681547e-08
one O 0 1.048727993335774e-09
of O 0 5.138160119599888e-09
the O 0 1.0779642733993455e-09
families O 0 1.2222876877299171e-10
, O 0 5.5860593928258595e-11
affected O 0 1.5208743986416806e-10
individuals O 0 2.272479253384585e-11
presented O 0 1.3029469725367449e-09
a O 0 7.292702552952335e-10
novel O 0 1.6048912199195797e-09
nonsense O 0 1.6690973936306364e-08
mutation O 0 2.668094190028114e-09
in O 0 4.905695988322023e-11
exon O 0 3.946468041249318e-09
3 O 0 2.4847608415257127e-09
of O 0 7.933203538534883e-10
the O 0 2.620132999453517e-10
gene O 0 1.2718437414349637e-10
, O 0 1.5610049711178853e-11
consisting O 0 9.95993131719386e-12
in O 0 7.644184590871461e-11
a O 0 3.8271936730893685e-09
G O 0 5.329124519448669e-07
to O 0 2.3789084480085876e-08
T O 0 1.391850787513249e-06
transition O 0 4.0183519445236016e-07
at O 0 3.9070592094958556e-08
nucleotide O 0 4.16765111310724e-08
2101 O 0 4.704510558894981e-07
, O 0 3.4863313624899916e-11
which O 0 6.504122327527506e-12
produces O 0 3.533447145986912e-11
a O 0 2.841877011494631e-10
stop O 0 4.2380143838727236e-09
signal O 0 2.312517288771687e-08
in O 0 1.0644063408449256e-09
codon O 0 8.072063195641022e-08
82 O 0 1.462269665353233e-07
( O 0 9.023567670851662e-09
Glu O 0 1.531545422039926e-06
) O 0 1.6607448749539344e-09
of O 0 7.471748375564857e-08
NPII O 0 0.006873965263366699
. O 0 1.3844928616890684e-06

The O 0 2.0727788978547323e-06
premature O 0 4.745592832477996e-06
termination O 0 1.0793360161187593e-06
eliminates O 0 3.158959316351684e-07
part O 0 2.087078243562246e-08
of O 0 1.1885979489534293e-07
the O 0 1.6377510902998438e-08
C O 0 4.208239715808304e-06
- O 0 5.5236213825082814e-08
terminal O 0 4.9076781749590737e-08
domain O 0 1.2823510253667791e-08
of O 0 5.320712315182163e-09
NPII O 0 5.2399369451450184e-05
, O 0 4.202786729745611e-10
including O 0 6.005988761881298e-11
a O 0 9.629672614863694e-10
cysteine O 0 1.7434292898244053e-09
residue O 0 8.019487296451189e-08
in O 0 1.4048816276979181e-10
position O 0 8.272881935056375e-09
85 O 0 5.859250862272347e-09
, O 0 1.5941629960547488e-11
which O 0 6.163278221116286e-12
could O 0 9.139542594960304e-11
be O 0 9.425167590837447e-11
involved O 0 1.4261755665323506e-10
in O 0 6.746098124565947e-11
the O 0 3.1005958911478615e-10
correct O 0 1.9275130824780717e-08
folding O 0 4.00844228920505e-08
of O 0 3.4803303350372516e-08
the O 0 9.342633688902424e-08
prohormone O 0 0.000304429791867733
. O 0 8.521616905454721e-07

In O 0 1.6859786455825088e-08
the O 0 6.778530625695112e-09
second O 0 8.377431015560433e-08
family O 0 9.380730636721069e-10
, O 0 7.272461105545247e-11
a O 0 5.592810659038605e-10
G279A O 0 1.8725697259469598e-07
substitution O 0 1.273051264405467e-08
at O 0 2.3522607861536926e-08
position O 0 2.1019916474074307e-08
- O 0 8.908867421553168e-09
1 O 0 5.989295459585264e-08
of O 0 2.3156674355817586e-09
the O 0 1.7089413217874494e-10
signal O 0 2.235646112680456e-09
peptide O 0 1.773639235480573e-09
was O 0 1.995910325902628e-09
observed O 0 6.507342442674258e-10
in O 0 1.850432654326717e-11
all O 0 2.2722799336571953e-11
affected O 0 3.1214650308974967e-10
individuals O 0 4.600283487476986e-10
. O 0 1.108399132476734e-07

This O 0 6.243617178824934e-08
missense O 0 1.3785501323582139e-05
mutation O 0 1.1224507261431427e-06
, O 0 1.973628371843006e-09
which O 0 9.16520859206571e-10
replaces O 0 7.587658501506667e-07
Ala O 0 3.099823970842408e-06
with O 0 1.1206254812989869e-09
Thr O 0 1.970851189980749e-05
, O 0 6.270907126904035e-10
is O 0 2.314297642413976e-10
frequent O 0 1.573225660855826e-09
among O 0 1.3190055270229095e-08
FNDI B-Disease 1 1.0
patients O 0 2.4884576532713254e-07
and O 0 1.7155096232457367e-09
is O 0 1.2771316226789509e-09
thought O 0 1.1377344621976704e-09
to O 0 1.7491573467420807e-10
reduce O 0 1.1430331126049964e-09
the O 0 2.7525773327319314e-10
efficiency O 0 1.6074400699395142e-09
of O 0 3.5892928629266407e-09
cleavage O 0 2.6156666166343712e-08
by O 0 7.245300470692939e-10
signal O 0 5.672000611411931e-07
peptidases O 0 2.4500227482349146e-06
. O 0 2.0159903968419712e-08
. O 0 1.1188559767560946e-07

Genetic O 0 6.78552578392555e-06
heterogeneity O 0 3.577214738470502e-05
of O 0 5.5090167734306306e-05
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.9258999728322124e-08
due O 0 3.547411324689165e-07
to O 0 8.755889346900858e-09
TWIST O 0 1.647291355766356e-05
and O 0 4.8732772484072484e-08
FGFR O 1 0.6888105869293213
mutations O 0 7.134568477340508e-06
. O 0 4.5588072339342034e-07

Thirty O 0 3.407999247428961e-05
- O 0 1.5668740616092691e-06
two O 0 6.645162198282151e-10
unrelated O 0 2.6575113665217032e-08
patients O 0 8.640346771393581e-11
with O 0 1.1768567891035087e-12
features O 0 5.8116633033789e-11
of O 0 2.557444815920462e-07
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 8.167704845796209e-10
a O 0 5.100350697340161e-10
common O 0 4.32003766093203e-08
autosomal B-Disease 1 0.9872753620147705
dominant I-Disease 1 0.9999988079071045
condition I-Disease 1 0.9999974966049194
of O 1 0.99998939037323
craniosynostosis B-Disease 1 1.0
and O 0 0.0027336275670677423
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9992669224739075
, O 0 1.1071051853051017e-09
were O 0 2.7018717818627636e-10
screened O 0 1.4226116951121526e-09
for O 0 4.242943843490998e-11
mutations O 0 1.6507464284387652e-09
in O 0 2.702840729007505e-10
TWIST O 0 2.7002674869436305e-06
, O 0 4.889260551976804e-09
FGFR2 O 0 0.21264377236366272
, O 0 1.057637533108391e-08
and O 0 3.0811971640787306e-08
FGFR3 O 1 0.9996694326400757
. O 0 7.32952094040229e-06

Nine O 0 3.612109935602348e-07
novel O 0 2.7428948001784192e-08
and O 0 3.062826658961626e-09
three O 0 5.952164872091714e-10
recurrent O 0 3.84942978826075e-07
TWIST O 0 4.080871349287918e-06
mutations O 0 6.437930011315984e-08
were O 0 7.859450312786009e-10
found O 0 9.031823205996048e-11
in O 0 1.0646412917925119e-10
12 O 0 3.5447573765168272e-09
families O 0 1.2254770531683334e-09
. O 0 5.762883148463516e-08

Seven O 0 5.011818871025753e-08
families O 0 6.642197347694889e-10
were O 0 8.367969095424144e-10
found O 0 2.1009634310065195e-10
to O 0 1.1251568426962066e-10
have O 0 6.9507961886206e-11
the O 0 1.3632386330897361e-09
FGFR3 O 0 0.0062480950728058815
P250R O 0 9.004878847918008e-06
mutation O 0 4.600340730576136e-08
, O 0 7.219749104114825e-11
and O 0 2.042234784060959e-11
one O 0 3.022213729275691e-11
individual O 0 3.700349922308721e-12
was O 0 3.3257829823440943e-09
found O 0 6.916332784268064e-11
to O 0 9.266733907997704e-11
have O 0 9.941033413118916e-11
an O 0 1.3472691851035279e-09
FGFR2 O 0 0.0011129778577014804
VV269 O 0 6.964666681597009e-05
- O 0 3.21100014843978e-06
270 O 0 3.2574953934272344e-07
deletion O 0 3.1839254006627016e-06
. O 0 2.0081428431240056e-07

To O 0 6.770522276156044e-08
date O 0 8.351678957296826e-07
, O 0 1.1878547034882558e-09
our O 0 1.8141033120144812e-10
detection O 0 9.677403767227588e-09
rate O 0 1.2609291388798738e-09
for O 0 8.918159266624315e-11
TWIST O 0 1.1490500355648692e-06
or O 0 2.7288784565371316e-08
FGFR O 0 0.001095408690162003
mutations O 0 3.55481368785604e-08
is O 0 2.607261073706013e-10
68 O 0 7.374211019595123e-09
% O 0 1.4970563677607629e-09
in O 0 9.451108645697204e-11
our O 0 4.666619979332154e-09
Saethre B-Disease 1 0.9999995231628418
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.3446871172106967e-08
, O 0 1.3175607826987346e-10
including O 0 1.1482505918314345e-10
our O 0 2.2407604660656943e-09
five O 0 6.765842885947393e-10
patients O 0 1.0920359755361986e-10
elsewhere O 0 3.675733328822872e-10
reported O 0 8.283899122218941e-10
with O 0 2.2464852200698715e-10
TWIST O 0 2.0407078409334645e-05
mutations O 0 2.3655618406337453e-06
. O 0 2.503143150534015e-07

More O 0 4.423537092179686e-09
than O 0 1.1965022306270612e-09
35 O 0 4.677616516346461e-09
different O 0 1.6616557088622308e-11
TWIST O 0 1.0951224282962357e-07
mutations O 0 9.417234991815349e-09
are O 0 1.7565216642312365e-11
now O 0 4.406042891647033e-11
known O 0 1.8094793718947955e-10
in O 0 5.252343351913602e-11
the O 0 4.089298899501159e-10
literature O 0 2.1698332020037014e-08
. O 0 5.2109609072203966e-08

The O 0 2.966079932775756e-07
most O 0 9.883829310552983e-10
common O 0 6.930148677142256e-10
phenotypic O 0 2.1285629259182315e-08
features O 0 4.100575087817582e-11
, O 0 2.8750182790027168e-11
present O 0 3.421521746482803e-11
in O 0 7.048922209818009e-12
more O 0 3.1325956368830066e-13
than O 0 2.548153745299264e-12
a O 0 7.842825000548004e-11
third O 0 4.023814170750484e-09
of O 0 2.6956652465770503e-09
our O 0 4.0150874291988714e-10
patients O 0 1.1640431674120322e-11
with O 0 3.7914987989495774e-12
TWIST O 0 1.1329447033858742e-06
mutations O 0 1.1856668180598717e-07
, O 0 2.9566010750770033e-10
are O 0 7.46790476680026e-11
coronal B-Disease 0 0.0006264631520025432
synostosis I-Disease 0 0.00014432866009883583
, O 0 2.1555719431631815e-09
brachycephaly B-Disease 0 7.101103619788773e-06
, O 0 2.609739979675396e-09
low B-Disease 0 1.572665678395424e-05
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 2.183777041864232e-06
facial B-Disease 1 0.9999454021453857
asymmetry I-Disease 1 0.9999959468841553
, O 0 3.279160978308937e-07
ptosis B-Disease 1 0.9997405409812927
, O 0 3.6534405722932206e-08
hypertelorism B-Disease 0 8.7932770838961e-05
, O 0 9.6053360820747e-09
broad B-Disease 0 7.95593859947985e-06
great I-Disease 0 0.0001464280649088323
toes I-Disease 0 0.00028378673596307635
, O 0 1.4204866616296385e-08
and O 0 3.720803931628325e-08
clinodactyly B-Disease 0 0.002064801985397935
. O 0 2.7028540898754727e-06

Significant O 0 8.022428664844483e-05
intra O 1 0.9930353164672852
- O 0 0.0006714515620842576
and O 0 4.768148187395127e-08
interfamilial O 0 4.8415175115223974e-05
phenotypic O 0 2.6956747660733527e-06
variability O 0 6.298840162344277e-06
is O 0 3.3119562647954126e-10
present O 0 1.184062847769951e-10
for O 0 1.334621024806637e-10
either O 0 1.3494738659858285e-08
TWIST O 0 1.147328566730721e-05
mutations O 0 6.412176958292548e-07
or O 0 1.789876478142105e-07
FGFR O 1 0.9513915777206421
mutations O 0 9.121317816607188e-06
. O 0 3.2925794357652194e-07

The O 0 2.872995139568957e-07
overlap O 0 2.0238466902355867e-07
in O 0 7.534610158010935e-10
clinical O 0 5.93817484073611e-09
features O 0 1.782227143642956e-11
and O 0 3.69949071377107e-11
the O 0 1.811178290678228e-10
presence O 0 8.51018838732287e-11
, O 0 1.1480046947787148e-11
in O 0 3.422812597589364e-12
the O 0 5.950024761086636e-12
same O 0 1.0574623642012337e-11
genes O 0 7.704840238043076e-12
, O 0 1.5710821315781387e-12
of O 0 3.4879009402910555e-11
mutations O 0 4.659322233591112e-11
for O 0 2.0237145292867353e-12
more O 0 7.222771100830194e-13
than O 0 2.8408241037336524e-11
one O 0 1.6486310927543713e-10
craniosynostotic B-Disease 0 6.15883664067951e-07
condition I-Disease 0 9.605376050103587e-08
- O 0 4.4151500233624574e-09
such O 0 7.530828044499671e-11
as O 0 6.75923872428541e-10
Saethre B-Disease 0 7.739319585198245e-07
- I-Disease 0 5.1898727093657726e-08
Chotzen I-Disease 0 1.781538571776764e-06
, I-Disease 0 8.208654311836483e-10
Crouzon I-Disease 0 1.753607466525864e-05
, I-Disease 0 5.4136424232353875e-09
and I-Disease 0 1.7625012560529285e-08
Pfeiffer I-Disease 0 0.00021587034279946238
syndromes I-Disease 0 0.00014623398601543158
- O 0 8.076880817498022e-07
support O 0 1.1115235842851234e-08
the O 0 4.9361390530577864e-09
hypothesis O 0 2.2522277376424427e-08
that O 0 3.439870263632905e-11
TWIST O 0 5.6415967009115775e-08
and O 0 1.4652241919765885e-10
FGFRs O 0 1.127334527950552e-07
are O 0 9.23479261810689e-12
components O 0 5.12699716015419e-10
of O 0 9.110863730121821e-10
the O 0 1.9344427448775292e-10
same O 0 1.599292226428517e-10
molecular O 0 2.6082072057675987e-09
pathway O 0 1.0009074680183971e-09
involved O 0 2.5443282897219532e-11
in O 0 4.405292970688368e-12
the O 0 2.3257661421749454e-11
modulation O 0 2.365759321776295e-08
of O 0 1.7319399603366037e-07
craniofacial O 1 0.9999998807907104
and O 0 7.101294841049821e-07
limb O 1 0.9999995231628418
development O 0 6.527947107315413e-07
in O 0 4.252378449365324e-09
humans O 0 4.976904222075973e-09
. O 0 2.545524679931077e-09
. O 0 3.689757832603391e-08

Mutation O 0 1.1030844859760691e-07
analysis O 0 1.1850853631756308e-08
of O 0 9.709871164886863e-07
UBE3A O 1 1.0
in O 1 0.9868636131286621
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0025248441379517317
. O 0 1.2405839697748888e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0002702201309148222
AS B-Disease 1 1.0
) O 0 4.704368894437039e-09
is O 0 4.877233616973342e-10
caused O 0 3.662061542897277e-09
by O 0 7.920095690394646e-10
chromosome O 0 1.968668402696494e-05
15q11 O 0 6.961677718209103e-05
- O 0 5.545890076064097e-07
q13 O 0 1.5579813634758466e-06
deletions O 0 9.49630951652125e-09
of O 0 1.3126759235149166e-08
maternal O 0 4.0986577687363024e-08
origin O 0 3.0821301066907836e-09
, O 0 1.232017543539854e-10
by O 0 2.0156806779247916e-10
paternal O 0 3.4059896734106587e-06
uniparental B-Disease 1 0.9964510202407837
disomy I-Disease 1 0.9998250603675842
( O 0 1.276907823921647e-06
UPD B-Disease 1 1.0
) O 0 1.892864309738229e-09
15 O 0 1.4175628448853672e-09
, O 0 1.2560359870239513e-11
by O 0 8.156599701214517e-11
imprinting O 0 4.542835813481361e-05
defects O 0 0.17279136180877686
, O 0 3.603524700857008e-10
and O 0 1.1190401383309734e-10
by O 0 1.5159654087604224e-10
mutations O 0 9.716540461113254e-09
in O 0 1.8579817684383215e-09
the O 0 8.182306743265144e-08
UBE3A O 0 0.0007439331966452301
gene O 0 1.031668261930463e-06
. O 0 4.323261180161353e-07

UBE3A O 0 0.009744162671267986
encodes O 0 8.443665819868329e-07
a O 0 8.178125909807932e-08
ubiquitin O 0 1.485392203903757e-06
- O 0 5.470307087307447e-07
protein O 0 1.0316505871799109e-08
ligase O 0 6.811917696580849e-09
and O 0 1.3629838369055847e-09
shows O 0 5.573038919237661e-09
brain O 0 3.3797807645896683e-06
- O 0 2.5141150672425283e-07
specific O 0 8.087689451485858e-08
imprinting O 0 4.327452552388422e-05
. O 0 8.190049811673816e-07

Here O 0 1.497379003012611e-06
we O 0 4.795674612978473e-08
describe O 0 2.1155447882392764e-07
UBE3A O 0 0.00037566595710814
coding O 0 1.9765919205383398e-05
- O 0 6.4073255998664536e-06
region O 0 1.2534768529803841e-06
mutations O 0 5.4756835510261226e-08
detected O 0 6.63346444440549e-09
by O 0 9.394369310244954e-11
SSCP O 0 2.5219935196219012e-05
analysis O 0 1.1912125730262346e-09
in O 0 1.8954211811195165e-10
13 O 0 2.460515124980134e-09
AS B-Disease 0 0.0013762087328359485
individuals O 0 1.4764373057474245e-10
or O 0 3.6080176624153637e-09
families O 0 2.987764702311324e-09
. O 0 4.8469878777268605e-08

Two O 0 6.496583893067509e-08
identical O 0 4.461423586121782e-08
de O 0 4.4138951125205494e-06
novo O 0 3.053675027331337e-05
5 O 0 3.1573893011227483e-06
- O 0 9.166874974653183e-07
bp O 0 5.953334039077163e-07
duplications O 0 3.48379160186596e-07
in O 0 8.679832852465097e-09
exon O 0 1.874485207054022e-07
16 O 0 2.996566550450552e-08
were O 0 5.1877910856035214e-09
found O 0 1.2348301936526695e-08
. O 0 8.66235581042929e-08

Among O 0 1.0728435739792985e-07
the O 0 1.2074084843050059e-08
other O 0 2.1896122415210328e-10
11 O 0 7.902411502946904e-10
unique O 0 8.307470683588392e-11
mutations O 0 4.496583994040293e-09
, O 0 5.344714115729232e-10
8 O 0 1.7172881783267258e-08
were O 0 7.635634902136701e-10
small O 0 4.2811934553022013e-10
deletions O 0 1.1485101758523797e-08
or O 0 8.486789937478534e-09
insertions O 0 1.1207718131345246e-07
predicted O 0 1.6921907786127122e-07
to O 0 1.5885249782243704e-09
cause O 0 3.9913913951750146e-07
frameshifts O 0 9.144183422904462e-05
, O 0 5.761899291023553e-10
1 O 0 3.113577662361422e-08
was O 0 3.063457709728823e-09
a O 0 1.2228985879492171e-10
mutation O 0 1.4833952122206284e-10
to O 0 5.693822843766405e-11
a O 0 6.388981010907457e-10
stop O 0 3.6469636199853994e-09
codon O 0 1.5418148535673026e-08
, O 0 1.232170337983618e-10
1 O 0 9.3675041057395e-09
was O 0 2.160107648307985e-09
a O 0 2.344558713840428e-10
missense O 0 2.817146160793982e-08
mutation O 0 9.50036849189928e-09
, O 0 1.006107488987773e-10
and O 0 1.1730393045805698e-10
1 O 0 9.931495981163607e-08
was O 0 4.3070222943697445e-08
predicted O 0 2.7417126347017984e-08
to O 0 2.847373170578038e-10
cause O 0 2.52069565220836e-09
insertion O 0 1.4487602228996366e-08
of O 0 4.0463042694227624e-08
an O 0 2.0296087033244703e-09
isoleucine O 0 1.6068622699094703e-06
in O 0 2.2259438736682569e-10
the O 0 9.94949900245956e-10
hect O 0 5.001959380024346e-07
domain O 0 4.267802822255362e-08
of O 0 1.6661202195678015e-08
the O 0 8.731690037677708e-09
UBE3A O 0 1.7219121218658984e-05
protein O 0 5.334267694223627e-09
, O 0 1.0614958564914012e-11
which O 0 4.911817046843181e-12
functions O 0 1.1393300192175104e-10
in O 0 1.8316122230022103e-10
E2 O 0 1.821577484406589e-07
binding O 0 3.442809415332704e-08
and O 0 6.688705589397159e-09
ubiquitin O 0 5.771159408141102e-07
transfer O 0 7.101855317159789e-06
. O 0 1.9263868580310373e-06

Eight O 0 8.981879062730513e-08
of O 0 2.5619799615128613e-08
the O 0 7.858581008157728e-10
cases O 0 2.753595962357025e-10
were O 0 5.418442361460052e-10
familial O 0 2.4910741558414884e-07
, O 0 2.3449846509038252e-09
and O 0 8.048195443421946e-10
five O 0 2.531550968853935e-09
were O 0 5.521459289781205e-09
sporadic O 0 2.72794494549089e-07
. O 0 2.2885993189447618e-07

In O 0 6.945651165324307e-08
two O 0 1.4686748484038503e-09
familial O 0 1.947665623447392e-06
cases O 0 1.4262176328827536e-08
and O 0 1.819745909514836e-09
one O 0 8.620959501826064e-10
sporadic O 0 1.4587423713408043e-08
case O 0 5.2898290192615605e-09
, O 0 2.905404805630951e-10
mosaicism O 0 2.573067831690423e-06
for O 0 1.7485979331155477e-09
UBE3A O 0 9.805151785258204e-05
mutations O 0 1.765162416234034e-08
was O 0 5.525673252293473e-09
detected O 0 4.0885267393875324e-10
in O 0 5.691604739593847e-12
the O 0 2.8320219433441984e-11
mother O 0 2.021192761769708e-11
of O 0 3.837102857673358e-10
three O 0 1.4393665426215563e-10
AS B-Disease 1 0.9999994039535522
sons O 0 1.960984086224471e-08
, O 0 8.98244412878002e-12
in O 0 5.891021611498237e-12
the O 0 6.414509895469322e-11
maternal O 0 4.3795709281369e-09
grandfather O 0 1.4559375927092333e-08
of O 0 2.7797300461429586e-08
two O 0 9.318493754406632e-10
AS B-Disease 1 0.9999885559082031
first O 0 3.745445731340169e-09
cousins O 0 5.707572636737268e-09
, O 0 1.4849768983915546e-11
and O 0 6.34031932858492e-12
in O 0 1.3766469734999287e-11
the O 0 9.927239585927339e-11
mother O 0 1.1293192769823435e-10
of O 0 1.6037039474170456e-09
an O 0 1.62824431715336e-09
AS B-Disease 1 1.0
daughter O 0 1.1423552678024862e-05
. O 0 1.1503383348099305e-06

The O 0 7.084114628241878e-08
frequencies O 0 2.3410889227193366e-08
with O 0 2.5768054356944958e-11
which O 0 3.164078166140172e-10
we O 0 5.017773418991567e-10
detected O 0 3.232053735757745e-09
mutations O 0 1.1479489581134317e-09
were O 0 1.9178883481352216e-10
5 O 0 1.6795586033069299e-09
( O 0 1.2158191120548167e-10
14 O 0 1.5255614549403163e-09
% O 0 3.4990571551318794e-10
) O 0 1.876449169657679e-11
of O 0 6.686508569053728e-10
35 O 0 3.7002638730854187e-09
in O 0 4.8960023535382646e-11
sporadic O 0 2.220733152924481e-09
cases O 0 1.6719922668606557e-10
and O 0 1.331871973819787e-10
8 O 0 5.171391759262178e-09
( O 0 1.4092185751657382e-10
80 O 0 1.8449649585861039e-09
% O 0 3.0614233370585e-10
) O 0 1.5631530791981874e-11
of O 0 4.670696052144763e-10
10 O 0 8.309883892110292e-10
in O 0 1.1868801774728155e-10
familial O 0 1.0454196797127224e-07
cases O 0 7.135425139637164e-09
. O 0 1.9776310367092265e-08
. O 0 1.6727680929307098e-07

The O 0 2.560984830779489e-05
hemochromatosis B-Disease 1 0.9999998807907104
845 O 0 2.076444616250228e-05
G O 0 4.102485036128201e-06
- O 0 2.3864438958298706e-07
- O 0 6.959933074313085e-08
> O 0 9.067669282103452e-08
A O 0 2.382636488107437e-08
and O 0 3.0932240102643505e-10
187 O 0 8.415105834380654e-10
C O 0 6.598726542961231e-08
- O 0 4.4516482944345626e-08
- O 0 7.741106600178682e-08
> O 0 5.057075895820162e-07
G O 0 3.7306890021682193e-07
mutations O 0 1.0580975207119536e-08
: O 0 2.458843961772317e-10
prevalence O 0 1.2512412439491527e-08
in O 0 4.3596498633391434e-10
non O 0 2.7495607923810894e-07
- O 0 1.5600539882143494e-06
Caucasian O 0 3.985172043030616e-06
populations O 0 4.414747678538333e-08
. O 0 4.842810952254695e-08

Hemochromatosis B-Disease 1 0.9999610185623169
, O 0 8.993536226853394e-08
the O 0 2.236954060208518e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9929670095443726
, O 0 2.9069697760064628e-09
leads O 0 1.2128140269851428e-08
, O 0 4.137273301729749e-10
if O 0 1.6539082992039766e-08
untreated O 0 0.0008245842182077467
, O 0 1.7289504550266344e-10
to O 0 2.5199218267601964e-09
progressive O 1 0.8431272506713867
iron B-Disease 1 0.9936410784721375
overload I-Disease 0 0.0013612753245979548
and O 0 8.510979654374751e-08
premature B-Disease 0 2.6236662961309776e-05
death I-Disease 0 6.165586910356069e-06
. O 0 7.569084914393898e-07

The O 0 2.530905658204574e-05
hemochromatosis B-Disease 1 1.0
gene O 0 1.0181225661654025e-05
, O 0 7.021093040293636e-08
HFE O 1 0.9999986886978149
, O 0 3.652451141533675e-08
recently O 0 8.270105489316393e-09
has O 0 1.1715590997329883e-10
been O 0 6.518394851662279e-11
identified O 0 2.1870828759151806e-10
, O 0 4.530521791057396e-12
and O 0 3.1696080222270995e-12
characterization O 0 3.0228222147599126e-09
of O 0 2.666094900405369e-09
this O 0 1.0237012626479469e-10
gene O 0 6.75690559059916e-10
has O 0 1.040893239656615e-11
shown O 0 4.706820870559181e-12
that O 0 1.4344702726001857e-12
it O 0 2.8981404949501854e-12
contains O 0 9.319514777950122e-12
two O 0 1.2002655813692087e-11
mutations O 0 3.780771251626902e-10
that O 0 3.00550868914673e-11
result O 0 3.657873115514576e-09
in O 0 2.568672163860697e-09
amino O 0 8.91949447634488e-09
acid O 0 2.081539385301312e-09
substitutions O 0 1.2870673415932288e-09
- O 0 4.982507739725861e-09
cDNA O 0 7.349357566965864e-09
nucleotides O 0 3.119536573503723e-10
845 O 0 2.121816944367083e-09
G O 0 6.345095115989352e-09
- O 0 4.01505895197829e-09
- O 0 4.386995211547173e-09
> O 0 2.1587823084701085e-08
A O 0 3.3383045661139477e-08
( O 0 8.44084191431449e-10
C282Y O 0 1.5278676812613412e-07
) O 0 5.0844776305902784e-11
and O 0 3.440657481146303e-11
187 O 0 8.224890768460114e-10
C O 0 5.231385458159821e-08
- O 0 4.7377699985418076e-08
- O 0 1.1282368461706938e-07
> O 0 9.683164989837678e-07
G O 0 1.972851805476239e-06
( O 0 2.720039304904276e-08
H63D O 0 0.00027876353124156594
) O 0 7.310731575671525e-08
. O 0 2.546510131651303e-07

Although O 0 1.3337921700440347e-05
hemochromatosis B-Disease 1 1.0
is O 0 1.0107963532846043e-07
common O 0 4.0753803887128015e-08
in O 0 6.9894370291478936e-09
Caucasians O 0 7.993760391400428e-07
, O 0 5.935012481472768e-10
affecting O 0 3.672736115234443e-09
> O 0 3.8511851130351715e-07
= O 0 8.52537525020125e-08
1 O 0 5.456556664285017e-07
/ O 0 6.416122033670035e-08
300 O 0 5.66754802810987e-11
individuals O 0 4.83053137420586e-12
of O 0 1.6624554510791256e-10
northern O 0 1.0914804615680396e-09
European O 0 2.14452833269263e-09
origin O 0 1.5290309018922699e-09
, O 0 1.786018034855008e-11
it O 0 2.8949418817009187e-12
has O 0 3.4404193903492253e-12
not O 0 8.786993702103452e-12
been O 0 2.1459745438989763e-11
recognized O 0 5.6101904372107825e-11
in O 0 6.038518990392205e-11
other O 0 7.060470957886977e-11
populations O 0 9.761116359641164e-10
. O 0 1.6349794407233276e-08

The O 0 1.9574868304061965e-07
present O 0 9.11298947414707e-09
study O 0 7.836114535031413e-10
used O 0 5.634576139001979e-11
PCR O 0 1.041331132434209e-09
and O 0 1.5146936482857143e-10
restriction O 0 3.536026138561965e-09
- O 0 3.677993465345253e-09
enzyme O 0 2.2811311173320803e-10
digestion O 0 4.0213798957466906e-10
to O 0 2.980436383803742e-11
analyze O 0 1.3386439179363663e-10
the O 0 5.7816564036361484e-11
frequency O 0 3.6297187477885018e-09
of O 0 1.2547489713909954e-09
the O 0 8.452135102920977e-10
845 O 0 8.81746231584657e-09
G O 0 1.94777687312353e-08
- O 0 1.1863721560700924e-08
- O 0 8.471297441303705e-09
> O 0 1.3155885270066392e-08
A O 0 7.001004664886068e-09
and O 0 1.1636642344159398e-10
187 O 0 4.5296968953500993e-10
C O 0 1.5844468848058568e-08
- O 0 8.373577387033038e-09
- O 0 2.5864409280984546e-08
> O 0 1.6311987849348952e-07
G O 0 1.3786623753730964e-07
mutations O 0 4.371125683633181e-09
in O 0 1.4409550219696143e-09
HLA O 0 1.3989421177029726e-07
- O 0 4.387229690649974e-09
typed O 0 8.796426920198996e-10
samples O 0 2.3508982954778546e-11
from O 0 8.412180674266523e-11
non O 0 1.6612176523267408e-08
- O 0 2.0706272252368763e-08
Caucasian O 0 4.912801188083904e-08
populations O 0 3.2445535147473947e-10
, O 0 9.131104726500805e-12
comprising O 0 3.655100527799604e-11
Australian O 0 7.287835335212378e-10
Aboriginal O 0 6.206850589052237e-10
, O 0 2.477550976875964e-11
Chinese O 0 1.0940645611690059e-10
, O 0 2.9356747588416e-10
and O 0 1.9425334674139094e-09
Pacific O 0 7.49565685964626e-07
Islanders O 0 1.733592171149212e-06
. O 0 2.286326150624518e-07

Results O 0 8.016648394004733e-07
showed O 0 2.7420892223517512e-08
that O 0 3.5636080197853914e-10
the O 0 3.3357316908677603e-09
845 O 0 5.8321933948946025e-08
G O 0 1.1635815155841556e-07
- O 0 3.7511810546675406e-08
- O 0 1.6786627199394388e-08
> O 0 2.291293732525901e-08
A O 0 3.9668823781369156e-09
mutation O 0 3.126757963656246e-09
was O 0 7.073198693419158e-10
present O 0 5.5726083469931353e-11
in O 0 1.7969934568151658e-11
these O 0 3.6706293386756794e-12
populations O 0 2.2356781356758226e-11
( O 0 1.736835848753504e-11
allele O 0 4.2656336796120797e-10
frequency O 0 3.0711684306794496e-09
0 O 0 7.258800227560869e-10
. O 0 1.1852462587780277e-11
32 O 0 3.6061786889973746e-10
% O 0 2.0334010863987118e-10
) O 0 1.2865873297296382e-11
, O 0 1.6993030246825747e-11
and O 0 1.4766533482091226e-11
, O 0 2.715965473354398e-11
furthermore O 0 5.529107727220151e-10
, O 0 2.1698134608505448e-11
it O 0 1.5997370095277574e-11
was O 0 6.520764816997371e-09
always O 0 3.828111716508431e-10
seen O 0 2.4939234011256417e-10
in O 0 1.6030052285564977e-11
conjunction O 0 3.217971999980307e-10
with O 0 3.0958682839532514e-10
HLA O 0 1.6893905922188424e-05
haplotypes O 0 8.05537538894896e-08
common O 0 3.0872842060603034e-09
in O 0 1.0546876705319619e-09
Caucasians O 0 7.329762041763388e-08
, O 0 1.0752018719806244e-10
suggesting O 0 6.939910868197785e-10
that O 0 1.2018445960659818e-10
845 O 0 4.666844688472338e-08
G O 0 1.0988180747517617e-06
- O 0 5.08881214500434e-07
- O 0 2.2412324085507862e-07
> O 0 3.0690301855429425e-07
A O 0 7.03098308463268e-08
may O 0 2.629596540515422e-09
have O 0 3.6970218553200596e-11
been O 0 1.5488985094513907e-11
introduced O 0 5.143466381973827e-12
into O 0 7.921991188042377e-12
these O 0 2.6323512597112297e-13
populations O 0 4.451927975573922e-12
by O 0 6.515188388789284e-11
Caucasian O 0 4.872538852396247e-07
admixture O 0 8.886146133590955e-06
. O 0 7.385502271972655e-07

187 O 0 8.817901289148722e-07
C O 0 2.162464170396561e-06
- O 0 2.8339536584098823e-07
- O 0 1.716182254085652e-07
> O 0 5.083666110294871e-07
G O 0 1.6320467466357513e-07
was O 0 4.087124860774338e-09
present O 0 1.369142715867966e-10
at O 0 6.500519011964911e-10
an O 0 1.672377340777853e-11
allele O 0 1.147725581240877e-09
frequency O 0 2.46109834733943e-08
of O 0 5.0990720978916215e-08
2 O 0 3.3175535918417154e-06
. O 0 3.603487641612446e-07

68 O 0 1.6388143194490112e-05
% O 0 2.590055316886719e-07
in O 0 1.078132916276786e-09
the O 0 1.882294098365378e-09
two O 0 1.8393002398919833e-10
populations O 0 2.4707333401430276e-10
analyzed O 0 1.888173173369978e-09
( O 0 4.443974632728498e-10
Australian O 0 4.544107312653978e-09
Aboriginal O 0 7.423457959454538e-10
and O 0 6.138574371039596e-11
Chinese O 0 3.9632574999615144e-10
) O 0 9.272077550193103e-10
. O 0 2.345737470932363e-08

In O 0 1.0841118580628972e-07
the O 0 2.867831661035325e-08
Australian O 0 9.39394873000765e-09
Aboriginal O 0 1.768083013331534e-09
samples O 0 2.9615438573715736e-11
, O 0 1.1054455094361426e-11
187 O 0 4.299671729768306e-10
C O 0 5.237026101667652e-08
- O 0 2.7737085517287596e-08
- O 0 6.815559316919462e-08
> O 0 3.177378005148057e-07
G O 0 2.1263053895381745e-07
was O 0 5.428127725082277e-09
found O 0 3.665887732262618e-11
to O 0 2.5612723747459043e-11
be O 0 1.9980120335993945e-10
associated O 0 3.90680421347156e-09
with O 0 1.5595363889175928e-09
HLA O 0 0.16455811262130737
haplotypes O 0 1.8867670803501824e-07
common O 0 3.628355171869657e-09
in O 0 1.0084846291391614e-09
Caucasians O 0 1.0757367618907665e-07
, O 0 3.026159184349453e-11
suggesting O 0 1.8538991175542918e-10
that O 0 7.390364362147572e-12
it O 0 1.0233220520960984e-11
was O 0 4.2067882510821164e-10
introduced O 0 3.1395556293611904e-11
by O 0 6.368926913635775e-11
recent O 0 1.7437351562676895e-09
admixture O 0 7.822143288649386e-07
. O 0 5.109012022330717e-07

In O 0 1.3701321677217493e-07
the O 0 1.9934915940211795e-08
Chinese O 0 1.3060968973022113e-09
samples O 0 1.4060451414277253e-10
analyzed O 0 3.139215831726716e-10
, O 0 1.808498489852539e-11
187 O 0 4.5135006843111114e-10
C O 0 2.856754477420509e-08
- O 0 1.0553281803993286e-08
- O 0 1.9050860444735918e-08
> O 0 9.130703659820938e-08
G O 0 5.0636579373986024e-08
was O 0 1.4573787732174992e-09
present O 0 8.336072804260297e-11
in O 0 4.781693097033468e-11
association O 0 6.59896859378506e-11
with O 0 6.806764353550765e-12
a O 0 1.7990393619271572e-09
wide O 0 5.149534132442568e-08
variety O 0 6.727678858453601e-09
of O 0 6.88160241679725e-07
HLA O 0 0.00027866149321198463
haplotypes O 0 7.27351192608694e-08
, O 0 6.550563563800793e-11
showing O 0 1.9247109114828298e-11
this O 0 3.717611721937297e-12
mutation O 0 5.489436682992732e-11
to O 0 2.3018028455501494e-11
be O 0 1.1092309015747759e-10
widespread O 0 1.9220933733521406e-09
and O 0 7.892705933265631e-11
likely O 0 2.0080761498064703e-09
to O 0 1.55425050607505e-09
predate O 0 2.1182277976095065e-07
the O 0 1.5417112031457236e-09
more O 0 5.110163334154372e-11
genetically O 0 6.631082904995367e-10
restricted O 0 7.223857068083817e-10
845 O 0 2.1300170516269645e-08
G O 0 1.5278196485724038e-07
- O 0 1.7318342315775226e-07
- O 0 1.6317355289174884e-07
> O 0 3.587946650895901e-07
A O 0 2.6712328349276504e-07
mutation O 0 3.7554914911197557e-07
. O 0 1.3245399088646082e-07

Genotype O 0 0.00017802957154344767
- O 0 2.5960151106119156e-05
phenotype O 0 9.184823284158483e-07
correlations O 0 3.697955662573804e-06
in O 0 2.112464301262662e-07
attenuated B-Disease 1 0.9925364255905151
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 0.00010531662701396272

Germ O 0 0.0024006764870136976
- O 0 9.503572073299438e-06
line O 0 3.620949655669392e-07
mutations O 0 2.3431036666465843e-08
of O 0 1.2964872730947263e-08
the O 0 4.090751737351184e-09
tumor B-Disease 0 8.96346136869397e-07
suppressor O 0 5.374054580897791e-06
APC O 0 1.2790684422725462e-07
are O 0 2.959935629931465e-10
implicated O 0 3.6294164829087094e-07
in O 0 4.869393421813584e-08
attenuated B-Disease 1 0.9999191761016846
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.00024822558043524623
AAPC B-Disease 1 1.0
) O 0 8.143034579966013e-10
, O 0 5.1936874939650934e-11
a O 0 1.310518221719903e-10
variant O 0 2.7684581027642707e-07
of O 0 0.00179672718513757
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 5.9562538808677346e-05
FAP B-Disease 0 3.1194947951007634e-05
) O 0 4.543849385640897e-08
. O 0 1.6866741248122707e-07

AAPC B-Disease 1 1.0
is O 0 4.663489860945447e-08
recognized O 0 3.0232429892862456e-09
by O 0 2.0811177781077106e-10
the O 0 1.2761770529223782e-09
occurrence O 0 3.415489402414096e-08
of O 0 2.2924307074845274e-07
< O 0 0.0005901571712456644
100 O 0 1.2888962430679385e-07
colonic B-Disease 0 7.157814980018884e-05
adenomas I-Disease 0 1.2551523468573578e-05
and O 0 1.5681857201688132e-10
a O 0 3.508018042719385e-10
later O 0 9.039881732064714e-09
onset O 0 0.0010682863648980856
of O 1 0.7548995018005371
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.543759964306446e-08
age O 0 2.949980739685998e-07
> O 0 8.655601391183154e-08
40 O 0 7.608162100325444e-09
years O 0 1.4206729126442497e-09
) O 0 6.805758734351741e-10
. O 0 1.0905321978782467e-08

The O 0 5.0533149220655105e-08
aim O 0 8.792073913355125e-08
of O 0 1.2315794606365671e-08
this O 0 3.0467786626964255e-10
study O 0 2.845103874715704e-10
was O 0 1.5352817905878169e-09
to O 0 2.6570676214809907e-10
assess O 0 1.2968237150801087e-08
genotype O 0 8.345660376107844e-07
- O 0 1.3690862488147104e-06
phenotype O 0 2.1325337229427532e-07
correlations O 0 1.4932206795492675e-06
in O 0 8.493077530147275e-08
AAPC B-Disease 1 1.0
families O 0 6.77989078212704e-08
. O 0 2.4152123501153255e-07

By O 0 4.9710056515550605e-08
protein O 0 7.645391519872646e-08
- O 0 4.3572018881832264e-08
truncation O 0 4.5344557975113275e-07
test O 0 2.4105705875854255e-08
( O 0 2.8725215539537885e-09
PTT O 0 6.370090090968006e-07
) O 0 8.199355083782223e-11
assay O 0 2.472172022649488e-09
, O 0 2.2943601879488185e-11
the O 0 4.925619634388312e-11
entire O 0 8.165150222616546e-10
coding O 0 8.90572504630427e-09
region O 0 2.0118340771091425e-08
of O 0 1.4600895603678055e-08
the O 0 5.054681118110693e-09
APC B-Disease 0 2.797665743514699e-08
gene O 0 2.550641087228911e-10
was O 0 3.8924766188053184e-10
screened O 0 3.6373404288525535e-10
in O 0 1.172211112898669e-11
affected O 0 6.525983226035592e-11
individuals O 0 9.044718446427069e-11
from O 0 9.550042534556269e-08
11 O 0 3.729604486579774e-06
AAPC B-Disease 1 1.0
kindreds O 0 3.632177322288044e-05
, O 0 2.83367285192071e-09
and O 0 7.02332358937241e-10
their O 0 2.515819219617299e-10
phenotypic O 0 2.5198420416927547e-07
differences O 0 2.37978952100093e-07
were O 0 3.0422640406868595e-08
examined O 0 8.180853683370515e-07
. O 0 2.364318447689584e-07

Five O 0 2.3927472625473456e-07
novel O 0 1.5081892001944652e-07
germ O 0 1.261534089280758e-05
- O 0 9.501936233391461e-07
line O 0 2.915551249316195e-07
APC B-Disease 0 2.3075720889664808e-07
mutations O 0 9.33660970758865e-09
were O 0 7.879233376861805e-10
identified O 0 3.3594711457141102e-09
in O 0 1.6271420877345122e-09
seven O 0 2.5913788448406194e-08
kindreds O 0 1.845821680035442e-05
. O 0 5.308875188347884e-07

Mutations O 0 1.0158248642255785e-06
were O 0 6.9506578270761565e-09
located O 0 2.6175768219616202e-09
in O 0 3.911542270640389e-11
three O 0 3.934451722753529e-12
different O 0 1.7317672903333081e-12
regions O 0 4.4655137920734944e-10
of O 0 2.5650981338998236e-09
the O 0 2.699771295411324e-09
APC B-Disease 0 1.0536226113799785e-08
gene O 0 2.9296393089239814e-10
( O 0 4.1324523664121315e-11
1 O 0 1.0962171614892213e-08
) O 0 4.0098431519641764e-11
at O 0 1.6334918973015533e-09
the O 0 1.2050811737385203e-10
5 O 0 1.4178576090984052e-09
end O 0 3.6530063418638292e-09
spanning O 0 1.7114384576188968e-08
exons O 0 2.1613036693679533e-08
4 O 0 2.707702728699246e-09
and O 0 7.40636996177102e-11
5 O 0 3.061775277757306e-09
, O 0 1.357824824799181e-10
( O 0 2.17976151017929e-10
2 O 0 6.000762109437119e-09
) O 0 2.103416225918142e-11
within O 0 2.9100136189619263e-10
exon O 0 2.952804001310483e-09
9 O 0 2.777089669336874e-09
, O 0 4.485392265940469e-11
and O 0 1.1462374105430939e-10
( O 0 3.81341985766781e-10
3 O 0 1.3713133739656769e-08
) O 0 1.1692062595880515e-10
at O 0 3.769741852011066e-09
the O 0 9.146348123323378e-10
3 O 0 2.2524083931330097e-08
distal O 0 5.17016189860442e-07
end O 0 7.02061129231879e-08
of O 0 5.448450934864013e-08
the O 0 3.0615900925567985e-08
gene O 0 6.228416538078818e-08
. O 0 1.0067422806514514e-07

Variability O 0 0.00031557679176330566
in O 0 5.930986812785477e-09
the O 0 2.8581481625877814e-09
number O 0 3.3196989601691484e-09
of O 0 4.1387462260900065e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.00027369504095986485
most O 0 2.3646648528163894e-10
apparent O 0 8.38254266000149e-09
in O 0 1.4507434316357593e-11
individuals O 0 3.2075208374754416e-12
with O 0 2.047959891948725e-12
mutations O 0 7.382330746708021e-09
in O 0 7.819407343845342e-10
region O 0 1.915545226438553e-06
1 O 0 0.0011341586941853166
, O 0 2.978052693336508e-09
and O 0 4.343152504304726e-09
upper O 1 0.9507952928543091
- O 0 0.003207958536222577
gastrointestinal O 0 1.839902688516304e-05
manifestations O 0 1.3103318451612722e-05
were O 0 3.1920117660177993e-09
more O 0 5.667645172624525e-11
severe O 0 4.558337352023045e-08
in O 0 1.4617160815078023e-09
them O 0 9.953978752363923e-10
. O 0 4.570020450955781e-08

In O 0 1.1651778208943142e-08
individuals O 0 6.154990961348972e-10
with O 0 8.424014263930246e-11
mutations O 0 2.0075180628964517e-08
in O 0 9.261225675238904e-10
either O 0 2.3208333033153394e-08
region O 0 8.261301900347462e-07
2 O 0 7.398247703349625e-07
or O 0 8.765280057332347e-09
region O 0 1.0421924656611736e-07
3 O 0 4.185431734526901e-08
, O 0 1.1734689608910998e-10
the O 0 1.4540905979298913e-10
average O 0 1.8223150766161211e-10
number O 0 1.4716014518079135e-10
of O 0 7.714644922884872e-09
adenomas B-Disease 0 8.474082278553396e-06
tended O 0 5.324753082902589e-09
to O 0 2.613494698433527e-10
be O 0 4.444008494530749e-10
lower O 0 2.6636095551424432e-09
than O 0 3.627680100759534e-11
those O 0 8.793365341430714e-12
in O 0 3.642008569726407e-12
individuals O 0 1.209466663106007e-12
with O 0 1.7221818589263638e-12
mutations O 0 9.907874520820315e-10
in O 0 9.46985614924678e-11
region O 0 1.5733313318833098e-08
1 O 0 1.0565893404645976e-07
, O 0 5.312138229296437e-11
although O 0 7.760550535529376e-11
age O 0 3.1501155017821247e-09
at O 0 5.022649851582628e-09
diagnosis O 0 4.5457220210209925e-08
was O 0 1.0254434634759946e-08
similar O 0 3.76152531345042e-09
. O 0 1.520917294328683e-07

In O 0 1.006719003271428e-06
all O 0 4.4812560417994973e-07
AAPC B-Disease 1 1.0
kindreds O 0 5.707236414309591e-05
, O 0 1.2018773754007839e-09
a O 0 1.0933725036466058e-09
predominance O 0 9.851573850028217e-07
of O 0 2.158179268008098e-05
right O 1 0.9999998807907104
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9989450573921204
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999473094940186
sparing O 0 2.883260094677098e-06
was O 0 1.1773641972467885e-06
observed O 0 1.1119650622504196e-07
. O 0 4.524633112623633e-08

No O 0 8.748914842726663e-05
desmoid B-Disease 1 0.9999994039535522
tumors I-Disease 1 1.0
were O 0 2.0463716055019177e-07
found O 0 3.222144107084546e-09
in O 0 6.564550014687143e-10
these O 0 1.6951547943122591e-09
kindreds O 0 1.6790148947620764e-05
. O 0 4.3384025616433064e-07

Our O 0 1.5425833055360272e-07
data O 0 3.92549281968968e-09
suggest O 0 1.5203850400880015e-09
that O 0 1.340685618078652e-10
, O 0 6.317172895897727e-10
in O 0 5.719450690833128e-09
AAPC B-Disease 1 1.0
families O 0 1.4055256958300788e-09
, O 0 9.039820281220301e-11
the O 0 1.0360686614196979e-10
location O 0 3.2755831380626432e-09
of O 0 1.3014027189228727e-08
the O 0 1.6711426908955218e-08
APC B-Disease 0 1.1581826129258843e-06
mutation O 0 5.28472924088419e-07
may O 0 2.824845957150046e-08
partially O 0 1.8517988564781263e-07
predict O 0 1.1341236927364662e-07
specific O 0 1.6209012798640288e-08
phenotypic O 0 2.5646502308518393e-06
expression O 0 7.211005481622124e-07
. O 0 2.673088204119267e-07

This O 0 1.2788874848013165e-08
should O 0 5.145280201901414e-09
help O 0 2.8697272336231094e-10
in O 0 7.105024207865185e-11
the O 0 6.114501960308161e-11
design O 0 6.251608120066976e-10
of O 0 1.4343163323715657e-09
tailored O 0 1.9064372303034816e-09
clinical O 0 4.1562128672012477e-07
- O 0 2.2052439874187257e-07
management O 0 1.004078331590108e-08
protocols O 0 5.974771255523592e-08
in O 0 2.674502563859704e-10
this O 0 6.435919158720438e-11
subset O 0 3.529653369582775e-08
of O 0 3.0984946164380744e-08
FAP B-Disease 0 5.561116722674342e-07
patients O 0 2.661928455438556e-09
. O 0 6.581025946417185e-09
. O 0 1.2512143143794674e-07

Wilms B-Disease 1 0.9999923706054688
' I-Disease 0 7.144190749386325e-05
tumor I-Disease 0 0.00013413258420769125
1 O 0 8.876500032783952e-06
and O 0 5.08436848178917e-08
Dax O 0 0.006169263739138842
- O 0 6.967862304918526e-07
1 O 0 4.1132324213322136e-07
modulate O 0 8.638114223913362e-09
the O 0 2.4667650144749587e-09
orphan O 0 9.565935599198383e-09
nuclear O 0 2.708043211896438e-07
receptor O 0 2.940282115559967e-07
SF O 0 8.868020086083561e-05
- O 0 2.3295929452160635e-07
1 O 0 3.883981491981103e-08
in O 0 1.307307595510565e-10
sex O 0 1.3929946085511347e-10
- O 0 1.530313931130678e-10
specific O 0 1.2898190848709135e-10
gene O 0 1.3588307146150669e-09
expression O 0 2.3287082484557686e-08
. O 0 5.146460679839038e-08

Products O 0 1.6192178975416027e-07
of O 0 2.720706788750249e-07
steroidogenic O 0 4.3510815885383636e-05
factor O 0 3.787625360018865e-07
1 O 0 4.674506328683492e-07
( O 0 2.5347979271117538e-09
SF O 0 0.0019150986336171627
- O 0 1.4543052202498075e-06
1 O 0 4.6543283360733767e-07
) O 0 2.626828199403519e-10
and O 0 9.60527657412058e-10
Wilms B-Disease 0 0.0005327272228896618
tumor I-Disease 0 9.388250327901915e-05
1 O 0 1.908535750771989e-06
( O 0 1.2033620322426941e-08
WT1 O 0 2.2904559955350123e-06
) O 0 5.002779301932492e-10
genes O 0 2.3231561119274602e-10
are O 0 9.450436093405568e-12
essential O 0 4.699963196408419e-10
for O 0 2.314906738520861e-10
mammalian O 0 8.57887840766125e-08
gonadogenesis O 0 7.614821129209304e-07
prior O 0 2.3769489487790452e-08
to O 0 7.765059706343891e-09
sexual O 0 5.297788518987545e-08
differentiation O 0 1.9127651285089087e-06
. O 0 2.1006293593472947e-07

In O 0 6.792252094101059e-08
males O 0 3.314525187647632e-08
, O 0 5.2916862003371534e-09
SF O 0 0.4017997980117798
- O 0 1.5019046259112656e-05
1 O 0 2.3748609692120226e-06
participates O 0 4.686957932875657e-09
in O 0 1.286323131344247e-10
sexual O 0 2.1332266508800046e-10
development O 0 1.1082749995505736e-10
by O 0 2.276305532955547e-11
regulating O 0 6.0066365215050155e-09
expression O 0 5.357045917975256e-09
of O 0 1.1575865599411372e-08
the O 0 6.610742175894302e-09
polypeptide O 0 5.783307983620034e-07
hormone O 0 3.0305289389076506e-09
Mullerian O 0 7.263363244192078e-08
inhibiting O 0 1.7782197048177295e-08
substance O 0 6.517657880067418e-08
( O 0 7.069088425737391e-09
MIS O 0 0.00016385513299610466
) O 0 1.4615913812576764e-08
. O 0 7.191967910102903e-08

Here O 0 3.689962113639922e-07
, O 0 6.091739113145422e-09
we O 0 2.4204656057236207e-09
show O 0 6.434695554169423e-10
that O 0 4.302584122317654e-10
WT1 O 0 2.6769330361275934e-05
- O 0 6.184596713865176e-06
KTS O 0 0.0006876335828565061
isoforms O 0 1.6218390896938217e-07
associate O 0 2.8160503262597558e-08
and O 0 6.316426270913666e-10
synergize O 0 1.1366748253749392e-07
with O 0 1.2615594124909535e-09
SF O 1 0.6422373056411743
- O 0 2.4047765236900887e-06
1 O 0 4.818073193746386e-07
to O 0 1.0886908263785244e-08
promote O 0 9.302181780412866e-08
MIS O 0 0.0004423040372785181
expression O 0 1.0084158930112608e-06
. O 0 6.21768037945003e-07

In O 0 9.067375827953583e-08
contrast O 0 1.5897268212938798e-07
, O 0 6.698500243373928e-08
WT1 O 0 0.00039921863935887814
missense O 0 2.2775113393436186e-05
mutations O 0 5.5035764034983e-07
, O 0 3.1969821234767437e-10
associated O 0 1.8039874039033066e-09
with O 0 1.1142798489460759e-10
male B-Disease 0 2.7482572662052007e-08
pseudohermaphroditism I-Disease 1 1.0
in O 0 6.546662945083881e-08
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.4734179387687618e-07
fail O 0 1.1844095979540725e-06
to O 0 3.574912810222486e-08
synergize O 0 2.305582256667549e-06
with O 0 1.9771935200196822e-08
SF O 1 0.9999889135360718
- O 0 0.00015324103878811002
1 O 0 2.8784834285033867e-05
. O 0 4.1145352724925033e-07

Additionally O 0 1.4971691086884675e-07
, O 0 2.145751576421162e-09
the O 0 1.7764663073904785e-09
X O 0 7.389317033812404e-06
- O 0 5.086425289846375e-07
linked O 0 7.144593183738834e-08
, O 0 1.2256892722994905e-10
candidate O 0 2.2984885106325237e-09
dosage O 0 2.489794042048743e-07
- O 0 4.2220090534783594e-08
sensitive O 0 3.288900884967916e-08
sex O 0 6.975129918096457e-10
- O 0 1.7337000723927076e-09
reversal O 0 3.690853844773301e-09
gene O 0 1.4998429165302696e-09
, O 0 1.5337393577397052e-09
Dax O 0 0.00014758339966647327
- O 0 5.447317334983381e-07
1 O 0 2.5762772111193044e-06
, O 0 2.082822136983964e-09
antagonizes O 0 1.1605095551203704e-07
synergy O 0 4.89355471700037e-08
between O 0 7.559693671055356e-08
SF O 0 0.0023018200881779194
- O 0 4.143667240441573e-07
1 O 0 1.564423826039274e-07
and O 0 3.171957974057449e-10
WT1 O 0 9.069759698832058e-07
, O 0 4.1701975206365205e-11
most O 0 3.795579735926813e-12
likely O 0 1.5921276796948547e-10
through O 0 1.0180190891662111e-11
a O 0 1.1059522048162407e-10
direct O 0 1.7284765840841487e-09
interaction O 0 4.927879881932995e-09
with O 0 1.6490155907433746e-09
SF O 1 0.9949204325675964
- O 0 3.472619573585689e-05
1 O 0 1.3657186173077207e-05
. O 0 2.222514581262658e-07

We O 0 1.418192852042921e-07
propose O 0 1.6264485225292447e-07
that O 0 5.4735926902083065e-09
WT1 O 0 0.0001517555065220222
and O 0 2.2976925606599252e-07
Dax O 0 0.018249057233333588
- O 0 3.9609645341442956e-07
1 O 0 1.5461799307558977e-07
functionally O 0 5.9557105913654595e-09
oppose O 0 1.3924825736921775e-09
each O 0 4.8410393749254155e-11
other O 0 1.2652451135408693e-11
in O 0 9.557245272961978e-11
testis O 0 7.825412495776618e-08
development O 0 4.75638972652348e-10
by O 0 3.2496197399645155e-10
modulating O 0 5.014487101107079e-07
SF O 0 0.010973851196467876
- O 0 3.7806278214702616e-06
1 O 0 2.244946927021374e-06
- O 0 1.2552145278732496e-07
mediated O 0 5.564097591559403e-07
transactivation O 0 3.1694805784354685e-06
. O 0 1.3451232128147694e-08
. O 0 2.5486061261403847e-08

A O 0 5.321872436070407e-07
mouse O 0 2.0510757536840174e-08
model O 0 1.1193486137983655e-08
for O 0 1.8549344815710356e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.9999983310699463
centre O 0 0.0002814807230606675
mutations O 0 6.040259904693812e-06
. O 0 5.647663101626677e-07

Imprinting O 0 4.083039311808534e-05
in O 0 3.881337917732708e-08
the O 0 4.963312605354986e-08
15q11 O 0 0.0001456600584788248
- O 0 2.7878118089574855e-06
q13 O 0 1.1214127880521119e-05
region O 0 2.45498483764095e-08
involves O 0 1.175023855992663e-09
an O 0 1.5708979950179724e-10
imprinting O 0 5.662947160089971e-07
centre O 0 2.269737109372727e-07
( O 0 8.661636408113793e-10
IC O 0 6.119252248026896e-06
) O 0 6.13499528956396e-10
, O 0 8.595374412223578e-11
mapping O 0 1.3020798883545126e-09
in O 0 3.8472728475236195e-11
part O 0 2.5039376128077606e-10
to O 0 4.6169498779669027e-10
the O 0 2.243394803258525e-09
promoter O 0 2.1391670088632964e-06
and O 0 1.8443879756802062e-09
first O 0 1.547731187656609e-08
exon O 0 3.9368623561131244e-07
of O 0 7.160022050811676e-07
SNRPN O 1 0.9968656897544861
. O 0 4.485340468818322e-06

Deletion O 0 3.247013592044823e-05
of O 0 5.512033567356411e-07
this O 0 9.03767460869176e-09
IC O 0 0.0004276552645023912
abolishes O 0 7.64254218665883e-06
local O 0 4.265733544173145e-09
paternally O 0 1.320792986092556e-08
derived O 0 3.0142419116252483e-10
gene O 0 7.445660754612504e-11
expression O 0 1.3767158246746902e-10
and O 0 2.2343054489892822e-11
results O 0 4.178424273248993e-10
in O 0 4.029868350130528e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.8941749334335327
PWS B-Disease 1 1.0
) O 0 7.876608378865058e-07
. O 0 1.0261370562147931e-06

We O 0 2.0416815971202595e-07
have O 0 6.280542752534757e-10
created O 0 1.611867306294812e-09
two O 0 3.3828098655597216e-10
deletion O 0 3.0112343551991216e-07
mutations O 0 5.760882970662351e-08
in O 0 1.3268471876770604e-09
mice O 0 2.6437381173138874e-09
to O 0 6.003083030670098e-10
understand O 0 3.324310853258794e-07
PWS B-Disease 1 1.0
and O 0 3.2478306710714833e-09
the O 0 1.8357297904003644e-09
mechanism O 0 6.132553576065902e-09
of O 0 9.661652811132626e-09
this O 0 6.961550447215359e-09
IC O 0 0.0001428175310138613
. O 0 6.052410981283174e-07

Mice O 0 1.6754558600950986e-05
harbouring O 0 1.668282857281156e-05
an O 0 1.755951473114692e-08
intragenic O 0 0.00016151083400472999
deletion O 0 2.9808401450281963e-05
in O 0 2.1420602180910464e-08
Snrpn O 0 0.11280740797519684
are O 0 2.8818396557994674e-09
phenotypically O 0 7.937787813716568e-06
normal O 0 8.100642645558764e-08
, O 0 2.2250185027772318e-10
suggesting O 0 7.364058807191043e-10
that O 0 2.702942557275545e-11
mutations O 0 3.890638033965388e-09
of O 0 3.0182434329617536e-08
SNRPN O 1 0.6623975038528442
are O 0 1.1367100316572731e-10
not O 0 2.632214446407488e-10
sufficient O 0 2.7235940169845207e-09
to O 0 9.727666672176838e-09
induce O 0 1.4841777556284796e-05
PWS B-Disease 1 1.0
. O 0 1.8875258319894783e-05

Mice O 0 4.1841903453132545e-07
with O 0 1.6537142488726175e-10
a O 0 1.8686507896603644e-09
larger O 0 4.782153784077536e-09
deletion O 0 9.798655753456842e-08
involving O 0 4.63168170483641e-09
both O 0 1.7161837506662891e-09
Snrpn O 0 1.4503310922009405e-05
and O 0 2.7697155680073138e-09
the O 0 3.254771385741151e-08
putative O 0 3.925840792362578e-05
PWS O 1 1.0
- O 0 0.00012856662215199322
IC O 0 0.0005243783816695213
lack O 0 6.858554257860305e-08
expression O 0 1.1112014419722982e-08
of O 0 1.3119100472636092e-08
the O 0 3.017839089736185e-09
imprinted O 0 1.934149373994387e-08
genes O 0 5.249514600791372e-09
Zfp127 O 0 1.0322883099433966e-06
( O 0 4.474048076463788e-10
mouse O 0 6.472006042201883e-09
homologue O 0 2.3356103895366687e-07
of O 0 5.2167482778031626e-08
ZNF127 O 0 0.012039829976856709
) O 0 7.058485351763011e-09
, O 0 5.984976958472998e-09
Ndn O 0 1.9745608369703405e-05
and O 0 1.2586855113738693e-08
Ipw O 0 7.37669552108855e-07
, O 0 1.6050044626680915e-09
and O 0 7.224187359433643e-10
manifest O 0 1.840544250342191e-08
several O 0 4.2004302813758443e-10
phenotypes O 0 2.4351738403538548e-08
common O 0 3.4751298727542235e-08
to O 0 1.3376367178352666e-06
PWS B-Disease 1 1.0
infants O 0 0.0005243573687039316
. O 0 1.3140910368747427e-06

These O 0 3.1382834109194846e-09
data O 0 1.8711259208714637e-09
demonstrate O 0 4.3344938749356743e-10
that O 0 1.0380085679884132e-11
both O 0 1.9969441031331137e-11
the O 0 1.7804273333421605e-10
position O 0 3.0762279390472713e-09
of O 0 9.566952785533545e-10
the O 0 2.1241645942193799e-10
IC O 0 7.217417419269623e-07
and O 0 6.369267613326457e-11
its O 0 2.612745610142131e-11
role O 0 6.341241420848576e-11
in O 0 4.53487074281167e-12
the O 0 7.5670069168976e-12
coordinate O 0 9.099396930389858e-11
expression O 0 7.699104132008472e-10
of O 0 1.741408572897285e-09
genes O 0 2.7747903974528754e-10
is O 0 1.2525144116315445e-11
conserved O 0 3.410122184632769e-10
between O 0 2.544455479647212e-10
mouse O 0 1.9664139205843867e-09
and O 0 6.987296852223324e-11
human O 0 2.6447000145424227e-10
, O 0 1.6086623352840057e-11
and O 0 8.980217611198604e-12
indicate O 0 1.4844453444240457e-10
that O 0 5.657123207380987e-12
the O 0 1.0713983172871977e-10
mouse O 0 1.996899451350842e-10
is O 0 6.099123810165974e-12
a O 0 7.054167579928494e-12
suitable O 0 1.4802353787146671e-10
model O 0 3.27401855626519e-11
system O 0 1.529633919528095e-10
in O 0 2.80841842836832e-11
which O 0 1.677866352800539e-11
to O 0 9.123101579744386e-11
investigate O 0 7.20665416231725e-10
the O 0 9.324783306619011e-11
molecular O 0 2.0436239367427333e-09
mechanisms O 0 1.0778183900939098e-09
of O 0 1.5237119344035932e-09
imprinting O 0 5.931793367608407e-08
in O 0 2.7679065636720956e-11
this O 0 1.8733381165758622e-11
region O 0 3.0663920291829072e-09
of O 0 5.0418171859689664e-09
the O 0 1.5858669932811154e-09
genome O 0 1.2531711668373191e-08
. O 0 1.932588533648527e-09
. O 0 2.287167433223658e-08

Mutations O 0 1.2511790146163548e-06
of O 0 3.979100142714742e-07
the O 0 2.7823187309650166e-08
ATM O 0 0.0037999970372766256
gene O 0 2.9293126146967552e-08
detected O 0 7.994105999387102e-08
in O 0 2.7931856827478896e-09
Japanese O 0 0.24338442087173462
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 7.646049198228866e-06
: O 0 4.943052633876732e-10
possible O 0 5.5512372476584915e-09
preponderance O 0 2.1943205297247914e-07
of O 0 8.045007326984432e-09
the O 0 9.853748927923789e-10
two O 0 1.0191464339115441e-10
founder O 0 2.994389802779551e-08
mutations O 0 4.5048786034840305e-08
4612del165 O 0 8.595003237132914e-06
and O 0 4.909709616640612e-08
7883del5 O 0 0.00025072594871744514
. O 0 1.3507223002307e-06

The O 0 5.165509833204851e-07
ATM O 0 0.3767440617084503
( O 0 2.7704943477147026e-06
A O 1 1.0
- O 1 1.0
T O 1 1.0
, O 0 8.596202860644553e-09
mutated O 0 3.4638980572765377e-09
) O 0 9.733149702872979e-11
gene O 0 4.028849753812125e-10
on O 0 3.7922709417159695e-09
human O 0 7.1004793156248525e-09
chromosome O 0 1.9899942344636656e-05
11q22 O 0 0.00012952099496033043
. O 0 6.754913783879601e-07

3 O 0 7.3758201324380934e-06
has O 0 3.651132729487472e-09
recently O 0 2.362412265810576e-09
been O 0 3.4296779305442726e-10
identified O 0 2.6479407555513035e-10
as O 0 1.3291102593515625e-11
the O 0 2.2406599145541328e-11
gene O 0 4.5481347854536835e-11
responsible O 0 4.2101516717352183e-10
for O 0 8.784250410398542e-11
the O 0 9.483024143719376e-09
human O 0 2.6820202947419602e-06
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.06027306988835335
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 7.794755418899513e-08
. O 0 1.2067549448602222e-07

In O 0 6.7554917215773e-09
order O 0 1.0019810536832097e-09
to O 0 4.4327322368253874e-10
define O 0 1.2871145926851568e-08
the O 0 3.370521639567414e-10
types O 0 3.4893017364368006e-09
of O 0 5.9580887779020486e-08
disease O 0 3.675713287520921e-06
- O 0 7.270404722703461e-08
causing O 0 4.165187306170992e-08
ATM O 0 6.676113844150677e-05
mutations O 0 1.2016785788659945e-08
in O 0 4.552094534648887e-10
Japanese O 0 4.6446800183730375e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.5983813161923877e-09
as O 0 5.980166362107298e-11
well O 0 2.899623943730667e-11
as O 0 1.8546799512852985e-11
to O 0 3.853544566778666e-11
look O 0 7.658486345096804e-11
for O 0 9.417477214723746e-11
possible O 0 2.5336682085708162e-08
mutational O 0 7.80523714638548e-06
hotspots O 0 4.387981107356609e-07
, O 0 2.57115106983008e-10
reverse O 0 5.837910599382212e-09
- O 0 3.278664673089793e-09
transcribed O 0 1.1444292180584625e-09
RNA O 0 1.1273570965641966e-09
derived O 0 3.0491317803971185e-11
from O 0 2.6170846739725917e-11
ten O 0 7.60200444260839e-11
patients O 0 3.439291169568537e-12
belonging O 0 3.859760427937786e-11
to O 0 2.572920869414741e-11
eight O 0 1.636353552658676e-10
unrelated O 0 2.508288465818964e-09
Japanese O 0 1.4548194826602412e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
families O 0 3.361405320756461e-10
was O 0 2.4764950090627735e-09
analyzed O 0 1.0434108022039368e-09
for O 0 3.064564921273494e-11
mutations O 0 1.196266696812387e-10
by O 0 2.587408932941404e-11
the O 0 2.9915439569982993e-10
restriction O 0 1.8427810388743637e-09
endonuclease O 0 6.33573762343076e-08
fingerprinting O 0 2.7038336014584274e-08
method O 0 4.162153999232032e-08
. O 0 3.5020647715100495e-08

As O 0 2.8268345886317547e-08
has O 0 6.297659616016915e-10
been O 0 9.451540938787417e-11
reported O 0 4.62436824943957e-11
by O 0 1.3952249078297285e-11
others O 0 1.6834930671727477e-10
, O 0 6.541336222687377e-11
mutations O 0 6.485162962199809e-10
that O 0 1.491048534640882e-10
lead O 0 2.7301942928659173e-09
to O 0 7.421989689504471e-09
exon O 0 1.755601829245279e-06
skipping O 0 1.0230434099867125e-06
or O 0 4.0253667066281196e-08
premature O 0 1.0572021835741907e-07
protein O 0 3.543351390078442e-09
truncation O 0 1.287463788912646e-07
were O 0 6.791067153066876e-10
also O 0 1.4216020027824072e-10
predominant O 0 1.082297451659997e-08
in O 0 5.773461153602e-10
our O 0 3.774267121059438e-09
mutants O 0 7.797194712111377e-08
. O 0 3.8618502173903835e-08

Six O 0 1.3757984973494786e-08
different O 0 8.856945732382826e-11
mutations O 0 1.4680082704998654e-09
were O 0 1.99690319835355e-10
identified O 0 9.159424330107413e-10
on O 0 3.1528024635463225e-09
12 O 0 1.820884665271194e-09
of O 0 2.069224569467565e-09
the O 0 3.63931995650546e-09
16 O 0 5.0191854228387456e-08
alleles O 0 5.1780077114926826e-08
examined O 0 7.372314598796947e-07
. O 0 3.034576820937218e-07

Four O 0 3.813721960455041e-08
were O 0 3.881905907832106e-09
deletions O 0 4.107469564473831e-08
involving O 0 7.462444884254182e-09
a O 0 7.165333659742146e-09
loss O 0 1.6575090455717145e-07
of O 0 5.423002562565671e-07
a O 0 3.185268582228673e-08
single O 0 2.5288208860274608e-08
exon O 0 8.704440546125625e-08
exon O 0 1.8265335199885158e-07
7 O 0 1.240172053940114e-07
, O 0 2.062002790736983e-09
exon O 0 1.4204303511178296e-07
16 O 0 7.116481270941222e-08
, O 0 5.6754831945227124e-09
exon O 0 5.222184427111642e-07
33 O 0 2.3166985840816778e-07
or O 0 1.3791225228487747e-07
exon O 0 6.138974185887491e-06
35 O 0 3.450216127021122e-06
. O 0 5.712388428946724e-07

The O 0 2.537126704282855e-07
others O 0 8.380064642210527e-09
were O 0 4.535535058636242e-09
minute O 0 2.0616310791865544e-07
deletions O 0 1.8385414080057672e-07
, O 0 4.227986405425099e-09
4649delA O 0 3.3519273756610346e-07
in O 0 5.607050823641657e-09
exon O 0 3.9578458199684974e-07
33 O 0 1.2206679400605935e-07
and O 0 4.218400739830486e-09
7883del5 O 0 1.3186367141315714e-05
in O 0 5.8065531050033314e-08
exon O 0 5.856030384165933e-06
55 O 0 1.921553803185816e-06
. O 0 2.420506746148021e-07

The O 0 4.2551315004857315e-07
mutations O 0 7.914906632322527e-07
4612del165 O 0 2.427494473522529e-05
and O 0 6.366467797391806e-09
7883del5 O 0 1.2866532415500842e-05
were O 0 1.8434982429482716e-09
found O 0 4.0653282823432946e-11
in O 0 1.4783969404588704e-12
more O 0 1.2243438413713642e-13
than O 0 1.7781517360968002e-12
two O 0 8.498630401851393e-13
unrelated O 0 7.615429120644279e-11
families O 0 2.087516140850121e-12
; O 0 8.714589813663132e-12
44 O 0 1.771046309606561e-09
% O 0 7.998460227476301e-10
( O 0 1.0636894143267739e-10
7 O 0 1.0246242965195052e-08
of O 0 2.812752919467698e-09
16 O 0 1.987969788785904e-09
) O 0 2.298880877327214e-11
of O 0 3.2180028086692403e-10
the O 0 2.0605117612149115e-10
mutant O 0 8.376624394124121e-10
alleles O 0 2.38728758983342e-10
had O 0 1.4849380058912232e-10
one O 0 2.0534605266187e-11
of O 0 4.474167425438935e-10
the O 0 6.274448738352589e-10
two O 0 1.182636988339425e-09
mutations O 0 2.763915460946009e-07
. O 0 2.5539983994349313e-07

The O 0 6.149493287921359e-07
4612del165 O 0 5.4559710406465456e-05
mutations O 0 2.74692091295492e-08
in O 0 6.935169799549001e-11
three O 0 2.3162472374133047e-12
different O 0 4.672969910329838e-13
families O 0 2.0346753795696948e-12
were O 0 1.3022350558999918e-11
all O 0 5.827911504080463e-12
ascribed O 0 8.050207167542567e-10
to O 0 6.686581149883963e-11
the O 0 1.4208727250331066e-10
same O 0 7.421815939601117e-10
T O 0 1.9151924490756755e-08
- O 0 1.4820193960929373e-08
- O 0 9.173573012333236e-09
> O 0 1.3362728701338256e-08
A O 0 4.55425919199115e-09
substitution O 0 4.4346117888949266e-09
at O 0 3.4492027012333892e-09
the O 0 1.966705409639502e-10
splice O 0 3.6323939411886386e-08
donor O 0 5.18963227946756e-09
site O 0 1.4921452518024125e-08
in O 0 1.2615697819740035e-08
intron O 0 4.875474041909911e-05
33 O 0 6.601498171221465e-06
. O 0 8.795862527222198e-07

Microsatellite O 0 0.0003401739813853055
genotyping O 0 3.787556579482043e-06
around O 0 5.6553512983725795e-09
the O 0 2.174630031603897e-09
ATM O 0 4.40174244431546e-06
locus O 0 2.842747903741838e-07
also O 0 1.0637501990373721e-10
indicated O 0 7.021314640809351e-10
that O 0 7.135169191596624e-12
a O 0 1.495431695142102e-10
common O 0 9.488121399670035e-10
haplotype O 0 7.109235866664676e-07
was O 0 1.0259267213541534e-08
shared O 0 4.6384489998940737e-11
by O 0 1.6978840208792256e-11
the O 0 3.569036455264296e-10
mutant O 0 1.584905318097185e-09
alleles O 0 3.474370791067827e-10
in O 0 9.122022581742328e-11
both O 0 1.0022295215961208e-09
mutations O 0 3.868508144933003e-07
. O 0 2.2095765928042965e-07

This O 0 9.572196368878849e-09
suggests O 0 1.5584873835905455e-08
that O 0 4.8154660814425654e-11
these O 0 2.106523809553007e-11
two O 0 8.59383397777691e-11
founder O 0 5.1429868364039066e-08
mutations O 0 7.655106770698694e-09
may O 0 2.248929931170096e-09
be O 0 1.2537897386977193e-09
predominant O 0 5.5956117961386553e-08
among O 0 2.2416914158274182e-10
Japanese O 0 1.2423377881987108e-08
ATM O 0 5.477879312820733e-06
mutant O 0 3.856116848055535e-07
alleles O 0 1.8971165616221697e-07
. O 0 6.78709710655312e-08

W474C O 0 0.00025395702687092125
amino O 0 2.1866142674298317e-07
acid O 0 5.671068059598383e-09
substitution O 0 5.828531435270179e-09
affects O 0 1.3067498194629934e-09
early O 0 1.078943490107065e-09
processing O 0 2.1107084968718937e-09
of O 0 1.9523880290250872e-09
the O 0 4.6552206534045126e-10
alpha O 0 2.327765757925704e-09
- O 0 8.508467541634701e-11
subunit O 0 3.078814980739253e-10
of O 0 2.6230231875423726e-10
beta O 0 1.4693480210326015e-08
- O 0 2.9838009840688073e-09
hexosaminidase O 0 3.818256288923294e-08
A O 0 1.5140706466354459e-09
and O 0 2.178230859573027e-11
is O 0 3.3362757001498267e-11
associated O 0 4.995599489632241e-10
with O 0 1.9370678672192554e-10
subacute O 0 0.055865578353405
G B-Disease 0 0.0007727127522230148
( I-Disease 0 4.024675703817593e-08
M2 I-Disease 0 4.755712870974094e-05
) I-Disease 0 4.600358138873162e-08
gangliosidosis I-Disease 0 5.330739440978505e-05
. O 0 8.758128728914016e-07

Mutations O 0 6.195502351147297e-07
in O 0 7.648495170542446e-09
the O 0 1.944818173171825e-08
HEXA O 0 2.943838080682326e-05
gene O 0 1.4251292368427926e-09
, O 0 3.706949677773075e-11
encoding O 0 1.5291408417272834e-10
the O 0 3.563390693628321e-10
alpha O 0 9.34881061454007e-10
- O 0 4.0307385901217074e-11
subunit O 0 1.8599946582931182e-10
of O 0 1.8666122814092745e-10
beta O 0 9.758626795530745e-09
- O 0 3.285224980942303e-09
hexosaminidase O 0 7.365822085603213e-08
A O 0 4.7797307445307524e-08
( O 0 1.3327570158594426e-09
Hex O 0 1.0554291662856485e-07
A O 0 2.146583888418263e-08
) O 0 1.12374561045403e-10
, O 0 3.644929497115257e-11
that O 0 3.859178948628639e-11
abolish O 0 1.2546591676709795e-07
Hex O 0 3.4574253504615626e-07
A O 0 1.2880454924868445e-08
enzyme O 0 3.168258988495154e-09
activity O 0 1.222323842142714e-08
cause O 0 0.06303946673870087
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999988079071045
( O 0 1.5359679750304167e-08
TSD B-Disease 0 0.00046772314817644656
) O 0 1.431536139628875e-10
, O 0 5.3686187440060706e-11
the O 0 5.304051642340823e-10
fatal O 0 5.408793413153035e-07
infantile B-Disease 0 7.651422606613778e-07
form I-Disease 0 2.42709621289805e-08
of I-Disease 0 1.192562558571808e-05
G I-Disease 0 3.252039823564701e-05
( I-Disease 0 4.206477832724431e-09
M2 I-Disease 0 5.235595835983986e-06
) I-Disease 0 1.5146742748939346e-09
gangliosidosis I-Disease 0 7.169649620664131e-07
, I-Disease 0 7.932401957511104e-10
Type I-Disease 0 1.619687424181393e-07
1 I-Disease 0 6.62959200781188e-06
. O 0 3.955076408601599e-07

Less O 0 5.139533641340677e-06
severe O 1 0.9529461860656738
, O 0 1.1052241433162635e-07
subacute O 1 0.999660849571228
( O 0 4.2779575437634776e-08
juvenile O 0 0.0006371481576934457
- O 0 1.960823283297941e-06
onset O 1 0.9999980926513672
) O 0 1.5618173421216852e-08
and O 0 1.5456285495929478e-07
chronic O 1 1.0
( O 0 5.491623511488797e-08
adult O 0 5.680506092176074e-06
- O 0 1.4758861652808264e-06
onset O 0 0.0005222425097599626
) O 0 1.9124929417912995e-10
variants O 0 1.537107330307208e-09
are O 0 1.1713394143519906e-11
characterized O 0 1.6203710595519283e-10
by O 0 1.7515301709014608e-11
a O 0 3.1231980890389366e-10
broad O 0 1.0527227090051383e-08
spectrum O 0 7.679662985538016e-07
of O 0 1.1564257107465892e-08
clinical O 0 6.058115786800045e-08
manifestations O 0 1.0876348000010694e-07
and O 0 9.196812061906812e-11
are O 0 5.623879834049106e-12
associated O 0 1.4311321572257896e-10
with O 0 1.8540504201358665e-11
residual O 0 1.029664053930901e-05
levels O 0 6.346901670895022e-08
of O 0 8.514357574540554e-08
Hex O 0 6.248395152397279e-07
A O 0 2.976305424340353e-08
enzyme O 0 3.6503875477933434e-09
activity O 0 5.81271120125848e-09
. O 0 1.0982429188288734e-08

We O 0 1.6091151167074713e-07
identified O 0 1.2434615115353154e-08
a O 0 9.001031919808611e-09
1422 O 0 4.303058176446939e-06
G O 0 1.2067612260580063e-06
- O 0 6.562514727193047e-07
- O 0 5.042026600676763e-07
> O 0 6.987066285546462e-07
C O 0 1.5824525689822622e-06
( O 0 8.394345774043188e-10
amino O 0 2.0368995379271837e-09
acid O 0 4.653010199362484e-10
W474C O 0 4.701857125866127e-09
) O 0 1.2647473129553943e-12
substitution O 0 4.1807338840849084e-11
in O 0 9.872663450649632e-12
the O 0 5.273665185101528e-11
first O 0 1.3660125808279133e-10
position O 0 3.763104050591437e-09
of O 0 4.1762988622906505e-09
exon O 0 4.200306236157303e-08
13 O 0 5.758726828730687e-09
of O 0 1.1228490137682456e-08
HEXA O 0 7.28549639461562e-05
of O 0 1.686499651043505e-08
a O 0 9.301309056297669e-09
non O 0 4.1209284518117784e-07
- O 0 1.183056639320057e-07
Jewish O 0 2.3593429432366975e-07
proband O 0 4.2139454308198765e-05
who O 0 1.9054340327784303e-09
manifested O 0 1.1138702182833526e-09
a O 0 4.2971382008261116e-10
subacute O 0 9.420487003808375e-07
variant O 0 6.314673584029151e-08
of O 0 4.43291173723992e-06
G B-Disease 0 5.785272878711112e-05
( I-Disease 0 2.3639458390789514e-08
M2 I-Disease 0 4.5678141759708524e-05
) I-Disease 0 4.5969024142777926e-08
gangliosidosis I-Disease 0 6.853838567622006e-05
. O 0 9.256162911697174e-07

On O 0 2.084056859530392e-06
the O 0 2.8620936731726943e-08
second O 0 6.800859608802057e-08
maternally O 0 2.9013941116318165e-07
inherited O 0 5.933597435614502e-07
allele O 0 2.3106484547952277e-07
, O 0 2.517513697508633e-10
we O 0 1.4567000383713946e-10
identified O 0 6.323803702912301e-10
the O 0 2.5358412591991453e-10
common O 0 3.34554016490074e-07
infantile O 1 1.0
disease O 1 0.9999959468841553
- O 0 0.00035496894270181656
causing O 0 1.3598911209555808e-05
4 O 0 3.4489726203901228e-06
- O 0 2.7108001177111873e-07
bp O 0 1.8908777121851017e-07
insertion O 0 1.3653698260895908e-07
, O 0 1.1832558932667325e-08
+ O 0 1.9091078229394043e-07
TATC O 0 0.00016882621275726706
1278 O 0 1.7401633158442564e-05
, O 0 8.567313081186967e-09
in O 0 1.478258937481769e-08
exon O 0 1.967264324775897e-06
11 O 0 3.5143983723173733e-07
. O 0 1.7721886536037346e-07

Pulse O 0 0.00017255674174521118
- O 0 1.3676899470738135e-06
chase O 0 2.4183902880281494e-08
analysis O 0 2.2479254568885665e-10
using O 0 3.3592773007740107e-10
proband O 0 1.786564553185599e-06
fibroblasts O 0 6.270433772215256e-08
revealed O 0 1.1972539404325744e-08
that O 0 9.779708987078806e-11
the O 0 1.6460806051554755e-09
W474C O 0 1.8991111971899954e-07
- O 0 5.7565956446126165e-09
containing O 0 4.1484068957764464e-10
alpha O 0 8.278090213309497e-09
- O 0 7.791062239803637e-10
subunit O 0 3.536497983347431e-09
precursor O 0 5.396672886348597e-09
was O 0 1.6474154262979823e-09
normally O 0 7.591745981860853e-11
synthesized O 0 5.616295761790013e-10
, O 0 2.9852380983852456e-11
but O 0 2.3183078720623307e-11
not O 0 7.345369451572381e-11
phosphorylated O 0 1.1593188631309204e-08
or O 0 1.4426654315613519e-09
secreted O 0 2.042540581115304e-09
, O 0 1.3726569880745387e-10
and O 0 2.1404895911292243e-10
the O 0 3.735257880776999e-09
mature O 0 2.1542740924473947e-08
lysosomal O 0 5.339553581507062e-07
alpha O 0 3.9812174890130336e-08
- O 0 2.238782492725022e-09
subunit O 0 1.4745896947943038e-08
was O 0 1.3966355183470114e-08
not O 0 1.8167183313266833e-09
detected O 0 2.5923262114702084e-07
. O 0 7.448327465908733e-08

When O 0 4.403730713420373e-08
the O 0 1.4467057773970282e-08
W474C O 0 7.544128948211437e-07
- O 0 8.190391476148307e-09
containing O 0 1.5251010176964286e-10
alpha O 0 1.2889220801781676e-09
- O 0 7.547954622433295e-11
subunit O 0 1.0817458040435213e-09
was O 0 1.4310891360835853e-09
transiently O 0 9.246016396957657e-09
co O 0 6.063797797217774e-10
- O 0 1.0121671278895406e-09
expressed O 0 1.1586610837444056e-10
with O 0 1.8642025423343256e-11
the O 0 8.517694882748117e-10
beta O 0 4.360799721325748e-09
- O 0 2.3049057107371596e-10
subunit O 0 6.620340942120606e-10
to O 0 6.893049325773504e-11
produce O 0 4.942694586951291e-10
Hex O 0 1.1853570924813539e-07
A O 0 9.135198553167356e-08
( O 0 3.2258644644400647e-09
alphabeta O 0 1.1486457651699311e-06
) O 0 5.090185495326693e-10
in O 0 9.527328925784673e-10
COS O 0 3.2806701710796915e-06
- O 0 7.311972183288162e-08
7 O 0 1.581442710119063e-08
cells O 0 3.6078298681907484e-10
, O 0 2.347730169993678e-11
the O 0 9.859571492576436e-11
mature O 0 1.7245503636242887e-10
alpha O 0 4.540206266501201e-10
- O 0 2.2305327723737278e-11
subunit O 0 2.334692161820584e-10
was O 0 1.3641014706688992e-10
present O 0 1.392842438607822e-11
, O 0 4.613687903942676e-12
but O 0 1.57867577517401e-12
its O 0 1.9115247579248873e-12
level O 0 1.98845517829227e-09
was O 0 2.028099466144795e-09
much O 0 1.8900350728934256e-10
lower O 0 4.3324274723310907e-10
than O 0 2.8510888094857023e-11
that O 0 1.1654250481329953e-11
from O 0 1.0476743916854048e-09
normal O 0 7.23972259919492e-09
alpha O 0 4.5601700193742545e-09
- O 0 5.129598967812399e-10
subunit O 0 3.898779521449569e-09
transfections O 0 5.502422339986879e-08
, O 0 1.0973744482556391e-11
although O 0 8.593599790107653e-12
higher O 0 1.0026324215317572e-10
than O 0 1.1295686608292499e-11
in O 0 2.4218486591176536e-11
those O 0 1.803077305517764e-11
cells O 0 7.314026467808432e-11
transfected O 0 8.520165128977908e-10
with O 0 1.4087978830387704e-12
an O 0 2.06112783091017e-11
alpha O 0 1.3634129381046023e-09
- O 0 2.214425587343527e-10
subunit O 0 3.610667986819749e-09
associated O 0 1.9849084598178024e-09
with O 0 2.1976676034540787e-09
infantile O 0 0.0025411932729184628
TSD B-Disease 0 0.03555508330464363
. O 0 2.7417238470661687e-06

Furthermore O 0 2.961693041925173e-07
, O 0 2.8876943058975257e-09
the O 0 1.1191387816467113e-09
precursor O 0 2.472154569943541e-08
level O 0 6.415510256374546e-08
of O 0 2.197815263116354e-08
the O 0 5.196982399979788e-09
W474C O 0 2.0588882421179733e-07
alpha O 0 4.866057778940558e-09
- O 0 9.9215233251293e-11
subunit O 0 5.533633551380035e-10
was O 0 2.826454348348051e-10
found O 0 5.758322204479915e-12
to O 0 9.583050498973567e-12
accumulate O 0 2.0050286431150255e-10
in O 0 1.7126276091739e-11
comparison O 0 1.1144525302597685e-09
to O 0 5.086594478953543e-10
the O 0 2.6808522068932916e-09
normal O 0 4.4912717100942245e-08
alpha O 0 7.551795278004647e-08
- O 0 9.998127659116562e-09
subunit O 0 3.361876466101421e-08
precursor O 0 5.158656790626992e-08
levels O 0 4.029683964290598e-08
. O 0 2.3646766322826807e-08

We O 0 2.0138618594955915e-07
conclude O 0 8.476462767248449e-07
that O 0 1.359979351356344e-09
the O 0 1.558086282216209e-08
1422 O 0 6.391988335963106e-06
G O 0 3.0509711450577015e-06
- O 0 9.423649771633791e-07
- O 0 2.6840825739782304e-07
> O 0 2.3088378497959638e-07
C O 0 4.4475791582954116e-07
mutation O 0 1.806797156334028e-09
is O 0 2.2834676857708125e-11
the O 0 9.440280501760157e-11
cause O 0 1.1122658349904668e-08
of O 0 5.220700245445187e-07
Hex B-Disease 0 0.0002954431693069637
A I-Disease 0 0.002689030021429062
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 8.993086275665974e-09
the O 0 4.197551461970761e-08
proband O 0 4.552115933620371e-05
. O 0 4.812209226656705e-07

The O 0 1.6475206621180405e-07
resulting O 0 1.7285276499023894e-07
W474C O 0 4.960955266142264e-06
substitution O 0 2.2955767065013788e-07
clearly O 0 1.2068697152756158e-08
interferes O 0 8.395598882771083e-09
with O 0 8.032350479192374e-11
alpha O 0 1.1149591472303655e-08
- O 0 5.87718984590424e-10
subunit O 0 3.978239959678831e-09
processing O 0 1.0886321843983637e-09
, O 0 1.4854131813457627e-11
but O 0 1.0774596492790778e-11
because O 0 1.0801241845381782e-11
the O 0 2.1631110097564132e-11
base O 0 1.2391844494974436e-10
substitution O 0 2.0638522002514037e-09
falls O 0 1.857610598676729e-08
at O 0 1.296649787541071e-09
the O 0 1.8044957195151312e-10
first O 0 2.8583210798238667e-10
position O 0 1.072307131977368e-08
of O 0 8.908612514346714e-09
exon O 0 6.763681170696145e-08
13 O 0 9.713983395442938e-09
, O 0 1.7360948789679753e-10
aberrant O 0 2.8109508054541266e-09
splicing O 0 1.217398271080583e-08
may O 0 1.184483622296284e-09
also O 0 4.266966294186325e-11
contribute O 0 3.518679791980617e-10
to O 0 5.2263064986846075e-09
Hex B-Disease 0 0.00038312558899633586
A I-Disease 0 0.00026491819880902767
deficiency I-Disease 0 9.295550989918411e-05
in O 0 9.884318918906843e-10
this O 0 1.1202707650426191e-09
proband O 0 2.651072009030031e-06
. O 0 1.0785222492870616e-08
. O 0 5.200931951776511e-08

Two O 0 3.0734437217461164e-08
frequent O 0 5.520882595533294e-08
missense O 0 1.9111450455966406e-05
mutations O 0 1.4933980310161132e-05
in O 0 6.747594397893408e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0006580721237696707

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.397026608174201e-06
an O 0 1.286814722334384e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 2.1437095711007714e-05
by O 0 7.4104469227620484e-09
early O 0 0.0025605226401239634
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.999996542930603
goiter B-Disease 1 1.0
. O 0 0.002169765066355467

A O 0 2.8164700438537693e-07
century O 0 1.8511543942167918e-07
after O 0 1.298654628278939e-09
its O 0 1.1145088324449048e-11
recognition O 0 4.092708671965539e-10
as O 0 1.7091206228059264e-10
a O 0 6.4331522331428914e-09
syndrome O 0 6.099233360146172e-06
by O 0 2.2135220045793602e-10
Vaughan O 0 1.4475592990947916e-07
Pendred O 0 5.5368977882608306e-06
, O 0 1.8865486950403465e-10
the O 0 1.0640632819303164e-09
disease O 0 1.1272280886487351e-07
gene O 0 1.2899065815474842e-08
( O 0 6.938378760423802e-09
PDS O 0 3.536410804372281e-05
) O 0 6.450227574283929e-10
was O 0 7.636439924851857e-09
mapped O 0 1.170121954885417e-08
to O 0 1.8767455145507483e-08
chromosome O 0 0.00010066157847177237
7q22 O 0 0.0005742500652559102
- O 0 6.245179247343913e-05
q31 O 0 0.00028198675136081874
. O 0 9.556343911754084e-07

1 O 0 1.3615976058645174e-05
and O 0 1.0071625311525167e-08
, O 0 4.23894386258894e-09
recently O 0 1.1925271437007723e-08
, O 0 3.6253372526218186e-10
found O 0 2.404846044523623e-10
to O 0 4.2004785760774155e-10
encode O 0 4.0610390605877456e-09
a O 0 3.112651469905359e-08
putative O 0 3.3747433008102234e-06
sulfate O 0 9.88810552371433e-06
transporter O 0 0.00021951318194624037
. O 0 9.416983175469795e-07

We O 0 5.178402417982397e-08
performed O 0 1.3258808495564267e-09
mutation O 0 2.7893509724208343e-10
analysis O 0 9.217165919395143e-11
of O 0 4.311326851080821e-09
the O 0 1.2011652117394078e-08
PDS B-Disease 0 0.06567218154668808
gene O 0 3.617616650686273e-09
in O 0 1.258276122184654e-10
patients O 0 8.686250330125489e-11
from O 0 5.913238787513819e-10
14 O 0 3.653291891225763e-09
Pendred B-Disease 0 2.2097978558122122e-07
families O 0 2.0754955046276002e-11
originating O 0 2.1688710549749857e-10
from O 0 3.004633208902874e-10
seven O 0 5.860519708411616e-11
countries O 0 1.6053396459381197e-11
and O 0 1.062389759498572e-10
identified O 0 7.155950942916434e-09
all O 0 5.1549262636285675e-09
mutations O 0 2.0711452464183822e-07
. O 0 1.2754142630910792e-07

The O 0 2.288280711582047e-07
mutations O 0 5.72344802662883e-08
include O 0 9.833790448610102e-10
three O 0 6.250487349923617e-10
single O 0 1.3874560389481871e-09
base O 0 1.544387195906438e-08
deletions O 0 6.592486556655786e-08
, O 0 3.1605031924897276e-09
one O 0 2.269618493144776e-09
splice O 0 1.3107124630096223e-07
site O 0 7.969135573659969e-09
mutation O 0 7.307897842423472e-09
and O 0 2.2503974239640456e-09
10 O 0 8.456287048375088e-08
missense O 0 3.4614309697644785e-05
mutations O 0 2.2584912585443817e-05
. O 0 1.9635160697362153e-06

One O 0 1.6708627015304955e-07
missense O 0 3.395498197278357e-06
mutation O 0 3.2303057651006384e-07
( O 0 1.8293822012793726e-09
L236P O 0 2.1475436824403005e-06
) O 0 8.492157671513567e-11
was O 0 1.164915053308846e-09
found O 0 1.518224608532126e-11
in O 0 5.976161839699179e-12
a O 0 1.025221504913354e-10
homozygous O 0 5.527747148903472e-10
state O 0 7.614789354626339e-11
in O 0 4.7310710904469033e-11
two O 0 2.9756426489502275e-11
consanguineous O 0 4.1184372889802034e-07
families O 0 4.410499049312122e-11
and O 0 3.911049956117907e-11
in O 0 5.5723422404119205e-11
a O 0 3.0020669283814527e-10
heterozygous O 0 4.779124318510242e-10
state O 0 7.353920944419556e-11
in O 0 3.61702647000417e-11
five O 0 2.4331366782481822e-11
additional O 0 1.8286312741810917e-10
non O 0 2.2280279665665148e-07
- O 0 1.0999441428793943e-06
consanguineous O 0 1.1619547876762226e-05
families O 0 8.501111814496198e-09
. O 0 8.036499110630757e-08

Another O 0 2.9979617011122173e-07
missense O 0 1.1368962987035047e-05
mutation O 0 8.960863624452031e-07
( O 0 5.596462848700412e-09
T416P O 0 7.6038218139729e-06
) O 0 2.0149273916025834e-10
was O 0 2.1316253207004365e-09
found O 0 1.5447384690836508e-11
in O 0 3.1465919279882737e-12
a O 0 4.575097939385486e-11
homozygous O 0 6.056977697177501e-10
state O 0 7.877666574618303e-11
in O 0 7.064673845924574e-11
one O 0 1.1998588234085616e-10
family O 0 2.6438415692831008e-11
and O 0 6.911449711155537e-12
in O 0 2.120079285738985e-11
a O 0 3.709865747936192e-10
heterozygous O 0 5.302392969142034e-10
state O 0 1.8625045949960395e-10
in O 0 1.7621332171202653e-10
four O 0 3.857547059560318e-10
families O 0 1.0166714137227473e-09
. O 0 6.31927576932867e-08

Pendred B-Disease 1 0.9975764155387878
patients O 0 1.0733981525845593e-07
in O 0 3.1954596746430752e-09
three O 0 1.722940123904948e-09
non O 0 6.49626201720821e-07
- O 0 2.0367417619127082e-07
consanguineous O 0 1.5470693597308127e-06
families O 0 7.287332542960101e-11
were O 0 6.661554641240741e-11
shown O 0 1.0647402230723468e-11
to O 0 4.3851752090651175e-11
be O 0 2.441072899372898e-10
compound O 0 5.042134265664799e-09
heterozygotes O 0 6.018701537158222e-09
for O 0 8.722780275860487e-10
L236P O 0 4.0643226384418085e-06
and O 0 3.537640225204086e-08
T416P O 0 6.227142876014113e-05
. O 0 6.821957754254981e-07

In O 0 1.7308593669440597e-08
total O 0 1.261473414615466e-08
, O 0 5.774760669652323e-10
one O 0 2.415842803582535e-10
or O 0 7.421051551048663e-10
both O 0 1.0776718406546593e-10
of O 0 8.596870992860772e-10
these O 0 6.778533030021849e-12
mutations O 0 6.083654136013195e-10
were O 0 6.88146276073276e-11
found O 0 1.3228028915290846e-11
in O 0 9.181402166325014e-12
nine O 0 2.0083279483884553e-10
of O 0 4.6392303887365927e-10
the O 0 6.768139937385342e-10
14 O 0 5.8144076220401075e-09
families O 0 1.9960692820841786e-10
analyzed O 0 8.327170064603706e-08
. O 0 1.0301998543127411e-07

The O 0 1.5348550874705325e-08
identification O 0 1.176504493827224e-08
of O 0 3.7533283148150076e-08
two O 0 1.4831271766269083e-09
frequent O 0 6.966879340097876e-08
PDS B-Disease 0 0.004070798866450787
mutations O 0 4.900260819340474e-08
will O 0 1.4962477090652015e-10
facilitate O 0 3.8150346770571275e-10
the O 0 5.96038995936965e-10
molecular O 0 1.2042764296893438e-07
diagnosis O 0 1.7026339264702983e-05
of O 0 0.00894954428076744
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.5942404792876914e-05

Insertional O 0 0.00015482639719266444
mutation O 0 1.3529407283385808e-07
by O 0 1.183503517410145e-09
transposable O 0 2.1029275103501277e-06
element O 0 5.39566599400132e-07
, O 0 7.245966937574622e-09
L1 O 0 0.00016304035671055317
, O 0 1.1317133896682208e-09
in O 0 5.913148304337312e-10
the O 0 1.1751319917152614e-08
DMD B-Disease 1 1.0
gene O 0 4.650468099498539e-08
results O 0 3.9109493421563e-09
in O 0 2.638982365965603e-09
X B-Disease 1 0.9999949932098389
- I-Disease 1 0.9880067110061646
linked I-Disease 1 0.9187859892845154
dilated I-Disease 0 0.1632385104894638
cardiomyopathy I-Disease 1 1.0
. O 0 6.574013968929648e-05

X B-Disease 1 0.9999971389770508
- I-Disease 1 0.9999362230300903
linked I-Disease 1 0.9992707371711731
dilated I-Disease 1 0.9999966621398926
cardiomyopathy I-Disease 1 1.0
( O 0 3.491145662337658e-06
XLDCM B-Disease 1 1.0
) O 0 1.3399934495339494e-09
is O 0 1.42866107832873e-10
a O 0 2.7058943974367367e-10
clinical O 0 1.7997196621877265e-08
phenotype O 0 6.379452344162928e-08
of O 0 9.890587904237691e-08
dystrophinopathy B-Disease 0 4.452326538739726e-05
which O 0 9.465396522134739e-11
is O 0 1.635404485444969e-11
characterized O 0 6.371356914280923e-11
by O 0 2.0341487175223882e-11
preferential O 0 1.0819510976034508e-07
myocardial B-Disease 1 0.9138625264167786
involvement I-Disease 0 5.250578851700993e-07
without O 0 4.451866431054441e-09
any O 0 6.364124782720637e-09
overt O 0 1.731244765323936e-07
clinical O 0 4.978112428943859e-07
signs O 0 3.5871735803993943e-07
of O 0 7.233086944324896e-05
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.00034277397207915783

To O 0 1.9803563233722343e-08
date O 0 2.727864512053202e-07
, O 0 6.251679174340552e-10
several O 0 1.2593494302937103e-10
mutations O 0 3.2028613095036462e-09
in O 0 1.1140828259925684e-09
the O 0 2.2172896763095196e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 1 0.7711121439933777
, O 0 7.312766570066742e-07
DMD O 1 1.0
, O 0 5.824852600255781e-09
have O 0 6.319243045505019e-11
been O 0 1.3510975671593428e-10
identified O 0 1.771836150021855e-10
in O 0 1.6833799978965835e-11
patients O 0 1.877301265829079e-11
with O 0 4.343280596286192e-11
XLDCM B-Disease 1 1.0
, O 0 4.3378043379505016e-09
but O 0 1.3239949414600716e-10
a O 0 1.2804091120699468e-10
pathogenic O 0 9.879531637224659e-10
correlation O 0 2.177061864117036e-09
of O 0 1.0775654812889002e-09
these O 0 7.636839771674175e-11
cardiospecific O 0 1.1917584288312355e-06
mutations O 0 2.4728054270894972e-08
in O 0 5.505107480985316e-09
DMD O 1 1.0
with O 0 8.547640373279819e-10
the O 0 5.793587476432549e-08
XLDCM B-Disease 1 0.9954763054847717
phenotype O 0 8.223374834415154e-07
has O 0 1.1167933244848882e-09
remained O 0 6.617201009362361e-09
to O 0 2.755970729406698e-10
be O 0 3.871243769992816e-09
elucidated O 0 2.8166145966679323e-06
. O 0 1.5315775669932918e-07

We O 0 1.794003594568494e-07
report O 0 1.683516437367416e-09
here O 0 2.7437815908193386e-10
the O 0 6.31418320407029e-11
identification O 0 2.4317181601674065e-10
of O 0 7.150872116667983e-10
a O 0 7.241072741415167e-10
unique O 0 4.3772974134270726e-10
de O 0 6.202714644132357e-07
novo O 0 4.18474792240886e-06
L1 O 0 6.285572908382164e-06
insertion O 0 4.350832227828505e-08
in O 0 5.493419608093575e-10
the O 0 5.775619427161871e-10
muscle O 0 2.1613890677230074e-09
exon O 0 5.804847802437507e-08
1 O 0 4.579841572649457e-07
in O 0 3.155629979545438e-09
DMD O 1 1.0
in O 0 5.300292205134838e-09
three O 0 1.944572503020936e-09
XLDCM B-Disease 1 0.9315264225006104
patients O 0 8.923607963673419e-10
from O 0 8.81263284568945e-10
two O 0 1.6215366549499066e-10
unrelated O 0 6.274115893489807e-09
Japanese O 0 1.7825835030294e-08
families O 0 1.7743395641645066e-09
. O 0 4.465952585519517e-08

The O 0 8.653982774831093e-08
insertion O 0 1.5010262188752677e-07
was O 0 8.514746951959751e-08
a O 0 2.6168678335380946e-09
5 O 0 9.28009669109997e-09
- O 0 2.5218065413668e-09
truncated O 0 2.3967010598369143e-09
form O 0 1.1084362316893248e-09
of O 0 1.3164344281335616e-08
human O 0 7.51363327111676e-09
L1 O 0 1.3909232166042784e-06
inversely O 0 6.282034092919275e-08
integrated O 0 2.5227796740523445e-08
in O 0 3.393977876520182e-10
the O 0 6.539556118845269e-10
5 O 0 1.9439280407596016e-08
- O 0 4.4501199170099426e-08
untranslated O 0 7.028085292404285e-06
region O 0 3.839537399130677e-08
in O 0 2.4094326533941057e-10
the O 0 3.793484693037641e-10
muscle O 0 6.942849628543968e-10
exon O 0 1.0458181876060735e-08
1 O 0 2.1154574980641883e-08
, O 0 7.35114052963226e-12
which O 0 2.572649558663098e-12
affected O 0 2.056376596781817e-11
the O 0 2.0777612269595735e-11
transcription O 0 6.05680450238566e-10
or O 0 6.566262117368993e-11
the O 0 1.3311914071056918e-10
stability O 0 5.5381130792397926e-09
of O 0 1.9109369642222873e-09
the O 0 3.504995182979087e-10
muscle O 0 2.85423518153749e-10
form O 0 2.45224007766609e-10
of O 0 8.18386425294193e-09
dystrophin O 0 3.231248157931077e-08
transcripts O 0 1.8902630571915324e-09
but O 0 7.127062828793385e-12
not O 0 4.531947733754649e-12
that O 0 2.7390310072122892e-12
of O 0 5.964609361974738e-10
the O 0 1.8025529957554909e-09
brain O 0 1.4128177099337336e-06
or O 0 1.4259783576164864e-08
Purkinje O 0 2.0501061953837052e-05
cell O 0 7.803532042771621e-08
form O 0 6.74795441746312e-10
, O 0 1.5758735982807082e-10
probably O 0 3.5547440546679354e-09
due O 0 6.539596419941063e-09
to O 0 1.255947984502015e-10
its O 0 1.2326539094997813e-11
unique O 0 1.4219185724695382e-11
site O 0 1.2127995274724412e-09
of O 0 5.8013251980071345e-09
integration O 0 5.313549991114996e-07
. O 0 3.0415563401220425e-07

We O 0 2.3078736433035374e-07
speculate O 0 1.0927896454404618e-07
that O 0 3.9434844278929404e-11
this O 0 2.3057751888377886e-11
insertion O 0 2.6183257784140324e-09
of O 0 4.446071066865898e-09
an O 0 3.6644212664249665e-10
L1 O 0 3.4733225220406894e-06
sequence O 0 3.9735761347969856e-09
in O 0 7.84184106539243e-10
DMD O 1 1.0
is O 0 1.5507622963539802e-09
responsible O 0 1.8835186743615395e-09
for O 0 3.227461353727534e-11
some O 0 8.180543915881078e-12
of O 0 4.1372968939690224e-10
the O 0 2.8353619799248442e-11
population O 0 5.856203109250169e-12
of O 0 1.0364759051029182e-10
Japanese O 0 2.1864248189729096e-09
patients O 0 7.513080435561648e-11
with O 0 1.4878780152383086e-10
XLDCM B-Disease 0 0.064371757209301
. O 0 1.3457473357902927e-07
. O 0 3.8124096590763656e-07

Severe O 1 0.8679028153419495
early O 1 0.6951757669448853
- O 1 0.999794065952301
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.0008436103817075491
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 5.5353521020151675e-05
red O 0 0.00024347602447960526
hair O 0 0.007818818092346191
pigmentation O 0 0.0572441965341568
caused O 0 1.9486353721731575e-06
by O 0 5.8703729877152e-08
POMC O 1 0.945642352104187
mutations O 0 1.5611971093676402e-06
in O 0 1.8985566896390083e-08
humans O 0 6.865347046414172e-08
. O 0 7.986805172777167e-08

Sequential O 0 8.824067663226742e-07
cleavage O 0 3.2461653063364793e-06
of O 0 2.9904919074397185e-07
the O 0 5.789111412468628e-09
precursor O 0 1.091905854622155e-08
protein O 0 2.306652868711012e-09
pre O 0 3.560059269602789e-07
- O 0 6.412781772269227e-07
pro O 0 2.548874590502237e-06
- O 0 1.408657794854662e-06
opiomelanocortin O 0 1.4868297512293793e-05
( O 0 2.257836584362849e-08
POMC O 0 6.3438669712923e-06
) O 0 3.920567481774384e-10
generates O 0 1.317968734149133e-09
the O 0 1.213266820343506e-09
melanocortin O 0 1.996503215195844e-06
peptides O 0 1.8161822268325523e-08
adrenocorticotrophin O 0 3.213166110072052e-06
( O 0 7.616860031589567e-09
ACTH O 0 7.390490281977691e-07
) O 0 4.874601833293468e-10
, O 0 5.288575133377549e-10
melanocyte O 0 8.178669190783694e-07
- O 0 4.382707174954703e-07
stimulating O 0 3.5357174965611193e-08
hormones O 0 5.600360175606056e-09
( O 0 2.5401303282990284e-10
MSH O 0 4.848827757086838e-07
) O 0 1.2430287354980862e-10
alpha O 0 1.6184846796107877e-09
, O 0 1.0937259778409647e-11
beta O 0 8.363342240969018e-10
and O 0 3.2018318552040625e-11
gamma O 0 3.5253591157413666e-09
as O 0 4.0201737772083135e-11
well O 0 3.731494627179366e-11
as O 0 1.1680782729950323e-10
the O 0 7.2136130402356e-10
opioid O 0 1.32341611447373e-07
- O 0 6.036972166612031e-08
receptor O 0 4.403361231197778e-08
ligand O 0 2.034482093904444e-07
beta O 0 3.6227258988219546e-06
- O 0 1.3306288337844308e-06
endorphin O 0 8.878896551323123e-06
. O 0 1.8178739935592603e-07

While O 0 4.990766200307917e-08
a O 0 3.3785947373132785e-09
few O 0 3.5335701031868894e-10
cases O 0 3.6624858701372887e-10
of O 0 1.2326715648214304e-07
isolated O 1 0.9782674312591553
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
have O 0 4.852525936627217e-09
been O 0 2.5313482421296385e-09
reported O 0 1.4110643764553288e-09
( O 0 1.5658790930572764e-09
OMIM O 0 1.5343466657213867e-05
201400 O 0 4.67354340116799e-07
) O 0 7.774699634088833e-11
, O 0 4.5570002632500106e-11
an O 0 4.733979874771421e-10
inherited O 1 0.9994542002677917
POMC O 1 1.0
defect O 1 0.9972672462463379
has O 0 3.467844678084475e-09
not O 0 6.409315300714979e-10
been O 0 3.604541942703321e-10
described O 0 1.4278610516171852e-09
so O 0 1.0859501492488377e-10
far O 0 5.2750581680527375e-09
. O 0 4.5863405517820865e-08

Recent O 0 3.960503818234429e-07
studies O 0 3.993188002482384e-08
in O 0 4.3408646122067296e-10
animal O 0 1.9541156193181308e-10
models O 0 3.762612096891438e-11
elucidated O 0 7.130704027247248e-09
a O 0 2.0610030349033082e-10
central O 0 4.332859404598821e-09
role O 0 1.586351050519852e-09
of O 0 1.917934078221606e-08
alpha O 0 2.7485933173920785e-07
- O 0 6.583715617125563e-08
MSH O 0 2.3132688511395827e-06
in O 0 7.76737771324143e-11
the O 0 4.614103890632215e-11
regulation O 0 6.267104057933182e-10
of O 0 1.9394301442599016e-10
food O 0 2.1508097386435665e-11
intake O 0 2.468804024061133e-12
by O 0 4.309230110331047e-13
activation O 0 1.213229849916786e-09
of O 0 2.5034241346588715e-08
the O 0 7.040014082804191e-08
brain O 0 6.5417721089033876e-06
melanocortin O 0 1.6486586901010014e-05
- O 0 2.2321093240407208e-07
4 O 0 5.1043848259269e-08
- O 0 9.750068308278514e-09
receptor O 0 2.766494811012876e-09
( O 0 1.7920381845115685e-10
MC4 O 0 9.789966952666873e-07
- O 0 4.6979334200614176e-08
R O 0 2.7757671716699406e-08
; O 0 9.374911957849008e-11
refs O 0 5.12509323868926e-09
3 O 0 2.1596213706231993e-09
- O 0 7.475376984089621e-10
5 O 0 3.054435870897265e-10
) O 0 3.1504653486696954e-12
and O 0 5.583755680049762e-12
the O 0 5.6735938863683444e-11
linkage O 0 5.063638752744737e-08
of O 0 3.055138364516097e-08
human O 0 2.9605158147205657e-07
obesity B-Disease 1 1.0
to O 0 5.515932599564621e-09
chromosome O 0 2.094800947816111e-06
2 O 0 7.14234502652289e-08
in O 0 1.9604509682302762e-10
close O 0 5.254292556600149e-09
proximity O 0 2.0803179623385404e-08
to O 0 1.5191355950960883e-09
the O 0 3.717560259630659e-09
POMC O 0 4.102367711311672e-06
locus O 0 3.5449552626687364e-08
, O 0 4.44587144876607e-11
led O 0 2.4175425550332363e-11
to O 0 6.12058971213858e-12
the O 0 5.310423975557477e-12
proposal O 0 1.6131150581966125e-10
of O 0 4.546489296153311e-10
an O 0 3.5009911636407764e-11
association O 0 7.635984622389458e-10
of O 0 8.991786160095216e-08
POMC O 1 0.6799633502960205
with O 0 6.768453353345194e-09
human O 0 7.500028004869819e-06
obesity B-Disease 1 1.0
. O 0 1.2330000345173175e-06

The O 0 6.604758340245098e-08
dual O 0 1.746689548554059e-07
role O 0 1.2363884138721914e-07
of O 0 2.129916992998915e-06
alpha O 0 5.541631981031969e-05
- O 0 1.2389097719278652e-05
MSH O 0 0.00069767190143466
in O 0 2.1385524462402827e-09
regulating O 0 2.117160846637489e-08
food O 0 8.514738913945052e-10
intake O 0 4.5011383509319103e-10
and O 0 7.54973930594538e-11
influencing O 0 2.67120242369856e-07
hair O 0 2.133368980139494e-06
pigmentation O 0 2.474450957379304e-05
predicts O 0 2.0305234826878404e-08
that O 0 1.9904985645857742e-11
the O 0 1.184361081429941e-10
phenotype O 0 3.1922067211809235e-09
associated O 0 3.847751839369806e-10
with O 0 1.795968929130254e-11
a O 0 1.0358128577081516e-08
defect O 0 2.0560308257699944e-05
in O 0 5.167763550417703e-09
POMC O 0 2.4152146579581313e-05
function O 0 3.7955345533191576e-09
would O 0 2.6788932183663405e-10
include O 0 3.5304796863755428e-09
obesity B-Disease 1 1.0
, O 0 5.591160423534802e-09
alteration O 0 1.2098070328647736e-05
in O 0 8.956799035786389e-08
pigmentation O 1 0.9967842102050781
and O 0 3.4301447158213705e-05
ACTH B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999904632568359
. O 0 1.1033218470402062e-05

The O 0 1.414577042169185e-07
observation O 0 2.2146721221361076e-06
of O 0 2.5896059696606244e-07
these O 0 4.0105279097701896e-09
symptoms O 0 1.1791463521149126e-06
in O 0 3.5001268550161058e-09
two O 0 7.243172173154733e-10
probands O 0 4.167729457549285e-06
prompted O 0 4.469103309645561e-09
us O 0 3.6215916376924895e-10
to O 0 1.7295474774581265e-10
search O 0 1.9821154439991773e-10
for O 0 2.3678592073195226e-11
mutations O 0 1.1862629767378507e-09
within O 0 5.97907812149856e-09
their O 0 6.13475270583308e-09
POMC O 0 0.00018202974752057344
genes O 0 4.1374596548848785e-07
. O 0 1.401125189204322e-07

Patient O 0 1.0414753887744155e-05
1 O 0 1.6040710306697292e-06
was O 0 2.7189241080805004e-08
found O 0 3.967808720473087e-11
to O 0 1.7791840917213975e-11
be O 0 3.3312016339825945e-11
a O 0 9.128200972874367e-11
compound O 0 1.1086858098252605e-09
heterozygote O 0 2.703852697294451e-09
for O 0 2.76141019772691e-11
two O 0 3.908962042942221e-11
mutations O 0 1.41105360729199e-09
in O 0 5.158769522672912e-10
exon O 0 5.553093629373507e-08
3 O 0 7.385249745084366e-08
( O 0 1.982721320459291e-09
G7013T O 0 3.7267814150254708e-06
, O 0 1.3609732230079885e-09
C7133delta O 0 3.6284751558923745e-07
) O 0 2.923815703437249e-11
which O 0 1.1051166058650974e-11
interfere O 0 1.983772035529796e-10
with O 0 1.887248603921199e-12
appropriate O 0 5.779983713871673e-10
synthesis O 0 1.535540405939173e-08
of O 0 7.606381302593945e-08
ACTH O 0 4.905516107100993e-06
and O 0 7.049985129015113e-08
alpha O 0 1.6821386452647857e-05
- O 0 1.13208716356894e-05
MSH O 0 0.0003655718464870006
. O 0 6.156206495688821e-07

Patient O 0 7.85933752922574e-06
2 O 0 5.540815095628204e-07
was O 0 6.005333119674106e-08
homozygous O 0 1.4839364181895576e-09
for O 0 6.102059135759674e-11
a O 0 4.2375755682222405e-10
mutation O 0 3.935598513749028e-09
in O 0 8.031128539975896e-10
exon O 0 1.2725686815429071e-07
2 O 0 4.446259822543652e-07
( O 0 5.302233763160302e-09
C3804A O 0 3.4590455015859334e-06
) O 0 7.540332247479853e-10
which O 0 1.2495926515754263e-09
abolishes O 0 8.198542673198972e-06
POMC O 0 8.802170486887917e-05
translation O 0 2.1654814190696925e-06
. O 0 9.152618645202892e-07

These O 0 3.5066287651375205e-09
findings O 0 1.1596211768605258e-09
represent O 0 3.756977229318892e-10
the O 0 2.579442770489493e-10
first O 0 1.5947231035706722e-10
examples O 0 2.1506550706984484e-10
of O 0 2.2568191759830825e-09
a O 0 1.796362170125576e-08
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999996423721313
within O 0 6.0871187201883e-08
the O 0 1.0821074702960232e-08
POMC O 0 1.1511040611367207e-05
gene O 0 5.839411176822296e-10
and O 0 1.8857384403991873e-11
define O 0 1.9235530945849177e-09
a O 0 7.916138855534882e-10
new O 0 4.069164560860372e-09
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 0 0.1321767121553421
resulting O 0 9.148516610935076e-09
in O 0 2.0647647480664943e-10
early O 0 2.929134836904268e-07
- O 0 9.240480949301855e-07
onset O 1 0.9999986886978149
obesity B-Disease 1 1.0
, O 0 1.1896953765244689e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 2.3198258531920146e-06
red O 0 4.182310021860758e-06
hair O 0 1.064499701897148e-05
pigmentation O 0 1.836715455283411e-05
. O 0 6.179722333854443e-08
. O 0 2.0928031574385386e-07

A O 0 2.0012021195725538e-06
European O 0 8.555687145417323e-07
multicenter O 0 6.07284382567741e-05
study O 0 1.1826741541653973e-07
of O 0 8.135593088809401e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 9.487312269129689e-09
classification O 0 1.0994085641868878e-07
of O 0 5.966172977878159e-08
105 O 0 2.4331773929020528e-08
mutations O 0 1.3227234862966952e-09
and O 0 1.938829825853805e-11
a O 0 2.00638297642719e-10
general O 0 5.261781566012758e-10
system O 0 2.736568749384105e-10
for O 0 3.947442719920424e-11
genotype O 0 8.554266628379992e-09
- O 0 3.584579300053292e-09
based O 0 9.866762962218445e-10
prediction O 0 9.245155752068968e-08
of O 0 6.960915044373905e-08
metabolic O 0 6.584348739124835e-05
phenotype O 0 2.2205495042726398e-06
. O 0 1.527522499600309e-07

Phenylketonuria B-Disease 1 0.98661869764328
( O 0 3.2054258554126136e-06
PKU B-Disease 0 0.35123002529144287
) O 0 2.5358922073337453e-08
and O 0 2.478282645768104e-08
mild B-Disease 1 0.9999991655349731
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.9999876022338867
MHP B-Disease 1 1.0
) O 0 1.2843312191535006e-08
are O 0 8.165212395105925e-10
allelic B-Disease 0 0.00023432877787854522
disorders I-Disease 1 0.8242567181587219
caused O 0 6.673721486549766e-08
by O 0 5.091039811944142e-10
mutations O 0 4.814892040627683e-09
in O 0 1.5581469448022744e-10
the O 0 4.4240325292044247e-10
gene O 0 1.098585999947943e-09
encoding O 0 3.6855794860457536e-08
phenylalanine O 0 1.0044173905043863e-05
hydroxylase O 0 5.6135857448680326e-05
( O 0 5.528922883968335e-07
PAH O 1 0.9066271781921387
) O 0 8.828455122511514e-08
. O 0 2.818923405811802e-07

Previous O 0 2.1181429588068568e-07
studies O 0 3.416178451232099e-09
have O 0 8.088387598581548e-11
suggested O 0 6.563222743061203e-10
that O 0 1.6843049524539744e-11
the O 0 2.44865988596743e-10
highly O 0 1.990572595644835e-09
variable O 0 6.92251830969326e-07
metabolic O 0 0.36426979303359985
phenotypes O 0 0.00014446594286710024
of O 1 0.9998194575309753
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 9.547361696604639e-05
with O 0 2.087029997710488e-06
PAH O 1 1.0
genotypes O 0 0.0018870364874601364
. O 0 2.1810774342156947e-06

We O 0 1.5858049096095783e-07
identified O 0 1.1023562507261886e-08
both O 0 4.472085479712007e-10
causative O 0 4.9208946251155794e-08
mutations O 0 3.8172299099414886e-08
in O 0 1.9265933293155513e-09
686 O 0 1.0200243423241773e-06
patients O 0 3.096088274645581e-09
from O 0 1.1339978733815315e-08
seven O 0 1.1936945654156261e-08
European O 0 1.0441025466434439e-07
centers O 0 6.229854676575997e-08
. O 0 6.424228615742322e-08

On O 0 4.2028349866995995e-07
the O 0 2.647442043368642e-09
basis O 0 1.1039406722090916e-08
of O 0 3.3441727165239854e-09
the O 0 6.421588816252211e-10
phenotypic O 0 4.554452814886645e-08
characteristics O 0 6.510412209337346e-09
of O 0 1.5123799101957047e-08
297 O 0 2.2623629192253247e-08
functionally O 0 2.6276131848135265e-07
hemizygous O 0 8.450000677839853e-06
patients O 0 1.7025620913102557e-09
, O 0 9.589271737775462e-11
105 O 0 3.1087932228501813e-09
of O 0 1.4574232931607867e-09
the O 0 4.279160914499869e-10
mutations O 0 8.456279565471903e-10
were O 0 6.612841524367141e-11
assigned O 0 1.2292290796356298e-10
to O 0 3.5542454396297885e-11
one O 0 9.062262745773708e-11
of O 0 1.2668256443859605e-09
four O 0 1.7937994145622582e-10
arbitrary O 0 1.6391760837564107e-08
phenotype O 0 2.5825940497270494e-07
categories O 0 4.665660924274562e-08
. O 0 4.5290882155768486e-08

We O 0 5.359255439429944e-08
proposed O 0 1.8652404065733208e-08
and O 0 4.157619526434786e-10
tested O 0 1.9942350548696197e-10
a O 0 3.346478996690827e-11
simple O 0 2.0902184497129106e-11
model O 0 3.2712967751313826e-11
for O 0 2.2611688563212162e-11
correlation O 0 1.1212113459890816e-09
between O 0 2.4882469418230357e-09
genotype O 0 1.0620365742397553e-07
and O 0 1.1027637691896075e-09
phenotypic O 0 7.767438319206121e-07
outcome O 0 2.8600966288649943e-06
. O 0 3.6113934243076073e-07

The O 0 2.3043591568239208e-07
observed O 0 4.7214417264740405e-08
phenotype O 0 4.113176998998824e-08
matched O 0 2.8581592648180276e-09
the O 0 1.7713774891348066e-09
predicted O 0 1.0012654172442126e-07
phenotype O 0 2.035634416586163e-08
in O 0 1.793433318519888e-10
79 O 0 4.289475885599359e-09
% O 0 5.290633486865204e-10
of O 0 2.918011665631326e-10
the O 0 6.67581337432388e-11
cases O 0 8.442511967299282e-11
, O 0 5.193370386513685e-11
and O 0 2.220290444554518e-11
in O 0 2.445652708127355e-11
only O 0 4.3323261644800937e-11
5 O 0 1.541481831068836e-09
of O 0 1.2819419970000467e-09
184 O 0 3.1929858756996055e-09
patients O 0 1.2150587480608266e-10
was O 0 2.83121481814419e-09
the O 0 2.772367335701631e-10
observed O 0 1.358263279627181e-09
phenotype O 0 8.572195731026966e-10
more O 0 5.316947511609105e-13
than O 0 7.664736900725444e-12
one O 0 1.4925869568083172e-11
category O 0 8.248141614153326e-10
away O 0 2.849383506919878e-10
from O 0 8.665961698239855e-11
that O 0 5.777269287965403e-11
expected O 0 5.2891863333570655e-08
. O 0 1.3315410285485996e-07

Among O 0 3.62999053038493e-08
the O 0 2.728637760185393e-09
seven O 0 2.0757381924418894e-10
contributing O 0 3.300328066391245e-10
centers O 0 8.130304068876271e-11
, O 0 5.8691627946583225e-12
the O 0 3.1144104656322114e-11
proportion O 0 4.850663759548013e-10
of O 0 8.233900228304947e-10
patients O 0 4.6250208524112324e-11
for O 0 3.27345026085446e-11
whom O 0 1.3163408141281252e-09
the O 0 2.9417956959321145e-10
observed O 0 1.0848637543858786e-09
phenotype O 0 2.594235715136506e-09
did O 0 1.1816443656886833e-10
not O 0 1.1862781590377125e-10
match O 0 2.4629380757090757e-09
the O 0 3.6476710540966906e-10
predicted O 0 1.5726264734894357e-08
phenotype O 0 2.2122399467860987e-09
was O 0 3.227987654952358e-09
4 O 0 1.7773644778174003e-09
% O 0 8.408768126244581e-10
- O 0 2.3674642246618305e-09
23 O 0 4.577371814917797e-09
% O 0 1.813668104588828e-09
( O 0 3.842815787802323e-10
P O 0 2.5735193958098534e-06
< O 0 1.1824355397038744e-06
. O 0 1.7882184621953456e-09
0001 O 0 6.972828145990206e-07
) O 0 4.5968780865157655e-11
, O 0 2.8421301770387153e-11
suggesting O 0 3.291137640193398e-10
that O 0 3.0571854076066884e-11
differences O 0 2.5539965697873868e-09
in O 0 5.5104906748759674e-11
methods O 0 4.49601578189629e-10
used O 0 4.275919895935232e-11
for O 0 4.2415196355172213e-11
mutation O 0 1.945102967582102e-09
detection O 0 1.9667531603317912e-07
or O 0 1.80956050144232e-08
phenotype O 0 2.2313302849852334e-07
classification O 0 3.2119352511017496e-08
may O 0 3.5099523287840384e-10
account O 0 2.8359030401770013e-11
for O 0 5.447369118283252e-12
a O 0 5.140056436037099e-11
considerable O 0 7.740878493756043e-10
proportion O 0 2.8935385198991526e-09
of O 0 1.4461457809034073e-08
genotype O 0 5.5459340728702955e-06
- O 0 1.0742061022028793e-05
phenotype O 0 3.4856200272770366e-06
inconsistencies O 0 1.635188937143539e-06
. O 0 1.9382271432277776e-07

Our O 0 2.809430554862047e-07
data O 0 1.2280422012622694e-08
indicate O 0 1.718605346923141e-08
that O 0 1.7165178167743989e-09
the O 0 1.0111029524750847e-07
PAH O 1 0.9900584816932678
- O 0 1.0896422963924124e-06
mutation O 0 8.383565841540985e-09
genotype O 0 8.606735768523777e-09
is O 0 4.250136007022398e-11
the O 0 3.714069676807874e-11
main O 0 8.808078710842437e-10
determinant O 0 2.5310793461130743e-08
of O 0 2.7050186535149123e-09
metabolic O 0 1.6211585034398013e-06
phenotype O 0 5.112940115736819e-08
in O 0 4.117969021333323e-10
most O 0 8.412907592791896e-10
patients O 0 1.0323218724295202e-08
with O 0 4.794888468495628e-07
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0003438689454924315

In O 0 1.955735839942463e-08
the O 0 1.686711104120775e-09
present O 0 8.049239608176606e-10
study O 0 3.41712796947391e-10
, O 0 3.684674440562752e-11
the O 0 1.611516059485396e-10
classification O 0 4.819846921577664e-08
of O 0 2.9638349019478483e-07
105 O 0 1.0796430615300778e-05
PAH O 1 0.9999411106109619
mutations O 0 7.472561236454567e-08
may O 0 1.4225248756716269e-09
allow O 0 2.7700841620514893e-10
the O 0 3.4202515819536927e-10
prediction O 0 1.4543417137247161e-08
of O 0 3.677116833245009e-09
the O 0 5.613982612118207e-10
biochemical O 0 5.934460922674134e-09
phenotype O 0 3.0388076055487545e-08
in O 0 6.376393302254257e-10
> O 0 2.7212439590584836e-07
10 O 0 1.1907816066525356e-08
, O 0 3.3919717035146846e-10
000 O 0 3.752052446515108e-09
genotypes O 0 1.653703129989026e-08
, O 0 2.0671752504197727e-11
which O 0 8.692461681003572e-12
may O 0 6.832600457640225e-11
be O 0 1.4967950490163417e-11
useful O 0 1.6022409093929824e-11
for O 0 8.107783541766445e-12
the O 0 1.363024831890769e-10
management O 0 3.0514095694655907e-09
of O 0 1.1424107526636362e-07
hyperphenylalaninemia B-Disease 1 1.0
in O 0 9.68410745372239e-07
newborns O 0 7.089803943927109e-07
. O 0 1.5480360104902502e-07

Somatic O 0 0.0017962781712412834
instability O 0 0.07414710521697998
of O 0 6.944464985281229e-05
the O 0 3.7236125081108185e-06
CTG O 1 0.997367799282074
repeat O 0 1.6216949916270096e-06
in O 0 3.851027940982021e-09
mice O 0 1.787874071013107e-09
transgenic O 0 1.002317451259671e-09
for O 0 6.46268663584415e-11
the O 0 5.251660439853367e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.0009388340404257178
is O 0 7.44382244732833e-09
age O 0 1.1328931570631084e-08
dependent O 0 6.70218824883051e-10
but O 0 1.8411456387257275e-11
not O 0 2.3440253210660345e-11
correlated O 0 5.351936116504419e-10
to O 0 8.611981960893189e-11
the O 0 4.900340133673353e-10
relative O 0 4.4863316617238524e-08
intertissue O 0 1.075734189726063e-06
transcription O 0 1.6802442814878304e-07
levels O 0 4.925589536242114e-08
and O 0 8.034978016269179e-09
proliferative O 0 0.0002173698303522542
capacities O 0 3.11330381919106e-06
. O 0 4.864334641752066e-07

A O 0 7.421962800435722e-05
( O 0 7.416869607368426e-07
CTG O 0 0.0001648354809731245
) O 0 5.523313362232329e-09
nexpansion O 0 3.6856436054222286e-06
in O 0 1.6741598107827826e-09
the O 0 9.341508011573296e-09
3 O 0 9.209689437739144e-07
- O 0 1.2101195352443028e-06
untranslated O 0 0.003304900135844946
region O 0 1.456598056392977e-06
( O 0 1.1907883568085254e-08
UTR O 0 0.00010264851152896881
) O 0 1.3198856452234509e-09
of O 0 1.878822786238743e-08
the O 0 3.783689450642669e-08
DM O 1 1.0
protein O 0 1.3210654969952884e-07
kinase O 0 9.065456652024295e-08
gene O 0 3.5204807957711637e-09
( O 0 3.5378322493784253e-10
DMPK O 0 7.669880142202601e-05
) O 0 2.5651541654680976e-11
is O 0 2.145827265875866e-11
responsible O 0 7.003551627526861e-10
for O 0 9.566916148173732e-10
causing O 1 0.6477028131484985
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00018903540330938995
DM B-Disease 1 1.0
) O 0 3.444084200054931e-07
. O 0 3.3863065596051456e-07

Major O 0 8.14163067843765e-05
instability O 1 0.9995741248130798
, O 0 5.444033224222267e-09
with O 0 5.511804554436672e-11
very O 0 3.21440818407126e-10
large O 0 7.218967645883367e-10
expansions O 0 9.154818236822848e-09
between O 0 7.0347767611167455e-09
generations O 0 2.6264084240779084e-09
and O 0 1.0055530713648508e-10
high O 0 2.704987567270223e-09
levels O 0 1.2184058206798909e-09
of O 0 4.981348666888152e-09
somatic O 0 3.7644522308255546e-06
mosaicism O 0 8.716720913071185e-05
, O 0 6.412873565508903e-10
is O 0 3.309802987239152e-10
observed O 0 3.7974392519402045e-09
in O 0 9.306521664420586e-10
patients O 0 2.2651596154332765e-09
. O 0 4.350633275862492e-08

There O 0 3.6799811198307e-08
is O 0 2.451380654022728e-09
a O 0 2.829028344919493e-09
good O 0 2.9055393646615357e-09
correlation O 0 8.67466987131138e-09
between O 0 2.3727217968172454e-09
repeat O 0 1.1998508853139356e-08
size O 0 2.6617457127287025e-09
( O 0 4.4181636127405e-10
at O 0 3.919858659884312e-09
least O 0 1.0421095236745614e-10
in O 0 5.160115043589819e-11
leucocytes O 0 8.801654871604114e-08
) O 0 3.482709259872152e-11
, O 0 1.7452872480561155e-11
clinical O 0 5.565621297165535e-10
severity O 0 5.894922949778447e-08
and O 0 5.398317348692672e-10
age O 0 9.598416284006817e-08
of O 0 2.6505438199819764e-07
onset O 0 0.09375698119401932
. O 0 9.97818347059365e-07

The O 0 4.98248846270144e-05
trinucleotide O 1 0.9992606043815613
repeat O 0 1.2520368727564346e-05
instability O 0 4.1854626033455133e-05
mechanisms O 0 9.015207069751341e-07
involved O 0 7.973654447823719e-08
in O 0 8.283543451170772e-08
DM B-Disease 1 1.0
and O 0 8.569834619720496e-08
other O 0 5.6342810417220335e-09
human O 0 8.509761073582922e-07
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 6.559031096031731e-10
unknown O 0 1.1603877680954611e-07
. O 0 1.883419109560691e-08

We O 0 4.281590406662872e-07
studied O 0 8.433831339971221e-07
somatic O 0 2.148953717551194e-05
instability O 0 3.892729182553012e-06
by O 0 2.3630251089201693e-09
measuring O 0 1.4373906196851749e-05
the O 0 8.383025829061808e-08
CTG O 0 7.289035238500219e-06
repeat O 0 1.5784321405476476e-08
length O 0 2.0705077652394266e-09
at O 0 8.152918895554251e-10
several O 0 1.2343738010900385e-11
ages O 0 5.49331524712926e-10
in O 0 1.808229434241415e-11
various O 0 4.148927035263483e-11
tissues O 0 1.1813835465446232e-09
of O 0 6.1002034534851646e-09
transgenic O 0 2.4564133838111957e-08
mice O 0 6.301493216120946e-10
carrying O 0 1.098962726375774e-10
a O 0 1.221232559522889e-09
( O 0 7.00801905395565e-09
CTG O 0 1.1309777619317174e-05
) O 0 1.2597608511910607e-09
55expansion O 0 6.250945148167375e-07
surrounded O 0 3.0249043270202947e-09
by O 0 5.954409881825384e-11
45 O 0 1.3811384924622416e-08
kb O 0 3.6166321137898194e-07
of O 0 2.0541921941230612e-08
the O 0 2.7865779017588466e-08
human O 0 3.254201033087156e-07
DM B-Disease 1 1.0
region O 0 2.1311868749762652e-06
, O 0 6.030833055170604e-10
using O 0 8.563991737986498e-10
small O 0 4.739303616219104e-09
- O 0 4.4889937100833777e-08
pool O 0 1.2518571956832147e-08
PCR O 0 1.372821287759507e-07
. O 0 8.505787008061816e-08

These O 0 5.3331515204035895e-08
mice O 0 1.3988029401446056e-08
have O 0 7.360544118650836e-11
been O 0 3.908052353951419e-11
shown O 0 6.620309335458874e-12
to O 0 1.952516447134567e-11
reproduce O 0 1.686137757195283e-10
the O 0 2.684237832006886e-10
intergenerational O 0 2.0153290591906625e-08
and O 0 4.5063008879964173e-10
somatic O 0 3.3880940009112237e-06
instability O 0 0.0001526513951830566
of O 0 1.4881881043038447e-06
the O 0 1.2114827541154227e-07
55 O 0 7.647519737474795e-07
CTG O 0 2.0324578144936822e-05
repeat O 0 2.082596850527807e-08
suggesting O 0 1.504295021881319e-09
that O 0 3.1476859313483985e-11
surrounding O 0 5.893129317868784e-10
sequences O 0 1.902005219989178e-10
and O 0 1.9992688060632702e-11
the O 0 7.806364582529923e-11
chromatin O 0 9.785559917929731e-09
environment O 0 2.9736595408280664e-09
are O 0 1.999169753352792e-11
involved O 0 4.396710218124156e-10
in O 0 1.5094743233134977e-09
instability O 0 3.454753141340916e-06
mechanisms O 0 4.769940460391808e-06
. O 0 4.921556069348298e-07

As O 0 2.0330734429307995e-08
observed O 0 8.352251334997618e-09
in O 0 4.130293329573931e-11
some O 0 1.4237802777039565e-11
of O 0 1.3029544110310098e-09
the O 0 4.042867429721042e-10
tissues O 0 4.185150004332172e-09
of O 0 2.505780116734968e-07
DM B-Disease 1 1.0
patients O 0 7.763981813013743e-08
, O 0 9.243520532331573e-11
there O 0 4.13876294347304e-11
is O 0 3.0673952960968975e-11
a O 0 1.0194963623311182e-10
tendency O 0 1.4665082481712943e-09
for O 0 1.4877446496974756e-10
repeat O 0 3.872964615680985e-09
length O 0 6.143909825340188e-09
and O 0 7.546518410173064e-10
somatic O 0 1.479962406847335e-06
mosaicism O 0 4.535201242106268e-06
to O 0 2.8380039984732264e-10
increase O 0 6.527191287464262e-11
with O 0 4.787120352900409e-12
the O 0 2.820164657357793e-10
age O 0 4.9198223273094754e-09
of O 0 3.917893121041516e-09
the O 0 4.053223534583594e-09
mouse O 0 1.79008480927223e-07
. O 0 8.17825025478669e-08

Furthermore O 0 8.881579560693353e-07
, O 0 4.483583726511142e-09
we O 0 1.2476183419707354e-09
observed O 0 2.4583950430923096e-09
no O 0 2.1384492787657194e-10
correlation O 0 1.1183407533366108e-09
between O 0 4.819464827221509e-10
the O 0 9.588435601060041e-10
somatic O 0 1.1126524412929939e-07
mutation O 0 3.0570848963407116e-08
rate O 0 7.46147676977671e-09
and O 0 7.226833576012837e-10
tissue O 0 1.2316251059019123e-06
proliferation O 0 3.684563853312284e-05
capacity O 0 3.516308879625285e-07
. O 0 1.728656258137562e-07

The O 0 4.854334179071884e-07
somatic O 0 1.853683716035448e-05
mutation O 0 2.1461052313043183e-07
rates O 0 2.452615444070716e-09
in O 0 2.7851283779245506e-11
different O 0 1.046958266609499e-11
tissues O 0 2.661962594796563e-10
were O 0 4.319471169633715e-11
also O 0 2.66768313168797e-12
not O 0 3.09309695911697e-12
correlated O 0 6.72425934378218e-11
to O 0 1.8911880741989684e-11
the O 0 4.2849923609367124e-10
relative O 0 5.646235763379082e-07
inter O 1 0.9992722868919373
- O 0 3.951045528083341e-06
tissue O 0 7.415992797632498e-08
difference O 0 2.3685120531524717e-09
in O 0 9.888494537091397e-12
transcriptional O 0 3.8926104006797857e-10
levels O 0 1.0281157869496127e-10
of O 0 1.3818722555125618e-10
the O 0 6.312352723858439e-11
three O 0 1.7788853723388343e-11
genes O 0 7.306288213326795e-11
( O 0 1.0937432209923159e-10
DMAHP O 0 4.606914444593713e-05
, O 0 2.311096425344772e-09
DMPK O 0 0.00020116001542191952
and O 0 3.1647682252611276e-09
59 O 0 6.718089906598834e-08
) O 0 2.445597890865514e-10
surrounding O 0 5.69820679530153e-09
the O 0 5.904000399681308e-09
repeat O 0 9.817512847121179e-08
. O 0 2.6119424845205685e-08
. O 0 1.5606357806063897e-07

A O 0 7.29635473817325e-07
novel O 0 9.799907729757251e-08
missense O 0 2.756641833911999e-06
mutation O 0 1.371722078147286e-07
in O 0 6.839123156687776e-10
patients O 0 6.679268249598636e-10
from O 0 1.362981283392628e-09
a O 0 9.828712954629282e-09
retinoblastoma B-Disease 0 9.762348054209724e-05
pedigree O 0 2.986986089581478e-07
showing O 0 3.0403364270625843e-09
only O 0 2.410135979680206e-10
mild O 0 1.0615870138508399e-07
expression O 0 2.636835105818136e-08
of O 0 1.394948156985265e-07
the O 0 4.037823586600098e-08
tumor B-Disease 0 1.408877142239362e-05
phenotype O 0 1.33946730329626e-06
. O 0 1.4338034759475704e-07

We O 0 2.6450265977473464e-07
have O 0 4.45573827834167e-10
used O 0 2.3520610459293323e-10
single O 0 4.513853735232942e-10
strand O 0 2.0518418075710088e-09
conformation O 0 3.6265268565927045e-10
polymorphism O 0 5.898020960515282e-10
analysis O 0 5.724181545430085e-11
to O 0 3.704843376528544e-11
study O 0 1.4987783236719565e-10
the O 0 3.3292021917041836e-10
27 O 0 1.0690763829757088e-08
exons O 0 4.135620557121911e-08
of O 0 2.6606949976581973e-09
the O 0 1.6454652085329258e-09
RB1 O 0 7.339162380048947e-07
gene O 0 1.3138769239251502e-10
in O 0 6.897727181098823e-12
individuals O 0 5.352635435579289e-12
from O 0 2.886294259152322e-10
a O 0 2.2946951006019844e-09
family O 0 7.23898774257492e-10
showing O 0 5.745799391831952e-10
mild O 0 1.387753769677147e-07
expression O 0 1.4291455840975686e-07
of O 0 1.3789638160233153e-06
the O 0 2.2314983993965143e-07
retinoblastoma B-Disease 0 0.0001177031736006029
phenotype O 0 1.603073178557679e-05
. O 0 5.763387775914453e-07

In O 0 2.638802421017772e-08
this O 0 1.930669180083555e-09
family O 0 4.5510439861118357e-10
affected O 0 1.3855248892635785e-10
individuals O 0 1.9933898282031848e-11
developed O 0 5.806531078178523e-08
unilateral B-Disease 1 1.0
tumors I-Disease 1 1.0
and O 0 6.57119585412147e-08
, O 0 3.998839315233482e-10
as O 0 3.0926681354737084e-11
a O 0 3.139860940692962e-11
result O 0 2.4927487851655883e-10
of O 0 2.6516870921255986e-09
linkage O 0 3.073560961297517e-08
analysis O 0 1.4126532166258698e-09
, O 0 6.69076599679741e-11
unaffected O 0 1.63738167469063e-09
mutation O 0 5.128953928235092e-10
carriers O 0 3.6912022050028526e-11
were O 0 4.0070374102141315e-11
also O 0 1.1560843428404244e-11
identified O 0 1.1129863003445095e-10
within O 0 4.3333117649702046e-10
the O 0 1.6971282157385303e-09
pedigree O 0 1.1241695574426558e-07
. O 0 8.740292400943872e-08

A O 0 2.1689411369152367e-06
single O 0 4.837770006815845e-08
band O 0 1.5538097031253528e-08
shift O 0 2.4695612221847796e-09
using O 0 5.580694795170871e-10
SSCP O 0 0.0006661223596893251
was O 0 1.726636185139796e-07
identified O 0 5.881263476226195e-09
in O 0 5.247059453594716e-10
exon O 0 2.9360698761138337e-08
21 O 0 1.2581520270060764e-09
which O 0 1.3525613788700763e-11
resulted O 0 8.184141142564272e-10
in O 0 2.1264791316699672e-10
a O 0 3.3439173652283216e-09
missense O 0 9.246228387382871e-07
mutation O 0 1.2935115023537946e-07
converting O 0 1.089802736942147e-07
a O 0 4.7939920477801934e-08
cys O 0 9.356262125947978e-06
- O 0 2.2280969460553024e-06
- O 0 8.961025628195785e-07
> O 0 6.320867100839678e-07
arg O 0 1.2092066015156888e-07
at O 0 1.2903766055671895e-08
nucleotide O 0 3.2556766171865092e-09
position O 0 6.007461195167707e-09
28 O 0 3.181805707797025e-09
in O 0 1.8110332677956364e-10
the O 0 6.325786117145071e-09
exon O 0 1.204539785248926e-06
. O 0 1.915390299700448e-07

The O 0 8.257591730398417e-07
mutation O 0 5.728886094402696e-07
destroyed O 0 1.032546265378187e-06
an O 0 5.729146490551784e-09
NdeI O 0 7.278268640220631e-06
restriction O 0 2.7334428409631073e-07
enzyme O 0 7.498602627720174e-08
site O 0 1.1488612017274136e-07
. O 0 7.091441744933036e-08

Analysis O 0 2.4497179396121282e-08
of O 0 1.4196341169281368e-07
all O 0 3.025717676408135e-09
family O 0 3.5786340557564245e-10
members O 0 1.968213092506943e-11
demonstrated O 0 6.024748061550511e-11
that O 0 1.1400576663267437e-11
the O 0 5.21947984832849e-10
missense O 0 2.9093848752381746e-07
mutation O 0 3.551107568000589e-07
co O 0 1.1101850105887934e-07
- O 0 8.875423418430728e-07
segregated O 0 3.4765006429182677e-09
with O 0 3.511763579586158e-12
patients O 0 2.71763556103366e-10
with O 0 1.3577790003438395e-09
tumors B-Disease 1 1.0
or O 1 0.6974703669548035
who O 0 1.9807953322015237e-07
, O 0 9.777433723767714e-11
as O 0 1.4537072066944656e-11
a O 0 2.1654225287881523e-11
result O 0 2.2762199070047728e-10
of O 0 2.236034246649865e-09
linkage O 0 1.0701535657631212e-08
analysis O 0 1.155318507528591e-09
had O 0 9.141360446385249e-10
been O 0 1.6838366811988692e-10
predicted O 0 3.3677343136417903e-09
to O 0 1.6164106164673342e-10
carry O 0 4.3710066122137903e-10
the O 0 2.9784390509490777e-09
predisposing O 0 8.543506169189641e-07
mutation O 0 5.372662599256728e-07
. O 0 1.5287524490759097e-07

These O 0 5.624768206757835e-09
observations O 0 6.554846976314366e-08
point O 0 5.7219633475824594e-08
to O 0 2.7889468512398707e-10
another O 0 8.956176356100798e-10
region O 0 3.442625384764142e-08
of O 0 6.922558526412104e-08
the O 0 4.107469564473831e-08
RB1 O 0 1.7563690562383272e-05
gene O 0 5.044837436685157e-09
where O 0 4.908590756080855e-10
mutations O 0 8.225015668550384e-10
only O 0 1.9006261842147154e-11
modify O 0 4.807667597361842e-10
the O 0 1.0399611033440337e-10
function O 0 2.417760713857575e-10
of O 0 4.2899808705421094e-10
the O 0 2.2166145308144536e-10
gene O 0 1.5438231248943168e-10
and O 0 2.2197698540393773e-11
raise O 0 2.286362627001992e-10
important O 0 2.1525264903843322e-10
questions O 0 5.014969550742876e-10
for O 0 4.681396242878222e-11
genetic O 0 3.277307980553701e-09
counseling O 0 6.000175911680117e-10
in O 0 9.650698643004496e-12
families O 0 3.4446742333549274e-12
with O 0 4.519293793359136e-12
these O 0 3.3691705675353845e-11
distinctive O 0 2.7011002323718003e-09
phenotypes O 0 1.0537536354604526e-07
. O 0 1.4087578215082885e-08
. O 0 1.0788106408199383e-07

Maternal B-Disease 0 0.00042110454523935914
disomy I-Disease 1 0.7578501105308533
and O 0 0.0002507790341041982
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 6.952357125555864e-06
with O 0 1.0455902810235784e-09
gamete O 0 8.731641401027446e-07
complementation O 0 1.8415315935271792e-05
in O 0 1.5891364613107584e-10
a O 0 1.3899663364735915e-10
case O 0 2.076178562404607e-09
of O 0 1.66558002945294e-08
familial O 0 1.7091571180571918e-06
translocation O 0 1.9842524125124328e-05
( O 0 3.7035188249490147e-09
3 O 0 2.974148927137321e-08
; O 0 1.6932731605745488e-10
15 O 0 4.818971444109366e-09
) O 0 1.480119499186472e-10
( O 0 3.075293630860898e-10
p25 O 0 1.2271435423372168e-07
; O 0 4.616932391954265e-10
q11 O 0 5.618990144284908e-07
. O 0 1.6209251718635187e-09
2 O 0 1.146783574768051e-07
) O 0 6.9908234756610454e-09
. O 0 5.895305221770286e-08

Maternal B-Disease 0 0.33931097388267517
uniparental I-Disease 1 0.9999667406082153
disomy I-Disease 1 0.9999957084655762
( I-Disease 0 3.129264587187208e-05
UPD I-Disease 1 1.0
) I-Disease 0 5.76650815986568e-09
for I-Disease 0 1.1749521355852721e-09
chromosome I-Disease 0 5.902472253183078e-07
15 I-Disease 0 2.0853860860370332e-09
is O 0 2.917504085542255e-11
responsible O 0 2.636555973545285e-10
for O 0 2.71852592520494e-11
an O 0 4.451607485411735e-11
estimated O 0 5.725865892536319e-10
30 O 0 8.652852323542959e-10
% O 0 1.0694749946749127e-10
of O 0 7.572699411984019e-11
cases O 0 1.6139306557860778e-10
of O 0 2.1135797396709677e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0008745600935071707
PWS B-Disease 1 1.0
) O 0 2.260741638338004e-07
. O 0 3.7137002095732896e-07

We O 0 6.721793965880352e-08
report O 0 5.853774132091871e-10
on O 0 7.886449826521869e-10
an O 0 4.773762548454519e-12
unusual O 0 2.94669115497026e-11
case O 0 1.1265166577345553e-09
of O 0 8.058214540085373e-09
maternal B-Disease 0 5.839327741341549e-07
disomy I-Disease 0 0.0009075938141904771
15 I-Disease 0 1.3193256620525062e-07
in O 0 8.078035129699401e-09
PWS B-Disease 1 1.0
that O 0 2.6523078178186665e-10
is O 0 1.1823657330989334e-10
most O 0 7.369980493943107e-12
consistent O 0 3.532112796689191e-11
with O 0 1.8623713682330845e-12
adjacent O 0 3.893206645955161e-09
- O 0 1.1630640450732699e-08
1 O 0 2.3231257273437222e-07
segregation O 0 1.4268762171809612e-08
of O 0 3.218266764193345e-10
a O 0 4.6548298548998446e-10
paternal O 0 4.147010557176145e-08
t O 0 9.846839787996942e-09
( O 0 4.889640359273528e-10
3 O 0 1.3771085605185363e-08
; O 0 2.2896966267449415e-10
15 O 0 5.717302187235873e-09
) O 0 1.5378337492322203e-10
( O 0 4.644365170225484e-10
p25 O 0 1.8642235488641745e-07
; O 0 6.560306742287025e-10
q11 O 0 4.05767764277698e-07
. O 0 2.733173132263289e-10
2 O 0 2.6908724137797435e-09
) O 0 1.111464652953087e-11
with O 0 8.00475484508123e-12
simultaneous O 0 8.266336060103185e-09
maternal O 0 4.064947631832183e-07
meiotic O 0 9.996127118938603e-06
nondisjunction O 0 2.6742593036033213e-05
for O 0 7.000032553605706e-08
chromosome O 0 4.1328734369017184e-05
15 O 0 2.1105945506860735e-06
. O 0 2.1310252407147345e-07

The O 0 5.291774982651987e-07
patient O 0 2.0289947144647158e-07
( O 0 2.036810053951399e-09
J O 0 7.171393008320592e-07
. O 0 4.34885322198042e-10
B O 0 4.376200024580612e-08
. O 0 2.3060831022547745e-11
) O 0 8.350869475093337e-12
, O 0 1.2120652571889767e-11
a O 0 2.3629337375652426e-10
17 O 0 1.6951547943122591e-09
- O 0 3.936724723985208e-09
year O 0 2.4432631473558786e-09
- O 0 3.9798432993620736e-08
old O 0 3.085460775764659e-08
white O 0 3.216892030533103e-10
male O 0 3.8464363638635035e-11
with O 0 5.651536964107473e-12
PWS B-Disease 1 1.0
, O 0 4.0050696092919225e-09
was O 0 8.043384980283008e-08
found O 0 3.020255989749643e-10
to O 0 2.3268678650545382e-10
have O 0 1.0932384858497457e-10
47 O 0 7.362096265950413e-09
chromosomes O 0 8.754248437270462e-10
with O 0 7.311902819329141e-12
a O 0 1.0612742906701556e-09
supernumerary O 0 2.080430931528099e-06
, O 0 7.995561990270517e-10
paternal O 0 5.727652023779228e-07
der O 0 0.0020626834593713284
( O 0 1.500340851556814e-09
15 O 0 2.5033466410917526e-09
) O 0 4.5810334692308885e-12
consisting O 0 7.861631484695764e-12
of O 0 1.7676234087549147e-10
the O 0 1.4275824966603068e-10
short O 0 3.506740453573798e-10
arm O 0 1.0794564353489022e-08
and O 0 2.5541316284183324e-10
the O 0 2.6816142639773943e-09
proximal O 0 1.3893673894926906e-05
long O 0 1.088188472664342e-08
arm O 0 2.8983453859154906e-08
of O 0 1.604335153615466e-08
chromosome O 0 7.17366447133827e-07
15 O 0 3.1184391957594926e-08
, O 0 5.325359597740942e-10
and O 0 2.968270518266536e-09
distal O 0 9.219349885825068e-05
chromosome O 0 0.007015647832304239
arm O 0 0.00012125098874093965
3p O 0 0.00820218026638031
. O 0 3.014170033566188e-06

The O 0 3.238855015297304e-06
t O 0 2.0804218081593717e-07
( O 0 2.390861508771991e-09
3 O 0 1.7206883029530218e-08
; O 0 1.3837447854214702e-10
15 O 0 1.206017619104216e-09
) O 0 1.5911008621749545e-11
was O 0 3.1764380015175675e-10
present O 0 2.3460023854116052e-11
in O 0 1.2356150824732737e-11
the O 0 3.229764372614241e-11
balanced O 0 2.0395576894038925e-10
state O 0 1.1642724284666173e-10
in O 0 8.394277634105052e-11
the O 0 5.281730608430735e-10
patients O 0 3.5098388084797705e-10
father O 0 4.029820477313706e-09
and O 0 9.570347847542848e-10
a O 0 5.525644652948358e-08
sister O 0 2.3004799913906027e-06
. O 0 6.462658461714454e-07

Fluorescent O 0 1.0570753147476353e-05
in O 0 7.780036526128242e-08
situ O 0 4.304266951749014e-07
hybridization O 0 3.384599489564266e-09
analysis O 0 3.1977259729032426e-10
demonstrated O 0 1.013250247594577e-10
that O 0 2.2752723316532553e-11
the O 0 2.6130821950687277e-09
PWS B-Disease 1 1.0
critical O 0 1.889004579425091e-06
region O 0 3.417960101614881e-07
resided O 0 5.729433283363505e-08
on O 0 1.8439376692214182e-09
the O 0 6.14675185750535e-11
derivative O 0 1.9478465507205556e-09
chromosome O 0 1.5513489159957317e-08
3 O 0 9.05476860157961e-10
and O 0 3.84270913700302e-12
that O 0 1.2414494345719396e-12
there O 0 1.4985603036254957e-11
was O 0 8.409762330963133e-10
no O 0 5.742246261819517e-11
deletion O 0 4.568806222238209e-09
of O 0 2.8566875531765845e-09
the O 0 7.765045495489176e-09
PWS B-Disease 1 1.0
region O 0 8.958607509157446e-07
on O 0 6.703766075588646e-08
the O 0 1.6325979457221251e-09
normal O 0 6.074821534696184e-09
pair O 0 5.719011375582284e-10
of O 0 2.726504799710483e-09
15s O 0 9.401459237778909e-07
present O 0 7.387105593892329e-09
in O 0 1.3309388258164745e-08
J O 0 3.976322113885544e-05
. O 0 3.3694522016958217e-07

B O 0 0.003271273570135236
. O 0 8.039784916036297e-06

Methylation O 0 2.628400352477911e-06
analysis O 0 6.24251015324262e-08
at O 0 1.4954824223423202e-07
exon O 0 1.1083548656642961e-07
alpha O 0 2.0729338245928375e-07
of O 0 7.783877542522077e-09
the O 0 1.787137660080873e-09
small O 0 2.4600366188565204e-09
nuclear O 0 4.12424060414196e-06
ribonucleoprotein O 0 2.4919108909671195e-05
- O 0 7.314949925785186e-07
associated O 0 2.9792927236371725e-08
polypeptide O 0 7.053164949866186e-07
N O 0 2.811060255680786e-07
( O 0 5.752883169840572e-10
SNRPN O 0 3.386026719454094e-06
) O 0 7.683974984074027e-11
gene O 0 1.274687716490419e-10
showed O 0 1.669515220514839e-11
a O 0 2.1837302799365688e-11
pattern O 0 1.2279104399937069e-09
characteristic O 0 2.3939552562524113e-09
of O 0 1.7442940425382858e-09
only O 0 2.0398222000395094e-10
the O 0 5.180037510044144e-10
maternal O 0 1.6517487821943178e-08
chromosome O 0 8.084278988462756e-07
15 O 0 6.451487877257023e-08
in O 0 1.1709257563552455e-08
J O 0 6.511393439723179e-05
. O 0 6.746319058947847e-07

B O 0 0.003472662065178156
. O 0 9.778119419934228e-06

Maternal B-Disease 0 0.00041916468762792647
disomy I-Disease 0 0.00407728785648942
was O 0 1.45863873513008e-06
confirmed O 0 5.453584250858512e-09
by O 0 1.8169980797733132e-10
polymerase O 0 7.864706930149623e-08
chain O 0 2.97437430241132e-09
reaction O 0 3.2403973948547105e-10
analysis O 0 5.312130735291021e-10
of O 0 3.5354865701719973e-09
microsatellite O 0 5.101562692289008e-07
repeats O 0 2.2680572087097062e-08
at O 0 1.5288625476728157e-08
the O 0 1.468041799235209e-09
gamma O 0 3.111663318122737e-07
- O 0 9.037315606974516e-08
aminobutyric O 0 4.467797225515824e-07
acid O 0 1.0069647338184495e-08
receptor O 0 1.5268138753299354e-08
beta3 O 0 1.4747028842521104e-07
subunit O 0 2.1776533287720667e-07
( O 0 7.700415416422857e-09
GABRB3 O 0 2.7795353162218817e-05
) O 0 1.112543834835833e-08
locus O 0 8.483191322739003e-07
. O 0 7.091901466083073e-08

A O 0 8.607536983618047e-06
niece O 0 4.8213642003247514e-06
( O 0 6.652495443404405e-09
B O 0 2.3724859943285992e-07
. O 0 1.3604405102451977e-10
B O 0 7.803826918006962e-09
. O 0 8.254144763519822e-12
) O 0 6.4496546124670484e-12
with O 0 5.766720000827119e-12
45 O 0 3.8002290203564826e-09
chromosomes O 0 1.8720685002193704e-09
and O 0 3.292617567485223e-11
the O 0 6.974275323923251e-11
derivative O 0 2.2889250494984026e-09
3 O 0 6.149757370010889e-10
but O 0 7.335258268847955e-12
without O 0 1.0476518957913683e-10
the O 0 1.3377844387818527e-09
der O 0 3.716791616170667e-05
( O 0 1.882240363570986e-09
15 O 0 5.159588756242783e-09
) O 0 4.8007282177353616e-11
demonstrated O 0 8.784082489166067e-11
a O 0 9.434718284406785e-11
phenotype O 0 2.5143767068414036e-09
consistent O 0 1.7157378295884484e-10
with O 0 1.236498642191719e-12
that O 0 1.3872852519525303e-11
reported O 0 2.489384809400974e-10
for O 0 2.0380448717549626e-10
haploinsufficiency O 0 1.824235255298845e-06
of O 0 6.481811283265415e-07
distal O 0 0.0007292342488653958
3 O 0 3.283273326815106e-05
p O 0 6.840551941422746e-05
. O 0 5.652356094287825e-07

Uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999998807907104
associated O 0 6.988039444877359e-07
with O 0 2.198371928940901e-09
unbalanced O 0 5.867295112693682e-05
segregation O 0 7.040079708531266e-06
of O 0 6.366761908793706e-07
non O 0 6.507722446258413e-06
- O 0 7.034603868305567e-07
Robertsonian O 0 2.114012386300601e-05
translocations O 0 8.562984703530674e-07
has O 0 5.78404213413819e-10
been O 0 8.268456058724283e-11
reported O 0 5.832317961917965e-11
previously O 0 5.7447883256012133e-11
but O 0 3.111552682177887e-12
has O 0 4.245434732930153e-12
not O 0 1.2527366297088172e-11
, O 0 8.933987230563822e-12
to O 0 6.444407507633088e-11
our O 0 2.4462135095326687e-10
knowledge O 0 1.740326216470578e-09
, O 0 1.0007809858603167e-10
been O 0 1.1592446447217242e-10
observed O 0 3.065419862391394e-10
in O 0 8.429522704855863e-12
a O 0 3.001185133744144e-10
case O 0 2.4138371301773986e-08
of O 0 8.411500402871752e-07
PWS B-Disease 1 1.0
. O 0 1.1300850928819273e-05

Furthermore O 0 6.401382506737718e-06
, O 0 2.8658957873517465e-08
our O 0 3.6304457218250263e-09
findings O 0 7.42844397105813e-10
are O 0 1.357218244041336e-11
best O 0 3.8996233325816476e-11
interpreted O 0 4.726816160705027e-10
as O 0 1.5488312021805228e-10
true O 0 1.8261295808841282e-09
gamete O 0 8.153905639574077e-08
complementation O 0 1.2060686458426062e-06
resulting O 0 1.923575965179225e-08
in O 0 1.0707865705228414e-08
maternal B-Disease 0 2.201350980612915e-05
UPD I-Disease 1 1.0
15 I-Disease 0 3.5763587220571935e-05
and O 0 5.056032478023553e-06
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9999490976333618
- I-Disease 1 1.0
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
type I-Disease 0 1.1643118341453373e-05
2 I-Disease 0 3.1092508834262844e-06
and O 0 2.2205774996564287e-08
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 1.2927406922713658e-09
a O 0 8.035955234575454e-10
case O 0 2.5308557471959148e-09
for O 0 6.59136190073184e-10
" O 0 1.790888504160648e-08
lumping O 0 9.936516676134488e-08
" O 0 2.0337178341378603e-07
. O 0 9.474458551039788e-08

Recent O 0 1.9102381898505882e-08
studies O 0 1.6467870400660445e-09
demonstrated O 0 5.604375297174613e-10
the O 0 3.493588751624088e-10
existence O 0 4.455799729186083e-09
of O 0 2.277410926510015e-09
a O 0 1.7880240621437338e-09
genetically O 0 5.5170903401347005e-09
distinct O 0 1.352417622335622e-10
, O 0 4.824472418785142e-12
usually O 0 4.354277355345104e-12
lethal O 0 6.599937957263435e-11
form O 0 3.8678078101428426e-11
of O 0 1.8439202387199316e-09
the O 0 2.282908084794144e-09
Schwartz B-Disease 0 0.0002780840150080621
- I-Disease 1 0.9993427395820618
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.985527771670604e-07
SJS B-Disease 1 0.9998327493667603
) O 0 2.566204138076955e-09
of O 0 6.868502850920777e-07
myotonia B-Disease 1 0.9999998807907104
and O 0 5.500131919689011e-06
skeletal B-Disease 1 0.9999997615814209
dysplasia I-Disease 1 1.0
, O 0 7.595276230176751e-08
which O 0 9.745754425694031e-09
we O 0 2.362548556789079e-08
called O 0 3.068278147111414e-07
SJS B-Disease 0 0.0006680863443762064
type I-Disease 0 1.22336859931238e-06
2 I-Disease 0 5.875542228750419e-06
. O 0 2.0961148550213693e-07

This O 0 1.8757507547206842e-08
disorder O 1 0.5782018303871155
is O 0 6.687222442458562e-10
reminiscent O 0 4.281680077156125e-08
of O 0 3.264675996206279e-08
another O 0 1.943497140999284e-09
rare O 0 1.3957426325816868e-09
condition O 0 4.626898544302094e-07
, O 0 5.583249973462046e-10
the O 0 1.431521212680309e-08
Stuve B-Disease 1 0.9999972581863403
- I-Disease 1 0.9999998807907104
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 8.663825610710774e-06
SWS B-Disease 1 0.9998934268951416
) O 0 8.79208317261515e-10
, O 0 6.431967458642163e-11
which O 0 4.270125225636079e-11
comprises O 0 2.347359806531557e-10
campomelia B-Disease 0 1.8636491176948766e-06
at O 0 2.6248332574141386e-07
birth O 0 1.1570880786848647e-07
with O 0 2.1997350607705357e-09
skeletal B-Disease 0 0.2864081859588623
dysplasia I-Disease 1 1.0
, O 0 2.473730660312867e-07
contractures B-Disease 0 0.021450117230415344
, O 0 9.399146350119736e-09
and O 0 3.0108247006666033e-09
early B-Disease 0 9.152636835096928e-07
death I-Disease 0 1.8708076368056936e-06
. O 0 2.2402772970053775e-07

To O 0 1.7400946461521016e-08
test O 0 1.6187253759625264e-09
for O 0 5.1250784866008203e-11
possible O 0 1.2172542973587497e-08
nosologic O 0 0.09615389257669449
identity O 0 4.21001153938505e-08
between O 0 4.116449758839735e-08
these O 0 2.3470161369942844e-09
disorders O 0 0.0016523342346772552
, O 0 1.2845675911865584e-10
we O 0 6.30816371360865e-11
reviewed O 0 2.1702863117756266e-10
the O 0 2.5343506807051774e-11
literature O 0 2.091885692445672e-11
and O 0 4.999156470730792e-13
obtained O 0 1.1511577281686503e-11
a O 0 9.955050672694199e-12
follow O 0 3.754146299383976e-11
- O 0 2.3363805334852827e-10
up O 0 5.7457087698775666e-11
of O 0 9.457906680054862e-11
the O 0 1.6417424711367978e-11
only O 0 1.3936503860667582e-11
two O 0 8.708392514045205e-12
surviving O 0 2.915031327432871e-09
patients O 0 7.589646272565531e-11
, O 0 4.961544369797011e-11
one O 0 1.1801712385128837e-10
with O 0 6.597596774460257e-11
SJS B-Disease 0 1.7300071704084985e-05
type I-Disease 0 5.3621594275909956e-08
2 I-Disease 0 1.2611202748757933e-07
at O 0 1.3681364485762515e-08
age O 0 2.0047696835945317e-09
10 O 0 2.0423683577686091e-10
years O 0 4.2391902488336797e-11
and O 0 4.576684083795746e-12
another O 0 2.0853295479295042e-10
with O 0 1.722295361883397e-10
SWS B-Disease 0 0.00011170941434102133
at O 0 8.763930736677139e-08
age O 0 7.351645336939328e-08
7 O 0 1.3539435883558326e-07
years O 0 5.231974142816398e-08
. O 0 1.0139437733869272e-07

Patients O 0 2.206557837780565e-06
reported O 0 9.735926731480049e-09
as O 0 7.357123799067722e-10
having O 0 3.9467540347004615e-09
either O 0 2.6701505362325406e-07
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 2.9751927286270075e-06
SWS B-Disease 0 0.00027524473262019455
presented O 0 2.9598282158538325e-10
a O 0 2.0954715393428636e-11
combination O 0 8.468671597317012e-11
of O 0 9.33030319671957e-10
a O 0 1.034755947593169e-09
severe O 0 7.192295470304089e-06
, O 0 8.598089351607996e-09
prenatal O 0 6.716963980579749e-05
- O 0 0.0003211712755728513
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 9.130199174478548e-08
with O 0 6.918584745108092e-07
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.999995231628418
respiratory O 1 1.0
and O 0 4.135363269597292e-06
feeding O 0 2.7739656616176944e-06
difficulties O 0 5.540270535675518e-07
, O 0 3.253812219661256e-10
tendency O 0 3.749291099808261e-09
to O 0 1.4072746301607708e-09
hyperthermia B-Disease 1 0.7523688673973083
, O 0 4.0936609657649115e-10
and O 0 4.19551234032145e-11
frequent O 0 4.758967109275147e-10
death O 0 2.1538427930067883e-08
in O 0 7.355973052902698e-10
infancy O 0 6.80978970990509e-08
) O 0 4.446666559271284e-12
with O 0 1.0958532258714682e-12
a O 0 3.267207893120627e-10
distinct O 0 1.0068514022520958e-08
campomelic B-Disease 0 0.016116734594106674
- I-Disease 0 0.3158891797065735
metaphyseal I-Disease 1 0.9998001456260681
skeletal I-Disease 1 0.9992840886116028
dysplasia I-Disease 1 1.0
. O 0 2.0731384211103432e-05

The O 0 2.640837521994399e-07
similarity O 0 2.2248876518915495e-07
of O 0 7.690788379477453e-07
the O 0 5.4502386603871855e-08
clinical O 0 4.0248374943985255e-07
and O 0 1.1508910491286883e-09
radiographic O 0 1.4728111636941321e-06
findings O 0 2.982397262485392e-08
is O 0 1.004219485345459e-09
so O 0 3.11988629375648e-11
extensive O 0 5.247789980344919e-10
that O 0 4.37969209510225e-11
these O 0 2.2182006231830087e-10
disorders O 0 8.757713658269495e-06
appear O 0 1.352320366798665e-09
to O 0 1.8127403744738757e-10
be O 0 1.5006061671041238e-10
a O 0 4.047365775861067e-10
single O 0 1.234556235019113e-09
entity O 0 3.127532579583203e-07
. O 0 5.599390533461701e-07

The O 0 5.6999599706841764e-08
follow O 0 8.31469115780692e-09
- O 0 1.3081095318057123e-08
up O 0 3.873265597142961e-10
observation O 0 4.316889512523403e-09
of O 0 3.218027233575782e-10
an O 0 1.0636056271828842e-11
identical O 0 4.1663811289893715e-11
and O 0 3.3485139574324085e-12
unique O 0 5.4517974336365516e-12
pattern O 0 3.3807991961509742e-09
of O 0 1.468132779791631e-07
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 4.632232020185256e-08
the O 0 1.4352776744885887e-08
two O 0 2.0416048018834232e-10
patients O 0 1.3853822256049142e-10
( O 0 4.6144470189357634e-11
one O 0 1.0618893264702223e-10
with O 0 1.8535764936822297e-11
SJS B-Disease 0 1.135491061177163e-06
type I-Disease 0 2.0450990234621713e-08
2 I-Disease 0 1.2298158935664105e-07
, O 0 2.565175294400035e-10
one O 0 2.2666322985198661e-10
with O 0 3.6140834769327057e-10
SWS B-Disease 0 0.0004136412753723562
) O 0 1.814657757392979e-09
surviving O 0 8.309542209872234e-08
beyond O 0 1.2286066066735657e-06
infancy O 0 5.064865717940847e-07
adds O 0 2.2577782698984805e-10
to O 0 4.662220262630079e-11
the O 0 3.282422250672212e-11
evidence O 0 5.296547575528443e-11
in O 0 1.3687869414302778e-11
favor O 0 1.4542049786570033e-09
of O 0 8.306606957830809e-09
identity O 0 6.602037672109873e-08
. O 0 8.154403730031845e-08

The O 0 9.289890954278235e-07
hypothesis O 0 5.064410288468935e-06
that O 0 2.7195360630116738e-08
SWS B-Disease 1 0.9997907280921936
and O 0 2.398660399194341e-07
SJS B-Disease 1 0.9998785257339478
type I-Disease 0 1.2571712204589858e-06
2 I-Disease 0 2.1133890015789802e-07
are O 0 2.1624096610550758e-11
the O 0 1.4907043655032481e-10
same O 0 2.714968694306208e-09
disorder O 0 4.738447785257449e-07
should O 0 2.09349626523192e-09
be O 0 1.1894257800904029e-09
testable O 0 2.7512466971302274e-08
by O 0 1.6184929785278968e-10
molecular O 0 9.286046598333542e-09
methods O 0 9.179471405218464e-09
. O 0 2.517462238671442e-09
. O 0 2.8306653021559214e-08

A O 0 6.940630896679068e-07
mouse O 0 1.1318693537987201e-08
model O 0 1.87534210382978e-09
of O 0 9.5213383843884e-09
severe O 1 0.9934282898902893
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9084916114807129
defects O 1 0.9999998807907104
in O 0 5.731771466344071e-07
hemostasis O 1 0.892030656337738
and O 0 1.259656528418418e-06
thrombosis B-Disease 1 0.9999998807907104
. O 0 0.00037734207580797374

von B-Disease 1 0.9999841451644897
Willebrand I-Disease 1 1.0
factor I-Disease 1 0.9999094009399414
( I-Disease 0 5.854868959431769e-06
vWf I-Disease 1 1.0
) I-Disease 0 3.591472705011256e-05
deficiency I-Disease 1 1.0
causes O 1 0.9999865293502808
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.03056352771818638
humans O 0 1.242483176611131e-05
. O 0 6.247882424759155e-07

We O 0 6.216619397036993e-08
generated O 0 2.054159953246426e-09
a O 0 3.267569548270899e-10
mouse O 0 2.735744408788321e-10
model O 0 4.630157715568295e-11
for O 0 1.06392221421725e-11
this O 0 6.029840515786589e-11
disease O 0 5.693522320271427e-10
by O 0 1.4456554009445455e-11
using O 0 3.695134753733953e-10
gene O 0 6.035658195457927e-09
targeting O 0 3.711638996151123e-08
. O 0 4.912688922331654e-08

vWf B-Disease 1 0.9998030066490173
- I-Disease 1 0.9999983310699463
deficient I-Disease 0 0.07569500058889389
mice O 0 1.2257622472588992e-07
appeared O 0 6.655059170412869e-09
normal O 0 8.839976750607548e-09
at O 0 7.614289643242955e-09
birth O 0 1.1779903719144613e-09
; O 0 2.6470001537881593e-11
they O 0 6.865442242487418e-11
were O 0 3.48495010626948e-10
viable O 0 4.0437122095227096e-08
and O 0 3.8100123056494795e-09
fertile O 0 1.1455409548943862e-05
. O 0 1.0914727681665681e-06

Neither O 0 0.0001536833879072219
vWf O 0 0.005690950434654951
nor O 0 7.874846050981432e-05
vWf O 0 0.001444031484425068
propolypeptide O 0 0.0008685807697474957
( O 0 8.175457821835153e-08
von B-Disease 0 0.003615688532590866
Willebrand I-Disease 0 0.0019067951943725348
antigen O 0 1.170717405329924e-05
II O 1 0.9999947547912598
) O 0 5.459464436086137e-09
were O 0 3.6726166552369932e-09
detectable O 0 1.0433878117055428e-07
in O 0 3.1980737502657064e-10
plasma O 0 7.216688402422733e-08
, O 0 3.230030687362273e-10
platelets O 0 1.7925527728834822e-08
, O 0 2.2436119628821416e-10
or O 0 1.8075693164476547e-09
endothelial O 0 3.9660119632856095e-09
cells O 0 1.6088572696304482e-09
of O 0 7.211359953629426e-09
the O 0 2.5451765139905547e-08
homozygous O 0 2.1678873451946856e-07
mutant O 0 9.285498094868672e-07
mice O 0 2.8809790819650516e-07
. O 0 5.099033018041155e-08

The O 0 2.4132309590640943e-06
mutant O 0 8.637328392069321e-06
mice O 0 1.850552564519603e-07
exhibited O 0 4.391417718352386e-08
defects O 0 0.00025866457144729793
in O 0 2.4173836266072612e-09
hemostasis O 0 5.234577201918e-06
with O 0 7.583424166401898e-11
a O 0 7.439223459471123e-09
highly O 0 1.0190194643655559e-07
prolonged O 1 0.9999986886978149
bleeding O 1 0.9999997615814209
time O 0 1.1523982266226085e-06
and O 0 8.387275762800073e-09
spontaneous O 0 1.4558315797330579e-06
bleeding O 0 3.219037171220407e-05
events O 0 2.7240135147543754e-10
in O 0 3.490010364037843e-11
approximately O 0 1.551175715652775e-10
10 O 0 8.053816502595623e-10
% O 0 1.8399607393249084e-09
of O 0 1.604690069711978e-08
neonates O 0 1.573644226482429e-06
. O 0 3.352509168053075e-07

As O 0 6.692179255196606e-08
in O 0 3.181557017839509e-09
the O 0 1.2062483456531936e-08
human O 0 3.5740672643669313e-08
disease O 0 1.2669366356021783e-07
, O 0 5.5942160626099025e-11
the O 0 2.262403597796947e-10
factor O 0 5.579952500056606e-09
VIII O 0 0.28215834498405457
level O 0 4.1480816435068846e-06
in O 0 1.3825741662643054e-09
these O 0 1.2403240934322213e-10
mice O 0 1.2506011781709958e-09
was O 0 8.06582245438392e-10
reduced O 0 5.830964044939435e-10
strongly O 0 1.0013767592909062e-10
as O 0 4.421278013838625e-12
a O 0 2.0988235455154935e-11
result O 0 1.1439397346046931e-10
of O 0 1.2520475767274775e-09
the O 0 3.244355339937499e-10
lack O 0 2.0007280276956863e-09
of O 0 1.0225387203632863e-09
protection O 0 7.633435550324918e-10
provided O 0 2.983258917677034e-10
by O 0 2.5148418902887215e-09
vWf O 0 1.9636321667348966e-05
. O 0 3.02667785945232e-07

Defective O 0 0.14803212881088257
thrombosis B-Disease 1 0.9999713897705078
in O 0 4.2546361100903596e-07
mutant O 0 1.220086460307357e-06
mice O 0 7.855198269623997e-09
was O 0 1.8129072687500525e-09
also O 0 1.9138822471287398e-11
evident O 0 4.404121234369285e-10
in O 0 2.229571562095689e-11
an O 0 1.4349388864631774e-11
in O 0 4.0756623770343836e-11
vivo O 0 1.6309918970947024e-09
model O 0 4.4547607269684875e-10
of O 0 1.6531394919638842e-07
vascular B-Disease 1 1.0
injury I-Disease 1 1.0
. O 0 0.0001376596192130819

In O 0 7.141225832896225e-09
this O 0 1.81511722319172e-10
model O 0 7.494992959600211e-10
, O 0 2.342390725829091e-10
the O 0 1.3954019051354294e-09
exteriorized O 0 2.361364977332414e-06
mesentery O 0 1.1259864550083876e-05
was O 0 3.8889265852048993e-07
superfused O 0 2.0428669813554734e-06
with O 0 2.782057251238257e-09
ferric O 0 1.773110852809623e-05
chloride O 0 7.030037068034289e-07
and O 0 1.4458065855649238e-08
the O 0 3.780602497727159e-08
accumulation O 0 3.9615342757315375e-06
of O 0 1.2694042652583448e-06
fluorescently O 0 6.671947630820796e-06
labeled O 0 1.8527457257278002e-07
platelets O 0 8.209428870031843e-08
was O 0 1.4212536036950496e-08
observed O 0 2.6480480030954823e-09
by O 0 5.531364810629213e-10
intravital O 0 2.0332090571173467e-06
microscopy O 0 3.693796770676272e-06
. O 0 6.760649284842657e-07

We O 0 9.90190983429784e-07
conclude O 0 6.645980647590477e-06
that O 0 4.7307509021266014e-09
these O 0 3.1333848848902335e-09
mice O 0 6.392217244410858e-08
very O 0 1.0842556852352914e-09
closely O 0 2.05853787349497e-08
mimic O 0 7.970687875058502e-06
severe O 1 0.9998286962509155
human O 0 0.0042204344645142555
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.0257627991450136e-07
will O 0 2.5827571192849064e-09
be O 0 3.785338986705966e-10
very O 0 1.062285849562361e-11
useful O 0 1.2960601342149047e-11
for O 0 3.3466365529505326e-12
investigating O 0 1.2497136658851105e-10
the O 0 1.7011946018552493e-10
role O 0 4.980567069878816e-10
of O 0 2.3473385457606355e-09
vWf O 0 7.962375434544811e-07
in O 0 4.413615306564367e-10
normal O 0 1.73257035385177e-08
physiology O 0 1.18861231968026e-08
and O 0 1.2090987933088826e-10
in O 0 4.2968761881923e-10
disease O 0 8.270294671319789e-09
models O 0 8.127052364415022e-10
. O 0 2.9449409577608776e-09
. O 0 5.4503633606373114e-08

Oral O 0 9.607309038983658e-05
contraceptives O 0 1.7808433767640963e-05
and O 0 9.358623875854732e-10
the O 0 2.4429043232743197e-09
risk O 0 3.40396923093067e-07
of O 0 0.06505817174911499
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9999358654022217

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 0 0.0150366872549057
Study O 0 2.1136643226782326e-06
Group O 0 6.808750896425408e-08
. O 0 7.700095494556081e-08

BACKGROUND O 0 1.2266477824596222e-05
Women O 0 1.368605673235379e-09
with O 0 1.6641868438860286e-11
mutations O 0 1.2985555963851425e-09
in O 0 8.47067416209768e-11
either O 0 1.4673195991576904e-09
the O 0 3.671489334777789e-09
BRCA1 O 0 8.749449875722348e-08
or O 0 1.8647199340193765e-09
the O 0 3.057101016779029e-09
BRCA2 O 0 4.6533077835420045e-08
gene O 0 2.827166278862592e-10
have O 0 6.180441575187601e-12
a O 0 6.994297502282976e-11
high O 0 4.172079126618655e-09
lifetime O 0 1.7699600007858862e-08
risk O 0 1.72235672835086e-06
of O 1 0.9999589920043945
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0018845237791538239

Oral O 1 0.9492643475532532
contraceptives O 1 0.9984684586524963
protect O 0 1.5690746295149438e-05
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 8.298137004203454e-07
general O 0 6.59281965909031e-07
, O 0 2.7551824710592143e-10
but O 0 1.2113464745167057e-11
it O 0 2.5630988217256734e-12
is O 0 3.684475901460926e-12
not O 0 4.076958388943286e-12
known O 0 7.590544165436697e-11
whether O 0 1.179136233098177e-10
they O 0 2.1348253026465258e-11
also O 0 2.2522157749893523e-11
protect O 0 7.077918112718962e-11
against O 0 3.782814506081422e-09
hereditary B-Disease 1 0.9974433183670044
forms I-Disease 0 0.4129442274570465
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0005062041454948485

METHODS O 0 4.540039299172349e-06
We O 0 2.4718245228427804e-08
enrolled O 0 1.3682983635021628e-08
207 O 0 5.273046443932117e-09
women O 0 5.6707919610099466e-11
with O 0 2.3998331100116843e-10
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.6045898121319624e-07
161 O 0 1.3271870713538192e-08
of O 0 1.8082735309121745e-08
their O 0 1.7154892784088105e-10
sisters O 0 4.2897926877394355e-10
as O 0 2.1870233055110155e-11
controls O 0 8.918775162847226e-10
in O 0 2.6590637677847972e-11
a O 0 4.3010414674249375e-10
case O 0 7.3444246240228495e-09
- O 0 5.6927564884290405e-08
control O 0 8.386480487843073e-08
study O 0 2.724520342667347e-08
. O 0 4.459653624167004e-08

All O 0 6.477949199279465e-08
the O 0 7.84518139340662e-09
patients O 0 3.2546440542624566e-10
carried O 0 7.094678317054459e-11
a O 0 4.0228893133376076e-11
pathogenic O 0 3.495401468267545e-10
mutation O 0 9.703108316827525e-10
in O 0 5.777908360093953e-11
either O 0 1.509966707224919e-09
BRCA1 O 0 6.682421371806413e-08
( O 0 1.9405252404958162e-10
179 O 0 1.2307053154358982e-09
women O 0 8.63157982589069e-12
) O 0 8.213625959929693e-12
or O 0 7.505135402041674e-10
BRCA2 O 0 1.7824991971338022e-07
( O 0 1.878499578111814e-09
28 O 0 1.3587644787094177e-07
women O 0 3.6950076331976334e-10
) O 0 1.2114447223154912e-09
. O 0 3.0697879793706306e-08

The O 0 2.5026301386787964e-07
control O 0 6.552359650413564e-07
women O 0 1.664441501292302e-10
were O 0 5.41427666589378e-11
enrolled O 0 1.9547828633559305e-10
regardless O 0 6.075907554858873e-10
of O 0 6.876113012310725e-10
whether O 0 2.980818925024664e-10
or O 0 9.062128825121363e-10
not O 0 4.2776593378590633e-10
they O 0 1.414879879924058e-10
had O 0 1.0108610615233715e-09
either O 0 5.501937128116197e-09
mutation O 0 1.4537793902036356e-07
. O 0 1.062812700070026e-07

Lifetime O 0 8.874561899574474e-06
histories O 0 1.340259586868342e-06
of O 0 1.3310475424077595e-06
oral O 0 5.281079211272299e-06
- O 0 2.559479810315679e-07
contraceptive O 0 6.642808969559155e-09
use O 0 3.431495018690889e-11
were O 0 1.1292756660341574e-11
obtained O 0 2.5968970029932592e-11
by O 0 8.38985565049244e-12
interview O 0 3.9066233581408483e-10
or O 0 1.9285840285876432e-11
by O 0 2.2736704012593645e-12
written O 0 8.678396543060352e-12
questionnaire O 0 2.232967630244609e-11
and O 0 6.200703579067879e-12
were O 0 1.712013690535752e-11
compared O 0 9.417548685330956e-11
between O 0 6.299894494965486e-10
patients O 0 8.289680053508164e-11
and O 0 3.309877025237107e-11
control O 0 1.1560661761222946e-08
women O 0 7.756861993002406e-12
, O 0 2.802424091397082e-12
after O 0 2.2574886404669314e-11
adjustment O 0 5.157992366555675e-10
for O 0 1.8038752783167133e-11
year O 0 1.408804600755431e-10
of O 0 4.09037737014728e-09
birth O 0 1.3240619267662623e-08
and O 0 2.570446300254048e-09
parity O 0 2.3444504222425167e-06
. O 0 6.368067602124938e-07

RESULTS O 0 2.2982126210990828e-06
The O 0 3.343530252664095e-08
adjusted O 0 1.6922319545642495e-08
odds O 0 4.624269323016961e-08
ratio O 0 5.6669589021396405e-09
for O 0 1.5641580830560997e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 4.1511494686119477e-08
with O 0 2.5616534934935764e-11
any O 0 1.195265997289141e-09
past O 0 7.271022117727455e-10
use O 0 1.170317315279945e-10
of O 0 1.032415819501864e-09
oral O 0 7.892777631468562e-08
contraceptives O 0 4.559698538741941e-07
was O 0 1.5420641830132809e-07
0 O 0 2.284998714685571e-07
. O 0 7.379053812428538e-08

5 O 0 7.20563662071072e-07
( O 0 5.724296592291012e-09
95 O 0 1.1970557523000025e-07
percent O 0 5.5203773996481686e-08
confidence O 0 1.1063964855395625e-08
interval O 0 7.890625397521944e-08
, O 0 6.61276866598115e-10
0 O 0 3.326379394152923e-09
. O 0 8.096444348293375e-11
3 O 0 2.2851995851169704e-09
to O 0 1.1168634905800445e-09
0 O 0 1.7711418109911392e-08
. O 0 1.12397768869954e-09
8 O 0 6.173655009433787e-08
) O 0 7.491967046746595e-09
. O 0 9.897438246753154e-08

The O 0 3.228199147997657e-07
risk O 0 3.960806225222768e-07
decreased O 0 5.623749022021229e-09
with O 0 3.4826076484445467e-12
increasing O 0 2.1444125641867373e-10
duration O 0 1.500493240769174e-08
of O 0 6.325396317841125e-10
use O 0 2.3156486450570668e-10
( O 0 5.437336692004635e-10
P O 0 8.199200465242029e-07
for O 0 3.9979089483388464e-10
trend O 0 5.412795545112203e-09
, O 0 1.0605250705397751e-10
< O 0 1.1135441013720992e-07
0 O 0 4.659469254875148e-09
. O 0 8.600294781890838e-11
001 O 0 1.489488643535708e-09
) O 0 1.6591372373198077e-12
; O 0 1.0439945349188795e-12
use O 0 9.922540220030918e-12
for O 0 2.949322730483317e-11
six O 0 5.647110556949997e-11
or O 0 4.1015919827191993e-11
more O 0 3.2882353524082975e-12
years O 0 9.856375438044296e-11
was O 0 4.918665474917816e-10
associated O 0 2.223854954352955e-11
with O 0 8.036310874572072e-13
a O 0 2.0941141876118508e-10
60 O 0 1.9938672934927126e-09
percent O 0 2.8561537579463447e-09
reduction O 0 2.2592148596345396e-08
in O 0 4.4989518777072135e-09
risk O 0 1.6160629456862807e-06
. O 0 7.592884685436729e-07

Oral O 0 0.00020725569629576057
- O 0 5.389842044678517e-06
contraceptive O 0 2.036633048874137e-07
use O 0 2.448231395391076e-09
protected O 0 8.991252116175019e-07
against O 1 0.9891786575317383
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 9.990440696938663e-10
for O 0 5.6043936852434584e-11
carriers O 0 2.3348736138961712e-11
of O 0 4.183112745081985e-10
the O 0 3.259887637607761e-10
BRCA1 O 0 6.071624536474474e-09
mutation O 0 2.669050980230736e-09
( O 0 1.0794493077170841e-10
odds O 0 2.0214038443100435e-08
ratio O 0 8.272388885011139e-10
, O 0 2.946078450638545e-11
0 O 0 4.4973538781967193e-10
. O 0 2.0862674435240258e-11
5 O 0 2.6141927511602603e-10
; O 0 2.0628819832890777e-11
95 O 0 4.750127402530779e-09
percent O 0 2.974567037128395e-09
confidence O 0 2.0798169853009085e-09
interval O 0 1.1779483166662885e-08
, O 0 1.437270580328942e-10
0 O 0 1.4686859506340966e-09
. O 0 3.33682283193415e-11
3 O 0 4.851496426816482e-10
to O 0 1.0577695663815945e-10
0 O 0 2.3351387490322395e-09
. O 0 5.690251048129369e-11
9 O 0 2.0403678746561127e-09
) O 0 8.211198214425064e-12
and O 0 2.375430581402771e-12
for O 0 5.100997315515832e-12
carriers O 0 2.532389055398543e-11
of O 0 7.508671462375105e-10
the O 0 1.6929220247874355e-09
BRCA2 O 0 1.0121526372586231e-07
mutation O 0 1.2301802243541715e-08
( O 0 4.3766881785423095e-10
odds O 0 6.255955042888672e-08
ratio O 0 1.3057781522718415e-09
, O 0 4.465060265967935e-11
0 O 0 7.097172294301402e-10
. O 0 2.8177007602159243e-11
4 O 0 7.195858353625795e-10
; O 0 3.9715189470435064e-11
95 O 0 7.774707100338674e-09
percent O 0 1.235329616378067e-08
confidence O 0 4.5511332480430156e-09
interval O 0 3.4305777774079615e-08
, O 0 6.769224625280401e-10
0 O 0 6.81597267515599e-09
. O 0 1.6434445471169568e-10
2 O 0 3.0306215315079044e-09
to O 0 4.766615990803302e-10
1 O 0 4.6179319923567164e-08
. O 0 1.3202986481886114e-09
1 O 0 2.3509785762598767e-07
) O 0 9.030040715174437e-09
. O 0 7.981490313113682e-08

CONCLUSIONS O 0 0.0001501138467574492
Oral O 0 9.31630638660863e-05
- O 0 3.7927395624137716e-06
contraceptive O 0 1.4715193685788108e-07
use O 0 1.9417620289452486e-10
may O 0 2.0144201584582078e-10
reduce O 0 5.119902835026835e-10
the O 0 3.2168490093908986e-10
risk O 0 2.9637246257152583e-07
of O 1 0.9565215706825256
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 9.576801573984994e-08
women O 0 1.3966573557400164e-11
with O 0 7.802620854112374e-13
pathogenic O 0 1.6277403036557558e-10
mutations O 0 3.464035169820079e-10
in O 0 9.748161999834082e-11
the O 0 1.5278385223638224e-09
BRCA1 O 0 2.3764873446907586e-07
or O 0 3.13359635129018e-07
BRCA2 O 0 3.777765596169047e-05
gene O 0 1.2341256478975993e-05

A O 0 2.6043469461001223e-06
Japanese O 0 8.346106028511713e-07
family O 0 9.229682795819372e-09
with O 0 1.3781878971386163e-09
adrenoleukodystrophy B-Disease 1 1.0
with O 0 3.2280740303036737e-09
a O 0 4.6078579174491097e-08
codon O 0 4.64177531966925e-07
291 O 0 2.5904844491719814e-08
deletion O 0 1.9875238876920776e-07
: O 0 1.59859084303271e-10
a O 0 7.392429446362314e-10
clinical O 0 3.627097555636283e-08
, O 0 8.642428439564753e-10
biochemical O 0 9.594408112434394e-08
, O 0 5.120784241086085e-09
pathological O 0 0.011708073318004608
, O 0 8.767956138910904e-09
and O 0 4.730660752017002e-09
genetic O 0 7.504010568482045e-07
report O 0 9.140737056156922e-09
. O 0 9.215718677069162e-08

We O 0 5.500701760752236e-08
report O 0 6.802617913415077e-10
a O 0 9.808688306023328e-10
Japanese O 0 1.6749112319303094e-08
family O 0 5.681524140044303e-10
with O 0 1.0416747464603304e-09
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.0007146539865061641
ALD B-Disease 1 1.0
) O 0 9.27282084450809e-10
with O 0 2.8119130288106753e-11
a O 0 6.43103903463782e-10
three O 0 8.785640964736885e-11
base O 0 1.29320931741006e-09
pair O 0 3.0045815835322287e-10
deletion O 0 2.400421550419196e-08
( O 0 1.342359667866333e-09
delGAG O 0 1.024092739498883e-06
291 O 0 5.504435129921603e-09
) O 0 2.244232577552907e-10
in O 0 1.716282116426271e-09
the O 0 1.670607900905452e-07
ALD B-Disease 1 1.0
gene O 0 4.095006443094462e-05
. O 0 2.8309516437730053e-06

A O 0 5.231575528341637e-07
variety O 0 7.495940756996333e-09
of O 0 2.2220774553716183e-08
phenotypes O 0 2.7632479415728994e-08
were O 0 2.4346838434219364e-10
observed O 0 4.938679465382734e-10
within O 0 4.419317967130354e-10
this O 0 6.138998753790759e-10
family O 0 6.468168667339569e-09
. O 0 3.7754858794869506e-08

While O 0 7.80268436528786e-08
the O 0 2.753105121655608e-08
proband O 0 0.00018870909116230905
( O 0 3.627900113656324e-08
patient O 0 1.873368233873407e-07
1 O 0 5.658817485709733e-07
) O 0 4.667365383070887e-10
was O 0 1.52125601005082e-08
classified O 0 7.148362457520818e-10
as O 0 8.270065188220599e-11
having O 0 2.529493836611607e-10
a O 0 1.0532760080783632e-10
rare O 0 5.021312879383011e-11
intermediate O 0 1.2851613107045523e-09
type O 0 2.249745056914776e-09
of O 0 1.087474643668429e-08
adult O 0 5.9193155266257236e-08
cerebral O 0 4.0659200749360025e-05
and O 0 1.9157404551606305e-08
cerebello O 1 0.999969482421875
- O 0 0.00025642706896178424
brain O 0 5.446722752822097e-06
stem O 0 3.907295820226864e-09
forms O 0 3.132074877232327e-10
, O 0 1.9474135845576335e-11
his O 0 6.94729690442486e-11
younger O 0 2.2824454826153584e-10
brother O 0 3.2022748897020392e-09
( O 0 7.606660440417912e-11
patient O 0 1.1829799362317317e-09
2 O 0 4.740596803998187e-09
) O 0 2.8174535621205976e-11
and O 0 1.4884088406219576e-10
nephew O 0 4.3570773300416477e-07
( O 0 1.764404178317136e-09
patient O 0 2.571438351139932e-08
3 O 0 3.420646166318875e-08
) O 0 4.165024991564792e-10
had O 0 6.4179430658839465e-09
a O 0 6.289359077982226e-08
childhood O 0 0.0010523092932999134
ALD B-Disease 1 1.0
type O 0 0.0007976123015396297
. O 0 8.449468623439316e-06

Another O 0 3.216992354282411e-06
nephew O 0 0.0006245130789466202
( O 0 9.32337229642144e-08
patient O 0 5.790383852399827e-07
4 O 0 2.7318998263581307e-07
) O 0 4.424057786778235e-10
of O 0 1.4680117566001627e-08
patient O 0 4.412567733425021e-08
1 O 0 6.761861186532769e-07
was O 0 6.957252196571062e-08
classified O 0 8.969288090021621e-10
as O 0 1.7106990823911872e-10
having O 0 4.850709833803535e-10
an O 0 4.928704666617989e-10
adolescent O 0 8.350120594968757e-08
form O 0 1.5226493843556455e-08
. O 0 2.752732939370617e-07

The O 0 5.235248750068422e-07
tau O 0 1.4077714922677842e-06
level O 0 1.2136128191286844e-07
in O 0 7.902591914188406e-10
the O 0 3.3124631926284565e-09
cerebrospinal O 0 1.1659579968181788e-06
fluid O 0 1.1503668702061987e-06
( O 0 1.049121038931844e-07
CSF O 1 0.9997745156288147
) O 0 8.960550634817821e-10
in O 0 1.5071432990509948e-10
patient O 0 1.1574203817588113e-09
1 O 0 2.3357008771540677e-08
was O 0 6.619056414081115e-09
as O 0 3.3285339762212374e-11
high O 0 2.7792182444308366e-10
as O 0 3.780039215667275e-12
that O 0 2.7442028684154796e-12
of O 0 6.858979495483197e-10
patients O 0 3.010673932379859e-10
with O 0 1.8673325108409244e-09
Alzheimers B-Disease 1 1.0
disease I-Disease 0 0.016347847878932953
( O 0 6.049903689131497e-09
AD B-Disease 0 3.83534006687114e-06
) O 0 3.6768870614878324e-08
. O 0 1.2067170018781326e-07

His O 0 1.3059031516604591e-05
brain O 0 9.276945638703182e-05
magnetic O 0 1.0413006748422049e-05
resonance O 0 4.633739536075154e-06
image O 0 2.359903277238118e-07
( O 0 9.905800624210315e-09
MRI O 0 6.918162853253307e-06
) O 0 9.824772106981072e-10
showed O 0 2.5287567595455585e-09
abnormalities B-Disease 0 3.976668381255877e-07
in I-Disease 0 3.1088151497549177e-10
the I-Disease 0 2.3567596763029997e-09
bilateral I-Disease 0 0.00019647879526019096
cerebellar I-Disease 1 1.0
hemispheres I-Disease 1 0.9999942779541016
and O 0 2.133961913841631e-07
brain O 0 0.0003775711520574987
stem O 0 6.299948296373259e-08
, O 0 1.7775151142651602e-11
but O 0 2.1185301776749377e-12
not O 0 4.438260956668438e-12
in O 0 7.90062459898877e-12
the O 0 7.215467112686724e-11
cerebral O 0 9.922935078066075e-07
white O 0 2.325688752691235e-09
matter O 0 1.2661402593039384e-08
, O 0 2.8393018838834827e-11
where O 0 2.213351897595306e-11
marked O 0 5.14176271004807e-11
reductions O 0 1.112911007794537e-08
of O 0 9.22083209786706e-09
the O 0 5.878201925213489e-09
cerebral O 0 5.845072337251622e-06
blood O 0 4.915172624464503e-08
flow O 0 2.6970655042646285e-08
and O 0 1.3768268747327284e-09
oxygen O 0 4.947733334148552e-09
metabolism O 0 5.319697571337656e-09
were O 0 4.9243047139935214e-11
clearly O 0 1.1431327412436687e-10
demonstrated O 0 2.2994771017859073e-11
by O 0 3.9766731574353287e-11
positron O 0 1.361802759447528e-07
emission O 0 4.3825400553032523e-07
tomography O 0 2.023106844717404e-06
( O 0 9.517202670394909e-08
PET O 0 4.580148015520535e-06
) O 0 2.265143450586038e-08
. O 0 1.2372801450055704e-07

In O 0 2.0515773258011905e-07
patients O 0 1.689970829943377e-08
2 O 0 1.4470596454430051e-07
and O 0 8.449733690518713e-10
3 O 0 5.102301869897019e-08
, O 0 2.0239405984501246e-10
the O 0 3.953261884515058e-10
autopsy O 0 4.150957799708976e-09
findings O 0 4.760837279960128e-10
showed O 0 7.565484905214248e-10
massive O 0 2.46030595008051e-07
demyelination B-Disease 1 1.0
of I-Disease 0 0.0003301762917544693
the I-Disease 0 4.939579412166495e-07
cerebral I-Disease 1 0.9649320840835571
white I-Disease 0 9.723028604469164e-09
matter I-Disease 0 2.897968087722802e-09
with O 0 3.7456543942882e-12
sparing O 0 2.172014124113275e-09
of O 0 4.980078216476613e-08
the O 0 4.7770146949233094e-08
U O 0 0.0012236894108355045
- O 0 6.392448881342716e-07
fibers O 0 1.6416352721648764e-08
, O 0 4.9456338330200467e-11
compatible O 0 8.019969133243876e-10
with O 0 8.002847516619394e-12
the O 0 3.3510474950482205e-10
findings O 0 1.8502863685654347e-09
of O 0 1.5404663145091035e-07
childhood O 0 0.0015571920666843653
ALD B-Disease 1 1.0
. O 0 1.2794452231901232e-05

Oleic O 0 0.0016987917479127645
and O 0 2.371362143094302e-06
erucic O 0 0.004614006727933884
acids O 0 1.1910881312360289e-06
( O 0 1.1288832979516883e-08
Lorenzos O 0 6.57247574054054e-06
Oil O 0 2.393069280515192e-07
) O 0 5.781932571613524e-11
were O 0 3.5598766989775044e-11
administered O 0 1.3162397560773087e-10
to O 0 9.784429516601634e-11
patients O 0 2.3234263124560783e-10
1 O 0 3.191635755683819e-08
and O 0 3.762441469490341e-10
4 O 0 1.7797772144945156e-08
, O 0 7.491958442518154e-11
but O 0 1.8803115314769414e-11
sufficient O 0 3.2503014169016353e-10
effectiveness O 0 6.976114685919299e-10
was O 0 3.585646002335352e-09
not O 0 3.551760274778104e-10
obtained O 0 2.8433328580490524e-08
. O 0 8.239642568241834e-08

The O 0 1.1728685933576344e-07
findings O 0 3.902767442554023e-09
in O 0 6.23289961310114e-11
this O 0 8.278919216841985e-11
family O 0 4.1527746519332e-11
suggest O 0 6.285884313061985e-11
that O 0 7.166238956413107e-12
delGAG291 O 0 9.139516699008254e-09
is O 0 4.640865122751414e-11
part O 0 1.7117207651295985e-10
of O 0 1.603755905854598e-09
the O 0 5.831942706535642e-10
cause O 0 1.0368509606450971e-07
of O 0 1.440130859009514e-06
Japanese O 0 1.7620361177250743e-05
ALD B-Disease 1 1.0
with O 0 5.062824826040924e-09
phenotypic O 0 3.367696081113536e-06
variations O 0 1.717601548989478e-06
. O 0 2.1241974934582686e-07

Moreover O 0 1.416517079633195e-06
, O 0 1.1077642136925192e-09
although O 0 1.6310221229165478e-10
the O 0 7.793436729297554e-11
scale O 0 2.0508645448558127e-08
of O 0 3.888568134158277e-09
the O 0 1.6294549043394113e-10
study O 0 5.354669832535741e-11
is O 0 1.03100583626059e-11
limited O 0 4.263256414560601e-11
, O 0 2.5731024949626757e-11
there O 0 3.4690850886365254e-11
is O 0 7.605035351465617e-11
a O 0 3.6732103469994115e-10
possibility O 0 5.437518879602976e-08
that O 0 9.990688276673154e-10
PET O 0 1.7147752373602998e-07
can O 0 6.350879822036859e-10
detect O 0 7.977762095379148e-08
an O 0 2.3147048722194086e-09
insidious B-Disease 0 2.009384479606524e-05
lesion I-Disease 0 0.21371173858642578
which O 0 1.6868333396757862e-09
is O 0 3.619133048804457e-10
undetectable O 0 3.0803319894801007e-09
by O 0 3.942070628260019e-11
computed O 0 5.5718516023262055e-08
tomogram O 0 2.1581503460765816e-05
( O 0 3.013423111042357e-08
CT O 0 0.00048064711154438555
) O 0 1.9984016663698867e-09
or O 0 1.145258887724765e-09
MRI O 0 6.909736782745313e-08
analysis O 0 3.0436886344631375e-10
, O 0 1.1957230344750158e-11
and O 0 3.2966001890094576e-12
that O 0 1.5017986854104493e-12
the O 0 2.196424986333767e-11
higher O 0 4.26879143144987e-10
level O 0 4.539637110667627e-09
of O 0 1.3181447044985362e-09
tau O 0 1.2855713826809279e-08
reflects O 0 8.578505267253789e-11
the O 0 3.006689688889175e-11
process O 0 6.046704803530645e-10
of O 0 6.1107892079803605e-09
neuronal B-Disease 0 2.9098977393005043e-05
degeneration I-Disease 1 1.0
in O 0 7.541470040450804e-06
ALD B-Disease 1 1.0
. O 0 7.598182492074557e-06

Lorenzos O 0 0.0003444280300755054
Oil O 0 1.0504641068109777e-06
should O 0 2.1550004003501044e-09
be O 0 9.505433246070893e-11
given O 0 3.693399405757525e-11
in O 0 1.3258238257263244e-11
the O 0 6.890157194794355e-11
early O 0 4.660135832779133e-09
stage O 0 1.3090006412141975e-08
. O 0 1.5635422956350453e-09
. O 0 4.5850548247017286e-08

Nonsense O 0 8.265905489679426e-05
mutation O 0 8.57660154451878e-07
in O 0 6.919427697482661e-09
exon O 0 2.2984070824350056e-07
4 O 0 4.751389326429489e-08
of O 0 6.1840359499854e-09
human O 0 1.109688563261102e-09
complement O 0 3.752897104192243e-09
C9 O 0 0.0004162164404988289
gene O 0 1.9493182623619987e-09
is O 0 8.513369870177812e-11
the O 0 1.0001322686692404e-10
major O 0 2.8353543957138072e-09
cause O 0 3.021192185315158e-08
of O 0 3.0631204595010786e-07
Japanese O 0 5.996863592372392e-07
complement B-Disease 0 2.479531758581288e-06
C9 I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9996634721755981
. O 0 4.574770173348952e-06

Deficiency B-Disease 1 0.9972681999206543
of I-Disease 0 2.8168777134851553e-05
the I-Disease 0 3.9670283058512723e-07
ninth I-Disease 0 1.6989026789815398e-06
component I-Disease 0 1.0705704056590548e-07
of I-Disease 0 3.7626321613970504e-08
human I-Disease 0 1.709173580444201e-09
complement I-Disease 0 5.067732455898977e-09
( O 0 1.1847824943345131e-08
C9 O 1 0.9758415222167969
) O 0 4.76505279678463e-10
is O 0 8.638007670258574e-11
the O 0 6.899020243977816e-11
most O 0 1.9246998092525835e-11
common O 0 6.129103891083787e-09
complement B-Disease 1 0.9999991655349731
deficiency I-Disease 1 1.0
in O 0 7.427852111163702e-09
Japan O 0 7.157370696120324e-09
but O 0 1.0412075368559925e-10
is O 0 5.753823806298186e-11
rare O 0 9.052191635161577e-11
in O 0 7.529276507822757e-11
other O 0 6.941072022703665e-11
countries O 0 9.886731433539353e-10
. O 0 9.536572065371729e-08

We O 0 1.3750160121617228e-07
studied O 0 8.122179195879653e-08
the O 0 6.634954252682235e-10
molecular O 0 7.509076915823698e-09
basis O 0 2.0408283063488852e-08
of O 0 1.0502878922125092e-06
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999984502792358
in O 0 3.4246479430066756e-08
four O 0 4.7235473310536236e-09
Japanese O 0 2.3632208012713818e-07
C9 B-Disease 1 0.9994285702705383
- I-Disease 0 4.418729440658353e-05
deficient I-Disease 0 1.7814705870478065e-06
patients O 0 4.338855053021007e-09
who O 0 5.05842301379289e-09
had O 0 5.2139732531486516e-08
suffered O 0 7.780096348142251e-05
from O 0 1.137316030508373e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 4.9429536375100724e-06

Direct O 0 1.1054577271352173e-06
sequencing O 0 1.0415421911602607e-06
of O 0 1.0189820613959455e-06
amplified O 0 2.375314124947181e-06
C9 O 0 0.00015952768444549292
cDNA O 0 3.3895830142682826e-07
and O 0 1.2743285315863773e-09
DNA O 0 1.4468272802048432e-08
revealed O 0 4.4039807356455185e-09
a O 0 5.021717486286548e-10
nonsense O 0 3.85521943258027e-08
substitution O 0 4.209706361280041e-08
( O 0 2.3402306759123803e-09
CGA O 0 2.0373168752030324e-07
- O 0 4.236392214806983e-07
- O 0 2.2511461850172054e-07
> O 0 2.3746159172333137e-07
TGA O 0 2.2290906542821176e-07
) O 0 1.401883747975674e-10
at O 0 1.2272360905285495e-09
codon O 0 1.8255724709703713e-09
95 O 0 1.6582727413450016e-09
in O 0 1.611153432889978e-10
exon O 0 1.5254691732025094e-08
4 O 0 1.0476749245924566e-08
in O 0 2.685605349217468e-10
the O 0 2.9678628443718935e-09
four O 0 1.9619866620246285e-08
C9 B-Disease 1 0.9425578117370605
- I-Disease 0 5.967140896245837e-05
deficient I-Disease 0 2.1655928321706597e-06
individuals O 0 1.2863342391256083e-08
. O 0 2.8611313496185176e-07

An O 0 3.048665320193322e-08
allele O 0 1.9641288417915348e-07
- O 0 1.3234357609803737e-08
specific O 0 6.13370854107842e-10
polymerase O 0 4.727127844716961e-08
chain O 0 1.891492962258212e-09
reaction O 0 8.903100479074055e-11
system O 0 6.891129333830293e-11
designed O 0 1.0354641449827895e-10
to O 0 4.3839962909908436e-11
detect O 0 4.367598227528191e-10
exclusively O 0 1.5935183728110758e-11
only O 0 7.805095111890203e-12
one O 0 1.1013626642630836e-11
of O 0 5.735547453644685e-11
the O 0 3.681948496092602e-11
normal O 0 9.643417314686431e-11
and O 0 1.1245512333835084e-11
mutant O 0 2.3190256659422204e-10
alleles O 0 4.438771225578897e-11
indicated O 0 6.801057633731844e-11
that O 0 2.8832539654410905e-12
all O 0 1.8104450230649327e-11
the O 0 5.049164558679209e-11
four O 0 1.1318072347388242e-11
patients O 0 3.276965721346614e-12
were O 0 1.3777447932517006e-11
homozygous O 0 4.8858528334250195e-11
for O 0 8.835496570491763e-12
the O 0 1.0361358993016268e-10
mutation O 0 1.318692932628096e-09
in O 0 2.6942864606027683e-10
exon O 0 2.081302241663252e-08
4 O 0 4.101744721651812e-09
and O 0 1.2827306057616727e-11
that O 0 8.532059607435638e-12
the O 0 2.0558441060636312e-10
parents O 0 7.597293627537027e-11
of O 0 3.6067928643745972e-09
patient O 0 1.1403247235364233e-08
2 O 0 2.0458251981381181e-07
were O 0 2.10778097198272e-08
heterozygous O 0 3.951968707838205e-08
. O 0 7.742406182842387e-08

The O 0 2.6990423407369235e-07
common O 0 8.526708938916272e-08
mutation O 0 1.1176530279044528e-07
at O 0 4.034251688267432e-08
codon O 0 3.3368532825761577e-08
95 O 0 2.303202961684292e-08
in O 0 4.281920651383331e-10
exon O 0 2.7314822403923245e-08
4 O 0 4.428762689911991e-09
might O 0 1.9733262246468541e-10
be O 0 7.912285410194286e-11
responsible O 0 1.8395361900402918e-09
for O 0 3.0221805613628305e-10
most O 0 1.8595345263605623e-09
Japanese O 0 4.845989224122604e-06
C9 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.5236656069755554
. O 0 2.3753000277793035e-07
. O 0 4.806930178347102e-07

BRCA1 O 0 1.1293957413727185e-06
required O 0 1.2044275798928084e-08
for O 0 3.579099905337557e-09
transcription O 0 1.3180797395762056e-06
- O 0 6.756098969162849e-07
coupled O 0 1.9620058822056308e-07
repair O 0 4.327903752709972e-06
of O 0 3.6965666367905214e-06
oxidative O 0 4.881056520389393e-05
DNA O 0 6.484079494839534e-05
damage O 0 0.47972843050956726
. O 0 1.5052909247970092e-06

The O 0 3.804823791142553e-05
breast B-Disease 1 1.0
and I-Disease 1 0.999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 1.0
gene O 0 3.664142786874436e-05
BRCA1 O 0 5.526262611965649e-06
encodes O 0 2.136176746603269e-08
a O 0 5.72619685001996e-09
zinc O 0 2.7298449367663125e-07
finger O 0 2.3740271615224628e-07
protein O 0 4.173092094106323e-08
of O 0 4.8532132979062226e-08
unknown O 0 1.3144452282176644e-07
function O 0 5.867831731620754e-08
. O 0 6.980034328307738e-08

Association O 0 1.26461429772462e-07
of O 0 3.348182815443579e-07
the O 0 5.8084363985244636e-08
BRCA1 O 0 1.1836354474326072e-07
protein O 0 1.519022685414484e-09
with O 0 8.57578504737111e-12
the O 0 6.293829901693471e-10
DNA O 0 2.2851310177429696e-08
repair O 0 2.1521350390685257e-07
protein O 0 4.143776877185701e-08
Rad51 O 0 9.978356985129722e-08
and O 0 3.992953190312676e-11
changes O 0 5.3032397917540663e-11
in O 0 4.6789322416529444e-11
the O 0 6.723131079633404e-11
phosphorylation O 0 8.344476776223075e-10
and O 0 1.3252303421307232e-10
cellular O 0 6.5590088915712386e-09
localization O 0 1.623733254518811e-07
of O 0 2.4184780400560157e-08
the O 0 2.1249435544490325e-09
protein O 0 3.1023366098281713e-09
after O 0 1.6213519415941846e-09
exposure O 0 7.785139644056471e-09
to O 0 3.4935221382426107e-10
DNA O 0 3.5079413152061534e-08
- O 0 8.837060860855672e-09
damaging O 0 6.8843575284915914e-09
agents O 0 4.1598779976226297e-11
are O 0 1.667916564411509e-12
consistent O 0 2.3425816841893266e-11
with O 0 2.162366152021894e-13
a O 0 4.924257529514975e-11
role O 0 2.708212543112154e-10
for O 0 2.074467542190206e-10
BRCA1 O 0 6.674192576383575e-08
in O 0 5.427599703011765e-09
DNA O 0 1.1734318832168356e-06
repair O 0 4.3270443711662665e-05
. O 0 2.258410859212745e-06

Here O 0 1.86774357757713e-07
, O 0 7.085837472331491e-10
it O 0 4.7896159260929494e-11
is O 0 7.811146174319106e-11
shown O 0 7.256222012141933e-11
that O 0 6.860598894542491e-11
mouse O 0 5.927065771516027e-08
embryonic O 0 1.3877818219043547e-06
stem O 0 2.4656637265252357e-07
cells O 0 9.27530141581201e-09
deficient B-Disease 0 1.709604724453584e-08
in I-Disease 0 4.102986839171763e-10
BRCA1 I-Disease 0 3.4854455321919886e-08
are O 0 5.220751608803198e-11
defective O 0 1.5553901278053672e-08
in O 0 3.725330877113464e-10
the O 0 2.5183685692375946e-10
ability O 0 2.7807972938220793e-11
to O 0 5.424592719460719e-11
carry O 0 1.1634511409841508e-10
out O 0 1.046491573952757e-10
transcription O 0 1.4667495662479269e-08
- O 0 1.7263490192931386e-08
coupled O 0 1.0628102842247245e-08
repair O 0 2.5565768169144576e-07
of O 0 1.0688138019077087e-07
oxidative O 0 4.0573874571236956e-07
DNA O 0 1.4878290812703199e-06
damage O 0 0.00022860211902298033
, O 0 1.7206546187864546e-09
and O 0 4.968801481375351e-10
are O 0 2.0672827338863442e-10
hypersensitive O 0 3.5614041848930356e-07
to O 0 7.956138148301761e-08
ionizing O 0 0.00010669906623661518
radiation O 0 9.911453526001424e-05
and O 0 2.520230779623489e-08
hydrogen O 0 1.8641027565990953e-07
peroxide O 0 2.0231568669260014e-06
. O 0 2.548806037339091e-07

These O 0 1.0036494302312349e-08
results O 0 7.684319847101051e-09
suggest O 0 1.4736956543970336e-08
that O 0 1.077822497919101e-09
BRCA1 O 0 5.079357379145222e-07
participates O 0 2.5818409632449857e-09
, O 0 4.516055931991225e-11
directly O 0 5.941819813948257e-10
or O 0 1.1734828664344832e-09
indirectly O 0 2.73030487107917e-08
, O 0 2.719439951004432e-10
in O 0 2.439327351222431e-10
transcription O 0 8.135496898376005e-08
- O 0 5.4404857507961424e-08
coupled O 0 2.2708883662403423e-08
repair O 0 4.1005779394254205e-07
of O 0 2.985191827065137e-07
oxidative O 0 1.327217091784405e-06
DNA O 0 2.6795148642122513e-06
damage O 0 2.773344749584794e-05
. O 0 5.5388976960557557e-08
. O 0 1.2410617955538328e-07

Truncation O 0 0.00012063721806043759
mutations O 0 1.147100078924268e-06
in O 0 1.3884143834630436e-09
the O 0 2.8523101658350924e-09
transactivation O 0 1.2209874512336683e-05
region O 0 7.655502258785418e-07
of O 0 1.1512514674905105e-06
PAX6 O 1 0.8780543208122253
result O 0 1.5409395359711198e-07
in O 0 6.756870174484675e-09
dominant O 0 5.883852054466843e-07
- O 0 9.113357180012827e-08
negative O 0 3.539347659398118e-08
mutants O 0 3.950973592736773e-08
. O 0 1.4642366430450693e-08

PAX6 O 0 0.0016412289114668965
is O 0 1.7570302546232597e-08
a O 0 2.8030482379648447e-09
transcription O 0 4.51724311290036e-08
factor O 0 1.7408174901589746e-09
with O 0 2.0018932258419886e-12
two O 0 1.0317809107096565e-11
DNA O 0 1.7239658589573992e-09
- O 0 2.8196980306205432e-09
binding O 0 3.634015399711643e-08
domains O 0 2.286810314444665e-07
( O 0 4.798286767915272e-10
paired O 0 5.213818266014414e-10
box O 0 6.0719953509646984e-09
and O 0 4.2322445548137466e-10
homeobox O 0 7.323640716094815e-08
) O 0 2.369622276177097e-10
and O 0 3.118126867818205e-10
a O 0 7.000497515008419e-09
proline O 0 2.7379562084206555e-07
- O 0 3.606176051107468e-07
serine O 0 3.901809861872607e-07
- O 0 1.0741555342974607e-06
threonine O 0 3.624923692768789e-06
( O 0 5.216509535443947e-08
PST O 0 0.00040412673843093216
) O 0 1.4083574306766877e-08
- O 0 2.4897917683119886e-07
rich O 0 5.88211896968005e-08
transactivation O 0 1.1744208677555434e-05
domain O 0 3.7376801174104912e-06
. O 0 4.4801109311265463e-07

PAX6 O 1 0.9999904632568359
regulates O 0 0.00010886151721933857
eye O 0 0.036239899694919586
development O 0 1.2189979088361724e-06
in O 0 4.896371752494133e-09
animals O 0 3.337384535395671e-10
ranging O 0 4.723504432035952e-08
from O 0 2.160339285239843e-08
jellyfish O 0 4.653500695894763e-09
to O 0 1.1518704878810127e-09
Drosophila O 0 7.171377269798995e-09
to O 0 8.223666747575464e-10
humans O 0 1.0127719995978168e-08
. O 0 5.3412342992942285e-08

Heterozygous O 0 1.1537442787812324e-06
mutations O 0 9.558169722367893e-08
in O 0 8.585531729998763e-10
the O 0 3.4533105264245023e-09
human O 0 1.3926692687959985e-08
PAX6 O 0 0.0003339772520121187
gene O 0 1.1914903730314563e-08
result O 0 2.8211775138231587e-09
in O 0 4.932398239843039e-11
various O 0 3.316904390038289e-11
phenotypes O 0 3.2038205421969224e-09
, O 0 3.286776059652219e-11
including O 0 1.7249385253492733e-10
aniridia B-Disease 1 1.0
, O 0 2.543658297327056e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 3.34672023427629e-08
autosomal B-Disease 0 8.105840970529243e-05
dominant I-Disease 0 0.4290105700492859
keratitis I-Disease 1 0.9999994039535522
, O 0 1.6389971335684095e-07
and O 0 1.622562990633014e-07
familial B-Disease 1 0.9999998807907104
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.4844852685928345

It O 0 5.066727037927876e-09
is O 0 1.1575262970353606e-09
believed O 0 1.92045179758793e-09
that O 0 2.88527986225251e-11
the O 0 2.1410491435336354e-10
mutated O 0 2.3544231009253735e-09
allele O 0 2.8552783248869673e-08
of O 0 4.418134125216966e-08
PAX6 O 0 7.243204890983179e-05
produces O 0 2.1287731577501745e-09
an O 0 1.8577044069711945e-10
inactive O 0 2.9470257345565187e-09
protein O 0 1.947185301887089e-09
and O 0 5.898572186247009e-10
aniridia B-Disease 1 1.0
is O 0 3.786736257893608e-08
caused O 0 4.50744039426354e-07
due O 0 8.64320043092448e-07
to O 0 9.273642831431061e-08
genetic O 0 4.820407866645837e-06
haploinsufficiency O 0 0.0001043972370098345
. O 0 6.698883225908503e-07

However O 0 2.9789188715767523e-07
, O 0 1.9205688150947253e-09
several O 0 1.2353283673771642e-10
truncation O 0 2.680417026112991e-07
mutations O 0 2.125901410465758e-08
have O 0 1.6374464284485413e-10
been O 0 1.2703746388176285e-10
found O 0 1.5635498104571433e-11
to O 0 8.07475700886906e-12
occur O 0 4.530930491908336e-11
in O 0 3.593227798637244e-11
the O 0 2.1668655758588784e-10
C O 0 6.881333547426038e-07
- O 0 3.2618249434790414e-08
terminal O 0 8.595518607990016e-08
half O 0 1.9774943904593556e-09
of O 0 2.7292674786849602e-09
PAX6 O 0 1.0061708962894045e-05
in O 0 6.11035499975543e-10
patients O 0 1.0862587912496835e-10
with O 0 7.582729583122116e-11
Aniridia B-Disease 1 1.0
resulting O 0 1.6723963369713601e-07
in O 0 1.9141945806211424e-09
mutant O 0 2.0038903869590285e-09
proteins O 0 7.05588972665927e-12
that O 0 1.7761959437978536e-12
retain O 0 7.399380413941614e-11
the O 0 5.701538546842855e-11
DNA O 0 1.3667169618258868e-09
- O 0 5.028004679275e-10
binding O 0 2.7214648312678946e-09
domains O 0 1.572116659076528e-08
but O 0 1.501949120630286e-10
have O 0 8.905682441495699e-11
lost O 0 2.7110513833861205e-09
most O 0 1.4708375142835628e-11
of O 0 4.5906942136575424e-10
the O 0 1.6524254187189058e-09
transactivation O 0 2.4794230739644263e-06
domain O 0 1.401609097229084e-06
. O 0 1.2210195166062476e-07

It O 0 3.5365521622310325e-09
is O 0 5.056028928862588e-10
not O 0 1.310573177759622e-10
clear O 0 2.071921967328194e-09
whether O 0 1.9999908673629108e-10
such O 0 3.144129678833707e-10
mutants O 0 1.2356386491774174e-07
really O 0 3.335744569454846e-09
behave O 0 5.2528070781932e-10
as O 0 2.6679247699945563e-10
loss O 0 7.725188488905133e-09
- O 0 8.781348270758826e-08
of O 0 1.9316762234211637e-07
- O 0 7.87694105497394e-08
function O 0 4.029505173974712e-09
mutants O 0 4.5660075720377336e-10
as O 0 2.3897283457641194e-11
predicted O 0 5.871366948184686e-09
by O 0 9.61422053080696e-10
haploinsufficiency O 0 4.748951687361114e-05
. O 0 7.63926834679296e-07

Contrary O 0 1.4236607626116893e-07
to O 0 7.529911694170721e-10
this O 0 2.971027590614739e-10
theory O 0 6.134462893214732e-08
, O 0 1.9297884124025444e-10
our O 0 9.34486654724509e-11
data O 0 1.458251297492552e-10
showed O 0 4.6506829637360525e-11
that O 0 5.6390894558056015e-12
these O 0 3.4444112059078824e-12
mutants O 0 3.1354341345490866e-10
are O 0 1.3082448319101658e-11
dominant O 0 1.9213686641705863e-08
- O 0 1.1857817838745177e-08
negative O 0 2.3230286583242332e-09
in O 0 1.820345402192558e-10
transient O 0 1.1252309306541974e-08
transfection O 0 9.593050798173408e-09
assays O 0 1.2477420208156786e-09
when O 0 4.003660597495795e-11
they O 0 1.3460759416827894e-11
are O 0 6.2647556413331085e-12
coexpressed O 0 1.0588550480861159e-07
with O 0 2.7439908678594804e-10
wild O 0 3.912391477456367e-08
- O 0 4.0273869217344327e-07
type O 0 4.696312316809781e-06
PAX6 O 0 0.13088537752628326
. O 0 1.802281076379586e-06

We O 0 9.351779794997128e-08
found O 0 7.377780608663898e-10
that O 0 1.8353181821528786e-11
the O 0 7.995927808757131e-10
dominant O 0 1.2974797414244676e-07
- O 0 1.9604192047495417e-08
negative O 0 2.5875646070261382e-09
effects O 0 1.1477348849098234e-08
result O 0 1.6405576896971752e-09
from O 0 6.375274197445435e-10
the O 0 1.5697029787098415e-10
enhanced O 0 2.462575143802326e-10
DNA O 0 1.0259341154394974e-09
binding O 0 2.3466892873358347e-09
ability O 0 2.737811366504417e-10
of O 0 5.587919016392107e-09
these O 0 6.096966265189963e-10
mutants O 0 2.833971457505413e-08
. O 0 1.821757500408694e-08

Kinetic O 0 2.4997559648909373e-06
studies O 0 2.9216790764508005e-08
of O 0 1.1338139316308116e-08
binding O 0 7.386996259128864e-08
and O 0 2.523269371224046e-09
dissociation O 0 2.3846078534006665e-07
revealed O 0 7.690903913726288e-09
that O 0 1.6970034752428198e-11
various O 0 2.3266492898965652e-11
truncation O 0 7.080453201524506e-08
mutants O 0 3.584825325475549e-09
have O 0 5.057289656495989e-11
3 O 0 2.6175517309212637e-09
- O 0 6.538174890380333e-09
5 O 0 6.818702935618148e-09
- O 0 6.968671417695305e-09
fold O 0 3.3821343503603885e-09
higher O 0 1.1502985231004459e-09
affinity O 0 2.480048666431145e-10
to O 0 6.572038052654605e-11
various O 0 2.3156122852530103e-11
DNA O 0 4.63089316893317e-10
- O 0 1.509617431061372e-10
binding O 0 2.5760696353849255e-10
sites O 0 6.414668796139722e-11
when O 0 1.0569461972309568e-11
compared O 0 3.9523093131599296e-11
with O 0 3.203668883997035e-12
the O 0 1.1908536379223733e-09
wild O 0 1.379487812869229e-08
- O 0 1.0692888707808379e-07
type O 0 1.2018134611935238e-06
PAX6 O 0 0.0031887146178632975
. O 0 2.4638025024614763e-06

These O 0 6.741435853996336e-09
results O 0 2.907457608003483e-09
provide O 0 1.4052943531073225e-10
a O 0 7.326372286620142e-10
new O 0 1.752045591940643e-10
insight O 0 7.153873049503545e-10
into O 0 8.976830390139412e-11
the O 0 4.8285903053724155e-11
role O 0 1.621542761176542e-10
of O 0 1.2447042285756993e-09
mutant O 0 3.912413859552544e-08
PAX6 O 0 2.6949246603180654e-05
in O 0 6.259115892248701e-09
causing O 0 1.494118123446242e-06
aniridia B-Disease 1 1.0
. O 0 5.356496899366903e-07
. O 0 7.209093269011646e-07

Reversal O 0 1.2250626241439022e-05
of O 0 1.0002592716773506e-05
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 2.044545362878125e-05
excellent O 0 4.5220835431791784e-07
neuropsychologic O 1 0.5267806649208069
outcome O 0 0.0001608283637324348
in O 0 1.345980393807622e-08
very B-Disease 0 1.0472633427127676e-08
- I-Disease 0 2.858303105313098e-07
long I-Disease 0 7.522870504317325e-08
- I-Disease 0 5.662532132078013e-08
chain I-Disease 0 9.82916326108807e-09
acyl I-Disease 0 3.3106772434621234e-08
- I-Disease 0 8.236436599418084e-08
coenzyme I-Disease 0 2.9787416977455905e-08
A I-Disease 0 4.546460331766866e-06
dehydrogenase I-Disease 0 0.00048664212226867676
deficiency I-Disease 1 0.8747339844703674
. O 0 5.470012183650397e-06

Very B-Disease 0 2.9738764624198666e-06
- I-Disease 0 1.2883453564427327e-05
long I-Disease 0 5.119351840221498e-07
- I-Disease 0 1.273961487413544e-07
chain I-Disease 0 5.950896220241475e-09
acyl I-Disease 0 4.471132797334576e-09
- I-Disease 0 2.014075350942335e-09
coenzyme I-Disease 0 4.970412414984082e-10
A I-Disease 0 7.521060219062292e-09
dehydrogenase I-Disease 0 4.8403084207393476e-08
( I-Disease 0 2.826283207468805e-09
VLCAD I-Disease 1 0.999995231628418
) I-Disease 0 1.1122043730438236e-08
deficiency I-Disease 0 1.933516841745586e-06
is O 0 4.310272139207427e-10
a O 0 8.313549848537605e-09
disorder O 1 0.9836993217468262
of O 0 0.0002989831264130771
fatty O 0 3.1075376227818197e-06
acid O 0 5.1725489669252056e-08
beta O 0 2.164699175466467e-08
oxidation O 0 1.7778762906317525e-09
that O 0 5.819228432457635e-11
reportedly O 0 2.645326846462126e-09
has O 0 1.5388452664910623e-11
high O 0 2.8072735802631144e-10
rates O 0 3.166831519241242e-10
of O 0 3.6567848749058385e-09
morbidity O 0 8.75261832788965e-07
and O 0 1.4626371225290313e-08
mortality O 0 3.729085392478737e-06
. O 0 2.7566420612856746e-07

We O 0 2.2697451029785043e-08
describe O 0 3.0401972050952963e-09
the O 0 4.5193151998468295e-10
outcome O 0 1.1887800077658994e-08
of O 0 2.715812907894133e-09
a O 0 2.9508884225037946e-10
5 O 0 1.139608851730145e-09
- O 0 1.0384709758781696e-09
year O 0 4.132407194212817e-10
- O 0 9.38420718910038e-09
old O 0 1.3766279671756365e-08
girl O 0 5.467454267105154e-10
with O 0 1.1357217943874787e-10
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 5.585470717051066e-07
was O 0 1.5780686624111695e-07
first O 0 4.852514501330063e-10
seen O 0 3.342525700666954e-10
at O 0 1.5924314644699678e-10
5 O 0 8.666028311621332e-11
months O 0 2.087318165533425e-11
of O 0 1.1013568529394391e-10
age O 0 1.0859071419844213e-09
with O 0 6.294462867595385e-11
severe O 1 0.9997033476829529
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.8335608243942261
hepatomegaly B-Disease 1 1.0
, O 0 0.001082215690985322
encephalopathy B-Disease 1 0.9999991655349731
, O 0 8.274288347820402e-07
and O 0 1.6987310118565802e-06
hypotonia B-Disease 0 0.4325321614742279
. O 0 2.384801882726606e-05

Biochemical O 0 4.121928668610053e-06
studies O 0 8.325572480316623e-07
indicated O 1 0.9409275650978088
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 1.4330436897580512e-05
by O 0 1.0806714412225915e-09
a O 0 4.970225564449038e-09
stable O 0 4.912567064252471e-08
yet O 0 1.0853238308072832e-08
inactive O 0 6.302496302623695e-08
enzyme O 0 4.673320219694688e-08
. O 0 5.773026501287859e-08

Molecular O 0 2.9955549507576507e-06
genetic O 0 5.566539940105031e-08
analysis O 0 8.86102746733286e-09
of O 0 2.6574559797154507e-07
her O 0 2.1935521843374772e-08
VLCAD O 1 0.9999755620956421
gene O 0 1.519864554211381e-07
revealed O 0 1.7976070409986278e-07
a O 0 1.8907220677988335e-08
T1372C O 0 2.7610312827164307e-05
( O 0 1.410344019348031e-08
F458L O 0 7.639292562089395e-06
) O 0 2.2769244267806243e-09
missense O 0 5.102993441141734e-07
mutation O 0 7.769581600314268e-08
and O 0 4.00531430244655e-09
a O 0 1.3399485965237545e-07
1668 O 0 0.0006190864951349795
ACAG O 1 0.9954042434692383
1669 O 0 0.0001304399047512561
splice O 0 2.663028681126889e-05
site O 0 5.408886067925778e-07
mutation O 0 6.775482006560196e-07
. O 0 2.0790056964870018e-07

After O 0 1.792498665054154e-07
initial O 0 3.9748439206732655e-08
treatment O 0 3.673746462595773e-08
with O 0 5.886074960770316e-10
intravenous O 0 1.2822903272535768e-07
glucose O 0 2.468974798830459e-06
and O 0 1.6539548619576294e-09
carnitine O 0 1.2277932626147958e-07
, O 0 6.088367587864241e-10
the O 0 1.9636927639510304e-09
patient O 0 1.5233842631801053e-08
has O 0 2.598994075508898e-10
thrived O 0 3.5187486258081435e-09
on O 0 1.1935550325858912e-09
a O 0 7.989341965775054e-10
low O 0 3.3740633398338105e-07
- O 0 1.488541414573774e-07
fat O 0 1.4703886108691222e-07
diet O 0 1.331024512829515e-09
supplemented O 0 3.487548097536042e-11
with O 0 5.816151813636816e-12
medium O 0 9.528572775252542e-08
- O 0 1.2927198156376107e-07
chain O 0 3.5199452241840845e-08
triglyceride O 0 1.7117231720931159e-07
oil O 0 1.8619510910866666e-07
and O 0 1.622162404402161e-09
carnitine O 0 3.099339807022261e-08
and O 0 6.982051603543482e-10
avoidance O 0 2.092424011834737e-07
of O 0 9.346641149932111e-07
fasting O 0 4.767657628690358e-06
. O 0 1.6339826913736033e-07

Her O 0 1.3056900343144662e-06
ventricular O 1 0.9998449087142944
hypertrophy O 1 0.9999904632568359
resolved O 0 4.310495933168568e-05
significantly O 0 2.285331568430138e-08
over O 0 3.91820709211288e-09
1 O 0 4.6598799485764175e-08
year O 0 2.348577721189571e-10
, O 0 2.050572038558851e-11
and O 0 2.9255337735678566e-11
cognitively O 0 6.591945833633872e-08
, O 0 7.992264489109502e-11
she O 0 1.854708227277957e-11
is O 0 6.6096347145494505e-12
in O 0 6.71628334544816e-12
the O 0 3.011373095329617e-11
superior O 0 5.02945596281279e-09
range O 0 3.378454493940808e-08
for O 0 9.793831523552399e-09
age O 0 2.6646275728126056e-06
. O 0 3.05390670973793e-07

Clinical O 0 6.240454695216613e-06
recognition O 0 5.989546480122954e-06
of O 1 1.0
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 4.674385820635507e-07
important O 0 2.4202440052079055e-09
because O 0 2.2768266438877305e-11
it O 0 1.2605689062028524e-12
is O 0 2.636141088405153e-12
one O 0 4.259352853058784e-12
of O 0 8.24939561105964e-11
the O 0 5.170637529250399e-11
few O 0 2.3259614720383404e-11
directly O 0 1.0585975429577843e-09
treatable O 0 0.17687535285949707
causes O 0 1.6070185893113376e-07
of O 0 5.519449769053608e-05
cardiomyopathy B-Disease 1 1.0
in O 0 7.200380423455499e-06
children O 0 2.135655208235221e-08
. O 0 5.541790581986561e-09
. O 0 5.8949339631908515e-08

Cloning O 0 2.9272359824972227e-07
of O 0 8.599811529563794e-09
a O 0 5.811045533654635e-10
novel O 0 1.0376394188327254e-09
member O 0 3.777787249692466e-10
of O 0 1.8088728293008671e-09
the O 0 1.7053928269561425e-09
low O 0 3.141741444778745e-07
- O 0 5.794493773692011e-08
density O 0 2.213017680219309e-08
lipoprotein O 0 8.619012078270316e-06
receptor O 0 1.6237785530393012e-05
family O 0 1.0407642747622958e-07
. O 0 2.0119728105782997e-07

A O 0 8.954703503150085e-07
gene O 0 5.7311355661227026e-09
encoding O 0 1.0278912832006881e-08
a O 0 1.864940646356672e-09
novel O 0 6.1459846101286075e-09
transmembrane O 0 2.149997442302265e-07
protein O 0 2.3699218143491407e-09
was O 0 7.032492366221277e-10
identified O 0 1.9163516259967928e-11
by O 0 1.5613435024042221e-12
DNA O 0 6.398831464693444e-11
sequence O 0 7.36790056049541e-12
analysis O 0 2.4920237314679516e-12
within O 0 3.00732043434504e-11
the O 0 1.1791406739902754e-10
insulin B-Disease 0 8.831923878460657e-06
- I-Disease 0 0.0002122078149113804
dependent I-Disease 0 0.13026711344718933
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.1648138809050579e-07
IDDM B-Disease 0 0.00022567695123143494
) O 0 2.0651595988852023e-09
locus O 0 1.685220638592e-07
IDDM4 O 0 1.1035343959520105e-05
on O 0 1.5130412123198766e-07
chromosome O 0 1.4999578525021207e-05
11q13 O 0 6.548418605234474e-05
. O 0 7.170873459472205e-07

Based O 0 5.2782212378588156e-08
on O 0 4.194318137251685e-08
its O 0 5.175237460797177e-10
chromosomal O 0 2.898683078456088e-06
position O 0 2.0205315820476244e-07
, O 0 4.1186817845151324e-11
this O 0 1.175049554186236e-11
gene O 0 5.007177311666666e-11
is O 0 8.082939699505243e-12
a O 0 5.271693498398733e-11
candidate O 0 3.459830644203521e-09
for O 0 1.3315570868144277e-10
conferring O 0 6.446076383781474e-08
susceptibility O 0 2.671343281690497e-05
to O 0 1.2804991911252728e-06
diabetes B-Disease 1 1.0
. O 0 3.659616777440533e-05

The O 0 3.059275854866428e-07
gene O 0 2.6930663921120868e-08
, O 0 1.5147983978280877e-09
termed O 0 5.94210860072053e-07
low O 0 1.2511893146438524e-05
- O 0 5.880178264305869e-07
density O 0 3.296393202845138e-08
lipoprotein O 0 9.378910590385203e-07
receptor O 0 1.7285638875819131e-07
related O 0 7.557729553298032e-09
protein O 0 6.585433975914157e-09
5 O 0 3.352404576162371e-09
( O 0 5.375476730407058e-10
LRP5 O 0 9.391241292178165e-06
) O 0 1.909890162687944e-10
, O 0 9.378471610421713e-11
encodes O 0 1.0383576637407188e-10
a O 0 4.443568013545729e-10
protein O 0 6.356506432325659e-09
of O 0 2.8625688486272338e-08
1615 O 0 4.663464551413199e-06
amino O 0 6.782141781513928e-08
acids O 0 1.0515521786658155e-09
that O 0 5.147863905985428e-12
contains O 0 2.1158255703035422e-11
conserved O 0 5.007256276279293e-10
modules O 0 2.7233745814037036e-10
which O 0 3.381097268481681e-12
are O 0 1.2552928531708862e-12
characteristic O 0 7.84647555263085e-11
of O 0 3.022330441471155e-10
the O 0 2.78274042697646e-10
low O 0 7.753711628311066e-08
- O 0 2.895726325391479e-08
density O 0 1.205429533968072e-08
lipoprotein O 0 1.471419864174095e-06
( O 0 1.5765486693908315e-08
LDL O 0 2.707701969484333e-05
) O 0 9.83422676625878e-09
receptor O 0 9.61272235144861e-07
family O 0 2.748718586076393e-08
. O 0 9.431834513407011e-08

These O 0 2.0158442026740886e-08
modules O 0 1.2606561483607948e-07
include O 0 1.925773984723378e-09
a O 0 1.3572566182062928e-08
putative O 0 3.477709924482042e-07
signal O 0 1.0120329818619211e-07
peptide O 0 5.121624457871121e-09
for O 0 1.2619534583979686e-10
protein O 0 2.714868885256294e-10
export O 0 7.198466822622152e-10
, O 0 5.64283619830519e-11
four O 0 7.549408320706164e-11
epidermal O 0 1.5724944901762683e-08
growth O 0 6.662371210275353e-10
factor O 0 5.057574359312866e-09
( O 0 6.407628316829062e-10
EGF O 0 3.1198140959531884e-07
) O 0 8.298824127894733e-11
repeats O 0 5.677818770699616e-10
with O 0 7.5284249320684e-12
associated O 0 1.6590763207702253e-09
spacer O 0 9.696493918909255e-08
domains O 0 7.900052167997274e-08
, O 0 4.0792497157937646e-10
three O 0 3.10770076339395e-10
LDL O 0 1.396192715219513e-06
- O 0 4.343585544575035e-07
receptor O 0 5.467510959533683e-07
( O 0 5.841241268456088e-09
LDLR O 0 0.00012352973863016814
) O 0 7.418292091720957e-10
repeats O 0 3.87650489486191e-09
, O 0 4.3950815209470306e-11
a O 0 2.3275603666661482e-10
single O 0 2.19779749954796e-09
transmembrane O 0 2.0339079753739497e-07
spanning O 0 9.943797607547822e-08
domain O 0 1.1568629076919024e-07
, O 0 5.118125923075922e-10
and O 0 3.6815853143856714e-10
a O 0 1.1583374259771517e-08
cytoplasmic O 0 1.1220204214623664e-06
domain O 0 1.4537449715135153e-06
. O 0 1.6417770609677973e-07

The O 0 7.224717535336822e-08
encoded O 0 8.806419593554438e-09
protein O 0 4.853664581361272e-09
has O 0 1.4280174265302037e-11
a O 0 1.4556661431797124e-11
unique O 0 1.7327231663366582e-11
organization O 0 5.86941495406279e-10
of O 0 3.0830605624032614e-08
EGF O 0 0.0001627491437830031
and O 0 1.320994513775986e-08
LDLR O 1 0.9999299049377441
repeats O 0 1.1042675396311097e-07
; O 0 2.0465250327728057e-10
therefore O 0 4.841146150624809e-09
, O 0 4.416318422073573e-10
LRP5 O 0 0.013062569312751293
likely O 0 1.1094393848054551e-08
represents O 0 2.7212040953905614e-10
a O 0 6.054260565102609e-11
new O 0 1.4017279524602966e-11
category O 0 6.033973876107268e-10
of O 0 1.6497234689438756e-09
the O 0 7.390995371281406e-09
LDLR O 1 0.9753397107124329
family O 0 1.3177789526253036e-07
. O 0 2.4619700411676604e-07

Both O 0 4.1935504668799695e-07
human O 0 1.269039557882934e-07
and O 0 7.87310749927883e-09
mouse O 0 3.023077681518771e-07
LRP5 O 1 0.9954570531845093
cDNAs O 0 0.00020505343854893
have O 0 2.6091526716953695e-09
been O 0 3.0270166373469465e-09
isolated O 0 8.368228776589604e-09
and O 0 6.869895624594946e-11
the O 0 2.946939914316715e-10
encoded O 0 7.020377057465055e-10
mature O 0 5.060351027097454e-10
proteins O 0 8.250051683478254e-12
are O 0 1.6994060238889608e-12
95 O 0 5.765031785287533e-10
% O 0 4.954785470800971e-10
identical O 0 1.0594333049729343e-10
, O 0 3.5342558740714125e-11
indicating O 0 9.174688231361472e-10
a O 0 4.777957474111361e-10
high O 0 8.857226063696544e-09
degree O 0 1.1534170596405602e-07
of O 0 2.044045999127775e-08
evolutionary O 0 3.4520216019018335e-08
conservation O 0 3.221959588017853e-09
. O 0 1.0374929804157773e-09
. O 0 1.9281971574969248e-08

The O 0 6.397656875378743e-07
APC B-Disease 0 6.819967097726476e-07
variants O 0 5.6099853651403464e-08
I1307K O 0 1.574515954416711e-05
and O 0 1.5188749147299063e-09
E1317Q O 0 5.2648165365098976e-06
are O 0 1.400857346789408e-10
associated O 0 1.0952123119523094e-07
with O 0 7.498088234569877e-05
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.432902246913727e-07
but O 0 3.7321370993659286e-10
not O 0 6.720823203520965e-11
always O 0 2.0620952861927222e-11
with O 0 7.312038344600702e-13
a O 0 4.723868518574648e-10
family O 0 9.249398469357573e-10
history O 0 1.9526012806636572e-08
. O 0 6.799108831501144e-08

Classical O 1 0.6074303388595581
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 9.110139217227697e-06
FAP B-Disease 0 6.101967755967053e-06
) O 0 3.328510245204086e-10
is O 0 1.2502071600195563e-10
a O 0 5.903753041991422e-09
high O 0 0.00018599470786284655
- O 1 0.9970148801803589
penetrance O 1 0.9999998807907104
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999963045120239
that O 0 2.268588428222529e-09
predisposes O 0 3.400189427793521e-07
to O 0 1.024725415632588e-09
hundreds O 0 1.6401001390331515e-10
or O 0 5.886883203132243e-10
thousands O 0 6.565840093841757e-10
of O 0 1.3359742752072634e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999985694885254
carcinoma I-Disease 1 1.0
and O 0 1.0303237019115841e-07
that O 0 1.168203644930088e-09
results O 0 1.8299439741298329e-09
from O 0 3.0444970988696696e-09
truncating O 0 5.36397024575308e-08
mutations O 0 4.9614357067184756e-09
in O 0 4.882091952929102e-10
the O 0 8.489542402401185e-09
APC B-Disease 0 2.3471412191611307e-07
gene O 0 5.28418482304005e-08
. O 0 4.765784566984621e-08

A O 0 3.1769081942911725e-07
variant O 0 7.684629963478073e-07
of O 0 2.0693066744570388e-06
FAP B-Disease 0 7.264531450346112e-05
is O 0 5.461195087264059e-07
attenuated B-Disease 1 0.9137297868728638
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999984502792358
coli I-Disease 1 0.9999855756759644
, O 0 6.502457683410512e-09
which O 0 2.159599721274219e-10
results O 0 5.153114601696984e-10
from O 0 2.805947474371351e-09
germ O 0 3.6124722555541666e-06
- O 0 3.3860345638458966e-08
line O 0 7.63977592299625e-09
mutations O 0 8.978171539553159e-10
in O 0 2.9351358149520834e-11
the O 0 1.443683228519177e-10
5 O 0 7.403520574378319e-10
and O 0 3.4314166091897746e-11
3 O 0 2.274354926612432e-09
regions O 0 2.405223575863147e-09
of O 0 2.264953380404222e-08
the O 0 5.757862098221267e-08
APC B-Disease 0 8.058830758272961e-07
gene O 0 1.3269168164242728e-07
. O 0 8.200650114531527e-08

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 0.00015047383203636855
have O 0 2.8338524415971733e-08
" O 0 1.92262291420775e-07
multiple O 0 8.442779630968289e-07
" O 1 0.9997428059577942
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 5.425242832757249e-08
typically O 0 3.6467480146740172e-09
fewer O 0 4.67525705649674e-11
than O 0 4.544189330379922e-11
100 O 0 1.6187060025707467e-10
) O 0 7.620858805124087e-12
without O 0 1.0925568783015649e-10
the O 0 7.059908768702883e-10
florid O 0 2.0139616196956922e-07
phenotype O 0 5.040973505288093e-08
of O 0 3.881167742747493e-08
classical O 0 2.2434594484366244e-06
FAP B-Disease 0 6.893406407471048e-06
. O 0 2.903818767663324e-07

Another O 0 2.723040211094485e-07
group O 0 9.719135718455618e-09
of O 0 4.176276746648e-08
patients O 0 2.0511490284036427e-09
with O 0 6.048835737848535e-11
multiple O 0 4.579243295665947e-07
adenomas B-Disease 1 0.9999998807907104
has O 0 9.634822717430325e-09
no O 0 1.6281137549256641e-09
mutations O 0 2.1588513199333192e-09
in O 0 8.711270593764198e-11
the O 0 3.1604954764397064e-10
APC B-Disease 0 4.026285971292509e-09
gene O 0 5.432112537562261e-10
, O 0 2.517536526469577e-11
and O 0 2.488149443424792e-11
their O 0 1.1622772189134878e-11
phenotype O 0 7.1247363564452826e-09
probably O 0 2.532285048317817e-09
results O 0 3.1776620224022167e-10
from O 0 3.4627667400144446e-10
variation O 0 1.2263895676767333e-08
at O 0 5.899494781580472e-10
a O 0 3.296790271334338e-11
locus O 0 4.350547921916359e-09
, O 0 1.7599657842204408e-11
or O 0 1.9843623966231405e-10
loci O 0 1.0817236884008707e-08
, O 0 1.1313286418790369e-10
elsewhere O 0 4.426986832672952e-10
in O 0 1.558542322976919e-10
the O 0 1.690411810528758e-09
genome O 0 5.076442022300398e-08
. O 0 7.772487009560791e-08

Recently O 0 1.68194333127758e-06
, O 0 3.780217916471429e-09
however O 0 2.4522786024050447e-09
, O 0 1.7723768286348474e-10
a O 0 2.9224342390499203e-10
missense O 0 4.641535866767299e-08
variant O 0 1.2960971673692256e-07
of O 0 9.34558738663327e-06
APC B-Disease 0 2.627999265314429e-06
( O 0 3.584558649905034e-09
I1307K O 0 5.618456725642318e-06
) O 0 6.596313772977425e-11
was O 0 6.067291669076269e-10
described O 0 7.326367984505922e-11
that O 0 1.365656936494486e-12
confers O 0 1.5777923412230166e-10
an O 0 5.424838529777265e-12
increased O 0 1.1473929584226994e-09
risk O 0 1.8998807718162425e-06
of O 1 0.9999998807907104
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 9.807889682633686e-07
including O 0 2.340471594308724e-09
multiple O 0 5.232692856793619e-08
adenomas B-Disease 0 0.00045811262680217624
, O 0 7.103635901728467e-09
in O 0 2.0347609819282297e-08
Ashkenazim O 0 0.00014569784980267286
. O 0 8.070798571679916e-07

We O 0 1.1140115674379558e-07
have O 0 5.423250737379703e-10
studied O 0 8.083692826232891e-09
a O 0 6.529223828266595e-10
set O 0 1.5265801955877123e-09
of O 0 1.76282999309052e-09
164 O 0 7.85314657747449e-09
patients O 0 1.2048030628708517e-10
with O 0 1.1271630850906433e-10
multiple O 1 0.9693524241447449
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.999983549118042
/ I-Disease 1 1.0
or I-Disease 1 0.9999980926513672
carcinoma I-Disease 1 1.0
and O 0 4.946801936966949e-07
analyzed O 0 2.1653809767485654e-07
codons O 0 4.207338406558847e-07
1263 O 0 3.776980747716152e-06
- O 0 2.432034591492993e-07
1377 O 0 9.909590517054312e-07
( O 0 6.585358480748482e-09
exon O 0 2.6093835003848653e-07
15G O 0 5.109479843667941e-07
) O 0 1.0487255508451199e-10
of O 0 1.3619547711840596e-09
the O 0 1.4420877825216394e-09
APC B-Disease 0 3.188629804640186e-08
gene O 0 1.3080565519629772e-09
for O 0 9.603627892929012e-10
germ O 0 1.7671993191470392e-05
- O 0 2.017676933974144e-06
line O 0 7.691287464695051e-07
variants O 0 3.31833376776558e-07
. O 0 2.2616214323534223e-07

Three O 0 5.74582728063433e-08
patients O 0 1.2245003899735707e-09
with O 0 2.4302795886832484e-11
the O 0 4.43119629878197e-09
I1307K O 0 7.769431249471381e-07
allele O 0 1.5882623216612046e-08
were O 0 2.4291130218401236e-10
detected O 0 5.635052424679543e-10
, O 0 5.171423619193538e-12
each O 0 1.69235528368894e-11
of O 0 5.818257431400298e-09
Ashkenazi O 0 7.26257076166803e-06
descent O 0 1.578662522661034e-05
. O 0 4.351264237811847e-07

Four O 0 1.7173381650081865e-07
patients O 0 1.907078406304663e-08
had O 0 1.943227445622142e-08
a O 0 2.123380760110649e-08
germ O 0 0.00047561959945596755
- O 0 5.198827238928061e-06
line O 0 4.955220447300235e-07
E1317Q O 0 1.2770113926308113e-06
missense O 0 1.818629513650194e-08
variant O 0 6.994051116038236e-09
of O 0 4.2711576497822534e-08
APC O 0 7.013902791896953e-09
that O 0 4.594526582107905e-12
was O 0 2.3085662548272268e-10
not O 0 7.15214649657514e-12
present O 0 1.371086317397685e-11
in O 0 6.388755410119407e-12
controls O 0 4.4914902352921615e-10
; O 0 1.935622669091419e-11
one O 0 3.5090003819293614e-11
of O 0 7.663893131226729e-11
these O 0 1.2935552151996377e-12
individuals O 0 1.7127257945226404e-11
had O 0 4.0795142264293816e-10
an O 0 3.6022376054267724e-11
unusually O 0 4.591780566887138e-10
large O 0 1.743814120880316e-10
number O 0 4.2953848811144724e-10
of O 0 2.9451841854211125e-08
metaplastic B-Disease 0 0.00026820527273230255
polyps I-Disease 0 5.8259220168110915e-06
of I-Disease 0 6.682013236058992e-07
the I-Disease 0 3.7368923244684993e-07
colorectum I-Disease 0 0.0004588542797137052
. O 0 1.8564081756267115e-06

There O 0 2.067221771540062e-08
is O 0 6.355266313207153e-10
increasing O 0 4.708298195765792e-10
evidence O 0 5.83601555970148e-10
that O 0 3.264589987228561e-11
there O 0 1.4136443404755283e-10
exist O 0 1.904394864027381e-09
germ O 0 2.3413061001065216e-07
- O 0 5.610260256361244e-09
line O 0 1.6039057859629224e-09
variants O 0 2.5907140321912436e-10
of O 0 1.3010843513683312e-09
the O 0 6.831809007401546e-10
APC B-Disease 0 5.126647995012945e-09
gene O 0 3.490636252267976e-11
that O 0 4.534334279576724e-12
predispose O 0 4.785000395912675e-09
to O 0 3.065437348404032e-10
the O 0 1.3065752924035223e-09
development O 0 2.2820211498242315e-08
of O 0 4.1521005300637626e-07
multiple O 1 0.9999639987945557
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
carcinoma I-Disease 1 1.0
, O 0 3.413678584252011e-08
but O 0 3.258122382998607e-10
without O 0 5.164135230550926e-10
the O 0 2.0378779219676346e-10
florid O 0 1.548478323343261e-08
phenotype O 0 5.402666758413943e-09
of O 0 5.379684253625783e-09
classical O 0 1.0791173110646923e-07
FAP B-Disease 0 1.0626283142300963e-07
, O 0 3.1447275339324676e-11
and O 0 4.020240737534486e-12
possibly O 0 1.4764484079776707e-10
with O 0 3.5669366765800348e-12
importance O 0 5.76015750652914e-08
for O 0 0.00025391977396793664
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 1 0.8515799045562744
in O 0 1.044864528232381e-09
the O 0 5.229654487237667e-10
general O 0 1.3736058956936859e-09
population O 0 7.965449827507243e-11
. O 0 3.0454538890722915e-10
. O 0 1.3891514605290922e-08

Genomic O 0 7.451041739159336e-08
structure O 0 2.2000886445994183e-08
of O 0 2.1565605834439339e-07
the O 0 8.730759191166726e-07
human O 1 0.9572925567626953
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.016817525029182434
CLD B-Disease 1 0.9999994039535522
) O 0 6.214734327159022e-08
gene O 0 2.2874493765812076e-07
. O 0 1.6933530844198685e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9916433095932007
CLD B-Disease 1 1.0
) O 0 4.934049613325442e-09
is O 0 4.5956793925938655e-10
caused O 0 3.231986012153243e-09
by O 0 1.522084541738522e-10
mutations O 0 5.7534235153866575e-09
in O 0 2.7782326439407257e-10
a O 0 3.8420536196959176e-10
gene O 0 2.394858478194095e-10
which O 0 6.396416035725494e-11
encodes O 0 8.913571547530807e-10
an O 0 5.138098835288929e-10
intestinal O 0 1.1886599168065004e-05
anion O 0 1.761918429110665e-05
transporter O 0 0.00020799531193915755
. O 0 1.09621498722845e-06

We O 0 2.872655215924169e-07
report O 0 2.163022205792231e-09
here O 0 3.1676652967327357e-10
the O 0 6.158815818446683e-11
complete O 0 3.1838987002430486e-10
genomic O 0 3.8456993145530305e-09
organization O 0 8.236256121563201e-10
of O 0 6.291636545086021e-09
the O 0 6.3905076785886195e-09
human O 0 4.189033475654469e-08
CLD B-Disease 0 0.004133754409849644
gene O 0 2.82209233759545e-09
which O 0 5.948484760320838e-11
spans O 0 4.383131191332268e-09
approximately O 0 8.967903086798401e-10
39kb O 0 8.433573839283781e-07
, O 0 8.582469734896847e-10
and O 0 8.99790297825831e-10
comprises O 0 7.079802077925024e-09
21 O 0 2.1944731543044327e-07
exons O 0 3.1931208468449768e-06
. O 0 2.5876531140056613e-07

All O 0 1.1905225392183638e-06
exon O 0 6.011102414049674e-06
/ O 0 3.86582678402192e-06
intron O 0 1.567859158058127e-06
boundaries O 0 2.135891641330545e-08
conform O 0 4.011537768633389e-09
to O 0 2.6598119262644104e-09
the O 0 1.2122381320978093e-08
GT O 0 6.783526714571053e-06
/ O 0 5.583602251135744e-05
AG O 1 0.8478718996047974
rule O 0 1.3023959581914824e-05
. O 0 1.9539295408321777e-06

An O 0 5.7356079885551026e-09
analysis O 0 9.24908594157614e-09
of O 0 6.03852754466061e-08
the O 0 2.2314893044494966e-08
putative O 0 1.1124418961117044e-05
promoter O 0 0.00025272610946558416
region O 0 2.1048205667284492e-07
sequence O 0 1.2176839092603586e-08
shows O 0 7.391358081143551e-10
a O 0 4.754378224447464e-09
putative O 0 5.304792466631625e-06
TATA O 0 7.699691195739433e-05
box O 0 1.046373299118386e-07
and O 0 1.4550400884161263e-09
predicts O 0 4.228811434359159e-08
multiple O 0 1.3095542428231965e-09
transcription O 0 3.4894235056981415e-08
factor O 0 6.245592487630347e-09
binding O 0 3.3501436291771824e-08
sites O 0 8.98690046824413e-08
. O 0 1.0602595068576193e-07

The O 0 1.7973017918393452e-07
genomic O 0 1.8048214656118944e-07
structure O 0 1.3118124364552841e-08
was O 0 5.406707970223579e-09
determined O 0 4.79345674264664e-10
using O 0 8.171751469943089e-11
DNA O 0 2.7046367367944413e-09
from O 0 1.7574172672674138e-10
several O 0 1.1085281997891272e-11
sources O 0 3.288088412656265e-10
including O 0 2.0560981736639228e-11
multiple O 0 2.1602918065521948e-10
large O 0 7.253794009898229e-09
- O 0 4.8562970533794214e-08
insert O 0 3.591670960645388e-08
libaries O 0 1.3772787497146055e-06
and O 0 2.918590646938668e-10
genomic O 0 7.502148235971617e-09
DNA O 0 3.9694949549584635e-08
from O 0 1.4073102683198613e-08
Finnish O 0 6.419441342586651e-05
CLD B-Disease 1 0.9998362064361572
patients O 0 3.5629454941954464e-08
and O 0 5.740785180563535e-09
controls O 0 2.107647787852329e-06
. O 0 8.197598049264343e-07

Exon O 0 1.1767684554797597e-05
- O 0 2.2847918046409177e-07
specific O 0 3.010784510593112e-09
primers O 0 5.553400583835355e-08
developed O 0 1.3682611710308379e-09
in O 0 1.1150090573064375e-10
this O 0 4.9308366417699645e-11
study O 0 1.0097582492374357e-10
will O 0 6.5643805495507745e-12
facilitate O 0 8.712200405547321e-11
mutation O 0 2.833336343321946e-10
screening O 0 9.29831975304829e-11
studies O 0 2.6900025609788436e-11
of O 0 1.527939719192517e-10
patients O 0 1.9480302787533432e-11
with O 0 1.7836622803746316e-11
the O 0 3.491074096473312e-08
disease O 0 1.2359077118162531e-05
. O 0 3.078137353895727e-07

Genomic O 0 5.227805104368599e-07
sequencing O 0 1.573707351099074e-07
of O 0 2.8654892503254814e-07
a O 0 2.42024583485545e-07
BAC O 1 0.9998891353607178
clone O 0 0.0019521111389622092
H O 1 1.0
_ O 0 1.8047732908144098e-07
RG364P16 O 0 1.61940206453437e-05
revealed O 0 9.114831556189529e-09
the O 0 1.7966927945423095e-10
presence O 0 7.193247386627633e-11
of O 0 8.547509922074426e-10
another O 0 6.212962366802799e-10
, O 0 1.3104131668661978e-10
highly O 0 2.806031795810071e-10
homologous O 0 7.334146068238567e-10
gene O 0 6.250963635601181e-10
3 O 0 5.8083449161472345e-09
of O 0 9.699615333147449e-09
the O 0 2.539648491506341e-08
CLD B-Disease 1 0.9684688448905945
gene O 0 2.6724654489385102e-08
, O 0 8.325776179596289e-11
with O 0 2.0858406148127617e-12
a O 0 9.146326057640763e-11
similar O 0 3.245888974268141e-11
genomic O 0 5.756244814136835e-09
structure O 0 2.5346722498653662e-09
, O 0 2.902501156087922e-11
recently O 0 9.234480541353562e-11
identified O 0 1.3829005995891208e-10
as O 0 5.819516743499342e-11
the O 0 9.237749232227088e-09
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.896397861855803e-06
( O 0 6.172219002564816e-08
PDS B-Disease 0 8.480189717374742e-05
) O 0 6.454131895594628e-09
. O 0 8.196783696234888e-09
. O 0 9.87174146871439e-08

The O 0 7.237902650558681e-07
APCI1307K O 1 0.9996895790100098
allele O 0 1.6578756913077086e-05
and O 0 3.125918723867471e-08
cancer B-Disease 0 0.21005253493785858
risk O 0 3.5184359603590565e-07
in O 0 4.4590622860773976e-10
a O 0 6.828200227460002e-10
community O 0 3.121078118173415e-10
- O 0 5.407468361973145e-10
based O 0 8.086844388577319e-11
study O 0 1.4565139372368918e-10
of O 0 1.7568283494640013e-09
Ashkenazi O 0 3.448461711741402e-07
Jews O 0 2.844722359895968e-07
. O 0 1.3955522604192083e-07

Mutations O 0 1.9007997025255463e-06
in O 0 9.141696288850198e-09
APC O 0 8.214473012913004e-08
are O 0 6.768084703789867e-11
classically O 0 5.54898562654671e-08
associated O 0 4.796415709051871e-08
with O 0 7.810561442056496e-08
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.00016054566367529333
FAP B-Disease 0 1.182504820462782e-05
) O 0 4.0740708029396444e-10
, O 0 5.90767781916135e-11
a O 0 8.258656536419551e-10
highly O 0 2.3320447439800773e-07
penetrant O 1 0.9999998807907104
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.00035407597897574306
by O 0 1.2120370485035892e-08
multiple O 0 1.7904636706589372e-06
intestinal O 1 0.9999997615814209
polyps B-Disease 0 0.00010644967551343143
and O 0 1.547869277196412e-09
, O 0 2.885885280745626e-11
without O 0 6.783335004811875e-11
surgical O 0 6.4006229649749e-08
intervention O 0 1.9475692170090042e-07
, O 0 1.7888111825126174e-10
the O 0 3.8629366372333607e-10
development O 0 6.173360844741183e-08
of O 1 0.9778982996940613
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.004291550721973181
CRC B-Disease 0 0.02481592819094658
) O 0 3.313608587518502e-08
. O 0 1.4658971281278355e-07

APC B-Disease 0 2.2857708245282993e-05
is O 0 2.132740739568817e-08
a O 0 5.2248140036681434e-08
tumour O 1 1.0
- O 0 2.457358732499415e-06
suppressor O 0 1.3324433894013055e-06
gene O 0 3.250402391685725e-09
, O 0 1.6546228276403951e-10
and O 0 1.2554528527886077e-09
somatic O 0 0.0013253366341814399
loss O 0 8.093590440694243e-05
occurs O 0 6.605459475395037e-06
in O 0 1.5946510529829538e-06
tumours B-Disease 1 1.0
. O 0 1.070907455869019e-05

The O 0 6.095116532378597e-06
germline O 0 0.00025562106748111546
T O 0 1.4661490013168077e-06
- O 0 5.5987719349559484e-08
to O 0 1.7888768244489484e-09
- O 0 5.775028011356653e-09
A O 0 7.841904903216346e-09
transversion O 0 9.44769666944012e-08
responsible O 0 2.1914934311695333e-09
for O 0 1.7887188952236954e-10
the O 0 3.28914362413002e-09
APC O 0 3.8230297150221304e-08
I1307K O 0 1.8891941522269917e-07
allele O 0 7.110589894665509e-09
converts O 0 1.3420269340258528e-09
the O 0 3.459743047606878e-10
wild O 0 2.8160151988032567e-10
- O 0 1.1286818701883305e-10
type O 0 2.2055314519153768e-10
sequence O 0 1.193540821731176e-10
to O 0 6.334013175068876e-11
a O 0 3.4613951704898227e-09
homopolymer O 0 0.00825466588139534
tract O 0 0.00011578125122468919
( O 0 3.0737190570562234e-08
A8 O 0 4.199648174108006e-05
) O 0 1.0056182275786085e-10
that O 0 2.6258148433377926e-11
is O 0 4.408231002450691e-10
genetically O 0 4.081183391235754e-08
unstable O 0 4.15631802752614e-06
and O 0 6.764452553653655e-09
prone O 0 5.986411906633293e-06
to O 0 3.9906984738991014e-07
somatic O 0 0.0004591148463077843
mutation O 0 5.159264037501998e-05
. O 0 1.1828833521576598e-06

The O 0 6.490521400337457e-07
I1307K O 0 1.729178984533064e-05
allele O 0 2.8527696827040927e-07
was O 0 8.536586193486073e-08
found O 0 2.160878143087075e-09
in O 0 1.6342678321734638e-09
6 O 0 7.735696385680058e-07
. O 0 2.6971176225742965e-07

1 O 0 1.6946591131272726e-05
% O 0 2.244445056476252e-07
of O 0 1.0367995884053016e-07
unselected O 0 0.00013250512711238116
Ashkenazi O 0 9.815649718802888e-06
Jews O 0 4.8797602403283236e-08
and O 0 4.082454166387528e-11
higher O 0 2.4373228435514704e-10
proportions O 0 1.0498808489245448e-09
of O 0 6.572932198523063e-10
Ashkenazim O 0 2.6795302687787625e-07
with O 0 1.0595459405682295e-11
family O 0 1.7770548921269835e-10
or O 0 4.3808720540106094e-10
personal O 0 5.166088001828939e-09
histories O 0 4.5292694039744674e-08
of O 0 8.501076990796719e-06
CRC B-Disease 0 0.0006083468906581402
( O 0 2.8969747489782094e-08
ref O 0 9.55479026742978e-06
. O 0 7.048825523270352e-09
2 O 0 1.6203223651700682e-07
) O 0 5.885494314128437e-09
. O 0 6.296921384318921e-08

To O 0 1.7847403555038e-08
evaluate O 0 2.0461524030679357e-08
the O 0 1.6551223724903252e-09
role O 0 4.792517938057017e-09
of O 0 3.56727696271264e-08
I1307K O 0 0.000334052718244493
in O 0 2.051529612856484e-08
cancer B-Disease 0 6.427159678423777e-05
, O 0 3.880899157593376e-09
we O 0 1.227412216309176e-08
genotyped O 0 2.5539513444527984e-05
5 O 0 2.2639864027951262e-07
, O 0 2.2884012462753844e-09
081 O 0 3.0086648621363565e-06
Ashkenazi O 0 3.3676468547128025e-07
volunteers O 0 3.2948557771028675e-10
in O 0 7.141259111831388e-11
a O 0 1.0492663404804148e-09
community O 0 6.386621009824012e-09
survey O 0 7.88161500508977e-08
. O 0 1.7313917055616912e-07

Risk O 0 3.791415292653255e-05
of O 0 4.343939963291632e-06
developing O 1 0.8051627278327942
colorectal B-Disease 1 1.0
, I-Disease 0 0.41616910696029663
breast I-Disease 1 1.0
and I-Disease 0 3.673634978440532e-07
other I-Disease 0 4.451359458812476e-08
cancers I-Disease 1 0.9999991655349731
were O 0 1.6086586285268822e-08
compared O 0 4.3519090553445494e-09
between O 0 5.510243816786442e-09
genotyped O 0 6.884267804707633e-07
I1307K O 0 7.90127288041731e-08
carriers O 0 3.467021114644808e-11
and O 0 4.116215701621684e-11
non O 0 1.1525231879971898e-09
- O 0 1.738871963086197e-10
carriers O 0 6.965298129935071e-12
and O 0 5.446205986192609e-12
their O 0 2.3889067807258968e-12
first O 0 6.145837311288815e-11
- O 0 9.351897034548529e-10
degree O 0 6.198090574116577e-08
relatives O 0 2.51282923358076e-08
. O 0 4.041830337087049e-08

Sperm O 0 1.9406390094900416e-07
DNA O 0 4.303720757548035e-08
analysis O 0 2.8792797035492868e-09
in O 0 8.286585306827021e-10
a O 0 7.533812151905295e-08
Friedreich B-Disease 1 0.999972939491272
ataxia I-Disease 1 0.9999994039535522
premutation O 1 0.931598961353302
carrier O 0 9.47655166783079e-07
suggests O 0 5.2955659413100875e-08
both O 0 3.784474511547842e-09
meiotic O 0 1.7984608575716265e-06
and O 0 7.590465145312919e-09
mitotic O 0 4.105285142941284e-07
expansion O 0 3.0480319423986657e-07
in O 0 8.74202132905566e-09
the O 0 5.5334488990865793e-08
FRDA B-Disease 0 0.0014663634356111288
gene O 0 4.314537704885879e-07
. O 0 1.5637658634659601e-07

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 5.353300025490171e-07
usually O 0 6.911685002108925e-09
caused O 0 4.197293179686312e-09
by O 0 1.5620652341064023e-11
an O 0 8.175707506830054e-12
expansion O 0 4.565774869291772e-09
of O 0 3.897012135212208e-08
a O 0 2.4083789185169735e-07
GAA O 1 0.9102523326873779
trinucleotide O 0 0.008166535757482052
repeat O 0 2.68859935204091e-07
in O 0 4.017686627832973e-09
intron O 0 6.545732844642771e-07
1 O 0 2.2911717678653076e-07
of O 0 3.469527243282755e-08
the O 0 5.0872785095634754e-08
FRDA B-Disease 0 0.0032853398006409407
gene O 0 9.02048782336351e-07
. O 0 2.786730135539983e-07

Occasionally O 0 5.815042527501646e-07
, O 0 2.5433117833983943e-09
a O 0 1.2059486742543868e-09
fully O 0 3.365917100595084e-09
expanded O 0 3.636986545263454e-10
allele O 0 1.2097459922699727e-08
has O 0 7.13296921528439e-11
been O 0 5.218332710388296e-11
found O 0 1.1128455795761383e-11
to O 0 2.4295844849864245e-11
arise O 0 1.4655994196033362e-09
from O 0 2.784290575874593e-10
a O 0 1.1850530556856143e-09
premutation O 0 7.530665584454255e-07
of O 0 4.5839708917583266e-08
100 O 0 8.591564792936879e-09
or O 0 4.0538421508529154e-09
less O 0 1.0758454749293378e-07
triplet O 0 3.694148108479567e-05
repeats O 0 9.02690771908965e-06
. O 0 7.596078717142518e-07

We O 0 1.9482342850096757e-07
have O 0 1.0215913670563737e-09
examined O 0 9.996107053211745e-09
the O 0 1.175909369877104e-09
sperm O 0 1.1891649887019184e-09
DNA O 0 2.403609089540737e-09
of O 0 3.5668332731830787e-09
a O 0 9.735870776239608e-09
premutation O 0 3.3878117392305285e-05
carrier O 0 2.288704990860424e-06
. O 0 9.658540420787176e-07

This O 0 1.0633743841026444e-07
mans O 0 5.878854153706925e-06
leucocyte O 0 4.8292422434315085e-06
DNA O 0 1.2115462766359997e-07
showed O 0 2.9461995065815927e-09
one O 0 2.4778737395259043e-10
normal O 0 1.3228849127244757e-09
allele O 0 2.638559593037826e-09
and O 0 6.543882102860721e-11
one O 0 1.512245745294294e-10
allele O 0 5.568629557473059e-09
of O 0 5.348877785138484e-09
approximately O 0 8.894216030341795e-09
100 O 0 3.716612084758708e-08
repeats O 0 1.651424952342495e-07
. O 0 7.199790985623622e-08

His O 0 6.66398420889891e-07
sperm O 0 7.326281092900899e-08
showed O 0 1.5117678220377684e-09
an O 0 2.9495135500656744e-11
expanded O 0 2.72500605413839e-10
allele O 0 8.464126288743046e-09
in O 0 1.4390261204866306e-10
a O 0 1.6917826028972627e-09
tight O 0 1.2506543356494149e-08
range O 0 3.8358482612466105e-08
centering O 0 1.6858137996678124e-07
on O 0 4.885466697857055e-09
a O 0 8.743335500049909e-10
size O 0 4.070142889389672e-09
of O 0 1.6785282497266962e-08
approximately O 0 1.0615748635700584e-07
320 O 0 7.623373221576912e-07
trinucleotide O 0 9.996080916607752e-05
repeats O 0 3.2907882996369153e-06
. O 0 5.870596737622691e-07

His O 0 3.988928256148938e-06
affected O 0 2.2188473849382717e-06
son O 0 1.3636533367389347e-05
has O 0 3.982749685604858e-09
repeat O 0 1.7932265450326668e-08
sizes O 0 9.507945541997742e-09
of O 0 9.059942129852061e-08
1040 O 0 1.469294261369214e-06
and O 0 4.1238209291805106e-08
540 O 0 1.5986145172064425e-06
. O 0 4.325224267631711e-07

These O 0 3.5859057945231143e-09
data O 0 2.307422919400892e-09
suggest O 0 8.483160840455639e-10
that O 0 2.0401751468779317e-11
expansion O 0 4.469034919907244e-09
occurs O 0 2.4317786673222486e-10
in O 0 1.0993687730997959e-11
two O 0 6.848697824135552e-12
stages O 0 1.4485107557860033e-09
, O 0 2.729498918552231e-11
the O 0 2.1494125923560148e-10
first O 0 3.50120682446331e-10
during O 0 5.555863547002104e-10
meiosis O 0 9.811963463945972e-10
followed O 0 1.413892475321532e-10
by O 0 4.308346734926971e-11
a O 0 2.6308506484440386e-09
second O 0 5.242992884291198e-08
mitotic O 0 6.475268605754536e-07
expansion O 0 1.9738811261049705e-06
. O 0 1.4158200656311237e-06

We O 0 8.20180758864808e-08
also O 0 8.781407268010355e-10
show O 0 2.1356613699730076e-10
that O 0 1.4371109337274479e-11
in O 0 4.528062300113156e-11
all O 0 1.7578655545080757e-11
informative O 0 5.613072229238014e-10
carrier O 0 2.3657487080441797e-09
father O 0 1.7420132003564959e-09
to O 0 2.4573340584588266e-10
affected O 0 1.2014579331420805e-09
child O 0 1.1159756452272518e-09
transmissions O 0 9.062301464801692e-10
, O 0 8.630690780109251e-12
with O 0 1.0917433406962274e-12
the O 0 7.301816096205727e-11
notable O 0 4.817734752804448e-11
exception O 0 5.583122297814214e-10
of O 0 4.326558222800259e-09
the O 0 1.1190854909415293e-09
premutation O 0 2.450146325827518e-07
carrier O 0 4.3122971860043435e-09
, O 0 2.32839497682491e-10
the O 0 3.5803818243529406e-10
expansion O 0 5.7256177576903156e-09
size O 0 6.675845654058321e-09
decreases O 0 5.527731516963286e-08
. O 0 7.240496202598479e-09
. O 0 1.6355541276880103e-07

The O 0 5.125653501636407e-07
R496H O 0 2.9927174182375893e-05
mutation O 0 1.0656667370767536e-07
of O 0 8.083711122708337e-08
arylsulfatase O 0 0.0005862329271622002
A O 0 1.539903792036057e-06
does O 0 9.162835823417481e-09
not O 0 3.2245679904008284e-08
cause O 0 0.00023436007904820144
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 1.6530950233573094e-05

Deficiency B-Disease 1 0.9999935626983643
of I-Disease 0 0.005084080621600151
arylsulfatase I-Disease 1 1.0
A I-Disease 1 0.9952292442321777
( O 0 5.303243142407155e-07
ARSA O 0 0.17632244527339935
) O 0 1.098238167074328e-09
enzyme O 0 3.434287965120575e-09
activity O 0 7.3974266712184544e-09
causes O 0 1.183185872832837e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 8.283745046355762e-06
MLD B-Disease 1 1.0
) O 0 1.0375829617714771e-07
. O 0 2.2433408730648807e-07

A O 0 2.401070787527715e-06
number O 0 1.2576248487050634e-08
of O 0 7.663143719582877e-08
ARSA O 0 0.0003890649531967938
gene O 0 2.229319839841537e-08
mutations O 0 1.725683951292467e-08
responsible O 0 3.3077423466920663e-08
for O 0 5.724900375980724e-08
MLD B-Disease 1 1.0
have O 0 3.603177844979655e-08
been O 0 1.1591817283829187e-08
identified O 0 1.5133263531197372e-08
. O 0 1.605443245011884e-08

Recently O 0 4.583428392379574e-07
, O 0 2.7070314878585577e-09
the O 0 3.392931047230263e-09
R496H O 0 1.6786294736448326e-06
mutation O 0 2.4291896494332832e-08
of O 0 1.7089080017740343e-07
ARSA O 1 0.5203591585159302
was O 0 1.6304856131910128e-08
proposed O 0 6.738231084213453e-10
to O 0 9.610549162042403e-11
be O 0 1.0672619732421396e-10
a O 0 8.949414542769318e-10
cause O 0 1.2601921639543434e-07
of O 0 5.031568434787914e-06
MLD B-Disease 1 1.0
( O 0 2.421626099646801e-08
Draghia O 0 3.8006764953024685e-06
et O 0 1.500482369465317e-07
al O 0 1.1245083442190662e-07
. O 0 2.380894370546116e-10
, O 0 1.860328280312018e-10
1997 O 0 2.724996894798437e-09
) O 0 3.0979609988435186e-09
. O 0 6.01730292260072e-08

We O 0 2.1978914332976274e-07
have O 0 1.413553385454236e-09
investigated O 0 4.552402899093977e-08
the O 0 2.41292918978786e-09
R496H O 0 6.287140195126995e-07
mutation O 0 3.62636254358506e-09
and O 0 2.4046476615469103e-11
found O 0 1.462534607310495e-11
this O 0 5.0066973136808635e-12
mutation O 0 6.587502765498243e-10
at O 0 6.080916326034469e-10
a O 0 4.0847599608317964e-11
relatively O 0 5.983487316729708e-11
high O 0 1.6651718892646272e-10
frequency O 0 1.131380988894648e-09
in O 0 2.0110023021824297e-11
an O 0 1.48649582226712e-11
African O 0 1.4838281992002322e-10
American O 0 5.941069164405732e-11
population O 0 9.838995937427875e-12
( O 0 4.390824856481679e-11
f O 0 1.5185078083845838e-08
= O 0 4.323629898550507e-09
0 O 0 2.3968016460429453e-09
. O 0 9.082231494650372e-11
09 O 0 5.7228013439214465e-09
, O 0 2.7902449795114137e-10
n O 0 1.6796940727203946e-08
= O 0 3.595804543010672e-08
61 O 0 2.7281499725972935e-08
subjects O 0 1.8737662088597062e-08
) O 0 6.705925148509095e-09
. O 0 6.437905142320233e-08

The O 0 2.096063781209523e-06
ARSA O 0 0.0002988982305396348
enzyme O 0 2.3053212672152767e-08
activity O 0 4.0243359755720576e-09
in O 0 5.5864642772851525e-11
subjects O 0 7.010314551081365e-10
with O 0 2.634361478959235e-12
and O 0 3.068155798868766e-11
without O 0 3.53626711246946e-10
the O 0 4.0718958760344037e-10
R496H O 0 3.768449730046086e-08
mutation O 0 3.8282721437354894e-10
was O 0 3.7075029157840333e-10
determined O 0 4.0811795609663193e-10
and O 0 1.1332501777261417e-11
found O 0 2.3487423811419106e-11
to O 0 1.1171932823295094e-10
be O 0 2.1002914962764407e-09
normal O 0 1.5716496193363128e-07
. O 0 2.3139563154472853e-07

It O 0 9.754569596509555e-09
is O 0 1.0298905062100516e-09
therefore O 0 3.754071276063087e-09
concluded O 0 7.705909688127122e-09
that O 0 5.57922319455173e-11
the O 0 1.8089832964918173e-09
R496H O 0 2.525929630792234e-06
mutation O 0 7.245030531066732e-08
of O 0 1.2123565795718605e-07
ARSA O 1 0.9928568601608276
does O 0 1.0050722476506735e-09
not O 0 1.7756252024270225e-10
negatively O 0 9.81106529351905e-10
influence O 0 8.851124833064716e-10
the O 0 5.040292835878368e-11
activity O 0 2.237803831128815e-10
of O 0 1.3873766580019264e-09
ARSA O 0 2.5580609872122295e-05
and O 0 6.258572132766815e-11
is O 0 4.3118817544263166e-11
not O 0 1.177985348155275e-10
a O 0 4.734009184659271e-09
cause O 0 2.5564895622665063e-06
of O 0 0.00019665122090373188
MLD B-Disease 1 1.0

Down O 0 2.3238193534780294e-05
- O 0 7.015296432655305e-07
regulation O 0 2.2529309262608876e-07
of O 0 1.5164737021677865e-07
transmembrane O 0 2.6863493985729292e-05
carbonic O 0 0.02416168712079525
anhydrases O 1 0.9994924068450928
in O 0 5.968500317976577e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.999716579914093
lines O 0 2.0642791298541852e-07
by O 0 3.5203664427996273e-09
wild O 0 3.430806927440244e-08
- O 0 2.536467924585395e-08
type O 0 1.9928954486658768e-07
von B-Disease 1 0.9998610019683838
Hippel I-Disease 1 0.9998586177825928
- I-Disease 0 0.42969393730163574
Lindau I-Disease 1 0.8325626850128174
transgenes O 0 0.00025787384947761893
. O 0 2.492400653864024e-06

To O 0 1.7466244628394634e-07
discover O 0 3.958169614293183e-08
genes O 0 2.4042237090071694e-09
involved O 0 1.5116496943079483e-09
in O 0 7.395504209029014e-10
von B-Disease 1 0.9999840259552002
Hippel I-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
Lindau I-Disease 1 1.0
( O 0 3.660967422547401e-07
VHL B-Disease 0 0.00040854696999303997
) O 0 7.794604073296796e-09
- O 0 1.4840622952760896e-07
mediated O 0 1.1804304449469782e-05
carcinogenesis O 1 0.9999816417694092
, O 0 1.4276574589189295e-08
we O 0 9.518034360667116e-09
used O 0 2.3185420161553338e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999994039535522
lines O 0 5.3312276577344164e-05
stably O 0 2.3162128854892217e-05
transfected O 0 2.776122869363462e-07
with O 0 4.3016648576532646e-10
wild O 0 3.721478236684561e-08
- O 0 1.1351083628596825e-07
type O 0 1.1768916010623798e-06
VHL O 0 0.0006471924716606736
- O 0 7.389965503534768e-06
expressing O 0 4.982919676876918e-07
transgenes O 0 5.0209229812026024e-05
. O 0 1.1411741525080288e-06

Large O 0 1.1709836371665006e-06
- O 0 9.252870540876756e-07
scale O 0 1.6864712506503565e-06
RNA O 0 8.013857950572856e-07
differential O 0 1.893808558861565e-07
display O 0 1.2977162677785259e-09
technology O 0 3.3718736691668028e-09
applied O 0 2.6366226979490648e-09
to O 0 6.1344075652503e-11
these O 0 1.0408614942170047e-11
cell O 0 4.863246250152997e-09
lines O 0 3.895306577295088e-10
identified O 0 1.0750952905702604e-10
several O 0 2.932839951799715e-12
differentially O 0 6.498118043651857e-09
expressed O 0 1.802803045736212e-10
genes O 0 3.12444348171681e-10
, O 0 4.543045453719863e-11
including O 0 5.589512533377139e-11
an O 0 1.0287302121270159e-09
alpha O 0 1.590833846876194e-07
carbonic O 0 8.631009791315591e-07
anhydrase O 0 2.106187139361282e-06
gene O 0 1.3450411451287891e-08
, O 0 1.521371251200776e-09
termed O 0 2.846105644493946e-06
CA12 O 1 0.975059986114502
. O 0 2.732670736804721e-06

The O 0 4.4541496890815324e-07
deduced O 0 2.8669299467765086e-07
protein O 0 3.273747051224518e-09
sequence O 0 3.4662295256282505e-10
was O 0 1.0439243913751284e-09
classified O 0 1.8906336218815767e-10
as O 0 2.5145706697426995e-11
a O 0 7.247138444910206e-10
one O 0 2.8796420803445244e-09
- O 0 2.3310019514610758e-07
pass O 0 5.386955876929278e-07
transmembrane O 0 0.000740313611458987
CA O 0 8.044471542234533e-06
possessing O 0 3.757740785204078e-08
an O 0 1.7687238340613476e-09
apparently O 0 2.8180060951399355e-08
intact O 0 1.0122815474744584e-08
catalytic O 0 7.588930373003677e-09
domain O 0 4.81628141812962e-08
in O 0 2.923377984132003e-09
the O 0 1.23934862372721e-08
extracellular O 0 5.031443834013771e-06
CA O 0 0.0001371145190205425
module O 0 3.207912595826201e-05
. O 0 3.077952328567335e-07

Reintroduced O 0 1.8323904441786e-05
wild O 0 3.8839226590425824e-07
- O 0 2.866333943529753e-07
type O 0 6.137517516435764e-07
VHL B-Disease 0 4.457752584130503e-05
strongly O 0 1.8660943013060205e-08
inhibited O 0 9.448396731670528e-09
the O 0 6.373888639110703e-10
overexpression O 0 1.2415513950259083e-08
of O 0 5.788879153811877e-09
the O 0 1.853189490752527e-09
CA12 O 0 0.00012604730727616698
gene O 0 6.775166538908195e-10
in O 0 7.151972764019021e-11
the O 0 8.139121598915722e-10
parental O 0 1.9976212115579983e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999998807907104
lines O 0 0.00026660162257030606
. O 0 5.6818066695996094e-06

Similar O 0 1.4470038500746796e-08
results O 0 1.1719199832782579e-08
were O 0 1.2982187547194712e-09
obtained O 0 2.2455137749233245e-09
with O 0 3.394780567766986e-10
CA9 O 0 0.001468079281039536
, O 0 1.2695443585286625e-09
encoding O 0 9.456184280054458e-09
another O 0 2.7922922640755132e-08
transmembrane O 0 1.523279115644982e-05
CA O 0 8.890401090866362e-07
with O 0 1.985414749272607e-10
an O 0 1.166860830181804e-09
intact O 0 3.2964809548730045e-08
catalytic O 0 1.1055445980900913e-07
domain O 0 1.6643820117678843e-06
. O 0 2.1134133021405432e-07

Although O 0 1.6576759520603446e-08
both O 0 1.8589352279718696e-09
domains O 0 1.757701397764322e-07
of O 0 1.9360416558811266e-07
the O 0 5.28848005387772e-08
VHL B-Disease 0 6.379150818247581e-06
protein O 0 1.797968995909116e-09
contribute O 0 1.553757678074419e-10
to O 0 1.544132460784553e-10
regulation O 0 1.239535407648873e-08
of O 0 6.502980909317557e-08
CA12 O 1 0.9998511075973511
expression O 0 1.165277225823047e-07
, O 0 8.982881660735131e-10
the O 0 1.302616459142314e-09
elongin O 0 6.548024344965597e-08
binding O 0 2.6074825854038863e-08
domain O 0 9.452472937709899e-08
alone O 0 4.640188233651088e-09
could O 0 4.737125802733999e-09
effectively O 0 1.0531468319641135e-07
regulate O 0 3.3767349805202684e-07
CA9 O 0 0.011083265766501427
expression O 0 9.654850146034732e-06
. O 0 1.3548610695579555e-06

We O 0 1.8278645939062699e-06
mapped O 0 1.4533274224959314e-05
CA12 O 0 0.1598159819841385
and O 0 7.287369498953922e-07
CA9 O 0 0.02454523928463459
loci O 0 2.878570285247406e-06
to O 0 8.329965339726186e-08
chromosome O 0 4.514160991675453e-06
bands O 0 7.095567866599595e-07
15q22 O 0 4.0624625398777425e-05
and O 0 1.682670500713357e-07
17q21 O 0 0.00022040956537239254
. O 0 2.0869642867182847e-06

2 O 0 1.6677420717314817e-05
respectively O 0 4.954960672876041e-07
, O 0 6.193715318403292e-09
regions O 0 9.847106241522852e-08
prone O 0 7.557486583209538e-07
to O 0 5.822320403581216e-09
amplification O 0 5.16660861649143e-07
in O 0 2.4804991394233866e-09
some O 0 2.8611153446433946e-09
human O 0 3.8157597259669274e-07
cancers B-Disease 0 0.13010726869106293
. O 0 8.098563171188289e-07

Additional O 0 4.133089248625765e-08
experiments O 0 1.613030597980014e-08
are O 0 4.506840040052751e-11
needed O 0 5.210358811069682e-10
to O 0 1.3835547985063812e-10
define O 0 5.078724996110395e-09
the O 0 4.760909999568241e-10
role O 0 1.1114127396183449e-09
of O 0 1.061339638397385e-08
CA O 0 2.842842150130309e-06
IX O 0 0.23905067145824432
and O 0 2.0531816247171264e-08
CA O 0 3.4360637073405087e-06
XII O 0 1.8618851754581556e-05
enzymes O 0 1.1468284100146775e-09
in O 0 8.404194007383126e-11
the O 0 1.0258317806322026e-10
regulation O 0 2.982765368031437e-09
of O 0 9.770210418480474e-09
pH O 0 1.3461968819683534e-06
in O 0 1.349733214084381e-09
the O 0 2.751938010803201e-09
extracellular O 0 1.7296258647547802e-07
microenvironment O 0 1.0464086699357722e-06
and O 0 2.5057242392101386e-10
its O 0 1.1438350266956832e-10
potential O 0 2.8658670991887902e-09
impact O 0 9.191160899035822e-08
on O 0 3.358224489602435e-07
cancer B-Disease 0 1.696847175480798e-05
cell O 0 2.52659947364009e-06
growth O 0 1.1109919739737961e-07
. O 0 1.4849146623419074e-07

A O 0 1.2009049896732904e-06
gene O 0 1.5597869662542507e-08
encoding O 0 2.1975553821107496e-08
a O 0 1.5384777896088053e-08
transmembrane O 0 2.0612351363524795e-06
protein O 0 8.366856540931167e-09
is O 0 2.596688836176142e-11
mutated O 0 2.999588633034733e-10
in O 0 3.3882455868772254e-11
patients O 0 2.3977378416084605e-10
with O 0 5.150189164027097e-09
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999998807907104
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9999256134033203
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 6.701644394979667e-08
. O 0 9.581076909626063e-08

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00012843648437410593
WFS B-Disease 1 0.9999406337738037
; O 0 1.6907905830976233e-07
OMIM O 0 0.3733863830566406
222300 O 0 1.0254139851895161e-05
) O 0 1.8026001524784618e-10
is O 0 1.6143278380731374e-10
an O 0 1.3604126714028553e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 4.4241215135798484e-08
by O 0 3.829944417166331e-10
young O 0 3.828712014097846e-09
- O 0 1.3247722563392017e-07
onset O 1 0.9999960660934448
non O 1 0.9999501705169678
- O 0 0.0015948404325172305
immune O 0 8.630384513708123e-07
insulin B-Disease 1 0.9997715353965759
- I-Disease 1 0.9080221056938171
dependent I-Disease 0 0.42395222187042236
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 1.735569276206661e-05
progressive O 1 0.9999997615814209
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999998807907104
. O 0 7.509258284699172e-05

Linkage O 0 3.911752355634235e-05
to O 0 6.554296305694152e-08
markers O 0 4.3827657236761297e-07
on O 0 1.0891980650740152e-07
chromosome O 0 7.177125553425867e-06
4p O 1 0.6552922129631042
was O 0 1.408320429163723e-07
confirmed O 0 5.20029397321764e-09
in O 0 3.392346958897008e-10
five O 0 7.200251506134236e-10
families O 0 1.1017041723349053e-09
. O 0 5.846683492904958e-08

On O 0 3.4659822745197744e-07
the O 0 1.884269629215396e-09
basis O 0 1.8698854020726685e-08
of O 0 2.515610653119893e-08
meiotic O 0 0.1458190232515335
recombinants O 1 0.999998927116394
and O 0 2.0752221985276265e-07
disease O 0 0.00459482055157423
- O 0 2.104872720565254e-07
associated O 0 3.599187081704258e-08
haplotypes O 0 1.7616284253563208e-07
, O 0 4.743180848088002e-10
the O 0 6.860422008259093e-09
WFS B-Disease 0 5.596088158199564e-06
gene O 0 1.7847224809131035e-09
was O 0 8.600435030814424e-09
localized O 0 4.604519077133773e-08
to O 0 8.064242607019878e-09
a O 0 1.428172708983766e-07
BAC O 1 0.886269748210907
/ O 0 3.122429552604444e-05
P1 O 0 0.00022430450189858675
contig O 0 5.68123232369544e-06
of O 0 4.102849970877287e-08
less O 0 1.0166002262224083e-08
than O 0 6.232228511038329e-09
250 O 0 5.23670635743656e-08
kb O 0 9.147207492787857e-06
. O 0 3.801456216478982e-07

Mutations O 0 6.546881650137948e-07
in O 0 8.557232145101068e-10
a O 0 6.899076310240559e-10
novel O 0 5.231731936561346e-09
gene O 0 2.928785880484952e-09
( O 0 1.0225699176302783e-09
WFS1 O 0 0.00010303803719580173
) O 0 4.122125973893276e-10
encoding O 0 2.7539648339569567e-09
a O 0 5.085859733355846e-09
putative O 0 2.3999143650144106e-07
transmembrane O 0 2.658553626133653e-07
protein O 0 3.4761691303231146e-09
were O 0 9.141477158580713e-11
found O 0 1.3189784334177723e-11
in O 0 5.750661231929133e-12
all O 0 4.497614954079854e-12
affected O 0 4.000103373535957e-11
individuals O 0 1.986906472684069e-11
in O 0 6.738359870084309e-10
six O 0 2.1273899974971755e-08
WFS B-Disease 0 0.011862261220812798
families O 0 4.733131664380608e-10
, O 0 4.7800881308734944e-11
and O 0 1.3162290701806967e-11
these O 0 6.127270999606305e-12
mutations O 0 6.251989481675935e-10
were O 0 8.936668072223597e-11
associated O 0 1.0796289418024685e-09
with O 0 6.452291478886707e-11
the O 0 5.368330135979704e-08
disease O 0 8.192477253032848e-06
phenotype O 0 5.712972324545262e-06
. O 0 5.60213550215849e-07

WFS1 O 1 0.999842643737793
appears O 0 1.7606205915399187e-07
to O 0 1.6768411104095549e-09
function O 0 4.753507809596158e-09
in O 0 2.564480572342376e-10
survival O 0 2.695162848453947e-08
of O 0 2.4536181086887154e-08
islet O 0 0.00010226220183540136
beta O 0 4.3172549339942634e-05
- O 0 4.5255825398271554e-07
cells O 0 2.077882088613592e-09
and O 0 3.4506353330243655e-10
neurons O 0 1.1651200892970337e-08
. O 0 7.433210047480543e-09
. O 0 5.271902736581069e-08

Stable O 0 2.5404597181477584e-05
interaction O 0 9.15333728812584e-08
between O 0 3.226259792654673e-08
the O 0 2.6204940439811253e-09
products O 0 9.91086213097958e-10
of O 0 3.378504587203679e-09
the O 0 2.243874197560558e-09
BRCA1 O 0 3.777430634954726e-08
and O 0 1.564317786417746e-09
BRCA2 O 0 2.8370740778882464e-07
tumor B-Disease 0 9.211525480168348e-07
suppressor O 0 5.886788017051003e-07
genes O 0 2.7475952624200772e-09
in O 0 5.39268796284631e-10
mitotic O 0 1.7125297802067507e-07
and O 0 2.2041165337327584e-08
meiotic O 0 0.00021200376795604825
cells O 0 1.313693883275846e-05
. O 0 3.0444170988630503e-06

BRCA1 O 0 2.800717811624054e-05
and O 0 1.5628007332679772e-08
BRCA2 O 0 1.9351870150785544e-07
account O 0 1.9175737386856184e-10
for O 0 2.2442613739626083e-11
most O 0 7.071922908385986e-12
cases O 0 1.6221513715608538e-11
of O 0 1.914169045491576e-09
familial O 0 7.238185730784608e-07
, O 0 1.955194006697525e-09
early O 0 7.187908295236412e-07
onset O 1 0.9999994039535522
breast B-Disease 1 0.9999949932098389
and I-Disease 0 0.0003083927440457046
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.4295430617039528e-08
encode O 0 4.676971587791456e-10
products O 0 5.983121637020972e-11
that O 0 5.689987543633368e-12
each O 0 1.8236008189620456e-11
interact O 0 8.04541364085587e-11
with O 0 8.44444444925152e-11
hRAD51 O 0 1.3853606333213975e-06
. O 0 3.5871187265001936e-07

Results O 0 2.553526030624198e-07
presented O 0 5.436761796318024e-08
here O 0 3.4098899259760174e-09
show O 0 3.386786961989685e-10
that O 0 7.071657148749466e-11
BRCA1 O 0 5.3892076579131754e-08
and O 0 4.976059120309628e-09
BRCA2 O 0 5.628018698189408e-06
coexist O 0 7.658526612885908e-08
in O 0 3.1954824897262313e-10
a O 0 6.431333243739346e-10
biochemical O 0 1.8575077476157276e-08
complex O 0 7.919299882530595e-09
and O 0 3.905312184748766e-10
colocalize O 0 1.6661321069477708e-06
in O 0 3.90114518467044e-09
subnuclear O 0 4.534271283773705e-06
foci O 0 7.615598178745131e-07
in O 0 1.010645123145082e-09
somatic O 0 1.1539760436107827e-07
cells O 0 2.9198392592633127e-09
and O 0 1.8275363167230552e-10
on O 0 1.882157762977954e-09
the O 0 1.48002360367272e-10
axial O 0 1.759980938764727e-09
elements O 0 1.3170263768458312e-09
of O 0 1.0459897836767595e-08
developing O 0 4.069368486625535e-08
synaptonemal O 0 1.02179428722593e-05
complexes O 0 4.254076486631675e-07
. O 0 2.5227203082067717e-07

Like O 0 1.0070262987937895e-06
BRCA1 O 0 8.668007467349526e-06
and O 0 1.0061010868867015e-07
RAD51 O 0 0.0013586641289293766
, O 0 1.1232350516365841e-07
BRCA2 O 0 1.7098890339184436e-06
relocates O 0 1.6892239784738194e-07
to O 0 2.417689337619322e-08
PCNA O 0 2.269051719849813e-06
+ O 0 1.3198284243287617e-08
replication O 0 2.1506645353497333e-09
sites O 0 4.2524897492235425e-10
following O 0 5.079477949365696e-10
exposure O 0 4.49897967769175e-08
of O 0 5.4867548726633686e-08
S O 0 3.633992491813842e-06
phase O 0 1.1679077260851045e-06
cells O 0 4.361689676102287e-09
to O 0 4.048124058186886e-09
hydroxyurea O 0 1.0033413673227187e-06
or O 0 2.0471874506711174e-07
UV O 0 0.001506405882537365
irradiation O 0 1.928799247252755e-05
. O 0 5.875704118807334e-07

Thus O 0 3.929173146843823e-07
, O 0 8.812788721002107e-09
BRCA1 O 0 7.423606263046167e-08
and O 0 1.2355998446622607e-09
BRCA2 O 0 8.686594554774274e-08
participate O 0 1.6625387733171237e-09
, O 0 1.0522197696483104e-10
together O 0 2.7990386050613658e-11
, O 0 2.062000917235629e-11
in O 0 2.1901916044675396e-11
a O 0 4.4888867622994155e-10
pathway O 0 2.3555339012659715e-08
( O 0 4.573067480251325e-10
s O 0 5.671717318023184e-09
) O 0 2.8600866466832464e-11
associated O 0 1.3628324857517526e-10
with O 0 2.0827276535351213e-12
the O 0 1.7084425540936365e-10
activation O 0 7.794366041480316e-09
of O 0 3.3761160977974214e-08
double O 0 1.1134714483773678e-08
- O 0 6.493647219940613e-08
strand O 0 4.3148499884182456e-08
break O 0 1.5357247917791028e-08
repair O 0 8.641941917630902e-08
and O 0 9.239969678276339e-09
/ O 0 1.0545142004048103e-06
or O 0 4.83995776789925e-08
homologous O 0 1.0174172615506905e-07
recombination O 0 2.2647337516445987e-07
. O 0 1.4559245187228953e-07

Dysfunction O 1 0.9999972581863403
of O 0 1.1376870133972261e-05
this O 0 7.679265223714538e-09
pathway O 0 4.169297653788817e-07
may O 0 7.04981684140904e-10
be O 0 3.9094689291419016e-11
a O 0 5.241904826869259e-11
general O 0 7.814815461415492e-10
phenomenon O 0 2.416208122468788e-09
in O 0 1.7256870845500094e-12
the O 0 2.169129459383967e-12
majority O 0 6.154781545530952e-13
of O 0 1.2749204469919562e-11
cases O 0 1.2988367326105532e-11
of O 0 5.6216578059320454e-09
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.6220059990882874
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5553150660707615e-05
. O 0 1.7531824596517254e-06

A O 0 1.0516409929550719e-06
novel O 0 1.0495794100506828e-07
Arg362Ser O 0 6.92268395141582e-06
mutation O 0 1.951067574168519e-08
in O 0 9.367744774335662e-11
the O 0 3.311097229730109e-10
sterol O 0 4.369660899783412e-08
27 O 0 6.513594286161606e-08
- O 0 5.989307538811772e-08
hydroxylase O 0 1.8232493914638326e-07
gene O 0 9.856686133957737e-09
( O 0 2.3868609311250566e-09
CYP27 O 1 0.9844418168067932
) O 0 1.0965510721661076e-09
: O 0 9.239907450275808e-11
its O 0 6.916293232572812e-11
effects O 0 7.80223441410044e-09
on O 0 1.757043754935239e-08
pre O 0 2.7710387939805514e-07
- O 0 2.7767308452553152e-08
mRNA O 0 1.5669733954837284e-08
splicing O 0 3.2270028871295153e-09
and O 0 7.053256589895085e-11
enzyme O 0 5.254891521921934e-10
activity O 0 4.930418295856498e-09
. O 0 1.8833292259046175e-08

A O 0 5.565159426623723e-07
novel O 0 2.3688114580977526e-08
C O 0 3.5182881674700184e-07
to O 0 4.366640660169452e-10
A O 0 2.1010656325870514e-08
mutation O 0 5.371820321897758e-09
in O 0 1.4413061022455764e-10
the O 0 4.1509398696071287e-10
sterol O 0 2.2425702184136753e-08
27 O 0 8.863059974828502e-08
- O 0 6.847430711331981e-08
hydroxylase O 0 2.070477762572409e-07
gene O 0 7.89295473424545e-09
( O 0 1.6314524176053169e-09
CYP27 O 0 0.0006413646624423563
) O 0 2.91507457061968e-10
was O 0 3.97649513317333e-09
identified O 0 2.1817662954060069e-10
by O 0 2.5122504770935805e-11
sequencing O 0 5.401904257240631e-09
amplified O 0 2.986655189829435e-08
CYP27 O 0 1.427803908882197e-05
gene O 0 5.393017143973111e-10
products O 0 9.92095502971857e-11
from O 0 1.9967584530267146e-10
a O 0 3.4922428837624864e-10
patient O 0 2.03360772665917e-09
with O 0 5.882976883420099e-10
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 1.4582006997443386e-06
CTX B-Disease 0 0.0006530950195156038
) O 0 4.210557591477482e-08
. O 0 1.4146120008717844e-07

The O 0 2.840574495621695e-07
mutation O 0 1.824352011681185e-07
changed O 0 1.7033034538371794e-08
the O 0 2.520873509936905e-09
adrenodoxin O 0 1.5840213052342733e-07
cofactor O 0 5.3348783168871705e-09
binding O 0 1.1293893820152334e-08
residue O 0 6.201165092534211e-08
362Arg O 0 1.2149626194002394e-08
to O 0 6.533509289141648e-10
362Ser O 0 3.602649201184249e-07
( O 0 1.0329166855171934e-08
CGT O 0 1.140514541475568e-05
362Arg O 0 1.8664970014015125e-07
to O 0 5.723379548072671e-09
AGT O 0 2.117543226631824e-05
362Ser O 0 8.271591411812551e-08
) O 0 1.1563649343626636e-10
, O 0 2.3407104379757904e-11
and O 0 1.1413499485801726e-11
was O 0 2.8712452415646794e-09
responsible O 0 1.3906095830407139e-08
for O 0 2.3327093146008337e-08
deficiency O 1 0.9627029299736023
in O 0 3.014998029016169e-08
the O 0 5.207920139582711e-08
sterol O 0 3.645081392278371e-07
27 O 0 3.0184051524884126e-07
- O 0 6.919733408494722e-08
hydroxylase O 0 4.101973516412727e-08
activity O 0 3.663640502082899e-09
, O 0 3.1494334917780975e-11
as O 0 1.8795512021774208e-11
confirmed O 0 5.718997844739171e-11
by O 0 1.1283778598991656e-11
expression O 0 1.094482504626626e-09
of O 0 8.462995637614767e-09
mutant O 0 7.714586303109172e-09
cDNA O 0 3.2078272482749526e-08
into O 0 1.881512545764963e-08
COS O 0 1.7412821762263775e-05
- O 0 9.696749430077034e-07
1 O 0 1.5439417211382533e-06
cells O 0 5.8700930338773105e-08
. O 0 4.6112514695551e-08

Quantitative O 0 7.036724696263263e-07
analysis O 0 1.474766886389034e-08
showed O 0 1.6704406746725908e-09
that O 0 1.8418971209355206e-11
the O 0 1.4607956511092368e-10
expression O 0 1.34029509712974e-09
of O 0 1.449688991073117e-08
CYP27 O 0 1.8560876924311742e-05
gene O 0 1.120937564991209e-09
mRNA O 0 6.689152343142268e-09
in O 0 3.795907338455251e-11
the O 0 1.1111959963283624e-10
patient O 0 1.67336799972162e-09
represented O 0 4.36099911738097e-09
52 O 0 1.405820739819319e-06
. O 0 3.319713641758426e-07

5 O 0 9.738954531712807e-07
% O 0 8.083525671054304e-08
of O 0 3.129694903236668e-08
the O 0 2.87248465014045e-08
normal O 0 4.5544831550614617e-07
level O 0 6.621611191803822e-06
. O 0 6.11707150710572e-07

As O 0 4.2823415924431174e-08
the O 0 5.724700713471975e-09
mutation O 0 9.869628669889607e-09
occurred O 0 3.043320262463567e-08
at O 0 4.3978025665580844e-09
the O 0 2.943631172147576e-10
penultimate O 0 3.611592447327894e-08
nucleotide O 0 3.0393971783837515e-09
of O 0 3.0955922269981784e-09
exon O 0 1.3215061045457333e-08
6 O 0 1.547731187656609e-08
( O 0 2.7719654349667167e-10
- O 0 2.493293393968088e-08
2 O 0 3.922874824979772e-08
position O 0 3.123546932215504e-08
of O 0 1.579251396321979e-08
exon O 0 8.133076789818006e-08
6 O 0 1.6400682056882943e-07
- O 0 1.0833635855078683e-07
intron O 0 6.386184736584255e-07
6 O 0 3.557404681941989e-08
splice O 0 3.7971872757225356e-08
site O 0 4.099787176414793e-10
) O 0 1.0030469510535767e-11
of O 0 2.273677079944747e-10
the O 0 4.807850784160905e-10
gene O 0 1.3365551998489877e-09
, O 0 1.5199493053064117e-10
we O 0 4.609347625805782e-10
hypothesized O 0 1.0091123492372844e-08
that O 0 3.438807225086826e-11
the O 0 2.9114183286438333e-10
mutation O 0 4.8555444109865675e-09
may O 0 2.4142872145915817e-09
partially O 0 1.6254803725246347e-08
affect O 0 2.153040856711641e-09
the O 0 8.369757664716815e-10
normal O 0 3.078364230191255e-09
splicing O 0 3.4238167856415203e-09
efficiency O 0 6.606238334150305e-10
in O 0 1.2427466000719534e-10
exon O 0 1.1421139589629092e-08
6 O 0 4.179605550547194e-09
and O 0 2.100689934503297e-11
cause O 0 3.20984377966127e-10
alternative O 0 1.0814962259075855e-09
splicing O 0 2.4103072870929054e-09
elsewhere O 0 1.175511910034288e-10
, O 0 2.1787699682612738e-12
which O 0 1.4220587598104406e-12
resulted O 0 1.5699724853490693e-10
in O 0 4.2198695926476404e-11
decreased O 0 1.5524196372851407e-09
transcript O 0 9.646075938007925e-09
in O 0 3.4972688633949645e-10
the O 0 2.648674168881371e-09
patient O 0 3.618101374058824e-08
. O 0 1.5023036326056172e-07

Transfection O 0 5.1844966947101057e-05
of O 0 4.000186493158253e-07
constructed O 0 2.576938129550399e-07
minigenes O 0 2.3635058823856525e-05
, O 0 2.489384809400974e-10
with O 0 3.850765192825456e-12
or O 0 3.698434614118895e-10
without O 0 1.1427474522207604e-09
the O 0 6.733696378269372e-10
mutation O 0 3.954802263450574e-09
, O 0 1.9893114933111633e-10
into O 0 1.0258406568652845e-08
COS O 0 9.889305511023849e-05
- O 0 5.718406441701518e-07
1 O 0 2.0224034358307108e-07
cells O 0 3.6086969523729806e-10
confirmed O 0 7.230745863173738e-11
that O 0 4.046527869727701e-12
the O 0 5.1011361801300836e-11
mutant O 0 1.878299071833567e-09
minigene O 0 5.673656744420441e-08
was O 0 2.5764002042905076e-09
responsible O 0 7.898914855530847e-10
for O 0 1.5071548176148752e-10
a O 0 2.9881579433066463e-09
mRNA O 0 8.693854880448271e-08
species O 0 6.283091408265662e-11
alternatively O 0 6.233869420668725e-09
spliced O 0 1.2321719111696439e-07
at O 0 4.147509002905281e-08
an O 0 2.7755697740161622e-09
activated O 0 5.443432655738434e-07
cryptic O 0 4.269240037046984e-07
5 O 0 7.313171579426125e-08
splice O 0 3.388994400665979e-07
site O 0 3.571654971779026e-08
88 O 0 2.4953200394861597e-08
bp O 0 3.153141037159912e-08
upstream O 0 7.260742673764753e-09
from O 0 6.033548105577324e-10
the O 0 9.535291445317284e-10
3 O 0 1.7936608642799e-08
end O 0 5.874158404139962e-08
of O 0 1.3109774954500608e-07
exon O 0 1.8743238570095855e-06
6 O 0 1.107864022742433e-06
. O 0 1.6942512104378693e-07

Our O 0 9.310186754873939e-08
data O 0 2.114383335083403e-09
suggest O 0 7.941666768651601e-10
that O 0 2.3176714020189948e-11
the O 0 2.0249289744977972e-10
C O 0 3.291894046242305e-08
to O 0 1.089200674098123e-10
A O 0 9.532096001407808e-09
mutation O 0 5.233768085588508e-09
at O 0 4.9083124231685815e-09
the O 0 6.761714521630324e-10
penultimate O 0 3.9217827207949085e-08
nucleotide O 0 4.5269352710874955e-09
of O 0 1.801618076946454e-09
exon O 0 1.845170061187673e-08
6 O 0 7.09912528762402e-09
of O 0 1.148207307011262e-09
the O 0 5.284945259198537e-10
CYP27 O 0 6.063646651455201e-06
gene O 0 2.770205731472686e-10
not O 0 3.683683566513274e-11
only O 0 1.1233555752276914e-10
causes O 0 2.0034633507748367e-08
the O 0 1.8417383174096358e-08
deficiency B-Disease 0 8.250953214883339e-06
in I-Disease 0 1.0902966307568818e-09
the I-Disease 0 2.179970426396949e-09
sterol I-Disease 0 4.4796024667448364e-08
27 I-Disease 0 5.149878035126676e-08
- I-Disease 0 1.2169340202206058e-08
hydroxylase I-Disease 0 2.0386533350347236e-08
activity I-Disease 0 6.1490799119212625e-09
, O 0 1.8973166093783078e-10
but O 0 1.4739949538711272e-10
also O 0 1.934531285163743e-10
partially O 0 9.14136499829965e-09
leads O 0 5.295055505172286e-10
to O 0 1.7536537499918126e-10
alternative O 0 5.014388904100997e-09
pre O 0 7.405618163147665e-08
- O 0 5.189968899088626e-09
mRNA O 0 3.991069252862189e-09
splicing O 0 1.6970602700894233e-09
of O 0 5.091787547151227e-10
the O 0 7.015062974957686e-10
gene O 0 7.765844856066906e-09
. O 0 2.3176129460011907e-08

To O 0 1.506256808170292e-08
our O 0 2.3199777654525633e-09
knowledge O 0 5.262777769132754e-09
, O 0 4.304190684423226e-11
this O 0 1.4899418504521478e-11
is O 0 4.077893578369185e-11
the O 0 7.937620005726842e-11
first O 0 1.535814114772549e-10
report O 0 1.175211594706127e-10
regarding O 0 8.646319216154552e-10
effects O 0 6.379826889002516e-09
on O 0 6.43363096131111e-09
pre O 0 4.3448284969827e-08
- O 0 3.020424577115932e-09
mRNA O 0 2.417475775118305e-09
splicing O 0 3.512015123163792e-10
of O 0 4.744245968302252e-11
a O 0 2.3385595543379267e-11
mutation O 0 3.0445304610715596e-10
at O 0 9.352253416139433e-10
the O 0 2.5211707721517485e-10
- O 0 4.605184678041496e-09
2 O 0 2.7037923899797534e-08
position O 0 2.2738529281696174e-08
of O 0 6.963024379302851e-09
a O 0 1.1445039582724803e-08
5 O 0 2.0496294439453777e-07
splice O 0 1.5129099892874365e-06
site O 0 1.353050294028435e-07
. O 0 6.558411058676938e-08

ATM O 1 0.9817675948143005
germline O 0 0.004634224809706211
mutations O 0 3.730301614268683e-06
in O 0 2.3839412222059764e-08
classical O 1 0.9997642636299133
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 3.7689999317080947e-06
in O 0 4.675529297060166e-09
the O 0 8.790460803709266e-09
Dutch O 0 1.5989072608135757e-06
population O 0 4.365143357887291e-09
. O 0 2.4620092631266743e-08

Germline O 0 0.003064319957047701
mutations O 0 1.0445720590723795e-06
in O 0 1.7921144568333602e-09
the O 0 2.045917213422399e-09
ATM O 0 1.8688086811380344e-06
gene O 0 2.035733387417693e-10
are O 0 1.0736290328994258e-12
responsible O 0 1.1765123597573535e-10
for O 0 1.3325987535672823e-10
the O 0 4.32844672104693e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 7.445456139976159e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.0386740001422368e-07
. O 0 2.841650257323636e-07

In O 0 4.718750190590981e-08
our O 0 4.320472424268473e-09
study O 0 1.447033493029437e-09
, O 0 1.0964753410780403e-10
we O 0 1.1141481487397797e-10
have O 0 6.906099823955625e-12
determined O 0 5.664362867641159e-10
the O 0 3.0700073039291453e-10
ATM O 0 5.839829100295901e-07
mutation O 0 4.493874605770998e-09
spectrum O 0 1.510998117737472e-07
in O 0 2.3596818943261155e-10
19 O 0 2.7597648610822034e-09
classical O 0 7.922669169602159e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 8.329532619200108e-09
, O 0 2.7796993873341336e-11
including O 0 3.5254678950463747e-12
some O 0 5.935063204787205e-12
immigrant O 0 8.595149592061091e-10
populations O 0 4.996997607364939e-11
, O 0 1.1975055495827558e-11
as O 0 2.0740907255567542e-11
well O 0 4.604670464369853e-11
as O 0 9.615205853741315e-11
12 O 0 1.7961866438653828e-09
of O 0 2.941948684664908e-09
Dutch O 0 4.413948317960603e-07
ethnic O 0 3.842673024223586e-08
origin O 0 1.0248749049424077e-07
. O 0 1.0620670565231194e-07

Both O 0 1.564423826039274e-07
the O 0 5.449718898375977e-08
protein O 0 2.3384826519645685e-08
truncation O 0 3.0446850018961413e-07
test O 0 2.235984197795915e-08
( O 0 6.152212073118335e-09
PTT O 0 2.7864082312589744e-06
) O 0 2.898475071066997e-10
and O 0 7.271531293762123e-11
the O 0 1.8532203549526116e-10
restriction O 0 1.3394058084870153e-09
endonuclease O 0 1.1153679935205218e-07
fingerprinting O 0 8.300323628418482e-08
( O 0 1.3798132636466676e-09
REF O 0 7.896931606410362e-07
) O 0 1.9437472464911565e-11
method O 0 1.275582695026145e-10
were O 0 1.2266474294642116e-11
used O 0 1.7437001495479443e-11
and O 0 1.721499678919436e-11
compared O 0 4.4059109138849806e-10
for O 0 7.779535349250466e-11
their O 0 1.7865188495225226e-11
detection O 0 2.1850157239100554e-09
efficiency O 0 7.453138661794867e-10
, O 0 6.645361344537193e-11
identifying O 0 5.919129075770968e-10
76 O 0 9.720173999028248e-09
% O 0 6.02130512117327e-10
and O 0 1.6454886064831697e-11
60 O 0 7.580044369959182e-10
% O 0 4.149079413373613e-10
of O 0 4.984254675655109e-10
the O 0 1.348760325647902e-09
mutations O 0 1.9182341048917806e-08
, O 0 3.3932030518712963e-09
respectively O 0 1.2797615056570066e-07
. O 0 9.558717550817164e-08

Most O 0 2.0807354417229362e-07
patients O 0 1.3125307063432956e-08
were O 0 1.2426714102176106e-09
found O 0 2.0989446292141167e-10
to O 0 5.971199645848912e-10
be O 0 2.640543117493621e-09
compound O 0 2.894117869800539e-07
heterozygote O 0 2.6185250590060605e-06
. O 0 1.6736632346692204e-07

Seventeen O 0 1.962857140824781e-06
mutations O 0 4.686674159870563e-08
were O 0 4.243609630361078e-10
distinct O 0 1.9865738221103157e-10
, O 0 5.907035277585848e-11
of O 0 6.435726396247787e-10
which O 0 4.1846109910537166e-11
10 O 0 4.632934036408187e-10
were O 0 1.0405026840132336e-10
not O 0 3.0295793651546887e-10
reported O 0 7.972662530164598e-09
previously O 0 4.0502577292045316e-08
. O 0 7.757424214105413e-08

Mutations O 0 6.11403720540693e-06
are O 0 1.8591940209589097e-09
small O 0 3.6365168654128865e-09
deletions O 0 2.6257845320287743e-07
or O 0 3.472447076546814e-07
point O 0 2.86420345219085e-05
mutations O 0 2.8667056994891027e-07
frequently O 0 5.7589679691716356e-09
affecting O 0 1.4334748499322814e-08
splice O 0 7.368954584308085e-07
sites O 0 1.1552907608347596e-07
. O 0 7.957655867585345e-08

Moreover O 0 4.773649379785638e-06
, O 0 8.749883306791162e-08
a O 0 3.566502186913567e-07
16 O 0 4.283642738300841e-06
. O 0 7.20539560461475e-07

7 O 0 8.431656169705093e-05
- O 0 7.579814337077551e-06
kb O 0 5.476181740959873e-06
genomic O 0 2.71915041594184e-07
deletion O 0 7.500976835217443e-07
of O 0 7.931955536832902e-08
the O 0 2.7872144592322456e-09
3 O 0 1.055481213541043e-08
end O 0 8.12868439226122e-09
of O 0 1.1931134968889978e-09
the O 0 1.3906240048378038e-10
gene O 0 2.011724675732296e-10
, O 0 1.2159576297243735e-11
most O 0 3.330831053680039e-12
likely O 0 1.2438303165218656e-10
a O 0 1.5871189085192583e-10
result O 0 1.097256174809047e-09
of O 0 4.675618114902136e-09
recombination O 0 2.112182651003991e-09
between O 0 1.5286664156732854e-09
two O 0 7.312435379436266e-11
LINE O 0 4.2035363634340683e-08
elements O 0 2.0221742058623704e-09
, O 0 3.2377903136371344e-10
was O 0 1.9441207754766765e-08
identified O 0 2.5928621028015186e-08
. O 0 2.3269810967008198e-08

The O 0 2.2740140082078142e-07
most O 0 6.733400503833309e-10
frequently O 0 2.740120630395637e-10
found O 0 4.7955941301358607e-11
mutation O 0 4.1817888041251194e-10
, O 0 2.8021101064479303e-11
identified O 0 5.327584484682291e-10
in O 0 3.143138527228473e-11
three O 0 1.2826914877472895e-11
unrelated O 0 7.498180965015422e-10
Turkish O 0 1.1270474686853049e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
individuals O 0 3.234722489864339e-10
, O 0 9.6978300390127e-11
was O 0 3.6808147640954303e-09
previously O 0 1.3803391762934325e-10
described O 0 5.045236797784902e-11
to O 0 9.533499857605765e-12
be O 0 3.4596228659644623e-11
a O 0 3.206435394975671e-10
Turkish O 0 3.71080460581652e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
founder O 0 2.5878733140416443e-05
mutation O 0 1.3944336387794465e-06
. O 0 2.1258877325180947e-07

The O 0 6.716616951507604e-08
presence O 0 2.9543363311290705e-09
of O 0 3.2123210758072673e-08
a O 0 3.243121682316996e-08
founder O 0 3.460744892436196e-06
mutation O 0 1.8214454655662848e-07
among O 0 5.366182498356409e-11
relatively O 0 8.078735597161213e-11
small O 0 1.493871519542278e-11
ethnic O 0 1.2025967721651654e-10
population O 0 2.2866873325422254e-12
groups O 0 5.85243713300404e-13
in O 0 1.8186813817086533e-12
Western O 0 5.632569965996481e-10
Europe O 0 1.6825789650454226e-09
could O 0 5.999649110854932e-10
indicate O 0 7.814696112440345e-10
a O 0 5.213221521138678e-10
high O 0 2.1422144058647064e-09
carrier O 0 2.2420247602905619e-10
frequency O 0 4.311820678282174e-09
in O 0 2.9384071564830805e-11
such O 0 1.0844370540441517e-10
communities O 0 4.442671563964495e-09
. O 0 1.1139775324409129e-07

In O 0 1.0137194550452477e-07
patients O 0 8.038871790461144e-09
of O 0 2.509428753683096e-08
Dutch O 0 4.989794433640782e-06
ethnic O 0 2.6783951057041122e-08
origin O 0 4.5565355932808416e-09
, O 0 2.3305888469105085e-11
however O 0 4.217029156428076e-11
, O 0 1.878891833784202e-11
no O 0 6.520508438745409e-11
significant O 0 6.293673360246999e-10
founder O 0 3.0586306820623577e-08
effect O 0 1.8299239457064687e-08
could O 0 2.437142709865725e-09
be O 0 6.115896233893636e-09
identified O 0 7.399377466299484e-08
. O 0 6.007888231351899e-08

The O 0 1.2635099722047016e-07
observed O 0 7.311023608735923e-08
genetic O 0 5.5964765266480754e-08
heterogeneity O 0 1.524448833833958e-07
including O 0 1.453214493185584e-10
the O 0 1.7313207534286335e-09
relative O 0 2.622460897327983e-07
high O 0 1.001330360850261e-07
percentage O 0 4.3669281524216785e-08
of O 0 1.0950426343470099e-08
splice O 0 7.725618047516036e-07
- O 0 7.746852759282774e-08
site O 0 3.927275393778018e-09
mutations O 0 1.5738348402294378e-09
had O 0 4.794499242066763e-10
no O 0 4.796859021105604e-10
reflection O 0 3.100823775525896e-08
on O 0 3.481067167854235e-08
the O 0 8.621391600627248e-09
phenotype O 0 4.589136608501576e-07
. O 0 1.4789844726692536e-07

All O 0 3.156926098313306e-08
patients O 0 2.1343347089697318e-09
manifested O 0 2.897266204726634e-09
classical O 0 1.512144081061706e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 0.9999998807907104
and O 0 9.075590945428758e-09
increased O 0 2.8437831645078404e-08
cellular O 0 1.0585461041046074e-07
radioresistant O 0 8.419639243584243e-07
DNA O 0 1.2791464598649327e-07
synthesis O 0 2.7450755624158774e-07
. O 0 5.5206090365800264e-08

Determination O 0 2.2232511582842562e-06
of O 0 6.261219596126466e-07
the O 0 6.783199779647475e-09
genomic O 0 2.513078456445328e-08
structure O 0 9.38085964463653e-09
of O 0 2.6443547795906852e-08
the O 0 6.805787933217289e-09
COL4A4 O 0 0.3185099959373474
gene O 0 1.855966491604022e-09
and O 0 5.811286521439918e-11
of O 0 1.8073073038138432e-09
novel O 0 3.106613633008237e-08
mutations O 0 2.4279170247609727e-06
causing O 0 3.0243976652855054e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.01092049852013588

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 2.3586005681863753e-07
a O 0 1.0382322557234147e-07
progressive O 1 0.999927282333374
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.0005177672137506306
by O 0 1.2994821929623868e-07
glomerular B-Disease 1 1.0
basement I-Disease 1 0.9999992847442627
membrane I-Disease 1 0.9254335165023804
abnormalities I-Disease 1 0.9999161958694458
and O 0 1.9836974285425413e-09
associated O 0 9.159673020064929e-09
with O 0 9.127452266222136e-11
mutations O 0 2.603591298111496e-08
in O 0 5.70269498290088e-10
either O 0 6.6241843121872535e-09
the O 0 9.815336987628598e-09
COL4A3 O 0 0.1700558364391327
or O 0 8.655728578332855e-09
the O 0 6.481654324375086e-09
COL4A4 O 0 6.891385419294238e-05
gene O 0 1.3876493287767744e-09
, O 0 1.5134511699432807e-11
which O 0 5.654253974751722e-12
encode O 0 1.6573517558349238e-10
the O 0 9.957092927947997e-10
alpha3 O 0 1.9666083517222432e-06
and O 0 2.663924636436832e-09
alpha4 O 0 2.9172078939154744e-06
type O 0 2.2854549115436384e-06
IV O 1 0.9999890327453613
collagen O 0 2.134202077286318e-05
chains O 0 5.188962859392632e-07
, O 0 1.1511133379826788e-08
respectively O 0 1.923492192190679e-07
. O 0 1.7141802288733743e-07

To O 0 2.3818731875735466e-08
date O 0 1.493808952091058e-07
, O 0 2.1921529869128875e-10
mutation O 0 3.826666206130369e-10
screening O 0 3.978435081375409e-10
in O 0 3.303563672618637e-11
the O 0 1.7894015436059618e-10
two O 0 3.52234422185127e-11
genes O 0 3.137019255472495e-10
has O 0 2.1795690252623956e-11
been O 0 7.273737168134176e-11
hampered O 0 3.6590175334083597e-09
by O 0 5.7386224244782014e-11
the O 0 1.2121519343821774e-09
lack O 0 4.5196282272286226e-09
of O 0 5.033860883685293e-09
genomic O 0 2.2592926640641053e-08
structure O 0 6.483670045298595e-09
information O 0 4.287193711149939e-09
. O 0 2.5375760159818128e-08

We O 0 8.071801005371526e-08
report O 0 5.063053865050904e-10
here O 0 1.0328662924941057e-10
the O 0 7.04873798218486e-11
complete O 0 2.8310837008049816e-10
characterization O 0 8.065165424397946e-09
of O 0 6.61122090406252e-09
the O 0 1.2545169347788487e-09
48 O 0 1.168217522717896e-08
exons O 0 3.7495002658261e-08
of O 0 8.471765511330887e-09
the O 0 6.260631568721919e-09
COL4A4 O 0 0.18442970514297485
gene O 0 4.7096389010903295e-09
, O 0 4.586806282014244e-11
a O 0 8.686183716744011e-11
comprehensive O 0 2.981337621221769e-09
gene O 0 1.1077937456249742e-09
screen O 0 4.84277107304365e-09
, O 0 1.4669269965406073e-10
and O 0 2.9777433990796354e-11
the O 0 5.79134691591765e-11
subsequent O 0 9.009799850634437e-11
detection O 0 3.860942232591924e-09
of O 0 1.0914783521442928e-09
10 O 0 2.1401384830976866e-10
novel O 0 9.251651528208171e-11
mutations O 0 3.6042394069291106e-10
in O 0 5.6233035589103864e-11
eight O 0 1.3174157320605673e-09
patients O 0 4.121577745763716e-09
diagnosed O 0 0.002670535584911704
with O 0 7.494127629570357e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0034609062131494284

Furthermore O 0 5.410021231000428e-07
, O 0 6.791549989060286e-09
we O 0 2.102976903728404e-09
identified O 0 2.428873324689107e-09
a O 0 1.9834742737145916e-09
glycine O 0 3.124225855799523e-08
to O 0 2.2428898738269254e-09
alanine O 0 4.4831239165432635e-08
substitution O 0 6.197215896008856e-08
in O 0 1.1665515220471434e-09
the O 0 1.6301460181722405e-09
collagenous O 0 4.170836973571568e-07
domain O 0 3.54005469382912e-09
that O 0 8.310636033515006e-12
is O 0 2.3923141245774104e-11
apparently O 0 1.9492503444684672e-10
silent O 0 7.407220947719395e-10
in O 0 8.73802506046184e-12
the O 0 3.34347410868574e-11
heterozygous O 0 7.100296045559062e-11
carriers O 0 8.621086483584506e-11
, O 0 2.1866616850552134e-10
in O 0 1.5694492372375635e-09
11 O 0 1.3067996462723386e-07
. O 0 1.3937354026438697e-07

5 O 0 4.183388568890223e-07
% O 0 2.624386929994671e-08
of O 0 2.205196247828667e-09
all O 0 5.09296008144311e-11
control O 0 1.2315035657906037e-09
individuals O 0 4.5970359463520793e-11
, O 0 5.0179044946974116e-11
and O 0 2.0188038740709402e-11
in O 0 2.920783406801242e-11
one O 0 2.6669211977692342e-11
control O 0 2.89178819778968e-10
individual O 0 7.286869892209058e-12
homozygous O 0 1.6899949495385869e-10
for O 0 5.885510134806538e-11
this O 0 4.1763206781730844e-10
glycine O 0 3.2606067179585807e-07
substitution O 0 1.3251049040263752e-06
. O 0 4.72131574724699e-07

There O 0 7.119169254110602e-08
has O 0 1.3075076576996025e-09
been O 0 2.893371375822795e-10
no O 0 1.1774461960989413e-10
previous O 0 6.21413642765134e-10
finding O 0 2.954261557608362e-10
of O 0 3.44853007261392e-10
a O 0 9.110667775757975e-11
glycine O 0 2.4021791222850197e-09
substitution O 0 1.641697111587348e-09
that O 0 6.520655109615303e-12
is O 0 1.3861373854284764e-11
not O 0 1.4020140083614852e-11
associated O 0 1.1640238078980403e-10
with O 0 2.057442540989718e-12
any O 0 9.115209698151716e-10
obvious O 0 1.3898723061345208e-08
phenotype O 0 3.207851761999336e-08
in O 0 8.142816976253187e-10
homozygous O 0 1.1219691842256907e-08
individuals O 0 1.5278385223638224e-09
. O 0 1.2655914360948373e-07

Founder O 0 0.00028122984804213047
BRCA1 O 0 1.5101053577382118e-05
and O 0 4.7066151864783023e-08
BRCA2 O 0 9.165956953438581e-07
mutations O 0 1.279128891695791e-08
in O 0 1.2404778593211319e-10
French O 0 8.868081380342119e-08
Canadian O 0 1.9408921616559383e-06
breast B-Disease 1 1.0
and I-Disease 1 0.9999964237213135
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.5783645721967332e-05
. O 0 3.842431397060864e-06

We O 0 1.2749885058838117e-07
have O 0 6.524095153004339e-10
identified O 0 1.651332071084255e-09
four O 0 2.2184492090571162e-11
mutations O 0 1.4198865694314833e-10
in O 0 6.891349036558525e-12
each O 0 2.246312684472951e-11
of O 0 7.063144735752758e-09
the O 0 1.2170528407295933e-07
breast B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999905824661255
- O 0 0.0023968105670064688
susceptibility O 0 8.295762381749228e-05
genes O 0 3.026556072427411e-08
, O 0 6.767778559790827e-10
BRCA1 O 0 5.237924938228389e-08
and O 0 2.285164724113997e-09
BRCA2 O 0 6.898305855429498e-07
, O 0 8.990299477096286e-11
in O 0 3.0128781414173744e-11
French O 0 2.1299520369666425e-08
Canadian O 0 2.294482328579761e-07
breast B-Disease 1 0.9964401125907898
cancer I-Disease 1 0.9986968636512756
and O 1 0.6172777414321899
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.173309318706742e-07
from O 0 3.755488080514624e-07
Quebec O 0 3.5540995213523274e-06
. O 0 1.937232809723355e-07

To O 0 3.622987492235552e-07
identify O 0 1.666987145654275e-06
founder O 0 5.3205010772217065e-05
effects O 0 0.00022924819495528936
, O 0 1.7759859360921837e-08
we O 0 3.253311398054848e-09
examined O 0 4.536884645744976e-09
independently O 0 4.4363779316825003e-10
ascertained O 0 3.606870180306032e-08
French O 0 3.941565651643941e-08
Canadian O 0 4.2641737252324674e-08
cancer B-Disease 0 1.7920440598118148e-07
families O 0 1.0538341033150544e-11
for O 0 6.546900174764225e-12
the O 0 4.3999293791729954e-11
distribution O 0 4.794828423193565e-10
of O 0 1.1789232923220538e-09
these O 0 1.4161163908177343e-10
eight O 0 5.513513645638568e-09
mutations O 0 9.657566835130638e-08
. O 0 8.986917521269788e-08

Mutations O 0 8.244175546678889e-07
were O 0 6.0148912517377084e-09
found O 0 5.002903091799737e-10
in O 0 3.845455343043369e-10
41 O 0 1.6129014568377897e-08
of O 0 2.4507182061483945e-08
97 O 0 3.327815534248657e-07
families O 0 1.0110041692712457e-08
. O 0 2.48771243605006e-07

Six O 0 2.2136893562674231e-07
of O 0 1.279978647517055e-07
eight O 0 5.2947752848808705e-09
mutations O 0 7.734580087515042e-09
were O 0 1.6102846833732087e-09
observed O 0 1.0191163468675768e-08
at O 0 1.0527026361728531e-08
least O 0 5.7532369979185205e-09
twice O 0 2.3814855865111895e-07
. O 0 1.2330053777986905e-07

The O 0 1.453728373235208e-06
BRCA1 O 0 9.482532732363325e-06
C4446T O 0 3.0782175599597394e-05
mutation O 0 1.2063614462931582e-07
was O 0 7.08138259142288e-09
the O 0 1.1075861061637937e-10
most O 0 8.142700055890906e-12
common O 0 1.1418383599748338e-10
mutation O 0 1.9992023592152464e-09
found O 0 1.327909865400656e-10
, O 0 1.1120520303220527e-11
followed O 0 1.0863954874595905e-10
by O 0 1.281171280176352e-10
the O 0 1.1546602785017512e-08
BRCA2 O 0 1.5093663705556537e-06
8765delAG O 0 3.5929397199652158e-06
mutation O 0 2.462071506670327e-06
. O 0 3.871696776514e-07

Together O 0 3.785927304988945e-08
, O 0 8.932463102517829e-10
these O 0 3.19435970730364e-11
mutations O 0 2.3655684078249806e-09
were O 0 4.2762074436986097e-10
found O 0 6.67149807620504e-11
in O 0 2.9818581631646524e-11
28 O 0 2.210746696817978e-09
of O 0 2.343303551199938e-09
41 O 0 9.442054249575449e-09
families O 0 3.043977570005296e-11
identified O 0 4.750460580460469e-10
to O 0 2.9066909990049794e-10
have O 0 7.057915918373681e-10
a O 0 2.3475010380025196e-08
mutation O 0 7.020670977908594e-07
. O 0 1.861221363697041e-07

The O 0 1.1286963541579098e-07
odds O 0 3.3353614981024293e-07
of O 0 3.723024111224049e-09
detection O 0 2.564717860309429e-08
of O 0 7.2787962324127875e-09
any O 0 2.9763662645621025e-09
of O 0 2.7427901727605786e-08
the O 0 2.1156016938306266e-09
four O 0 4.3994533016622484e-10
BRCA1 O 0 2.880928917647907e-08
mutations O 0 5.2428127617076825e-08
was O 0 3.6213398857398715e-07
18 O 0 4.7149265469670354e-07
. O 0 1.0411414308464373e-07

7x O 0 0.0025824708864092827
greater O 0 3.5103519735457667e-07
if O 0 3.324839425999926e-08
one O 0 1.0096432578876602e-09
or O 0 1.334796578822406e-10
more O 0 1.9285243974681565e-12
cases O 0 1.2851557318338536e-10
of O 0 2.5953911517717643e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 2.828927492259936e-08
also O 0 6.56789067576824e-11
present O 0 8.173654114651541e-11
in O 0 7.578536409535985e-11
the O 0 1.706971231030252e-09
family O 0 6.509270011889612e-09
. O 0 2.2362186768987158e-08

The O 0 1.4119716240657e-07
odds O 0 4.779270170729433e-07
of O 0 6.324832657611523e-09
detection O 0 5.018926785282929e-08
of O 0 1.3398330445113515e-08
any O 0 4.36917479973431e-09
of O 0 6.096298221791585e-08
the O 0 4.155599420130329e-09
four O 0 7.285806402634876e-10
BRCA2 O 0 6.96276103440141e-08
mutations O 0 2.3946368443716892e-08
was O 0 1.7064553503587376e-07
5 O 0 3.081609349919745e-07
. O 0 7.419614433956667e-08

3x O 0 7.883983926149085e-05
greater O 0 2.3999601239665935e-07
if O 0 1.1396810606356667e-08
there O 0 9.83756076600173e-10
were O 0 5.534562808051646e-10
at O 0 4.149230126149206e-10
least O 0 1.9562218164792533e-11
five O 0 2.929183588393225e-12
cases O 0 9.687066253316612e-12
of O 0 4.0783332266869365e-09
breast B-Disease 0 0.31490740180015564
cancer I-Disease 0 0.00022055651061236858
in O 0 2.517458597139921e-08
the O 0 2.2670545263281383e-07
family O 0 5.139260750297581e-08
. O 0 1.4567508799245843e-07

Interestingly O 0 9.829567488850444e-07
, O 0 2.239700869210992e-09
the O 0 6.649638062405927e-10
presence O 0 5.098230171363127e-10
of O 0 1.588980502731374e-08
a O 0 3.225934221973148e-07
breast B-Disease 1 0.9999954700469971
cancer I-Disease 0 0.0396123006939888
case O 0 4.314718751174951e-07
< O 0 0.0002377073251409456
36 O 0 2.3412676242173802e-08
years O 0 4.6537113052025347e-10
of O 0 4.226033412102481e-10
age O 0 1.244186864646224e-09
was O 0 2.7243354794315167e-10
strongly O 0 4.198394062959743e-11
predictive O 0 3.992422226151149e-10
of O 0 1.9379953197784516e-10
the O 0 1.6986549319919497e-11
presence O 0 1.2735108974315512e-11
of O 0 1.7858690914973607e-10
any O 0 2.43087883156079e-10
of O 0 2.3690722716906976e-09
the O 0 6.936972662963115e-10
eight O 0 1.4327552477766403e-09
mutations O 0 7.46819761587858e-09
screened O 0 9.892153940427306e-08
. O 0 5.07649033920643e-08

Carriers O 0 1.327202259204796e-08
of O 0 8.686789065848188e-09
the O 0 4.854365798223625e-10
same O 0 1.8433811421747492e-10
mutation O 0 2.1852490927898316e-09
, O 0 8.62618136643345e-12
from O 0 2.1950722489672003e-11
different O 0 2.4061054797880344e-12
families O 0 7.907891355629637e-12
, O 0 9.564808146900194e-12
shared O 0 1.1942689025212783e-11
similar O 0 3.3326948839507153e-11
haplotypes O 0 2.1552319040551993e-08
, O 0 9.859026789404979e-11
indicating O 0 1.1312342174107926e-09
that O 0 1.6756658560712623e-11
the O 0 1.4571725770462507e-10
mutant O 0 7.060164675110059e-10
alleles O 0 1.2480128042113847e-10
were O 0 1.780636922632528e-11
likely O 0 4.682806920008886e-11
to O 0 7.275634521936025e-12
be O 0 1.2476504204772532e-11
identical O 0 6.2149356841456616e-12
by O 0 4.914009737316816e-12
descent O 0 7.93924836983706e-09
for O 0 1.3961832558140319e-11
a O 0 1.1630938573370386e-10
mutation O 0 1.1854306425362893e-09
in O 0 1.2425829809536992e-10
the O 0 1.7800207974261184e-09
founder O 0 2.4005893806133827e-07
population O 0 2.6943853814742624e-09
. O 0 3.0485139745906054e-08

The O 0 2.2743821048720747e-08
identification O 0 1.0699780617073884e-08
of O 0 2.3025704010137815e-08
common O 0 8.365902459672725e-08
BRCA1 O 0 7.976824235811364e-06
and O 0 8.305850229817224e-08
BRCA2 O 0 7.254257070599124e-06
mutations O 0 6.472551916658631e-08
will O 0 1.9701407172334484e-10
facilitate O 0 2.1042279030325517e-10
carrier O 0 2.8686600317406885e-10
detection O 0 8.655662853129797e-09
in O 0 8.448020755169594e-11
French O 0 3.8956446957172375e-08
Canadian O 0 3.481473243027722e-07
breast B-Disease 0 0.07599183171987534
cancer I-Disease 0 0.2549170255661011
and O 0 0.0020771725103259087
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.3469570149027277e-05
. O 0 3.451249313002336e-06

Are O 0 1.8322751316190988e-07
Dp71 O 0 0.007169878575950861
and O 0 5.401122962211957e-07
Dp140 O 1 0.998755693435669
brain O 0 0.00042082584695890546
dystrophin O 0 4.611353688233066e-06
isoforms O 0 1.1377550634961153e-07
related O 0 5.745681708191341e-09
to O 0 1.2579552954861128e-09
cognitive B-Disease 0 5.738825348089449e-05
impairment I-Disease 1 0.9999430179595947
in O 0 2.50102693826193e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9989620447158813

Molecular O 0 5.749061074311612e-06
study O 0 1.1356883433677467e-08
and O 0 1.4774795276117914e-10
neuropsychological O 0 4.984142432107319e-09
analysis O 0 3.08222281031334e-10
were O 0 6.84244674808987e-11
performed O 0 1.6929622634331842e-11
concurrently O 0 5.248818393810417e-11
on O 0 9.694617331135191e-10
49 O 0 1.4901202050054962e-08
patients O 0 1.7214808745169563e-10
with O 0 9.55542756031491e-10
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.3965665400028229
DMD B-Disease 1 1.0
) O 0 4.449182133825502e-10
in O 0 2.7012520692482056e-11
order O 0 1.9683745952625564e-11
to O 0 1.7917365507935656e-11
find O 0 3.302082912659543e-11
a O 0 4.0190160227604466e-11
molecular O 0 1.409837580013118e-09
explanation O 0 2.873802584790752e-10
for O 0 4.158331318171449e-11
the O 0 6.85551393431183e-10
cognitive B-Disease 0 6.420433692255756e-06
impairment I-Disease 0 7.674656808376312e-05
observed O 0 1.528318023247266e-07
in O 0 4.074484749594376e-09
most O 0 1.9300516740372586e-08
DMD B-Disease 1 1.0
patients O 0 1.132279521698365e-06
. O 0 6.809620458625432e-07

Complete O 0 1.2515734226781206e-07
analysis O 0 1.1330789639885097e-08
of O 0 5.3919940512514586e-08
the O 0 1.3483700378458252e-08
dystrophin O 0 7.166805175984337e-07
gene O 0 1.884820655106978e-08
was O 0 2.4712022650419385e-08
performed O 0 2.55449716934919e-10
to O 0 1.3743493842977017e-10
define O 0 8.451897848260614e-09
the O 0 1.025969309509378e-09
localization O 0 3.181534964369348e-07
of O 0 3.404192128186878e-08
deletions O 0 9.21891825100829e-08
and O 0 2.3402841886621673e-09
duplications O 0 5.135033234182629e-07
in O 0 1.102137159314509e-09
relation O 0 2.0821280699578892e-08
to O 0 1.3224813466550245e-09
the O 0 4.107232776107139e-09
different O 0 1.7338098956543035e-08
DMD B-Disease 1 1.0
promoters O 0 0.00021148915402591228
. O 0 1.7209496263603796e-06

Qualitative O 0 8.694324833413702e-07
analysis O 0 3.209546761695492e-08
of O 0 1.1914954001213118e-07
the O 0 2.8801927953736595e-08
Dp71 O 0 9.374025466968305e-06
transcript O 0 1.0041341624855704e-07
and O 0 1.5586493207209173e-10
testing O 0 8.912105081693156e-11
for O 0 7.499446376402208e-12
the O 0 3.669084480684148e-11
specific O 0 1.3255968545067276e-10
first O 0 1.0350895696120688e-09
exon O 0 2.036741264532793e-08
of O 0 2.0949233459077732e-08
Dp140 O 0 3.4553593195596477e-06
were O 0 3.3946205846291377e-09
also O 0 4.971835165790139e-10
carried O 0 1.5110470652501817e-09
out O 0 1.7587494793858127e-09
. O 0 1.794283654987794e-08

Neuropsychological O 0 9.848570698522963e-06
analysis O 0 1.0920312121243114e-07
assessed O 0 1.1203010217286646e-06
verbal O 0 9.173477906188054e-07
and O 0 3.1221887297760986e-08
visuospatial O 0 3.967644261138048e-06
intelligence O 0 3.266463366458083e-08
, O 0 1.2636979240809865e-09
verbal O 0 2.2465330573595566e-07
memory O 0 4.528656791080721e-05
, O 0 5.165250893668372e-09
and O 0 2.7026256788076353e-09
reading O 0 2.873219671073457e-07
skills O 0 1.6711831563043233e-07
. O 0 1.4599969233586307e-07

Comparison O 0 6.789739472878864e-06
of O 0 3.5260109143564478e-06
molecular O 0 3.030767175005167e-06
and O 0 3.628216616036184e-09
psychometric O 0 1.2360117125354009e-06
findings O 0 7.0116419337296065e-09
demonstrated O 0 1.9689283536905577e-09
that O 0 8.746700586037548e-11
deletions O 0 1.6038333328083354e-08
and O 0 3.4417946270792754e-10
duplications O 0 6.887591297299878e-08
that O 0 2.0563774294490855e-10
were O 0 2.076799426875553e-10
localized O 0 3.989046604147006e-08
in O 0 4.4698345025295794e-10
the O 0 1.0961183072311087e-09
distal O 0 2.8092563297832385e-06
part O 0 1.445136632582944e-08
of O 0 9.439627035590092e-08
the O 0 4.712190637690128e-09
gene O 0 3.1112132869992593e-09
seemed O 0 1.0966368924059111e-09
to O 0 4.3310455916101276e-11
be O 0 5.0506671761541e-11
preferentially O 0 1.8287681369244524e-09
associated O 0 2.8339754987172228e-09
with O 0 9.324681027322868e-10
cognitive B-Disease 0 0.06054988503456116
impairment I-Disease 1 0.9999780654907227
. O 0 1.7686777937342413e-05

Two O 0 1.9716959798188327e-07
altered O 0 5.924002266510797e-07
Dp71 O 0 6.271032907534391e-05
transcripts O 0 1.1060545830332558e-06
and O 0 1.3080671656950926e-08
two O 0 1.3156982170414722e-09
deleted O 0 2.3982341446071587e-08
Dp140 O 0 9.401946954312734e-08
DNA O 0 1.084301204379301e-09
sequences O 0 5.3785812609286054e-11
were O 0 1.50120939984566e-11
found O 0 2.9850544779053134e-12
in O 0 2.30822067188996e-12
four O 0 7.199406869273783e-12
patients O 0 2.6622100357531764e-11
with O 0 1.770140423129618e-10
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.00833897478878498

These O 0 1.6290153226350412e-08
findings O 0 1.721101838825234e-08
suggest O 0 6.4906116037377615e-09
that O 0 1.1340680478033605e-10
some O 0 2.792074904611752e-11
sequences O 0 1.4395368230779582e-10
located O 0 5.537783009934572e-10
in O 0 3.56667993750559e-11
the O 0 7.173367455592938e-11
distal O 0 1.9700438258496433e-07
part O 0 1.627803336567979e-09
of O 0 8.350816926849802e-09
the O 0 6.336565716580367e-10
gene O 0 6.229539661894989e-10
and O 0 6.275653607890064e-11
, O 0 3.2741059863283795e-11
in O 0 1.882105409023449e-11
particular O 0 5.626996646412863e-10
, O 0 7.07905262187225e-11
some O 0 2.2066171112555821e-10
DMD B-Disease 1 1.0
isoforms O 0 1.1677813915866864e-07
expressed O 0 1.9933081851775114e-09
in O 0 4.056376901040437e-10
the O 0 2.2784971687173083e-09
brain O 0 6.117707016528584e-07
may O 0 9.686816904164175e-10
be O 0 1.0770368624735127e-10
related O 0 2.0766172115216364e-10
to O 0 1.1134448918426187e-10
the O 0 9.190310734652485e-10
cognitive B-Disease 0 3.2294481115968665e-06
impairment I-Disease 0 1.6542304365430027e-05
associated O 0 3.0990148047749244e-07
with O 0 4.790756236161542e-08
DMD B-Disease 1 1.0
. O 0 9.254979431716492e-07
. O 0 5.175025989956339e-07

I1307K O 0 0.0006507526850327849
APC O 0 2.0984839466109406e-06
and O 0 2.3484221234326697e-09
hMLH1 O 0 2.409881574294559e-07
mutations O 0 2.9657862832266346e-09
in O 0 4.4119631559258465e-11
a O 0 2.826928691135322e-10
non O 0 6.315203648910028e-08
- O 0 2.37664981028729e-08
Jewish O 0 4.934805275524923e-08
family O 0 1.2503667545793462e-10
with O 0 7.018632203203978e-11
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9998142123222351

We O 0 6.039552147285576e-08
describe O 0 1.4602845155309296e-08
a O 0 1.844127739403234e-09
French O 0 5.322450533640222e-07
Canadian O 0 3.0642709134554025e-06
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9980798959732056
HNPCC B-Disease 1 1.0
) O 0 1.3834849710292474e-08
kindred O 0 1.0905721836707016e-07
which O 0 1.6540706304635222e-10
carries O 0 2.5163135464190134e-10
a O 0 1.643187530486756e-10
novel O 0 2.2148238798536113e-09
truncating O 0 1.5287814392195287e-07
mutation O 0 3.6932359392949365e-08
in O 0 6.173665134667772e-09
hMLH1 O 0 2.9419218208204256e-06
. O 0 6.204956548572227e-07

Interestingly O 0 1.5412392713187728e-06
, O 0 1.0677457140673141e-08
the O 0 8.330168554948614e-09
I1307K O 0 2.1749272036686307e-06
APC O 0 7.44101456007229e-08
polymorphism O 0 3.971691242554698e-08
, O 0 7.411032898474446e-11
associated O 0 1.3018780498086358e-10
with O 0 1.0800887094430944e-12
an O 0 1.0358310563451933e-11
increased O 0 2.699874324108009e-09
risk O 0 1.9619772501755506e-05
of O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.886755391453335e-07
is O 0 9.757300523105528e-10
also O 0 2.223854954352955e-11
present O 0 3.6425244764881626e-11
in O 0 3.8776690192143803e-11
this O 0 2.350043215582076e-10
family O 0 2.4338537851775754e-09
. O 0 2.5315671337011736e-08

The O 0 8.57391853514855e-07
I1307K O 0 4.1270879592048004e-05
polymorphism O 0 2.7267926725471625e-06
has O 0 8.229441572638052e-10
previously O 0 2.0034536529767166e-10
only O 0 9.037505119269262e-12
been O 0 1.975306029855517e-11
identified O 0 2.242776450667172e-11
in O 0 1.045473061421498e-12
individuals O 0 8.945770339774395e-12
of O 0 6.083030523740263e-09
self O 0 5.553845312533667e-07
- O 0 9.610027973394608e-07
reported O 0 4.044398593805454e-08
Ashkenazi O 0 1.6146301504704752e-06
Jewish O 0 1.694361202453365e-07
origins O 0 3.377682276095584e-07
. O 0 9.167839465362704e-08

In O 0 3.796244207876498e-09
addition O 0 3.6847186413169197e-10
, O 0 6.346081993235941e-11
in O 0 1.084568893028326e-11
this O 0 3.1983953679981525e-11
family O 0 7.470682406029994e-11
, O 0 5.179646642150537e-12
there O 0 1.0718106957519069e-11
appears O 0 6.908738858779628e-11
to O 0 1.8524560357890962e-11
be O 0 2.472897164818022e-10
no O 0 4.602846159773577e-10
relationship O 0 4.300024503134381e-10
between O 0 2.499501050579056e-09
the O 0 1.890602119303253e-09
I1307K O 0 4.184585478128611e-08
polymorphism O 0 2.1151658202711587e-09
and O 0 1.0967236667436264e-11
the O 0 2.8422059844546155e-11
presence O 0 3.302466980437124e-11
or O 0 6.670433094768669e-10
absence O 0 2.9358121267364368e-08
of O 0 1.3574020840678713e-07
cancer B-Disease 0 6.048018349247286e-06
. O 0 2.829677470117531e-08
. O 0 1.5733591851585516e-07

Identification O 0 9.51836369722514e-08
of O 0 2.8915096095261106e-08
a O 0 1.2139380611841943e-09
novel O 0 2.1437962516301923e-09
mutation O 0 4.374211659552429e-09
of O 0 1.9127940120711173e-08
the O 0 2.240364160854824e-08
CPO O 0 1.745953159115743e-05
gene O 0 4.911119289019439e-10
in O 0 5.763071964093314e-11
a O 0 1.521458403708209e-09
Japanese O 0 3.1207096640173404e-07
hereditary B-Disease 1 0.9999986886978149
coproporphyria I-Disease 1 0.9999988079071045
family O 0 1.2142904779466335e-06
. O 0 4.1248210891353665e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 0.000708955863956362
HCP B-Disease 1 1.0
) O 0 9.576670123578879e-09
is O 0 1.821357065168172e-09
an O 0 3.2037961172903806e-09
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999970197677612
characterized O 0 9.099635889242563e-08
by O 0 7.350825503849023e-10
a O 0 5.504648115106647e-08
deficiency B-Disease 0 0.04998594522476196
of I-Disease 0 0.0034857753198593855
coproporphyrinogen I-Disease 0 0.017645850777626038
oxidase I-Disease 0 2.7318369575368706e-06
( O 0 1.651484105025247e-08
CPO O 0 2.851474164344836e-06
) O 0 4.277624782167422e-11
caused O 0 3.3445154978828384e-10
by O 0 2.071762032762603e-11
a O 0 5.897177191016567e-10
mutation O 0 7.647853017545003e-09
in O 0 2.8016746700387785e-09
the O 0 1.0002213457482867e-07
CPO O 0 7.554103649454191e-05
gene O 0 2.63688605173229e-07
. O 0 1.386909644907064e-07

Only O 0 4.648765639103658e-08
11 O 0 1.0301503650111954e-08
mutations O 0 4.938663256126574e-09
of O 0 6.074543534850818e-09
the O 0 1.956555584214925e-09
gene O 0 1.7383886552480021e-09
have O 0 1.4004244985876824e-10
been O 0 9.988859739351597e-10
reported O 0 4.030927147624652e-09
in O 0 7.457223283324765e-09
HCP B-Disease 1 0.9999985694885254
patients O 0 7.331089477702335e-07
. O 0 2.66609185928246e-06

We O 0 3.065931508672293e-08
report O 0 2.03782338226155e-10
another O 0 3.0307584220068406e-10
mutation O 0 1.51118539903905e-09
in O 0 7.823909575765953e-11
a O 0 1.579822939135056e-09
Japanese O 0 1.1670021393683783e-07
family O 0 1.123455284357533e-08
. O 0 4.553167443077655e-08

Polymerase O 0 1.1168362107127905e-05
chain O 0 3.396186798454437e-07
reaction O 0 3.418820071487971e-08
- O 0 6.704009791747012e-08
single O 0 1.56347668145429e-09
strand O 0 4.2889523044209454e-09
conformational O 0 1.1972304259089128e-09
polymorphism O 0 3.934983006104176e-09
and O 0 3.7263737234782823e-11
direct O 0 3.200361919919459e-10
sequence O 0 3.972793483075776e-10
analyses O 0 2.412094968207157e-10
demonstrated O 0 9.245125498491547e-11
a O 0 4.921321128392719e-10
C O 0 1.4076356080749974e-07
to O 0 6.983383871173032e-10
T O 0 4.3900838520016805e-09
substitution O 0 1.1980985092918672e-09
in O 0 1.1079517164835906e-10
exon O 0 3.71530606280146e-09
1 O 0 1.2760317247284547e-08
of O 0 3.5108649321102803e-09
the O 0 6.412180120207722e-09
CPO O 0 9.384153258906736e-07
gene O 0 4.262591946080363e-10
at O 0 1.0725438315262181e-09
nucleotide O 0 1.7045052036479547e-09
position O 0 4.205434667170493e-09
85 O 0 3.5899161421326653e-09
, O 0 4.8023404697339345e-11
which O 0 5.916642870085198e-11
lies O 0 5.877689446265322e-08
in O 0 4.274902376533163e-10
the O 0 1.5362161542853414e-09
putative O 0 6.937852248256604e-08
presequence O 0 2.4424963385172305e-07
for O 0 4.31766122854782e-10
targeting O 0 1.3628025818945844e-08
to O 0 3.089341760187381e-08
mitochondria O 0 5.087890144750418e-07
. O 0 3.7523409446293954e-07

This O 0 1.4904669498605472e-08
mutation O 0 2.089272932437325e-08
changes O 0 1.4301150264017792e-09
the O 0 1.3237027030044146e-09
codon O 0 1.569192598083191e-08
for O 0 5.42490607990942e-10
glutamine O 0 3.5764931016757373e-09
to O 0 8.169574461369677e-10
a O 0 6.762917337255203e-09
termination O 0 4.6563042133129784e-07
codon O 0 5.990769977870514e-07
at O 0 1.8386886324606166e-07
amino O 0 1.4283029869943675e-08
acid O 0 4.141230469656421e-09
position O 0 2.8670056551050038e-08
29 O 0 3.055902197957039e-07
. O 0 7.82489095740857e-08

MaeI O 0 8.740267367102206e-05
restriction O 0 2.538709509281034e-07
analysis O 0 1.2107984836973174e-08
showed O 0 2.184407321692561e-09
two O 0 2.2130058202618486e-11
other O 0 8.828320886833385e-12
carriers O 0 5.858686452642203e-11
in O 0 1.3821199740249313e-10
the O 0 2.565313517166601e-09
family O 0 5.7619566895539265e-09
. O 0 5.726570861952496e-08

The O 0 1.6772629578554188e-06
C O 0 0.1877269595861435
- O 0 0.0004406568477861583
T O 0 4.317157163313823e-06
mutation O 0 1.28438033542011e-08
is O 0 7.720908634656354e-11
located O 0 3.6653860502333657e-10
within O 0 7.035149129919205e-10
a O 0 9.65527435781155e-10
recently O 0 1.2529314252773815e-09
proposed O 0 4.972103173628284e-09
putative O 0 1.3322748237953874e-08
alternative O 0 2.6778728123844076e-09
translation O 0 3.692079086903277e-09
initiation O 0 6.658436468853779e-09
codon O 0 9.13475961539234e-09
( O 0 3.1645611131558837e-10
TIC O 0 2.7913229061482525e-08
- O 0 2.7763071841491183e-08
1 O 0 4.001101672201912e-08
) O 0 3.6932162189584616e-11
, O 0 2.1389541179916982e-11
supporting O 0 1.1313674302959598e-10
that O 0 8.973920911925504e-11
TIC O 0 1.0381312876006632e-07
- O 0 7.339862406752218e-08
1 O 0 1.052990228345152e-07
is O 0 5.311938111596248e-10
the O 0 1.1905629815345264e-09
real O 0 1.9977629506229277e-07
TIC O 0 3.364568215147301e-07
rather O 0 8.569813303438423e-09
than O 0 6.484820680441317e-09
TIC O 0 5.661597697326215e-07
- O 0 3.223609326141741e-07
2 O 0 1.9420460262153938e-07
. O 0 4.863478064720539e-09
. O 0 4.63873028877515e-08

Human B-Disease 0 8.267254258953471e-08
complement I-Disease 0 1.6863749863205157e-07
factor I-Disease 0 0.0002810826990753412
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999980926513672
associated O 0 0.00011964327859459445
with O 0 7.074793393258005e-05
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999959468841553

This O 0 5.3032045421730345e-09
study O 0 1.2739955757012922e-09
reports O 0 1.4183626495523072e-10
on O 0 1.1091002560803531e-09
six O 0 6.237883126702926e-11
cases O 0 8.219194075342884e-11
of O 0 8.990088673499486e-08
deficiency B-Disease 1 0.9613732099533081
in I-Disease 0 5.9385261153011015e-09
the I-Disease 0 2.6053732504749405e-09
human I-Disease 0 2.3083990274841426e-10
complement I-Disease 0 5.0577909915805463e-11
regulatory I-Disease 0 9.210421869632057e-10
protein I-Disease 0 4.5792232228336616e-09
Factor I-Disease 0 2.2076674710547195e-08
H I-Disease 0 0.03100336156785488
( O 0 4.898433880740072e-10
FH O 0 3.8716450490028365e-07
) O 0 4.719568486022396e-12
in O 0 1.2115538607082588e-12
the O 0 1.2151548213837349e-12
context O 0 6.243656286430976e-11
of O 0 6.058838430966773e-10
an O 0 8.92473561719953e-09
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.00011282275954727083

Five O 0 6.952503639467977e-08
of O 0 1.1907725472326547e-08
the O 0 7.791448597416206e-10
cases O 0 7.130058349291701e-11
were O 0 1.1328941257326974e-10
observed O 0 5.695759419666047e-10
in O 0 3.5822855098954776e-11
children O 0 1.5076254480939077e-11
presenting O 0 4.86881257533156e-10
with O 0 7.679572533447754e-09
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9998828172683716
HUS B-Disease 1 1.0
) O 0 9.50495461893297e-07
. O 0 1.3033784398430726e-06

Two O 0 4.5151735683646166e-09
of O 0 2.0808654355164435e-08
the O 0 5.523660639994432e-09
children O 0 3.0559157981890905e-10
exhibited O 0 1.6398038482634547e-09
a O 0 1.6310735873048543e-08
homozygous O 0 6.676065822830424e-06
deficiency O 0 0.2344558984041214
characterized O 0 1.80011792139112e-08
by O 0 5.693326365907581e-10
the O 0 1.3027563028344957e-08
absence O 0 8.007977925217347e-08
of O 0 4.087875637992511e-08
the O 0 1.2547441974319895e-09
150 O 0 3.4995442654839337e-10
- O 0 1.7496577797704305e-10
kD O 0 1.5864296543099954e-09
form O 0 1.3834775339227612e-11
of O 0 5.402963076939216e-10
Factor O 0 6.874700364534192e-09
H O 0 0.06749695539474487
and O 0 2.94994133287485e-11
the O 0 5.478903788991296e-11
presence O 0 2.673996093993658e-11
, O 0 1.1131300742261985e-11
upon O 0 3.276843796307105e-10
immunoblotting O 0 1.2452943565222085e-07
, O 0 1.4752830901354486e-10
of O 0 2.5314159657341406e-09
the O 0 1.8172311433417576e-09
42 O 0 5.823053594866678e-09
- O 0 7.744337615633867e-09
kD O 0 1.0389335614036099e-07
Factor O 0 2.709471047523948e-08
H O 0 0.0007965829572640359
- O 0 5.093045629678272e-08
like O 0 4.0514439025862714e-10
protein O 0 2.8187678857705123e-09
1 O 0 1.1995718196544658e-08
( O 0 1.737678473334725e-10
FHL O 0 3.249028566187917e-07
- O 0 6.506157035346405e-08
1 O 0 6.146924391714492e-08
) O 0 9.713158055646431e-11
and O 0 7.937876744801287e-11
other O 0 1.7362405957399574e-10
FH O 0 9.310645623372693e-07
- O 0 3.300394268990203e-08
related O 0 6.1555809338642575e-09
protein O 0 8.955497676765845e-09
( O 0 1.2748512245863708e-09
FHR O 0 1.9571858501876704e-05
) O 0 5.530723878877097e-09
bands O 0 1.433415235396751e-07
. O 0 1.134366058863634e-07

Southern O 0 2.4995365492941346e-06
blot O 0 5.48521393284318e-06
and O 0 7.615229002944091e-10
PCR O 0 2.330591275523375e-09
analysis O 0 7.349518216237527e-11
of O 0 1.8372385557352544e-10
DNA O 0 7.783635957991919e-10
of O 0 9.877194617757823e-10
one O 0 1.719866193905517e-10
patient O 0 1.0139912243189997e-09
with O 0 1.8621387765094255e-10
homozygous O 0 4.496295787248528e-06
deficiency O 1 0.9622499346733093
ruled O 0 1.204580348712625e-05
out O 0 3.567579842655988e-10
the O 0 9.59578597137245e-11
presence O 0 2.7539829791645154e-11
of O 0 2.1492280177781709e-10
a O 0 4.849625215297415e-11
large O 0 1.123972859229383e-10
deletion O 0 1.502580992962521e-08
of O 0 1.3847284208168276e-08
the O 0 6.0968301518471435e-09
FH O 0 3.226501803510473e-06
gene O 0 3.735199372023601e-10
as O 0 1.516884534646934e-11
the O 0 1.0020224927576038e-10
underlying O 0 9.962097635707323e-08
defect O 0 3.795681777774007e-07
for O 0 3.965074046874406e-09
the O 0 1.22367896437936e-06
deficiency O 1 0.999911904335022
. O 0 8.890299795893952e-06

The O 0 1.5195021774161432e-07
other O 0 6.085302262093251e-10
four O 0 2.4148524846445696e-10
children O 0 1.8907118926048128e-11
presented O 0 2.1727632193435653e-10
with O 0 2.3360108292180826e-10
heterozygous O 0 5.8922860262100585e-06
deficiency O 1 0.9994441866874695
and O 0 7.807965829442765e-09
exhibited O 0 1.9123087113825932e-08
a O 0 6.280330033803239e-09
normal O 0 8.035641485548695e-08
immunoblotting O 0 7.696372108512151e-07
pattern O 0 2.1192295918126547e-08
of O 0 5.815428139044343e-09
proteins O 0 1.2928509651732867e-10
of O 0 3.3762110884794083e-09
the O 0 1.1472402583478924e-08
FH O 0 0.0002105764433508739
family O 0 1.9357141667342148e-08
. O 0 5.8667911417842333e-08

Factor B-Disease 1 0.9999971389770508
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999921321868896
is O 0 3.0951496921005628e-09
the O 0 9.94005322496605e-10
only O 0 2.0446064841195266e-09
complement B-Disease 1 0.9978371262550354
deficiency I-Disease 1 1.0
associated O 0 2.481334377080202e-06
with O 0 1.1885332895644751e-07
HUS B-Disease 1 1.0
. O 0 1.530678491690196e-05

These O 0 7.475380314758695e-09
observations O 0 2.1306183484171015e-08
suggest O 0 2.4553536981386515e-09
a O 0 1.2068921417807132e-09
role O 0 2.999040793483232e-09
for O 0 1.574954944238982e-09
FH O 0 5.036402217228897e-05
and O 0 2.1771876745901864e-08
/ O 0 2.4762237444519997e-05
or O 0 2.5951982252081507e-07
FH O 0 8.216450805775821e-05
receptors O 0 2.3138586158211183e-08
in O 0 3.253868285924e-10
the O 0 1.2766396828567395e-09
pathogenesis O 0 1.2646059985854663e-06
of O 0 3.892466224897362e-07
idiopathic O 1 0.9999994039535522
HUS B-Disease 1 1.0
. O 0 1.3900189514970407e-06
. O 0 9.813991255214205e-07

Further O 0 2.038350288557922e-08
evidence O 0 4.2030769975553994e-09
for O 0 2.4745297477757333e-10
a O 0 1.4556842398150138e-09
major O 0 7.3162098601642356e-09
ancient O 0 4.684547505462433e-08
mutation O 0 2.0821360067202477e-06
underlying O 0 0.014368019066751003
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.3379544725466985e-06
linkage O 0 2.5827641820797e-06
disequilibrium O 0 7.657221431145445e-06
studies O 0 8.790188021912115e-10
in O 0 3.328013212233749e-11
the O 0 2.138237364945894e-10
Japanese O 0 4.895941874138998e-09
population O 0 4.018519961235256e-10
. O 0 8.199613432680053e-09

The O 0 0.00010407171066617593
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.1964173609158024e-05
DM B-Disease 1 1.0
) O 0 2.8057978163076314e-09
mutation O 0 7.0831109866276165e-09
is O 0 1.8950742364243212e-10
an O 0 3.199861486891109e-10
unstable O 0 5.878203864995157e-06
( O 0 3.270390891429997e-08
CTG O 0 9.84531197900651e-06
) O 0 4.73938277512076e-10
n O 0 8.396527917398089e-09
repeat O 0 5.088615306902966e-09
, O 0 5.937534491851082e-11
present O 0 8.678765345271344e-11
at O 0 8.337126544688545e-10
a O 0 5.0953893881988677e-11
copy O 0 3.9606276591719336e-10
number O 0 8.118448968641445e-11
of O 0 9.015064250661453e-10
5 O 0 5.131049807260979e-09
- O 0 1.2835990048642998e-08
37 O 0 7.00514535267871e-09
repeats O 0 2.606695526097269e-09
on O 0 7.0060943713201596e-09
normal O 0 7.707174454196775e-09
chromosomes O 0 1.957832562737849e-09
but O 0 1.6558225623963807e-10
amplified O 0 2.0800472455562158e-09
to O 0 7.517097500020498e-10
50 O 0 1.2598215803905077e-08
- O 0 9.21706888590279e-09
3000 O 0 1.6201834318607666e-09
copies O 0 1.3373966378793511e-09
on O 0 1.6951757686456403e-07
DM B-Disease 1 0.9999969005584717
chromosomes O 0 3.298479896329809e-06
. O 0 1.6605689268089918e-07

Previous O 0 3.096645571076806e-07
findings O 0 1.4486635002697312e-08
in O 0 8.444674404195496e-10
Caucasian O 0 2.2297244584024156e-07
populations O 0 1.1470953076297974e-09
of O 0 5.874178476972247e-09
a O 0 3.085388016188517e-07
DM B-Disease 1 1.0
founder O 0 0.00016009117825888097
chromosome O 0 4.889169304078678e-06
raise O 0 1.7044595734816426e-09
a O 0 7.601790308342515e-10
question O 0 4.4006722710321355e-09
about O 0 3.7955742715478635e-11
the O 0 5.293740099054922e-11
molecular O 0 5.771325084502621e-10
events O 0 8.203543747087316e-12
involved O 0 6.476581770886725e-11
in O 0 4.658735897056232e-11
the O 0 9.695653169217167e-10
expansion O 0 1.910002112026632e-07
mutation O 0 9.82860115072981e-07
. O 0 3.346982566654333e-07

To O 0 3.2460672372280897e-08
investigate O 0 2.358316564254892e-08
whether O 0 1.5602503733447293e-09
a O 0 2.2083783690618475e-09
founder O 0 2.191502979087545e-08
chromosome O 0 3.174890750301529e-08
for O 0 2.6108540329694563e-10
the O 0 9.717096460803987e-09
DM B-Disease 1 1.0
mutation O 0 1.1446637415701844e-07
exists O 0 5.715740103440226e-10
in O 0 1.3160934148048753e-11
the O 0 2.617339331378865e-11
Japanese O 0 2.8377766803089344e-10
population O 0 1.3045570700087605e-11
, O 0 3.449771718289085e-11
we O 0 3.3847333269498847e-10
genotyped O 0 4.5839709628126e-07
families O 0 5.973486288946006e-11
using O 0 2.471364779488283e-10
polymorphic O 0 4.009474352528741e-08
markers O 0 1.1057217363941163e-07
near O 0 2.202868785161627e-07
the O 0 2.2512743669267365e-08
( O 0 3.786620794699047e-08
CTG O 0 1.9448407329036854e-05
) O 0 3.7092451332654264e-09
n O 0 6.996094725764124e-08
repeat O 0 4.535294806373713e-08
region O 0 8.281774199758729e-08
and O 0 8.036971088642986e-09
constructed O 0 1.1992694908258272e-06
haplotypes O 0 1.934227839228697e-05
. O 0 9.426148608326912e-07

Six O 0 3.37586492094033e-08
different O 0 1.491005791054434e-10
haplotypes O 0 4.1600824118859236e-08
were O 0 2.1444628295341772e-09
found O 0 3.047150587409675e-10
and O 0 1.2040731744988875e-09
DM B-Disease 1 1.0
alleles O 0 3.053786556961313e-08
were O 0 2.285164724113997e-09
always O 0 2.8373559057826014e-09
haplotype O 0 1.1582135357457446e-06
A O 0 2.3718687316431897e-06
. O 0 6.19966272097372e-07

To O 0 7.795465606363905e-09
find O 0 7.313443739498382e-10
an O 0 2.4365546039128994e-11
origin O 0 6.923173145878536e-10
of O 0 6.728294810187663e-09
the O 0 4.6741561732233095e-09
( O 0 9.730023009524302e-09
CTG O 0 5.655253062286647e-06
) O 0 4.4945752675218387e-10
n O 0 4.03777589141896e-09
repeat O 0 1.9832131492591998e-09
mutation O 0 5.990569706959548e-10
and O 0 1.726181871053445e-11
to O 0 3.76773959254173e-11
investigate O 0 1.8469568929813107e-10
the O 0 5.3158581703183216e-11
mechanism O 0 5.457014840004604e-10
of O 0 5.021181248565654e-10
the O 0 8.854598304575134e-11
expansion O 0 1.48848333658691e-09
mutation O 0 1.5231598204934471e-09
in O 0 3.320696148612079e-11
the O 0 5.239995590211599e-11
Japanese O 0 2.376815133597887e-10
population O 0 6.480321921437104e-12
we O 0 1.3654935689111358e-11
have O 0 6.938527009892059e-12
studied O 0 1.8221145703378738e-09
90 O 0 3.871672316080321e-09
Japanese O 0 1.7433835708402512e-08
DM B-Disease 1 0.9999951124191284
families O 0 3.3565616952557775e-10
comprising O 0 1.437769625578511e-10
190 O 0 1.2027625562183175e-09
affected O 0 1.2614583821957126e-09
and O 0 5.086895349393217e-10
130 O 0 2.5606412989986893e-08
unaffected O 0 3.2573120734014083e-07
members O 0 1.585462605646626e-08
. O 0 1.9510382287535322e-07

The O 0 1.6711209127606708e-07
results O 0 1.2654281178470228e-08
suggest O 0 9.176478243944075e-09
that O 0 1.1813085232237341e-10
a O 0 1.1346744654971985e-09
few O 0 2.9551239233427395e-10
common O 0 5.933756264120404e-10
ancestral O 0 4.4728727388587686e-09
mutations O 0 1.7198014123920302e-09
in O 0 8.225168462994148e-11
both O 0 1.9540671858386816e-10
Caucasian O 0 4.3251333181615337e-07
and O 0 3.7954672738038653e-10
Japanese O 0 1.5687908749839607e-09
populations O 0 1.9887643615268402e-11
have O 0 4.90899530226907e-13
originated O 0 2.867968015851652e-12
by O 0 6.721456616114174e-13
expansion O 0 1.0676413086940784e-09
of O 0 1.5192921365425605e-09
an O 0 1.80388995407732e-10
ancestral O 0 4.569155276357151e-09
n O 0 9.31368315804093e-09
= O 0 4.59557636389718e-09
5 O 0 2.420206923758883e-09
repeat O 0 1.939149951724062e-09
to O 0 1.6128022251038487e-09
n O 0 4.697099953432371e-08
= O 0 4.4410217725499024e-08
19 O 0 3.3349316197472945e-08
- O 0 3.793777736404991e-08
37 O 0 1.5140713571781816e-08
copies O 0 1.2415513950259083e-08
. O 0 4.712660484074149e-08

These O 0 4.442307410812418e-09
data O 0 9.517810983794561e-10
support O 0 3.7274344721893726e-10
multistep O 0 8.384417071738426e-08
models O 0 4.985217127995156e-09
of O 0 5.035649408569043e-08
triplet O 0 4.4264274947636295e-06
repeat O 0 4.335622705298192e-08
expansion O 0 1.4922933999628185e-08
that O 0 2.8705414781282634e-11
have O 0 5.411383147135851e-12
been O 0 8.099406562100953e-12
proposed O 0 4.598088229612607e-11
for O 0 8.226596487359572e-11
both O 0 3.083053368158062e-09
DM B-Disease 1 1.0
and O 0 4.5613293764290574e-07
Friedreichs B-Disease 0 0.4215817451477051
ataxia I-Disease 1 0.9737405180931091
. O 0 1.4587418490918935e-06
. O 0 1.7858013734439737e-06

The O 0 6.92800057322529e-08
molecular O 0 7.12370606947843e-08
basis O 0 2.1805377059536113e-07
of O 0 0.0024669889826327562
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.3121803199567239e-08
the O 0 1.6519653422975011e-09
western O 0 9.324223171347512e-09
Cape O 0 7.774577426289397e-08
, O 0 5.151404858239061e-10
South O 0 5.355482723956584e-09
Africa O 0 7.679528124526769e-09
. O 0 1.791472747925127e-08

Deficiency B-Disease 1 0.9988484382629395
of I-Disease 0 4.3162752263015136e-05
the I-Disease 0 8.73235819653928e-07
sixth I-Disease 0 7.44317162570951e-07
component I-Disease 0 1.367226616366679e-07
of I-Disease 0 5.7481397419678615e-08
human I-Disease 0 1.5250348761597365e-09
complement I-Disease 0 3.066129128370676e-09
( O 0 5.19537657339697e-09
C6 O 1 0.7656703591346741
) O 0 2.5822088911553465e-10
has O 0 3.083162197770051e-11
been O 0 2.6854091866868046e-11
reported O 0 1.483196378215812e-11
in O 0 1.0274775821828008e-12
a O 0 5.067753508503081e-12
number O 0 4.906264630677448e-12
of O 0 4.7733823838047584e-11
families O 0 3.0689151307022877e-12
from O 0 5.11794773228047e-11
the O 0 1.207531574731746e-10
western O 0 4.186131885575151e-09
Cape O 0 5.691855164968729e-08
, O 0 5.748605480526692e-10
South O 0 7.707614990692946e-09
Africa O 0 1.160075235873137e-08
. O 0 2.3163666540426675e-08

Meningococcal B-Disease 1 0.9999995231628418
disease I-Disease 1 0.999841570854187
is O 0 2.529226073022528e-08
endemic O 0 7.460680073734238e-09
in O 0 1.8975844506829986e-10
the O 0 7.000267032708507e-10
Cape O 0 2.4779517104889237e-08
and O 0 5.885038983910462e-11
almost O 0 2.0509642595367694e-10
all O 0 3.181954352782235e-11
pedigrees O 0 1.0128063943071197e-09
of O 0 5.643336908889296e-09
total O 0 2.7537462301552296e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.240543549054564e-07
C6Q0 O 1 0.8301568627357483
) O 0 3.700191264499608e-10
have O 0 1.763140848598521e-11
been O 0 3.9777580534972046e-11
ascertained O 0 1.1051224824143446e-08
because O 0 4.083764715279159e-10
of O 0 3.055173181110149e-08
recurrent O 1 0.7430038452148438
disease O 1 0.8187522292137146
. O 0 2.711265324251144e-06

We O 0 1.4938773063022381e-07
have O 0 6.7283550952979e-10
sequenced O 0 5.41570743806119e-09
the O 0 5.934955860098512e-10
expressed O 0 5.477986397828261e-10
exons O 0 7.854931993733771e-08
of O 0 2.6093035287999555e-08
the O 0 9.731118133515793e-09
C6 O 0 1.7599333659745753e-05
gene O 0 1.42897260690944e-09
from O 0 2.3475255073179824e-10
selected O 0 1.8675014659685907e-11
cases O 0 8.322945631300538e-12
and O 0 1.056909941510309e-11
have O 0 1.2292776171984876e-11
found O 0 4.562314068201623e-11
three O 0 3.580735360997345e-11
molecular O 0 2.364870965720911e-07
defects O 0 5.2979910833528265e-05
leading O 0 1.1276759970257899e-08
to O 0 1.3577297064415461e-09
total O 0 7.303581384121571e-08
deficiency O 0 0.00015120129683054984
879delG O 0 1.0314942073819111e-06
, O 0 5.998433000309333e-11
which O 0 9.10958634914305e-12
is O 0 1.5587140952955103e-11
the O 0 5.4439758256918935e-11
common O 0 1.2417070704984212e-09
defect O 0 2.037796917875312e-07
in O 0 5.196246211092159e-10
the O 0 1.4586135632654873e-09
Cape O 0 4.1226336122690554e-08
and O 0 2.248251307346294e-10
hitherto O 0 4.933102104587306e-08
unreported O 0 2.9615593533094398e-08
, O 0 4.98754232358678e-11
and O 0 3.325887482086287e-11
1195delC O 0 1.5421031562823373e-08
and O 0 2.536179877221656e-10
1936delG O 0 4.5968935324935956e-08
, O 0 3.276742072122474e-11
which O 0 6.626272013726675e-12
have O 0 6.252292954200822e-12
been O 0 6.165915000799771e-11
previously O 0 2.839422585942941e-10
reported O 0 1.5886877924309317e-10
in O 0 2.5028773498192436e-10
African O 0 5.335427655239755e-09
- O 0 4.234541961523064e-08
Americans O 0 7.46079376057196e-09
. O 0 6.279996966895851e-08

We O 0 1.8459519424141035e-07
also O 0 1.2284984141075483e-09
show O 0 8.667945528006982e-11
that O 0 8.754674069022528e-12
the O 0 1.2095047186022612e-10
879delG O 0 4.184218127534223e-08
and O 0 7.968234405630881e-10
1195delC O 0 1.3062818652542774e-05
defects O 0 0.053175147622823715
are O 0 1.306634522801886e-10
associated O 0 9.370041631484582e-09
with O 0 1.2371279556333548e-09
characteristic O 1 0.6038532257080078
C6 O 1 1.0
/ O 1 1.0
C7 O 1 0.999984860420227
region O 0 1.0147879038413521e-05
DNA O 0 1.5176382248682785e-06
marker O 0 8.911928830457327e-07
haplotypes O 0 1.1454653758846689e-07
, O 0 1.189804227363922e-10
although O 0 7.130928486587251e-11
small O 0 3.64706598254827e-10
variations O 0 2.2702300483956606e-08
were O 0 9.507836296052119e-09
observed O 0 8.594223288582725e-08
. O 0 1.0039732956101943e-07

The O 0 2.958421418952639e-07
1936delG O 0 7.529225058533484e-06
defect O 0 1.2199748198327143e-05
was O 0 1.439228611843646e-07
observed O 0 5.622279974915045e-09
only O 0 2.2179003078548476e-10
once O 0 4.1597530975323593e-10
in O 0 3.77068723467211e-11
the O 0 2.0878128392798345e-10
Cape O 0 2.0639555842194568e-08
, O 0 5.3995297816245014e-11
but O 0 3.46983934640388e-11
its O 0 6.386346312892144e-11
associated O 0 3.669444970100244e-09
haplotype O 0 6.414476274585468e-07
could O 0 2.9609381613227015e-08
be O 0 2.3361108603126013e-08
deduced O 0 1.0317075975763146e-06
. O 0 6.993066392624314e-08

The O 0 1.589557001580033e-07
data O 0 8.910244098103703e-09
from O 0 3.045159013836951e-09
the O 0 2.0196377903403118e-09
haplotypes O 0 5.0570942988770184e-08
indicate O 0 2.139437738080119e-09
that O 0 5.406660882889547e-11
these O 0 3.307712090339088e-11
three O 0 1.1894547846669212e-10
molecular O 0 2.136032577482183e-07
defects O 0 1.6698623994670925e-07
account O 0 1.1444679232086585e-10
for O 0 3.375089097090722e-10
the O 0 3.1310623427316386e-08
defects O 0 0.01844269596040249
in O 0 1.761932488797413e-09
all O 0 7.821734371304956e-10
the O 0 1.2109665492587851e-09
38 O 0 1.1406792843615676e-08
unrelated O 0 8.600598455643649e-09
C6Q0 O 0 3.2783766073407605e-05
individuals O 0 3.5436470424698996e-10
we O 0 1.6582191175729122e-09
have O 0 1.6750213716054674e-10
studied O 0 1.0578633968805207e-08
from O 0 3.5551646071496634e-09
the O 0 4.589996382975414e-09
Cape O 0 4.754580515964335e-07
. O 0 7.383559363915992e-08

We O 0 1.3859457226317318e-07
have O 0 2.7496702137419504e-10
also O 0 4.99857030766826e-11
observed O 0 3.9377892613323695e-10
the O 0 1.5808107600712162e-10
879delG O 0 7.763760123680186e-08
defect O 0 1.8857380723602546e-07
in O 0 1.2542321625730324e-09
two O 0 3.210218757487837e-09
Dutch O 1 0.9999122619628906
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 7.562457085441565e-06
, O 0 1.7269993768387337e-10
but O 0 3.600747131016213e-11
the O 0 2.399773713079867e-10
879delG O 0 7.577477845188696e-08
defect O 0 1.8700195880683168e-07
in O 0 3.982056628881736e-10
the O 0 1.4027243810943446e-09
Cape O 0 2.6034770783667227e-08
probably O 0 1.3945186116970376e-09
did O 0 1.0766261493433404e-10
not O 0 4.8267025792858576e-11
come O 0 8.063526235613239e-11
from O 0 2.0598084349288115e-10
The O 0 6.551253983744232e-10
Netherlands O 0 2.8832049636662305e-08
. O 0 2.887826422437456e-09
. O 0 7.903020815547279e-08

Complement B-Disease 1 0.9999979734420776
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 8.704407150617044e-08
seven O 0 4.911018702813408e-09
further O 0 7.09317005131993e-09
molecular O 0 4.2043889152409974e-06
defects O 0 4.4982440158491954e-05
and O 0 8.122775230212653e-10
their O 0 4.966944078255153e-10
associated O 0 6.837720434305083e-08
marker O 0 6.038716037437553e-06
haplotypes O 0 1.6311616491293535e-05
. O 0 7.424809496114904e-07

Seven O 0 1.0391020310862586e-07
further O 0 1.000331639744445e-08
molecular O 0 1.000580098775572e-07
bases O 0 5.3567010382948865e-08
of O 0 0.010141214355826378
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.9540450086074088e-08
described O 0 2.3014030148260645e-07
. O 0 7.122754652755248e-08

All O 0 4.3860769238790454e-08
these O 0 3.5657021779655906e-10
new O 0 9.338991802110286e-10
molecular O 0 4.483171380798012e-07
defects O 0 3.962536538892891e-07
involve O 0 6.28702701011008e-10
single O 0 2.431974621686095e-09
- O 0 9.52373646612159e-09
nucleotide O 0 5.775787847994707e-09
events O 0 8.81079653680672e-11
, O 0 2.7479019060194787e-11
deletions O 0 1.0162333197172302e-09
and O 0 3.751885746527961e-10
substitutions O 0 1.7507277405570676e-08
, O 0 2.103738294678692e-10
some O 0 4.358890678957117e-11
of O 0 1.6672703218034712e-09
which O 0 2.7143512437710626e-10
alter O 0 2.384887309858641e-08
splice O 0 1.2938593840772228e-07
sites O 0 4.378969631346763e-09
, O 0 2.675870081070286e-10
and O 0 6.70955513371041e-10
others O 0 9.621490271172206e-09
codons O 0 2.0103398128412664e-06
. O 0 3.7270191910465655e-07

They O 0 1.1491500195859317e-08
are O 0 1.0704158392993435e-10
distributed O 0 1.8424638204006527e-10
along O 0 4.597818792362318e-10
the O 0 3.542466098238606e-09
C7 O 0 3.456183185335249e-05
gene O 0 1.7112025130217035e-09
, O 0 4.4988356789898987e-11
but O 0 1.0422123233877478e-11
predominantly O 0 5.898658644865051e-11
towards O 0 1.2493519552236876e-09
the O 0 1.0690717200390054e-09
3 O 0 7.203376384268267e-08
end O 0 7.169088576119975e-07
. O 0 3.3016601719282335e-07

All O 0 9.045455584555384e-08
were O 0 5.680313108769042e-09
found O 0 3.8649855538253064e-10
in O 0 1.6896953280998162e-10
compound O 0 1.5722545043672653e-08
heterozygous O 0 3.0438989107040015e-09
individuals O 0 1.3376670882081498e-09
. O 0 1.0416121654088784e-07

The O 0 0.0001499936479376629
C6 O 1 0.9999953508377075
/ O 1 0.9999297857284546
C7 O 0 0.15189681947231293
marker O 0 2.921592795246397e-06
haplotypes O 0 3.127314585071872e-07
associated O 0 1.616150235861369e-08
with O 0 9.999000516458523e-10
most O 0 3.095550198395358e-07
C7 B-Disease 1 1.0
defects I-Disease 1 0.9999988079071045
are O 0 8.299116949217478e-09
tabulated O 0 1.8403552815016155e-07
. O 0 1.2146937677925962e-08
. O 0 6.02619323331055e-08

A O 0 3.5179361930204323e-06
genome O 0 4.415207115471276e-07
- O 0 2.347716474560002e-07
wide O 0 2.6484331172582642e-08
search O 0 2.319336278588935e-09
for O 0 3.4960417893969975e-10
chromosomal O 0 7.903027835709509e-06
loci O 0 2.219446287199389e-06
linked O 0 2.1282946818246273e-06
to O 0 2.4296575418247812e-08
mental O 1 0.9999996423721313
health O 0 1.4013863619766198e-05
wellness O 0 5.5224929383257404e-05
in O 0 1.20988608021122e-09
relatives O 0 2.8709987720532126e-09
at O 0 4.107553852605861e-09
high O 0 1.3585567337770499e-08
risk O 0 4.127913300067121e-08
for O 0 7.396992884878273e-08
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 1.0488625967752796e-08
the O 0 9.581165194560981e-09
Old O 0 3.803849324413022e-08
Order O 0 4.687610744014137e-09
Amish O 0 1.4627634925545863e-07
. O 0 3.2221333157167464e-08

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.00023691609385423362
BPAD B-Disease 1 1.0
; O 1 0.9853931069374084
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 3.2023541596259975e-09
is O 0 2.2580839975638867e-10
characterized O 0 3.0748828483417867e-10
by O 0 4.397546563006394e-11
episodes O 0 3.541864579403864e-09
of O 0 1.8387092737270905e-08
mania B-Disease 0 4.3811714931507595e-06
and O 0 4.00788415788611e-08
/ O 0 0.0009061063174158335
or O 0 7.176428198363283e-07
hypomania B-Disease 0 0.0012391529744490981
interspersed O 0 1.8361472342576235e-08
with O 0 4.6727965247184144e-11
periods O 0 8.35568059187608e-08
of O 0 3.3872692029035534e-07
depression B-Disease 0 0.0004872515855822712
. O 0 5.779162393082515e-07

Compelling O 0 1.725011657072173e-06
evidence O 0 5.826233717698415e-08
supports O 0 1.5255972485306302e-08
a O 0 2.7830922011418124e-09
significant O 0 7.343332164566618e-09
genetic O 0 3.366477230315468e-08
component O 0 2.7212898601192137e-08
in O 0 2.681490030020939e-10
the O 0 1.5980642364965547e-09
susceptibility O 0 1.361956094569905e-07
to O 0 1.0962589946927892e-08
develop O 0 7.53922631702153e-06
BPAD B-Disease 1 1.0
. O 0 5.207725916989148e-05

To O 0 2.0136385003866053e-08
date O 0 3.097623277881212e-07
, O 0 8.555469666049476e-10
however O 0 1.0552954066156417e-09
, O 0 6.851657574635794e-10
linkage O 0 1.1069519700868113e-07
studies O 0 9.306557191557374e-10
have O 0 3.118363206544572e-11
attempted O 0 4.351502269628327e-09
only O 0 7.098333032473647e-11
to O 0 6.983033595808763e-11
identify O 0 1.0439561437536327e-09
chromosomal O 0 2.900618710555136e-06
loci O 0 1.242938054701881e-07
that O 0 7.956824782384686e-11
cause O 0 1.340773803093498e-08
or O 0 4.5011122606908316e-10
increase O 0 2.7812122049830634e-10
the O 0 7.961565295921957e-10
risk O 0 2.6345476911160404e-08
of O 0 3.240821797589888e-07
developing O 0 7.282365004357416e-06
BPAD B-Disease 1 1.0
. O 0 1.8758364603854716e-05

To O 0 1.129497029239701e-08
determine O 0 1.990919251682044e-08
whether O 0 2.475673444024551e-09
there O 0 6.168859312261077e-10
could O 0 8.514202676224158e-10
be O 0 3.6573127859540477e-10
protective O 0 1.0790298654583808e-09
alleles O 0 2.543514288078086e-10
that O 0 3.022661764981449e-12
prevent O 0 2.004340304839758e-10
or O 0 2.933648601821659e-10
reduce O 0 2.9925497635474585e-09
the O 0 1.0201230971063069e-09
risk O 0 3.34779279853592e-08
of O 0 9.06689194835053e-08
developing O 0 3.5209552152082324e-05
BPAD B-Disease 1 1.0
, O 0 5.446969542077795e-10
similar O 0 2.1358883411926044e-11
to O 0 2.2719938777560067e-11
what O 0 5.9528623350124654e-12
is O 0 4.305100113205507e-12
observed O 0 9.481386509246903e-11
in O 0 1.6881610692687232e-11
other O 0 3.395259629002112e-10
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 2.2388166875941806e-09
we O 0 5.43986800050078e-10
used O 0 3.167207607290834e-09
mental O 0 5.065490768174641e-05
health O 0 2.4498675088580057e-08
wellness O 0 3.831983974578179e-07
( O 0 2.2739372884661435e-10
absence O 0 5.457454932411565e-09
of O 0 1.5943081521641034e-08
any O 0 1.998075447318115e-07
psychiatric B-Disease 1 1.0
disorder I-Disease 1 0.9999098777770996
) O 0 2.0749345297499389e-10
as O 0 9.18741471789275e-11
the O 0 2.1572284236714978e-10
phenotype O 0 6.0789941969119354e-09
in O 0 1.5294179811498054e-10
our O 0 4.817296006542904e-10
genome O 0 3.2132327909550895e-09
- O 0 2.67271520471013e-08
wide O 0 4.281859489196904e-08
linkage O 0 2.5093385147556546e-07
scan O 0 3.4185012509624357e-07
of O 0 3.633939016367549e-08
several O 0 3.3953959088783847e-10
large O 0 2.2036992231022623e-09
multigeneration O 0 3.0914013677829644e-06
Old O 0 1.3248406105503818e-07
Order O 0 7.418875735965003e-09
Amish O 0 4.040242629343993e-08
pedigrees O 0 7.51007966925954e-09
exhibiting O 0 5.083820586726517e-10
an O 0 1.8418698510824782e-10
extremely O 0 1.2472049171208255e-08
high O 0 5.56622637759574e-07
incidence O 0 0.0015930132940411568
of O 0 0.0028148607816547155
BPAD B-Disease 1 1.0
. O 0 9.949311788659543e-05

We O 0 2.249262109899064e-07
have O 0 1.032559593383553e-09
found O 0 1.9165134756971014e-10
strong O 0 6.384689998917281e-11
evidence O 0 1.5620063575916276e-10
for O 0 4.6565858807801064e-11
a O 0 9.404306222648984e-10
locus O 0 3.260226577594949e-08
on O 0 7.816488789558207e-09
chromosome O 0 3.1971566727406753e-07
4p O 0 0.0006272887694649398
at O 0 1.5567353273127083e-07
D4S2949 O 0 8.168691465471056e-07
( O 0 4.766870231875941e-10
maximum O 0 1.3550688038321823e-07
GENEHUNTER O 0 2.4908060368034057e-05
- O 0 2.390619329162291e-07
PLUS O 0 6.686514097964391e-08
nonparametric O 0 4.937902886581469e-08
linkage O 0 3.4063941001249987e-08
score O 0 6.641921679317875e-09
= O 0 2.0201387229690226e-09
4 O 0 2.1558390628229063e-09
. O 0 7.59349805257159e-11
05 O 0 2.8423730924487245e-08
, O 0 6.916626160702322e-10
P O 0 1.4778806871618144e-06
= O 0 1.0269702421794591e-08
5 O 0 2.103338170300617e-09
. O 0 5.410942527372953e-11
22 O 0 3.778097001916336e-10
x O 0 4.706361522721636e-09
10 O 0 2.3806592253095005e-09
( O 0 4.240607587302492e-10
- O 0 4.925382768306008e-08
4 O 0 3.609278920180259e-08
) O 0 1.71734224063691e-10
; O 0 4.832674260768499e-10
SIBPAL O 0 2.147437771782279e-05
Pempirical O 0 1.342413838756329e-06
value O 0 1.2219765643806113e-08
< O 0 2.275758248515558e-07
3 O 0 2.6164386213167745e-09
x O 0 4.789675767113977e-09
10 O 0 1.4532595127292325e-09
( O 0 1.2813618222029532e-10
- O 0 1.2239546265391255e-08
5 O 0 4.779837414758958e-09
) O 0 5.0084669050987074e-11
) O 0 2.3221138553686238e-11
and O 0 4.0600356410180893e-11
suggestive O 0 8.289952613260709e-10
evidence O 0 1.121172321649766e-10
for O 0 2.959138142855089e-11
a O 0 1.1252475617951063e-09
locus O 0 1.4232534795155516e-07
on O 0 7.965294201994766e-08
chromosome O 0 1.80805418494856e-05
4q O 0 8.880081622919533e-06
at O 0 4.272396481042051e-08
D4S397 O 0 5.218609544499486e-07
( O 0 4.731308123062661e-10
maximum O 0 1.3531368381336506e-07
GENEHUNTER O 0 1.87953937711427e-05
- O 0 1.5104434680779377e-07
PLUS O 0 5.978977668519292e-08
nonparametric O 0 7.047403727256096e-08
linkage O 0 2.6005489317526553e-08
score O 0 4.488160953997067e-09
= O 0 1.7542635122325123e-09
3 O 0 1.0295153618500308e-09
. O 0 4.436595882340022e-11
29 O 0 2.83875256634758e-09
, O 0 1.2900626400469406e-10
P O 0 5.489679892889399e-07
= O 0 3.465973508198772e-09
2 O 0 1.6723885609692957e-09
. O 0 2.7162400800806452e-11
57 O 0 9.663860822684e-10
x O 0 3.922626223840098e-09
10 O 0 1.5923836693687576e-09
( O 0 5.064039187985259e-10
- O 0 3.2359785961944e-08
3 O 0 2.004342469774656e-08
) O 0 1.4081250054864825e-10
; O 0 2.416755406908777e-10
SIBPAL O 0 1.0914936865447089e-05
Pempirical O 0 6.109708010626491e-07
value O 0 8.485738334229609e-09
< O 0 2.2714866076967155e-07
1 O 0 1.0889483093023955e-08
x O 0 1.0942994066454048e-08
10 O 0 1.4546461812869893e-09
( O 0 2.5407020931567104e-10
- O 0 1.9242879290004566e-08
3 O 0 4.088583249739486e-09
) O 0 8.927071755426841e-12
) O 0 2.5823247620099243e-12
that O 0 1.5695606706694898e-12
are O 0 6.2273593399997385e-12
linked O 0 6.075748792966351e-09
to O 0 7.231580223532319e-09
mental O 1 0.9234511256217957
health O 0 1.048327158059692e-05
wellness O 0 4.5017150114290416e-05
. O 0 7.151422778406413e-07

These O 0 5.668407965231381e-09
findings O 0 3.608416898615019e-09
are O 0 3.640711690455767e-11
consistent O 0 3.907413281822869e-10
with O 0 4.780003649840214e-12
the O 0 1.3942440257874722e-10
hypothesis O 0 2.0027974834135875e-09
that O 0 2.482298654821191e-12
certain O 0 6.894705639748366e-11
alleles O 0 8.811506524430968e-10
could O 0 4.152571064786059e-10
prevent O 0 3.4670049053886487e-09
or O 0 8.809321605518505e-10
modify O 0 6.33426111562585e-09
the O 0 1.1393370691337168e-09
clinical O 0 1.93825222538635e-08
manifestations O 0 3.738645943940355e-07
of O 0 1.723862055769132e-06
BPAD B-Disease 1 1.0
and O 0 2.2345547634472496e-09
perhaps O 0 1.807355487493112e-09
other O 0 3.132719916809634e-10
related O 0 1.1143019946757704e-06
affective B-Disease 1 0.9999995231628418
disorders I-Disease 1 1.0
. O 0 1.2291068742342759e-05

Segregation O 0 0.0006129546090960503
distortion O 1 0.9927149415016174
in O 0 7.698516128584743e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0008296207524836063

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.026298290118575096
DM B-Disease 1 1.0
) O 0 4.324619773399263e-09
is O 0 2.9649249722041304e-10
an O 0 2.4438120971304045e-10
autosomal B-Disease 1 0.9998953342437744
dominant I-Disease 1 1.0
disease I-Disease 1 0.9988526105880737
which O 0 7.228708187589916e-10
, O 0 6.813937608596277e-11
in O 0 1.983839134633847e-11
the O 0 3.216908683878472e-11
typical O 0 3.9214420599620325e-10
pedigree O 0 1.126271742535323e-09
, O 0 2.976232801876755e-11
shows O 0 5.204972564065713e-11
a O 0 4.0434150472279384e-10
three O 0 6.725994206036034e-10
generation O 0 1.08438690915591e-07
anticipation O 0 1.322792684277374e-07
cascade O 0 5.251111360848881e-05
. O 0 3.6460935461946065e-06

This O 0 4.427411326446418e-09
results O 0 1.049610975911719e-08
in O 0 1.912812308546563e-08
infertility B-Disease 1 0.9999998807907104
and O 1 0.998420238494873
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.774798986138194e-06
CDM B-Disease 0 1.6324374882970005e-05
) O 0 3.3169106350428024e-11
with O 0 5.751758444527688e-12
the O 0 1.2489278500282808e-09
disappearance O 0 1.0126643701369176e-07
of O 0 1.9453379707101703e-07
DM B-Disease 1 1.0
in O 0 1.314715536437916e-08
that O 0 3.902737688576963e-09
pedigree O 0 4.998015583623783e-07
. O 0 1.438830423694526e-07

The O 0 7.205530838660934e-09
concept O 0 4.3160826024291055e-09
of O 0 2.5573564599312704e-08
segregation O 0 2.2550052847236657e-07
distortion O 0 1.810980938898865e-05
, O 0 1.166328422730345e-10
where O 0 2.7624107862278535e-11
there O 0 4.490320441863371e-12
is O 0 1.0955090133657475e-11
preferential O 0 1.0246922199641517e-09
transmission O 0 2.6253368368145402e-09
of O 0 1.024487050749201e-09
the O 0 2.0492045560427385e-10
larger O 0 3.7502687066925944e-10
allele O 0 4.641462769683358e-09
at O 0 2.200750692793463e-09
the O 0 9.046378646182518e-10
DM B-Disease 1 0.999998927116394
locus O 0 2.4516702978871763e-07
, O 0 7.237506427504314e-11
has O 0 1.06975608926696e-11
been O 0 2.6406009323576285e-11
put O 0 1.1047884135306774e-10
forward O 0 1.0551425289051508e-09
to O 0 1.2869071086551997e-10
explain O 0 2.115984942818727e-09
partially O 0 1.1120664389352442e-08
the O 0 6.915149008968058e-10
maintenance O 0 3.0609708545625836e-08
of O 0 2.017664257891738e-07
DM B-Disease 1 1.0
in O 0 8.07513877987276e-09
the O 0 9.161054137507563e-09
population O 0 2.430416534693336e-09
. O 0 2.0989709526020306e-08

In O 0 2.561906597975394e-08
a O 0 4.541170106620029e-09
survey O 0 8.310617083395755e-09
of O 0 3.172445701693505e-07
DM B-Disease 1 1.0
in O 0 4.569331579773461e-08
Northern O 0 4.054424493915576e-07
Ireland O 0 9.877128093194187e-08
, O 0 3.2589879683797562e-09
59 O 0 1.0517516813024486e-07
pedigrees O 0 4.688427068799683e-08
were O 0 2.2786634801263972e-08
ascertained O 0 7.0001851781853475e-06
. O 0 5.372119176172419e-07

Sibships O 0 6.541989569086581e-05
where O 0 3.34531446988251e-09
the O 0 4.777994111471173e-10
status O 0 2.756513683976891e-09
of O 0 2.279514133007865e-09
all O 0 1.3794021480606489e-10
the O 0 2.499843110292943e-10
members O 0 2.926499320654585e-11
had O 0 2.467469562006386e-10
been O 0 1.0760636132145507e-10
identified O 0 2.2067433991246332e-10
were O 0 5.2907622727360604e-11
examined O 0 1.0517602760939937e-10
to O 0 2.151244633818994e-11
determine O 0 3.6379996237734247e-10
the O 0 2.506728158380156e-10
transmission O 0 7.622106501514736e-09
of O 0 2.597366410839186e-08
the O 0 3.884648336338614e-08
DM B-Disease 1 1.0
expansion O 0 7.680519615860248e-07
from O 0 2.0963742741741953e-08
affected O 0 2.824257050448864e-09
parents O 0 1.1595741034042817e-10
to O 0 5.942998315688897e-10
their O 0 6.671450614170737e-10
offspring O 0 4.359970162681748e-08
. O 0 6.301594623892015e-08

Where O 0 8.051858202406947e-08
the O 0 6.73908306936255e-09
transmitting O 0 1.30994763480885e-07
parent O 0 2.046847136227825e-08
was O 0 3.431010213716945e-07
male O 0 1.0232708902435661e-08
, O 0 1.72977598911217e-09
58 O 0 2.9809785928591737e-07
. O 0 1.6452315776405158e-07

3 O 0 9.488380783295725e-07
% O 0 4.775374762289175e-08
of O 0 7.649910038765029e-09
the O 0 6.601581503673515e-09
offspring O 0 1.0550182949486953e-08
were O 0 5.397514102334355e-10
affected O 0 6.229931570622682e-10
, O 0 5.361251026458902e-11
and O 0 2.0939774220130047e-11
in O 0 2.4909510218384945e-11
the O 0 3.350636781918048e-11
case O 0 2.32588712179016e-10
of O 0 3.298905593140944e-10
a O 0 4.454454860525203e-10
female O 0 1.813646594017726e-10
transmitting O 0 1.4557405059179018e-08
parent O 0 9.644161913513472e-09
, O 0 1.329444465625329e-08
68 O 0 2.0033792225149227e-06
. O 0 6.466887612077699e-07

7 O 0 1.8065509721054696e-05
% O 0 1.2231597565914853e-06
were O 0 6.448818368198772e-08
affected O 0 1.9323874766996596e-07
. O 0 3.861011350636545e-07

Studies O 0 6.228107736205857e-07
on O 0 1.4118248259364918e-07
meiotic O 0 5.815347321913578e-06
drive O 0 1.9468116363441368e-07
in O 0 2.314582481233174e-08
DM B-Disease 1 1.0
have O 0 2.5204782705401385e-10
shown O 0 3.778044543878423e-11
increased O 0 3.657506589260784e-11
transmission O 0 3.1897218200072075e-10
of O 0 3.033037154764884e-10
the O 0 5.017789656003302e-11
larger O 0 8.180765787013655e-11
allele O 0 1.7638926985696912e-09
at O 0 2.0335377826086187e-09
the O 0 7.665476031704088e-10
DM B-Disease 1 0.9991329312324524
locus O 0 6.79690401739208e-08
in O 0 1.4170844497840562e-09
non O 0 5.304664796312863e-07
- O 0 5.981435606372543e-06
DM O 1 1.0
heterozygotes O 0 1.8421497998133418e-06
for O 0 4.004804310397958e-08
CTGn O 0 9.10696544451639e-05
. O 0 6.679719604107959e-07

This O 0 2.4060458514441052e-08
study O 0 3.079462684851819e-09
provides O 0 1.1905397501177362e-10
further O 0 2.67340094506352e-10
evidence O 0 1.2191821996410113e-09
that O 0 1.5934645269943815e-10
the O 0 2.3099604007370544e-08
DM B-Disease 1 1.0
expansion O 0 2.260543851662078e-06
tends O 0 8.903945314386874e-08
to O 0 3.94874222209296e-09
be O 0 5.9692553122658865e-09
transmitted O 0 5.480092468701514e-08
preferentially O 0 1.9037607046357152e-07
. O 0 9.056970640131112e-08

Diagnosis O 1 0.9999134540557861
of O 1 0.9969378709793091
hemochromatosis B-Disease 1 1.0
. O 0 0.02001548931002617

If O 0 0.0037939762696623802
untreated O 1 1.0
, O 0 9.71264967120078e-07
hemochromatosis B-Disease 1 1.0
can O 0 4.1014266116690123e-07
cause O 1 0.9998012185096741
serious O 1 0.9999998807907104
illness O 1 0.9999594688415527
and O 0 1.5161976119060228e-09
early B-Disease 0 4.281631049707357e-08
death I-Disease 0 1.0780614623229212e-08
, O 0 9.04899245812718e-12
but O 0 8.252193199609348e-12
the O 0 1.9662403649700622e-10
disease O 0 4.531643504890326e-09
is O 0 3.5185569735585176e-11
still O 0 5.736575797721244e-11
substantially O 0 2.9496856068789157e-09
under O 0 2.462653810653137e-06
- O 0 0.43746697902679443
diagnosed O 0 0.027633635327219963
. O 0 8.816598437988432e-07

The O 0 2.691369900276186e-07
cornerstone O 0 8.786876605881844e-06
of O 0 7.021682080221581e-08
screening O 0 1.0885123025161647e-08
and O 0 8.106983834244019e-11
case O 0 4.953897292381271e-10
detection O 0 1.4369788026158403e-08
is O 0 1.2920868541765884e-10
the O 0 1.8453652494976325e-10
measurement O 0 3.43601946894978e-08
of O 0 1.5576524958760274e-08
serum O 0 9.291379221565421e-09
transferrin O 0 6.46003357474001e-08
saturation O 0 1.1718333325916319e-07
and O 0 4.4537926124910143e-10
the O 0 1.4054613028946505e-09
serum O 0 3.0141357854063244e-08
ferritin O 0 1.010379719446064e-06
level O 0 8.323087286044029e-07
. O 0 1.8454697681136167e-07

Once O 0 6.218777457434044e-07
the O 0 1.072102673305153e-08
diagnosis O 0 6.761146778444527e-06
is O 0 2.1361308277789703e-09
suspected O 0 2.114941537456616e-07
, O 0 7.835950777135281e-10
physicians O 0 3.0741220680141623e-09
must O 0 5.936951819052183e-09
use O 0 6.037626842925192e-09
serum O 0 2.9471013363036036e-07
ferritin O 0 7.216100584628293e-06
levels O 0 2.0185535731798154e-07
and O 0 1.206984823198809e-08
hepatic O 1 0.9999626874923706
iron O 0 0.07763629406690598
stores O 0 9.304665837817083e-08
on O 0 3.0509838211401075e-07
liver O 0 4.2169735934294295e-06
biopsy O 0 5.520734589481435e-07
specimens O 0 8.934644135649705e-10
to O 0 2.46857118080257e-10
assess O 0 1.2285576111992214e-08
patients O 0 2.8907787275045393e-10
for O 0 1.0686349027899666e-10
the O 0 1.5648430329306962e-09
presence O 0 4.0358045794164354e-09
of O 0 8.303662752950913e-07
iron B-Disease 0 0.018200388178229332
overload I-Disease 0 9.734719787957147e-05
. O 0 7.312690399885469e-07

Liver O 1 0.999990701675415
biopsy O 1 0.9951552152633667
is O 0 2.070619231631099e-08
also O 0 5.972723010616576e-11
used O 0 1.96067814761669e-11
to O 0 2.6929285190657737e-11
establish O 0 1.343250233265536e-10
the O 0 8.837051229670934e-11
presence O 0 1.0074670264703656e-10
or O 0 2.5262740788178917e-09
absence O 0 7.796808176863124e-08
of O 0 6.180100626806961e-07
cirrhosis B-Disease 1 1.0
, O 0 5.660442670141208e-10
which O 0 5.359451771269619e-11
can O 0 1.9607127033083316e-10
affect O 0 3.370216461462405e-08
prognosis O 0 1.4476615433522966e-05
and O 0 1.1834680790911989e-08
management O 0 3.8634348697996757e-07
. O 0 3.160728283546632e-07

A O 0 8.235728046201984e-07
DNA O 0 1.1092726737160774e-07
- O 0 9.146544854843341e-09
based O 0 2.7436558580618e-10
test O 0 1.2477938127197774e-10
for O 0 3.427694586499719e-11
the O 0 6.508136807248377e-10
HFE O 0 5.4620468290522695e-06
gene O 0 1.467381216535557e-09
is O 0 2.6255846455325305e-11
commercially O 0 1.5703408018374887e-10
available O 0 2.5590848884426975e-11
, O 0 7.892671759213155e-12
but O 0 5.977415611091441e-12
its O 0 6.901648957197137e-12
place O 0 4.546116261217037e-10
in O 0 1.6935501612191928e-11
the O 0 1.2582378194903043e-10
diagnosis O 0 2.8053293021912395e-07
of O 0 2.9052426953057875e-07
hemochromatosis B-Disease 1 1.0
is O 0 1.09024767880328e-07
still O 0 9.992675131798023e-09
being O 0 5.151211013298962e-09
evaluated O 0 4.2062552552124544e-08
. O 0 4.8984762912596125e-08

Currently O 0 2.6130143737645994e-07
, O 0 1.6234438238171833e-09
the O 0 3.2698013741061516e-10
most O 0 9.335384028308358e-12
useful O 0 7.867306112130379e-11
role O 0 9.44200967412101e-11
for O 0 1.0217461425543473e-11
this O 0 1.054051203958073e-11
test O 0 5.177604525674617e-11
is O 0 6.573326518516387e-12
in O 0 3.942745435692174e-12
the O 0 1.709693497886633e-11
detection O 0 2.4296157974390553e-08
of O 0 5.014477437725873e-07
hemochromatosis B-Disease 1 1.0
in O 0 1.2098128721049761e-08
the O 0 7.1344454788402345e-09
family O 0 1.9043501497950643e-10
members O 0 1.1599207705437209e-11
of O 0 4.927351304750971e-10
patients O 0 4.48889293791499e-11
with O 0 1.8623501178705038e-12
a O 0 7.74076025500392e-10
proven O 0 3.351172495058563e-08
case O 0 5.692351923158867e-09
of O 0 2.938198484514487e-08
the O 0 5.3729912963262905e-08
disease O 0 2.936747478088364e-06
. O 0 3.176108407387801e-07

It O 0 8.600435030814424e-09
is O 0 2.979586799511935e-09
crucial O 0 1.344569682260044e-07
to O 0 9.972971781735396e-08
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.0034933481365442276
because O 0 9.561269820324014e-08
phlebotomy O 0 0.45253124833106995
therapy O 0 6.031891643942799e-07
can O 0 2.6860984547738553e-09
avert O 1 0.9999984502792358
serious O 1 1.0
chronic O 1 1.0
disease O 1 0.9999979734420776
and O 0 9.161189029605055e-10
can O 0 1.577347141790142e-10
even O 0 4.0342942875248866e-10
lead O 0 1.7114562544939815e-10
to O 0 1.1002252581215899e-10
normal O 0 1.1600421068180822e-08
life O 0 2.1252921644787648e-09
expectancy O 0 8.327944556185685e-09
. O 0 8.555502417628702e-10
. O 0 3.2587593068456044e-08

Prevalence O 0 7.192697376012802e-05
of O 0 8.411677185904409e-07
the O 0 2.824243381382985e-07
I1307K O 0 0.00013492378639057279
APC B-Disease 0 2.2314686987101595e-07
gene O 0 2.5620308652385404e-10
variant O 0 8.313720822883397e-10
in O 0 3.269824688789669e-11
Israeli O 0 6.824219855872116e-09
Jews O 0 3.358932909591772e-09
of O 0 1.0061477345724157e-10
differing O 0 1.887101933051305e-11
ethnic O 0 5.889575632744837e-11
origin O 0 7.820716296791375e-11
and O 0 3.206947554734718e-11
risk O 0 1.2848996533421086e-08
for O 0 2.8403766805240593e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.005612090229988098

BACKGROUND O 0 3.5721568565350026e-06
& O 0 1.1343443873101933e-07
AIMS O 0 5.9256418438735636e-08
Israeli O 0 9.620447372071794e-08
Jews O 0 2.4751175331516606e-08
of O 0 4.467126224483309e-09
European O 0 4.9876067720333594e-08
birth O 0 1.2576025198995922e-07
, O 0 9.118200083868544e-10
i O 0 7.803796719940692e-09
. O 0 1.0422923635289294e-10
e O 0 1.5027228073005716e-10
. O 0 2.303577294193726e-11
, O 0 5.139958250688359e-11
Ashkenazim O 0 1.0797447203003685e-06
, O 0 7.964568587981447e-11
have O 0 4.953186125145059e-11
the O 0 3.259808645239559e-09
highest O 1 0.978488564491272
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.9873799085617065
of O 0 3.6922574508935213e-07
any O 0 2.1782010861670642e-08
Israeli O 0 3.865933706492797e-07
ethnic O 0 2.785631991741866e-08
group O 0 4.079780513421838e-09
. O 0 1.1016543233210996e-08

The O 0 1.0340854714741e-06
I1307K O 0 5.0125028792535886e-05
APC B-Disease 0 3.1445770787286165e-07
gene O 0 1.3039289648020258e-09
variant O 0 9.095172615047886e-09
was O 0 3.322715613762739e-08
found O 0 1.2028703588740086e-09
in O 0 1.3975434143276289e-09
6 O 0 9.609395874576876e-07
. O 0 2.5287832272624655e-07

1 O 0 1.1456558013378526e-06
% O 0 1.3811674470787239e-08
of O 0 1.7424451881353775e-09
American O 0 8.081791902370128e-10
Jews O 0 7.037701976742028e-09
, O 0 7.116145867014367e-11
28 O 0 1.961398155003735e-09
% O 0 1.1066343397203582e-09
of O 0 2.835278456458923e-09
their O 0 6.144109221395411e-09
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 4.122158543395926e-07
, O 0 1.980871994211597e-10
but O 0 2.2808775701488315e-11
not O 0 2.320360570351454e-11
in O 0 8.981044380407255e-11
non O 0 3.5902328221482094e-08
- O 0 7.593407502781702e-08
Jews O 0 2.4322778813257173e-07
. O 0 1.0429361907426937e-07

We O 0 3.2293877438860363e-07
assessed O 0 2.402965264991508e-06
the O 0 3.664543868353576e-08
I1307K O 0 3.406289761187509e-05
prevalence O 0 7.093389342571754e-08
in O 0 4.312046206211839e-11
Israeli O 0 1.081847500472577e-08
Jews O 0 4.299854250433555e-09
of O 0 1.5794726637707868e-10
differing O 0 4.473030279505963e-11
ethnic O 0 1.3613671301371255e-10
origin O 0 1.8193216377859756e-10
and O 0 6.589874479434599e-11
risk O 0 1.428796103652985e-08
for O 0 6.126944072093465e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00688383262604475

METHODS O 0 1.525095854049141e-06
DNA O 0 1.246261405185578e-07
samples O 0 6.835732535570571e-10
from O 0 3.634365308702314e-10
500 O 0 3.0417618424039006e-10
unrelated O 0 8.143966612195186e-10
Jews O 0 3.0405336026717578e-09
of O 0 8.023457453987248e-10
European O 0 2.603425919289748e-09
or O 0 8.926127059716293e-10
non O 0 1.5033178257795043e-08
- O 0 4.675500542283828e-10
European O 0 2.132994891823614e-10
origin O 0 5.2499997404975574e-11
, O 0 1.072583103063629e-12
with O 0 4.2825406442641503e-14
or O 0 7.79340307566212e-12
without O 0 2.938003659802568e-11
a O 0 1.262328991336048e-10
personal O 0 8.754832969692927e-10
and O 0 9.062647854385375e-10
/ O 0 5.1259844440210145e-06
or O 0 1.1283429302011427e-08
family O 0 3.579453400348598e-10
history O 0 5.137589242920626e-10
of O 0 8.549711494332257e-10
neoplasia B-Disease 0 1.1798317245848011e-05
, O 0 4.997409708273892e-10
were O 0 3.371794787820903e-10
examined O 0 1.0631037161701329e-09
for O 0 2.934229248463538e-11
the O 0 2.621677597236527e-10
I1307K O 0 1.7625215065208977e-08
variant O 0 4.4533166043692063e-10
by O 0 4.1158153274434284e-11
the O 0 3.075199817015317e-10
allele O 0 1.4617996813015566e-09
- O 0 6.284904818798509e-10
specific O 0 3.1397548450051715e-10
oligonucleotide O 0 2.193527421923136e-07
( O 0 1.0212040990609239e-08
ASO O 0 3.827675391221419e-05
) O 0 1.9993167121867828e-09
method O 0 7.297009574358526e-08
. O 0 5.716356810125944e-08

RESULTS O 0 1.63336571858963e-05
In O 0 4.905198025539903e-08
persons O 0 9.825714464284374e-09
at O 0 2.8119697681461275e-09
average O 0 9.300807901624353e-10
risk O 0 5.9394803741952273e-08
for O 0 1.4373263184097596e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 9.020505444823357e-07
I1307K O 0 5.746437091147527e-05
was O 0 4.178444257263436e-08
found O 0 2.431356505017135e-10
in O 0 2.6150703824612265e-10
5 O 0 3.449941488042896e-08
. O 0 2.4935976838946772e-08

0 O 0 1.646300233915099e-06
% O 0 5.106089417949988e-08
of O 0 2.093952566895041e-08
120 O 0 2.531310983044932e-08
European O 0 5.6453639984965776e-08
and O 0 3.015159322217187e-08
1 O 0 1.7079844838008285e-05
. O 0 6.576850068995554e-07

6 O 0 2.8615891096706036e-06
% O 0 7.965856241298752e-08
of O 0 1.805203098115271e-08
188 O 0 6.977981303890601e-09
non O 0 4.3678941352709444e-08
- O 0 1.6567529570465922e-08
European O 0 2.667851362048168e-08
Jews O 0 1.0340919232021406e-07
( O 0 2.1558803631194223e-09
P O 0 2.301625727341161e-06
= O 0 1.74551963993963e-08
0 O 0 6.974601785003642e-09
. O 0 3.7872310842956836e-10
08 O 0 8.288186137406228e-09
) O 0 1.371166180597072e-09
. O 0 2.638686780187527e-08

It O 0 2.6968649535774603e-08
occurred O 0 5.782767971140856e-07
in O 0 1.2883083932990758e-08
15 O 0 2.28469588137159e-07
. O 0 1.6508109013102512e-07

4 O 0 8.30955684705259e-07
% O 0 2.8326962109304077e-08
of O 0 1.0743256950718205e-08
52 O 0 2.4426215716744082e-08
Ashkenazi O 0 1.3521513153591513e-07
Israelis O 0 4.3817877326546295e-08
with O 0 4.097824857218768e-10
familial O 1 0.7768538594245911
cancer B-Disease 1 0.9999960660934448
( O 0 5.018314297444704e-08
P O 0 0.00026156409876421094
= O 0 1.1976079683506669e-08
0 O 0 2.9449298555306314e-09
. O 0 1.0239824960178723e-10
02 O 0 1.2199986576533206e-09
) O 0 1.7505850935517486e-11
and O 0 2.3903256110568982e-11
was O 0 3.4658347303206938e-09
not O 0 2.3132736004516374e-10
detected O 0 4.296681677118386e-09
in O 0 1.976249025537058e-10
51 O 0 2.540442878284921e-08
non O 0 9.593968997023694e-08
- O 0 1.6580679940148002e-08
European O 0 1.615986988667828e-08
Jews O 0 3.344512222724916e-08
at O 0 8.9816358794792e-09
increased O 0 7.749716424143571e-09
cancer B-Disease 0 1.0323001333745196e-06
risk O 0 1.95543435665968e-07
. O 0 2.1734166466558236e-07

Colorectal B-Disease 1 0.9999995231628418
neoplasia I-Disease 1 0.9999727010726929
occurred O 0 0.00017393410962540656
personally O 0 2.3963966100382095e-07
or O 0 1.9764914149789092e-09
in O 0 9.426606023543727e-11
the O 0 1.2376442926065323e-10
families O 0 2.7247343270531132e-11
of O 0 1.8370186483096518e-09
13 O 0 6.222441673031653e-09
of O 0 6.474166980297014e-09
20 O 0 5.4456217313259e-09
Ashkenazi O 0 5.2814439044368555e-08
I1307K O 0 4.60525697576486e-08
carriers O 0 4.8581239725509207e-11
, O 0 2.0403347414377215e-11
8 O 0 1.1533566324217759e-09
of O 0 8.810934759573286e-10
whom O 0 1.088856449449338e-09
also O 0 6.806689240024255e-11
had O 0 2.5862312291735634e-10
a O 0 2.79499090538593e-10
personal O 0 4.9858353001752675e-09
or O 0 5.751042753132651e-09
family O 0 6.209574521243155e-10
history O 0 6.2549743162776394e-09
of O 0 8.544649432451479e-08
noncolonic O 0 0.00011411945160944015
neoplasia B-Disease 1 0.9924309849739075
. O 0 9.175226296065375e-06

CONCLUSIONS O 0 7.996665954124182e-05
The O 0 1.0639500942488667e-06
I1307K O 0 0.0001852453569881618
APC O 0 5.309179300638789e-07
variant O 0 7.858408679339846e-08
may O 0 3.855798347274231e-09
represent O 0 6.578136368950993e-10
a O 0 1.8220659425693952e-09
susceptibility O 0 5.040608357376186e-07
gene O 0 1.5073689851874406e-08
for O 0 4.611647241858918e-08
colorectal B-Disease 1 1.0
, I-Disease 0 1.7672698959358968e-05
or I-Disease 0 2.3406470063491724e-05
other I-Disease 0 1.868737342647364e-08
, I-Disease 0 1.2011881267426361e-08
cancers I-Disease 0 0.0033993946854025126
in O 0 3.806823301033546e-09
Ashkenazi O 0 1.9314276869408786e-05
Jews O 0 4.143193166328274e-07
, O 0 4.0275896506791753e-10
and O 0 2.490153916401283e-10
partially O 0 3.544414539646823e-08
explains O 0 6.279703979039652e-10
the O 0 1.1120589865631914e-10
higher O 0 3.804035753063317e-09
incidence O 0 3.2254467896564165e-06
of O 0 6.074325574445538e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.015408841453791e-07
European O 0 3.4272105153831944e-07
Israelis O 0 8.436727512162179e-07
. O 0 1.6436021610388707e-07

Systematic O 0 2.8679798447228677e-07
analysis O 0 2.2599735416406475e-08
of O 0 1.6749534381688136e-07
coproporphyrinogen O 0 0.0006382299470715225
oxidase O 0 1.074690771929454e-05
gene O 0 1.014392069009773e-06
defects O 0 6.659733480773866e-05
in O 0 1.9223069358531575e-08
hereditary B-Disease 1 0.9999998807907104
coproporphyria I-Disease 1 0.9999948740005493
and O 0 1.2509403859439772e-06
mutation O 0 8.473953130305745e-06
update O 0 7.512975912504771e-07
. O 0 6.881996910124144e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 3.2487601856701076e-05
HC B-Disease 1 1.0
) O 0 4.760424232586047e-08
is O 0 1.0213969225958408e-08
an O 0 2.3368684765046055e-08
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 1.1079464456997812e-05
autosomal O 1 1.0
dominant O 1 1.0
inheritance O 1 0.9986093044281006
caused O 0 1.7191616734635318e-06
by O 0 5.367065680772498e-10
deficient B-Disease 0 1.8832142956171083e-08
activity I-Disease 0 1.3407117638308819e-09
of I-Disease 0 7.1906076648531325e-09
coproporphyrinogen I-Disease 0 1.483322535023035e-06
III I-Disease 1 0.5376505255699158
oxidase I-Disease 0 2.592037162685301e-06
( O 0 5.200415742478981e-08
CPO O 0 1.3311085240275133e-05
) O 0 1.002363791968719e-08
. O 0 4.186669144701227e-08

Clinical O 0 0.00028204693808220327
manifestations O 0 0.057718098163604736
of O 0 0.00012915900151710957
the O 0 5.90251056564739e-06
disease O 1 0.7010595798492432
are O 0 9.817461427141794e-11
characterized O 0 2.0653092569489218e-09
by O 0 2.0345689022427393e-10
acute O 0 0.018130408599972725
attacks O 0 1.285883627133444e-06
of O 1 0.9999788999557495
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 2.772469365197594e-09
precipitated O 0 8.045897281760972e-09
by O 0 2.128819689972694e-11
drugs O 0 2.1141968731264171e-10
, O 0 5.040254671961897e-11
fasting O 0 1.8551673974798177e-08
, O 0 8.954093022595089e-10
cyclical O 0 1.613072640793689e-06
hormonal O 0 6.689792257930094e-07
changes O 0 6.852785006117301e-09
, O 0 1.0612019707423315e-08
or O 0 2.8311810638115276e-06
infectious B-Disease 0 0.35278385877609253
diseases I-Disease 0 0.0015392312780022621
. O 0 1.5471136975975242e-06

Skin O 1 0.9999998807907104
photosensitivity O 1 0.9999966621398926
may O 0 4.148904281464638e-06
also O 0 1.1388510579024569e-08
be O 0 6.315189260419629e-09
present O 0 2.745113825142198e-08
. O 0 1.3723082759042882e-07

The O 0 4.0302685988535814e-07
seven O 0 3.012945981595294e-08
exons O 0 2.2768567475850432e-07
, O 0 1.4086012356528954e-09
the O 0 6.2275948842227535e-09
exon O 0 4.3998565502079146e-07
/ O 0 8.141284979501506e-07
intron O 0 1.0969523600579123e-06
boundaries O 0 9.133313660925069e-09
and O 0 3.2020533446974753e-10
part O 0 4.378886142575311e-09
of O 0 8.41826022224268e-08
3 O 0 1.1677769862217247e-07
noncoding O 0 1.21549618370409e-07
sequence O 0 3.403294757120534e-09
of O 0 5.754619891717994e-09
the O 0 3.982385088363571e-09
CPO O 0 1.1940164768020622e-06
gene O 0 5.543183134726348e-10
were O 0 1.454731335392978e-10
systematically O 0 7.244166932984797e-10
analyzed O 0 1.1591252263576379e-10
by O 0 1.433376854709234e-11
an O 0 1.1195182975098916e-10
exon O 0 1.6432142757594193e-08
- O 0 2.3058975173739782e-08
by O 0 8.339038792826159e-09
- O 0 8.218278821914282e-07
exon O 0 4.0428565739603073e-07
denaturing O 0 4.318837454775348e-06
gradient O 0 3.7410823097161483e-06
gel O 0 4.809708684661018e-07
electrophoresis O 0 8.482813029786485e-08
( O 0 8.201955781217407e-10
DGGE O 0 4.889047886535991e-06
) O 0 7.366499077399169e-11
strategy O 0 4.349284543625487e-10
followed O 0 5.0061937234557874e-11
by O 0 4.093758752127252e-12
direct O 0 2.3205830312900133e-10
sequencing O 0 1.1118028719891981e-09
in O 0 1.0085341589638475e-10
seven O 0 1.5774855033345858e-10
unrelated O 0 3.5905667328250956e-09
heterozygous O 0 1.1716674741535371e-08
HC B-Disease 1 0.9999955892562866
patients O 0 1.1172156533234556e-08
from O 0 5.224871202358372e-09
France O 0 2.111136510052347e-08
, O 0 2.013367528252985e-10
Holland O 0 5.894976062847945e-09
, O 0 1.9277905660697314e-10
and O 0 4.346141779798529e-10
Czech O 0 1.7262128721995396e-06
Republic O 0 1.4520916010951623e-05
. O 0 5.014715497964062e-06

Seven O 0 7.34147249659145e-08
novel O 0 1.5042097345485672e-08
mutations O 0 1.211939970602316e-08
and O 0 3.6173528061844706e-10
two O 0 1.348780254151194e-10
new O 0 4.4037262725282744e-10
polymorphisms O 0 3.770697105665022e-07
were O 0 1.2525215709047188e-07
detected O 0 2.125019136656192e-06
. O 0 6.887696031299129e-07

Among O 0 1.6776384725858406e-08
these O 0 1.987005976422651e-10
mutations O 0 3.955058502924658e-09
two O 0 6.358925191962683e-11
are O 0 1.0754275248103795e-10
missense O 0 1.051017306963331e-06
( O 0 1.0879436018740307e-08
G197W O 0 3.745127469301224e-05
, O 0 2.4392914355075845e-09
W427R O 0 1.9763092495850287e-06
) O 0 3.0377556026195407e-10
, O 0 4.935946443240802e-11
two O 0 9.115426295724927e-12
are O 0 1.190143903567753e-11
nonsense O 0 5.014659265611954e-08
( O 0 2.1196124855293874e-09
Q306X O 0 8.029472155612893e-06
, O 0 1.6427527116391616e-09
Q385X O 0 1.005039280244091e-06
) O 0 2.5049884389005683e-10
, O 0 1.0661185823046537e-10
two O 0 2.0674354589411692e-11
are O 0 1.394562416934253e-11
small O 0 3.405416504342895e-10
deletions O 0 3.779376456236605e-08
( O 0 1.741701716184707e-08
662de14bp O 0 7.32826947569265e-06
; O 0 2.100563722962079e-09
1168del3bp O 0 5.592964953393675e-07
removing O 0 1.8031075299518307e-08
a O 0 1.1309408964876866e-09
glycine O 0 2.515850461293212e-08
at O 0 1.9320330224559257e-08
position O 0 3.885468835562733e-09
390 O 0 8.517077598746425e-10
) O 0 2.797923004393965e-11
, O 0 1.7123240325656042e-11
and O 0 1.213334988037218e-11
one O 0 3.355689337514178e-11
is O 0 3.47377265841331e-11
a O 0 3.8828443238436705e-10
splicing O 0 1.3965049561193155e-08
mutation O 0 6.112689021620099e-09
( O 0 3.6537431413741217e-10
IVS1 O 0 1.4754310541320592e-05
- O 0 3.688013237024279e-07
15c O 0 2.4866076273610815e-06
- O 0 2.0956990454124025e-07
- O 0 1.1206351047121643e-07
> O 0 1.9684831897848198e-07
g O 0 5.6486570976233e-09
) O 0 2.1370946678977987e-11
which O 0 1.2851207077668736e-11
creates O 0 6.752138848042932e-10
a O 0 8.275876650642999e-10
new O 0 1.1782690378936422e-09
acceptor O 0 3.590917430074114e-08
splice O 0 1.6969256648735609e-06
site O 0 2.3081025801729993e-07
. O 0 1.1468731742070304e-07

The O 0 2.2820566414338828e-07
pathological O 0 2.1368965462897904e-05
significance O 0 3.5797029340756126e-07
of O 0 1.470998824970593e-07
the O 0 1.060069099168004e-08
point O 0 1.5605793635131704e-07
mutations O 0 1.0272621864260145e-08
G197W O 0 1.286110659748374e-06
, O 0 4.0604405948663214e-10
W427R O 0 4.964693744113902e-06
, O 0 4.07044398187395e-10
and O 0 1.2017094264127337e-10
the O 0 9.57080414920597e-10
in O 0 4.5924633540472826e-10
- O 0 8.259920747377691e-09
frame O 0 1.6059944485391497e-08
deletion O 0 3.739522824730557e-08
390delGly O 0 1.5495123406594757e-08
were O 0 9.60109491909833e-11
assessed O 0 2.304959556553854e-09
by O 0 1.3322219195865959e-11
their O 0 1.2040696564796782e-11
respective O 0 1.6074086506279173e-10
expression O 0 4.495946948068763e-10
in O 0 4.487163418609441e-11
a O 0 1.2475225019681346e-10
prokaryotic O 0 1.8410199753571277e-10
system O 0 3.7196506985637257e-10
using O 0 2.158566103638293e-10
site O 0 4.0519787525283846e-09
- O 0 5.76224223891586e-09
directed O 0 3.1327573868367153e-09
mutagenesis O 0 3.4063630209857365e-06
. O 0 2.1225997670626384e-07

These O 0 1.5070634740155242e-09
mutations O 0 3.1073110751123068e-09
resulted O 0 3.207856202891435e-09
in O 0 1.448336034437503e-10
the O 0 8.441678467363545e-10
absence O 0 1.415885542144224e-08
or O 0 1.7537148400137426e-09
a O 0 2.3177886276926074e-09
dramatic O 0 3.232413092746356e-08
decrease O 0 1.8147041203064873e-07
of O 0 6.514333676932438e-07
CPO O 0 6.47663910058327e-05
activity O 0 1.288753708195145e-07
. O 0 6.671837837757266e-08

The O 0 9.466871375707342e-08
two O 0 7.41324224229345e-10
polymorphisms O 0 8.468942525041712e-08
were O 0 4.641639961278088e-09
localized O 0 2.111537753535231e-07
in O 0 6.639106486794333e-10
noncoding O 0 1.9292718889118987e-07
part O 0 3.139277282571129e-09
of O 0 8.345658386588184e-09
the O 0 5.816323533913703e-10
gene O 0 1.3591203162910404e-10
1 O 0 7.103107435568745e-09
) O 0 3.271977133678661e-11
a O 0 9.270734180333307e-10
C O 0 7.510533350796322e-07
/ O 0 1.538195277817067e-07
G O 0 2.24820198013731e-08
polymorphism O 0 3.820133986920382e-09
in O 0 1.3713589985808738e-10
the O 0 5.162519856050096e-10
promotor O 0 4.088499281351687e-06
region O 0 2.937084389031952e-07
, O 0 1.0025511976152757e-08
142 O 0 4.916991613868049e-08
bp O 0 1.1595315640988701e-07
upstream O 0 2.935823317784525e-08
from O 0 7.241804933499907e-10
the O 0 2.020384276546494e-10
transcriptional O 0 3.0159861275080857e-09
initiation O 0 3.3129814447363515e-09
site O 0 7.414218128332095e-10
( O 0 1.434001112299299e-10
- O 0 1.5125760199907745e-08
142C O 0 9.169297072730842e-07
/ O 0 2.894744284276385e-07
G O 0 1.6033675365179079e-07
) O 0 2.2678472988424403e-10
, O 0 1.7932144658061588e-10
and O 0 2.542282218076508e-10
2 O 0 3.508777979277511e-08
) O 0 4.700151379211093e-10
a O 0 9.161403191626505e-09
6 O 0 1.0359634217138591e-07
bp O 0 4.965036026760572e-08
deletion O 0 1.9840767251366742e-08
polymorphism O 0 1.8312299232547957e-08
in O 0 4.219831151175413e-10
the O 0 9.655384269890988e-10
3 O 0 1.0143689443964377e-08
noncoding O 0 7.501492405026511e-08
part O 0 6.076026792811717e-09
of O 0 4.700953937231134e-08
the O 0 4.8541579644734156e-08
CPO O 0 8.182810233847704e-06
gene O 0 9.032589787238976e-09
, O 0 4.901293260139994e-10
574 O 0 2.061221415772252e-08
bp O 0 3.366965373174935e-08
downstream O 0 1.1929093268747692e-08
of O 0 2.9970450565741658e-09
the O 0 5.200965769169841e-10
last O 0 7.638388255237771e-10
base O 0 1.1169316582737565e-09
of O 0 9.040979631613766e-10
the O 0 4.191418878640718e-10
normal O 0 5.176256756556086e-09
termination O 0 5.7488087179535796e-08
codon O 0 1.6437667227364727e-07
( O 0 6.0374540922225606e-09
+ O 0 7.929867962275239e-08
574 O 0 9.049596627619394e-08
delATTCTT O 0 8.504341053594544e-07
) O 0 5.858033169658938e-09
. O 0 3.867452136319116e-08

Five O 0 2.8824027253904205e-07
intragenic O 0 0.00012444671301636845
dimorphisms O 0 0.00015709197032265365
are O 0 6.578299571735613e-10
now O 0 4.0892678132564697e-10
well O 0 4.5875761522928826e-11
characterized O 0 6.371700389529167e-10
and O 0 5.3760169926864165e-11
the O 0 4.3941952854176236e-10
high O 0 2.8411466512778816e-09
degree O 0 1.1817057554708299e-07
of O 0 2.5082513843699417e-08
allelic O 0 9.707334811537294e-07
heterogeneity O 0 3.2098093925014837e-06
in O 0 6.22887785795001e-09
HC B-Disease 1 1.0
is O 0 6.323831236443311e-09
demonstrated O 0 7.93113130725942e-10
with O 0 6.774203160225811e-12
seven O 0 2.0280973081487907e-11
new O 0 9.136362456516056e-13
different O 0 7.371524180996292e-13
mutations O 0 2.976953752953371e-11
making O 0 2.4496956546604665e-11
a O 0 2.0688527280210423e-10
total O 0 1.4007831561357875e-09
of O 0 3.251173197327262e-08
nineteen O 0 5.229523139860248e-06
CPO O 0 0.0008707261295057833
gene B-Disease 0 1.5362060139523237e-06
defects I-Disease 0 1.9769953723880462e-05
reported O 0 4.2151997448058864e-09
so O 0 1.754650730267926e-10
far O 0 3.156930494796484e-09
. O 0 2.0633248443147068e-09
. O 0 2.6893344440281908e-08

Coincidence O 0 5.849600256624399e-06
of O 0 2.683949560378096e-07
two O 0 6.637080884885904e-10
novel O 0 6.758442694376754e-09
arylsulfatase O 0 1.2152091812822619e-06
A O 0 9.53992014274263e-08
alleles O 0 8.551004349044433e-09
and O 0 1.564678830945354e-09
mutation O 0 7.782247024579192e-08
459 O 0 1.0004789174899997e-07
+ O 0 1.1353660767099427e-07
1G O 0 3.4787756248988444e-06
> O 0 1.0168139397137566e-07
A O 0 9.853603266662958e-09
within O 0 2.8347431069164486e-09
a O 0 3.437309104015185e-09
family O 0 1.2197847176764753e-09
with O 0 2.116675279495439e-09
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 4.823927923780502e-09
molecular O 0 1.5689980870092768e-08
basis O 0 4.014339083369123e-09
of O 0 6.4570007118902595e-09
phenotypic O 0 1.691517809376819e-06
heterogeneity O 0 2.7287482225801796e-05
. O 0 5.168840857550094e-07

In O 0 7.04483360536301e-09
a O 0 2.4190440761628906e-09
family O 0 2.542195065569075e-10
with O 0 1.0125348476330842e-11
three O 0 2.980329871782317e-10
siblings O 0 5.085665666371142e-09
, O 0 3.7556430187990486e-11
one O 0 2.7684873490918527e-11
developed O 0 4.101030626202373e-10
classical O 0 2.0756398555477062e-07
late O 0 0.00011685214121825993
infantile O 1 0.9999585151672363
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 5.450954745356285e-07
MLD B-Disease 1 1.0
) O 0 2.574391144705146e-09
, O 0 4.460542490924979e-10
fatal O 0 5.974429484467692e-08
at O 0 1.9954278229761258e-08
age O 0 1.929712922787985e-08
5 O 0 9.806075063067965e-09
years O 0 1.2900042145602697e-09
, O 0 7.854111805372099e-11
with O 0 5.365353647479587e-11
deficient O 0 2.985954949963343e-07
arylsulfatase O 0 1.06449560917099e-05
A O 0 2.460334599163616e-06
( O 0 1.6536590763394088e-08
ARSA O 0 1.0509458661545068e-05
) O 0 1.5234845329725744e-10
activity O 0 3.1016131329941743e-10
and O 0 3.941130755080735e-11
increased O 0 3.829223604867593e-09
galactosylsulfatide O 0 6.918215149198659e-06
( O 0 1.6046357131926925e-07
GS O 1 0.7268518209457397
) O 0 3.997775621655819e-08
excretion O 0 1.2673754667957837e-07
. O 0 3.023048478212331e-08

The O 0 5.9931807072644e-08
two O 0 6.668422480871072e-10
other O 0 2.1007309780607386e-10
siblings O 0 7.831411963366008e-09
, O 0 7.640078014681251e-10
apparently O 0 1.1298573809881418e-07
healthy O 0 5.757101018133426e-09
at O 0 4.577950463158231e-08
12 O 0 8.479347890499866e-09
( O 0 4.36160413341824e-10
1 O 0 5.13761392539891e-07
/ O 0 1.0269393158068851e-07
2 O 0 1.9124000161241383e-08
) O 0 3.060983758129687e-11
and O 0 1.8712024985045872e-11
15 O 0 3.3787733721979407e-10
years O 0 8.814325658246247e-11
, O 0 5.433889449513174e-12
respectively O 0 1.3522732933424209e-10
, O 0 1.2067826772599322e-11
and O 0 1.2109120997583211e-11
their O 0 1.2686523706562092e-11
father O 0 4.339177905876568e-09
, O 0 5.211123754733649e-10
apparently O 0 3.229011724670272e-08
healthy O 0 3.236395040850937e-10
as O 0 4.732109148974928e-11
well O 0 8.826540193185295e-11
, O 0 2.774049323583938e-10
presented O 0 3.754029975766571e-08
ARSA O 0 0.0008508316241204739
and O 0 3.1409079781496985e-08
GS O 1 0.8828223347663879
values O 0 4.8871999780431e-09
within O 0 1.924455927948543e-09
the O 0 7.099040799651846e-10
range O 0 8.383648975041069e-08
of O 0 1.1246214626225992e-06
MLD B-Disease 1 1.0
patients O 0 9.737328809933388e-07
. O 0 6.243284360607504e-07

Mutation O 0 3.491620930162753e-07
screening O 0 1.7934761231686025e-08
and O 0 7.023132075900662e-11
sequence O 0 1.1859976889461166e-10
analysis O 0 7.371896842967018e-11
disclosed O 0 4.575451573174405e-09
the O 0 4.5458559139177623e-10
involvement O 0 3.205343901413471e-08
of O 0 2.2016878986619304e-08
three O 0 2.3808988114382146e-10
different O 0 1.6987142248403586e-10
ARSA O 0 5.471529220812954e-05
mutations O 0 2.00938359284919e-08
being O 0 8.350176106119989e-10
the O 0 2.0154655722137704e-10
molecular O 0 2.7170614647076263e-09
basis O 0 6.5162137907748274e-09
of O 0 2.477148441926147e-08
intrafamilial O 0 1.8258615455124527e-05
phenotypic O 0 1.6792841051938012e-05
heterogeneity O 0 9.813571523409337e-05
. O 0 1.2846701338276034e-06

The O 0 3.9638734961044975e-08
late O 0 4.611639269569423e-06
infantile O 0 0.16358771920204163
patient O 0 8.267488738056272e-07
inherited O 0 7.462685061909724e-06
from O 0 2.1130666993940395e-07
his O 0 6.66451214215158e-08
mother O 0 4.253497998263356e-09
the O 0 1.2364085311133977e-09
frequent O 0 7.73205388604481e-10
0 O 0 7.89200704787163e-09
- O 0 7.990275996405671e-09
type O 0 3.117231983651436e-08
mutation O 0 3.266126924472701e-08
459 O 0 1.1394767795991356e-08
+ O 0 5.3869029237318955e-09
1G O 0 1.3036391521836777e-07
> O 0 9.869101091908306e-09
A O 0 9.043847448708675e-09
, O 0 8.557260455788196e-11
and O 0 2.952975711179029e-11
from O 0 5.076417619598317e-10
his O 0 6.967816323921738e-10
father O 0 1.4446231988429759e-09
a O 0 1.8357393383183762e-10
novel O 0 4.054767632766243e-10
, O 0 4.49649380229733e-11
single O 0 3.3930977472174106e-10
basepair O 0 3.169074034303776e-07
microdeletion O 0 7.075309440551791e-07
of O 0 7.062406837121671e-08
guanine O 0 3.915382684738233e-09
at O 0 1.3934929654624284e-08
nucleotide O 0 1.3417254862702066e-08
7 O 0 8.509012161539431e-09
in O 0 2.916631658411717e-10
exon O 0 3.2306008534987996e-08
1 O 0 1.3783757424334908e-07
( O 0 4.9480544106472735e-09
7delG O 0 1.1610047749854857e-06
) O 0 1.959817375052353e-08
. O 0 1.225877923616281e-07

The O 0 8.060122240749479e-07
two O 0 2.486587469263668e-08
clinically O 0 0.00011840110528282821
unaffected O 0 9.363868684886256e-07
siblings O 0 1.4822852278939536e-08
carried O 0 6.799141250013463e-10
the O 0 1.6414591907931708e-09
maternal O 0 3.282226757050921e-08
mutation O 0 3.933244130394087e-08
459 O 0 6.558999388062148e-08
+ O 0 6.295552168467111e-08
1G O 0 1.4762634918952244e-06
> O 0 1.3045345781392825e-07
A O 0 5.141691872267984e-08
and O 0 6.210344460910733e-10
, O 0 3.896800104818965e-10
on O 0 2.510720076287498e-09
their O 0 1.2035415199174171e-11
paternal O 0 2.819660505082311e-09
allele O 0 1.4825340066693116e-08
, O 0 1.7764043014345532e-10
a O 0 9.589387062192145e-10
novel O 0 5.05430497454995e-09
cytosine O 0 8.94464058376343e-09
to O 0 1.4777339352178842e-09
thymidine O 0 4.4586928993339825e-07
transition O 0 4.1389199623154127e-07
at O 0 9.922615618052077e-08
nucleotide O 0 1.2980416386199067e-07
2435 O 0 1.695678406576917e-06
in O 0 5.361683874660628e-10
exon O 0 5.1136620271563515e-08
8 O 0 9.065954209575011e-09
, O 0 5.228135632751041e-11
resulting O 0 4.4750378402902413e-10
in O 0 1.0039814812845549e-10
substitution O 0 4.835525757584946e-09
of O 0 2.2155642653842733e-08
alanine O 0 1.1150106615787081e-07
464 O 0 8.207331347875879e-08
by O 0 1.4268163539554735e-08
valine O 0 4.112621900276281e-05
( O 0 1.6720743190035137e-07
A464V O 0 5.071116902399808e-05
) O 0 7.613043351284432e-08
. O 0 1.7710699751205539e-07

The O 0 4.707966354544624e-07
fathers O 0 1.957770621174859e-07
genotype O 0 1.23328533163658e-07
thus O 0 2.1656902049471682e-08
was O 0 3.750673727154208e-07
7delG O 0 1.3460875379678328e-05
/ O 0 0.00013164208212401718
A464V O 0 0.0003503226616885513
. O 0 1.2776557696270174e-06

Mutation O 0 3.0494142265524715e-05
A464V O 0 0.00010896775347646326
was O 0 1.6745381969940354e-07
not O 0 1.398551385811686e-09
found O 0 3.7559816368215593e-10
in O 0 2.0233846542705436e-10
18 O 0 4.362723871054186e-08
unrelated O 0 2.3798672827979317e-06
MLD B-Disease 1 1.0
patients O 0 1.471749584425197e-07
and O 0 1.163205975984738e-08
50 O 0 2.01598709281825e-07
controls O 0 1.435485160072858e-06
. O 0 4.5183071506471606e-07

A464V O 0 0.002264421433210373
, O 0 2.3180550812185174e-08
although O 0 3.6703968753215577e-09
clearly O 0 1.2086942113853638e-08
modifying O 0 7.882442076834195e-08
ARSA O 1 0.6703683137893677
and O 0 1.7783426642381528e-07
GS O 1 1.0
levels O 0 2.430462302527303e-07
, O 0 1.0841522124493963e-09
apparently O 0 1.4935405800997614e-08
bears O 0 1.3891003902699595e-09
little O 0 2.4989468827563144e-10
significance O 0 1.490159329264884e-09
for O 0 9.657921684613768e-11
clinical O 0 1.7848492461780552e-08
manifestation O 0 2.7185565159015823e-06
of O 0 4.679789344663732e-05
MLD B-Disease 1 1.0
, O 0 4.419904087171744e-08
mimicking O 0 1.911357685457915e-07
the O 0 2.7297739180198732e-08
frequent O 0 1.5818565657355066e-07
ARSA O 0 0.0030432783532887697
pseudodeficiency O 0 0.0004706561448983848
allele O 0 1.8656957763596438e-05
. O 0 9.945862302629394e-07

Our O 0 9.453320615193661e-08
results O 0 2.9877362806018937e-09
demonstrate O 0 6.40946185015423e-10
that O 0 1.728953091806318e-11
in O 0 3.0455103716686693e-11
certain O 0 3.5614203253153676e-10
genetic O 0 4.8658190365813425e-08
conditions O 0 2.492490921213175e-06
MLD B-Disease 1 1.0
- O 1 0.7373772859573364
like O 0 8.506209070446857e-08
ARSA O 1 0.9920984506607056
and O 0 7.556085535043167e-09
GS O 1 0.9995867609977722
values O 0 1.3995653525000762e-09
need O 0 6.995017759470201e-11
not O 0 1.0027371294407672e-11
be O 0 9.25185882766355e-12
paralleled O 0 1.5334607195160999e-10
by O 0 2.0779673121085196e-11
clinical O 0 8.97670631161418e-08
disease O 0 4.66462886095087e-08
, O 0 5.198464228528543e-11
a O 0 2.4252519437162334e-10
finding O 0 1.3927961006743317e-09
with O 0 2.665802301127229e-11
serious O 0 2.3046227681788878e-07
diagnostic O 0 5.697339702237514e-07
and O 0 2.6294875610233248e-08
prognostic O 0 0.2519412040710449
implications O 0 6.533497798955068e-05
. O 0 1.1457684649940347e-06

Moreover O 0 3.213779109501047e-06
, O 0 2.0630110952879477e-08
further O 0 9.226799591033341e-08
ARSA O 0 0.0011047129519283772
alleles O 0 5.435258287889155e-08
functionally O 0 1.3122804176646241e-08
similar O 0 4.559486815880476e-11
to O 0 4.533145525620341e-10
A464V O 0 1.870379492174834e-06
might O 0 1.3035087453872052e-09
exist O 0 3.6256209146046103e-10
which O 0 5.284801762872604e-11
, O 0 2.557084405330201e-11
together O 0 7.15570831755219e-12
with O 0 9.493687953832097e-12
0 O 0 1.9450629551442944e-08
- O 0 1.5949865428410703e-08
type O 0 4.5458609321258336e-08
mutations O 0 5.08592030712407e-08
, O 0 3.0010877116737333e-10
may O 0 7.814014324480922e-09
cause O 0 8.702280069883273e-07
pathological O 1 0.8215141892433167
ARSA O 1 0.9999340772628784
and O 0 1.7955612463538273e-07
GS O 1 0.9999998807907104
levels O 0 1.6886627207668425e-08
, O 0 1.551908948571601e-11
but O 0 3.4551432895324474e-12
not O 0 9.85103231626594e-12
clinical O 0 5.359230281776206e-10
outbreak O 0 8.876128165802299e-10
of O 0 9.571173187339355e-09
the O 0 9.102809173100468e-09
disease O 0 3.609623604461376e-07
. O 0 1.0535221584007104e-08
. O 0 1.4732886199908535e-07

Human O 1 0.9995728135108948
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.00024685318931005895
to O 0 6.312144478215487e-07
hematological B-Disease 1 0.9999995231628418
malignancy I-Disease 1 0.9999997615814209
and O 0 1.0655834614681226e-07
neurofibromatosis B-Disease 1 0.9999550580978394
type I-Disease 0 0.0007369465311057866
1 I-Disease 0 0.002639343496412039
. O 0 1.1938445823034272e-06

Heterozygous O 0 2.1923071926721605e-06
germ O 0 6.96721690474078e-05
- O 0 9.523137691758166e-07
line O 0 1.6251864565219876e-07
mutations O 0 1.305933317041763e-08
in O 0 2.1145193929150707e-10
the O 0 1.5111162321446159e-09
DNA O 0 1.17786335351866e-07
mismatch O 0 6.958079757168889e-05
repair O 0 3.2568818824074697e-06
genes O 0 1.6401205726879198e-08
lead O 0 4.542391796036327e-09
to O 0 9.061476902161303e-09
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.999448835849762

The O 0 5.683056656380359e-07
disease O 0 2.3009781671134988e-06
susceptibility O 0 7.577650649182033e-07
of O 0 8.58712851936616e-08
individuals O 0 2.2303137114931815e-09
who O 0 4.0166238335359594e-08
constitutionally O 0 2.5058925530174747e-06
lack O 0 1.0042893450190604e-07
both O 0 1.0319137766501285e-09
wild O 0 1.457462261988951e-09
- O 0 1.344629962929389e-09
type O 0 2.2103925356731224e-09
alleles O 0 1.783269421018474e-09
is O 0 3.9552602859593833e-10
unknown O 0 5.610520048549006e-08
. O 0 5.3504518149338764e-08

We O 0 5.852072249012963e-08
have O 0 2.729172166038296e-10
identified O 0 9.64671453829169e-10
three O 0 7.727892631370636e-11
offspring O 0 3.34521077505201e-10
in O 0 2.2753115364038123e-11
a O 0 5.8648299550156935e-09
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 0.77352374792099
who O 0 2.782987351679367e-08
developed O 0 6.704418353820074e-08
hematological B-Disease 1 0.9990469813346863
malignancy I-Disease 1 0.999962329864502
at O 0 1.3238699914097651e-08
a O 0 3.36260914945985e-11
very O 0 7.510010842370907e-12
early O 0 5.395414670594789e-10
age O 0 2.5531685654556213e-09
, O 0 1.3474579958761002e-11
and O 0 9.389134435211499e-12
at O 0 2.8232430282493226e-10
least O 0 3.7301852578996986e-11
two O 0 5.870036227928477e-12
of O 0 1.3129099196707017e-10
them O 0 6.9403007646462456e-12
displayed O 0 7.831736925645316e-10
signs O 0 2.927121878215644e-09
of O 0 9.018577884489787e-09
neurofibromatosis B-Disease 0 0.016203897073864937
type I-Disease 0 3.046368419745704e-06
1 I-Disease 0 2.6038154828711413e-05
( O 0 3.922859903582321e-08
NF1 B-Disease 0 2.3083097403286956e-05
) O 0 1.7614528502463145e-08
. O 0 5.6779978052645674e-08

DNA O 0 9.114035748325477e-08
sequence O 0 8.521822691953673e-10
analysis O 0 1.3073325755286191e-10
and O 0 1.9969061126889898e-11
allele O 0 6.580683775680995e-10
- O 0 1.3965407996696655e-10
specific O 0 2.0678061693479854e-11
amplification O 0 4.071773584968241e-09
in O 0 1.5862292035428993e-10
two O 0 1.3711184965181644e-10
siblings O 0 4.960432953282634e-09
revealed O 0 7.274520985589561e-09
a O 0 5.897394128595579e-09
homozygous O 0 5.701264527147032e-08
MLH1 O 0 7.636963709956035e-05
mutation O 0 1.7941199814686115e-07
( O 0 2.149188160771587e-09
C676T O 0 2.1601513253699522e-06
- O 0 5.663341653416865e-07
- O 0 4.6511161144735524e-07
> O 0 1.7328829926555045e-06
Arg226Stop O 0 1.1326163075864315e-05
) O 0 6.440445066147049e-09
. O 0 3.204763387998355e-08

Thus O 0 4.83532971884415e-07
, O 0 8.416538577193933e-09
a O 0 1.6787204515367193e-08
homozygous O 0 1.2754993861108233e-07
germ O 0 7.635988731635734e-05
- O 0 4.432087735040113e-06
line O 0 1.4022749610376195e-06
MLH1 O 0 0.005390743725001812
mutation O 0 2.446006988066074e-07
and O 0 3.6010394666163847e-09
consequent O 0 0.12505091726779938
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 3.028522996828542e-07
in O 0 1.3641178187029368e-09
a O 0 1.2365169999029035e-09
mutator O 0 1.7642792045080569e-06
phenotype O 0 9.643445153528774e-09
characterized O 0 4.814026399735383e-10
by O 0 2.869946225114717e-10
leukemia B-Disease 1 0.9999996423721313
and O 0 6.0630163716268726e-06
/ O 1 1.0
or O 1 0.9999948740005493
lymphoma B-Disease 1 1.0
associated O 0 0.00014440876839216799
with O 0 5.2014743623374216e-09
neurofibromatosis B-Disease 1 0.9999798536300659
type I-Disease 0 3.453975295997225e-05
1 I-Disease 0 1.7303238564636558e-05
. O 0 1.800633064874546e-08
. O 0 7.012661740191106e-08

Missense O 0 0.0003604269295465201
mutations O 0 3.035800773432129e-06
in O 0 4.72210581747845e-09
the O 0 4.483267090904519e-09
most O 0 1.9724870348181156e-10
ancient O 0 4.008554821410826e-09
residues O 0 9.01933816521705e-08
of O 0 8.26389268127059e-09
the O 0 6.957116660544216e-09
PAX6 O 0 0.00016425937064923346
paired O 0 1.3751977334663934e-08
domain O 0 1.207056641305826e-07
underlie O 0 1.3703962054023577e-07
a O 0 2.241833607641297e-09
spectrum O 0 2.2781978259445168e-05
of O 0 5.478682214743458e-05
human O 1 0.9999982118606567
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.021333087235689163

Mutations O 0 1.0283961273671594e-06
of O 0 3.389014011645486e-07
the O 0 2.7583926254237667e-08
human O 0 4.573682943487256e-08
PAX6 O 0 0.0012822741409763694
gene O 0 3.317258006063639e-07
underlie O 1 0.9992449283599854
aniridia B-Disease 1 1.0
( O 1 0.9999998807907104
congenital B-Disease 1 1.0
absence I-Disease 1 0.99996018409729
of I-Disease 1 0.976049542427063
the I-Disease 0 2.392059059275198e-06
iris I-Disease 0 3.2734529668232426e-05
) O 0 8.105132121016823e-10
, O 0 8.256920147609037e-11
a O 0 6.615897829576056e-10
rare O 0 2.6815744291752708e-08
dominant O 1 0.9999061822891235
malformation B-Disease 1 1.0
of I-Disease 1 0.9999996423721313
the I-Disease 0 0.4364392161369324
eye I-Disease 1 0.999650239944458
. O 0 7.540808383055264e-06

The O 0 2.1292984797582903e-07
spectrum O 0 1.6273610526695848e-05
of O 0 2.9525376703531947e-06
PAX6 O 1 0.9998548030853271
mutations O 0 1.6247373423539102e-05
in O 0 9.046852511573888e-08
aniridia B-Disease 1 1.0
patients O 0 4.166697209484482e-08
is O 0 2.770638996008046e-10
highly O 0 2.4535123932523106e-10
biased O 0 4.716192325560087e-09
, O 0 2.0609234804847e-11
with O 0 2.467462215452465e-12
92 O 0 9.249226273766453e-09
% O 0 1.4355973076973783e-09
of O 0 1.9881933877030633e-09
all O 0 1.6505755096041241e-10
reported O 0 1.4151828597874783e-09
mutations O 0 5.254011892219523e-09
leading O 0 2.083016870102483e-09
to O 0 4.140975895516874e-10
premature O 0 4.623246141477466e-08
truncation O 0 4.1677236595205613e-07
of O 0 9.530953803960074e-08
the O 0 8.010326624230402e-09
protein O 0 5.114303203157533e-09
( O 0 1.370961538738058e-10
nonsense O 0 2.6697957622445756e-08
, O 0 1.7243924343990358e-10
splicing O 0 2.6774591432854322e-09
, O 0 3.2108767034078056e-11
insertions O 0 1.1913762199000644e-09
and O 0 8.226942044275987e-11
deletions O 0 7.622964481868166e-09
) O 0 1.4831914862956097e-10
and O 0 1.6975999772572692e-10
just O 0 2.853061120688949e-09
2 O 0 2.651496266992126e-08
% O 0 1.409724781353816e-09
leading O 0 1.6049761519809636e-10
to O 0 3.431305586887312e-11
substitution O 0 1.97001770452232e-09
of O 0 5.133301339554919e-09
one O 0 4.2989828363815263e-10
amino O 0 2.775753793482494e-10
acid O 0 2.46921025293112e-11
by O 0 5.292364203129951e-12
another O 0 7.79263764627558e-10
( O 0 7.106983002103107e-09
missense O 0 3.4944366689160233e-06
) O 0 3.271470205845617e-08
. O 0 1.4310795393157605e-07

The O 0 8.913154658785061e-08
extraordinary O 0 2.1338880884513856e-08
conservation O 0 2.0365975572644857e-08
of O 0 6.109334549364576e-08
the O 0 3.528462144686273e-08
PAX6 O 0 0.00010960657527903095
protein O 0 9.248100951708693e-08
at O 0 3.2300711438892904e-08
the O 0 3.803535264523816e-09
amino O 0 4.5945355964249757e-08
acid O 0 1.61658491037997e-08
level O 0 1.8754006703147752e-07
amongst O 0 2.2544369926436048e-08
vertebrates O 0 4.552316568151582e-07
predicts O 0 2.190072336816229e-07
that O 0 1.331395105275135e-09
pathological O 0 7.36894435249269e-05
missense O 0 4.915646422887221e-05
mutations O 0 7.36136883006111e-07
should O 0 1.0578345976952619e-09
in O 0 7.332603274567973e-11
fact O 0 1.1417032597105248e-10
be O 0 6.183393380654323e-11
common O 0 1.8632544118712957e-10
even O 0 7.659538281412637e-11
though O 0 4.167120468134833e-11
they O 0 1.4030654242602747e-11
are O 0 5.8066299164771795e-12
hardly O 0 2.7553308523664555e-09
ever O 0 3.5692220290428622e-09
seen O 0 3.6942908732129354e-09
in O 0 4.863051294989873e-09
aniridia B-Disease 1 1.0
patients O 0 3.075300298860384e-07
. O 0 7.71803286170325e-07

This O 0 7.162860526932491e-09
indicates O 0 1.6412315062552807e-08
that O 0 6.080982939415946e-11
there O 0 6.59039073314105e-11
is O 0 3.435286777264679e-11
a O 0 1.4437769035868797e-10
heavy O 0 1.349919642734676e-07
ascertainment O 0 9.703811883809976e-06
bias O 0 2.415274593658978e-07
in O 0 1.2563816653710091e-10
the O 0 9.483267643384252e-11
selection O 0 5.978219586033617e-10
of O 0 2.350985850441134e-09
patients O 0 2.34942482135736e-10
for O 0 3.9963077291815807e-10
PAX6 O 0 8.807482117845211e-06
mutation O 0 6.222204085304384e-09
analysis O 0 4.0845046789250716e-10
and O 0 3.883997984344134e-11
that O 0 9.21753437466144e-11
the O 0 1.1992194792753708e-08
missing O 0 3.7710674405389e-07
PAX6 O 0 0.011862960644066334
missense O 0 0.00034889348899014294
mutations O 0 7.497767910535913e-06
frequently O 0 1.9197861078623646e-08
may O 0 1.7874759450364763e-08
underlie O 0 1.1768701142500504e-06
phenotypes O 0 1.6443374306618352e-07
distinct O 0 3.816368554510063e-09
from O 0 1.683703487742605e-08
textbook O 0 8.092416464933194e-06
aniridia B-Disease 1 0.9999997615814209
. O 0 1.4973061297496315e-06

Here O 0 3.719151209224947e-07
we O 0 3.782713253741576e-09
present O 0 1.57875956752207e-09
four O 0 2.3445542729483293e-10
novel O 0 4.317309176826711e-09
PAX6 O 0 8.390818948100787e-06
missense O 0 1.793678507056029e-06
mutations O 0 1.1376997122169996e-07
, O 0 3.9134395724005344e-10
two O 0 5.7040296097543575e-11
in O 0 1.7306199528999144e-10
association O 0 5.186245877197848e-10
with O 0 1.3334784665364197e-10
atypical O 0 5.228253598943411e-07
phenotypes O 0 1.345761688753555e-06
ectopia B-Disease 0 0.0001208216417580843
pupillae I-Disease 0 0.0001434803707525134
( O 0 1.4573983131427326e-09
displaced B-Disease 0 2.8542093133410162e-09
pupils I-Disease 0 1.4836250006311502e-09
) O 0 9.586424987162445e-10
and O 0 1.6875976882602117e-07
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9584233164787292
( O 0 3.579968677058787e-08
searching B-Disease 0 1.3666895881669916e-07
gaze I-Disease 0 2.572479047557863e-07
) O 0 6.224096932294643e-11
, O 0 1.762505419389271e-11
and O 0 9.985915740140516e-12
two O 0 8.344229820989035e-12
in O 0 2.6201365729838777e-11
association O 0 1.4947529325404219e-10
with O 0 7.915833266647354e-11
more O 0 2.138214050262377e-09
recognizable O 0 5.619094281428261e-06
aniridia B-Disease 1 1.0
phenotypes O 0 2.385038351349067e-05
. O 0 8.423814961133758e-07

Strikingly O 0 2.3322791093960404e-06
, O 0 1.3649826158257383e-08
all O 0 1.654244963233964e-09
four O 0 2.868096593555691e-10
mutations O 0 1.7073586988658462e-09
are O 0 1.625251495884772e-11
located O 0 1.8345360786042875e-09
within O 0 7.753782504948958e-09
the O 0 9.098104492011316e-09
PAX6 O 0 3.664614268927835e-05
paired O 0 6.756612602742962e-09
domain O 0 5.247244772021986e-08
and O 0 8.903614512334457e-10
affect O 0 1.048526510061265e-08
amino O 0 4.784608265140378e-09
acids O 0 1.473902111470693e-10
which O 0 4.1148321729134185e-12
are O 0 2.5230874247522683e-12
highly O 0 4.6445753493218334e-11
conserved O 0 1.3832704981453503e-09
in O 0 4.533938849360375e-11
all O 0 9.98586421885328e-11
known O 0 1.19377363549944e-09
paired O 0 1.4774577117293575e-09
domain O 0 4.041013212940925e-08
proteins O 0 3.1544988843279498e-09
. O 0 8.68198579695445e-09

Our O 0 6.483734438234023e-08
results O 0 1.7902012094950237e-09
support O 0 5.893713850291249e-10
the O 0 3.7594144464137003e-10
hypothesis O 0 1.9495414171899483e-09
that O 0 1.0989824501816958e-12
the O 0 1.0789650423115305e-11
under O 0 5.977991435202057e-10
- O 0 1.4126532166258698e-09
representation O 0 1.828422857563794e-09
of O 0 5.381080470101551e-09
missense O 0 4.168790837866254e-06
mutations O 0 2.2373244235041057e-07
is O 0 1.8492622710919449e-10
caused O 0 5.590026774804358e-10
by O 0 1.2982478980738676e-10
ascertainment O 0 0.00011854568583657965
bias O 0 2.2557373995368835e-06
and O 0 1.0957561247249004e-10
suggest O 0 2.5439217399281233e-10
that O 0 4.068716284028051e-12
a O 0 4.071870271515898e-11
substantial O 0 3.868689812946968e-09
burden O 0 3.5505249229572655e-07
of O 0 1.5076557247084565e-06
PAX6 B-Disease 1 1.0
- I-Disease 1 0.9998621940612793
related I-Disease 0 0.16864873468875885
disease I-Disease 1 0.9763544797897339
remains O 0 4.2554148649287526e-08
to O 0 4.412891441152311e-10
be O 0 1.208039002165151e-09
uncovered O 0 2.5126982450274227e-07
. O 0 6.3763234692260085e-09
. O 0 4.2999879212857195e-08

The O 0 2.794797069327615e-07
chromosomal O 0 9.29761790757766e-06
order O 0 1.834501972552971e-08
of O 0 1.9590405031522096e-07
genes O 0 3.235300027881749e-08
controlling O 0 1.3037179087405093e-06
the O 0 2.5333687148076933e-08
major O 0 3.77516954586099e-07
histocompatibility O 0 0.11488930881023407
complex O 0 1.0456789567570013e-07
, O 0 6.755626613674792e-11
properdin O 0 1.2067569166163139e-08
factor O 0 4.785527529804767e-10
B O 0 1.4505048717694535e-08
, O 0 1.4879568063785875e-11
and O 0 1.5588218216233685e-10
deficiency B-Disease 0 2.5635398515078123e-07
of I-Disease 0 6.532107477141835e-07
the I-Disease 0 3.368224099631334e-08
second I-Disease 0 2.0312517889919945e-08
component I-Disease 0 1.8981944904794545e-08
of I-Disease 0 1.8053167849529927e-08
complement I-Disease 0 2.3577317875833614e-08
. O 0 1.3636768869673688e-07

The O 0 5.88603548123956e-08
relationship O 0 1.2550752437334722e-08
of O 0 3.4517583458182344e-08
the O 0 2.5067772302378444e-09
genes O 0 2.1230465996335823e-10
coding O 0 2.772395202299549e-09
for O 0 5.556626825331534e-10
HLA O 0 3.291631287538621e-07
to O 0 2.0304208314669836e-10
those O 0 8.545773463874973e-12
coding O 0 5.481027853804221e-10
for O 0 1.994028726859387e-11
properdin O 0 1.6680598236007427e-08
Factor O 0 8.74555372565311e-10
B O 0 7.524016076843054e-09
allotypes O 0 1.1920132436671338e-08
and O 0 2.515510889866679e-11
for O 0 3.833606210257301e-10
deficiency B-Disease 0 8.942236036091344e-07
of I-Disease 0 5.006115770811448e-07
the I-Disease 0 1.1334118532602133e-08
second I-Disease 0 7.128488022090096e-09
component I-Disease 0 4.1809933293279755e-09
of I-Disease 0 3.930227698845101e-09
complement I-Disease 0 1.765649737528463e-09
( O 0 1.5772336769970252e-09
C2 O 0 5.438819812297879e-07
) O 0 4.248450202748444e-11
was O 0 5.099397570873521e-10
studied O 0 2.039977770040835e-10
in O 0 5.494106038173019e-12
families O 0 9.543523089849959e-12
of O 0 4.121670227341667e-10
patients O 0 4.0883937901803336e-10
with O 0 7.796711609664442e-10
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 1.4174374882713892e-05

Patients O 0 5.767462312178395e-07
were O 0 4.69835192973278e-09
selected O 0 4.4286083134004173e-10
because O 0 1.0508439257650437e-10
they O 0 3.842491255734437e-11
were O 0 1.4529984160294163e-10
heterozygous O 0 4.738786030245024e-10
or O 0 4.041936563226045e-09
homozygous O 0 2.157955378834231e-07
for O 0 1.6381092109440942e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 2.6952227926813066e-05

12 O 0 9.380126471114636e-07
families O 0 7.302018101285057e-09
with O 0 6.893827730891644e-10
15 O 0 8.04057762593402e-08
matings O 0 2.009814807024668e-06
informative O 0 4.990975526197872e-07
for O 0 2.5864858343993546e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 3.84150098398095e-07
found O 0 3.6985795759392204e-08
. O 0 6.815974984419881e-08

Of O 0 1.7546313756611198e-05
57 O 0 1.865669219114352e-06
informative O 0 1.9116384919470875e-07
meioses O 0 7.55481596570462e-06
, O 0 6.184445733303789e-10
two O 0 3.120469507789103e-11
crossovers O 0 1.2341559996187357e-09
were O 0 1.858983939007075e-10
noted O 0 1.209001926349984e-10
between O 0 3.700334483269785e-09
the O 0 1.8968088966175856e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999775886535645
gene O 0 1.3106787877248394e-09
and O 0 1.4299370021397806e-10
the O 0 1.6806706026883944e-09
HLA O 0 2.1744533285072976e-07
- O 0 2.1409247707993018e-08
B O 0 5.254465662574148e-08
gene O 0 2.966349041400029e-11
, O 0 4.113372403108384e-12
with O 0 1.3607323818068395e-12
a O 0 4.382677554204406e-10
recombinant O 0 2.7478259667645943e-09
fraction O 0 5.496297106333259e-08
of O 0 1.7402746266270697e-07
0 O 0 1.302748501075257e-06
. O 0 2.752318266630027e-07

035 O 0 0.012997676618397236
. O 0 2.4002602003747597e-05

A O 0 3.1606273296347354e-06
lod O 0 7.755829574307427e-05
score O 0 2.8041567290415514e-08
of O 0 1.634246871162759e-08
13 O 0 1.5523751173418532e-09
was O 0 4.3852446673930956e-10
calculated O 0 7.108240662745402e-10
for O 0 1.4403223058678805e-10
linkage O 0 1.3677629340236308e-06
between O 1 0.8424235582351685
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 9.27063652511606e-08
HLA O 0 3.648618758234079e-06
- O 0 4.079113224975117e-08
B O 0 3.812056803553787e-08
at O 0 6.330945490073958e-11
a O 0 5.221695038165608e-12
maximum O 0 6.49479359182692e-10
likelihood O 0 1.775585456442741e-09
value O 0 7.470416507615596e-10
of O 0 1.979252761685757e-09
the O 0 6.194480484111864e-10
recombinant O 0 4.639035544595771e-10
fraction O 0 8.290004238631354e-09
of O 0 2.3108153612838578e-08
0 O 0 2.7881523578798806e-07
. O 0 8.386943761706789e-08

04 O 0 0.006156974006444216
. O 0 4.3612340959953144e-05

18 O 0 1.1727136097761104e-06
families O 0 1.5887583471041467e-09
with O 0 1.5216838900045104e-10
21 O 0 2.5652854063196173e-08
informative O 0 3.957533856180362e-09
matings O 0 1.057165945894667e-07
for O 0 4.812731324577157e-10
both O 0 7.618512487539419e-10
properdin O 0 9.139623102782934e-07
Factor O 0 2.7130445445777696e-08
B O 0 5.597981811433783e-08
allotype O 0 8.668222761798461e-08
and O 0 1.1830746382557322e-09
HLA O 0 2.9980162707943236e-07
- O 0 5.6025747596777364e-08
B O 0 2.7095543941868527e-07
were O 0 7.155728787289206e-10
found O 0 1.2559366879827394e-09
. O 0 9.67985869237964e-09

Of O 0 4.996524876332842e-05
72 O 0 5.880351636733394e-06
informative O 0 1.9546550333870982e-07
meioses O 0 2.714491347433068e-05
, O 0 3.3809732791212355e-09
three O 0 3.465079334574739e-10
recombinants O 0 1.337134222012537e-06
were O 0 2.9886140229251623e-09
found O 0 3.5266214948315167e-10
, O 0 2.7089552823156282e-11
giving O 0 3.4664656561878004e-11
a O 0 2.7154126169826043e-10
recombinant O 0 1.1259516652373236e-09
fraction O 0 5.832994176557804e-08
of O 0 1.3746083027399436e-07
0 O 0 1.6351187923646648e-06
. O 0 2.2615047612362105e-07

042 O 0 0.017636168748140335
. O 0 3.91028261219617e-05

A O 0 2.030687937804032e-06
lod O 0 6.191620923345909e-05
score O 0 7.096988952071115e-08
of O 0 4.944217479874169e-08
16 O 0 1.68809588529939e-08
between O 0 2.72824358660273e-08
HLA O 0 2.79103051070706e-06
- O 0 9.87445289979405e-08
B O 0 1.0277485529286423e-07
and O 0 1.1652211140411595e-10
Factor O 0 2.007180199825598e-09
B O 0 2.9606782803170972e-08
allotypes O 0 6.817887054921812e-08
was O 0 1.3873925341911786e-09
calculated O 0 2.2479993422308553e-09
at O 0 3.394327319217183e-10
a O 0 3.187883290678428e-11
maximum O 0 2.0538621914312216e-09
likelihood O 0 3.696912997952495e-09
value O 0 1.4852900021011806e-09
of O 0 3.2507498914924327e-09
the O 0 5.973967986960815e-10
recombinant O 0 3.268915971244013e-10
fraction O 0 6.268948471443991e-09
of O 0 1.4152266913924905e-08
0 O 0 3.173038578552223e-07
. O 0 7.055984951875871e-08

04 O 0 0.006499107461422682
. O 0 3.51927665178664e-05

A O 0 1.386909644907064e-07
crossover O 0 1.178591517714267e-07
was O 0 1.357875412111298e-08
shown O 0 8.222282577019513e-11
to O 0 4.1010913415240324e-11
have O 0 1.0776116977917471e-11
occurred O 0 5.950031023438385e-10
between O 0 5.5122881953417746e-11
genes O 0 3.6658297924985206e-12
for O 0 1.6703297816070273e-12
Factor O 0 6.372377625574188e-11
B O 0 7.637542820404519e-10
and O 0 3.806115145277289e-11
HLA O 0 5.3634892083209706e-08
- O 0 4.25546389237752e-08
D O 0 7.089088427392198e-08
, O 0 5.518431892004294e-11
in O 0 4.7190487628689937e-11
which O 0 3.4836208917532474e-10
HLA O 0 1.681313364088055e-07
- O 0 3.78993014749085e-08
D O 0 6.018061071699776e-08
segregared O 0 1.642115279310019e-07
with O 0 5.604118835655925e-10
HLA O 0 1.2552616226457758e-06
- O 0 4.421911015128899e-08
A O 0 1.2245540403910127e-07
and O 0 8.197392986630803e-09
B O 0 2.9252228159748483e-06
. O 0 5.119663626373949e-08

These O 0 2.034461266120502e-09
studies O 0 1.1491647633476987e-09
suggest O 0 4.86797713250553e-10
that O 0 6.503812245706175e-12
the O 0 1.9757959157651328e-11
genes O 0 4.712875489171209e-12
for O 0 3.5148464000434032e-12
Factor O 0 1.8384593847287078e-09
B O 0 4.921955223835539e-06
and O 0 7.185592210134928e-08
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 5.454035834073778e-11
located O 0 4.924645136128447e-10
outside O 0 1.7702146692943899e-10
those O 0 4.240255715992625e-12
for O 0 7.472265167729475e-11
HLA O 0 2.765257534065313e-07
, O 0 5.76907402058402e-12
that O 0 5.337329970350746e-13
the O 0 2.9922141153715387e-12
order O 0 1.1447161794853056e-11
of O 0 2.339872462453485e-10
genese O 0 1.1278130784830864e-07
is O 0 4.944769038672803e-10
HLA O 0 5.118023693739815e-08
- O 0 2.803000054285576e-09
A O 0 8.148771435401159e-09
, O 0 7.042932209655461e-11
- O 0 9.449616644729986e-10
B O 0 1.757761047826989e-08
, O 0 2.4650222835154167e-11
- O 0 1.7479309111223529e-09
D O 0 9.325894723133388e-09
, O 0 5.25200265222292e-11
Factor O 0 9.45203249003157e-10
B O 0 9.329687600256875e-08
allotype O 0 5.46887486052583e-06
, O 0 2.6163982624893833e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 4.5712619800575283e-10
that O 0 2.264077640645734e-11
the O 0 1.1459422993853607e-10
genes O 0 4.997988828359112e-11
coding O 0 8.077881474832793e-09
for O 0 2.4056925340687485e-08
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 5.232550392975099e-09
Factor O 0 2.524599373998626e-08
B O 0 5.3362850138682916e-08
allotypes O 0 2.9122599443098807e-08
are O 0 4.0278392600401336e-12
approximately O 0 4.658238031418627e-11
3 O 0 2.6582233636496255e-10
- O 0 6.592769663527065e-10
- O 0 1.0084922896780313e-09
5 O 0 7.64407204201234e-10
centimorgans O 0 9.636991649131232e-09
from O 0 2.3400956172814347e-10
the O 0 1.887423273227995e-10
HLA O 0 1.1381170672564167e-08
- O 0 5.483736242872794e-10
A O 0 2.941527910138575e-09
and O 0 2.3205830312900133e-10
HLA O 0 2.7619410758461527e-08
- O 0 1.65085034531387e-09
B O 0 7.55121565276795e-09
loci O 0 4.914380014042763e-10
, O 0 1.6159960739350887e-12
and O 0 4.724951983489656e-13
that O 0 7.289673964287757e-13
the O 0 6.20446888310866e-11
apparent O 0 1.5226959249048377e-08
lack O 0 4.836282041509321e-09
of O 0 2.379639063576633e-08
recombinants O 0 1.2190663483124808e-06
between O 0 5.691874527258278e-09
the O 0 1.951840689073947e-09
Factor O 0 1.20909078304976e-08
B O 0 4.6523848595825257e-07
gene O 0 1.993712217540633e-08
and O 0 2.352485779510971e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.77036686924248e-08
suggests O 0 1.1243593833754062e-09
that O 0 4.020876947369301e-12
these O 0 4.990927376241627e-12
two O 0 2.0616468601741822e-11
genes O 0 5.543912551253527e-10
lie O 0 4.248651208627052e-08
in O 0 7.919789823951362e-11
close O 0 1.1471768424087259e-08
proximity O 0 1.307882602219479e-08
to O 0 3.452256924774133e-09
one O 0 5.372506883816186e-09
another O 0 5.353269116881165e-08
. O 0 1.237147984056719e-07

Distribution O 0 4.4829059220319323e-07
of O 0 5.414656243374338e-07
emerin O 0 0.0023296833969652653
and O 0 5.0664979767134355e-08
lamins O 0 6.140804180176929e-05
in O 0 2.8433422283313803e-09
the O 0 1.023138107569821e-08
heart O 0 2.021146201514057e-07
and O 0 6.560594845161916e-10
implications O 0 1.7499975513146637e-07
for O 0 8.598547651672561e-09
Emery B-Disease 1 0.9238038063049316
- I-Disease 1 0.9999793767929077
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0007827786612324417

Emerin O 0 0.005745747592300177
is O 0 6.047621070592868e-08
a O 0 2.8160609844007922e-08
nuclear O 0 2.027645905400277e-06
membrane O 0 5.4724260678540304e-08
protein O 0 1.597293297628255e-09
which O 0 3.6754231602653675e-11
is O 0 2.597502490875314e-10
missing O 0 1.480541134135649e-09
or O 0 1.2646286240425297e-09
defective O 0 9.373530929224216e-08
in O 0 3.882143051470166e-09
Emery B-Disease 0 0.0025940260384231806
- I-Disease 1 0.9975658655166626
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 5.038770905230194e-05
EDMD B-Disease 1 1.0
) O 0 7.010775107119116e-07
. O 0 9.894075674310443e-07

It O 0 4.771418815607831e-10
is O 0 1.185728459862645e-10
one O 0 5.5018687522556675e-11
member O 0 2.352195660471068e-10
of O 0 2.119260766875186e-09
a O 0 5.3438911074010775e-09
family O 0 3.268961101809964e-09
of O 0 2.352743706524052e-07
lamina O 1 0.9999854564666748
- O 0 0.00010698085679905489
associated O 0 6.649098338584736e-08
proteins O 0 7.177212990594484e-11
which O 0 1.7977990623974094e-11
includes O 0 7.120599249121895e-11
LAP1 O 0 5.269074972602539e-05
, O 0 9.117282928627901e-09
LAP2 O 0 0.0007131754537113011
and O 0 5.400320546300463e-08
lamin O 0 4.069667193107307e-05
B O 0 2.1531588572543114e-05
receptor O 0 5.256207714410266e-06
( O 0 1.666311675307952e-07
LBR O 0 8.215683919843286e-05
) O 0 5.2851724774427566e-08
. O 0 2.627898822993302e-07

A O 0 5.0326725613558665e-06
panel O 0 6.987666552049632e-07
of O 0 1.5890962856701663e-07
16 O 0 8.699556630631378e-09
monoclonal O 0 1.2706248275762277e-09
antibodies O 0 7.607767193995585e-10
( O 0 9.966935055061299e-10
mAbs O 0 1.1337625238638793e-07
) O 0 1.8912250931979457e-10
has O 0 1.0493457491822511e-10
been O 0 9.969516184815674e-11
mapped O 0 1.3945903321044284e-09
to O 0 3.2829558516134227e-10
six O 0 1.6447992967627556e-10
specific O 0 1.3920145591761468e-10
sites O 0 7.929043532861613e-10
throughout O 0 1.6534429381209748e-10
the O 0 1.4516887691939928e-09
emerin O 0 1.96611352976106e-07
molecule O 0 2.2473005678591562e-09
using O 0 3.9790043482312853e-10
phage O 0 8.002340123880458e-09
- O 0 1.4626029276598729e-09
displayed O 0 7.732669365934086e-11
peptide O 0 7.45103423405169e-10
libraries O 0 2.6831681321226597e-10
and O 0 4.532235697851661e-11
has O 0 3.3252595121879835e-11
been O 0 2.2539605598614898e-11
used O 0 1.513283769127849e-11
to O 0 2.500978035779866e-10
localize O 0 9.397927556165087e-07
emerin O 0 1.4100169209996238e-05
in O 0 4.563502464804969e-09
human O 0 1.2072242761007601e-08
and O 0 4.395907193810444e-09
rabbit O 0 7.782409170431492e-07
heart O 0 1.619437534827739e-05
. O 0 1.992123316085781e-06

Several O 0 8.51166177540108e-08
mAbs O 0 1.8269931842951337e-06
against O 0 3.55808325025464e-08
different O 0 1.5305628986439501e-09
emerin O 0 4.598727173288353e-06
epitopes O 0 1.0878646889977972e-06
did O 0 6.692687293252675e-09
not O 0 9.84563319761378e-10
recognize O 0 6.266259067189139e-09
intercalated O 0 1.3782718610855227e-07
discs O 0 4.182838040378556e-07
in O 0 1.388613002362149e-09
the O 0 5.275984094055275e-09
heart O 0 4.526488908140891e-07
, O 0 1.3137366194904132e-10
though O 0 3.246885746377437e-11
they O 0 1.617884298754646e-11
recognized O 0 1.6042722705833512e-10
cardiomyocyte O 0 1.0673979033981595e-07
nuclei O 0 1.788097421240309e-07
strongly O 0 8.222166059113079e-09
, O 0 2.1937422711726384e-10
both O 0 1.3956993893948777e-10
at O 0 2.158555822973085e-08
the O 0 2.936975551648402e-09
rim O 0 1.232418753716047e-07
and O 0 5.311077133640651e-10
in O 0 1.969860052852823e-09
intranuclear O 0 1.115493978431914e-05
spots O 0 2.075127270018129e-07
or O 0 3.623474498226642e-08
channels O 0 7.815999083504721e-07
. O 0 2.220645995976156e-07

A O 0 2.003097688429989e-05
polyclonal O 0 1.9671557311085053e-05
rabbit O 0 3.31941606646069e-07
antiserum O 0 1.0556411780271446e-06
against O 0 2.092599657999017e-07
emerin O 0 3.554543945938349e-05
did O 0 2.0777800813220892e-08
recognize O 0 1.2516947478502516e-08
both O 0 5.983356032857046e-09
nuclear O 0 2.6332274956075707e-06
membrane O 0 7.223298581493509e-08
and O 0 4.585566371062555e-10
intercalated O 0 4.322079583118921e-09
discs O 0 1.0183118348550124e-08
but O 0 1.4871034959007545e-10
, O 0 3.476675891622705e-11
after O 0 1.732158860789923e-10
affinity O 0 3.834352280129849e-10
purification O 0 1.080255107588357e-09
against O 0 3.981418528198333e-10
a O 0 9.543896783981154e-10
pure O 0 1.2951964833973761e-07
- O 0 4.7003531733480486e-08
emerin O 0 5.729771714868548e-07
band O 0 1.0219425305990626e-08
on O 0 2.1051200782551405e-09
a O 0 3.5945321719133005e-10
western O 0 6.399668794898616e-09
blot O 0 1.9929973404941848e-06
, O 0 4.362502858956674e-10
it O 0 1.4503789835806913e-10
stained O 0 2.995326653376651e-08
only O 0 1.3672800669439766e-09
the O 0 9.611072826487543e-09
nuclear O 0 4.673392595577752e-06
membrane O 0 3.010510226886254e-06
. O 0 2.7194874974156846e-07

These O 0 4.503742268013866e-09
results O 0 2.0331267780449025e-09
would O 0 1.088092393963791e-09
not O 0 4.3134962268709387e-10
be O 0 4.980063583737149e-10
expected O 0 8.17249290463451e-09
if O 0 5.2148352303049705e-09
immunostaining O 0 8.8957103798748e-06
at O 0 8.901466230781807e-08
intercalated O 0 4.316603252618734e-08
discs O 0 1.275954275570257e-07
were O 0 1.0436058683893634e-09
due O 0 4.314732571231161e-09
to O 0 6.670874963532469e-11
a O 0 1.4239384671377309e-10
product O 0 4.1042078069430943e-10
of O 0 1.473753785674603e-09
the O 0 8.321907052355471e-10
emerin O 0 6.083393486733257e-07
gene O 0 1.1933228849514421e-09
and O 0 7.519589118043513e-11
, O 0 4.533800418426992e-11
therefore O 0 1.3142986698966297e-09
, O 0 8.0781804856489e-11
cast O 0 2.2004388589014212e-10
some O 0 8.026082402856627e-12
doubt O 0 8.179927846185819e-10
upon O 0 3.6331315733661995e-10
the O 0 1.9451872057540953e-10
hypothesis O 0 1.1412276457178905e-08
that O 0 1.9239630721923362e-10
cardiac B-Disease 1 0.8496268391609192
defects I-Disease 1 0.8802688121795654
in O 0 5.609332731637551e-08
EDMD B-Disease 1 1.0
are O 0 8.651300786866045e-10
caused O 0 7.778682586945251e-09
by O 0 2.9062030559856566e-10
absence O 0 6.07896240012451e-08
of O 0 3.769568195366446e-07
emerin O 0 5.5996522860368714e-05
from O 0 4.2220739260301343e-07
intercalated O 0 1.5506676618315396e-06
discs O 0 1.66556619660696e-05
. O 0 8.39939673369372e-07

Although O 0 2.2542440092365723e-07
emerin O 0 0.0005898766103200614
was O 0 1.1763944485210232e-06
abundant O 0 9.17311826498235e-09
in O 0 2.372643748138614e-10
the O 0 9.33177979334232e-10
membranes O 0 1.0822313711855713e-08
of O 0 2.1559470653187418e-08
cardiomyocyte O 0 4.698830252891639e-06
nuclei O 0 1.3010103430133313e-06
, O 0 1.999300447419472e-10
it O 0 5.6604717441066654e-11
was O 0 1.8201772533643634e-08
absent O 0 5.527876822952749e-09
from O 0 2.1544240003112947e-10
many O 0 3.931820841129863e-11
non O 0 3.591670960645388e-08
- O 0 7.445074601264423e-08
myocyte O 0 5.636379682982806e-07
cells O 0 8.400816708942216e-10
in O 0 2.4383320362808547e-10
the O 0 4.942092957094246e-09
heart O 0 2.1651137558365008e-06
. O 0 7.163225177464483e-07

This O 0 4.071579073894327e-09
distribution O 0 1.6091219023905978e-08
of O 0 1.2799953097442085e-08
emerin O 0 1.1392525266273879e-05
was O 0 6.149408093847342e-09
similar O 0 1.3901672347993443e-11
to O 0 3.540584492256471e-11
that O 0 1.200977772092271e-11
of O 0 3.977389972931178e-09
lamin O 0 3.0444721232925076e-06
A O 0 1.2396016657589826e-08
, O 0 3.126665246155902e-11
a O 0 6.791568696318251e-11
candidate O 0 1.662300963545249e-09
gene O 0 2.5189773877887234e-11
for O 0 7.718976499648811e-12
an O 0 2.8040028632325686e-11
autosomal O 0 1.1401359500951003e-07
form O 0 4.280953191937442e-07
of O 1 0.9999792575836182
EDMD B-Disease 1 1.0
. O 0 0.0006824589218012989

In O 0 7.108382504839028e-08
contrast O 0 1.1937747501633567e-07
, O 0 3.766703571272956e-08
lamin O 0 0.0006463966565206647
B1 O 0 0.00444347457960248
was O 0 6.170300821395358e-07
absent O 0 6.89874042336669e-08
from O 0 4.3985575182148295e-09
cardiomyocyte O 0 1.7830478782343562e-06
nuclei O 0 2.1324372028175276e-06
, O 0 1.8984109839692564e-09
showing O 0 2.947031285671642e-09
that O 0 1.4935056524834067e-09
lamin O 0 3.52752540493384e-05
B1 O 0 1.117684405471664e-05
is O 0 2.948092325816276e-10
not O 0 1.0852398840688338e-10
essential O 0 5.183110607376307e-10
for O 0 1.845097824526576e-10
localization O 0 2.9696943215640204e-07
of O 0 7.513735766906393e-08
emerin O 0 5.148511263541877e-06
to O 0 1.6975304717448125e-08
the O 0 7.775452104397118e-08
nuclear O 0 8.958026592154056e-05
lamina O 1 0.9915749430656433
. O 0 5.203648470342159e-06

Lamin O 1 0.9999828338623047
B1 O 1 0.998690664768219
is O 0 1.2150506378816317e-08
also O 0 3.971081519171804e-10
almost O 0 2.8080033853683517e-09
completely O 0 9.073707474271941e-08
absent O 0 2.9375942744991335e-07
from O 0 6.357806370260732e-08
skeletal O 0 3.992186066170689e-06
muscle O 0 8.926226655603386e-07
nuclei O 0 0.00017611293878871948
. O 0 2.7139299163536634e-06

In O 0 8.421863526564266e-07
EDMD B-Disease 1 1.0
, O 0 5.721349616294447e-09
the O 0 5.030451055709761e-10
additional O 0 1.670044796897585e-10
absence O 0 2.1904750013845842e-08
of O 0 7.035301905489177e-07
lamin O 1 0.9956421852111816
B1 O 1 0.9999809265136719
from O 0 9.923454626914463e-07
heart O 1 0.9875792860984802
and O 0 1.2267901183804497e-07
skeletal O 0 0.0003295294882263988
muscle O 0 6.251219701880473e-07
nuclei O 0 0.21166518330574036
which O 0 2.0811830481193283e-08
already O 0 1.558930584621976e-08
lack O 0 2.427508150049107e-08
emerin O 0 1.1192588544872706e-06
may O 0 5.342553621723312e-10
offer O 0 4.2267567917919635e-11
an O 0 7.213041362114092e-12
alternative O 0 6.377195438389549e-10
explanation O 0 8.77678540955884e-10
of O 0 2.7230642185571696e-09
why O 0 6.33558705498416e-10
these O 0 7.05589336957857e-11
tissues O 0 3.348072041831074e-09
are O 0 4.008856441251041e-11
particularly O 0 1.015965866990598e-09
affected O 0 5.2724731247622e-09
. O 0 8.332424528134652e-09
. O 0 1.143145311743865e-07

Genetic O 0 3.5495909287419636e-06
mapping O 0 1.659294525779842e-06
of O 0 6.798499725846341e-06
the O 0 7.541560762547306e-07
copper B-Disease 0 4.799239832209423e-05
toxicosis I-Disease 1 0.8170068264007568
locus O 0 3.4454681099305162e-06
in O 0 1.0248002446644477e-08
Bedlington O 0 1.7286722595599713e-06
terriers O 0 1.313788544621275e-07
to O 0 2.9943083568184647e-09
dog O 0 7.194025641865665e-08
chromosome O 0 1.4142533473204821e-06
10 O 0 8.263278061804158e-09
, O 0 5.4041455338493805e-11
in O 0 4.579375767477245e-11
a O 0 8.08632438786816e-10
region O 0 3.016218101947743e-07
syntenic O 0 2.391725683992263e-05
to O 0 9.693844837954657e-09
human O 0 1.7621852421711992e-08
chromosome O 0 5.889129170100205e-06
region O 0 3.0276125926320674e-06
2p13 O 0 9.668102575233206e-05
- O 0 5.9262793001835234e-06
p16 O 0 3.428129502935917e-06
. O 0 1.4538903769789613e-07

Abnormal O 1 1.0
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9904292821884155
accumulation I-Disease 1 0.7830401659011841
is O 0 3.44529071938382e-09
recognized O 0 3.531063774708798e-10
as O 0 5.7832672678559405e-11
an O 0 6.413167219498916e-10
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 1.418122792529175e-06
man O 0 1.683313826106314e-06
, O 0 4.746013582135333e-10
mouse O 0 1.5141694120757165e-08
, O 0 2.272056764951458e-09
rat O 0 5.888235818929388e-07
and O 0 1.0444307640966599e-08
dog O 0 2.5437532258365536e-06
. O 0 7.677634243918874e-07

The O 0 2.870998514481471e-07
major O 0 1.6139850913532428e-06
cause O 0 0.0009241328225471079
of O 1 0.9997521042823792
hepatic B-Disease 1 1.0
copper I-Disease 1 1.0
accumulation I-Disease 1 1.0
in O 0 4.823341441806406e-07
man O 0 4.2097346408809244e-07
is O 0 2.994146874879533e-10
a O 0 6.284005538148563e-10
dysfunctional O 0 1.0874336453525757e-07
ATP7B O 0 0.04338650777935982
gene O 0 1.4904728118381172e-08
, O 0 3.3388999898242844e-10
causing O 0 7.48681145523733e-07
Wilson B-Disease 0 2.2242384147830307e-05
disease I-Disease 0 0.010055064223706722
( O 0 1.7326405554740631e-07
WD B-Disease 0 0.004230550955981016
) O 0 9.739477491166326e-08
. O 0 2.775601330995414e-07

Mutations O 0 1.3711206747757387e-06
in O 0 5.186208351659616e-09
the O 0 1.1035006686199722e-08
ATP7B O 1 0.955022394657135
genes O 0 8.594924771898604e-09
have O 0 5.2299907460362505e-11
also O 0 3.069900583740903e-11
been O 0 6.48827727656176e-11
demonstrated O 0 1.851492847926295e-10
in O 0 1.409379835060065e-10
mouse O 0 1.773278235361886e-08
and O 0 1.161618534695208e-08
rat O 0 8.214806257456075e-06
. O 0 2.736927626756369e-07

The O 0 6.827099241490941e-07
ATP7B O 1 0.9528143405914307
gene O 0 2.7618620279667994e-08
has O 0 4.686777077544946e-10
been O 0 2.6546462250642833e-10
excluded O 0 8.037951637618335e-09
in O 0 7.047944172722254e-11
the O 0 6.202010571776384e-10
much O 0 1.5470877912093783e-08
rarer O 0 1.1528287359396927e-05
human O 0 1.0714994687077706e-06
copper B-Disease 0 0.001936333253979683
overload I-Disease 1 0.9003692269325256
disease O 0 0.007230128161609173
non B-Disease 0 4.504845492192544e-06
- I-Disease 0 3.868555893404846e-07
Indian I-Disease 0 2.7002103664131027e-08
childhood I-Disease 0 8.534483413313865e-07
cirrhosis I-Disease 1 0.9999001026153564
, O 0 4.983059298524495e-09
indicating O 0 2.064609958551955e-07
genetic O 0 2.7589801447902573e-06
heterogeneity O 0 5.816865814267658e-05
. O 0 1.0425637810840271e-06

By O 0 7.512314326163505e-09
investigating O 0 1.0579001497035279e-07
the O 0 5.521756918369647e-08
common O 0 5.264394985715626e-06
autosomal O 1 0.9999977350234985
recessive O 1 1.0
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 0 1.1138622539874632e-06
CT B-Disease 1 0.9959225654602051
) O 0 2.9789957167736247e-09
in O 0 1.7992451972759227e-09
Bedlington O 0 5.048410002927994e-06
terriers O 0 7.701460162934382e-07
, O 0 9.411951218396553e-10
we O 0 3.1642230502448854e-10
have O 0 1.0800459485094116e-11
identified O 0 6.287646792113577e-11
a O 0 6.656953200484539e-12
new O 0 1.3956926976990691e-12
locus O 0 2.038254981462373e-10
involved O 0 5.775814895803144e-11
in O 0 5.444684147981604e-10
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0005915380315855145

We O 0 1.657583368341875e-07
examined O 0 1.413120713777971e-07
whether O 0 4.769528327841499e-09
the O 0 9.042157245175986e-09
WD B-Disease 0 2.4082666641334072e-05
gene O 0 4.694126687354583e-08
ATP7B O 1 0.991926908493042
was O 0 2.1151716111944552e-07
also O 0 2.638930463039202e-10
causative O 0 3.7160219346077383e-09
for O 0 2.4888388572286146e-10
CT B-Disease 0 4.99092323025252e-07
by O 0 1.695024537395895e-10
investigating O 0 6.599000457185866e-09
the O 0 5.3284510137530106e-09
chromosomal O 0 2.0861089069512673e-05
co O 0 1.1148659950777073e-07
- O 0 1.2224572287777846e-07
localization O 0 3.873775767715415e-06
of O 0 4.1122425500361715e-06
ATP7B O 1 0.9915022850036621
and O 0 1.4972599160500977e-08
C04107 O 0 1.997257413677289e-06
, O 0 4.5326786768384864e-10
using O 0 1.0002910721951253e-09
fluorescence O 0 1.0685874940463691e-07
in O 0 1.348267186784824e-08
situ O 0 1.0850443459275994e-06
hybridization O 0 1.3559244393945846e-07
( O 0 1.384981995755652e-08
FISH O 0 5.313438578014029e-07
) O 0 8.639136517274437e-09
. O 0 5.808203340507134e-08

C04107 O 0 0.0009541978943161666
is O 0 1.3880338656235836e-08
an O 0 1.0718219645156069e-09
anonymous O 0 1.9783779947601943e-08
microsatellite O 0 3.3352168884448474e-06
marker O 0 2.7873597900907043e-06
closely O 0 3.7971730648678204e-08
linked O 0 6.798823051212821e-07
to O 0 7.332102995860623e-07
CT B-Disease 1 0.9997720122337341
. O 0 1.3662801393365953e-05

However O 0 1.367242589367379e-06
, O 0 1.9973363407643774e-07
BAC O 0 0.00043932601693086326
clones O 0 5.404286298471561e-07
containing O 0 2.21999325589195e-08
ATP7B O 0 0.0002954493975266814
and O 0 1.4666375669492027e-08
C04107 O 0 2.961530981338001e-06
mapped O 0 6.172006550286824e-08
to O 0 2.7423809889626227e-09
the O 0 3.3962204160076226e-09
canine O 0 1.0896385305159129e-07
chromosome O 0 1.4110941037870361e-06
regions O 0 5.033988159652836e-08
CFA22q11 O 0 1.1340992386976723e-05
and O 0 2.2483124251237996e-09
CFA10q26 O 0 1.1802863809862174e-05
, O 0 7.69348196261177e-10
respectively O 0 5.006046244204754e-09
, O 0 8.75077163509097e-11
demonstrating O 0 4.774131645568502e-10
that O 0 1.5071519032794356e-10
WD B-Disease 0 3.4843139928852906e-06
cannot O 0 2.004946608735736e-08
be O 0 3.408303195229223e-09
homologous O 0 1.679085315231532e-08
to O 0 3.062687881083548e-08
CT B-Disease 0 0.0004615490906871855
. O 0 6.835307999608631e-07

The O 0 4.4503512981464155e-06
copper O 0 2.292151748406468e-06
transport O 0 9.399795430908853e-08
genes O 0 2.375693419764957e-08
CTR1 O 0 0.00014747663226444274
and O 0 3.4865275111428673e-09
CTR2 O 0 0.007452336139976978
were O 0 2.079658445452992e-09
also O 0 8.081417479655073e-11
excluded O 0 1.3939016607622534e-09
as O 0 3.707946796827066e-11
candidate O 0 2.3068242871460143e-09
genes O 0 2.0733126326888396e-10
for O 0 2.3773411017558033e-10
CT B-Disease 0 0.00015431274368893355
since O 0 3.4684155991726584e-08
they O 0 4.763743843838597e-10
both O 0 1.5023761401611324e-10
mapped O 0 1.7050293621423407e-08
to O 0 5.958687765428294e-09
canine O 0 7.065518730087206e-07
chromosome O 0 4.322346649132669e-05
region O 0 3.358058529556729e-05
CFA11q22 O 0 0.016555318608880043
. O 0 2.8294430194364395e-06

2 O 0 0.0001474681921536103
- O 0 5.103090370539576e-05
22 O 0 5.41107647222816e-06
. O 0 7.817541813892603e-07

5 O 0 0.00011050596367567778
. O 0 7.271705271705287e-06

A O 0 1.3924110362495412e-06
transcribed O 0 1.3038904000950424e-07
sequence O 0 1.617503242457019e-09
identified O 0 9.947449530756103e-10
from O 0 3.759902111877267e-10
the O 0 6.426256748959247e-10
C04107 O 0 4.885897624262725e-07
- O 0 1.8523069300613315e-08
containing O 0 8.966021813883174e-10
BAC O 0 6.373325959430076e-06
was O 0 3.824639716043521e-09
found O 0 2.2088266979358728e-11
to O 0 2.93780208493466e-11
be O 0 7.05678224188766e-11
homologous O 0 2.078919814074709e-10
to O 0 7.026321191538898e-11
a O 0 6.474731861771943e-10
gene O 0 1.4019699845491118e-09
expressed O 0 5.565823357756017e-10
from O 0 1.996321552510949e-09
human O 0 2.4315294222532202e-09
chromosome O 0 1.0131664112122962e-06
2p13 O 0 2.657194954736042e-06
- O 0 5.583351736504483e-08
p16 O 0 2.4594653424969692e-08
, O 0 2.7135939328903902e-11
a O 0 1.1028220003872491e-10
region O 0 1.3879225768675951e-08
devoid O 0 4.218258098376282e-08
of O 0 1.9942436590980606e-09
any O 0 1.065793897581102e-09
positional O 0 3.629562002060993e-07
candidate O 0 1.1771978734032018e-06
genes O 0 1.131030273882061e-07
. O 0 2.6642002382004648e-08

Molecular O 0 2.3527012160684535e-07
analysis O 0 2.5803492675890993e-09
of O 0 1.8059161277506064e-08
the O 0 5.306867389975878e-09
APC B-Disease 0 3.966308881331315e-08
gene O 0 2.550548661162111e-10
in O 0 4.659339927770567e-11
205 O 0 4.218060900562648e-10
families O 0 5.659327173557216e-11
: O 0 4.90784878015571e-11
extended O 0 6.395324270158653e-09
genotype O 0 3.098270440204942e-07
- O 0 3.615894001995912e-07
phenotype O 0 4.1380587845196715e-08
correlations O 0 2.3618456523877285e-08
in O 0 4.530932573576507e-10
FAP B-Disease 0 5.2573403408473496e-09
and O 0 1.8115019900788454e-11
evidence O 0 8.788674649151673e-11
for O 0 2.0889390911493777e-11
the O 0 2.563111389797257e-10
role O 0 1.1201126692839125e-09
of O 0 1.5896835847684088e-08
APC B-Disease 0 7.936328927371505e-08
amino O 0 5.852538009776254e-09
acid O 0 1.0217803270151649e-09
changes O 0 1.6790141499356537e-09
in O 0 1.3445200011119596e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 1.0
. O 0 0.0003311702748760581

BACKGROUND O 0 2.1918889615335502e-05
/ O 0 1.1168532182637136e-05
AIMS O 0 1.3397612974586082e-06
The O 0 1.1686944745292749e-08
development O 0 9.906824516292545e-08
of O 0 0.0024782675318419933
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 5.589059437483002e-09
a O 0 3.134106585367391e-10
variable O 0 1.2616653277675027e-09
range O 0 3.7251408624427995e-09
of O 0 7.274659985512244e-09
extracolonic O 0 0.0001122213652706705
manifestations O 0 7.37198133720085e-05
in O 0 3.600121374347509e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.6772568162414245e-07
FAP B-Disease 0 1.5005167597337277e-07
) O 0 1.1408101893706224e-11
is O 0 3.386060095506016e-12
the O 0 3.751037674915025e-12
result O 0 5.525867610711721e-11
of O 0 1.029723528667148e-09
the O 0 1.372265079346846e-09
dominant O 0 2.2877046035318926e-07
inheritance O 0 2.6564539439277723e-05
of O 0 0.0005269527900964022
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 0.9999969005584717
( O 0 1.437862096054232e-07
APC B-Disease 0 3.0397586670005694e-07
) O 0 2.2248880515718383e-09
gene O 0 2.00368486247271e-08
mutations O 0 2.3796010850674065e-07
. O 0 1.846321708853793e-07

In O 0 8.169858567441679e-09
this O 0 2.4974602941263413e-10
study O 0 9.191797323282458e-11
, O 0 4.7385463608495826e-12
direct O 0 8.241798910013642e-11
mutation O 0 2.024658635191301e-10
analysis O 0 1.1881123862522713e-10
of O 0 2.491780115576603e-09
the O 0 2.577658531066618e-09
APC B-Disease 0 2.3605533527870648e-08
gene O 0 5.654733903348585e-10
was O 0 2.469646043223861e-09
performed O 0 6.9092391530301e-11
to O 0 4.483613480488202e-11
determine O 0 1.3491128214582204e-09
genotype O 0 1.2687033290603722e-07
- O 0 1.347208637980657e-07
phenotype O 0 2.8294453002786213e-08
correlations O 0 2.6404437747373777e-08
for O 0 3.996315500742753e-10
nine O 0 3.00691072041559e-09
extracolonic O 0 8.824429755804886e-07
manifestations O 0 8.40401384039069e-08
and O 0 4.579052761966018e-11
to O 0 4.693465754934678e-11
investigate O 0 1.2680530236952592e-10
the O 0 8.931640843590216e-11
incidence O 0 4.910225115395406e-08
of O 0 1.0171742559350605e-08
APC B-Disease 0 4.014356491666149e-08
mutations O 0 1.8073080809699604e-08
in O 0 1.2342743715976212e-08
non O 1 0.9990059733390808
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0002022541593760252

METHODS O 0 4.871074906986905e-06
The O 0 2.2280961786691478e-07
APC B-Disease 0 2.647136057021271e-07
gene O 0 4.348390980624117e-09
was O 0 5.770722566467157e-09
analysed O 0 2.203371485265393e-09
in O 0 5.0793595024467564e-11
190 O 0 7.907748345026278e-10
unrelated O 0 2.4733699532930586e-09
FAP B-Disease 0 3.45135013901654e-08
and O 0 1.6663928015248075e-09
15 O 0 7.32855937712884e-07
non O 1 0.9993677735328674
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.2575917196500086e-07
using O 0 3.1013325241247e-08
denaturing O 0 7.938378075778019e-06
gradient O 0 2.7494006644701585e-06
gel O 0 1.953048780478639e-07
electrophoresis O 0 3.410620053045932e-08
, O 0 2.747410632331082e-10
the O 0 5.237900113641558e-10
protein O 0 9.47273370854873e-10
truncation O 0 3.904317935621293e-08
test O 0 1.6790268064781344e-09
, O 0 9.536704759227632e-11
and O 0 2.0905464859222178e-10
direct O 0 3.0124919447871434e-08
sequencing O 0 4.322085942476406e-07
. O 0 2.530727840621694e-07

RESULTS O 0 1.2982392945559695e-05
Chain O 0 3.22281948683667e-07
terminating O 0 1.1067535865549871e-07
signals O 0 8.465901757404026e-09
were O 0 1.4268283776708302e-10
only O 0 2.7363746685216128e-11
identified O 0 9.958189828296327e-11
in O 0 9.972782148703896e-12
patients O 0 1.2535803124713585e-11
belonging O 0 2.0859340643664126e-10
to O 0 3.4443820018381643e-10
the O 0 2.926206166264933e-09
FAP B-Disease 0 8.585556798834659e-08
group O 0 1.2802681137458194e-09
( O 0 1.131819082900165e-09
105 O 0 9.210728535435919e-08
patients O 0 4.168937195458966e-09
) O 0 8.031698861543646e-09
. O 0 1.8912383836777735e-07

Amino O 0 6.920789132891514e-07
acid O 0 1.2239079971720912e-08
changes O 0 2.9873356566234577e-10
were O 0 2.7961852278046706e-10
identified O 0 3.544532445332038e-10
in O 0 2.2986572714711606e-11
four O 0 2.0060756875106556e-11
patients O 0 2.0141539477935844e-11
, O 0 3.934752263595742e-12
three O 0 1.31518502685668e-11
of O 0 6.129384555464412e-09
whom O 0 3.0667666184314157e-09
belonged O 0 2.2229718510402563e-08
to O 0 2.9131683176863987e-10
the O 0 4.731599112517415e-09
non O 0 4.533331718903355e-07
- O 0 2.9704477810810204e-07
FAP O 0 1.3614365457215172e-07
group O 0 1.0590586185799111e-08
of O 0 0.00014598152483813465
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9820992946624756
. O 0 0.00010219962132396176

Genotype O 0 0.002862878143787384
- O 0 0.00010811984975589439
phenotype O 0 1.4847745433144155e-06
correlations O 0 3.8177762462510145e-07
identified O 0 7.126068179985623e-09
significant O 0 1.8516631561382724e-09
differences O 0 2.1456340704162358e-08
in O 0 2.5162319450267034e-10
the O 0 3.996993847010799e-10
nature O 0 1.1661021037667751e-09
of O 0 1.8807437829337914e-09
certain O 0 5.356330490258188e-09
extracolonic O 0 3.172482320223935e-05
manifestations O 0 1.5575728866679128e-06
in O 0 3.2862277343781443e-09
FAP B-Disease 0 5.557713578241419e-08
patients O 0 1.4562055727918022e-10
belonging O 0 8.022432718135519e-10
to O 0 9.341271089979841e-10
three O 0 1.3961872769030492e-09
mutation O 0 3.717108825185278e-07
subgroups O 0 3.3184867334057344e-06
. O 0 1.4533496539570478e-07

CONCLUSIONS O 0 2.7275282263872214e-05
Extended O 0 1.2949669780937256e-06
genotype O 0 6.2165286180970725e-06
- O 0 1.6869377077455283e-06
phenotype O 0 1.9688924624006177e-07
correlations O 0 1.4536129810949205e-07
made O 0 7.164196458298022e-10
in O 0 5.518431892004294e-11
this O 0 3.712851553983043e-11
study O 0 1.5552788223960334e-10
may O 0 2.2263303700587045e-10
have O 0 1.1933443816447564e-11
the O 0 6.365538651742497e-11
potential O 0 1.5343325221461868e-10
to O 0 3.194883593793385e-11
determine O 0 3.240724910646975e-10
the O 0 1.3794021480606489e-10
most O 0 1.212879189443905e-11
appropriate O 0 3.4184577391016546e-10
surveillance O 0 4.998756519825065e-09
and O 0 5.73726788299922e-10
prophylactic O 0 1.865898593678139e-05
treatment O 0 1.8521326694553863e-07
regimens O 0 5.120608381758984e-09
for O 0 6.235539862231576e-11
those O 0 6.510206262966278e-11
patients O 0 1.9131670206395945e-11
with O 0 3.170768985913397e-12
mutations O 0 6.882335590319144e-09
associated O 0 5.4178568298368646e-09
with O 0 2.799744880377375e-10
life O 0 6.553084119786945e-08
threatening O 0 5.227959150033712e-07
conditions O 0 4.5845577005820815e-06
. O 0 7.097624461493979e-07

This O 0 1.2307529217991942e-08
study O 0 2.525455178314928e-09
also O 0 4.426056049444682e-11
provided O 0 2.8519808042970496e-11
evidence O 0 3.792037794880798e-10
for O 0 1.6342045772166358e-10
the O 0 2.916266117480859e-09
pathological O 0 6.795556600991404e-06
nature O 0 1.178642783372652e-08
of O 0 2.6969525279696427e-08
amino O 0 1.3952103916636815e-09
acid O 0 1.167436841642555e-10
changes O 0 1.507688765500781e-11
in O 0 4.9839667115580966e-11
APC O 0 1.903033286509981e-09
associated O 0 9.843675180531974e-11
with O 0 2.6318203259073636e-12
both O 0 2.1501833646908608e-10
FAP B-Disease 0 1.1389133192096779e-07
and O 0 5.1803684897322455e-08
non O 1 0.999998927116394
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 2.4038683932303684e-06
. O 0 2.1923040094407042e-07
. O 0 4.5906421064501046e-07

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 0.0006955325952731073
cancer B-Disease 1 0.9999983310699463
risk O 0 0.0013068408006802201
of O 0 0.002052087802439928
the O 0 4.4758289732271805e-06
APC O 0 3.478915004961891e-06
I1307K O 0 8.387522939301562e-06
polymorphism O 0 1.3781078678221093e-06
. O 0 1.8720805883276626e-07

Germ O 0 0.000630686292424798
- O 0 7.784140507283155e-06
line O 0 4.427194255640643e-07
and O 0 4.608409653883427e-09
somatic O 0 2.1807539951623767e-07
truncating O 0 2.1352688861497882e-07
mutations O 0 2.426957479428893e-08
of O 0 2.654618391773056e-08
the O 0 4.370058537261912e-09
APC B-Disease 0 2.2040660851985194e-08
gene O 0 2.324951342558279e-10
are O 0 6.01279442902225e-12
thought O 0 1.7550791375775532e-10
to O 0 3.69538843969508e-10
initiate O 0 1.1257030791966827e-06
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9999991655349731
formation O 0 0.3924539387226105
in O 0 0.0004036113969050348
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.01891566999256611
sporadic O 1 0.9999631643295288
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 2.045611836365424e-06
respectively O 0 3.7028610222478164e-06
. O 0 5.041800932303886e-07

Recently O 0 4.5141769078327343e-07
, O 0 5.899025268263358e-09
an O 0 7.123798440034079e-09
isoleucine O 0 7.613131401740247e-06
- O 0 3.2853070024430053e-06
- O 0 1.5131929558265256e-06
> O 0 8.102278457045031e-07
lysine O 0 1.6924425949582655e-07
polymorphism O 0 2.3071466515034444e-08
at O 0 7.323874839926248e-09
codon O 0 1.010668704282125e-08
1307 O 0 1.5574451595057326e-07
( O 0 1.1925789245026408e-09
I1307K O 0 3.9607456869816815e-07
) O 0 7.781494198999539e-11
of O 0 8.921565708419621e-10
the O 0 1.0398782945841845e-09
APC B-Disease 0 1.1983825487504873e-08
gene O 0 2.879970151248301e-10
has O 0 1.590663885331356e-11
been O 0 2.039937836706418e-11
identified O 0 5.6192508979258093e-11
in O 0 1.110096042866715e-11
6 O 0 2.92112045663373e-09
% O 0 1.723656883889646e-09
- O 0 5.198766306335756e-09
7 O 0 8.626326319927102e-09
% O 0 5.497559629752402e-10
of O 0 4.992360413957897e-10
the O 0 7.24358684145443e-10
Ashkenazi O 0 2.1676041228602116e-07
Jewish O 0 5.548054105020128e-08
population O 0 3.6842704442818786e-09
. O 0 2.050215286431012e-08

To O 0 3.80855382786649e-08
assess O 0 1.2398669468893786e-07
the O 0 5.103389710825468e-09
risk O 0 5.4481390066030144e-08
of O 0 1.61598077141889e-08
this O 0 4.3944548000496297e-10
common O 0 1.5309723266909714e-08
APC B-Disease 0 1.4997928587945353e-07
allelic O 0 1.2903056756385922e-07
variant O 0 4.489224920689594e-07
in O 0 1.2057506637574988e-07
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 8.110367133440377e-08
we O 0 5.60923307801886e-09
have O 0 9.27683208029606e-11
analyzed O 0 6.251059669892811e-10
a O 0 7.63203458764572e-11
large O 0 3.5628536232401586e-10
cohort O 0 1.815918970748953e-08
of O 0 5.1182649229986055e-09
unselected O 0 4.7325902414740995e-06
Ashkenazi O 0 1.1493601732581737e-06
Jewish O 0 6.867495017104375e-08
subjects O 0 2.63903903174878e-08
with O 0 1.6598415697455238e-10
adenomatous B-Disease 0 6.669235153822228e-05
polyps I-Disease 0 1.6888291156647028e-06
and O 0 9.420355606692965e-10
. O 0 4.493677430161824e-09
or O 0 0.23643505573272705
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.9461799283249093e-08
for O 0 4.463327929471461e-09
the O 0 4.5339454857185046e-08
APC O 0 4.0303453374690434e-07
I1307K O 0 1.8270593500346877e-06
polymorphism O 0 9.785673000806128e-07
. O 0 1.5684213394706603e-07

The O 0 1.3679665471499902e-06
APC O 0 1.577805278429878e-06
I1307K O 0 2.772770130832214e-06
allele O 0 6.75848355058406e-08
was O 0 1.1962496770934195e-08
identified O 0 1.0945723216693182e-09
in O 0 2.2916148145757376e-10
48 O 0 8.855485233993932e-09
( O 0 3.336010079291185e-10
10 O 0 1.3992611513913289e-09
. O 0 1.0203756589666213e-10
1 O 0 3.4087339173538567e-08
% O 0 3.022412764508431e-09
) O 0 1.488709849839509e-10
of O 0 6.297999899373963e-09
476 O 0 1.7167715782306914e-07
patients O 0 3.329344977487381e-08
. O 0 1.4072516307805927e-07

Compared O 0 4.464436642592773e-08
with O 0 6.290406390219161e-11
the O 0 2.2942824029481557e-10
frequency O 0 7.820395886426468e-09
in O 0 1.610624134062988e-11
two O 0 8.74248807028466e-13
separate O 0 2.2116713842279534e-12
population O 0 2.2457116461566118e-12
control O 0 5.36646907467464e-11
groups O 0 5.903630882764244e-12
, O 0 2.0054713098516253e-11
the O 0 3.3654468101218526e-10
APC O 0 2.052554926024186e-08
I1307K O 0 5.8260560820144747e-08
allele O 0 1.6125223378793407e-09
is O 0 5.737579682196792e-12
associated O 0 1.4913804566307753e-11
with O 0 3.5151596260510343e-13
an O 0 7.537994534123627e-12
estimated O 0 7.785209144017813e-10
relative O 0 2.02172785179755e-08
risk O 0 4.0394798617171546e-08
of O 0 6.39840152416582e-07
1 O 0 0.00019215676002204418
. O 0 6.591656642740418e-07

5 O 0 3.643355012172833e-05
- O 0 2.4530258087906986e-05
1 O 0 4.2752359149744734e-05
. O 0 8.013048500288278e-07

7 O 0 7.1369026954926085e-06
for O 0 2.2872333715895365e-07
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999995231628418
( O 0 3.234356142911565e-07
both O 0 1.2164099416622776e-07
P O 0 0.0028926848899573088
= O 0 9.861955163614766e-08
. O 0 3.349541088937258e-09
01 O 0 8.303759813088618e-08
) O 0 3.981807772390766e-09
. O 0 2.889458805555023e-08

Furthermore O 0 6.150355602585478e-07
, O 0 3.071074727856171e-09
compared O 0 5.5568203372047265e-09
with O 0 3.0437291576035364e-10
noncarriers O 0 4.019633342977613e-05
, O 0 2.25689795740891e-08
APC O 0 5.017429316467314e-07
I1307K O 0 1.088817498384742e-06
carriers O 0 4.5731021747208445e-10
had O 0 4.329618885634545e-10
increased O 0 1.0093115232479022e-10
numbers O 0 4.370570919065564e-11
of O 0 5.163979910349781e-09
adenomas B-Disease 0 0.12880262732505798
and O 0 6.801307335990714e-06
colorectal B-Disease 1 1.0
cancers I-Disease 1 1.0
per O 0 9.692796447779983e-05
patient O 0 3.3866144804051146e-06
( O 0 6.466293722695582e-09
P O 0 3.679107248899527e-05
= O 0 5.0997890355120035e-09
. O 0 4.039019119161935e-11
03 O 0 6.965664156588502e-10
) O 0 5.804526130581689e-12
, O 0 3.3985995441521144e-12
as O 0 2.4876973311188655e-12
well O 0 3.756816038813504e-12
as O 0 2.0367110775687536e-11
a O 0 5.245518464036536e-10
younger O 0 3.5423106670151583e-09
age O 0 4.645034223926814e-08
at O 0 1.2926828674153512e-07
diagnosis O 0 6.3259058151743375e-06
. O 0 2.057924319842641e-07

We O 0 1.2709095642549073e-07
conclude O 0 2.676932808753918e-07
that O 0 1.1528750176736935e-09
the O 0 5.990584472925775e-09
APC O 0 2.909948193519085e-07
I1307K O 0 9.218775289809855e-07
variant O 0 5.5332172621547215e-08
leads O 0 4.604710390765376e-09
to O 0 3.4523078840109633e-10
increased O 0 3.058508113440439e-08
adenoma B-Disease 1 1.0
formation O 0 2.1722078145103296e-06
and O 0 1.6124207524725875e-09
directly O 0 4.752202631408409e-09
contributes O 0 1.2563392548514685e-09
to O 0 4.137075959587122e-10
3 O 0 8.347886826243212e-09
% O 0 9.933666111905382e-10
- O 0 7.443761718128883e-10
4 O 0 1.6464007934757774e-09
% O 0 1.5625369054195204e-10
of O 0 7.949573638255103e-11
all O 0 1.5825091237431366e-10
Ashkenazi O 0 2.6342975161242066e-06
Jewish O 0 0.0006891887751407921
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.1717271263478324e-05

The O 0 1.7407859331797226e-07
estimated O 0 9.152464741646327e-08
relative O 0 5.53817869786144e-07
risk O 0 1.1323513149363862e-07
for O 0 7.947758562387719e-10
carriers O 0 9.89035298104568e-10
may O 0 1.8467358753326835e-09
justify O 0 3.3147828926161083e-09
specific O 0 7.862295536842367e-11
clinical O 0 1.9787724236941528e-10
screening O 0 6.142626685079478e-11
for O 0 2.7209534972372218e-11
the O 0 2.4781618424007945e-10
360 O 0 3.4965705886236265e-09
, O 0 1.215457456904545e-10
000 O 0 9.688554403197713e-10
Americans O 0 4.4714350277974546e-11
expected O 0 4.704169276337211e-10
to O 0 1.314679060060442e-10
harbor O 0 1.1685295397967366e-08
this O 0 2.0257042571136807e-11
allele O 0 1.324359288901178e-09
, O 0 1.8187656242174555e-11
and O 0 5.9728224970079236e-12
genetic O 0 1.2402744109518693e-10
testing O 0 2.9131499296175534e-11
in O 0 3.5453267925589227e-12
the O 0 1.896056749106645e-11
setting O 0 8.82711681526871e-10
of O 0 5.77598635587151e-09
long O 0 2.262928155971622e-08
- O 0 4.482414439621607e-08
term O 0 3.6637266020989046e-07
- O 0 5.03607218149682e-08
outcome O 0 4.220222038497923e-08
studies O 0 3.2364322333222617e-10
may O 0 7.096248588744913e-11
impact O 0 1.5164982603010912e-09
significantly O 0 5.633829847084826e-09
on O 0 3.333426502649672e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 1.223034928443667e-06
in O 0 2.4449917090940687e-10
this O 0 3.62398250297602e-10
population O 0 6.154169396310749e-10
. O 0 1.3481154859107392e-08

Localization O 0 2.4253751689684577e-05
of O 0 1.3996323104947805e-06
human O 0 6.901504434608796e-08
BRCA1 O 0 3.9543218122162216e-07
and O 0 4.5347195443135035e-10
its O 0 2.449332403564597e-10
loss O 0 8.653946004244517e-09
in O 0 8.334328782666489e-10
high O 0 2.1999088062329974e-07
- O 0 1.9521959870871797e-07
grade O 0 1.0992907846230082e-06
, O 0 5.678146397514183e-09
non B-Disease 0 0.0001400710898451507
- I-Disease 1 0.5468329191207886
inherited I-Disease 1 0.9999998807907104
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.0010331494268029928

Although O 0 5.8117830548098937e-08
the O 0 5.293482541190997e-09
link O 0 1.7314933487000417e-08
between O 0 1.812465555417475e-08
the O 0 2.479686678213966e-08
BRCA1 O 0 3.889455911121331e-06
tumour B-Disease 1 1.0
- O 0 1.8919905642178492e-07
suppressor O 0 2.471174695983791e-07
gene O 0 3.0958227092980906e-09
and O 0 2.1940280703347526e-09
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.8941926782645169e-06
established O 0 3.798293679579956e-09
, O 0 1.1977934269435941e-11
the O 0 2.1571779085238774e-11
role O 0 5.0703378995375914e-11
, O 0 2.040742358086489e-12
if O 0 8.381970464932387e-12
any O 0 1.271977245753675e-10
, O 0 4.525713484526683e-11
of O 0 3.4094216339042305e-09
BRCA1 O 0 2.172111237541685e-07
in O 0 8.013154584318727e-09
non B-Disease 0 0.13161607086658478
- I-Disease 1 0.5734024047851562
familial I-Disease 1 0.9999977350234985
cancers I-Disease 1 1.0
is O 0 7.727224442533043e-07
unclear O 0 3.8913408388907555e-06
. O 0 4.2689592305578117e-07

BRCA1 O 0 9.395880624651909e-05
mutations O 0 1.3304307913131197e-06
are O 0 6.201100188896191e-10
rare O 0 1.5938634856382805e-09
in O 0 2.460327497288972e-09
sporadic B-Disease 0 6.906978524057195e-05
cancers I-Disease 1 1.0
, O 0 1.1360610230326529e-08
but O 0 3.392102820853893e-09
loss O 0 1.3790608477393107e-07
of O 0 9.231532658304786e-07
BRCA1 O 0 6.179110414450406e-07
resulting O 0 1.1096976670899039e-08
from O 0 1.5585283064112332e-09
reduced O 0 4.37518776763568e-09
expression O 0 7.691632886164257e-10
or O 0 1.4855781882427976e-10
incorrect O 0 1.429416918163895e-09
subcellular O 0 1.0078624512743772e-07
localization O 0 7.235308885356062e-08
is O 0 9.731405264945536e-11
postulated O 0 2.0301507142050923e-09
to O 0 3.4876879162482055e-11
be O 0 8.214382646309915e-11
important O 0 1.7548849873261219e-10
in O 0 7.115470435081761e-10
non B-Disease 0 4.183822056802455e-06
- I-Disease 0 5.277236414258368e-05
familial I-Disease 1 0.999937891960144
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 0.9955974221229553

Epigenetic O 1 0.9315948486328125
loss O 0 0.01676284149289131
, O 0 1.1169173141922784e-08
however O 0 2.826946454703716e-09
, O 0 6.447419681476774e-11
has O 0 5.263894355123089e-12
not O 0 4.183986490602365e-12
received O 0 4.4966138451618676e-11
general O 0 9.101415732182261e-10
acceptance O 0 1.3788248764967648e-08
due O 0 9.537297174233572e-09
to O 0 4.6194337244287453e-10
controversy O 0 5.2421702534388714e-09
regarding O 0 3.2598395094396437e-09
the O 0 6.941181518449469e-10
subcellular O 0 2.549268174334429e-07
localization O 0 1.7756109116362495e-07
of O 0 3.3490891837573145e-08
BRCA1 O 0 4.450587098858705e-08
proteins O 0 1.0009986589620823e-10
, O 0 1.108179433634282e-11
reports O 0 1.2176959961196498e-11
of O 0 7.06090186319841e-11
which O 0 9.748622048499911e-12
have O 0 1.3489134288724447e-11
ranged O 0 6.968604360224617e-09
from O 0 7.316401928747496e-10
exclusively O 0 3.655283575820789e-10
nuclear O 0 5.2847290987756423e-08
, O 0 6.718003930927807e-11
to O 0 1.5483971049778944e-10
conditionally O 0 4.336738967936071e-08
nuclear O 0 1.5264768649103644e-07
, O 0 1.7718056188886777e-10
to O 0 4.769425965278629e-10
the O 0 1.6978868089267962e-08
ER O 0 2.613971446407959e-05
/ O 0 1.0730292387961526e-06
golgi O 0 1.334543071607186e-06
, O 0 9.85540316023048e-10
to O 0 8.689138297768295e-10
cytoplasmic O 0 1.0458943933144838e-07
invaginations O 0 5.311391646500851e-07
into O 0 1.3256842734676866e-08
the O 0 1.0810141226613723e-08
nucleus O 0 3.9861873801783076e-07
. O 0 1.1563720647700393e-07

In O 0 8.715383970070434e-09
an O 0 2.0611683193560992e-10
attempt O 0 7.163257098596887e-09
to O 0 6.675727193261594e-10
resolve O 0 2.785637498448068e-08
this O 0 4.21839868591789e-10
issue O 0 1.0771572078738245e-08
, O 0 2.1293405927380604e-10
we O 0 2.814227184622098e-10
have O 0 9.486397084534914e-11
comprehensively O 0 2.5245512347282784e-08
characterized O 0 6.9433037097610395e-09
19 O 0 4.4309953040055916e-08
anti O 0 3.8291202031359717e-07
- O 0 8.818001902000105e-07
BRCA1 O 0 1.145148615933067e-07
antibodies O 0 1.1684359257913002e-08
. O 0 7.320568329305388e-08

These O 0 4.673855258374715e-08
reagents O 0 3.6128471947449725e-07
detect O 0 5.603247359431407e-07
a O 0 7.893440567841026e-08
220 O 0 1.8100305965162988e-07
- O 0 5.430263172456762e-07
kD O 0 1.8889431885327213e-06
protein O 0 6.307809830019551e-09
localized O 0 5.352207210762572e-08
in O 0 4.973400025143349e-10
discrete O 0 6.956429388083052e-08
nuclear O 0 6.420433692255756e-06
foci O 0 3.0424143915297464e-06
in O 0 4.5851639152161283e-10
all O 0 3.8057321183337933e-10
epithelial O 0 1.206325777047823e-07
cell O 0 4.7934435087881866e-08
lines O 0 7.944362945266903e-10
, O 0 2.1218473159057005e-11
including O 0 2.8757734041318095e-12
those O 0 1.1197568913767775e-11
derived O 0 1.296649787541071e-09
from O 0 3.148441507505595e-08
breast B-Disease 0 8.266438271675725e-06
malignancies I-Disease 0 3.09866045427043e-05
. O 0 8.837617997414782e-07

Immunohistochemical O 0 3.147506868117489e-05
staining O 0 6.285501058300724e-06
of O 0 5.1606625675049145e-06
human O 0 7.588946573378053e-07
breast O 0 1.5273144526872784e-05
specimens O 0 2.2847039815587777e-08
also O 0 1.428667295577668e-09
revealed O 0 1.31774370970561e-07
BRCA1 O 0 1.1192577176188934e-06
nuclear O 0 5.069458347861655e-05
foci O 0 3.4388111089356244e-05
in O 0 1.7726017986774423e-08
benign O 1 0.999991774559021
breast O 1 1.0
, O 0 4.480517873162171e-06
invasive B-Disease 1 0.9999792575836182
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 0 0.00020764359214808792
low B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
grade I-Disease 1 0.9999996423721313
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.00018727903079707175

Conversely O 0 7.979844667715952e-06
, O 0 2.130439646919058e-08
BRCA1 O 0 1.6535635438685858e-07
expression O 0 6.73132349859884e-09
was O 0 6.236795080383217e-09
reduced O 0 1.5891826743441584e-09
or O 0 2.4377833085509337e-10
undetectable O 0 3.2519031911704133e-09
in O 0 7.066367890135039e-12
the O 0 1.3110524818560343e-11
majority O 0 2.1888678369830217e-11
of O 0 2.9515876409647035e-09
high O 0 1.1757091442632372e-06
- O 0 7.072286280163098e-06
grade O 0 7.339804869843647e-05
, O 0 9.70631859331661e-08
ductal B-Disease 1 0.9999996423721313
carcinomas I-Disease 1 1.0
, O 0 1.741903510321663e-09
suggesting O 0 1.928365245262853e-09
that O 0 7.680956565225827e-11
absence O 0 1.3500016216028143e-08
of O 0 1.379446246119187e-07
BRCA1 O 0 9.0334867763886e-07
may O 0 2.638861573700524e-09
contribute O 0 5.520435220063291e-10
to O 0 2.6105154149469456e-10
the O 0 8.835202014445542e-10
pathogenesis O 0 1.8139843405151623e-07
of O 0 9.203555140224751e-10
a O 0 1.0065431127470603e-10
significant O 0 7.34503735611014e-10
percentage O 0 2.5056216657048935e-08
of O 0 5.145891179836326e-08
sporadic B-Disease 0 0.0001572434848640114
breast I-Disease 1 0.999998927116394
cancers I-Disease 1 1.0
. O 0 1.7083748389268294e-06
. O 0 2.082453647744842e-06

